nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,sponsor_name,agency_class,drug_name,intervention_type
NCT00566501,"ClinicalTrials.gov processed this data on January 31, 2020",2007-11-29,2012-05-16,,2014-06-26,2007-11-29,2007-12-03,Estimate,2012-05-16,2012-06-19,Estimate,,,,2014-06-26,2014-07-11,Estimate,December 2007,,2007-12-31,May 2012,2012-05-31,August 2010,Actual,2010-08-31,August 2010,Actual,2010-08-31,,Interventional,,,Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease,Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease,Completed,,Phase 3,915.0,Actual,Eisai Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:02:37.310425,2020-02-01 20:02:37.310425,Eisai Inc.,Industry,10 mg IR in Study 326,Drug
NCT01701089,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-27,,,2016-11-01,2012-10-03,2012-10-04,Estimate,,,,,,,2016-11-01,2016-11-02,Estimate,September 2012,,2012-09-30,November 2016,2016-11-30,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers,"An Open-Label, Parallel Group Study to Assess the Inhibition of Brain MAO-B by RO4602522 After Repeated Dosing in Patients With Alzheimer's Disease and in Healthy Control Subjects",Completed,,Phase 1,17.0,Actual,Hoffmann-La Roche,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 14:38:42.655878,2020-02-01 14:38:42.655878,Hoffmann-La Roche,Industry,11C-L-deprenyl-D2,Drug
NCT00407576,"ClinicalTrials.gov processed this data on January 31, 2020",2006-12-02,,,2017-06-30,2006-12-02,2006-12-05,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"December 1, 2006",,2006-12-01,"November 7, 2008",2008-11-07,,,,"November 7, 2008",Actual,2008-11-07,,Interventional,,,PET Imaging of Brain Amyloid Using [11C]MeS-IMPY,PET Imaging of Brain Amyloid Using [11C]MeS-IMPY,Completed,,Phase 1,30.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:54:08.027503,2020-02-01 20:54:08.027503,National Institute of Mental Health (NIMH),NIH,[11C]MeS-IMPY,Drug
NCT00459693,"ClinicalTrials.gov processed this data on January 31, 2020",2007-04-11,,,2019-12-13,2007-04-11,2007-04-12,Estimate,,,,,,,2019-12-13,2019-12-16,Actual,"April 9, 2007",,2007-04-09,"August 28, 2014",2014-08-28,"April 6, 2014",Actual,2014-04-06,"April 6, 2014",Actual,2014-04-06,,Interventional,,,PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD),PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using (11C)PBR28 in HIV-Seropositive Patients With (MCMD),Terminated,,N/A,40.0,Actual,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:36:42.154664,2020-02-01 20:36:42.154664,National Institute of Mental Health (NIMH),NIH,[11C]PBR28,Drug
NCT04251182,"ClinicalTrials.gov processed this data on January 31, 2020",2020-01-24,,,2020-01-29,2020-01-29,2020-01-31,Estimate,,,,,,,2020-01-29,2020-01-31,Estimate,"February 5, 2020",Anticipated,2020-02-05,January 2020,2020-01-31,"August 13, 2021",Anticipated,2021-08-13,"August 13, 2021",Anticipated,2021-08-13,,Interventional,,,Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects,"A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease",Not yet recruiting,,Phase 2,256.0,Anticipated,"T3D Therapeutics, Inc.",,4.0,,,,,,,True,True,False,,,,,,,,,No,A Clinical Study Report (CSR) will be generated within 9 months after database lock. Aggregate study data will be made available in this report.,2020-02-04 05:09:35.057386,2020-02-04 05:09:35.057386,"T3D Therapeutics, Inc.",Industry,15mg T3D-959,Drug
NCT01924858,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-15,,,2017-10-17,2013-08-15,2013-08-19,Estimate,,,,,,,2017-10-17,2017-10-19,Actual,"August 19, 2013",Actual,2013-08-19,October 2017,2017-10-31,"March 3, 2014",Actual,2014-03-03,"March 3, 2014",Actual,2014-03-03,,Interventional,,,A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.,An Open Label Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F-GSK2647544 in Healthy Subjects,Terminated,,Phase 1,4.0,Actual,GlaxoSmithKline,,1.0,,Study objectives met so study concluded earlier than planned hence we terminated the study.,False,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 13:39:49.836625,2020-02-01 13:39:49.836625,GlaxoSmithKline,Industry,[18F]GSK2647544 IV bolus,Drug
NCT03289143,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-18,,,2020-01-06,2017-09-18,2017-09-20,Actual,,,,,,,2020-01-06,2020-01-09,Actual,"October 4, 2017",Actual,2017-10-04,January 2020,2020-01-31,"September 20, 2022",Anticipated,2022-09-20,"June 24, 2020",Anticipated,2020-06-24,,Interventional,,,A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,457.0,Actual,"Genentech, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:45:33.720811,2020-02-01 08:45:33.720811,"Genentech, Inc.",Industry,[18F]GTP1,Drug
NCT03828747,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-29,,,2020-01-06,2019-01-31,2019-02-04,Actual,,,,,,,2020-01-06,2020-01-09,Actual,"January 30, 2019",Actual,2019-01-30,January 2020,2020-01-31,"June 2, 2023",Anticipated,2023-06-02,"May 7, 2021",Anticipated,2021-05-07,,Interventional,,,A Study of Semorinemab in Patients With Moderate Alzheimer's Disease,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease",Recruiting,,Phase 2,260.0,Anticipated,"Genentech, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)",2020-02-01 07:20:05.785221,2020-02-01 07:20:05.785221,"Genentech, Inc.",Industry,[18F]GTP1,Drug
NCT00566501,"ClinicalTrials.gov processed this data on January 31, 2020",2007-11-29,2012-05-16,,2014-06-26,2007-11-29,2007-12-03,Estimate,2012-05-16,2012-06-19,Estimate,,,,2014-06-26,2014-07-11,Estimate,December 2007,,2007-12-31,May 2012,2012-05-31,August 2010,Actual,2010-08-31,August 2010,Actual,2010-08-31,,Interventional,,,Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease,Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease,Completed,,Phase 3,915.0,Actual,Eisai Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:02:37.310425,2020-02-01 20:02:37.310425,Eisai Inc.,Industry,23 mg SR in Study 326,Drug
NCT01428453,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-01,2017-03-07,2015-04-27,2018-08-07,2011-09-01,2011-09-05,Estimate,2018-08-07,2018-09-24,Actual,2015-04-27,2015-05-13,Estimate,2018-08-07,2018-09-24,Actual,"October 1, 2011",,2011-10-01,July 2017,2017-07-31,"February 18, 2013",Actual,2013-02-18,"February 4, 2013",Actual,2013-02-04,,Interventional,,"The data for ITT population is presented and defined as participants who were randomized, received at least one dose of study medication and had at least one non-missing post Baseline efficacy assessment. One participant from each group was excluded from ITT population as no post-baseline efficacy data available and total ITT population was 121.",A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease,A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) on Biomarkers Related to the Pathogenesis and Progression of Alzheimer's Disease,Completed,,Phase 2,124.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 15:48:59.078910,2020-02-01 15:48:59.078910,GlaxoSmithKline,Industry,250mg rilapladib,Drug
NCT02168920,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-18,,,2017-10-13,2014-06-18,2014-06-20,Estimate,,,,,,,2017-10-13,2017-10-16,Actual,"June 11, 2014",Actual,2014-06-11,October 2017,2017-10-31,"March 18, 2016",Actual,2016-03-18,"March 18, 2016",Actual,2016-03-18,,Interventional,,,Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",Terminated,,Phase 3,150.0,Actual,"Otsuka Pharmaceutical Co., Ltd.",,4.0,,It was difficult to secure enrollment of the targeted number of subjects.,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:21.845361,2020-02-01 12:37:21.845361,"Otsuka Pharmaceutical Co., Ltd.",Industry,2 mg/day,Drug
NCT04251182,"ClinicalTrials.gov processed this data on January 31, 2020",2020-01-24,,,2020-01-29,2020-01-29,2020-01-31,Estimate,,,,,,,2020-01-29,2020-01-31,Estimate,"February 5, 2020",Anticipated,2020-02-05,January 2020,2020-01-31,"August 13, 2021",Anticipated,2021-08-13,"August 13, 2021",Anticipated,2021-08-13,,Interventional,,,Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects,"A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease",Not yet recruiting,,Phase 2,256.0,Anticipated,"T3D Therapeutics, Inc.",,4.0,,,,,,,True,True,False,,,,,,,,,No,A Clinical Study Report (CSR) will be generated within 9 months after database lock. Aggregate study data will be made available in this report.,2020-02-04 05:09:35.057386,2020-02-04 05:09:35.057386,"T3D Therapeutics, Inc.",Industry,30 mg T3D-959,Drug
NCT00088673,"ClinicalTrials.gov processed this data on January 31, 2020",2004-07-30,,,2007-02-27,2004-08-02,2004-08-03,Estimate,,,,,,,2007-02-27,2007-02-28,Estimate,June 2004,,2004-06-30,February 2007,2007-02-28,,,,,,,,Interventional,,,Evaluation of 3APS in Patients With Mild to Moderate Alzheimer’s Disease,A Phase III Study of the Efficacy and Safety of 3APS in Patients With Mild to Moderate Alzheimer’s Disease,Unknown status,"Active, not recruiting",Phase 3,950.0,,Bellus Health Inc,,,,,,,,,True,,,,,,,,,,,,,2020-02-01 22:23:05.010248,2020-02-01 22:23:05.010248,Bellus Health Inc,Industry,3APS,Drug
NCT02168920,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-18,,,2017-10-13,2014-06-18,2014-06-20,Estimate,,,,,,,2017-10-13,2017-10-16,Actual,"June 11, 2014",Actual,2014-06-11,October 2017,2017-10-31,"March 18, 2016",Actual,2016-03-18,"March 18, 2016",Actual,2016-03-18,,Interventional,,,Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",Terminated,,Phase 3,150.0,Actual,"Otsuka Pharmaceutical Co., Ltd.",,4.0,,It was difficult to secure enrollment of the targeted number of subjects.,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:21.845361,2020-02-01 12:37:21.845361,"Otsuka Pharmaceutical Co., Ltd.",Industry,3 mg/day,Drug
NCT03069014,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-03,,,2019-04-16,2017-03-01,2017-03-03,Actual,,,,,,,2019-04-16,2019-04-17,Actual,"February 15, 2017",Actual,2017-02-15,April 2019,2019-04-30,"October 31, 2019",Anticipated,2019-10-31,"October 10, 2019",Anticipated,2019-10-10,,Interventional,,,Study of LM11A-31-BHS in Mild-moderate AD Patients,"A 6-months Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Adaptive-trial-design Study to Evaluate Safety, Tolerability and Exploratory Endpoints of Either Placebo or Two Different Oral Doses of LM11A-31-BHS in Patients With Mild to Moderate Probable Alzheimer's Disease",Recruiting,,Phase 1/Phase 2,190.0,Anticipated,PharmatrophiX Inc.,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2020-02-01 09:24:45.384915,2020-02-01 09:24:45.384915,PharmatrophiX Inc.,Industry,400mg LM11A-31-BHS,Drug
NCT04251182,"ClinicalTrials.gov processed this data on January 31, 2020",2020-01-24,,,2020-01-29,2020-01-29,2020-01-31,Estimate,,,,,,,2020-01-29,2020-01-31,Estimate,"February 5, 2020",Anticipated,2020-02-05,January 2020,2020-01-31,"August 13, 2021",Anticipated,2021-08-13,"August 13, 2021",Anticipated,2021-08-13,,Interventional,,,Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects,"A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease",Not yet recruiting,,Phase 2,256.0,Anticipated,"T3D Therapeutics, Inc.",,4.0,,,,,,,True,True,False,,,,,,,,,No,A Clinical Study Report (CSR) will be generated within 9 months after database lock. Aggregate study data will be made available in this report.,2020-02-04 05:09:35.057386,2020-02-04 05:09:35.057386,"T3D Therapeutics, Inc.",Industry,45 mg T3D-959,Drug
NCT02168920,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-18,,,2017-10-13,2014-06-18,2014-06-20,Estimate,,,,,,,2017-10-13,2017-10-16,Actual,"June 11, 2014",Actual,2014-06-11,October 2017,2017-10-31,"March 18, 2016",Actual,2016-03-18,"March 18, 2016",Actual,2016-03-18,,Interventional,,,Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",Terminated,,Phase 3,150.0,Actual,"Otsuka Pharmaceutical Co., Ltd.",,4.0,,It was difficult to secure enrollment of the targeted number of subjects.,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:21.845361,2020-02-01 12:37:21.845361,"Otsuka Pharmaceutical Co., Ltd.",Industry,6 mg/day,Drug
NCT03069014,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-03,,,2019-04-16,2017-03-01,2017-03-03,Actual,,,,,,,2019-04-16,2019-04-17,Actual,"February 15, 2017",Actual,2017-02-15,April 2019,2019-04-30,"October 31, 2019",Anticipated,2019-10-31,"October 10, 2019",Anticipated,2019-10-10,,Interventional,,,Study of LM11A-31-BHS in Mild-moderate AD Patients,"A 6-months Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Adaptive-trial-design Study to Evaluate Safety, Tolerability and Exploratory Endpoints of Either Placebo or Two Different Oral Doses of LM11A-31-BHS in Patients With Mild to Moderate Probable Alzheimer's Disease",Recruiting,,Phase 1/Phase 2,190.0,Anticipated,PharmatrophiX Inc.,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2020-02-01 09:24:45.384915,2020-02-01 09:24:45.384915,PharmatrophiX Inc.,Industry,800mg LM11A-31-BHS,Drug
NCT00174525,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-09,,,2012-05-08,2005-09-09,2005-09-15,Estimate,,,,,,,2012-05-08,2012-05-09,Estimate,April 2005,,2005-04-30,May 2012,2012-05-31,April 2008,,2008-04-30,,,,,Interventional,,,Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease,"A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD",Unknown status,"Active, not recruiting",Phase 2,,,Pharmacology Research Institute,,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:56:20.667743,2020-02-01 21:56:20.667743,Pharmacology Research Institute,Other,AAB-001,Drug
NCT01193608,"ClinicalTrials.gov processed this data on January 31, 2020",2010-08-19,2016-06-15,,2017-01-03,2010-08-30,2010-09-02,Estimate,2017-01-03,2017-02-23,Actual,,,,2017-01-03,2017-02-23,Actual,September 2010,,2010-09-30,January 2017,2017-01-31,October 2013,Actual,2013-10-31,October 2013,Actual,2013-10-31,,Interventional,,All participants who were randomized.,Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease,"A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptive, Multiple Ascending Dose Study Of The Safety, Tolerability And Pharmacokinetics Of Aab-003 (Pf-05236812) In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 1,88.0,Actual,Pfizer,,6.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:54:41.851869,2020-02-01 16:54:41.851869,Pfizer,Industry,AAB-003 (PF-05236812),Drug
NCT01369225,"ClinicalTrials.gov processed this data on January 31, 2020",2011-05-10,2016-06-15,,2017-01-19,2011-06-07,2011-06-08,Estimate,2017-01-19,2017-03-10,Actual,,,,2017-01-19,2017-03-10,Actual,July 2011,,2011-07-31,January 2017,2017-01-31,August 2014,Actual,2014-08-31,August 2014,Actual,2014-08-31,,Interventional,,The baseline analysis population included all participants who were enrolled in the study and received at least 1 infusion of study medication.,Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease,"A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001",Completed,,Phase 1,52.0,Actual,Pfizer,,5.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:03:30.672831,2020-02-01 16:03:30.672831,Pfizer,Industry,AAB-003 (PF-05236812),Drug
NCT02031198,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-07,,,2017-03-15,2014-01-07,2014-01-09,Estimate,,,,,,,2017-03-15,2017-03-17,Actual,January 2014,,2014-01-31,March 2017,2017-03-31,December 2016,Actual,2016-12-31,August 2016,Actual,2016-08-31,,Interventional,FUNDAMANT,,"18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease","An 18-months Open Label Phase I Follow-up Study on Patients With Alzheimer's Disease Who Have Completed the AADvac1 Phase I Study ""AXON CO 18700""",Completed,,Phase 1,25.0,Actual,Axon Neuroscience SE,,1.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:10:58.294736,2020-02-01 13:10:58.294736,Axon Neuroscience SE,Industry,AADvac1,Drug
NCT04133454,"ClinicalTrials.gov processed this data on January 31, 2020",2017-12-28,,,2019-10-24,2019-10-17,2019-10-21,Actual,,,,,,,2019-10-24,2019-10-28,Actual,"October 10, 2019",Actual,2019-10-10,October 2019,2019-10-31,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,,Interventional,,,Evaluation of Safety and Tolerability of Libella Gene Therapy for Alzheimer's Disease: AAV- hTERT,Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for Alzheimer's Disease: AAV- hTERT,Recruiting,,Phase 1,5.0,Anticipated,Libella Gene Therapeutics,,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2020-02-01 06:35:37.155031,2020-02-01 06:35:37.155031,Libella Gene Therapeutics,Industry,AAV-hTERT,Drug
NCT02880956,"ClinicalTrials.gov processed this data on January 31, 2020",2016-08-24,,,2020-01-14,2016-08-24,2016-08-26,Estimate,,,,,,,2020-01-14,2020-01-18,Actual,"October 17, 2016",Actual,2016-10-17,January 2020,2020-01-31,"July 28, 2021",Anticipated,2021-07-28,"April 30, 2021",Anticipated,2021-04-30,,Interventional,,,A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease,"A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 2,453.0,Actual,AbbVie,,4.0,,,True,,,,True,True,False,,,False,,,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.","Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.",https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2020-02-01 10:02:59.856443,2020-02-01 10:02:59.856443,AbbVie,Industry,ABBV-8E12,Drug
NCT03712787,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-18,,,2020-01-30,2018-10-18,2018-10-19,Actual,,,,,,,2020-01-30,2020-01-31,Estimate,"March 22, 2019",Actual,2019-03-22,January 2020,2020-01-31,"August 11, 2026",Anticipated,2026-08-11,"August 11, 2026",Anticipated,2026-08-11,,Interventional,,,An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD),An Extension Study of ABBV-8E12 in Early Alzheimer's Disease,Enrolling by invitation,,Phase 2,360.0,Anticipated,AbbVie,,2.0,,,True,,,,True,True,False,,,False,,,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.","Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.",https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2020-02-04 05:13:51.142442,2020-02-04 05:13:51.142442,AbbVie,Industry,ABBV-8E12,Drug
NCT00069849,"ClinicalTrials.gov processed this data on January 31, 2020",2003-10-01,,,2006-08-31,2003-10-01,2003-10-02,Estimate,,,,,,,2006-08-31,2006-09-04,Estimate,July 2003,,2003-07-31,August 2006,2006-08-31,,,,,,,,Interventional,,,A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease,A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease,Terminated,,Phase 2,64.0,,Abbott,,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:31:22.595387,2020-02-01 22:31:22.595387,Abbott,Industry,ABT-089,Drug
NCT00555204,"ClinicalTrials.gov processed this data on January 31, 2020",2007-11-07,,2011-08-19,2011-08-19,2007-11-07,2007-11-08,Estimate,,,,2011-08-19,2011-08-23,Estimate,2011-08-19,2011-08-23,Estimate,November 2007,,2007-11-30,August 2011,2011-08-31,,,,June 2009,Actual,2009-06-30,,Interventional,,,Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of ABT-089 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",Terminated,,Phase 2,337.0,Actual,Abbott,,7.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:06:30.241600,2020-02-01 20:06:30.241600,Abbott,Industry,ABT-089,Drug
NCT00809510,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-15,,2011-09-01,2011-09-01,2008-12-16,2008-12-17,Estimate,,,,2011-09-01,2011-09-02,Estimate,2011-09-01,2011-09-02,Estimate,January 2009,,2009-01-31,September 2011,2011-09-30,,,,June 2009,Actual,2009-06-30,,Interventional,,,A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study,,Terminated,,Phase 2,63.0,Actual,Abbott,,1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:51:27.155613,2020-02-01 18:51:27.155613,Abbott,Industry,ABT-089,Drug
NCT00867399,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-19,,,2010-10-31,2009-03-20,2009-03-23,Estimate,,,,,,,2010-10-31,2010-11-02,Estimate,March 2009,,2009-03-31,September 2010,2010-09-30,,,,May 2009,Actual,2009-05-31,,Interventional,,,A Safety and Tolerability Study of ABT-126 in Elderly,"A Multiple Dose Study of Safety, Tolerability and Pharmacokinetics of ABT-126 in Elderly Subjects",Completed,,Phase 1,30.0,Actual,Abbott,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:34:03.373426,2020-02-01 18:34:03.373426,Abbott,Industry,ABT-126,Drug
NCT00948909,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-24,,2011-11-22,2013-01-29,2009-07-28,2009-07-29,Estimate,,,,2011-11-22,2011-11-24,Estimate,2013-01-29,2013-01-31,Estimate,October 2009,,2009-10-31,January 2013,2013-01-31,November 2010,Actual,2010-11-30,November 2010,Actual,2010-11-30,,Interventional,,,Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 2,274.0,Actual,AbbVie,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:10:27.171592,2020-02-01 18:10:27.171592,"AbbVie (prior sponsor, Abbott)",Industry,ABT-126,Drug
NCT01527916,"ClinicalTrials.gov processed this data on January 31, 2020",2012-02-03,,2014-11-06,2014-11-06,2012-02-03,2012-02-07,Estimate,,,,2014-11-06,2014-11-19,Estimate,2014-11-06,2014-11-19,Estimate,February 2012,,2012-02-29,November 2014,2014-11-30,November 2013,Actual,2013-11-30,November 2013,Actual,2013-11-30,,Interventional,,,Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,438.0,Actual,AbbVie,,5.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:22:19.770584,2020-02-01 15:22:19.770584,"AbbVie (prior sponsor, Abbott)",Industry,ABT-126,Drug
NCT01549834,"ClinicalTrials.gov processed this data on January 31, 2020",2012-03-07,,2014-10-24,2014-10-24,2012-03-07,2012-03-09,Estimate,,,,2014-10-24,2014-10-31,Estimate,2014-10-24,2014-10-31,Estimate,March 2012,,2012-03-31,October 2014,2014-10-31,October 2013,Actual,2013-10-31,October 2013,Actual,2013-10-31,,Interventional,,,Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",Completed,,Phase 2,434.0,Actual,AbbVie,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:17:02.274308,2020-02-01 15:17:02.274308,"AbbVie (prior sponsor, Abbott)",Industry,ABT-126,Drug
NCT01676935,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-29,,,2014-03-21,2012-08-29,2012-08-31,Estimate,,,,,,,2014-03-21,2014-03-26,Estimate,August 2012,,2012-08-31,March 2014,2014-03-31,March 2014,Actual,2014-03-31,March 2014,Actual,2014-03-31,,Interventional,,,This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease,Long-Term Safety and Tolerability of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease: An Open-Label Extension Study for Subjects Completing Study M10-985,Terminated,,Phase 2,349.0,Actual,AbbVie,,1.0,,Data obtained from the M11-427 study is not critical to the continued evaluation of ABT-126.,False,,,,False,,,,,,,,,,,,,2020-02-01 14:44:58.091343,2020-02-01 14:44:58.091343,"AbbVie (prior sponsor, Abbott)",Industry,ABT-126,Drug
NCT01690195,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-19,,,2014-03-21,2012-09-19,2012-09-21,Estimate,,,,,,,2014-03-21,2014-03-26,Estimate,September 2012,,2012-09-30,March 2014,2014-03-31,February 2014,Actual,2014-02-28,February 2014,Actual,2014-02-28,,Interventional,,,Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease,Long-Term Safety and Tolerability of ABT-126 in Adults With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793,Terminated,,Phase 2,343.0,Actual,AbbVie,,1.0,,Data obtained from the M11-428 study is not critical to the continued evaluation of ABT-126.,False,,,,False,,,,,,,,,,,,,2020-02-01 14:41:20.959540,2020-02-01 14:41:20.959540,"AbbVie (prior sponsor, Abbott)",Industry,ABT-126,Drug
NCT01018875,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-20,,2012-02-01,2018-06-01,2009-11-23,2009-11-24,Estimate,,,,2012-02-01,2012-02-03,Estimate,2018-06-01,2018-06-06,Actual,December 2009,,2009-12-31,January 2013,2013-01-31,February 2011,Actual,2011-02-28,February 2011,Actual,2011-02-28,,Interventional,,,Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Active- and Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 2,242.0,Actual,AbbVie,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:45:00.201179,2020-02-01 17:45:00.201179,"AbbVie (prior sponsor, Abbott)",Industry,ABT-288,Drug
NCT01908010,"ClinicalTrials.gov processed this data on January 31, 2020",2013-07-23,,,2013-12-09,2013-07-23,2013-07-25,Estimate,,,,,,,2013-12-09,2013-12-11,Estimate,July 2013,,2013-07-31,December 2013,2013-12-31,November 2013,Actual,2013-11-30,November 2013,Actual,2013-11-30,,Interventional,,,"Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors","A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",Completed,,Phase 1,20.0,Actual,AbbVie,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:43:36.072132,2020-02-01 13:43:36.072132,AbbVie,Industry,ABT-354,Drug
NCT01137526,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-07,,2012-07-20,2013-01-24,2010-06-03,2010-06-04,Estimate,,,,2012-07-20,2012-07-27,Estimate,2013-01-24,2013-01-29,Estimate,May 2010,,2010-05-31,January 2013,2013-01-31,July 2011,Actual,2011-07-31,July 2011,Actual,2011-07-31,,Interventional,,,Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 2,267.0,Actual,AbbVie,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:11:16.177593,2020-02-01 17:11:16.177593,"AbbVie (prior sponsor, Abbott)",Industry,ABT-384,Drug
NCT02220738,"ClinicalTrials.gov processed this data on January 31, 2020",2014-08-18,,,2016-06-14,2014-08-18,2014-08-20,Estimate,,,,,,,2016-06-14,2016-06-16,Estimate,September 2014,,2014-09-30,June 2016,2016-06-30,March 2016,Actual,2016-03-31,March 2016,Actual,2016-03-31,,Interventional,,,"Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors","A Multiple-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",Terminated,,Phase 1,19.0,Actual,AbbVie,,2.0,,Slow subject enrollment,False,,,,False,,,,,,,,,,,,,2020-02-01 12:24:40.493365,2020-02-01 12:24:40.493365,AbbVie,Industry,ABT-957,Drug
NCT02573740,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-08,,,2016-06-30,2015-10-08,2015-10-12,Estimate,,,,,,,2016-06-30,2016-07-01,Estimate,December 2015,,2015-12-31,June 2016,2016-06-30,June 2016,Actual,2016-06-30,June 2016,Actual,2016-06-30,,Interventional,,,"Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment","A Study to Evaluate the Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of Multiple Doses of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment Due to Alzheimer's Disease",Terminated,,Phase 1,8.0,Actual,AbbVie,,2.0,,Insufficient target engagement of ABT-957 (preclinical data),False,,,,False,,,,,,,,,,,,,2020-02-01 11:04:28.666758,2020-02-01 11:04:28.666758,AbbVie,Industry,ABT-957,Drug
NCT03113812,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-04,,,2017-04-10,2017-04-10,2017-04-14,Actual,,,,,,,2017-04-10,2017-04-14,Actual,"January 1, 2014",Actual,2014-01-01,April 2017,2017-04-30,"July 30, 2015",Actual,2015-07-30,"July 30, 2015",Actual,2015-07-30,,Interventional,,,Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients,"A Randomized, Placebo-controlled, Parallel Group, Double-blinded, Single-center Phase-I, Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of ABvac40 in Patients With Mild to Moderate Alzheimer's Disease.",Completed,,Phase 1,24.0,Actual,Araclon Biotech S.L.,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2020-02-01 09:16:52.146443,2020-02-01 09:16:52.146443,Araclon Biotech S.L.,Industry,ABvac40,Drug
NCT00359944,"ClinicalTrials.gov processed this data on January 31, 2020",2006-08-01,2011-04-11,,2013-05-28,2006-08-01,2006-08-03,Estimate,2013-05-28,2013-07-02,Estimate,,,,2013-05-28,2013-07-02,Estimate,February 2006,,2006-02-28,May 2013,2013-05-31,September 2008,Actual,2008-09-30,September 2008,Actual,2008-09-30,,Interventional,,"132 subjects were from the full analysis set, which was defined as all randomized subjects who took at least one dose of study drug and had greater than/equal to one post-baseline ADAS-Cog assessment",Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease,"A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Assessing the Efficacy and Safety of AC-3933 Tablets Twice Daily in Adults With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,171.0,Actual,Sunovion,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:08:48.235484,2020-02-01 21:08:48.235484,Sunovion,Industry,AC-3933,Drug
NCT00955409,"ClinicalTrials.gov processed this data on January 31, 2020",2009-08-04,,,2014-01-29,2009-08-07,2009-08-10,Estimate,,,,,,,2014-01-29,2014-01-31,Estimate,November 2009,,2009-11-30,January 2014,2014-01-31,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,,Interventional,,,"Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease","A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Long-Term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of ACC-001 With QS-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,50.0,Actual,Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:08:14.718450,2020-02-01 18:08:14.718450,Pfizer,Industry,ACC-001,Drug
NCT00955409,"ClinicalTrials.gov processed this data on January 31, 2020",2009-08-04,,,2014-01-29,2009-08-07,2009-08-10,Estimate,,,,,,,2014-01-29,2014-01-31,Estimate,November 2009,,2009-11-30,January 2014,2014-01-31,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,,Interventional,,,"Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease","A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Long-Term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of ACC-001 With QS-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,50.0,Actual,Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:08:14.718450,2020-02-01 18:08:14.718450,Pfizer,Industry,ACC-001 + QS21,Drug
NCT00955409,"ClinicalTrials.gov processed this data on January 31, 2020",2009-08-04,,,2014-01-29,2009-08-07,2009-08-10,Estimate,,,,,,,2014-01-29,2014-01-31,Estimate,November 2009,,2009-11-30,January 2014,2014-01-31,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,,Interventional,,,"Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease","A Phase IIa, Multicenter, Randomized, Third-Party Unblinded, Long-Term Extension Study To Determine Safety, Tolerability, And Immunogenicity Of ACC-001 With QS-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,50.0,Actual,Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:08:14.718450,2020-02-01 18:08:14.718450,Pfizer,Industry,ACC-001+ QS21,Drug
NCT01608217,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-25,,,2014-06-26,2012-05-25,2012-05-31,Estimate,,,,,,,2014-06-26,2014-06-30,Estimate,June 2012,,2012-06-30,June 2014,2014-06-30,June 2014,Actual,2014-06-30,June 2014,Actual,2014-06-30,,Interventional,,,Delta-THC in Dementia,Efficacy and Safety of Delta-9-tetrahydrocannabinol (∆9-THC) in Behavioural Disturbances and Pain in Dementia,Completed,,Phase 2,50.0,Actual,Radboud University,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:02:26.242272,2020-02-01 15:02:26.242272,Radboud University,Other,Acetaminophen,Drug
NCT00012857,"ClinicalTrials.gov processed this data on January 31, 2020",2001-03-14,,,2015-04-06,2001-03-15,2001-03-16,Estimate,,,,,,,2015-04-06,2015-04-07,Estimate,,,,February 2007,2007-02-28,March 2001,Actual,2001-03-31,,,,,Interventional,,,Pain Management and Behavioral Outcomes in Patients With Dementia,Pain Management and Behavioral Outcomes in Patients With Dementia,Completed,,Phase 2,66.0,Anticipated,VA Office of Research and Development,,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 22:48:34.079754,2020-02-01 22:48:34.079754,US Department of Veterans Affairs,U.S. Fed,acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN,Drug
NCT02955706,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-02,,,2016-11-06,2016-11-02,2016-11-04,Estimate,,,,,,,2016-11-06,2016-11-08,Estimate,April 2016,,2016-04-30,November 2016,2016-11-30,February 2019,Anticipated,2019-02-28,September 2018,Anticipated,2018-09-30,,Interventional,,,Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease,"A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease",Unknown status,Recruiting,Phase 4,328.0,Anticipated,"Dong-A ST Co., Ltd.",,2.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 09:45:59.593009,2020-02-01 09:45:59.593009,"Dong-A ST Co., Ltd.",Industry,Acetyl-L-Carnitine,Drug
NCT01852110,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-08,2018-01-08,,2018-08-20,2013-05-08,2013-05-13,Estimate,2018-01-08,2018-02-07,Actual,,,,2018-08-20,2018-09-18,Actual,"October 22, 2013",Actual,2013-10-22,August 2018,2018-08-31,"April 11, 2016",Actual,2016-04-11,"April 11, 2016",Actual,2016-04-11,,Interventional,,"Includes only participants in Stage 1 who were both randomized (i.e. started) and treated.
In stage 1:
MK-7622 High Dose - 45 mg: of the randomized participants (n=120), all but 1 randomized participant received study treatment (n=119).
Placebo: Of the randomized participants (n=120), all received study treatment (n=120).",Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012),"A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy for Symptomatic Treatment in Subjects With Alzheimer's Disease",Terminated,,Phase 2,240.0,Actual,Merck Sharp & Dohme Corp.,"Stage 1 Interim analysis of efficacy met the clinical criteria for early trial termination (futility). As a result, the trial was terminated at Stage 1 and did not proceed to Stage 2.",6.0,,"Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility).
    The trial was terminated at Stage 1; did not proceed to Stage 2.",False,,,,False,True,False,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2020-02-01 14:00:05.175571,2020-02-01 14:00:05.175571,Merck Sharp & Dohme Corp.,Industry,AChEI,Drug
NCT01078168,"ClinicalTrials.gov processed this data on January 31, 2020",2010-03-01,2016-03-14,,2017-07-18,2010-03-01,2010-03-02,Estimate,2017-07-18,2018-02-05,Actual,,,,2017-07-18,2018-02-05,Actual,March 2010,,2010-03-31,July 2017,2017-07-31,May 2013,Actual,2013-05-31,January 2013,Actual,2013-01-31,,Interventional,ADAM,,Alzheimer`s Disease Acitretin Medication,Changes of Cerebral Spinal Fluid APPSα Levels Under Oral Therapy With Acitretin 30 mg Daily in Patients With Mild to Moderate Alzheimer's Disease: a Multicenter Prospective Randomised Placebo-controlled Parallel-group Study,Completed,,Phase 2,22.0,Actual,Johannes Gutenberg University Mainz,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:28:20.384900,2020-02-01 17:28:20.384900,K. Lieb,Other,Acitretin,Drug
NCT01614886,"ClinicalTrials.gov processed this data on January 31, 2020",2012-06-06,2015-04-16,,2016-06-30,2012-06-07,2012-06-08,Estimate,2015-04-16,2015-05-12,Estimate,,,,2016-06-30,2016-08-01,Estimate,July 2012,,2012-07-31,June 2015,2015-06-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,"Randomized set (RAN) The RAN consisted of all randomized patients. Patients were analyzed according to the treatment group they were assigned to at randomization. A patient was diagnosed of dementia with Lewy Bodies, different from AD, after randomization and was excluded from all analysis (SAF and FAS).","Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)","A 24-week, Multicenter, Parallel-group, Randomized,Double-blind Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Methods of Rivastigmine Patch (ENA713D/ONO-2540) in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-20)",Completed,,Phase 3,216.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:00:51.368993,2020-02-01 15:00:51.368993,Novartis Pharmaceuticals,Industry,Active Comparator,Drug
NCT01230853,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-27,,,2013-05-20,2010-10-28,2010-10-29,Estimate,,,,,,,2013-05-20,2013-05-22,Estimate,August 2010,,2010-08-31,February 2013,2013-02-28,February 2013,Actual,2013-02-28,October 2012,Actual,2012-10-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study","A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer?s Disease",Completed,,Phase 1,80.0,Actual,Eisai Inc.,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:43:04.642093,2020-02-01 16:43:04.642093,Eisai Inc.,Industry,Active Comparator: A,Drug
NCT01230853,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-27,,,2013-05-20,2010-10-28,2010-10-29,Estimate,,,,,,,2013-05-20,2013-05-22,Estimate,August 2010,,2010-08-31,February 2013,2013-02-28,February 2013,Actual,2013-02-28,October 2012,Actual,2012-10-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study","A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer?s Disease",Completed,,Phase 1,80.0,Actual,Eisai Inc.,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:43:04.642093,2020-02-01 16:43:04.642093,Eisai Inc.,Industry,Active Comparator B,Drug
NCT03493282,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-14,,,2019-03-29,2018-04-03,2018-04-10,Actual,,,,,,,2019-03-29,2019-04-02,Actual,"April 20, 2018",Actual,2018-04-20,March 2019,2019-03-31,"July 30, 2020",Anticipated,2020-07-30,"January 31, 2020",Anticipated,2020-01-31,,Interventional,,,Effect of CT1812 Treatment on Brain Synaptic Density,A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease,Recruiting,,Phase 1/Phase 2,21.0,Anticipated,Cognition Therapeutics,,3.0,,,,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 08:11:27.828530,2020-02-01 08:11:27.828530,Cognition Therapeutics,Industry,Active Treatment- CT1812 100 mg,Drug
NCT03493282,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-14,,,2019-03-29,2018-04-03,2018-04-10,Actual,,,,,,,2019-03-29,2019-04-02,Actual,"April 20, 2018",Actual,2018-04-20,March 2019,2019-03-31,"July 30, 2020",Anticipated,2020-07-30,"January 31, 2020",Anticipated,2020-01-31,,Interventional,,,Effect of CT1812 Treatment on Brain Synaptic Density,A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease,Recruiting,,Phase 1/Phase 2,21.0,Anticipated,Cognition Therapeutics,,3.0,,,,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 08:11:27.828530,2020-02-01 08:11:27.828530,Cognition Therapeutics,Industry,Active Treatment- CT1812 300 mg,Drug
NCT03790982,"ClinicalTrials.gov processed this data on January 31, 2020",2018-12-18,,,2018-12-29,2018-12-29,2019-01-02,Actual,,,,,,,2018-12-29,2019-01-02,Actual,"December 1, 2018",Actual,2018-12-01,December 2018,2018-12-31,"July 30, 2021",Anticipated,2021-07-30,"December 30, 2020",Anticipated,2020-12-30,,Interventional,WAY,,Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease,"A Randomized, Double Blind, Placebo Controlled, Parallel-Group 52-week Multicenter Phase II Study to Investigate the Safety, Efficacy and Pharmacokinetics of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease","Active, not recruiting",,Phase 2,240.0,Anticipated,Zhejiang Hisun Pharmaceutical Co. Ltd.,,4.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:25:35.066475,2020-02-01 07:25:35.066475,Zhejiang Hisun Pharmaceutical Co. Ltd.,Industry,AD-35 30 mg + Placebo of AD-35 30 mg,Drug
NCT03790982,"ClinicalTrials.gov processed this data on January 31, 2020",2018-12-18,,,2018-12-29,2018-12-29,2019-01-02,Actual,,,,,,,2018-12-29,2019-01-02,Actual,"December 1, 2018",Actual,2018-12-01,December 2018,2018-12-31,"July 30, 2021",Anticipated,2021-07-30,"December 30, 2020",Anticipated,2020-12-30,,Interventional,WAY,,Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease,"A Randomized, Double Blind, Placebo Controlled, Parallel-Group 52-week Multicenter Phase II Study to Investigate the Safety, Efficacy and Pharmacokinetics of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease","Active, not recruiting",,Phase 2,240.0,Anticipated,Zhejiang Hisun Pharmaceutical Co. Ltd.,,4.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:25:35.066475,2020-02-01 07:25:35.066475,Zhejiang Hisun Pharmaceutical Co. Ltd.,Industry,AD-35 60 mg,Drug
NCT03625401,"ClinicalTrials.gov processed this data on January 31, 2020",2018-07-24,,,2019-01-09,2018-08-07,2018-08-10,Actual,,,,,,,2019-01-09,2019-01-11,Actual,"October 4, 2018",Actual,2018-10-04,January 2019,2019-01-31,"July 31, 2020",Anticipated,2020-07-31,"July 31, 2019",Anticipated,2019-07-31,,Interventional,ROAD,,Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease,"A Pilot, Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Tolerability, Efficacy, and Pharmacokinetics of AD-35 in Subjects With Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 2,88.0,Anticipated,Zhejiang Hisun Pharmaceutical Co. Ltd.,,3.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 07:50:18.156416,2020-02-01 07:50:18.156416,Zhejiang Hisun Pharmaceutical Co. Ltd.,Industry,AD-35 60mg group,Drug
NCT03625401,"ClinicalTrials.gov processed this data on January 31, 2020",2018-07-24,,,2019-01-09,2018-08-07,2018-08-10,Actual,,,,,,,2019-01-09,2019-01-11,Actual,"October 4, 2018",Actual,2018-10-04,January 2019,2019-01-31,"July 31, 2020",Anticipated,2020-07-31,"July 31, 2019",Anticipated,2019-07-31,,Interventional,ROAD,,Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease,"A Pilot, Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Tolerability, Efficacy, and Pharmacokinetics of AD-35 in Subjects With Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 2,88.0,Anticipated,Zhejiang Hisun Pharmaceutical Co. Ltd.,,3.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 07:50:18.156416,2020-02-01 07:50:18.156416,Zhejiang Hisun Pharmaceutical Co. Ltd.,Industry,AD-35 90mg group,Drug
NCT02434718,"ClinicalTrials.gov processed this data on January 31, 2020",2015-04-30,,,2017-04-07,2015-04-30,2015-05-05,Estimate,,,,,,,2017-04-07,2017-04-10,Actual,"June 30, 2015",Actual,2015-06-30,April 2017,2017-04-30,"December 9, 2016",Actual,2016-12-09,"December 9, 2016",Actual,2016-12-09,,Interventional,PROPEL,,Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Aducanumab (BIIB037) in Japanese Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,21.0,Actual,Biogen,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:36:45.852771,2020-02-01 11:36:45.852771,Biogen,Industry,Aducanumab,Drug
NCT03639987,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-17,,,2019-11-07,2018-08-17,2018-08-21,Actual,,,,,,,2019-11-07,2019-11-12,Actual,"December 20, 2018",Actual,2018-12-20,November 2019,2019-11-30,"July 30, 2019",Actual,2019-07-30,"July 30, 2019",Actual,2019-07-30,,Interventional,EVOLVE,,A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities,"A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Subjects With Asymptomatic Amyloid-Related Imaging Abnormalities",Terminated,,Phase 2,500.0,Actual,Biogen,,2.0,,"Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and
    NCT02484547) and not based on safety concerns.",False,,,,True,True,False,,,,,,,,,,,2020-02-01 07:47:53.971667,2020-02-01 07:47:53.971667,Biogen,Industry,Aducanumab,Drug
NCT04241068,"ClinicalTrials.gov processed this data on January 31, 2020",2020-01-22,,,2020-01-22,2020-01-22,2020-01-27,Actual,,,,,,,2020-01-22,2020-01-27,Actual,"March 31, 2020",Anticipated,2020-03-31,January 2020,2020-01-31,"September 1, 2023",Anticipated,2023-09-01,"September 1, 2023",Anticipated,2023-09-01,,Interventional,,,"A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205","Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205",Not yet recruiting,,Phase 3,2400.0,Anticipated,Biogen,,1.0,,,False,,,,True,True,False,,,False,,,,,,Yes,In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/,2020-02-01 06:21:29.510852,2020-02-01 06:21:29.510852,Biogen,Industry,Aducanumab,Drug
NCT02477800,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-18,,,2019-11-07,2015-06-18,2015-06-23,Estimate,,,,,,,2019-11-07,2019-11-12,Actual,"August 31, 2015",Actual,2015-08-31,November 2019,2019-11-30,"August 8, 2019",Actual,2019-08-08,"August 8, 2019",Actual,2019-08-08,,Interventional,ENGAGE,,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease",Terminated,,Phase 3,1647.0,Actual,Biogen,,2.0,,"Study was discontinued based on futility analysis done and not based on safety concerns.
    Follow-up visits and closing out study activities are completed",False,,,,True,,,,,,,,,,,,,2020-02-01 11:26:54.149156,2020-02-01 11:26:54.149156,Biogen,Industry,Aducanumab (BIIB037),Drug
NCT02484547,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-18,,,2019-11-07,2015-06-26,2015-06-29,Estimate,,,,,,,2019-11-07,2019-11-12,Actual,"September 30, 2015",Actual,2015-09-30,November 2019,2019-11-30,"August 5, 2019",Actual,2019-08-05,"August 5, 2019",Actual,2019-08-05,,Interventional,EMERGE,,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease",Terminated,,Phase 3,1638.0,Actual,Biogen,,2.0,,"Study was discontinued based on futility analysis done and not based on safety concerns.
    Follow-up visits and closing out study activities are completed",False,,,,True,,,,,,,,,,,,,2020-02-01 11:25:35.474212,2020-02-01 11:25:35.474212,Biogen,Industry,Aducanumab (BIIB037),Drug
NCT01677572,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-30,,,2019-11-07,2012-08-31,2012-09-03,Estimate,,,,,,,2019-11-07,2019-11-12,Actual,"October 5, 2012",Actual,2012-10-05,November 2019,2019-11-30,"July 31, 2019",Actual,2019-07-31,"March 21, 2019",Actual,2019-03-21,,Interventional,PRIME,,"Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease","A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease",Terminated,,Phase 1,197.0,Actual,Biogen,,9.0,,"Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and
    NCT02484547) and not based on safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 14:44:45.388276,2020-02-01 14:44:45.388276,Biogen,Industry,"Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)",Drug
NCT03486938,"ClinicalTrials.gov processed this data on January 31, 2020",2018-03-28,,,2020-01-02,2018-04-02,2018-04-03,Actual,,,,,,,2020-01-02,2020-01-03,Actual,"January 15, 2019",Actual,2019-01-15,November 2019,2019-11-30,November 2022,Anticipated,2022-11-30,November 2021,Anticipated,2021-11-30,,Interventional,HOPE4MCI,,Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease",Recruiting,,Phase 3,830.0,Anticipated,AgeneBio,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 08:12:28.060228,2020-02-01 08:12:28.060228,AgeneBio,Industry,AGB101 220 mg tablet,Drug
NCT03316898,"ClinicalTrials.gov processed this data on January 31, 2020",2017-10-18,,,2018-10-31,2017-10-18,2017-10-20,Actual,,,,,,,2018-10-31,2018-11-02,Actual,"September 30, 2018",Anticipated,2018-09-30,October 2018,2018-10-31,"November 4, 2018",Anticipated,2018-11-04,"November 4, 2018",Anticipated,2018-11-04,,Interventional,,,A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease",Withdrawn,,Phase 1,0.0,Actual,Allergan,,4.0,,Business decision to stop the study.,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:40:51.152227,2020-02-01 08:40:51.152227,Allergan,Industry,AGN-242071,Drug
NCT03441516,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-05,,,2019-10-21,2018-02-20,2018-02-22,Actual,,,,,,,2019-10-21,2019-10-23,Actual,"April 19, 2018",Actual,2018-04-19,October 2019,2019-10-31,"May 31, 2020",Anticipated,2020-05-31,"July 4, 2019",Actual,2019-07-04,,Interventional,ALFO-AD,,Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia,"Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia: A Multi-center, Randomized, Open-label, Pilot Study","Active, not recruiting",,Phase 4,79.0,Actual,Yuhan Corporation,,2.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 08:19:46.005803,2020-02-01 08:19:46.005803,Yuhan Corporation,Industry,Alfoatirin® Tab. + Aripezil® Tab.,Drug
NCT03748303,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-12,,,2020-01-27,2018-11-19,2018-11-20,Actual,,,,,,,2020-01-27,2020-01-29,Actual,"October 1, 2019",Actual,2019-10-01,January 2020,2020-01-31,October 2020,Anticipated,2020-10-31,August 2020,Anticipated,2020-08-31,,Interventional,Allo-IM,,Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study,Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: IV to IM Bridging Study,Recruiting,,Phase 1,12.0,Anticipated,University of Arizona,,1.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-02 05:34:09.909168,2020-02-02 05:34:09.909168,University of Arizona,Other,Allopregnanolone,Drug
NCT02221622,"ClinicalTrials.gov processed this data on January 31, 2020",2014-07-02,,,2019-07-02,2014-08-18,2014-08-20,Estimate,,,,,,,2019-07-02,2019-07-05,Actual,August 2014,,2014-08-31,May 2018,2018-05-31,February 2018,Actual,2018-02-28,February 2018,Actual,2018-02-28,,Interventional,Allo,,Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD,Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase 1,Completed,,Phase 1,24.0,Actual,University of Southern California,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:24:27.622064,2020-02-01 12:24:27.622064,University of Southern California,Other,Allopregnanolone injection (intravenous solution),Drug
NCT01594346,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-02,,,2012-05-08,2012-05-08,2012-05-09,Estimate,,,,,,,2012-05-08,2012-05-09,Estimate,September 2000,,2000-09-30,May 2012,2012-05-31,April 2010,Actual,2010-04-30,April 2010,Actual,2010-04-30,,Interventional,,,Multicenter Vitamin E Trial in Aging Persons With Down Syndrome,,Completed,,Phase 3,349.0,Actual,New York State Institute for Basic Research,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:06:16.500865,2020-02-01 15:06:16.500865,New York State Institute for Basic Research,Other,Alpha-Tocopherol,Drug
NCT04157712,"ClinicalTrials.gov processed this data on January 31, 2020",2019-11-04,,,2019-11-15,2019-11-06,2019-11-08,Actual,,,,,,,2019-11-15,2019-11-19,Actual,"September 26, 2015",Actual,2015-09-26,November 2019,2019-11-30,"July 4, 2016",Actual,2016-07-04,"July 4, 2016",Actual,2016-07-04,,Interventional,,,Multiple Ascending Dose Study of ALZ-801,"A Phase I, Single Centre, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics in Plasma and Urine of Multiple Ascending Doses of ALZ-801 in Healthy Elderly Subjects",Completed,,Phase 1,48.0,Actual,Alzheon Inc.,,4.0,,,False,,,,False,True,False,,,False,,,,,,No,,2020-02-01 06:32:20.379077,2020-02-01 06:32:20.379077,Alzheon Inc.,Industry,ALZ-801 or matching placebo,Drug
NCT02547818,"ClinicalTrials.gov processed this data on January 31, 2020",2015-09-10,,,2019-12-04,2015-09-10,2015-09-11,Estimate,,,,,,,2019-12-04,2019-12-05,Actual,September 2015,Actual,2015-09-30,July 2019,2019-07-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,,Interventional,COGNITE,,Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,"Active, not recruiting",,Phase 3,620.0,Actual,"AZTherapies, Inc.",,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:10:48.336799,2020-02-01 11:10:48.336799,"AZTherapies, Inc.",Industry,ALZT-OP1a,Drug
NCT02547818,"ClinicalTrials.gov processed this data on January 31, 2020",2015-09-10,,,2019-12-04,2015-09-10,2015-09-11,Estimate,,,,,,,2019-12-04,2019-12-05,Actual,September 2015,Actual,2015-09-30,July 2019,2019-07-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,,Interventional,COGNITE,,Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease,"Active, not recruiting",,Phase 3,620.0,Actual,"AZTherapies, Inc.",,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:10:48.336799,2020-02-01 11:10:48.336799,"AZTherapies, Inc.",Industry,ALZT-OP1b,Drug
NCT03533257,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-30,,,2020-01-15,2018-05-10,2018-05-23,Actual,,,,,,,2020-01-15,2020-01-18,Actual,"August 27, 2018",Actual,2018-08-27,January 2020,2020-01-31,"September 1, 2020",Anticipated,2020-09-01,"July 1, 2020",Anticipated,2020-07-01,,Interventional,PEGASUS,,Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease,"Phase II Study to Assess the Safety, Tolerability, and Target Engagement of AMX0035, a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimer's Disease",Recruiting,,Phase 2,100.0,Anticipated,Amylyx Pharmaceuticals Inc.,,2.0,,,,,,,False,True,False,,,,,,,,,Undecided,,2020-02-01 08:04:53.807069,2020-02-01 08:04:53.807069,Amylyx Pharmaceuticals Inc.,Industry,AMX0035,Drug
NCT02756858,"ClinicalTrials.gov processed this data on January 31, 2020",2016-03-08,,,2019-11-17,2016-04-27,2016-04-29,Estimate,,,,,,,2019-11-17,2019-11-19,Actual,March 2016,,2016-03-31,November 2019,2019-11-30,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,,Interventional,,,An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease,An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease,"Active, not recruiting",,Phase 2,32.0,Anticipated,Anavex Life Sciences Corp.,,1.0,,,False,,,,True,,,,,,,,,,,Yes,Study results will be presented at a scientific conference and/or published.,2020-02-01 10:25:49.710699,2020-02-01 10:25:49.710699,Anavex Life Sciences Corp.,Industry,ANAVEX2-73,Drug
NCT02244541,"ClinicalTrials.gov processed this data on January 31, 2020",2014-08-31,,,2018-11-26,2014-09-17,2014-09-19,Estimate,,,,,,,2018-11-26,2018-11-28,Actual,December 2014,Actual,2014-12-31,November 2018,2018-11-30,November 2016,Actual,2016-11-30,November 2015,Actual,2015-11-30,,Interventional,ANAVEX,,"Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease","Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period",Completed,,Phase 2,32.0,Actual,Anavex Life Sciences Corp.,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:19:15.730616,2020-02-01 12:19:15.730616,Anavex Life Sciences Corp.,Industry,ANAVEX2-73 Intravenous,Drug
NCT02244541,"ClinicalTrials.gov processed this data on January 31, 2020",2014-08-31,,,2018-11-26,2014-09-17,2014-09-19,Estimate,,,,,,,2018-11-26,2018-11-28,Actual,December 2014,Actual,2014-12-31,November 2018,2018-11-30,November 2016,Actual,2016-11-30,November 2015,Actual,2015-11-30,,Interventional,ANAVEX,,"Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease","Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period",Completed,,Phase 2,32.0,Actual,Anavex Life Sciences Corp.,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:19:15.730616,2020-02-01 12:19:15.730616,Anavex Life Sciences Corp.,Industry,ANAVEX2-73 Oral,Drug
NCT00392912,"ClinicalTrials.gov processed this data on January 31, 2020",2006-10-24,,,2010-08-18,2006-10-25,2006-10-26,Estimate,,,,,,,2010-08-18,2010-08-19,Estimate,April 2007,,2007-04-30,August 2010,2010-08-31,July 2010,Actual,2010-07-31,November 2009,Actual,2009-11-30,,Interventional,,,Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone,A Pilot Study of the Effect of Testosterone on Cerebral Glucose Metabolism in Hypogonadal Males With Alzheimer's Disease,Completed,,N/A,10.0,Actual,"VA Medical Center, Houston",,,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:58:37.874698,2020-02-01 20:58:37.874698,"VA Medical Center, Houston",U.S. Fed,AndroGel (Solvay Pharmaceuticals),Drug
NCT00736775,"ClinicalTrials.gov processed this data on January 31, 2020",2008-08-15,,,2010-10-26,2008-08-15,2008-08-18,Estimate,,,,,,,2010-10-26,2010-10-27,Estimate,August 2008,,2008-08-31,October 2010,2010-10-31,,,,May 2010,Actual,2010-05-31,,Interventional,,,"A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease","A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MABT5102A Administered in a Single-Dose, Dose-Escalation Stage Followed by a Multidose, Parallel-Treatment Stage in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,56.0,Actual,"Genentech, Inc.",,,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:12:36.840794,2020-02-01 19:12:36.840794,"Genentech, Inc.",Industry,anti-Abeta,Drug
NCT03806478,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-04,,,2019-01-15,2019-01-15,2019-01-16,Actual,,,,,,,2019-01-15,2019-01-16,Actual,June 2021,Anticipated,2021-06-30,January 2019,2019-01-31,December 2022,Anticipated,2022-12-31,September 2022,Anticipated,2022-09-30,,Interventional,,,Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease,"Safety, Tolerability and Efficacy Assessment of Intranasal Nanoparticles of APH-1105, A Novel Alpha Secretase Modulator For Mild to Moderate Cognitive Impairment Due to Alzheimer's Disease(AD)",Not yet recruiting,,Phase 2,60.0,Anticipated,Aphios,,4.0,,,False,,,,True,False,False,,,True,,,,,,No,,2020-02-01 07:23:10.105396,2020-02-01 07:23:10.105396,Aphios,Industry,APH-1105,Drug
NCT00582855,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-21,,,2016-04-15,2007-12-21,2007-12-28,Estimate,,,,,,,2016-04-15,2016-04-19,Estimate,December 2007,,2007-12-31,April 2016,2016-04-30,,,,February 2009,Actual,2009-02-28,,Interventional,,,Effect of AQW051 in Patients With Memory Impairment,"A 4-week, Parallel-group, Randomized, Double-blind, Placebo-controlled, Adaptive Proof of Concept Study of AQW051 at up to Three Dose Levels for the Treatment of Patients With Findings Consistent With Mild Alzheimer's Disease (AD) or Amnestic Mild Cognitive Impairment (Amnestic MCI)",Terminated,,Phase 2,54.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:58:11.171904,2020-02-01 19:58:11.171904,Novartis Pharmaceuticals,Industry,AQW051,Drug
NCT03625622,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-08,,,2019-03-28,2018-08-08,2018-08-10,Actual,,,,,,,2019-03-28,2019-04-01,Actual,"January 15, 2019",Actual,2019-01-15,March 2019,2019-03-31,"August 1, 2020",Anticipated,2020-08-01,"June 1, 2020",Anticipated,2020-06-01,,Interventional,,,Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease,"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 2,210.0,Anticipated,"AriBio Co., Ltd.",,3.0,,,,,,,False,True,False,,,,,,,,,,,2020-02-01 07:50:16.488873,2020-02-01 07:50:16.488873,"AriBio Co., Ltd.",Industry,AR1001,Drug
NCT00018278,"ClinicalTrials.gov processed this data on January 31, 2020",2001-07-03,,,2009-01-20,2001-07-04,2001-07-05,Estimate,,,,,,,2009-01-20,2009-01-21,Estimate,October 1998,,1998-10-31,December 2004,2004-12-31,September 2001,,2001-09-30,,,,,Interventional,,,Electrophysiologic Measures of Treatment Response in Alzheimer Disease,Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease,Completed,,Phase 4,,,VA Office of Research and Development,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:17.695761,2020-02-01 22:48:17.695761,US Department of Veterans Affairs,U.S. Fed,Aricept,Drug
NCT00031018,"ClinicalTrials.gov processed this data on January 31, 2020",2002-02-20,,,2008-02-04,2002-02-21,2002-02-22,Estimate,,,,,,,2008-02-04,2008-02-05,Estimate,,,,February 2008,2008-02-29,,,,,,,,Interventional,,,Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha,Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha,Unknown status,"Active, not recruiting",Phase 2,,,National Center for Research Resources (NCRR),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:45:20.829825,2020-02-01 22:45:20.829825,National Center for Research Resources (NCRR),NIH,Aricept,Drug
NCT00230568,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-29,,,2011-03-31,2005-09-29,2005-10-03,Estimate,,,,,,,2011-03-31,2011-04-01,Estimate,December 2005,,2005-12-31,March 2011,2011-03-31,December 2007,Actual,2007-12-31,April 2007,Actual,2007-04-30,,Interventional,,,EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD),"A 12-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 4,100.0,Actual,Eisai Inc.,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:43:45.475848,2020-02-01 21:43:45.475848,Eisai Inc.,Industry,Aricept,Drug
NCT00369603,"ClinicalTrials.gov processed this data on January 31, 2020",2006-08-28,,,2013-04-09,2006-08-28,2006-08-29,Estimate,,,,,,,2013-04-09,2013-04-11,Estimate,October 2006,,2006-10-31,June 2008,2008-06-30,November 2007,Actual,2007-11-30,October 2007,Actual,2007-10-31,,Interventional,,,Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients,Functional Neuroimaging (fMRI) Biomarker of Allosteric Nicotinic Receptor Modulation in Mild Alzheimer's Disease Patients: A Razadyne vs. Aricept Dose Escalation Trial,Terminated,,Phase 4,4.0,Actual,Duke University,,2.0,,Reduced access to AchEI medication-naive mild AD patients.,False,,,,True,,,,,,,,,,,,,2020-02-01 21:06:00.631738,2020-02-01 21:06:00.631738,Duke University,Other,Aricept,Drug
NCT01245530,"ClinicalTrials.gov processed this data on January 31, 2020",2010-11-01,,,2011-06-09,2010-11-18,2010-11-22,Estimate,,,,,,,2011-06-09,2011-06-13,Estimate,June 2008,,2008-06-30,June 2011,2011-06-30,March 2011,Actual,2011-03-31,February 2011,Actual,2011-02-28,,Interventional,,,An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia,"Probable Alzheimer Type Dementia Compare INM-176 1200~1600mg/Day With Donepezil 5~10mg/Day of Safety and Efficacy to Randomization, Multicenter, Double-blind, Double-dummy, Parallel Phase III Clinical Study",Completed,,Phase 3,280.0,Actual,Whanin Pharmaceutical Company,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:38:35.536182,2020-02-01 16:38:35.536182,Whanin Pharmaceutical Company,Industry,Aricept,Drug
NCT02968719,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-13,,,2018-07-31,2016-11-16,2016-11-21,Estimate,,,,,,,2018-07-31,2018-08-01,Actual,November 2016,Actual,2016-11-30,July 2018,2018-07-31,"July 11, 2017",Actual,2017-07-11,"July 11, 2017",Actual,2017-07-11,,Interventional,,,"A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®",Phase 1 Pharmacokinetic (PK) Study to Evaluate Once-weekly Corplex™ Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept® in Healthy Adult Subjects,Completed,,Phase 1,107.0,Actual,Corium International Inc.,,5.0,,,False,,,,False,,,,,,,,,,,No,No Plans,2020-02-01 09:43:14.203162,2020-02-01 09:43:14.203162,Corium International Inc.,Industry,Aricept,Drug
NCT03259958,"ClinicalTrials.gov processed this data on January 31, 2020",2017-08-21,,,2018-07-31,2017-08-23,2017-08-24,Actual,,,,,,,2018-07-31,2018-08-01,Actual,"October 30, 2017",Actual,2017-10-30,July 2018,2018-07-31,"March 14, 2018",Actual,2018-03-14,"March 13, 2018",Actual,2018-03-13,,Interventional,,,A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®,A Study to Assess the Steady-State Bioequivalence of Once-Weekly Corplex™ 10mg Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept®,Completed,,Phase 1,86.0,Actual,Corium International Inc.,,2.0,,,False,,,,False,True,False,,,,,,,,,No,No Plans,2020-02-01 08:51:15.666250,2020-02-01 08:51:15.666250,Corium International Inc.,Industry,Aricept,Drug
NCT03283059,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-12,,,2019-10-20,2017-09-12,2017-09-14,Actual,,,,,,,2019-10-20,2019-10-22,Actual,"August 16, 2017",Actual,2017-08-16,October 2019,2019-10-31,"February 16, 2021",Anticipated,2021-02-16,"September 16, 2020",Anticipated,2020-09-16,,Interventional,,,Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease,"Phase III Trial of Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease: a 26 Weeks, Randomized, Double-blind, Double-dummy, Placebo- and Positive- Parallel Controlled and Extended Single Arm to 54 Weeks Multicentre Study",Recruiting,,Phase 3,600.0,Anticipated,Shanghai Mental Health Center,,3.0,,,False,,,,,False,False,,,,,,,,,No,Other researchers should apply to the sponsor.,2020-02-01 08:46:31.811934,2020-02-01 08:46:31.811934,Shanghai Mental Health Center,Other,Aricept,Drug
NCT00478205,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-22,2012-11-12,2010-02-17,2014-06-26,2007-05-23,2007-05-24,Estimate,2013-01-02,2013-02-05,Estimate,2010-02-17,2010-04-27,Estimate,2014-06-26,2014-07-11,Estimate,June 2007,,2007-06-30,January 2013,2013-01-31,,,,June 2009,Actual,2009-06-30,,Interventional,,,Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease,"Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease",Completed,,Phase 3,1467.0,Actual,Eisai Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:31:01.160082,2020-02-01 20:31:01.160082,Eisai Inc.,Industry,Aricept (donepezil IR 10 mg),Drug
NCT00478205,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-22,2012-11-12,2010-02-17,2014-06-26,2007-05-23,2007-05-24,Estimate,2013-01-02,2013-02-05,Estimate,2010-02-17,2010-04-27,Estimate,2014-06-26,2014-07-11,Estimate,June 2007,,2007-06-30,January 2013,2013-01-31,,,,June 2009,Actual,2009-06-30,,Interventional,,,Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease,"Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease",Completed,,Phase 3,1467.0,Actual,Eisai Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:31:01.160082,2020-02-01 20:31:01.160082,Eisai Inc.,Industry,Aricept (donepezil SR 23 mg),Drug
NCT03197740,"ClinicalTrials.gov processed this data on January 31, 2020",2017-06-22,,,2019-02-18,2017-06-22,2017-06-23,Actual,,,,,,,2019-02-18,2019-02-20,Actual,"October 12, 2017",Actual,2017-10-12,February 2019,2019-02-28,"November 30, 2019",Anticipated,2019-11-30,"March 31, 2019",Anticipated,2019-03-31,,Interventional,,,"A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease","A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease",Recruiting,,Phase 3,346.0,Anticipated,Icure Pharmaceutical Inc.,,4.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 09:02:12.547717,2020-02-01 09:02:12.547717,Icure Pharmaceutical Inc.,Industry,aricept Tab,Drug
NCT03441516,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-05,,,2019-10-21,2018-02-20,2018-02-22,Actual,,,,,,,2019-10-21,2019-10-23,Actual,"April 19, 2018",Actual,2018-04-19,October 2019,2019-10-31,"May 31, 2020",Anticipated,2020-05-31,"July 4, 2019",Actual,2019-07-04,,Interventional,ALFO-AD,,Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia,"Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia: A Multi-center, Randomized, Open-label, Pilot Study","Active, not recruiting",,Phase 4,79.0,Actual,Yuhan Corporation,,2.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 08:19:46.005803,2020-02-01 08:19:46.005803,Yuhan Corporation,Industry,Aripezil® Tab.,Drug
NCT00036114,"ClinicalTrials.gov processed this data on January 31, 2020",2002-05-07,,,2013-11-07,2002-05-08,2002-05-09,Estimate,,,,,,,2013-11-07,2013-11-11,Estimate,March 2000,,2000-03-31,April 2011,2011-04-30,August 2003,Actual,2003-08-31,August 2003,Actual,2003-08-31,,Interventional,,,Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type,,Completed,,Phase 3,,,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:44:15.960709,2020-02-01 22:44:15.960709,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,aripiprazole,Drug
NCT00041678,"ClinicalTrials.gov processed this data on January 31, 2020",2002-07-12,,,2013-11-07,2002-07-12,2002-07-15,Estimate,,,,,,,2013-11-07,2013-11-11,Estimate,January 2000,,2000-01-31,September 2007,2007-09-30,March 2003,Actual,2003-03-31,March 2003,Actual,2003-03-31,,Interventional,,,Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type,,Completed,,Phase 3,,,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:43:23.025922,2020-02-01 22:43:23.025922,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,aripiprazole,Drug
NCT00095719,"ClinicalTrials.gov processed this data on January 31, 2020",2004-11-09,,,2013-11-07,2004-11-08,2004-11-09,Estimate,,,,,,,2013-11-07,2013-11-11,Estimate,December 2003,,2003-12-31,August 2008,2008-08-31,March 2005,Actual,2005-03-31,March 2005,Actual,2005-03-31,,Interventional,,,Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia,A Safety & Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia,Completed,,Phase 3,125.0,,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:19:47.546763,2020-02-01 22:19:47.546763,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,Aripiprazole,Drug
NCT00245206,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-25,,,2018-12-13,2005-10-25,2005-10-27,Estimate,,,,,,,2018-12-13,2018-12-17,Actual,August 2005,,2005-08-31,December 2018,2018-12-31,October 2010,Actual,2010-10-31,October 2010,Actual,2010-10-31,,Interventional,,,Side Effects of Newer Antipsychotics in Older Adults,Metabolic Effects of Newer Antipsychotics in Older Patients,Completed,,Phase 4,406.0,Actual,Veterans Medical Research Foundation,,3.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 21:39:57.227437,2020-02-01 21:39:57.227437,Veterans Medical Research Foundation,Other,Aripiprazole,Drug
NCT01438060,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-02,2012-02-01,,2013-11-07,2011-09-20,2011-09-21,Estimate,2012-02-01,2012-03-05,Estimate,,,,2013-11-07,2013-12-02,Estimate,August 2000,,2000-08-31,November 2013,2013-11-30,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type",Completed,,Phase 3,232.0,Actual,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Limitations of the study, such as early termination leading to small numbers of subjects analyzed and technical problems with measurement leading to unreliable or uninterpretable data",2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:46:23.659143,2020-02-01 15:46:23.659143,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,Aripiprazole (BMS-337039),Drug
NCT01406145,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-06,,,2019-01-28,2011-07-28,2011-08-01,Estimate,,,,,,,2019-01-28,2019-01-30,Actual,"June 16, 2011",Actual,2011-06-16,January 2019,2019-01-31,"November 4, 2011",Actual,2011-11-04,"November 4, 2011",Actual,2011-11-04,,Interventional,,,A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil,"A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Sequential Dose Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease on Donepezil",Completed,,Phase 1,60.0,Actual,Astellas Pharma Inc,,4.0,,,False,,,,False,,,,,,,,Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.,"Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.",https://www.clinicalstudydatarequest.com/,Yes,"Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.",2020-02-01 15:54:20.292494,2020-02-01 15:54:20.292494,Astellas Pharma Inc,Industry,ASP0777,Drug
NCT03117738,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-10,,,2019-12-30,2017-04-12,2017-04-18,Actual,,,,,,,2019-12-30,2020-01-02,Actual,"April 3, 2017",Actual,2017-04-03,December 2019,2019-12-31,"June 26, 2019",Actual,2019-06-26,"January 30, 2019",Actual,2019-01-30,,Interventional,,,A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease,"A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AstroStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Patients With Alzheimer's Disease",Completed,,Phase 1/Phase 2,21.0,Actual,Nature Cell Co. Ltd.,,2.0,,,False,,,,False,True,False,,,,,,,,,Undecided,,2020-02-01 09:16:10.503546,2020-02-01 09:16:10.503546,Nature Cell Co. Ltd.,Industry,AstroStem,Drug
NCT02569398,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-05,,,2019-01-18,2015-10-05,2015-10-06,Estimate,,,,,,,2019-01-18,2019-01-22,Actual,"October 29, 2015",Actual,2015-10-29,January 2019,2019-01-31,"December 20, 2018",Actual,2018-12-20,"December 20, 2018",Actual,2018-12-20,,Interventional,EARLY,,An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia,"A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic At Risk for Developing Alzheimer's Dementia",Completed,,Phase 2/Phase 3,596.0,Actual,"Janssen Research & Development, LLC",,3.0,,,False,,,,True,,False,,,,,,,,,,,2020-02-01 11:05:32.593875,2020-02-01 11:05:32.593875,"Janssen Research & Development, LLC",Industry,"Atabecestat, 25 mg",Drug
NCT02569398,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-05,,,2019-01-18,2015-10-05,2015-10-06,Estimate,,,,,,,2019-01-18,2019-01-22,Actual,"October 29, 2015",Actual,2015-10-29,January 2019,2019-01-31,"December 20, 2018",Actual,2018-12-20,"December 20, 2018",Actual,2018-12-20,,Interventional,EARLY,,An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia,"A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic At Risk for Developing Alzheimer's Dementia",Completed,,Phase 2/Phase 3,596.0,Actual,"Janssen Research & Development, LLC",,3.0,,,False,,,,True,,False,,,,,,,,,,,2020-02-01 11:05:32.593875,2020-02-01 11:05:32.593875,"Janssen Research & Development, LLC",Industry,"Atabecestat, 5 mg",Drug
NCT00191009,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-12,,,2007-11-05,2005-09-12,2005-09-19,Estimate,,,,,,,2007-11-05,2007-11-06,Estimate,October 2003,,2003-10-31,November 2007,2007-11-30,January 2006,Actual,2006-01-31,,,,,Interventional,,,Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease,Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer's Disease,Completed,,Phase 2/Phase 3,124.0,,Eli Lilly and Company,,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:51:38.399108,2020-02-01 21:51:38.399108,Eli Lilly and Company,Industry,atomoxetine hydrochloride,Drug
NCT00151502,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-06,,,2008-07-09,2005-09-08,2005-09-09,Estimate,,,,,,,2008-07-09,2008-07-11,Estimate,November 2002,,2002-11-30,July 2008,2008-07-31,July 2007,Actual,2007-07-31,,,,,Interventional,,,To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.,"An 80-Week, Randomized, Multi-Center, Parallel-Group, Double-Blind Study of the Efficacy and Safety of Atorvastatin 80 MG Plus an Acetylcholinesterase Inhibitor Versus an Acetylcholinesterase Inhibitor Alone in the Treatment of Mild to Moderate Alzheimer's Disease.",Completed,,Phase 3,600.0,,Pfizer,,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:02:19.998679,2020-02-01 22:02:19.998679,Pfizer,Industry,Atorvastatin,Drug
NCT00024531,"ClinicalTrials.gov processed this data on January 31, 2020",2001-09-19,,,2006-11-08,2001-09-19,2001-09-20,Estimate,,,,,,,2006-11-08,2006-11-09,Estimate,October 2000,,2000-10-31,November 2006,2006-11-30,August 2004,,2004-08-31,,,,,Interventional,,,Lipitor as a Treatment for Alzheimer's Disease,"Effect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium, Lipitor, in the Treatment of Alzheimer's Disease",Completed,,Phase 2,98.0,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:45:57.351716,2020-02-01 22:45:57.351716,Institute for the Study of Aging (ISOA),Other,Atorvastatin calcium,Drug
NCT00890890,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-29,,2015-09-23,2015-09-23,2009-04-29,2009-04-30,Estimate,,,,2015-09-23,2015-10-12,Estimate,2015-09-23,2015-10-12,Estimate,May 2009,,2009-05-31,September 2015,2015-09-30,July 2013,Actual,2013-07-31,July 2013,Actual,2013-07-31,,Interventional,,,"A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease","Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Prodromal Alzheimer's Disease",Terminated,,Phase 2,263.0,Actual,Bristol-Myers Squibb,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:27:25.082950,2020-02-01 18:27:25.082950,Bristol-Myers Squibb,Industry,Avagacestat,Drug
NCT00380302,"ClinicalTrials.gov processed this data on January 31, 2020",2006-09-22,,,2008-12-18,2006-09-22,2006-09-25,Estimate,,,,,,,2008-12-18,2008-12-19,Estimate,September 2006,,2006-09-30,December 2008,2008-12-31,July 2007,Actual,2007-07-31,July 2007,Actual,2007-07-31,,Interventional,,,Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.,A Double-Blind Placebo-Controlled Study of the Activity of AVE1625 at Doses of 10 mg and 40mg for 12 Weeks in Patients With Mild to Moderate Alzheimer's Disease,Completed,,Phase 1/Phase 2,162.0,Actual,Sanofi,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:02:35.890796,2020-02-01 21:02:35.890796,Sanofi,Industry,AVE1625,Drug
NCT02442765,"ClinicalTrials.gov processed this data on January 31, 2020",2015-05-11,,,2019-03-04,2015-05-11,2015-05-13,Estimate,,,,,,,2019-03-04,2019-03-06,Actual,September 2015,,2015-09-30,March 2019,2019-03-31,"February 27, 2019",Actual,2019-02-27,"January 30, 2019",Actual,2019-01-30,,Interventional,,,"Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Completed,,Phase 3,410.0,Actual,Avanir Pharmaceuticals,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:35:00.526050,2020-02-01 11:35:00.526050,Avanir Pharmaceuticals,Industry,AVP-786,Drug
NCT02442778,"ClinicalTrials.gov processed this data on January 31, 2020",2015-05-11,,,2019-10-13,2015-05-11,2015-05-13,Estimate,,,,,,,2019-10-13,2019-10-15,Actual,September 2015,,2015-09-30,October 2019,2019-10-31,"September 9, 2019",Actual,2019-09-09,"August 14, 2019",Actual,2019-08-14,,Interventional,,,"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.",Completed,,Phase 3,522.0,Actual,Avanir Pharmaceuticals,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:34:59.205605,2020-02-01 11:34:59.205605,Avanir Pharmaceuticals,Industry,AVP-786,Drug
NCT02446132,"ClinicalTrials.gov processed this data on January 31, 2020",2015-05-11,,,2020-01-24,2015-05-14,2015-05-18,Estimate,,,,,,,2020-01-24,2020-01-27,Actual,December 2015,,2015-12-31,January 2020,2020-01-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,,Interventional,,,"Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Recruiting,,Phase 3,1000.0,Anticipated,Avanir Pharmaceuticals,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:34:14.339484,2020-02-01 11:34:14.339484,Avanir Pharmaceuticals,Industry,AVP-786,Drug
NCT03393520,"ClinicalTrials.gov processed this data on January 31, 2020",2018-01-03,,,2020-01-24,2018-01-03,2018-01-08,Actual,,,,,,,2020-01-24,2020-01-27,Actual,"October 13, 2017",Actual,2017-10-13,January 2020,2020-01-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,,Interventional,,,"Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Recruiting,,Phase 3,412.0,Anticipated,Avanir Pharmaceuticals,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:27:50.083519,2020-02-01 08:27:50.083519,Avanir Pharmaceuticals,Industry,AVP-786,Drug
NCT00056524,"ClinicalTrials.gov processed this data on January 31, 2020",2003-03-15,,,2016-07-13,2003-03-17,2003-03-18,Estimate,,,,,,,2016-07-13,2016-07-14,Estimate,February 2003,,2003-02-28,July 2016,2016-07-31,June 2007,Actual,2007-06-30,June 2007,Actual,2007-06-30,,Interventional,,,Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter),An Open-Label Multicenter Study to Assess the Safety of AVP-923 in the Treatment of Patients With Pseudobulbar Affect.,Completed,,Phase 3,600.0,Anticipated,Avanir Pharmaceuticals,,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:34:54.393264,2020-02-01 22:34:54.393264,Avanir Pharmaceuticals,Industry,AVP-923,Drug
NCT01584440,"ClinicalTrials.gov processed this data on January 31, 2020",2012-04-23,,2018-01-08,2018-01-08,2012-04-24,2012-04-25,Estimate,,,,2018-01-08,2018-01-11,Actual,2018-01-08,2018-01-11,Actual,June 2012,,2012-06-30,January 2018,2018-01-31,September 2014,Actual,2014-09-30,July 2014,Actual,2014-07-31,,Interventional,,,"Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients","A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.",Completed,,Phase 2,220.0,Actual,Avanir Pharmaceuticals,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:08:45.066700,2020-02-01 15:08:45.066700,Avanir Pharmaceuticals,Industry,AVP-923 (dextromethorphan/quinidine),Drug
NCT03226522,"ClinicalTrials.gov processed this data on January 31, 2020",2017-07-20,,,2020-01-11,2017-07-20,2017-07-21,Actual,,,,,,,2020-01-11,2020-01-14,Actual,"July 13, 2017",Actual,2017-07-13,January 2020,2020-01-31,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,,Interventional,ADVANCE,,Addressing Dementia Via Agitation-Centered Evaluation,"A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type",Recruiting,,Phase 2/Phase 3,435.0,Anticipated,"Axsome Therapeutics, Inc.",,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 08:57:30.107770,2020-02-01 08:57:30.107770,"Axsome Therapeutics, Inc.",Industry,AXS-05,Drug
NCT02167256,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-12,2019-06-19,,2019-07-25,2014-06-16,2014-06-19,Estimate,2019-07-25,2019-08-14,Actual,,,,2019-07-25,2019-08-14,Actual,December 2014,Actual,2014-12-31,July 2019,2019-07-31,"February 27, 2018",Actual,2018-02-27,"February 27, 2018",Actual,2018-02-27,,Interventional,,,"A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease","A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease",Completed,,Phase 2,159.0,Actual,Yale University,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:40.784913,2020-02-01 12:37:40.784913,Yale University,Other,AZD0530 100mg daily,Drug
NCT02167256,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-12,2019-06-19,,2019-07-25,2014-06-16,2014-06-19,Estimate,2019-07-25,2019-08-14,Actual,,,,2019-07-25,2019-08-14,Actual,December 2014,Actual,2014-12-31,July 2019,2019-07-31,"February 27, 2018",Actual,2018-02-27,"February 27, 2018",Actual,2018-02-27,,Interventional,,,"A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease","A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease",Completed,,Phase 2,159.0,Actual,Yale University,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:40.784913,2020-02-01 12:37:40.784913,Yale University,Other,AZD0530 125mg daily,Drug
NCT01039701,"ClinicalTrials.gov processed this data on January 31, 2020",2009-12-20,,,2010-08-10,2009-12-24,2009-12-25,Estimate,,,,,,,2010-08-10,2010-08-11,Estimate,December 2009,,2009-12-31,August 2010,2010-08-31,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,ROBIN,,"4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease","Safety, Tolerability and Pharmacokinetics of 3 Dose Regimens of AZD1446 vs. Placebo as an Add-on Treatment to Donepezil: A Multi-centre, Double-blind, Randomised, Placebo Controlled, Parallel Group Phase IIa Study in Patients With Mild to Moderate Alzheimer's Disease During 4 Weeks of Treatment",Completed,,Phase 2,99.0,Actual,AstraZeneca,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:39:10.889364,2020-02-01 17:39:10.889364,AstraZeneca,Industry,AZD1446,Drug
NCT00501111,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-12,,,2014-07-22,2007-07-12,2007-07-13,Estimate,,,,,,,2014-07-22,2014-07-23,Estimate,July 2007,,2007-07-31,July 2014,2014-07-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,Sirocco,,Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease,"A Multi-centre, Double-blind, Double-dummy, Placebo Controlled Parallel Group Randomized Phase IIb Proof of Concept Study With 3 Oral Dose Groups of AZD3480 or Donepezil During 12 Weeks Treatment in Patients With Alzheimer's Disease",Completed,,Phase 2,659.0,Actual,AstraZeneca,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:24:11.554357,2020-02-01 20:24:11.554357,AstraZeneca,Industry,AZD3480,Drug
NCT01466088,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-02,,2015-05-11,2015-05-11,2011-11-04,2011-11-06,Estimate,,,,2015-05-11,2015-06-03,Estimate,2015-05-11,2015-06-03,Estimate,October 2011,,2011-10-31,July 2014,2014-07-31,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,"Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)","Double-Blind, Positive Comparator, Randomized, Parallel Study of Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients With Mild to Moderate Dementia of the Alzheimer's Type",Completed,,Phase 2,386.0,Actual,Targacept Inc.,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:38:14.385865,2020-02-01 15:38:14.385865,Targacept Inc.,Industry,AZD3480,Drug
NCT01548287,"ClinicalTrials.gov processed this data on January 31, 2020",2012-03-05,2015-01-26,,2016-12-14,2012-03-05,2012-03-08,Estimate,2016-10-12,2016-12-05,Estimate,,,,2016-12-14,2017-02-07,Estimate,April 2012,,2012-04-30,December 2016,2016-12-31,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,,A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment,"A Phase IIa Safety and Tolerability Study to Investigate the Effect on Sleep of 3 Doses of AZD5213 and Placebo in Patients With Mild Alzheimer's Disease and Mild Cognitive Impairment During 4 Weeks of Treatment, Placebo-Controlled",Completed,,Phase 2,164.0,Actual,AstraZeneca,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:17:18.548184,2020-02-01 15:17:18.548184,AstraZeneca,Industry,AZD5213,Drug
NCT02080364,"ClinicalTrials.gov processed this data on January 31, 2020",2014-02-25,,2019-05-08,2019-05-13,2014-03-04,2014-03-06,Estimate,,,,2019-05-13,2019-05-17,Actual,2019-05-13,2019-05-17,Actual,April 2015,Actual,2015-04-30,May 2019,2019-05-31,"June 1, 2018",Actual,2018-06-01,"June 1, 2018",Actual,2018-06-01,,Interventional,STEADFAST,,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,"Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine",Terminated,,Phase 3,880.0,Actual,vTv Therapeutics,,2.0,,Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.,False,,,,True,True,False,,,,,,,,,,,2020-02-01 12:58:28.399182,2020-02-01 12:58:28.399182,vTv Therapeutics,Industry,Azeliragon,Drug
NCT03980730,"ClinicalTrials.gov processed this data on January 31, 2020",2019-05-31,,,2020-01-13,2019-06-06,2019-06-10,Actual,,,,,,,2020-01-13,2020-01-14,Actual,"June 27, 2019",Actual,2019-06-27,January 2020,2020-01-31,July 2023,Anticipated,2023-07-31,April 2023,Anticipated,2023-04-30,,Interventional,Elevage,,Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance,"Randomized, Double-blind, Placebo-controlled, Multicenter Studies to Evaluate the Safety and Efficacy of Azeliragon as a Treatment for Subjects With Mild Alzheimer's Disease and Impaired Glucose Tolerance",Recruiting,,Phase 2/Phase 3,300.0,Anticipated,vTv Therapeutics,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 06:57:16.531793,2020-02-01 06:57:16.531793,vTv Therapeutics,Industry,Azeliragon,Drug
NCT02916056,"ClinicalTrials.gov processed this data on January 31, 2020",2016-08-10,,2019-05-08,2019-05-13,2016-09-22,2016-09-27,Estimate,,,,2019-05-13,2019-05-17,Actual,2019-05-13,2019-05-17,Actual,December 2016,Actual,2016-12-31,May 2019,2019-05-31,"June 1, 2018",Actual,2018-06-01,"June 1, 2018",Actual,2018-06-01,,Interventional,,,2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension),Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease,Terminated,,Phase 3,298.0,Actual,vTv Therapeutics,,1.0,,Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.,False,,,,True,True,False,,,,,,,,,,,2020-02-01 09:54:55.632698,2020-02-01 09:54:55.632698,vTv Therapeutics,Industry,Azeliragon 5mg,Drug
NCT02467413,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-04,,,2019-07-29,2015-06-05,2015-06-10,Estimate,,,,,,,2019-07-29,2019-07-31,Actual,"December 1, 2019",Anticipated,2019-12-01,July 2019,2019-07-31,December 2021,Anticipated,2021-12-31,June 2021,Anticipated,2021-06-30,,Interventional,,,BAC in Patient With Alzheimer's Disease or Vascular Dementia,"A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia",Withdrawn,,Phase 2,0.0,Actual,Charsire Biotechnology Corp.,,2.0,,At sponsor's decision,False,,,,False,True,False,,,,,,,,,,,2020-02-01 11:28:58.960261,2020-02-01 11:28:58.960261,Charsire Biotechnology Corp.,Industry,BAC,Drug
NCT02886494,"ClinicalTrials.gov processed this data on January 31, 2020",2016-08-29,,,2019-07-29,2016-08-31,2016-09-01,Estimate,,,,,,,2019-07-29,2019-07-30,Actual,December 2016,Actual,2016-12-31,July 2019,2019-07-31,"November 1, 2018",Actual,2018-11-01,"November 1, 2018",Actual,2018-11-01,,Interventional,,,A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia,"A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia",Completed,,Phase 2,80.0,Actual,Charsire Biotechnology Corp.,,2.0,,,False,,,,False,,False,,,,,,,,,Undecided,,2020-02-01 10:02:06.140425,2020-02-01 10:02:06.140425,Charsire Biotechnology Corp.,Industry,BAC,Drug
NCT03887455,"ClinicalTrials.gov processed this data on January 31, 2020",2019-03-21,,,2019-07-10,2019-03-21,2019-03-25,Actual,,,,,,,2019-07-10,2019-07-12,Actual,"March 27, 2019",Actual,2019-03-27,March 2019,2019-03-31,"March 7, 2024",Anticipated,2024-03-07,"February 24, 2022",Anticipated,2022-02-24,,Interventional,Clarity AD,,A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease,"A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",Recruiting,,Phase 3,1566.0,Anticipated,Eisai Inc.,,3.0,,,False,,,,True,True,False,,,False,,,,,,Yes,Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.,2020-02-01 07:11:13.548680,2020-02-01 07:11:13.548680,Eisai Inc.,Industry,BAN2401,Drug
NCT01767311,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-08,,,2019-12-02,2013-01-10,2013-01-14,Estimate,,,,,,,2019-12-02,2019-12-03,Actual,"December 20, 2012",Actual,2012-12-20,July 2018,2018-07-31,"January 27, 2022",Anticipated,2022-01-27,"January 27, 2022",Anticipated,2022-01-27,,Interventional,,,"A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease","A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 2,800.0,Actual,Eisai Inc.,,7.0,,,False,,,,True,True,,,,,,,,,,,,2020-02-01 14:20:49.513489,2020-02-01 14:20:49.513489,Eisai Inc.,Industry,BAN2401 10 mg/kg,Drug
NCT02094729,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-09,,,2015-06-04,2014-03-19,2014-03-24,Estimate,,,,,,,2015-06-04,2015-06-08,Estimate,September 2013,,2013-09-30,June 2015,2015-06-30,May 2015,Actual,2015-05-31,March 2015,Actual,2015-03-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease","A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease",Completed,,Phase 1,26.0,Actual,Eisai Inc.,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 12:55:16.323716,2020-02-01 12:55:16.323716,"Eisai Co., Ltd.",Industry,BAN2401 10 mg/kg,Drug
NCT01767311,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-08,,,2019-12-02,2013-01-10,2013-01-14,Estimate,,,,,,,2019-12-02,2019-12-03,Actual,"December 20, 2012",Actual,2012-12-20,July 2018,2018-07-31,"January 27, 2022",Anticipated,2022-01-27,"January 27, 2022",Anticipated,2022-01-27,,Interventional,,,"A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease","A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 2,800.0,Actual,Eisai Inc.,,7.0,,,False,,,,True,True,,,,,,,,,,,,2020-02-01 14:20:49.513489,2020-02-01 14:20:49.513489,Eisai Inc.,Industry,BAN2401 2.5 mg/kg,Drug
NCT02094729,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-09,,,2015-06-04,2014-03-19,2014-03-24,Estimate,,,,,,,2015-06-04,2015-06-08,Estimate,September 2013,,2013-09-30,June 2015,2015-06-30,May 2015,Actual,2015-05-31,March 2015,Actual,2015-03-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease","A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease",Completed,,Phase 1,26.0,Actual,Eisai Inc.,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 12:55:16.323716,2020-02-01 12:55:16.323716,"Eisai Co., Ltd.",Industry,BAN2401 2.5 mg/kg,Drug
NCT01767311,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-08,,,2019-12-02,2013-01-10,2013-01-14,Estimate,,,,,,,2019-12-02,2019-12-03,Actual,"December 20, 2012",Actual,2012-12-20,July 2018,2018-07-31,"January 27, 2022",Anticipated,2022-01-27,"January 27, 2022",Anticipated,2022-01-27,,Interventional,,,"A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease","A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 2,800.0,Actual,Eisai Inc.,,7.0,,,False,,,,True,True,,,,,,,,,,,,2020-02-01 14:20:49.513489,2020-02-01 14:20:49.513489,Eisai Inc.,Industry,BAN2401 5.0 mg/kg,Drug
NCT02094729,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-09,,,2015-06-04,2014-03-19,2014-03-24,Estimate,,,,,,,2015-06-04,2015-06-08,Estimate,September 2013,,2013-09-30,June 2015,2015-06-30,May 2015,Actual,2015-05-31,March 2015,Actual,2015-03-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease","A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease",Completed,,Phase 1,26.0,Actual,Eisai Inc.,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 12:55:16.323716,2020-02-01 12:55:16.323716,"Eisai Co., Ltd.",Industry,BAN2401 5 mg/kg,Drug
NCT00112073,"ClinicalTrials.gov processed this data on January 31, 2020",2005-05-27,,2012-03-12,2012-03-12,2005-05-27,2005-05-30,Estimate,,,,2012-03-12,2012-03-14,Estimate,2012-03-12,2012-03-14,Estimate,April 2005,,2005-04-30,March 2012,2012-03-31,December 2008,Actual,2008-12-31,November 2008,Actual,2008-11-30,,Interventional,,,AAB-001 in Patients With Mild to Moderate Alzheimer's Disease,"A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD",Completed,,Phase 2,234.0,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,8.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:14:07.780680,2020-02-01 22:14:07.780680,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,bapineuzumab,Drug
NCT00397891,"ClinicalTrials.gov processed this data on January 31, 2020",2006-11-08,2014-08-20,,2014-08-20,2006-11-09,2006-11-10,Estimate,2014-08-20,2014-09-04,Estimate,,,,2014-08-20,2014-09-04,Estimate,October 2006,,2006-10-31,August 2014,2014-08-31,February 2010,Actual,2010-02-28,February 2010,Actual,2010-02-28,,Interventional,,Safety data set included all randomized participants who received at least 1 dose of study medication.,Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, and Pharmakokinetic Study of Single Ascending Doses of AAB-001 in Japanese Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,80.0,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:57:04.432654,2020-02-01 20:57:04.432654,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,bapineuzumab,Drug
NCT00663026,"ClinicalTrials.gov processed this data on January 31, 2020",2008-04-17,2013-09-11,2012-03-27,2013-09-11,2008-04-19,2008-04-21,Estimate,2013-09-11,2013-11-15,Estimate,2012-03-27,2012-03-30,Estimate,2013-09-11,2013-11-15,Estimate,November 2008,,2008-11-30,September 2013,2013-09-30,October 2010,Actual,2010-10-31,October 2010,Actual,2010-10-31,,Interventional,,,Study Evaluating Bapineuzumab In Alzheimer Disease Subjects,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Safety, Tolerability, Reactogenicity, And Pharmacokinetic Study Of Bapineuzumab (AAB 001) Administered Subcutaneously In Subjects With Mild To Moderate AD",Completed,,Phase 2,79.0,Actual,Pfizer,"Designation of outcomes as primary, secondary was based on study team’s input as study did not specify them as primary or secondary.",3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:34:44.032122,2020-02-01 19:34:44.032122,Pfizer,Industry,bapineuzumab,Drug
NCT00667810,"ClinicalTrials.gov processed this data on January 31, 2020",2008-04-24,2013-10-22,,2015-12-04,2008-04-25,2008-04-28,Estimate,2015-12-04,2016-01-08,Estimate,,,,2015-12-04,2016-01-08,Estimate,June 2008,,2008-06-30,December 2015,2015-12-31,August 2013,Actual,2013-08-31,October 2012,Actual,2012-10-31,,Interventional,,Safety population included all randomized participants who received at least one infusion or portion of an infusion of study drug.,Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers",Terminated,,Phase 3,901.0,Actual,Pfizer,"The impact of study termination, the shorter observational periods and the resulting small sample size coupled with not having enough participants with post baseline assessments for various reasons were limiting factors for data interpretation.",3.0,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 19:33:15.927565,2020-02-01 19:33:15.927565,Pfizer,Industry,bapineuzumab,Drug
NCT00676143,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-02,2013-10-14,,2016-05-03,2008-05-09,2008-05-12,Estimate,2016-05-03,2016-06-10,Estimate,,,,2016-05-03,2016-06-10,Estimate,January 2008,,2008-01-31,May 2016,2016-05-31,November 2012,Actual,2012-11-30,October 2012,Actual,2012-10-31,,Interventional,,Safety population included all randomized participants who received at least one infusion or portion of an infusion of study drug.,Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients,"A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers",Terminated,,Phase 3,1100.0,Actual,Pfizer,,2.0,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 19:31:07.517307,2020-02-01 19:31:07.517307,Pfizer,Industry,bapineuzumab,Drug
NCT00916617,"ClinicalTrials.gov processed this data on January 31, 2020",2009-06-04,2013-09-25,,2017-04-27,2009-06-05,2009-06-09,Estimate,2017-04-27,2017-06-01,Actual,,,,2017-04-27,2017-06-01,Actual,June 2009,,2009-06-30,April 2017,2017-04-30,September 2012,Actual,2012-09-30,September 2012,Actual,2012-09-30,,Interventional,,All participants who received at least 1 dose of study medication in study NCT00916617 were included in the safety population.,Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab,"A Multicenter, Open Label, Multiple Dose, Parallel Group Investigation Of The Long-term Safety, Tolerability, Reactogenicity, Pharmacokinetics And Pharmacodynamics Of Aab-001 Administered Subcutaneously In Subjects With Mild To Moderate Alzheimer's Disease",Terminated,,Phase 2,62.0,Actual,Pfizer,,1.0,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 18:19:54.860155,2020-02-01 18:19:54.860155,Pfizer,Industry,bapineuzumab,Drug
NCT00937352,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-07,,2013-10-30,2013-11-26,2009-07-09,2009-07-13,Estimate,,,,2013-10-30,2013-11-25,Estimate,2013-11-26,2013-12-20,Estimate,July 2009,,2009-07-31,November 2013,2013-11-30,September 2012,Actual,2012-09-30,September 2012,Actual,2012-09-30,,Interventional,,,A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease,"A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who Participated in Study ELN115727-301 or Study ELN115727-302.",Terminated,,Phase 3,896.0,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:13:59.478829,2020-02-01 18:13:59.478829,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Bapineuzumab,Drug
NCT00574132,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-10,,2013-09-27,2013-10-30,2007-12-13,2007-12-17,Estimate,,,,2013-09-27,2013-10-28,Estimate,2013-10-30,2013-11-25,Estimate,December 2007,,2007-12-31,October 2013,2013-10-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,,,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers.",Completed,,Phase 3,1331.0,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:00:25.535905,2020-02-01 20:00:25.535905,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Bapineuzumab 0.5 mg/kg,Drug
NCT00575055,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-10,,2013-09-27,2013-10-30,2007-12-13,2007-12-17,Estimate,,,,2013-09-27,2013-10-28,Estimate,2013-10-30,2013-11-25,Estimate,December 2007,,2007-12-31,October 2013,2013-10-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,,,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.",Completed,,Phase 3,1121.0,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:00:04.969013,2020-02-01 20:00:04.969013,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Bapineuzumab 0.5 mg/kg,Drug
NCT00996918,"ClinicalTrials.gov processed this data on January 31, 2020",2009-10-14,2013-11-12,,2013-11-12,2009-10-15,2009-10-16,Estimate,2013-11-12,2014-01-01,Estimate,,,,2013-11-12,2014-01-01,Estimate,December 2009,,2009-12-31,November 2013,2013-11-30,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,,A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients,"A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety And Tolerability Trial Of Bapineuzumab (AAB-001, ELN115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Noncarriers And Participated In Study 3133K1-3000",Terminated,,Phase 3,198.0,Actual,Pfizer,Bapineuzumab program was discontinued prematurely. Efficacy results obtained after Week 78 are not presented due to the very small number of participants after this time point.,2.0,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 17:51:41.515235,2020-02-01 17:51:41.515235,Pfizer,Industry,Bapineuzumab 0.5 mg/kg,Drug
NCT00998764,"ClinicalTrials.gov processed this data on January 31, 2020",2009-10-16,2013-10-15,,2015-11-30,2009-10-19,2009-10-20,Estimate,2015-11-30,2016-01-01,Estimate,,,,2015-11-30,2016-01-01,Estimate,December 2009,,2009-12-31,November 2015,2015-11-30,November 2012,Actual,2012-11-30,October 2012,Actual,2012-10-31,,Interventional,,The safety population included all participants who consented to participate in the extension and received at least one dose of the investigational product (in the extension study).,A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients,"A Phase 3 Extension, Multicenter, Long Term Safety And Tolerability Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E 4 Carriers And Participated In Study 3133k1-3001-us Or Study 3133k1-3001-ww.",Terminated,,Phase 3,494.0,Actual,Pfizer,,1.0,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 17:51:11.879511,2020-02-01 17:51:11.879511,Pfizer,Industry,Bapineuzumab 0.5 mg/kg,Drug
NCT00574132,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-10,,2013-09-27,2013-10-30,2007-12-13,2007-12-17,Estimate,,,,2013-09-27,2013-10-28,Estimate,2013-10-30,2013-11-25,Estimate,December 2007,,2007-12-31,October 2013,2013-10-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,,,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers.",Completed,,Phase 3,1331.0,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:00:25.535905,2020-02-01 20:00:25.535905,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Bapineuzumab 1.0 m/kg,Drug
NCT00575055,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-10,,2013-09-27,2013-10-30,2007-12-13,2007-12-17,Estimate,,,,2013-09-27,2013-10-28,Estimate,2013-10-30,2013-11-25,Estimate,December 2007,,2007-12-31,October 2013,2013-10-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,,,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.",Completed,,Phase 3,1121.0,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:00:04.969013,2020-02-01 20:00:04.969013,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Bapineuzumab 1.0 m/kg,Drug
NCT00996918,"ClinicalTrials.gov processed this data on January 31, 2020",2009-10-14,2013-11-12,,2013-11-12,2009-10-15,2009-10-16,Estimate,2013-11-12,2014-01-01,Estimate,,,,2013-11-12,2014-01-01,Estimate,December 2009,,2009-12-31,November 2013,2013-11-30,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,,A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients,"A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety And Tolerability Trial Of Bapineuzumab (AAB-001, ELN115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Noncarriers And Participated In Study 3133K1-3000",Terminated,,Phase 3,198.0,Actual,Pfizer,Bapineuzumab program was discontinued prematurely. Efficacy results obtained after Week 78 are not presented due to the very small number of participants after this time point.,2.0,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 17:51:41.515235,2020-02-01 17:51:41.515235,Pfizer,Industry,Bapineuzumab 1.0 m/kg,Drug
NCT02292238,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-10,,,2019-02-27,2014-11-14,2014-11-17,Estimate,,,,,,,2019-02-27,2019-02-28,Actual,November 2014,,2014-11-30,February 2019,2019-02-28,November 2019,Anticipated,2019-11-30,November 2019,Anticipated,2019-11-30,,Interventional,Benfotiamine,,Benfotiamine in Alzheimer's Disease: A Pilot Study,Benfotiamine in Alzheimer's Disease: A Pilot Study,"Active, not recruiting",,Phase 2,76.0,Anticipated,Burke Medical Research Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:08:28.303175,2020-02-01 12:08:28.303175,Burke Medical Research Institute,Other,Benfotiamine,Drug
NCT03959124,"ClinicalTrials.gov processed this data on January 31, 2020",2019-02-21,,,2019-05-20,2019-05-20,2019-05-22,Actual,,,,,,,2019-05-20,2019-05-22,Actual,"July 15, 2019",Anticipated,2019-07-15,May 2019,2019-05-31,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2020",Anticipated,2020-09-30,,Interventional,,,Deep Brain Stimulation for Alzheimer's Disease,The Effect of Deep Brain Stimulation on Memory Network and Neurological Function of Alzheimer's Disease,Recruiting,,N/A,30.0,Anticipated,Buddhist Tzu Chi General Hospital,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2020-02-01 07:00:29.392030,2020-02-01 07:00:29.392030,Buddhist Tzu Chi General Hospital,Other,Best medical treatment for Alzheimer's disease,Drug
NCT01782742,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-29,2016-02-10,,2016-02-10,2013-02-01,2013-02-04,Estimate,2016-02-10,2016-02-12,Estimate,,,,2016-02-10,2016-02-12,Estimate,February 2013,,2013-02-28,February 2016,2016-02-29,December 2014,Actual,2014-12-31,August 2014,Actual,2014-08-31,,Interventional,BEAT-AD,,Bexarotene Amyloid Treatment for Alzheimer's Disease,A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and Safety of Bexarotene in Patients With Mild to Moderate Alzheimer's Disease,Completed,,Phase 2,20.0,Actual,The Cleveland Clinic,Sample size of this trial is small. There was 1 participant withdrawal due to adverse event. Primary outcome measures were completed by all 20 participants as anticipated.,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:16:32.938142,2020-02-01 14:16:32.938142,The Cleveland Clinic,Other,Bexarotene,Drug
NCT02240693,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-15,2018-09-11,,2018-10-31,2014-09-15,2014-09-16,Estimate,2018-10-31,2018-11-28,Actual,,,,2018-10-31,2018-11-28,Actual,"January 15, 2015",Actual,2015-01-15,October 2018,2018-10-31,"October 9, 2017",Actual,2017-10-09,"September 18, 2017",Actual,2017-09-18,,Interventional,,"Treated set:
The treated set (TS) included all patients who were randomised and treated with at least one dose of trial medication.",Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo,"A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease",Completed,,Phase 2,128.0,Actual,Boehringer Ingelheim,,5.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:20:03.237659,2020-02-01 12:20:03.237659,Boehringer Ingelheim,Industry,BI 409306,Drug
NCT02337907,"ClinicalTrials.gov processed this data on January 31, 2020",2014-12-23,2018-08-29,,2018-10-18,2015-01-09,2015-01-14,Estimate,2018-10-18,2018-11-14,Actual,,,,2018-10-18,2018-11-14,Actual,"January 21, 2015",Actual,2015-01-21,October 2018,2018-10-31,"October 10, 2017",Actual,2017-10-10,"September 15, 2017",Actual,2017-09-15,,Interventional,,Treated Set (TS) included all patients who were randomised and treated with at least one dose of trial medication.,BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,"A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease",Completed,,Phase 2,329.0,Actual,Boehringer Ingelheim,"There were 5 patients who were randomised to donepezil arm which was dropped from the trial with protocol amendment. No further patients were randomised to this arm, but patients already randomised continued in the trial as originally planned.",6.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 11:58:09.189083,2020-02-01 11:58:09.189083,Boehringer Ingelheim,Industry,BI 409306,Drug
NCT02392468,"ClinicalTrials.gov processed this data on January 31, 2020",2015-03-17,,,2017-12-18,2015-03-17,2015-03-19,Estimate,,,,,,,2017-12-18,2017-12-20,Actual,"April 15, 2015",Actual,2015-04-15,December 2017,2017-12-31,"August 10, 2017",Actual,2017-08-10,"August 10, 2017",Actual,2017-08-10,,Interventional,,,"Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers","Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers",Completed,,Phase 1,61.0,Actual,Boehringer Ingelheim,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 11:46:06.616666,2020-02-01 11:46:06.616666,Boehringer Ingelheim,Industry,BI 409306,Drug
NCT02392468,"ClinicalTrials.gov processed this data on January 31, 2020",2015-03-17,,,2017-12-18,2015-03-17,2015-03-19,Estimate,,,,,,,2017-12-18,2017-12-20,Actual,"April 15, 2015",Actual,2015-04-15,December 2017,2017-12-31,"August 10, 2017",Actual,2017-08-10,"August 10, 2017",Actual,2017-08-10,,Interventional,,,"Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers","Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers",Completed,,Phase 1,61.0,Actual,Boehringer Ingelheim,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 11:46:06.616666,2020-02-01 11:46:06.616666,Boehringer Ingelheim,Industry,BI 409306 matching placebo,Drug
NCT02788513,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-27,,,2019-10-24,2016-05-27,2016-06-02,Estimate,,,,,,,2019-10-24,2019-10-25,Actual,"August 11, 2016",Actual,2016-08-11,October 2019,2019-10-31,"October 11, 2019",Actual,2019-10-11,"September 12, 2019",Actual,2019-09-12,,Interventional,,,BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,"A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy and Safety of Orally Administered BI 425809 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease.",Completed,,Phase 2,611.0,Actual,Boehringer Ingelheim,,5.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 10:19:26.691184,2020-02-01 10:19:26.691184,Boehringer Ingelheim,Industry,BI 425809 dose 1,Drug
NCT02788513,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-27,,,2019-10-24,2016-05-27,2016-06-02,Estimate,,,,,,,2019-10-24,2019-10-25,Actual,"August 11, 2016",Actual,2016-08-11,October 2019,2019-10-31,"October 11, 2019",Actual,2019-10-11,"September 12, 2019",Actual,2019-09-12,,Interventional,,,BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,"A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy and Safety of Orally Administered BI 425809 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease.",Completed,,Phase 2,611.0,Actual,Boehringer Ingelheim,,5.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 10:19:26.691184,2020-02-01 10:19:26.691184,Boehringer Ingelheim,Industry,BI 425809 dose 2,Drug
NCT02788513,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-27,,,2019-10-24,2016-05-27,2016-06-02,Estimate,,,,,,,2019-10-24,2019-10-25,Actual,"August 11, 2016",Actual,2016-08-11,October 2019,2019-10-31,"October 11, 2019",Actual,2019-10-11,"September 12, 2019",Actual,2019-09-12,,Interventional,,,BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,"A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy and Safety of Orally Administered BI 425809 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease.",Completed,,Phase 2,611.0,Actual,Boehringer Ingelheim,,5.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 10:19:26.691184,2020-02-01 10:19:26.691184,Boehringer Ingelheim,Industry,BI 425809 dose 3,Drug
NCT02788513,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-27,,,2019-10-24,2016-05-27,2016-06-02,Estimate,,,,,,,2019-10-24,2019-10-25,Actual,"August 11, 2016",Actual,2016-08-11,October 2019,2019-10-31,"October 11, 2019",Actual,2019-10-11,"September 12, 2019",Actual,2019-09-12,,Interventional,,,BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,"A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy and Safety of Orally Administered BI 425809 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease.",Completed,,Phase 2,611.0,Actual,Boehringer Ingelheim,,5.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 10:19:26.691184,2020-02-01 10:19:26.691184,Boehringer Ingelheim,Industry,BI 425809 dose 4,Drug
NCT00160147,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-08,,2015-01-29,2015-01-29,2005-09-08,2005-09-12,Estimate,,,,2015-01-29,2015-02-09,Estimate,2015-01-29,2015-02-09,Estimate,December 2005,,2005-12-31,June 2009,2009-06-30,January 2008,Actual,2008-01-31,January 2008,Actual,2008-01-31,,Interventional,,,Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type,"A Randomized, Double-Blind, Placebo-controlled, Efficacy, Safety, and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type",Terminated,,Phase 3,60.0,Actual,Solvay Pharmaceuticals,,2.0,,The study was discontinued prematurely on 25 February 2008 due to slow enrollment,False,,,,,,,,,,,,,,,,,2020-02-01 21:59:51.819507,2020-02-01 21:59:51.819507,Solvay Pharmaceuticals,Industry,bifeprunox,Drug
NCT01397539,"ClinicalTrials.gov processed this data on January 31, 2020",2011-06-30,,,2015-03-19,2011-07-18,2011-07-19,Estimate,,,,,,,2015-03-19,2015-03-23,Estimate,June 2011,,2011-06-30,March 2015,2015-03-31,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,,,Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease,"A Randomized, Blinded, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB037 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,53.0,Actual,Biogen,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:56:14.428304,2020-02-01 15:56:14.428304,Biogen,Industry,BIIB037,Drug
NCT03056729,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-15,,,2019-11-08,2017-02-15,2017-02-17,Actual,,,,,,,2019-11-08,2019-11-12,Actual,"February 17, 2017",Actual,2017-02-17,November 2019,2019-11-30,"March 3, 2020",Anticipated,2020-03-03,"March 3, 2020",Anticipated,2020-03-03,,Interventional,,,Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease,"A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB076 in Healthy Volunteers and Subjects With Alzheimer's Disease","Active, not recruiting",,Phase 1,46.0,Actual,Biogen,,6.0,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:26:43.137705,2020-02-01 09:26:43.137705,Biogen,Industry,BIIB076,Drug
NCT03352557,"ClinicalTrials.gov processed this data on January 31, 2020",2017-11-21,,,2020-01-20,2017-11-21,2017-11-24,Actual,,,,,,,2020-01-20,2020-01-22,Actual,"May 3, 2018",Actual,2018-05-03,January 2020,2020-01-31,"March 26, 2024",Anticipated,2024-03-26,"March 26, 2024",Anticipated,2024-03-26,,Interventional,TANGO,,Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,654.0,Actual,Biogen,,4.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:34:31.539157,2020-02-01 08:34:31.539157,Biogen,Industry,BIIB092,Drug
NCT03682081,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-20,,,2019-12-26,2018-09-21,2018-09-24,Actual,,,,,,,2019-12-26,2019-12-27,Actual,January 2020,Anticipated,2020-01-31,December 2019,2019-12-31,"February 1, 2023",Anticipated,2023-02-01,"February 1, 2023",Anticipated,2023-02-01,,Interventional,,,Interventions for Patients With Alzheimer's Disease and Dysphagia,Development of Novel Therapeutic Interventions for Patients With Alzheimer's Disease and Comorbid Dysphagia,Not yet recruiting,,Early Phase 1,76.0,Anticipated,"University of Wisconsin, Madison",,4.0,,,False,,,,False,False,True,,,False,,,,,,No,,2020-02-01 07:41:45.679594,2020-02-01 07:41:45.679594,"University of Wisconsin, Madison",Other,Biotene,Drug
NCT01492374,"ClinicalTrials.gov processed this data on January 31, 2020",2011-12-13,,,2014-07-23,2011-12-13,2011-12-15,Estimate,,,,,,,2014-07-23,2014-07-24,Estimate,February 2012,,2012-02-29,October 2013,2013-10-31,October 2013,Actual,2013-10-31,October 2013,Actual,2013-10-31,,Interventional,,,"Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease",Completed,,Phase 1,40.0,Actual,Bristol-Myers Squibb,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:31:09.583952,2020-02-01 15:31:09.583952,Bristol-Myers Squibb,Industry,BMS-241027,Drug
NCT00726726,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-30,,,2008-11-04,2008-07-30,2008-08-01,Estimate,,,,,,,2008-11-04,2008-11-05,Estimate,August 2008,,2008-08-31,November 2008,2008-11-30,October 2008,Actual,2008-10-31,October 2008,Actual,2008-10-31,,Interventional,,,Drug Interaction Study With a Potential Alzheimer's Disease Compound,"Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Midazolam, Warfarin, Caffeine, Omeprazole and Dextromethorphan in Healthy Male Subjects by Administration of a Modified Cooperstown Cocktail",Completed,,Phase 1,22.0,Actual,Bristol-Myers Squibb,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:15:36.229229,2020-02-01 19:15:36.229229,Bristol-Myers Squibb,Industry,BMS-708163,Drug
NCT00810147,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-16,,2012-03-24,2015-09-23,2008-12-16,2008-12-17,Estimate,,,,2015-09-23,2015-10-12,Estimate,2015-09-23,2015-10-12,Estimate,February 2009,,2009-02-28,September 2015,2015-09-30,June 2010,Actual,2010-06-30,June 2010,Actual,2010-06-30,,Interventional,,,"A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease","Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,209.0,Actual,Bristol-Myers Squibb,,5.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:51:11.554481,2020-02-01 18:51:11.554481,Bristol-Myers Squibb,Industry,BMS-708163,Drug
NCT00726726,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-30,,,2008-11-04,2008-07-30,2008-08-01,Estimate,,,,,,,2008-11-04,2008-11-05,Estimate,August 2008,,2008-08-31,November 2008,2008-11-30,October 2008,Actual,2008-10-31,October 2008,Actual,2008-10-31,,Interventional,,,Drug Interaction Study With a Potential Alzheimer's Disease Compound,"Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Midazolam, Warfarin, Caffeine, Omeprazole and Dextromethorphan in Healthy Male Subjects by Administration of a Modified Cooperstown Cocktail",Completed,,Phase 1,22.0,Actual,Bristol-Myers Squibb,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:15:36.229229,2020-02-01 19:15:36.229229,Bristol-Myers Squibb,Industry,BMS-708163 + Cooperstown Cocktail,Drug
NCT01747213,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-08,,,2019-05-15,2012-12-08,2012-12-11,Estimate,,,,,,,2019-05-15,2019-05-16,Actual,"January 1, 2013",,2013-01-01,"May 7, 2019",2019-05-07,"January 8, 2019",Actual,2019-01-08,"January 8, 2019",Actual,2019-01-08,,Interventional,,,Bisnorcymserine in Healthy Adult Volunteers,"Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Bisnorcymserine (BNC), a Highly Selective Inhibitor of Butyrylcholinesterase, in Healthy Adult Volunteers",Completed,,Phase 1,75.0,Actual,National Institutes of Health Clinical Center (CC),,2.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 14:26:05.148752,2020-02-01 14:26:05.148752,National Institute on Aging (NIA),NIH,BNC,Drug
NCT04229927,"ClinicalTrials.gov processed this data on January 31, 2020",2020-01-13,,,2020-01-13,2020-01-13,2020-01-18,Actual,,,,,,,2020-01-13,2020-01-18,Actual,"February 3, 2020",Anticipated,2020-02-03,January 2020,2020-01-31,"March 1, 2023",Anticipated,2023-03-01,"February 28, 2022",Anticipated,2022-02-28,,Interventional,,,BPDO-1603 Intervention Trial,"A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of BPDO-1603 in Patients With Moderate-to-severe Alzheimer's Disease",Not yet recruiting,,Phase 3,712.0,Anticipated,"Hyundai Pharmaceutical Co., LTD.",,2.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 06:22:51.293968,2020-02-01 06:22:51.293968,"Hyundai Pharmaceutical Co., LTD.",Industry,BPDO-1603,Drug
NCT02648672,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-04,,,2017-01-17,2016-01-05,2016-01-07,Estimate,,,,,,,2017-01-17,2017-01-18,Estimate,December 2015,,2015-12-31,January 2017,2017-01-31,July 2016,Actual,2016-07-31,February 2016,Actual,2016-02-29,,Interventional,,,BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects,"A Single Ascending Dose Study to Examine the Safety, Tolerability, and Pharmacokinetic Profile of BPN14770 in Healthy Male and Female Subjects",Completed,,Phase 1,32.0,Actual,Tetra Discovery Partners,,2.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 10:47:58.768447,2020-02-01 10:47:58.768447,Tetra Discovery Partners,Industry,BPN14770,Drug
NCT02840279,"ClinicalTrials.gov processed this data on January 31, 2020",2016-07-19,,,2017-01-17,2016-07-19,2016-07-21,Estimate,,,,,,,2017-01-17,2017-01-18,Estimate,June 2016,,2016-06-30,December 2016,2016-12-31,December 2016,Actual,2016-12-31,November 2016,Actual,2016-11-30,,Interventional,,,A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects,"A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Examine the Safety, Tolerability, Pharmacokinetic, and Preliminary Cognitive Profile of BPN14770 in Healthy Young and Elderly Male and Female Subjects",Completed,,Phase 1,77.0,Actual,Tetra Discovery Partners,,2.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 10:09:58.152357,2020-02-01 10:09:58.152357,Tetra Discovery Partners,Industry,BPN14770,Drug
NCT03030105,"ClinicalTrials.gov processed this data on January 31, 2020",2017-01-17,,,2018-10-15,2017-01-20,2017-01-24,Estimate,,,,,,,2018-10-15,2018-10-16,Actual,January 2017,Actual,2017-01-31,October 2018,2018-10-31,June 2017,Actual,2017-06-30,May 2017,Actual,2017-05-31,,Interventional,,,Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers,"A Randomized, Double-blind, Placebo-controlled, Single-dose, 6-Period Crossover Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers",Completed,,Phase 1,38.0,Actual,Tetra Discovery Partners,,6.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 09:31:54.545833,2020-02-01 09:31:54.545833,Tetra Discovery Partners,Industry,BPN14770,Drug
NCT03817684,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-18,,,2019-10-30,2019-01-23,2019-01-25,Actual,,,,,,,2019-10-30,2019-10-31,Actual,"April 30, 2019",Actual,2019-04-30,October 2019,2019-10-31,February 2020,Anticipated,2020-02-29,February 2020,Anticipated,2020-02-29,,Interventional,,,Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects,"A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease","Active, not recruiting",,Phase 2,255.0,Actual,Tetra Discovery Partners,,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 07:21:36.297810,2020-02-01 07:21:36.297810,Tetra Discovery Partners,Industry,BPN14770,Drug
NCT03030105,"ClinicalTrials.gov processed this data on January 31, 2020",2017-01-17,,,2018-10-15,2017-01-20,2017-01-24,Estimate,,,,,,,2018-10-15,2018-10-16,Actual,January 2017,Actual,2017-01-31,October 2018,2018-10-31,June 2017,Actual,2017-06-30,May 2017,Actual,2017-05-31,,Interventional,,,Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers,"A Randomized, Double-blind, Placebo-controlled, Single-dose, 6-Period Crossover Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers",Completed,,Phase 1,38.0,Actual,Tetra Discovery Partners,,6.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 09:31:54.545833,2020-02-01 09:31:54.545833,Tetra Discovery Partners,Industry,BPN14770 placebo,Drug
NCT03548584,"ClinicalTrials.gov processed this data on January 31, 2020",2018-05-07,,,2019-11-08,2018-06-05,2018-06-07,Actual,,,,,,,2019-11-08,2019-11-13,Actual,"May 16, 2018",Actual,2018-05-16,November 2019,2019-11-30,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,,Interventional,,,"A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type","A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",Recruiting,,Phase 3,225.0,Anticipated,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,3.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 08:02:22.001085,2020-02-01 08:02:22.001085,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,Brexpiprazole,Drug
NCT03594123,"ClinicalTrials.gov processed this data on January 31, 2020",2018-07-11,,,2019-11-08,2018-07-11,2018-07-20,Actual,,,,,,,2019-11-08,2019-11-13,Actual,"October 12, 2018",Actual,2018-10-12,November 2019,2019-11-30,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,,Interventional,,,A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,"A 12-week, Multicenter, Active-treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",Recruiting,,Phase 3,250.0,Anticipated,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,2.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 07:55:08.643083,2020-02-01 07:55:08.643083,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,Brexpiprazole,Drug
NCT03620981,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-05,,,2019-07-09,2018-08-05,2018-08-08,Actual,,,,,,,2019-07-09,2019-07-11,Actual,"August 20, 2018",Actual,2018-08-20,July 2019,2019-07-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,,Interventional,,,Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,"A Phase 2/3 Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Comparison Trial to Evaluate the Efficacy and Safety of Brexpiprazole (OPC-34712) in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",Recruiting,,Phase 2/Phase 3,407.0,Anticipated,"Otsuka Pharmaceutical Co., Ltd.",,3.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2020-02-01 07:51:00.823260,2020-02-01 07:51:00.823260,"Otsuka Pharmaceutical Co., Ltd.",Industry,Brexpiprazole,Drug
NCT03724942,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-28,,,2019-12-26,2018-10-28,2018-10-30,Actual,,,,,,,2019-12-26,2019-12-27,Actual,"November 9, 2018",Actual,2018-11-09,December 2019,2019-12-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,,Interventional,,,Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,"A Multicenter, Uncontrolled, Open-label Trial to Evaluate the Safety of Extended Treatment With Brexpiprazole (OPC-34712) to Patients With Agitation Associated With Dementia of the Alzheimer's Type",Recruiting,,Phase 3,157.0,Anticipated,"Otsuka Pharmaceutical Co., Ltd.",,1.0,,,False,,,,True,False,False,,,,,,,,,No,,2020-02-01 07:35:16.624939,2020-02-01 07:35:16.624939,"Otsuka Pharmaceutical Co., Ltd.",Industry,Brexpiprazole,Drug
NCT01862640,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-22,,2018-01-22,2019-03-11,2013-05-22,2013-05-24,Estimate,,,,2018-01-22,2018-01-26,Actual,2019-03-11,2019-03-14,Actual,July 2013,,2013-07-31,March 2019,2019-03-31,March 2017,Actual,2017-03-31,March 2017,Actual,2017-03-31,,Interventional,,,Safety and Tolerability Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,"A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",Completed,,Phase 3,433.0,Actual,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:56:29.292305,2020-02-01 13:56:29.292305,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,"Brexpiprazole, OPC-34712",Drug
NCT01922258,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-12,,2018-05-15,2018-05-15,2013-08-12,2013-08-14,Estimate,,,,2018-05-15,2018-05-17,Actual,2018-05-15,2018-05-17,Actual,September 2013,Actual,2013-09-30,May 2018,2018-05-31,March 2017,Actual,2017-03-31,March 2017,Actual,2017-03-31,,Interventional,,,Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,"A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Flexible Dosing of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",Completed,,Phase 3,270.0,Actual,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:40:30.244190,2020-02-01 13:40:30.244190,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,"Brexpiprazole, OPC-34712",Drug
NCT03560245,"ClinicalTrials.gov processed this data on January 31, 2020",2018-06-06,,,2019-08-19,2018-06-06,2018-06-18,Actual,,,,,,,2019-08-19,2019-08-20,Actual,"June 20, 2018",Actual,2018-06-20,August 2019,2019-08-31,"July 25, 2019",Actual,2019-07-25,"July 25, 2019",Actual,2019-07-25,,Interventional,,,A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine,"A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment",Completed,,Phase 2,108.0,Actual,"Neurotrope Bioscience, Inc.",,2.0,,,False,,,,,True,False,,,,,,,,,No,,2020-02-01 08:00:22.661683,2020-02-01 08:00:22.661683,"Neurotrope Bioscience, Inc.",Industry,Bryostatin,Drug
NCT02221947,"ClinicalTrials.gov processed this data on January 31, 2020",2014-07-02,2016-03-21,,2017-10-03,2014-08-20,2014-08-21,Estimate,2016-03-21,2016-04-21,Estimate,,,,2017-10-03,2017-11-06,Actual,June 2014,,2014-06-30,October 2017,2017-10-31,December 2014,Actual,2014-12-31,December 2014,Actual,2014-12-31,,Interventional,,,"Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Preliminary Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Alzheimer's Disease",Terminated,,Phase 1/Phase 2,9.0,Actual,"Neurotrope Bioscience, Inc.",,2.0,,"Part 2 of study replaced by NTRP-101-202, assessing 3 doses of bryostatin.",False,,,,False,,,,,,,,,,,No,,2020-02-01 12:24:20.790879,2020-02-01 12:24:20.790879,"Neurotrope Bioscience, Inc.",Industry,Bryostatin 1,Drug
NCT02431468,"ClinicalTrials.gov processed this data on January 31, 2020",2015-04-22,2018-04-30,,2018-06-06,2015-04-27,2015-05-01,Estimate,2018-06-06,2018-07-06,Actual,,,,2018-06-06,2018-07-06,Actual,November 2015,,2015-11-30,June 2018,2018-06-30,February 2017,Actual,2017-02-28,February 2017,Actual,2017-02-28,,Interventional,,,A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease,"A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease",Completed,,Phase 2,147.0,Actual,"Neurotrope Bioscience, Inc.",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:37:32.174698,2020-02-01 11:37:32.174698,"Neurotrope Bioscience, Inc.",Industry,Bryostatin 1,Drug
NCT00606164,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-21,,,2008-01-21,2008-01-21,2008-02-01,Estimate,,,,,,,2008-01-21,2008-02-01,Estimate,April 2008,,2008-04-30,January 2008,2008-01-31,December 2008,Anticipated,2008-12-31,December 2008,Anticipated,2008-12-31,,Interventional,,,"Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Mild to Moderate Alzheimer's Disease",Unknown status,Not yet recruiting,Phase 2,9.0,Anticipated,Blanchette Rockefeller Neurosciences Insitute,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:51:23.445840,2020-02-01 19:51:23.445840,Blanchette Rockefeller Neurosciences Insitute,Other,Bryostatin for Injection,Drug
NCT03226522,"ClinicalTrials.gov processed this data on January 31, 2020",2017-07-20,,,2020-01-11,2017-07-20,2017-07-21,Actual,,,,,,,2020-01-11,2020-01-14,Actual,"July 13, 2017",Actual,2017-07-13,January 2020,2020-01-31,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,,Interventional,ADVANCE,,Addressing Dementia Via Agitation-Centered Evaluation,"A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type",Recruiting,,Phase 2/Phase 3,435.0,Anticipated,"Axsome Therapeutics, Inc.",,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 08:57:30.107770,2020-02-01 08:57:30.107770,"Axsome Therapeutics, Inc.",Industry,Bupropion,Drug
NCT02646982,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-04,,,2019-02-15,2016-01-04,2016-01-06,Estimate,,,,,,,2019-02-15,2019-02-18,Actual,June 2016,,2016-06-30,February 2019,2019-02-28,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,,Interventional,CEDAR,,Candesartan's Effects on Alzheimer's Disease And Related Biomarkers,Candesartan's Effects on Alzheimer's Disease And Related Biomarkers,Recruiting,,Phase 2,72.0,Anticipated,Emory University,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 10:48:22.473223,2020-02-01 10:48:22.473223,Emory University,Other,Candesartan,Drug
NCT01211782,"ClinicalTrials.gov processed this data on January 31, 2020",2010-09-24,,,2012-12-03,2010-09-28,2010-09-30,Estimate,,,,,,,2012-12-03,2012-12-04,Estimate,,,,December 2012,2012-12-31,,,,,,,,Interventional,ALERT,,AC-1204 Long-term Efficacy Response Trial (ALERT Protocol),"A Phase 2-3, 6-12 Month, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects With Mild to Moderate Alzheimer's Disease Who Are APOE4(-)",Withdrawn,,Phase 2/Phase 3,0.0,Actual,Cerecin,,2.0,,Study never started. Study was redesgined.,False,,,,False,,,,,,,,,,,,,2020-02-01 16:49:09.095841,2020-02-01 16:49:09.095841,Cerecin,Industry,caprylic triglyceride,Drug
NCT01354444,"ClinicalTrials.gov processed this data on January 31, 2020",2011-05-09,2017-10-26,,2018-01-08,2011-05-13,2011-05-16,Estimate,2018-01-08,2018-02-06,Actual,,,,2018-01-08,2018-02-06,Actual,June 2011,Actual,2011-06-30,January 2018,2018-01-31,January 2017,Actual,2017-01-31,December 2016,Actual,2016-12-31,,Interventional,,,Trial of Carvedilol in Alzheimer's Disease,Pilot Trial of Carvedilol in Alzheimer's Disease,Completed,,Phase 4,29.0,Actual,Johns Hopkins University,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:07:28.450704,2020-02-01 16:07:28.450704,Johns Hopkins University,Other,Carvedilol,Drug
NCT00876863,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-03,,,2019-11-18,2009-04-03,2009-04-07,Estimate,,,,,,,2019-11-18,2019-11-20,Actual,November 2008,Actual,2008-11-30,January 2017,2017-01-31,"August 13, 2015",Actual,2015-08-13,"August 13, 2015",Actual,2015-08-13,,Interventional,,,"Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease","A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,49.0,Actual,Sangamo Therapeutics,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 18:31:39.651990,2020-02-01 18:31:39.651990,Sangamo Therapeutics,Industry,CERE-110: Adeno-Associated Virus Delivery of NGF,Drug
NCT01822951,"ClinicalTrials.gov processed this data on January 31, 2020",2013-03-25,,,2015-10-23,2013-03-28,2013-04-04,Estimate,,,,,,,2015-10-23,2015-10-26,Estimate,,,,October 2015,2015-10-31,December 2016,Anticipated,2016-12-31,September 2016,Anticipated,2016-09-30,,Interventional,DAT,,Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT),"Comparison of Cerebrolysin and Donepezil: A Randomized, Double-blind, Controlled Trial on Efficacy and Safety in Patients With Mild to Moderate Alzheimer's Disease",Withdrawn,,Phase 4,0.0,Actual,Ever Neuro Pharma GmbH,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:07:07.136651,2020-02-01 14:07:07.136651,Ever Neuro Pharma GmbH,Industry,Cerebrolysin,Drug
NCT00911807,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-07,2009-04-07,,2009-06-04,2009-04-07,2009-06-02,Estimate,2009-04-07,2009-06-02,Estimate,,,,2009-06-04,2009-06-10,Estimate,October 2004,,2004-10-31,June 2009,2009-06-30,April 2008,Actual,2008-04-30,April 2008,Actual,2008-04-30,,Interventional,Combi,,Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease,"A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)",Completed,,Phase 2,217.0,Actual,Ever Neuro Pharma GmbH,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:21:22.041636,2020-02-01 18:21:22.041636,Ever Neuro Pharma GmbH,Industry,Cerebrolysin + donepezil,Drug
NCT00911807,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-07,2009-04-07,,2009-06-04,2009-04-07,2009-06-02,Estimate,2009-04-07,2009-06-02,Estimate,,,,2009-06-04,2009-06-10,Estimate,October 2004,,2004-10-31,June 2009,2009-06-30,April 2008,Actual,2008-04-30,April 2008,Actual,2008-04-30,,Interventional,Combi,,Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease,"A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)",Completed,,Phase 2,217.0,Actual,Ever Neuro Pharma GmbH,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:21:22.041636,2020-02-01 18:21:22.041636,Ever Neuro Pharma GmbH,Industry,Cerebrolysin + placebo,Drug
NCT01258452,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-09,,,2015-02-09,2010-12-09,2010-12-13,Estimate,,,,,,,2015-02-09,2015-02-10,Estimate,February 2011,,2011-02-28,February 2015,2015-02-28,March 2011,Actual,2011-03-31,March 2011,Actual,2011-03-31,,Interventional,CT03,,Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects,"Randomized, Balanced, Single Dose, Cross-Over Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects",Completed,,Phase 1,12.0,Actual,CERESPIR,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:34:50.996498,2020-02-01 16:34:50.996498,CERESPIR,Industry,CHF 5074,Drug
NCT01303744,"ClinicalTrials.gov processed this data on January 31, 2020",2011-02-23,2015-10-16,2012-05-18,2015-12-02,2011-02-23,2011-02-25,Estimate,2015-12-02,2016-01-11,Estimate,2012-05-18,2012-05-30,Estimate,2015-12-02,2016-01-11,Estimate,March 2011,,2011-03-31,December 2015,2015-12-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,CT04,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074,"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment",Completed,,Phase 2,96.0,Actual,CERESPIR,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:21:56.018097,2020-02-01 16:21:56.018097,CERESPIR,Industry,CHF 5074 1x,Drug
NCT01421056,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-05,,2014-01-07,2014-01-07,2011-08-19,2011-08-22,Estimate,,,,2014-01-07,2014-02-06,Estimate,2014-01-07,2014-02-06,Estimate,July 2011,,2011-07-31,January 2014,2014-01-31,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP),"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment",Completed,,Phase 2,74.0,Actual,Chiesi Farmaceutici S.p.A.,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:51:03.149079,2020-02-01 15:51:03.149079,Chiesi Farmaceutici S.p.A.,Industry,CHF 5074 1x,Drug
NCT01602393,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-17,,2014-01-07,2014-01-07,2012-05-17,2012-05-21,Estimate,,,,2014-01-07,2014-02-06,Estimate,2014-01-07,2014-02-06,Estimate,May 2012,,2012-05-31,January 2014,2014-01-31,October 2013,Actual,2013-10-31,October 2013,Actual,2013-10-31,,Interventional,CT04 POLEP,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase,"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment",Completed,,Phase 2,51.0,Actual,Chiesi Farmaceutici S.p.A.,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:03:58.230115,2020-02-01 15:03:58.230115,Chiesi Farmaceutici S.p.A.,Industry,CHF 5074 1x,Drug
NCT01203384,"ClinicalTrials.gov processed this data on January 31, 2020",2010-09-15,,,2015-02-09,2010-09-15,2010-09-16,Estimate,,,,,,,2015-02-09,2015-02-10,Estimate,September 2010,,2010-09-30,February 2015,2015-02-28,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,CT02,,"Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects","Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects",Completed,,Phase 1,48.0,Actual,CERESPIR,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:51:33.506485,2020-02-01 16:51:33.506485,CERESPIR,Industry,CHF5074 1x,Drug
NCT01303744,"ClinicalTrials.gov processed this data on January 31, 2020",2011-02-23,2015-10-16,2012-05-18,2015-12-02,2011-02-23,2011-02-25,Estimate,2015-12-02,2016-01-11,Estimate,2012-05-18,2012-05-30,Estimate,2015-12-02,2016-01-11,Estimate,March 2011,,2011-03-31,December 2015,2015-12-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,CT04,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074,"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment",Completed,,Phase 2,96.0,Actual,CERESPIR,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:21:56.018097,2020-02-01 16:21:56.018097,CERESPIR,Industry,CHF 5074 2x,Drug
NCT01421056,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-05,,2014-01-07,2014-01-07,2011-08-19,2011-08-22,Estimate,,,,2014-01-07,2014-02-06,Estimate,2014-01-07,2014-02-06,Estimate,July 2011,,2011-07-31,January 2014,2014-01-31,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP),"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment",Completed,,Phase 2,74.0,Actual,Chiesi Farmaceutici S.p.A.,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:51:03.149079,2020-02-01 15:51:03.149079,Chiesi Farmaceutici S.p.A.,Industry,CHF 5074 2x,Drug
NCT01602393,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-17,,2014-01-07,2014-01-07,2012-05-17,2012-05-21,Estimate,,,,2014-01-07,2014-02-06,Estimate,2014-01-07,2014-02-06,Estimate,May 2012,,2012-05-31,January 2014,2014-01-31,October 2013,Actual,2013-10-31,October 2013,Actual,2013-10-31,,Interventional,CT04 POLEP,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase,"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment",Completed,,Phase 2,51.0,Actual,Chiesi Farmaceutici S.p.A.,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:03:58.230115,2020-02-01 15:03:58.230115,Chiesi Farmaceutici S.p.A.,Industry,CHF 5074 2x,Drug
NCT01203384,"ClinicalTrials.gov processed this data on January 31, 2020",2010-09-15,,,2015-02-09,2010-09-15,2010-09-16,Estimate,,,,,,,2015-02-09,2015-02-10,Estimate,September 2010,,2010-09-30,February 2015,2015-02-28,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,CT02,,"Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects","Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects",Completed,,Phase 1,48.0,Actual,CERESPIR,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:51:33.506485,2020-02-01 16:51:33.506485,CERESPIR,Industry,CHF5074 2x,Drug
NCT01303744,"ClinicalTrials.gov processed this data on January 31, 2020",2011-02-23,2015-10-16,2012-05-18,2015-12-02,2011-02-23,2011-02-25,Estimate,2015-12-02,2016-01-11,Estimate,2012-05-18,2012-05-30,Estimate,2015-12-02,2016-01-11,Estimate,March 2011,,2011-03-31,December 2015,2015-12-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,CT04,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074,"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment",Completed,,Phase 2,96.0,Actual,CERESPIR,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:21:56.018097,2020-02-01 16:21:56.018097,CERESPIR,Industry,CHF 5074 3x,Drug
NCT01421056,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-05,,2014-01-07,2014-01-07,2011-08-19,2011-08-22,Estimate,,,,2014-01-07,2014-02-06,Estimate,2014-01-07,2014-02-06,Estimate,July 2011,,2011-07-31,January 2014,2014-01-31,November 2012,Actual,2012-11-30,November 2012,Actual,2012-11-30,,Interventional,,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP),"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment",Completed,,Phase 2,74.0,Actual,Chiesi Farmaceutici S.p.A.,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:51:03.149079,2020-02-01 15:51:03.149079,Chiesi Farmaceutici S.p.A.,Industry,CHF 5074 3x,Drug
NCT01602393,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-17,,2014-01-07,2014-01-07,2012-05-17,2012-05-21,Estimate,,,,2014-01-07,2014-02-06,Estimate,2014-01-07,2014-02-06,Estimate,May 2012,,2012-05-31,January 2014,2014-01-31,October 2013,Actual,2013-10-31,October 2013,Actual,2013-10-31,,Interventional,CT04 POLEP,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase,"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 (200, 400, 600 mg/Day for up to 12 Weeks) and to Explore the Effects on Potential Markers of Clinical Efficacy in Patient With Mild Cognitive Impairment",Completed,,Phase 2,51.0,Actual,Chiesi Farmaceutici S.p.A.,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:03:58.230115,2020-02-01 15:03:58.230115,Chiesi Farmaceutici S.p.A.,Industry,CHF 5074 3x,Drug
NCT01203384,"ClinicalTrials.gov processed this data on January 31, 2020",2010-09-15,,,2015-02-09,2010-09-15,2010-09-16,Estimate,,,,,,,2015-02-09,2015-02-10,Estimate,September 2010,,2010-09-30,February 2015,2015-02-28,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,CT02,,"Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects","Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects",Completed,,Phase 1,48.0,Actual,CERESPIR,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:51:33.506485,2020-02-01 16:51:33.506485,CERESPIR,Industry,CHF5074 3x,Drug
NCT01258452,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-09,,,2015-02-09,2010-12-09,2010-12-13,Estimate,,,,,,,2015-02-09,2015-02-10,Estimate,February 2011,,2011-02-28,February 2015,2015-02-28,March 2011,Actual,2011-03-31,March 2011,Actual,2011-03-31,,Interventional,CT03,,Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects,"Randomized, Balanced, Single Dose, Cross-Over Study to Evaluate the Effects of Food Ingestion on the Pharmacokinetics of CHF 5074 in Healthy Young Male Subjects",Completed,,Phase 1,12.0,Actual,CERESPIR,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:34:50.996498,2020-02-01 16:34:50.996498,CERESPIR,Industry,CHF 5974,Drug
NCT00548145,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-22,2011-12-28,,2012-05-14,2007-10-22,2007-10-23,Estimate,2012-05-14,2012-06-14,Estimate,,,,2012-05-14,2012-06-14,Estimate,November 2007,,2007-11-30,May 2012,2012-05-31,March 2012,Actual,2012-03-31,October 2011,Actual,2011-10-31,,Interventional,PIT-ROAD,,The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease,,Terminated,,N/A,38.0,Actual,Osaka University,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:09:00.633969,2020-02-01 20:09:00.633969,Osaka University,Other,"cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)",Drug
NCT02648906,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-05,,,2016-11-01,2016-01-05,2016-01-07,Estimate,,,,,,,2016-11-01,2016-11-02,Estimate,July 2015,,2015-07-31,November 2016,2016-11-30,,,,November 2018,Anticipated,2018-11-30,,Interventional,,,A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients,,Unknown status,Recruiting,Phase 4,128.0,Anticipated,Daewoong Pharmaceutical Co. LTD.,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 10:47:56.128964,2020-02-01 10:47:56.128964,Daewoong Pharmaceutical Co. LTD.,Industry,Choline alfoscerate,Drug
NCT02035982,"ClinicalTrials.gov processed this data on January 31, 2020",2013-11-25,,,2017-04-26,2014-01-13,2014-01-14,Estimate,,,,,,,2017-04-26,2017-04-28,Actual,July 2010,,2010-07-31,April 2017,2017-04-30,September 2015,Actual,2015-09-30,May 2014,Actual,2014-05-31,,Interventional,,,Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease,A Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease in Long Term Care Setting,Completed,,Phase 3,40.0,Actual,Sunnybrook Health Sciences Centre,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:09:43.530864,2020-02-01 13:09:43.530864,Sunnybrook Health Sciences Centre,Other,Cholinesterase Inhibitor,Drug
NCT03454646,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-09,,,2018-02-26,2018-02-26,2018-03-06,Actual,,,,,,,2018-02-26,2018-03-06,Actual,"March 15, 2018",Anticipated,2018-03-15,February 2018,2018-02-28,"September 15, 2021",Anticipated,2021-09-15,"March 15, 2018",Anticipated,2018-03-15,,Interventional,,,Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL),Comparison of Therapeutic Strategies With Cholinesterase Inhibitors: Stop or Still (SOS) Trial,Not yet recruiting,,Phase 4,1205.0,Anticipated,"University Hospital, Bordeaux",,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2020-02-01 08:17:34.193947,2020-02-01 08:17:34.193947,"University Hospital, Bordeaux",Other,"cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)",Drug
NCT01409564,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-03,2013-08-19,,2014-04-14,2011-08-03,2011-08-04,Estimate,2014-04-14,2014-05-13,Estimate,,,,2014-04-14,2014-05-13,Estimate,May 2010,,2010-05-31,April 2014,2014-04-30,July 2013,Actual,2013-07-31,June 2012,Actual,2012-06-30,,Interventional,,18 subjects for each group were enrolled in the final list.,Cilostazol Augmentation Study in Dementia,"Cilostazol Augmentation Study In Dementia (CASID): A Randomized, Placebo-controlled Pilot Study to Compare the Efficacy Between Donepezil Monotherapy and Cilostazol Augmentation Therapy in Alzheimer's Disease Patients With Subcortical White Matter Hyperintensities",Completed,,Phase 4,46.0,Actual,Seoul National University Hospital,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:53:37.059474,2020-02-01 15:53:37.059474,Seoul National University Hospital,Other,Cilostazol,Drug
NCT00940589,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-15,2018-03-28,,2018-05-29,2009-07-15,2009-07-16,Estimate,2018-05-29,2018-06-01,Actual,,,,2018-05-29,2018-06-01,Actual,September 2009,,2009-09-30,May 2018,2018-05-31,May 2013,Actual,2013-05-31,February 2013,Actual,2013-02-28,,Interventional,,,Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor,"A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor",Completed,,Phase 2,73.0,Actual,Neurim Pharmaceuticals Ltd.,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:12:57.684048,2020-02-01 18:12:57.684048,Neurim Pharmaceuticals Ltd.,Industry,Circadin,Drug
NCT00898807,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-11,2014-03-19,,2014-06-26,2009-05-11,2009-05-12,Estimate,2014-06-26,2014-06-27,Estimate,,,,2014-06-26,2014-06-27,Estimate,July 2009,,2009-07-31,June 2014,2014-06-30,September 2013,Actual,2013-09-30,September 2013,Actual,2013-09-30,,Interventional,CitAD,,Citalopram for Agitation in Alzheimer's Disease,A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease,Completed,,Phase 3,186.0,Actual,JHSPH Center for Clinical Trials,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:25:13.871439,2020-02-01 18:25:13.871439,JHSPH Center for Clinical Trials,Other,citalopram,Drug
NCT00015548,"ClinicalTrials.gov processed this data on January 31, 2020",2001-04-20,,,2015-06-16,2001-04-21,2001-04-23,Estimate,,,,,,,2015-06-16,2015-06-17,Estimate,March 2001,,2001-03-31,February 2009,2009-02-28,October 2004,,2004-10-31,,,,,Interventional,,,CATIE-Alzheimer's Disease Trial,Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial),Completed,,N/A,450.0,,National Institute of Mental Health (NIMH),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:23.664098,2020-02-01 22:48:23.664098,National Institute of Mental Health (NIMH),NIH,Citalopram,Drug
NCT00009204,"ClinicalTrials.gov processed this data on January 31, 2020",2001-01-23,,,2017-06-14,2001-01-23,2001-01-24,Estimate,,,,,,,2017-06-14,2017-06-16,Actual,September 1995,,1995-09-30,June 2017,2017-06-30,April 2002,Actual,2002-04-30,April 2000,Actual,2000-04-30,,Interventional,SPAD,,Serotonergic Pharmacotherapy for Agitation of Dementia,Serotonergic Pharmacotherapy for Agitation of Dementia,Completed,,Phase 3,,,University of Pittsburgh,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:44.953490,2020-02-01 22:48:44.953490,Bruce Pollock,Other,Citalopram [Celexa],Drug
NCT03802162,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-10,,,2019-10-21,2019-01-10,2019-01-14,Actual,,,,,,,2019-10-21,2019-10-23,Actual,"February 15, 2019",Actual,2019-02-15,October 2019,2019-10-31,"August 31, 2019",Actual,2019-08-31,"May 10, 2019",Actual,2019-05-10,,Interventional,,,"A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355","An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects",Completed,,Phase 1,60.0,Actual,Chong Kun Dang Pharmaceutical,,3.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:23:45.488096,2020-02-01 07:23:45.488096,Chong Kun Dang Pharmaceutical,Industry,CKD-355A (D797/Memantine HCl 20mg),Drug
NCT03802162,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-10,,,2019-10-21,2019-01-10,2019-01-14,Actual,,,,,,,2019-10-21,2019-10-23,Actual,"February 15, 2019",Actual,2019-02-15,October 2019,2019-10-31,"August 31, 2019",Actual,2019-08-31,"May 10, 2019",Actual,2019-05-10,,Interventional,,,"A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355","An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects",Completed,,Phase 1,60.0,Actual,Chong Kun Dang Pharmaceutical,,3.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:23:45.488096,2020-02-01 07:23:45.488096,Chong Kun Dang Pharmaceutical,Industry,CKD-355B (D797/Memantine HCl 20mg),Drug
NCT02565511,"ClinicalTrials.gov processed this data on January 31, 2020",2015-09-28,,,2019-10-25,2015-09-29,2015-10-01,Estimate,,,,,,,2019-10-25,2019-10-28,Actual,"November 30, 2015",Actual,2015-11-30,October 2019,2019-10-31,"March 31, 2025",Anticipated,2025-03-31,"December 31, 2024",Anticipated,2024-12-31,,Interventional,Generation S1,,A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.",Recruiting,,Phase 2/Phase 3,481.0,Anticipated,Novartis,,4.0,,,False,,,,True,True,False,,,,,,,,,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2020-02-01 11:06:28.630491,2020-02-01 11:06:28.630491,Novartis Pharmaceuticals,Industry,CNP520,Drug
NCT03131453,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-05,,,2019-10-03,2017-04-24,2017-04-27,Actual,,,,,,,2019-10-03,2019-10-07,Actual,"August 3, 2017",Actual,2017-08-03,September 2019,2019-09-30,"March 31, 2025",Anticipated,2025-03-31,"July 30, 2024",Anticipated,2024-07-30,,Interventional,Generation S2,,A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).","Active, not recruiting",,Phase 2/Phase 3,1145.0,Actual,Novartis,,3.0,,,False,,,,True,True,False,,,,,,,,https://www.clinicalstudydatarequest.com,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2020-02-01 09:13:42.422620,2020-02-01 09:13:42.422620,Novartis Pharmaceuticals,Industry,CNP520 15mg,Drug
NCT03131453,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-05,,,2019-10-03,2017-04-24,2017-04-27,Actual,,,,,,,2019-10-03,2019-10-07,Actual,"August 3, 2017",Actual,2017-08-03,September 2019,2019-09-30,"March 31, 2025",Anticipated,2025-03-31,"July 30, 2024",Anticipated,2024-07-30,,Interventional,Generation S2,,A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).","Active, not recruiting",,Phase 2/Phase 3,1145.0,Actual,Novartis,,3.0,,,False,,,,True,True,False,,,,,,,,https://www.clinicalstudydatarequest.com,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2020-02-01 09:13:42.422620,2020-02-01 09:13:42.422620,Novartis Pharmaceuticals,Industry,CNP520 50mg,Drug
NCT01883648,"ClinicalTrials.gov processed this data on January 31, 2020",2013-06-11,,,2017-04-26,2013-06-18,2013-06-21,Estimate,,,,,,,2017-04-26,2017-04-28,Actual,June 2013,,2013-06-30,January 2017,2017-01-31,"February 1, 2017",Actual,2017-02-01,"February 1, 2017",Actual,2017-02-01,,Interventional,,,Study to Evaluate Coconut Oil for Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled, 6 Month Cross-Over Study to Evaluate the Efficacy of Coconut Oil (Fuel for Thought™) Treatment for Subjects With Mild to Moderate Alzheimer's Disease",Terminated,,Phase 2/Phase 3,21.0,Actual,University of South Florida,,2.0,,Funding limitations and enrollment was too low.,False,,,,True,,,,,,,,,,,No,,2020-02-01 13:49:29.584007,2020-02-01 13:49:29.584007,University of South Florida,Other,Coconut Oil Beverage,Drug
NCT00117403,"ClinicalTrials.gov processed this data on January 31, 2020",2005-06-30,,,2009-04-01,2005-06-30,2005-07-06,Estimate,,,,,,,2009-04-01,2009-04-03,Estimate,January 2006,,2006-01-31,April 2008,2008-04-30,September 2007,Actual,2007-09-30,September 2007,Actual,2007-09-30,,Interventional,,,Anti-Oxidant Treatment of Alzheimer's Disease,"Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,75.0,Anticipated,National Institute on Aging (NIA),,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:12:02.293739,2020-02-01 22:12:02.293739,National Institute on Aging (NIA),NIH,Coenzyme Q,Drug
NCT00362024,"ClinicalTrials.gov processed this data on January 31, 2020",2006-08-08,,,2016-05-13,2006-08-08,2006-08-09,Estimate,,,,,,,2016-05-13,2016-05-16,Estimate,November 2006,,2006-11-30,May 2016,2016-05-31,November 2007,Actual,2007-11-30,November 2007,Actual,2007-11-30,,Interventional,,,MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED),MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease,Terminated,,Phase 2,24.0,Actual,Merck Sharp & Dohme Corp.,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:08:11.924466,2020-02-01 21:08:11.924466,Merck Sharp & Dohme Corp.,Industry,Comparator: Placebo,Drug
NCT00766363,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-01,2011-06-16,,2012-04-18,2008-10-02,2008-10-03,Estimate,2011-06-16,2011-07-14,Estimate,,,,2012-04-18,2012-04-20,Estimate,October 2008,,2008-10-31,April 2012,2012-04-30,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 1,49.0,Actual,FORUM Pharmaceuticals Inc,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:04:53.564244,2020-02-01 19:04:53.564244,FORUM Pharmaceuticals Inc,Industry,Comparator: Placebo,Drug
NCT00777608,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-21,2011-01-27,,2015-08-11,2008-10-21,2008-10-22,Estimate,2011-01-27,2011-02-24,Estimate,,,,2015-08-11,2015-08-25,Estimate,December 2008,,2008-12-31,August 2015,2015-08-31,April 2010,Actual,2010-04-30,October 2009,Actual,2009-10-31,,Interventional,,,A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial, With Placebo Run-In, and an Open-Label Treatment Period, to Evaluate the Performance of the CogState Computerized Neuropsychological Battery and the ADAS-Cog in Generally Cholinesterase-naive AD Patients",Completed,,Phase 1,106.0,Actual,Merck Sharp & Dohme Corp.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:01:34.894121,2020-02-01 19:01:34.894121,Merck Sharp & Dohme Corp.,Industry,Comparator: Placebo 5-10 mg,Drug
NCT00777608,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-21,2011-01-27,,2015-08-11,2008-10-21,2008-10-22,Estimate,2011-01-27,2011-02-24,Estimate,,,,2015-08-11,2015-08-25,Estimate,December 2008,,2008-12-31,August 2015,2015-08-31,April 2010,Actual,2010-04-30,October 2009,Actual,2009-10-31,,Interventional,,,A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial, With Placebo Run-In, and an Open-Label Treatment Period, to Evaluate the Performance of the CogState Computerized Neuropsychological Battery and the ADAS-Cog in Generally Cholinesterase-naive AD Patients",Completed,,Phase 1,106.0,Actual,Merck Sharp & Dohme Corp.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:01:34.894121,2020-02-01 19:01:34.894121,Merck Sharp & Dohme Corp.,Industry,Comparator: Placebo 5mg (run in),Drug
NCT00420420,"ClinicalTrials.gov processed this data on January 31, 2020",2007-01-09,2010-10-25,,2015-01-28,2007-01-10,2007-01-11,Estimate,2010-10-25,2010-11-18,Estimate,,,,2015-01-28,2015-02-12,Estimate,November 2006,,2006-11-30,January 2015,2015-01-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011),"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of MK0249 for the Symptomatic Treatment of Alzheimer's Disease",Completed,,Phase 2,144.0,Actual,Merck Sharp & Dohme Corp.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:49:44.724037,2020-02-01 20:49:44.724037,Merck Sharp & Dohme Corp.,Industry,Comparator: Placebo (unspecified),Drug
NCT03944460,"ClinicalTrials.gov processed this data on January 31, 2020",2019-04-26,,,2019-05-08,2019-05-08,2019-05-09,Actual,,,,,,,2019-05-08,2019-05-09,Actual,"April 9, 2018",Actual,2018-04-09,May 2019,2019-05-31,"July 27, 2018",Actual,2018-07-27,"July 27, 2018",Actual,2018-07-27,,Interventional,,,SAD Phase I Study (First-in-human) to Investigate Contraloid Acetate,"A Randomized, Double-blind and Placebo-controlled Single Ascending-dose Phase I Study (First-in-human) to Investigate the Safety, Tolerability and Pharmacokinetics of Contraloid Acetate (in Healthy Subjects).",Completed,,Phase 1,40.0,Actual,Forschungszentrum Juelich,,10.0,,,False,,,,True,False,False,,,,,,,,,No,Only as far as covered by the EU GDPR and regulated by GCP,2020-02-01 07:02:47.304616,2020-02-01 07:02:47.304616,Prof. Dr. Dieter Willbold,Other,Contraloid,Drug
NCT03955380,"ClinicalTrials.gov processed this data on January 31, 2020",2019-05-14,,,2019-05-17,2019-05-17,2019-05-20,Actual,,,,,,,2019-05-17,2019-05-20,Actual,"December 12, 2018",Actual,2018-12-12,May 2019,2019-05-31,"April 3, 2019",Actual,2019-04-03,"April 3, 2019",Actual,2019-04-03,,Interventional,,,MAD Phase I Study to Investigate Contraloid Acetate,"Single-center, Randomized, Prospective, Double-blind, Placebo Controlled Phase Ib Study With an Adaptive Multiple Ascending Dose (MAD) Design to Investigate the Safety, Tolerability, Pharmacokinetics of Contraloid Acetate (Healthy Subjects)",Completed,,Phase 1,24.0,Actual,Forschungszentrum Juelich,,4.0,,,False,,,,True,False,False,,,,,,,,,No,Only as far as covered by the EU GDPR and regulated by GCP,2020-02-01 07:01:11.779507,2020-02-01 07:01:11.779507,Prof. Dr. Dieter Willbold,Other,Contraloid,Drug
NCT03418688,"ClinicalTrials.gov processed this data on January 31, 2020",2018-01-26,,,2018-11-05,2018-01-26,2018-02-01,Actual,,,,,,,2018-11-05,2018-11-07,Actual,"March 6, 2018",Actual,2018-03-06,November 2018,2018-11-30,"October 15, 2018",Actual,2018-10-15,"October 15, 2018",Actual,2018-10-15,,Interventional,,,A Multiple Ascending Dose Study of COR388,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of COR388 in Older Healthy Volunteers and Patients With Alzheimer's Disease",Completed,,Phase 1,33.0,Actual,Cortexyme Inc.,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 08:23:47.480357,2020-02-01 08:23:47.480357,Cortexyme Inc.,Industry,COR388,Drug
NCT03823404,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-24,,,2020-01-10,2019-01-29,2019-01-30,Actual,,,,,,,2020-01-10,2020-01-13,Actual,"March 28, 2019",Actual,2019-03-28,December 2019,2019-12-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,,Interventional,,,GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease,"GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease",Recruiting,,Phase 2/Phase 3,573.0,Anticipated,Cortexyme Inc.,,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 07:20:47.948947,2020-02-01 07:20:47.948947,Cortexyme Inc.,Industry,COR388 capsule,Drug
NCT02185053,"ClinicalTrials.gov processed this data on January 31, 2020",2014-07-07,,,2016-07-25,2014-07-07,2014-07-09,Estimate,,,,,,,2016-07-25,2016-07-26,Estimate,July 2014,,2014-07-31,July 2016,2016-07-31,July 2016,Actual,2016-07-31,July 2016,Actual,2016-07-31,,Interventional,,,A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia,"A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia",Completed,,Phase 2,41.0,Actual,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",,1.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:33:37.765734,2020-02-01 12:33:37.765734,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",Industry,CPC-201,Drug
NCT02434666,"ClinicalTrials.gov processed this data on January 31, 2020",2015-04-28,,,2017-09-18,2015-05-04,2015-05-05,Estimate,,,,,,,2017-09-18,2017-09-20,Actual,"January 8, 2015",Actual,2015-01-08,September 2017,2017-09-30,"November 22, 2016",Actual,2016-11-22,"October 18, 2016",Actual,2016-10-18,,Interventional,,,Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07,Safety and Tolerability of CPC-201 in Patients With Dementia of the Alzheimer's Type Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07,Completed,,Phase 2,21.0,Actual,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",,1.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:36:46.147552,2020-02-01 11:36:46.147552,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",Industry,CPC-201,Drug
NCT02860065,"ClinicalTrials.gov processed this data on January 31, 2020",2016-07-26,,,2017-08-08,2016-08-08,2016-08-09,Estimate,,,,,,,2017-08-08,2017-08-09,Actual,"September 30, 2016",Anticipated,2016-09-30,August 2017,2017-08-31,"June 30, 2017",Anticipated,2017-06-30,"June 30, 2017",Anticipated,2017-06-30,,Interventional,,,CPC-201 Alzheimer's Disease Type Dementia: PET Study,"Phase II, Modified Single-Blind, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Cerebral Efficacy of CPC-201 in Patients With Alzheimer's Disease Type Dementia: PET Study",Withdrawn,,Phase 2,0.0,Actual,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 10:06:40.637557,2020-02-01 10:06:40.637557,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",Industry,CPC-201,Drug
NCT01723826,"ClinicalTrials.gov processed this data on January 31, 2020",2012-11-06,,2018-01-26,2019-02-21,2012-11-06,2012-11-08,Estimate,,,,2018-01-26,2018-01-29,Actual,2019-02-21,2019-02-22,Actual,"December 7, 2012",Actual,2012-12-07,February 2019,2019-02-28,"February 8, 2017",Actual,2017-02-08,"February 8, 2017",Actual,2017-02-08,,Interventional,,,A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab,"A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,360.0,Actual,"Genentech, Inc.",,1.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 14:31:59.534968,2020-02-01 14:31:59.534968,"Genentech, Inc.",Industry,Crenezumab,Drug
NCT01998841,"ClinicalTrials.gov processed this data on January 31, 2020",2013-11-22,,,2019-11-05,2013-11-25,2013-12-02,Estimate,,,,,,,2019-11-05,2019-11-06,Actual,"December 20, 2013",Actual,2013-12-20,November 2019,2019-11-30,"February 25, 2022",Anticipated,2022-02-25,"February 25, 2022",Anticipated,2022-02-25,,Interventional,,,"A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort","A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease","Active, not recruiting",,Phase 2,252.0,Actual,"Genentech, Inc.",,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 13:19:17.748616,2020-02-01 13:19:17.748616,"Genentech, Inc.",Industry,Crenezumab,Drug
NCT02670083,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-28,,,2019-09-23,2016-01-28,2016-02-01,Estimate,,,,,,,2019-09-23,2019-09-24,Actual,"March 22, 2016",Actual,2016-03-22,September 2019,2019-09-30,"May 31, 2019",Actual,2019-05-31,"May 31, 2019",Actual,2019-05-31,,Interventional,,,CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease",Completed,,Phase 3,813.0,Actual,Hoffmann-La Roche,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 10:44:00.131105,2020-02-01 10:44:00.131105,Hoffmann-La Roche,Industry,Crenezumab,Drug
NCT03114657,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-28,,,2019-10-03,2017-04-10,2017-04-14,Actual,,,,,,,2019-10-03,2019-10-04,Actual,"March 29, 2017",Actual,2017-03-29,October 2019,2019-10-31,"June 11, 2019",Actual,2019-06-11,"June 11, 2019",Actual,2019-06-11,,Interventional,CREAD 2,,A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease",Completed,,Phase 3,806.0,Actual,Hoffmann-La Roche,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 09:16:44.983523,2020-02-01 09:16:44.983523,Hoffmann-La Roche,Industry,Crenezumab,Drug
NCT02353598,"ClinicalTrials.gov processed this data on January 31, 2020",2015-01-23,,,2019-07-23,2015-01-30,2015-02-03,Estimate,,,,,,,2019-07-23,2019-07-24,Actual,"February 26, 2015",Actual,2015-02-26,July 2019,2019-07-31,"March 26, 2019",Actual,2019-03-26,"November 30, 2016",Actual,2016-11-30,,Interventional,,,A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease,"A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,77.0,Actual,"Genentech, Inc.",,5.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 11:54:27.261965,2020-02-01 11:54:27.261965,"Genentech, Inc.",Industry,Crenezumab dose level 1,Drug
NCT02353598,"ClinicalTrials.gov processed this data on January 31, 2020",2015-01-23,,,2019-07-23,2015-01-30,2015-02-03,Estimate,,,,,,,2019-07-23,2019-07-24,Actual,"February 26, 2015",Actual,2015-02-26,July 2019,2019-07-31,"March 26, 2019",Actual,2019-03-26,"November 30, 2016",Actual,2016-11-30,,Interventional,,,A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease,"A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,77.0,Actual,"Genentech, Inc.",,5.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 11:54:27.261965,2020-02-01 11:54:27.261965,"Genentech, Inc.",Industry,Crenezumab dose level 2,Drug
NCT03491150,"ClinicalTrials.gov processed this data on January 31, 2020",2018-03-15,,,2019-12-03,2018-04-05,2018-04-09,Actual,,,,,,,2019-12-03,2019-12-04,Actual,"April 11, 2018",Actual,2018-04-11,December 2019,2019-12-31,"May 31, 2019",Actual,2019-05-31,"May 31, 2019",Actual,2019-05-31,,Interventional,CREAD OLE,,An Open-Label Crenezumab Study in Patients With Alzheimer's Disease,"A Multicenter, Open-Label, Long-Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer's Disease",Completed,,Phase 3,149.0,Actual,Hoffmann-La Roche,,1.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:11:52.364738,2020-02-01 08:11:52.364738,Hoffmann-La Roche,Industry,Crenezumab (RO5490245),Drug
NCT02353598,"ClinicalTrials.gov processed this data on January 31, 2020",2015-01-23,,,2019-07-23,2015-01-30,2015-02-03,Estimate,,,,,,,2019-07-23,2019-07-24,Actual,"February 26, 2015",Actual,2015-02-26,July 2019,2019-07-31,"March 26, 2019",Actual,2019-03-26,"November 30, 2016",Actual,2016-11-30,,Interventional,,,A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease,"A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,77.0,Actual,"Genentech, Inc.",,5.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 11:54:27.261965,2020-02-01 11:54:27.261965,"Genentech, Inc.",Industry,Crenezumb dose level 3,Drug
NCT02907567,"ClinicalTrials.gov processed this data on January 31, 2020",2016-09-05,,,2018-07-24,2016-09-15,2016-09-20,Estimate,,,,,,,2018-07-24,2018-07-26,Actual,September 2016,Actual,2016-09-30,July 2018,2018-07-31,September 2017,Actual,2017-09-30,"August 24, 2017",Actual,2017-08-24,,Interventional,,,Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1/Phase 2,19.0,Actual,Cognition Therapeutics,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 09:57:57.979312,2020-02-01 09:57:57.979312,Cognition Therapeutics,Industry,CT1812,Drug
NCT03507790,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-10,,,2020-01-20,2018-04-16,2018-04-25,Actual,,,,,,,2020-01-20,2020-01-22,Actual,"October 2, 2018",Actual,2018-10-02,January 2020,2020-01-31,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,,Interventional,,,A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.",Recruiting,,Phase 2,120.0,Anticipated,Cognition Therapeutics,,3.0,,,,,,,True,True,False,,,,,,,,,No,,2020-02-01 08:09:06.429952,2020-02-01 08:09:06.429952,Cognition Therapeutics,Industry,CT1812,Drug
NCT03522129,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-30,,,2019-02-25,2018-04-30,2018-05-11,Actual,,,,,,,2019-02-25,2019-02-26,Actual,"May 16, 2018",Actual,2018-05-16,February 2019,2019-02-28,"December 31, 2019",Anticipated,2019-12-31,"September 30, 2019",Anticipated,2019-09-30,,Interventional,,,Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease,A Pilot Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease,Recruiting,,Phase 1,18.0,Anticipated,Cognition Therapeutics,,4.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:06:42.545213,2020-02-01 08:06:42.545213,Cognition Therapeutics,Industry,CT1812,Drug
NCT00621010,"ClinicalTrials.gov processed this data on January 31, 2020",2008-02-11,,,2008-07-07,2008-02-11,2008-02-22,Estimate,,,,,,,2008-07-07,2008-07-09,Estimate,June 2007,,2007-06-30,July 2008,2008-07-31,February 2008,Actual,2008-02-29,February 2008,Actual,2008-02-29,,Interventional,CTS,,Safety Study of CTS21166 to Treat Alzheimer Disease,A Phase 1 Single Escalating Dose Study to Assess the Safety and Pharmacokinetics of CTS21166 Administered Intravenously to Healthy Adult Males,Completed,,Phase 1,56.0,Actual,CoMentis,,1.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:46:49.730524,2020-02-01 19:46:49.730524,CoMentis,Industry,CTS21166 (ZPQ-21166),Drug
NCT00164749,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-09,,,2008-04-25,2005-09-09,2005-09-14,Estimate,,,,,,,2008-04-25,2008-04-30,Estimate,October 2004,,2004-10-31,April 2008,2008-04-30,July 2006,Actual,2006-07-31,July 2006,Actual,2006-07-31,,Interventional,,,A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease,A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease,Completed,,Phase 1/Phase 2,36.0,Actual,Chinese University of Hong Kong,,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:58:50.067117,2020-02-01 21:58:50.067117,Chinese University of Hong Kong,Other,Curcumin and ginkgo extract,Drug
NCT00001662,"ClinicalTrials.gov processed this data on January 31, 2020",1999-11-03,,,2008-03-03,1999-11-03,1999-11-04,Estimate,,,,,,,2008-03-03,2008-03-04,Estimate,December 1996,,1996-12-31,November 2005,2005-11-30,November 2005,,2005-11-30,,,,,Interventional,,,Treatment of Alzheimer's Disease With CX516 (Ampalex),Tolerability and Primary Efficacy of CX516 in Alzheimer's Disease,Completed,,Phase 2,40.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:50:32.826469,2020-02-01 22:50:32.826469,National Institute of Neurological Disorders and Stroke (NINDS),NIH,CX516 (Ampalex),Drug
NCT00013650,"ClinicalTrials.gov processed this data on January 31, 2020",2001-03-27,,,2017-06-30,2001-03-27,2001-03-28,Estimate,,,,,,,2017-06-30,2017-07-02,Actual,"March 22, 2001",,2001-03-22,"April 21, 2008",2008-04-21,"April 21, 2008",,2008-04-21,,,,,Interventional,,,Effects of an Anti-Inflammatory Drug in Alzheimer's Disease,Pilot Study of Immunomodulatory Versus Antiinflammatory Therapy in Alzheimer's Disease,Completed,,Phase 1,60.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:28.286287,2020-02-01 22:48:28.286287,National Institute of Mental Health (NIMH),NIH,Cyclophosphamate,Drug
NCT03802162,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-10,,,2019-10-21,2019-01-10,2019-01-14,Actual,,,,,,,2019-10-21,2019-10-23,Actual,"February 15, 2019",Actual,2019-02-15,October 2019,2019-10-31,"August 31, 2019",Actual,2019-08-31,"May 10, 2019",Actual,2019-05-10,,Interventional,,,"A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355","An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects",Completed,,Phase 1,60.0,Actual,Chong Kun Dang Pharmaceutical,,3.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:23:45.488096,2020-02-01 07:23:45.488096,Chong Kun Dang Pharmaceutical,Industry,D324 (Memantine HCl 10mg),Drug
NCT03802162,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-10,,,2019-10-21,2019-01-10,2019-01-14,Actual,,,,,,,2019-10-21,2019-10-23,Actual,"February 15, 2019",Actual,2019-02-15,October 2019,2019-10-31,"August 31, 2019",Actual,2019-08-31,"May 10, 2019",Actual,2019-05-10,,Interventional,,,"A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355","An Open-label, Randomized, Multiple-dosing Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355 With D797 and D324 in Healthy Subjects",Completed,,Phase 1,60.0,Actual,Chong Kun Dang Pharmaceutical,,3.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:23:45.488096,2020-02-01 07:23:45.488096,Chong Kun Dang Pharmaceutical,Industry,D797,Drug
NCT03752294,"ClinicalTrials.gov processed this data on January 31, 2020",2018-05-15,,,2018-11-20,2018-11-20,2018-11-23,Actual,,,,,,,2018-11-20,2018-11-23,Actual,November 2018,Anticipated,2018-11-30,November 2018,2018-11-30,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,,Interventional,,,A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.,"A 24-month, Randomized-control, Double-blind, Multi-center, Delayed-start, Pilot Study Evaluating Thrombin Inhibitions Alzheimer's Disease Using 150mg Dabigatran Daily: A Novel Therapeutic Target for Alzheimer's Disease",Not yet recruiting,,Phase 1,40.0,Anticipated,University of Rhode Island,,3.0,,,False,,,,True,False,False,,,False,,,,,,Undecided,,2020-02-01 07:31:02.811291,2020-02-01 07:31:02.811291,University of Rhode Island,Other,Dabigatran,Drug
NCT03752463,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-21,,,2018-11-21,2018-11-21,2018-11-26,Actual,,,,,,,2018-11-21,2018-11-26,Actual,"May 22, 2015",Actual,2015-05-22,April 2018,2018-04-30,"December 31, 2019",Anticipated,2019-12-31,"December 31, 2019",Anticipated,2019-12-31,,Interventional,,,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,Recruiting,,Phase 2,160.0,Anticipated,Chang Gung Memorial Hospital,,4.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 07:31:01.934898,2020-02-01 07:31:01.934898,Chang Gung Memorial Hospital,Other,DAOI-A group,Drug
NCT02103673,"ClinicalTrials.gov processed this data on January 31, 2020",2014-04-01,,,2018-01-23,2014-04-03,2014-04-04,Estimate,,,,,,,2018-01-23,2018-01-24,Actual,February 2014,,2014-02-28,January 2018,2018-01-31,November 2017,Actual,2017-11-30,November 2017,Actual,2017-11-30,,Interventional,,,DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia,,Completed,,Phase 2,90.0,Actual,Chang Gung Memorial Hospital,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:53:13.868291,2020-02-01 12:53:13.868291,Chang Gung Memorial Hospital,Other,DAOIB,Drug
NCT01600469,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-14,,,2013-06-03,2012-05-15,2012-05-17,Estimate,,,,,,,2013-06-03,2013-06-04,Estimate,January 2012,,2012-01-31,April 2011,2011-04-30,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease,NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease,Completed,,Phase 2,86.0,Actual,Chang Gung Memorial Hospital,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:04:31.673978,2020-02-01 15:04:31.673978,Chang Gung Memorial Hospital,Other,DAOI-B,Drug
NCT03752463,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-21,,,2018-11-21,2018-11-21,2018-11-26,Actual,,,,,,,2018-11-21,2018-11-26,Actual,"May 22, 2015",Actual,2015-05-22,April 2018,2018-04-30,"December 31, 2019",Anticipated,2019-12-31,"December 31, 2019",Anticipated,2019-12-31,,Interventional,,,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,Recruiting,,Phase 2,160.0,Anticipated,Chang Gung Memorial Hospital,,4.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 07:31:01.934898,2020-02-01 07:31:01.934898,Chang Gung Memorial Hospital,Other,DAOI-B group,Drug
NCT03752463,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-21,,,2018-11-21,2018-11-21,2018-11-26,Actual,,,,,,,2018-11-21,2018-11-26,Actual,"May 22, 2015",Actual,2015-05-22,April 2018,2018-04-30,"December 31, 2019",Anticipated,2019-12-31,"December 31, 2019",Anticipated,2019-12-31,,Interventional,,,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,Recruiting,,Phase 2,160.0,Anticipated,Chang Gung Memorial Hospital,,4.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 07:31:01.934898,2020-02-01 07:31:01.934898,Chang Gung Memorial Hospital,Other,DAOI-C group,Drug
NCT03801642,"ClinicalTrials.gov processed this data on January 31, 2020",2018-12-21,,,2019-06-04,2019-01-10,2019-01-11,Actual,,,,,,,2019-06-04,2019-06-05,Actual,"January 29, 2019",Actual,2019-01-29,June 2019,2019-06-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,,Interventional,,,Dapagliflozin In Alzheimer's Disease,Randomized Controlled Pilot Trial Of Dapagliflozin In Alzheimer's Disease,Recruiting,,Phase 1/Phase 2,48.0,Anticipated,University of Kansas Medical Center,,2.0,,,False,,,,True,True,False,,,False,,,,,,No,,2020-02-01 07:23:50.433150,2020-02-01 07:23:50.433150,"Jeff Burns, MD",Other,Dapagliflozin,Drug
NCT04070378,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-22,,,2019-11-06,2019-08-23,2019-08-28,Actual,,,,,,,2019-11-06,2019-11-08,Actual,"November 6, 2019",Actual,2019-11-06,November 2019,2019-11-30,"June 1, 2022",Anticipated,2022-06-01,"December 31, 2021",Anticipated,2021-12-31,,Interventional,DARZAD,,Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease,"An Open-Label, Pilot Study of Daratumumab SC in Patients With Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 2,15.0,Anticipated,Northwell Health,,1.0,,,False,,,,True,True,False,,,,,,,,,No,This study will comply with the Clinical Trials Registration and Results Information Submission rule. Result information from this trial will be submitted to ClinicalTrials.gov.,2020-02-01 06:44:17.594382,2020-02-01 06:44:17.594382,"Marc L Gordon, MD",Other,Daratumumab Injection,Drug
NCT04063124,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-01,,,2020-01-09,2019-08-16,2019-08-21,Actual,,,,,,,2020-01-09,2020-01-13,Actual,March 2020,Anticipated,2020-03-31,January 2020,2020-01-31,"December 31, 2022",Anticipated,2022-12-31,"August 31, 2021",Anticipated,2021-08-31,,Interventional,SToMP-AD,,Senolytic Therapy to Modulate Progression of Alzheimer's Disease,Pilot Study to Investigate the Safety and Feasibility of Senolytic Therapy to Modulate Progression of Alzheimer's Disease (SToMP-AD),Not yet recruiting,,Phase 1/Phase 2,5.0,Anticipated,The University of Texas Health Science Center at San Antonio,,1.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 06:45:22.479783,2020-02-01 06:45:22.479783,The University of Texas Health Science Center at San Antonio,Other,Dasatinib + Quercetin,Drug
NCT00154635,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-08,,,2005-09-08,2005-09-08,2005-09-12,Estimate,,,,,,,2005-09-08,2005-09-12,Estimate,September 2005,,2005-09-30,September 2005,2005-09-30,,,,,,,,Interventional,,,Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease,"A Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients With Mild to Moderate Alzheimer’s Disease",Unknown status,Not yet recruiting,Phase 2,80.0,,National Taiwan University Hospital,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:01:01.627223,2020-02-01 22:01:01.627223,National Taiwan University Hospital,Other,DCB-AD1,Drug
NCT03234686,"ClinicalTrials.gov processed this data on January 31, 2020",2017-07-23,,,2018-01-22,2017-07-26,2017-07-31,Actual,,,,,,,2018-01-22,2018-01-24,Actual,"January 19, 2018",Actual,2018-01-19,January 2018,2018-01-31,December 2021,Anticipated,2021-12-31,July 2021,Anticipated,2021-07-31,,Interventional,,,Deferiprone to Delay Dementia (The 3D Study),Deferiprone to Delay Dementia (The 3D Study): a Clinical Proof of Concept Study,Recruiting,,Phase 2,171.0,Anticipated,Neuroscience Trials Australia,,2.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 08:55:35.440556,2020-02-01 08:55:35.440556,Neuroscience Trials Australia,Other,Deferiprone 600mg delayed release tablets,Drug
NCT01608217,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-25,,,2014-06-26,2012-05-25,2012-05-31,Estimate,,,,,,,2014-06-26,2014-06-30,Estimate,June 2012,,2012-06-30,June 2014,2014-06-30,June 2014,Actual,2014-06-30,June 2014,Actual,2014-06-30,,Interventional,,,Delta-THC in Dementia,Efficacy and Safety of Delta-9-tetrahydrocannabinol (∆9-THC) in Behavioural Disturbances and Pain in Dementia,Completed,,Phase 2,50.0,Actual,Radboud University,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:02:26.242272,2020-02-01 15:02:26.242272,Radboud University,Other,delta-9-tetrahydrocannabinol (delta-THC),Drug
NCT04205539,"ClinicalTrials.gov processed this data on January 31, 2020",2019-12-17,,,2020-01-02,2019-12-18,2019-12-19,Actual,,,,,,,2020-01-02,2020-01-06,Actual,"April 10, 2019",Actual,2019-04-10,January 2020,2020-01-31,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,,Interventional,,,Lymphatic System Health in Alzheimer's Disease,Lymphatic System Health in Alzheimer's Disease,Enrolling by invitation,,Phase 1,50.0,Anticipated,Neurological Associates of West Los Angeles,,1.0,,,False,,,,False,True,False,,,True,,,,,,No,Data from this study will not be made publicly available due to ethical and privacy concerns. Anonymized data will be available upon reasonable request from any qualified investigator.,2020-02-01 06:25:55.080984,2020-02-01 06:25:55.080984,Neurological Associates of West Los Angeles,Other,Dexmedetomidine,Drug
NCT00254033,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-10,,,2017-04-26,2005-11-10,2005-11-15,Estimate,,,,,,,2017-04-26,2017-04-28,Actual,October 2003,,2003-10-31,April 2017,2017-04-30,October 2006,Actual,2006-10-31,,,,,Interventional,,,Apathy Associated With Alzheimer's Disease,The Role of the Dopaminergic Brain Reward System in Apathy Associated With Alzheimer's Disease,Completed,,Phase 4,40.0,,Sunnybrook Health Sciences Centre,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:37:52.210440,2020-02-01 21:37:52.210440,Sunnybrook Health Sciences Centre,Other,Dextroamphetamine,Drug
NCT00440050,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-22,2010-05-28,,2014-09-15,2007-02-22,2007-02-26,Estimate,2010-07-28,2010-08-30,Estimate,,,,2014-09-15,2014-09-25,Estimate,February 2007,,2007-02-28,September 2014,2014-09-30,May 2009,Actual,2009-05-31,May 2009,Actual,2009-05-31,,Interventional,DHA,,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease,Completed,,Phase 3,402.0,Actual,Alzheimer's Disease Cooperative Study (ADCS),,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:42:48.181086,2020-02-01 20:42:48.181086,Alzheimer's Disease Cooperative Study (ADCS),Other,DHA (Docosahexaenoic Acid),Drug
NCT03055741,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-14,,,2019-08-19,2017-02-15,2017-02-16,Actual,,,,,,,2019-08-19,2019-08-20,Actual,"December 28, 2016",Actual,2016-12-28,August 2019,2019-08-31,August 2019,Actual,2019-08-31,February 2019,Actual,2019-02-28,,Interventional,,,Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA),"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIb, Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)",Completed,,Phase 2,180.0,Actual,"Daehwa Pharmaceutical Co., Ltd.",,3.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:26:53.735013,2020-02-01 09:26:53.735013,"Daehwa Pharmaceutical Co., Ltd.",Industry,DHP1401,Drug
NCT00831506,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-27,,,2009-06-09,2009-01-27,2009-01-29,Estimate,,,,,,,2009-06-09,2009-06-12,Estimate,February 2009,,2009-02-28,June 2009,2009-06-30,May 2009,Actual,2009-05-31,May 2009,Actual,2009-05-31,,Interventional,,,Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy Subjects",Completed,,Phase 1,12.0,Actual,Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:44:44.911533,2020-02-01 18:44:44.911533,Pfizer,Industry,digoxin,Drug
NCT00704782,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-23,,2015-11-13,2015-11-13,2008-06-23,2008-06-25,Estimate,,,,2015-11-13,2015-12-10,Estimate,2015-11-13,2015-12-10,Estimate,April 2008,,2008-04-30,November 2015,2015-11-30,August 2010,Actual,2010-08-31,August 2010,Actual,2010-08-31,,Interventional,,,Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease,An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease,Terminated,,Phase 2,50.0,Actual,"Medivation, Inc.",,1.0,,The study was halted after a Phase 3 study of dimebon failed to show efficacy.,False,,,,,,,,,,,,,,,,,2020-02-01 19:22:31.164570,2020-02-01 19:22:31.164570,"Medivation, Inc.",Industry,dimebon,Drug
NCT00831506,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-27,,,2009-06-09,2009-01-27,2009-01-29,Estimate,,,,,,,2009-06-09,2009-06-12,Estimate,February 2009,,2009-02-28,June 2009,2009-06-30,May 2009,Actual,2009-05-31,May 2009,Actual,2009-05-31,,Interventional,,,Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy Subjects",Completed,,Phase 1,12.0,Actual,Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:44:44.911533,2020-02-01 18:44:44.911533,Pfizer,Industry,dimebon,Drug
NCT00377715,"ClinicalTrials.gov processed this data on January 31, 2020",2006-09-15,,,2015-11-09,2006-09-15,2006-09-18,Estimate,,,,,,,2015-11-09,2015-11-11,Estimate,September 2005,,2005-09-30,November 2015,2015-11-30,,,,August 2006,Actual,2006-08-31,,Interventional,,,"Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease","Phase 2, Double-Blind, Placebo-Controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,183.0,Actual,"Medivation, Inc.",,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:03:34.573776,2020-02-01 21:03:34.573776,"Medivation, Inc.",Industry,Dimebon,Drug
NCT00675623,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-07,,2016-09-24,2016-09-24,2008-05-08,2008-05-09,Estimate,,,,2016-09-24,2016-09-27,Estimate,2016-09-24,2016-09-27,Estimate,May 2008,,2008-05-31,September 2016,2016-09-30,,,,December 2009,Actual,2009-12-31,,Interventional,CONNECTION,,A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease,"A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease (CONNECTION)",Completed,,Phase 3,598.0,Actual,"Medivation, Inc.",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:31:17.244228,2020-02-01 19:31:17.244228,"Medivation, Inc.",Industry,Dimebon,Drug
NCT00824590,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-12,,,2009-12-29,2009-01-16,2009-01-19,Estimate,,,,,,,2009-12-29,2009-12-30,Estimate,February 2009,,2009-02-28,December 2009,2009-12-31,October 2009,Actual,2009-10-31,October 2009,Actual,2009-10-31,,Interventional,,,"A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function","A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function",Completed,,Phase 1,20.0,Actual,Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:46:46.838611,2020-02-01 18:46:46.838611,Pfizer,Industry,Dimebon,Drug
NCT00825084,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-12,,,2011-04-22,2009-01-16,2009-01-19,Estimate,,,,,,,2011-04-22,2011-04-26,Estimate,February 2009,,2009-02-28,April 2011,2011-04-30,May 2009,Actual,2009-05-31,May 2009,Actual,2009-05-31,,Interventional,,,"A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects","A Phase 1, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Placebo-Controlled, Parallel-Cohort, Single-Dose Escalation, And Multiple-Dose Titration Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects",Completed,,Phase 1,45.0,Actual,Pfizer,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:46:39.166582,2020-02-01 18:46:39.166582,Pfizer,Industry,Dimebon,Drug
NCT00827034,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-20,,,2018-10-11,2009-01-21,2009-01-22,Estimate,,,,,,,2018-10-11,2018-10-16,Actual,February 2009,,2009-02-28,October 2018,2018-10-31,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,,Interventional,,,"A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects","A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects",Completed,,Phase 1,14.0,Actual,Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:46:11.984947,2020-02-01 18:46:11.984947,Pfizer,Industry,Dimebon,Drug
NCT00829374,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-23,,2016-09-24,2016-09-24,2009-01-23,2009-01-27,Estimate,,,,2016-09-24,2016-09-27,Estimate,2016-09-24,2016-09-27,Estimate,March 2009,,2009-03-31,September 2016,2016-09-30,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,CONCERT,,Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil,"CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil",Completed,,Phase 3,1003.0,Actual,"Medivation, Inc.",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:45:29.101700,2020-02-01 18:45:29.101700,"Medivation, Inc.",Industry,Dimebon,Drug
NCT00829816,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-12,,,2015-11-06,2009-01-23,2009-01-27,Estimate,,,,,,,2015-11-06,2015-11-10,Estimate,December 2008,,2008-12-31,November 2015,2015-11-30,August 2010,Actual,2010-08-31,April 2009,Actual,2009-04-30,,Interventional,,,"Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil",A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2),Completed,,Phase 1,46.0,Actual,"Medivation, Inc.",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:45:21.480398,2020-02-01 18:45:21.480398,"Medivation, Inc.",Industry,Dimebon,Drug
NCT00838110,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-05,2012-10-11,2011-03-14,2018-11-06,2009-02-05,2009-02-06,Estimate,2013-01-07,2013-02-08,Estimate,2011-03-14,2011-03-25,Estimate,2018-11-06,2018-12-06,Actual,February 2009,,2009-02-28,November 2018,2018-11-30,January 2010,Actual,2010-01-31,January 2010,Actual,2010-01-31,,Interventional,,,A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease,"A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease",Completed,,Phase 3,742.0,Actual,Pfizer,This safety study did not specify primary or secondary outcome measures. Relevant summaries of all safety assessments are thus provided. Urine blood abnormalities seen are deemed due to interference with dipstick test by a metabolite of dimebon.,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:42:54.285215,2020-02-01 18:42:54.285215,Pfizer,Industry,Dimebon,Drug
NCT00939783,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-13,2012-10-11,2011-09-08,2012-10-11,2009-07-14,2009-07-15,Estimate,2012-10-11,2012-11-14,Estimate,2011-09-08,2011-09-12,Estimate,2012-10-11,2012-11-14,Estimate,September 2009,,2009-09-30,October 2012,2012-10-31,August 2010,Actual,2010-08-31,August 2010,Actual,2010-08-31,,Interventional,,,An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease,An Open Label Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon (PF 01913539) In Patients With Alzheimer's Disease,Terminated,,Phase 3,649.0,Actual,Pfizer,This safety study did not specify primary or secondary outcome measures. Relevant summaries of all safety assessments are thus provided. Urine blood abnormalities seen are deemed due to interference with dipstick test by a metabolite of dimebon.,1.0,,See termination reason in detailed description.,False,,,,True,,,,,,,,,,,,,2020-02-01 18:13:13.067029,2020-02-01 18:13:13.067029,Pfizer,Industry,Dimebon,Drug
NCT01152216,"ClinicalTrials.gov processed this data on January 31, 2020",2010-06-25,,2016-09-26,2016-09-26,2010-06-28,2010-06-29,Estimate,,,,2016-09-26,2016-09-27,Estimate,2016-09-26,2016-09-27,Estimate,April 2010,,2010-04-30,September 2016,2016-09-30,,,,May 2012,Actual,2012-05-31,,Interventional,CONCERT PLUS,,An Extension of the CONCERT Protocol (DIM18),An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients With Alzheimer's Disease,Terminated,,Phase 3,672.0,Actual,"Medivation, Inc.",,1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 17:07:07.232926,2020-02-01 17:07:07.232926,"Medivation, Inc.",Industry,Dimebon,Drug
NCT00912288,"ClinicalTrials.gov processed this data on January 31, 2020",2009-06-01,2012-07-30,2011-09-08,2012-08-30,2009-06-01,2009-06-03,Estimate,2012-08-30,2012-10-02,Estimate,2011-09-08,2011-09-12,Estimate,2012-08-30,2012-10-02,Estimate,September 2009,,2009-09-30,August 2012,2012-08-31,August 2010,Actual,2010-08-31,August 2010,Actual,2010-08-31,,Interventional,,,A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease",Terminated,,Phase 3,86.0,Actual,Pfizer,Results are not summarized because of early termination of the study due to modification in the development plan of the study medication following lack of demonstration of efficacy in the completed DIM14 CONNECTION (B1451002/NCT00675623) study.,2.0,,See termination reason in detailed description.,False,,,,True,,,,,,,,,,,,,2020-02-01 18:21:11.647277,2020-02-01 18:21:11.647277,Pfizer,Industry,Dimebon 20 mg po TID,Drug
NCT00954590,"ClinicalTrials.gov processed this data on January 31, 2020",2009-08-06,,2016-09-24,2016-09-24,2009-08-06,2009-08-07,Estimate,,,,2016-09-24,2016-09-27,Estimate,2016-09-24,2016-09-27,Estimate,October 2009,,2009-10-31,September 2016,2016-09-30,,,,August 2010,Actual,2010-08-31,,Interventional,CONTACT,,A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease,"CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease",Terminated,,Phase 3,89.0,Actual,"Medivation, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:08:26.614707,2020-02-01 18:08:26.614707,"Medivation, Inc.",Industry,Dimebon (latrepirdine),Drug
NCT01066546,"ClinicalTrials.gov processed this data on January 31, 2020",2010-02-09,2012-07-30,2011-09-08,2012-08-30,2010-02-09,2010-02-10,Estimate,2012-08-30,2012-10-02,Estimate,2011-09-08,2011-09-12,Estimate,2012-08-30,2012-10-02,Estimate,April 2010,,2010-04-30,August 2012,2012-08-31,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease,"An Open-Label Extension To The B1451006 Protocol To Evaluate The Safety And Efficacy Of Dimebon (Latrepirdine, PF-01913539) In Subjects With Moderate-To-Severe Alzheimer's Disease",Terminated,,Phase 3,5.0,Actual,Pfizer,Results are not summarized because of early termination of the study due to modification in the development plan of the study treatment following lack of demonstration of efficacy in the completed DIM14 CONNECTION (B1451002/NCT00675623) study.,1.0,,See termination reason in detailed description.,False,,,,True,,,,,,,,,,,,,2020-02-01 17:31:59.188993,2020-02-01 17:31:59.188993,Pfizer,Industry,Dimebon tablet for oral administration,Drug
NCT00208819,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-13,,,2013-11-12,2005-09-13,2005-09-21,Estimate,,,,,,,2013-11-12,2013-11-13,Estimate,September 2003,,2003-09-30,November 2013,2013-11-30,July 2007,Actual,2007-07-31,,,,,Interventional,,,A Comparison of Two Standard Therapies in the Management of Dementia With Agitation,"Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies",Completed,,Phase 4,50.0,Anticipated,Emory University,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:47:41.232383,2020-02-01 21:47:41.232383,Emory University,Other,divalproex,Drug
NCT00088387,"ClinicalTrials.gov processed this data on January 31, 2020",2004-07-23,,,2008-03-03,2004-07-23,2004-07-26,Estimate,,,,,,,2008-03-03,2008-03-04,Estimate,July 2004,,2004-07-31,March 2005,2005-03-31,March 2005,,2005-03-31,,,,,Interventional,,,Effect of Lithium and Divalproex in Alzheimer's Disease,Glycogen Synthetase Kinase 3 (GSK-3) Inhibition in Alzheimer's Disease,Completed,,Phase 2,35.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:23:17.991451,2020-02-01 22:23:17.991451,National Institute of Neurological Disorders and Stroke (NINDS),NIH,Divalproex,Drug
NCT00375557,"ClinicalTrials.gov processed this data on January 31, 2020",2006-09-11,,,2015-05-26,2006-09-11,2006-09-13,Estimate,,,,,,,2015-05-26,2015-05-27,Estimate,October 2006,,2006-10-31,May 2015,2015-05-31,September 2007,Actual,2007-09-30,,,,,Interventional,,,Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients,"An Open Label, Randomized, Flexible Dose, 6-week Clinical Trial of the Safety and Efficacy of Divalproex ER vs Quetiapine in the Treatment of Behavioral Symptoms in the Elderly With Moderate to Severe Alzheimer's Dementia",Withdrawn,,Phase 4,0.0,Actual,University of Cincinnati,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:04:09.030665,2020-02-01 21:04:09.030665,University of Cincinnati,Other,Divalproex ER,Drug
NCT00235716,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-06,2013-12-06,,2014-07-14,2005-10-06,2005-10-10,Estimate,2014-01-23,2014-01-29,Estimate,,,,2014-07-14,2014-07-23,Estimate,August 2007,,2007-08-31,July 2014,2014-07-31,October 2012,Actual,2012-10-31,September 2012,Actual,2012-09-30,,Interventional,TEAM-AD,,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease","CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)",Completed,,Phase 3,613.0,Actual,VA Office of Research and Development,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:42:18.318346,2020-02-01 21:42:18.318346,US Department of Veterans Affairs,U.S. Fed,dl-alpha-tocopherol,Drug
NCT00414622,"ClinicalTrials.gov processed this data on January 31, 2020",2006-12-19,,,2007-04-18,2006-12-20,2006-12-21,Estimate,,,,,,,2007-04-18,2007-04-19,Estimate,November 2006,,2006-11-30,December 2006,2006-12-31,April 2007,Actual,2007-04-30,,,,,Interventional,,,GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease,"A Double Blind, Placebo-Controlled Randomized Study to Compare the Safety and Tolerability of GTS-21 (25 Mg TID, 50 Mg TID, 75 Mg TID and 150 Mg TID) When Administered Daily for 28 Days to Participants With Probable Alzheimer’s Disease",Completed,,Phase 2,60.0,,CoMentis,,,,,True,,,,,,,,,,,,,,,,,2020-02-01 20:51:12.392877,2020-02-01 20:51:12.392877,CoMentis,Industry,DMXB-A,Drug
NCT03757325,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-27,,,2020-01-08,2018-11-27,2018-11-28,Actual,,,,,,,2020-01-08,2020-01-13,Actual,"February 13, 2019",Actual,2019-02-13,January 2020,2020-01-31,"December 5, 2019",Actual,2019-12-05,"December 5, 2019",Actual,2019-12-05,,Interventional,,,Study to Evaluate DNL747 in Subjects With Alzheimer's Disease,"A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Alzheimer's Disease",Completed,,Phase 1,16.0,Actual,Denali Therapeutics Inc.,,2.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 07:30:24.698174,2020-02-01 07:30:24.698174,Denali Therapeutics Inc.,Industry,DNL747,Drug
NCT03740178,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-12,,,2019-05-02,2018-11-12,2018-11-14,Actual,,,,,,,2019-05-02,2019-05-03,Actual,"September 27, 2019",Anticipated,2019-09-27,April 2019,2019-04-30,"February 28, 2020",Anticipated,2020-02-28,"February 28, 2020",Anticipated,2020-02-28,,Interventional,,,Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005),"A Randomized, Double-Blinded Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MK-4334 in Participants With Alzheimer's Clinical Syndrome on a Stable Dose of Donepezil",Not yet recruiting,,Phase 1,12.0,Anticipated,Merck Sharp & Dohme Corp.,,2.0,,,False,,,,False,True,False,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2020-02-01 07:32:49.642464,2020-02-01 07:32:49.642464,Merck Sharp & Dohme Corp.,Industry,Donepepzil,Drug
NCT00190021,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-11,,,2010-09-05,2005-09-11,2005-09-19,Estimate,,,,,,,2010-09-05,2010-09-08,Estimate,,,,October 2005,2005-10-31,,,,,,,,Interventional,,,Donepezil Treatment of Psychotic Symptoms in Dementia Patients,Donepezil as Add-On Treatment of Psychotic Symptoms in Patients With Dementia of the Alzheimer's Type,Unknown status,Not yet recruiting,Phase 3,80.0,Anticipated,Beersheva Mental Health Center,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:51:51.641122,2020-02-01 21:51:51.641122,Beersheva Mental Health Center,Other,donepezil,Drug
NCT00348192,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-30,,,2009-05-28,2006-06-30,2006-07-04,Estimate,,,,,,,2009-05-28,2009-06-02,Estimate,May 2006,,2006-05-31,May 2009,2009-05-31,,,,,,,,Interventional,,,SB-742457 And Donepezil In Alzheimer's Disease,"A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Investigate the Effects of SB-742457, Donepezil and Placebo on Cognition in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,200.0,,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:11:59.993954,2020-02-01 21:11:59.993954,GlaxoSmithKline,Industry,donepezil,Drug
NCT00480870,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-30,,,2007-12-03,2007-05-30,2007-05-31,Estimate,,,,,,,2007-12-03,2007-12-04,Estimate,April 1999,,1999-04-30,December 2007,2007-12-31,January 2005,Actual,2005-01-31,,,,,Interventional,ACHALZSLEEP,,The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients,The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients,Completed,,Phase 4,65.0,Actual,Associacao Fundo de Incentivo a Psicofarmcologia,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:30:18.858543,2020-02-01 20:30:18.858543,Associacao Fundo de Incentivo a Psicofarmcologia,Other,donepezil,Drug
NCT00602680,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-16,,,2009-07-17,2008-01-16,2008-01-28,Estimate,,,,,,,2009-07-17,2009-07-20,Estimate,January 2008,,2008-01-31,July 2009,2009-07-31,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,,,Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease,"A Multicenter, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance and Safety/Tolerability of SSR180711C for 4 Weeks, Using Donepezil as Calibrator, in Patients With Mild Alzheimer's Disease",Terminated,,Phase 2,1.0,Actual,Sanofi,,5.0,,Insufficient expected benefit risk,False,,,,True,,,,,,,,,,,,,2020-02-01 19:52:44.951641,2020-02-01 19:52:44.951641,Sanofi,Industry,donepezil,Drug
NCT00948909,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-24,,2011-11-22,2013-01-29,2009-07-28,2009-07-29,Estimate,,,,2011-11-22,2011-11-24,Estimate,2013-01-29,2013-01-31,Estimate,October 2009,,2009-10-31,January 2013,2013-01-31,November 2010,Actual,2010-11-30,November 2010,Actual,2010-11-30,,Interventional,,,Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 2,274.0,Actual,AbbVie,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:10:27.171592,2020-02-01 18:10:27.171592,"AbbVie (prior sponsor, Abbott)",Industry,donepezil,Drug
NCT01018875,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-20,,2012-02-01,2018-06-01,2009-11-23,2009-11-24,Estimate,,,,2012-02-01,2012-02-03,Estimate,2018-06-01,2018-06-06,Actual,December 2009,,2009-12-31,January 2013,2013-01-31,February 2011,Actual,2011-02-28,February 2011,Actual,2011-02-28,,Interventional,,,Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Active- and Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 2,242.0,Actual,AbbVie,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:45:00.201179,2020-02-01 17:45:00.201179,"AbbVie (prior sponsor, Abbott)",Industry,donepezil,Drug
NCT01023425,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-30,,,2016-01-04,2009-12-01,2009-12-02,Estimate,,,,,,,2016-01-04,2016-01-06,Estimate,February 2008,,2008-02-29,January 2016,2016-01-31,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,,Interventional,,,Clinical Trial of Donepezil Between the Naive Group and the Switching Group,Comparative Assessment of Clinical Efficacy of Donepezil Between the Naive Group and the Switching Group,Completed,,N/A,72.0,Actual,Samsung Medical Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:43:52.223238,2020-02-01 17:43:52.223238,Samsung Medical Center,Other,donepezil,Drug
NCT01023867,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-30,,,2016-01-04,2009-12-01,2009-12-02,Estimate,,,,,,,2016-01-04,2016-01-06,Estimate,March 2007,,2007-03-31,January 2016,2016-01-31,June 2010,Actual,2010-06-30,June 2010,Actual,2010-06-30,,Interventional,,,Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia,Comparative Assessment of Clinical Efficacy of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia,Completed,,N/A,88.0,Actual,Samsung Medical Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:43:43.140576,2020-02-01 17:43:43.140576,Samsung Medical Center,Other,donepezil,Drug
NCT01137526,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-07,,2012-07-20,2013-01-24,2010-06-03,2010-06-04,Estimate,,,,2012-07-20,2012-07-27,Estimate,2013-01-24,2013-01-29,Estimate,May 2010,,2010-05-31,January 2013,2013-01-31,July 2011,Actual,2011-07-31,July 2011,Actual,2011-07-31,,Interventional,,,Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 2,267.0,Actual,AbbVie,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:11:16.177593,2020-02-01 17:11:16.177593,"AbbVie (prior sponsor, Abbott)",Industry,donepezil,Drug
NCT01527916,"ClinicalTrials.gov processed this data on January 31, 2020",2012-02-03,,2014-11-06,2014-11-06,2012-02-03,2012-02-07,Estimate,,,,2014-11-06,2014-11-19,Estimate,2014-11-06,2014-11-19,Estimate,February 2012,,2012-02-29,November 2014,2014-11-30,November 2013,Actual,2013-11-30,November 2013,Actual,2013-11-30,,Interventional,,,Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,438.0,Actual,AbbVie,,5.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:22:19.770584,2020-02-01 15:22:19.770584,"AbbVie (prior sponsor, Abbott)",Industry,donepezil,Drug
NCT01849042,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-06,,,2014-08-12,2013-05-07,2013-05-08,Estimate,,,,,,,2014-08-12,2014-08-13,Estimate,January 2013,,2013-01-31,August 2014,2014-08-31,August 2015,Anticipated,2015-08-31,August 2014,Anticipated,2014-08-31,,Interventional,ROMEO-AD,,Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease,"A Multicenter, Randomized, Open-label, Prospective Study to Estimate the add-on Effects of Memantine as Ebixa Oral Pump on Language in Moderate to Severe Alzheimer's Disease Patients Already Receiving Donepezil.",Unknown status,Recruiting,Phase 4,188.0,Anticipated,Konkuk University Medical Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:00:52.134192,2020-02-01 14:00:52.134192,Konkuk University Medical Center,Other,donepezil,Drug
NCT02305836,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-13,,,2017-05-13,2014-11-28,2014-12-03,Estimate,,,,,,,2017-05-13,2017-05-16,Actual,June 2017,Anticipated,2017-06-30,May 2017,2017-05-31,December 2019,Anticipated,2019-12-31,June 2019,Anticipated,2019-06-30,,Interventional,,,Effect of Electroacupuncture Combined With Donepezil for Treating Alzheimer's Disease,The Effect of Electroacupuncture Combined With Donepezil on Cognitive Function in Alzheimer's Disease Patients: Study Protocol for a Randomized Controlled Trial,Unknown status,Recruiting,Phase 2,334.0,Anticipated,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,,2.0,,,False,,,,True,False,False,,,,,,,,,,,2020-02-01 12:05:20.079249,2020-02-01 12:05:20.079249,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,Other,donepezil,Drug
NCT02550665,"ClinicalTrials.gov processed this data on January 31, 2020",2015-09-10,,,2018-08-06,2015-09-14,2015-09-15,Estimate,,,,,,,2018-08-06,2018-08-07,Actual,December 2014,Actual,2014-12-31,August 2018,2018-08-31,October 2016,Actual,2016-10-31,August 2016,Actual,2016-08-31,,Interventional,ODESA,,Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg,"A Multicenter, Randomized, Open-label, Prospective Trial to Evaluate the Safety and Tolerability of Donepezil 23 mg With or Without Intermediate Dose Titration in Patients With Alzheimer's Disease Taking Donepezil Hydrochloride 10 mg",Completed,,Phase 3,176.0,Actual,Asan Medical Center,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 11:10:07.215800,2020-02-01 11:10:07.215800,Asan Medical Center,Other,donepezil,Drug
NCT00000173,"ClinicalTrials.gov processed this data on January 31, 2020",1999-10-29,,,2009-12-10,1999-10-29,1999-11-01,Estimate,,,,,,,2009-12-10,2009-12-11,Estimate,March 1999,,1999-03-31,June 2009,2009-06-30,January 2004,Actual,2004-01-31,January 2004,Actual,2004-01-31,,Interventional,,,Memory Impairment Study (Mild Cognitive Impairment Study),"A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)",Completed,,Phase 3,,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:51:08.456650,2020-02-01 22:51:08.456650,National Institute on Aging (NIA),NIH,Donepezil,Drug
NCT00006399,"ClinicalTrials.gov processed this data on January 31, 2020",2000-08-18,,,2009-01-13,2000-08-18,2000-08-21,Estimate,,,,,,,2009-01-13,2009-01-15,Estimate,September 1999,,1999-09-30,January 2009,2009-01-31,March 2004,Actual,2004-03-31,March 2004,Actual,2004-03-31,,Interventional,,,Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease,Estrogen Modulation Effects on Cholinergic Function in Normal Post-Menopausal Women and Patients With Alzheimer's Disease,Completed,,Phase 2,45.0,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:49:05.038881,2020-02-01 22:49:05.038881,National Center for Research Resources (NCRR),NIH,Donepezil,Drug
NCT00042172,"ClinicalTrials.gov processed this data on January 31, 2020",2002-07-24,,,2014-02-27,2002-07-25,2002-07-26,Estimate,,,,,,,2014-02-27,2014-03-03,Estimate,June 2002,,2002-06-30,February 2014,2014-02-28,September 2004,Actual,2004-09-30,September 2004,Actual,2004-09-30,,Interventional,,,Treatment for Early Memory Loss,Cognitive Enhancers Explored With PET Imaging,Completed,,Phase 4,40.0,,University of Iowa,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:43:17.651846,2020-02-01 22:43:17.651846,University of Iowa,Other,Donepezil,Drug
NCT00151398,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-06,,2013-02-07,2013-02-07,2005-09-07,2005-09-08,Estimate,,,,2013-02-07,2013-02-11,Estimate,2013-02-07,2013-02-11,Estimate,September 2005,,2005-09-30,July 2008,2008-07-31,March 2008,Actual,2008-03-31,March 2008,Actual,2008-03-31,,Interventional,,,Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD),"A 3-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study Of 3 Doses Of Lecozotan (SRA-333) SR In Outpatients With Mild To Moderate Alzheimer's Disease With Donepezil As Active Control.",Completed,,Phase 2,229.0,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:02:22.166435,2020-02-01 22:02:22.166435,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,Donepezil,Drug
NCT00174382,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-08,2009-04-24,,2015-03-04,2005-09-09,2005-09-15,Estimate,2009-04-24,2009-06-12,Estimate,,,,2015-03-04,2015-03-24,Estimate,June 2005,,2005-06-30,March 2015,2015-03-31,April 2008,Actual,2008-04-30,April 2008,Actual,2008-04-30,,Interventional,,,Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia,An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia,Terminated,,Phase 3,149.0,Actual,Pfizer,,1.0,,See Detailed Description,False,,,,False,,,,,,,,,,,,,2020-02-01 21:56:22.758430,2020-02-01 21:56:22.758430,Pfizer,Industry,Donepezil,Drug
NCT00381381,"ClinicalTrials.gov processed this data on January 31, 2020",2006-09-25,2010-08-03,,2012-08-23,2006-09-25,2006-09-27,Estimate,2012-06-20,2012-07-27,Estimate,,,,2012-08-23,2012-08-31,Estimate,May 2006,,2006-05-31,July 2010,2010-07-31,December 2008,Actual,2008-12-31,August 2008,Actual,2008-08-31,,Interventional,,,The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease,A Multi-center Study for the Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease,Completed,,Phase 4,199.0,Actual,Eisai Inc.,,1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:02:20.006665,2020-02-01 21:02:20.006665,Eisai Korea Inc.,Industry,Donepezil,Drug
NCT00423228,"ClinicalTrials.gov processed this data on January 31, 2020",2007-01-17,,,2015-01-13,2007-01-17,2007-01-18,Estimate,,,,,,,2015-01-13,2015-01-14,Estimate,February 2007,,2007-02-28,January 2015,2015-01-31,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,,Interventional,BRAINz,,Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease,"A Randomised, Double-blind, Double-dummy, Oral Donepezil Controlled Study on the Safety and Efficacy of Repeated Monthly Subcutaneous Injections of a Sustained-release Implant of ZT 1 in Patients With Moderate Alzheimer's Disease",Completed,,N/A,228.0,Actual,Debiopharm International SA,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:48:39.791345,2020-02-01 20:48:39.791345,Debiopharm International SA,Industry,Donepezil,Drug
NCT00501111,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-12,,,2014-07-22,2007-07-12,2007-07-13,Estimate,,,,,,,2014-07-22,2014-07-23,Estimate,July 2007,,2007-07-31,July 2014,2014-07-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,Sirocco,,Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease,"A Multi-centre, Double-blind, Double-dummy, Placebo Controlled Parallel Group Randomized Phase IIb Proof of Concept Study With 3 Oral Dose Groups of AZD3480 or Donepezil During 12 Weeks Treatment in Patients With Alzheimer's Disease",Completed,,Phase 2,659.0,Actual,AstraZeneca,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:24:11.554357,2020-02-01 20:24:11.554357,AstraZeneca,Industry,Donepezil,Drug
NCT00505167,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-20,,,2008-12-26,2007-07-20,2007-07-23,Estimate,,,,,,,2008-12-26,2008-12-29,Estimate,July 2007,,2007-07-31,December 2008,2008-12-31,December 2008,Actual,2008-12-31,July 2008,Actual,2008-07-31,,Interventional,,,Memantine Versus Donepezil in Early Stages of Alzheimer's Disease,Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy.,Completed,,Phase 4,64.0,Actual,Hospital Miguel Servet,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:23:03.403094,2020-02-01 20:23:03.403094,Hospital Miguel Servet,Other,Donepezil,Drug
NCT00693004,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-30,,,2009-07-28,2008-06-05,2008-06-06,Estimate,,,,,,,2009-07-28,2009-07-30,Estimate,May 2008,,2008-05-31,July 2009,2009-07-31,,,,January 2010,Anticipated,2010-01-31,,Interventional,,,Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of PRX-03140 as Monotherapy in Subjects With Alzheimer's Disease",Terminated,,Phase 2,236.0,Anticipated,"Epix Pharmaceuticals, Inc.",,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:26:04.087803,2020-02-01 19:26:04.087803,"Epix Pharmaceuticals, Inc.",Industry,Donepezil,Drug
NCT00708552,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-30,2017-07-24,2012-02-23,2018-05-31,2008-06-30,2008-07-02,Estimate,2017-07-24,2018-02-12,Actual,2012-02-23,2012-02-28,Estimate,2018-05-31,2018-07-27,Actual,"July 4, 2008",,2008-07-04,May 2018,2018-05-31,"March 9, 2010",Actual,2010-03-09,"March 1, 2010",Actual,2010-03-01,,Interventional,,"The population used to define the Baseline Characteristics was the Intent-to-Treat (ITT Population) which comprised of all participants randomized to treatment, and who received at least one dose of study medication and who had at least one post baseline assessment.",Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease,"Study AZ3110865, a Study Comparing SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease",Completed,,Phase 2,576.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:21:02.377486,2020-02-01 19:21:02.377486,GlaxoSmithKline,Industry,Donepezil,Drug
NCT00766363,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-01,2011-06-16,,2012-04-18,2008-10-02,2008-10-03,Estimate,2011-06-16,2011-07-14,Estimate,,,,2012-04-18,2012-04-20,Estimate,October 2008,,2008-10-31,April 2012,2012-04-30,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 1,49.0,Actual,FORUM Pharmaceuticals Inc,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:04:53.564244,2020-02-01 19:04:53.564244,FORUM Pharmaceuticals Inc,Industry,Donepezil,Drug
NCT00866060,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-19,,,2009-03-19,2009-03-19,2009-03-20,Estimate,,,,,,,2009-03-19,2009-03-20,Estimate,February 2008,,2008-02-29,March 2009,2009-03-31,June 2013,Anticipated,2013-06-30,February 2012,Anticipated,2012-02-29,,Interventional,DOMINO-AD,,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Unknown status,Recruiting,Phase 4,800.0,Anticipated,King's College London,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:34:35.920768,2020-02-01 18:34:35.920768,King's College London,Other,Donepezil,Drug
NCT00895895,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-07,2012-12-21,,2012-12-21,2009-05-07,2009-05-08,Estimate,2012-12-21,2013-01-31,Estimate,,,,2012-12-21,2013-01-31,Estimate,May 2009,,2009-05-31,December 2012,2012-12-31,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease,"A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease",Terminated,,Phase 2,526.0,Actual,Pfizer,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,5.0,,See termination reason in detailed description.,False,,,,True,,,,,,,,,,,,,2020-02-01 18:26:03.286124,2020-02-01 18:26:03.286124,Pfizer,Industry,Donepezil,Drug
NCT01266525,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-23,,2016-02-12,2016-02-12,2010-12-23,2010-12-24,Estimate,,,,2016-02-12,2016-03-14,Estimate,2016-02-12,2016-03-14,Estimate,February 2011,,2011-02-28,February 2016,2016-02-29,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,,Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil,"A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy",Completed,,Phase 2,291.0,Actual,Sanofi,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:32:09.069267,2020-02-01 16:32:09.069267,Sanofi,Industry,Donepezil,Drug
NCT01362686,"ClinicalTrials.gov processed this data on January 31, 2020",2011-05-26,2016-07-22,,2017-01-08,2011-05-27,2011-05-30,Estimate,2017-01-08,2017-02-27,Actual,,,,2017-01-08,2017-02-27,Actual,April 2011,,2011-04-30,January 2017,2017-01-31,October 2015,Actual,2015-10-31,October 2015,Actual,2015-10-31,,Interventional,COMET-AD,,Comparative Research of Alzheimer's Disease Drugs,Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs,Terminated,,N/A,200.0,Actual,Indiana University,Small sample size limits generalizability and may introduce type II error. The study took place at a time when most third-party payers declared donepezil the preferred AChEI due to cost that may have influenced study’s results.,3.0,,Low study accrual caused the study to be ended early.,False,,,,True,,,,,,,,,,,,,2020-02-01 16:05:14.947359,2020-02-01 16:05:14.947359,Indiana University,Other,Donepezil,Drug
NCT01466088,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-02,,2015-05-11,2015-05-11,2011-11-04,2011-11-06,Estimate,,,,2015-05-11,2015-06-03,Estimate,2015-05-11,2015-06-03,Estimate,October 2011,,2011-10-31,July 2014,2014-07-31,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,"Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)","Double-Blind, Positive Comparator, Randomized, Parallel Study of Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients With Mild to Moderate Dementia of the Alzheimer's Type",Completed,,Phase 2,386.0,Actual,Targacept Inc.,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:38:14.385865,2020-02-01 15:38:14.385865,Targacept Inc.,Industry,Donepezil,Drug
NCT01677754,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-30,,2016-07-20,2017-05-25,2012-08-30,2012-09-03,Estimate,,,,2016-07-20,2016-07-22,Estimate,2017-05-25,2017-05-30,Actual,"October 24, 2012",Actual,2012-10-24,May 2017,2017-05-31,"June 12, 2015",Actual,2015-06-12,"June 12, 2015",Actual,2015-06-12,,Interventional,MAyflOwer RoAD,,A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy,"A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease",Completed,,Phase 2,542.0,Actual,Hoffmann-La Roche,,3.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 14:44:43.645589,2020-02-01 14:44:43.645589,Hoffmann-La Roche,Industry,Donepezil,Drug
NCT01822951,"ClinicalTrials.gov processed this data on January 31, 2020",2013-03-25,,,2015-10-23,2013-03-28,2013-04-04,Estimate,,,,,,,2015-10-23,2015-10-26,Estimate,,,,October 2015,2015-10-31,December 2016,Anticipated,2016-12-31,September 2016,Anticipated,2016-09-30,,Interventional,DAT,,Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT),"Comparison of Cerebrolysin and Donepezil: A Randomized, Double-blind, Controlled Trial on Efficacy and Safety in Patients With Mild to Moderate Alzheimer's Disease",Withdrawn,,Phase 4,0.0,Actual,Ever Neuro Pharma GmbH,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:07:07.136651,2020-02-01 14:07:07.136651,Ever Neuro Pharma GmbH,Industry,Donepezil,Drug
NCT02051335,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-29,2015-05-17,,2016-12-02,2014-01-29,2014-01-31,Estimate,2015-07-20,2015-08-17,Estimate,,,,2016-12-02,2017-02-01,Estimate,January 2014,,2014-01-31,September 2016,2016-09-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults,"A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (Hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults",Completed,,Phase 1,27.0,Actual,AstraZeneca,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:05:37.068408,2020-02-01 13:05:37.068408,AstraZeneca,Industry,Donepezil,Drug
NCT02178124,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-27,,,2015-03-23,2014-06-27,2014-06-30,Estimate,,,,,,,2015-03-23,2015-03-25,Estimate,July 2014,,2014-07-31,March 2015,2015-03-31,December 2014,Actual,2014-12-31,December 2014,Actual,2014-12-31,,Interventional,,,"A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.",,Completed,,Phase 1,24.0,Actual,Icure Pharmaceutical Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:35:08.640851,2020-02-01 12:35:08.640851,Icure Pharmaceutical Inc.,Industry,Donepezil,Drug
NCT02337907,"ClinicalTrials.gov processed this data on January 31, 2020",2014-12-23,2018-08-29,,2018-10-18,2015-01-09,2015-01-14,Estimate,2018-10-18,2018-11-14,Actual,,,,2018-10-18,2018-11-14,Actual,"January 21, 2015",Actual,2015-01-21,October 2018,2018-10-31,"October 10, 2017",Actual,2017-10-10,"September 15, 2017",Actual,2017-09-15,,Interventional,,Treated Set (TS) included all patients who were randomised and treated with at least one dose of trial medication.,BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,"A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease",Completed,,Phase 2,329.0,Actual,Boehringer Ingelheim,"There were 5 patients who were randomised to donepezil arm which was dropped from the trial with protocol amendment. No further patients were randomised to this arm, but patients already randomised continued in the trial as originally planned.",6.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 11:58:09.189083,2020-02-01 11:58:09.189083,Boehringer Ingelheim,Industry,Donepezil,Drug
NCT02549196,"ClinicalTrials.gov processed this data on January 31, 2020",2015-08-27,2018-09-28,,2019-02-12,2015-09-11,2015-09-15,Estimate,2019-02-12,2019-03-05,Actual,,,,2019-02-12,2019-03-05,Actual,"October 7, 2015",Actual,2015-10-07,February 2019,2019-02-28,"September 28, 2017",Actual,2017-09-28,"September 28, 2017",Actual,2017-09-28,,Interventional,CPC-12,,A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type,"A Phase II, Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type",Completed,,Phase 2,28.0,Actual,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 11:10:22.839904,2020-02-01 11:10:22.839904,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",Industry,Donepezil,Drug
NCT02769065,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-10,2018-05-30,,2019-03-08,2016-05-10,2016-05-11,Estimate,2019-03-08,2019-06-10,Actual,,,,2019-03-08,2019-06-10,Actual,"May 5, 2016",Actual,2016-05-05,March 2019,2019-03-31,"June 8, 2017",Actual,2017-06-08,"June 8, 2017",Actual,2017-06-08,,Interventional,,Safety analysis set (SAS) included all participants who were enrolled and received at least 1 dose of the study drug.,Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants,"A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects",Terminated,,Phase 1,179.0,Actual,Takeda,,30.0,,Terminated prematurely as data from cohort no longer needed due to indication change.,False,,,,False,True,False,,,,,,,,,,,2020-02-01 10:23:19.348529,2020-02-01 10:23:19.348529,Takeda,Industry,Donepezil,Drug
NCT02787746,"ClinicalTrials.gov processed this data on January 31, 2020",2016-03-06,,,2019-03-04,2016-05-26,2016-06-01,Estimate,,,,,,,2019-03-04,2019-03-05,Actual,April 2016,Actual,2016-04-30,March 2019,2019-03-31,March 2019,Actual,2019-03-31,January 2019,Actual,2019-01-31,,Interventional,STDMMAD,,Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease,Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease: A Multi-center Single-arm Study in China,Completed,,Phase 4,241.0,Actual,Beijing Friendship Hospital,,1.0,,,False,,,,True,,,,,,,,,,,Undecided,No data will be share.,2020-02-01 10:19:35.636597,2020-02-01 10:19:35.636597,Beijing Friendship Hospital,Other,Donepezil,Drug
NCT03030105,"ClinicalTrials.gov processed this data on January 31, 2020",2017-01-17,,,2018-10-15,2017-01-20,2017-01-24,Estimate,,,,,,,2018-10-15,2018-10-16,Actual,January 2017,Actual,2017-01-31,October 2018,2018-10-31,June 2017,Actual,2017-06-30,May 2017,Actual,2017-05-31,,Interventional,,,Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers,"A Randomized, Double-blind, Placebo-controlled, Single-dose, 6-Period Crossover Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers",Completed,,Phase 1,38.0,Actual,Tetra Discovery Partners,,6.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 09:31:54.545833,2020-02-01 09:31:54.545833,Tetra Discovery Partners,Industry,Donepezil,Drug
NCT03055741,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-14,,,2019-08-19,2017-02-15,2017-02-16,Actual,,,,,,,2019-08-19,2019-08-20,Actual,"December 28, 2016",Actual,2016-12-28,August 2019,2019-08-31,August 2019,Actual,2019-08-31,February 2019,Actual,2019-02-28,,Interventional,,,Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA),"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIb, Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)",Completed,,Phase 2,180.0,Actual,"Daehwa Pharmaceutical Co., Ltd.",,3.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:26:53.735013,2020-02-01 09:26:53.735013,"Daehwa Pharmaceutical Co., Ltd.",Industry,Donepezil,Drug
NCT03090516,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-04,,,2019-08-05,2017-03-23,2017-03-24,Actual,,,,,,,2019-08-05,2019-08-07,Actual,"August 10, 2016",Actual,2016-08-10,August 2019,2019-08-31,"March 10, 2020",Anticipated,2020-03-10,"March 10, 2020",Anticipated,2020-03-10,,Interventional,,,Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease,Clinical Study on Improving the Cognitive Function of Patients With Mild to Moderate Alzheimer's Disease by Using Ginkgo Biloba Dispersible Tablets,Recruiting,,Phase 2/Phase 3,240.0,Anticipated,The First Affiliated Hospital with Nanjing Medical University,,3.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 09:20:54.354890,2020-02-01 09:20:54.354890,The First Affiliated Hospital with Nanjing Medical University,Other,Donepezil,Drug
NCT03316898,"ClinicalTrials.gov processed this data on January 31, 2020",2017-10-18,,,2018-10-31,2017-10-18,2017-10-20,Actual,,,,,,,2018-10-31,2018-11-02,Actual,"September 30, 2018",Anticipated,2018-09-30,October 2018,2018-10-31,"November 4, 2018",Anticipated,2018-11-04,"November 4, 2018",Anticipated,2018-11-04,,Interventional,,,A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease",Withdrawn,,Phase 1,0.0,Actual,Allergan,,4.0,,Business decision to stop the study.,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:40:51.152227,2020-02-01 08:40:51.152227,Allergan,Industry,Donepezil,Drug
NCT03698695,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-02,,,2020-01-21,2018-10-03,2018-10-09,Actual,,,,,,,2020-01-21,2020-01-22,Actual,"September 27, 2018",Actual,2018-09-27,January 2020,2020-01-31,"December 20, 2019",Actual,2019-12-20,"October 20, 2019",Actual,2019-10-20,,Interventional,,,"A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers","A Double Blind, Placebo-controlled, Randomized, 15-day Treatment, Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil Administered Orally to Healthy Male Volunteers Including a Scopolamine Challenge",Completed,,Phase 1,152.0,Actual,Theranexus,,3.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:39:11.698156,2020-02-01 07:39:11.698156,Theranexus,Industry,Donepezil,Drug
NCT03810794,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-17,,,2019-03-05,2019-01-17,2019-01-22,Actual,,,,,,,2019-03-05,2019-03-07,Actual,"March 1, 2019",Actual,2019-03-01,September 2018,2018-09-30,"September 30, 2021",Anticipated,2021-09-30,"March 30, 2021",Anticipated,2021-03-30,,Interventional,,,Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease,Clinical Evaluation on the Therapeutic Effect of Acupuncture Treatment for Alzheimer's Disease: Multicenter Randomized Controlled Trial,Recruiting,,N/A,180.0,Anticipated,Shanghai University of Traditional Chinese Medicine,,2.0,,,False,,,,True,False,False,,,False,,,,,,,,2020-02-01 07:22:35.344272,2020-02-01 07:22:35.344272,Shanghai University of Traditional Chinese Medicine,Other,Donepezil,Drug
NCT04117178,"ClinicalTrials.gov processed this data on January 31, 2020",2019-09-30,,,2019-10-02,2019-10-02,2019-10-07,Actual,,,,,,,2019-10-02,2019-10-07,Actual,November 2019,Anticipated,2019-11-30,October 2019,2019-10-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,,Interventional,MONANTI,,Monitoring Anti-Dementia Drugs by Serum Levels,"Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title)",Not yet recruiting,,Phase 4,110.0,Anticipated,Zealand University Hospital,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2020-02-01 06:37:51.700954,2020-02-01 06:37:51.700954,Zealand University Hospital,Other,Donepezil,Drug
NCT01487395,"ClinicalTrials.gov processed this data on January 31, 2020",2011-12-05,,,2015-04-08,2011-12-06,2011-12-07,Estimate,,,,,,,2015-04-08,2015-04-09,Estimate,December 2011,,2011-12-31,April 2015,2015-04-30,December 2013,Actual,2013-12-31,December 2012,Actual,2012-12-31,,Interventional,PharmacogWP3,,Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development,Effect of a 15-day Donepezil Treatment on Biomarkers of AD in Healthy Volunteers,Completed,,Phase 1,30.0,Actual,"University Hospital, Lille",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:32:28.068353,2020-02-01 15:32:28.068353,"University Hospital, Lille",Other,Donepezil .,Drug
NCT01255046,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-03,,,2014-08-19,2010-12-05,2010-12-07,Estimate,,,,,,,2014-08-19,2014-08-20,Estimate,December 2015,,2015-12-31,August 2014,2014-08-31,,,,December 2018,Anticipated,2018-12-31,,Interventional,,,Study of STA-1 as an Add-on Treatment to Donepezil,"A Phase II Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of STA-1 as an Add-on Treatment to Donepezil in Patients With Mild to Moderate Alzheimer's Disease",Unknown status,Not yet recruiting,Phase 2,136.0,Anticipated,"Sinphar Pharmaceutical Co., Ltd",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:35:48.924341,2020-02-01 16:35:48.924341,"Sinphar Pharmaceutical Co., Ltd",Other,"Donepezil,",Drug
NCT00777608,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-21,2011-01-27,,2015-08-11,2008-10-21,2008-10-22,Estimate,2011-01-27,2011-02-24,Estimate,,,,2015-08-11,2015-08-25,Estimate,December 2008,,2008-12-31,August 2015,2015-08-31,April 2010,Actual,2010-04-30,October 2009,Actual,2009-10-31,,Interventional,,,A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial, With Placebo Run-In, and an Open-Label Treatment Period, to Evaluate the Performance of the CogState Computerized Neuropsychological Battery and the ADAS-Cog in Generally Cholinesterase-naive AD Patients",Completed,,Phase 1,106.0,Actual,Merck Sharp & Dohme Corp.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:01:34.894121,2020-02-01 19:01:34.894121,Merck Sharp & Dohme Corp.,Industry,Donepezil 10 mg,Drug
NCT00710684,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-30,2017-08-18,2011-03-17,2017-11-03,2008-07-03,2008-07-04,Estimate,2017-11-03,2017-12-07,Actual,2011-04-21,2011-04-28,Estimate,2017-11-03,2017-12-07,Actual,"July 1, 2008",Actual,2008-07-01,November 2017,2017-11-30,"November 16, 2010",Actual,2010-11-16,"May 21, 2010",Actual,2010-05-21,,Interventional,,"Out of 682 participants, 5 participants did not have at least one post-Baseline or health outcomes assessment. Hence a total of 677 participants were included in intent-to-treat (ITT) population and they were used to assess Baseline characteristics.","A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease","Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease",Completed,,Phase 2,682.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:20:26.859390,2020-02-01 19:20:26.859390,GlaxoSmithKline,Industry,donepezil 5-10mg,Drug
NCT00777608,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-21,2011-01-27,,2015-08-11,2008-10-21,2008-10-22,Estimate,2011-01-27,2011-02-24,Estimate,,,,2015-08-11,2015-08-25,Estimate,December 2008,,2008-12-31,August 2015,2015-08-31,April 2010,Actual,2010-04-30,October 2009,Actual,2009-10-31,,Interventional,,,A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial, With Placebo Run-In, and an Open-Label Treatment Period, to Evaluate the Performance of the CogState Computerized Neuropsychological Battery and the ADAS-Cog in Generally Cholinesterase-naive AD Patients",Completed,,Phase 1,106.0,Actual,Merck Sharp & Dohme Corp.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:01:34.894121,2020-02-01 19:01:34.894121,Merck Sharp & Dohme Corp.,Industry,Donepezil 5 - 10 mg,Drug
NCT00874939,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-02,2015-05-26,,2018-09-18,2009-04-02,2009-04-03,Estimate,2015-05-26,2015-06-08,Estimate,,,,2018-09-18,2018-10-17,Actual,"April 6, 2009",Actual,2009-04-06,September 2018,2018-09-30,"April 20, 2009",Actual,2009-04-20,"April 20, 2009",Actual,2009-04-20,,Interventional,,,A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023),A Randomized Clinical Trial To Evaluate the Single Dose Acute Effects of MK-0249 and Donepezil On Cognitive Function In Adult Patients With Alzheimer's Disease,Terminated,,Phase 1,4.0,Actual,Merck Sharp & Dohme Corp.,,12.0,,,False,,,,False,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2020-02-01 18:32:14.819408,2020-02-01 18:32:14.819408,Merck Sharp & Dohme Corp.,Industry,Donepezil 5mg,Drug
NCT00467766,"ClinicalTrials.gov processed this data on January 31, 2020",2007-04-27,,,2007-05-03,2007-04-27,2007-05-01,Estimate,,,,,,,2007-05-03,2007-05-07,Estimate,July 1999,,1999-07-31,May 2007,2007-05-31,June 2003,Actual,2003-06-30,,,,,Interventional,,,Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer’s Disease,Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer’s Disease,Completed,,N/A,300.0,Actual,National Institute on Aging (NIA),,,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:34:14.041825,2020-02-01 20:34:14.041825,Pfizer,Industry,Donepezil (Aricept),Drug
NCT00630851,"ClinicalTrials.gov processed this data on January 31, 2020",2008-02-27,,,2015-03-04,2008-02-27,2008-03-07,Estimate,,,,,,,2015-03-04,2015-03-05,Estimate,October 2002,,2002-10-31,March 2015,2015-03-31,October 2004,Actual,2004-10-31,,,,,Interventional,,,A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes,"A Six-month, Multicenter, Double-blind, Parallel, Placebo-controlled Study of the Effect on Global/Behavioural/ADL Functions and Tolerability of Aricept in Patients Wtih Severe Alzheimer's Disease Living in an Assisted Care Facility",Completed,,Phase 3,249.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:44:05.194318,2020-02-01 19:44:05.194318,Pfizer,Industry,Donepezil (Aricept),Drug
NCT00571064,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-06,2018-02-07,,2018-08-28,2007-12-10,2007-12-11,Estimate,2018-02-07,2018-03-12,Actual,,,,2018-08-28,2018-09-27,Actual,January 2008,Actual,2008-01-31,February 2018,2018-02-28,"April 22, 2009",Actual,2009-04-22,December 2008,Actual,2008-12-31,,Interventional,,Safety population included all enrolled participants who took at least one dose of study medication.,The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility,"A 12-Week, Multicenter, Open Label Study To Evaluate The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility",Completed,,Phase 4,97.0,Actual,Eisai Inc.,,1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:01:14.298319,2020-02-01 20:01:14.298319,Eisai Inc.,Industry,Donepezil HCl,Drug
NCT02097056,"ClinicalTrials.gov processed this data on January 31, 2020",2014-03-24,2016-03-30,,2016-05-20,2014-03-25,2014-03-26,Estimate,2016-05-20,2016-06-27,Estimate,,,,2016-05-20,2016-06-27,Estimate,February 2014,,2014-02-28,May 2016,2016-05-31,May 2015,Actual,2015-05-31,May 2015,Actual,2015-05-31,,Interventional,SAVE,Safety population included all participants who received at least one dose of study treatment and had at least one postbaseline safety assessment.,Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease,Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease,Completed,,Phase 4,171.0,Actual,Eisai Inc.,,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 12:54:44.879115,2020-02-01 12:54:44.879115,Eisai Korea Inc.,Industry,Donepezil HCL,Drug
NCT00477659,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-23,,,2009-05-06,2007-05-23,2007-05-24,Estimate,,,,,,,2009-05-06,2009-05-07,Estimate,July 2007,,2007-07-31,May 2009,2009-05-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,Neural Correlates In Mild Alzheimer's Disease,A Single Center Study To Examine Neural Correlates Of Cognition In Subjects With Mild Alzheimer's Disease After Three Months Of Open Label Donepezil HCl (Aricept® ) Treatment,Completed,,Phase 4,14.0,Actual,Eisai Inc.,,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:31:07.909156,2020-02-01 20:31:07.909156,Eisai Inc.,Industry,donepezil HCl (Aricept),Drug
NCT00096473,"ClinicalTrials.gov processed this data on January 31, 2020",2004-11-09,,,2011-03-31,2004-11-09,2004-11-10,Estimate,,,,,,,2011-03-31,2011-04-01,Estimate,January 2001,,2001-01-31,March 2011,2011-03-31,September 2005,Actual,2005-09-30,June 2005,Actual,2005-06-30,,Interventional,,,Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease,"A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period",Completed,,Phase 3,229.0,Actual,Eisai Inc.,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:19:28.469382,2020-02-01 22:19:28.469382,Eisai Inc.,Industry,Donepezil hydrochloride,Drug
NCT00165724,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-12,,,2012-05-02,2005-09-12,2005-09-14,Estimate,,,,,,,2012-05-02,2012-05-04,Estimate,June 2004,,2004-06-30,July 2010,2010-07-31,December 2006,Actual,2006-12-31,July 2006,Actual,2006-07-31,,Interventional,,,Alzheimer's Disease Long-term Follow-up Study (ALF Study),Alzheimer's Disease Long-term Follow-up Study (ALF Study),Completed,,Phase 4,114.0,Actual,Eisai Inc.,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:58:42.472608,2020-02-01 21:58:42.472608,Eisai Korea Inc.,Industry,Donepezil Hydrochloride,Drug
NCT03151382,"ClinicalTrials.gov processed this data on January 31, 2020",2017-05-08,,,2017-05-10,2017-05-10,2017-05-12,Actual,,,,,,,2017-05-10,2017-05-12,Actual,"May 20, 2017",Anticipated,2017-05-20,May 2017,2017-05-31,"June 30, 2018",Anticipated,2018-06-30,"December 31, 2017",Anticipated,2017-12-31,,Interventional,,,A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease,A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease,Unknown status,Not yet recruiting,Phase 4,30.0,Anticipated,Zhejiang Provincial People’s Hospital,,2.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 09:10:15.470273,2020-02-01 09:10:15.470273,Zhejiang Provincial People’s Hospital,Other,Donepezil Hydrochloride,Drug
NCT00165659,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-12,,,2010-01-28,2005-09-12,2005-09-14,Estimate,,,,,,,2010-01-28,2010-01-29,Estimate,November 2002,,2002-11-30,January 2010,2010-01-31,,,,May 2005,Actual,2005-05-31,,Interventional,,,"A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020",,Completed,,Phase 2,,,Eisai Inc.,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:58:43.541174,2020-02-01 21:58:43.541174,Eisai Limited,Industry,DONEPEZIL HYDROCHLORIDE,Drug
NCT00165750,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-12,,,2013-11-19,2005-09-12,2005-09-14,Estimate,,,,,,,2013-11-19,2013-11-20,Estimate,March 2005,,2005-03-31,November 2013,2013-11-30,November 2008,Actual,2008-11-30,August 2008,Actual,2008-08-31,,Interventional,,,Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients,Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients,Terminated,,Phase 4,40.0,Actual,Eisai Inc.,,1.0,,Lack of patients to enroll.,False,,,,,,,,,,,,,,,,,2020-02-01 21:58:42.313177,2020-02-01 21:58:42.313177,Eisai Korea Inc.,Industry,DONEPEZIL HYDROCHLORIDE,Drug
NCT00711204,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-21,,,2012-12-06,2008-07-07,2008-07-08,Estimate,,,,,,,2012-12-06,2012-12-10,Estimate,January 2008,,2008-01-31,December 2012,2012-12-31,,,,June 2009,Actual,2009-06-30,,Interventional,,,Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease,"A 12-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease",Withdrawn,,Phase 4,0.0,Actual,Eisai Inc.,,2.0,,No patients were enrolled in the study.,False,,,,,,,,,,,,,,,,,2020-02-01 19:20:18.889152,2020-02-01 19:20:18.889152,Eisai Inc.,Industry,Donepezil Hydrochloride (Aricept),Drug
NCT01860625,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-15,,,2014-06-27,2013-05-22,2013-05-23,Estimate,,,,,,,2014-06-27,2014-06-30,Estimate,April 2013,,2013-04-30,June 2014,2014-06-30,February 2014,Actual,2014-02-28,December 2013,Actual,2013-12-31,,Interventional,,,"A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects",,Completed,,Phase 1,36.0,Actual,Icure Pharmaceutical Inc.,,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 13:56:59.008525,2020-02-01 13:56:59.008525,Icure Pharmaceutical Inc.,Industry,Donepezil patch,Drug
NCT03197740,"ClinicalTrials.gov processed this data on January 31, 2020",2017-06-22,,,2019-02-18,2017-06-22,2017-06-23,Actual,,,,,,,2019-02-18,2019-02-20,Actual,"October 12, 2017",Actual,2017-10-12,February 2019,2019-02-28,"November 30, 2019",Anticipated,2019-11-30,"March 31, 2019",Anticipated,2019-03-31,,Interventional,,,"A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease","A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease",Recruiting,,Phase 3,346.0,Anticipated,Icure Pharmaceutical Inc.,,4.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 09:02:12.547717,2020-02-01 09:02:12.547717,Icure Pharmaceutical Inc.,Industry,Donepezil patch,Drug
NCT02051335,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-29,2015-05-17,,2016-12-02,2014-01-29,2014-01-31,Estimate,2015-07-20,2015-08-17,Estimate,,,,2016-12-02,2017-02-01,Estimate,January 2014,,2014-01-31,September 2016,2016-09-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults,"A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (Hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults",Completed,,Phase 1,27.0,Actual,AstraZeneca,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:05:37.068408,2020-02-01 13:05:37.068408,AstraZeneca,Industry,Donepezil placebo,Drug
NCT03030105,"ClinicalTrials.gov processed this data on January 31, 2020",2017-01-17,,,2018-10-15,2017-01-20,2017-01-24,Estimate,,,,,,,2018-10-15,2018-10-16,Actual,January 2017,Actual,2017-01-31,October 2018,2018-10-31,June 2017,Actual,2017-06-30,May 2017,Actual,2017-05-31,,Interventional,,,Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers,"A Randomized, Double-blind, Placebo-controlled, Single-dose, 6-Period Crossover Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers",Completed,,Phase 1,38.0,Actual,Tetra Discovery Partners,,6.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 09:31:54.545833,2020-02-01 09:31:54.545833,Tetra Discovery Partners,Industry,Donepezil placebo,Drug
NCT00911807,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-07,2009-04-07,,2009-06-04,2009-04-07,2009-06-02,Estimate,2009-04-07,2009-06-02,Estimate,,,,2009-06-04,2009-06-10,Estimate,October 2004,,2004-10-31,June 2009,2009-06-30,April 2008,Actual,2008-04-30,April 2008,Actual,2008-04-30,,Interventional,Combi,,Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease,"A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)",Completed,,Phase 2,217.0,Actual,Ever Neuro Pharma GmbH,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:21:22.041636,2020-02-01 18:21:22.041636,Ever Neuro Pharma GmbH,Industry,Donepezil + placebo,Drug
NCT02769065,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-10,2018-05-30,,2019-03-08,2016-05-10,2016-05-11,Estimate,2019-03-08,2019-06-10,Actual,,,,2019-03-08,2019-06-10,Actual,"May 5, 2016",Actual,2016-05-05,March 2019,2019-03-31,"June 8, 2017",Actual,2017-06-08,"June 8, 2017",Actual,2017-06-08,,Interventional,,Safety analysis set (SAS) included all participants who were enrolled and received at least 1 dose of the study drug.,Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants,"A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects",Terminated,,Phase 1,179.0,Actual,Takeda,,30.0,,Terminated prematurely as data from cohort no longer needed due to indication change.,False,,,,False,True,False,,,,,,,,,,,2020-02-01 10:23:19.348529,2020-02-01 10:23:19.348529,Takeda,Industry,Donepezil Placebo,Drug
NCT03259958,"ClinicalTrials.gov processed this data on January 31, 2020",2017-08-21,,,2018-07-31,2017-08-23,2017-08-24,Actual,,,,,,,2018-07-31,2018-08-01,Actual,"October 30, 2017",Actual,2017-10-30,July 2018,2018-07-31,"March 14, 2018",Actual,2018-03-14,"March 13, 2018",Actual,2018-03-13,,Interventional,,,A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®,A Study to Assess the Steady-State Bioequivalence of Once-Weekly Corplex™ 10mg Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept®,Completed,,Phase 1,86.0,Actual,Corium International Inc.,,2.0,,,False,,,,False,True,False,,,,,,,,,No,No Plans,2020-02-01 08:51:15.666250,2020-02-01 08:51:15.666250,Corium International Inc.,Industry,Donepezil TDS,Drug
NCT03432195,"ClinicalTrials.gov processed this data on January 31, 2020",2018-01-31,,,2018-08-06,2018-02-07,2018-02-14,Actual,,,,,,,2018-08-06,2018-08-07,Actual,"January 31, 2018",Actual,2018-01-31,August 2018,2018-08-31,"June 28, 2018",Actual,2018-06-28,"June 28, 2018",Actual,2018-06-28,,Interventional,,,A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations,"A Phase 1, Crossover Study to Evaluate the Pharmacokinetics of Corplex™ Donepezil 10 mg Transdermal Delivery System Applied to Different Body Locations",Completed,,Phase 1,66.0,Actual,Corium International Inc.,,3.0,,,False,,,,False,True,False,,,,,,,,,No,no plans,2020-02-01 08:21:28.478722,2020-02-01 08:21:28.478722,Corium International Inc.,Industry,Donepezil TDS,Drug
NCT03438604,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-13,,,2018-09-13,2018-02-13,2018-02-19,Actual,,,,,,,2018-09-13,2018-09-14,Actual,"February 13, 2018",Actual,2018-02-13,September 2018,2018-09-30,"June 30, 2018",Actual,2018-06-30,"June 19, 2018",Actual,2018-06-19,,Interventional,,,A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS),"A Phase 1, 2-Way Crossover Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil 5 mg Transdermal Delivery System (TDS) in Healthy Volunteers",Completed,,Phase 1,24.0,Actual,Corium International Inc.,,3.0,,,False,,,,False,True,False,,,,,,,,,No,No plans,2020-02-01 08:20:15.224851,2020-02-01 08:20:15.224851,Corium International Inc.,Industry,Donepezil TDS,Drug
NCT02968719,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-13,,,2018-07-31,2016-11-16,2016-11-21,Estimate,,,,,,,2018-07-31,2018-08-01,Actual,November 2016,Actual,2016-11-30,July 2018,2018-07-31,"July 11, 2017",Actual,2017-07-11,"July 11, 2017",Actual,2017-07-11,,Interventional,,,"A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®",Phase 1 Pharmacokinetic (PK) Study to Evaluate Once-weekly Corplex™ Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept® in Healthy Adult Subjects,Completed,,Phase 1,107.0,Actual,Corium International Inc.,,5.0,,,False,,,,False,,,,,,,,,,,No,No Plans,2020-02-01 09:43:14.203162,2020-02-01 09:43:14.203162,Corium International Inc.,Industry,Donepezil TDS Version A,Drug
NCT02968719,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-13,,,2018-07-31,2016-11-16,2016-11-21,Estimate,,,,,,,2018-07-31,2018-08-01,Actual,November 2016,Actual,2016-11-30,July 2018,2018-07-31,"July 11, 2017",Actual,2017-07-11,"July 11, 2017",Actual,2017-07-11,,Interventional,,,"A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®",Phase 1 Pharmacokinetic (PK) Study to Evaluate Once-weekly Corplex™ Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept® in Healthy Adult Subjects,Completed,,Phase 1,107.0,Actual,Corium International Inc.,,5.0,,,False,,,,False,,,,,,,,,,,No,No Plans,2020-02-01 09:43:14.203162,2020-02-01 09:43:14.203162,Corium International Inc.,Industry,Donepezil TDS Version B,Drug
NCT02968719,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-13,,,2018-07-31,2016-11-16,2016-11-21,Estimate,,,,,,,2018-07-31,2018-08-01,Actual,November 2016,Actual,2016-11-30,July 2018,2018-07-31,"July 11, 2017",Actual,2017-07-11,"July 11, 2017",Actual,2017-07-11,,Interventional,,,"A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®",Phase 1 Pharmacokinetic (PK) Study to Evaluate Once-weekly Corplex™ Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept® in Healthy Adult Subjects,Completed,,Phase 1,107.0,Actual,Corium International Inc.,,5.0,,,False,,,,False,,,,,,,,,,,No,No Plans,2020-02-01 09:43:14.203162,2020-02-01 09:43:14.203162,Corium International Inc.,Industry,Donepezil TDS Version D,Drug
NCT02968719,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-13,,,2018-07-31,2016-11-16,2016-11-21,Estimate,,,,,,,2018-07-31,2018-08-01,Actual,November 2016,Actual,2016-11-30,July 2018,2018-07-31,"July 11, 2017",Actual,2017-07-11,"July 11, 2017",Actual,2017-07-11,,Interventional,,,"A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®",Phase 1 Pharmacokinetic (PK) Study to Evaluate Once-weekly Corplex™ Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept® in Healthy Adult Subjects,Completed,,Phase 1,107.0,Actual,Corium International Inc.,,5.0,,,False,,,,False,,,,,,,,,,,No,No Plans,2020-02-01 09:43:14.203162,2020-02-01 09:43:14.203162,Corium International Inc.,Industry,Donepezil TDS Version E,Drug
NCT00483028,"ClinicalTrials.gov processed this data on January 31, 2020",2007-06-05,,,2008-02-01,2007-06-05,2007-06-06,Estimate,,,,,,,2008-02-01,2008-02-05,Estimate,June 2004,,2004-06-30,February 2008,2008-02-29,January 2007,Actual,2007-01-31,,,,,Interventional,,,"A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI","A Randomized Double-Blind, Parallel, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil (5 mg QD for 6 Weeks) After Single Dose and Steady State Therapy (2 Weeks and 6 Weeks) in Subjects With Mild Cognitive Impairment",Completed,,N/A,38.0,,Pfizer,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:29:43.785041,2020-02-01 20:29:43.785041,Pfizer,Industry,donezepil (Aricept),Drug
NCT00439166,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-20,,,2018-03-15,2007-02-21,2007-02-23,Estimate,,,,,,,2018-03-15,2018-03-19,Actual,February 2007,,2007-02-28,March 2017,2017-03-31,December 2010,Actual,2010-12-31,April 2010,Actual,2010-04-30,,Interventional,,,Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Completed,,Phase 3,100.0,Actual,McMaster University,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:43:09.592414,2020-02-01 20:43:09.592414,Hamilton Health Sciences Corporation,Other,doxycycline,Drug
NCT00715858,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-11,,,2009-02-03,2008-07-11,2008-07-15,Estimate,,,,,,,2009-02-03,2009-02-04,Estimate,May 2008,,2008-05-31,February 2009,2009-02-28,October 2009,Anticipated,2009-10-31,August 2009,Anticipated,2009-08-31,,Interventional,,,A Pilot Study of Inflammatory Markers in Alzheimer's Disease,A Pilot Study Comparing Inflammatory Biomarkers in Blood and CSF in Patients With Alzheimer's Disease and Age-Matched Controls,Unknown status,Recruiting,Phase 3,21.0,Anticipated,McMaster University,,5.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:19:02.908370,2020-02-01 19:19:02.908370,McMaster University,Other,doxycycline,Drug
NCT02792257,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-26,,,2019-06-25,2016-06-01,2016-06-07,Estimate,,,,,,,2019-06-25,2019-06-27,Actual,"March 1, 2017",Actual,2017-03-01,June 2019,2019-06-30,December 2020,Anticipated,2020-12-31,August 2020,Anticipated,2020-08-31,,Interventional,THC-AD,,Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD),Pilot Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD),Recruiting,,Phase 2,160.0,Anticipated,Johns Hopkins University,,2.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 10:18:48.371685,2020-02-01 10:18:48.371685,Johns Hopkins University,Other,Dronabinol (Marinol®),Drug
NCT01978327,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-31,,,2017-06-07,2013-10-31,2013-11-07,Estimate,,,,,,,2017-06-07,2017-06-08,Actual,"November 22, 2013",Actual,2013-11-22,June 2017,2017-06-30,"March 3, 2014",Actual,2014-03-03,"March 3, 2014",Actual,2014-03-03,,Interventional,,,"GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers","Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of GSK2647544 and Its Potential Pharmacokinetic Interaction With Simvastatin in Healthy Volunteers",Terminated,,Phase 1,12.0,Actual,GlaxoSmithKline,,4.0,,"Given the strength of CYP3A4 inhibition observed in Cohort 1, there is no rationale to
    investigate higher doses of GSK2647544 in the following two cohorts",False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 13:24:18.754282,2020-02-01 13:24:18.754282,GlaxoSmithKline,Industry,drug-drug interaction,Drug
NCT01294540,"ClinicalTrials.gov processed this data on January 31, 2020",2011-02-10,,,2013-08-28,2011-02-10,2011-02-11,Estimate,,,,,,,2013-08-28,2013-08-29,Estimate,December 2010,,2010-12-31,August 2013,2013-08-31,December 2011,Actual,2011-12-31,October 2011,Actual,2011-10-31,,Interventional,,,"Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort","A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Doses of E2609 in Healthy Subjects and an Elderly Cohort",Completed,,Phase 1,73.0,Actual,Eisai Inc.,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:24:31.268851,2020-02-01 16:24:31.268851,Eisai Inc.,Industry,Drug: E2609,Drug
NCT01969123,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-21,,,2016-05-02,2013-10-24,2013-10-25,Estimate,,,,,,,2016-05-02,2016-05-03,Estimate,October 2013,,2013-10-31,September 2015,2015-09-30,January 2017,Anticipated,2017-01-31,January 2017,Anticipated,2017-01-31,,Interventional,,,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication",Terminated,,Phase 3,474.0,Actual,FORUM Pharmaceuticals Inc,,3.0,,Study has been suspended due to clinical hold.,False,,,,,,,,,,,,,,,,,2020-02-01 13:27:15.310397,2020-02-01 13:27:15.310397,FORUM Pharmaceuticals Inc,Industry,Drug: EVP-6124,Drug
NCT01969136,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-21,,,2016-05-02,2013-10-24,2013-10-25,Estimate,,,,,,,2016-05-02,2016-05-03,Estimate,October 2013,,2013-10-31,September 2015,2015-09-30,January 2017,Anticipated,2017-01-31,January 2017,Anticipated,2017-01-31,,Interventional,,,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication",Terminated,,Phase 3,403.0,Actual,FORUM Pharmaceuticals Inc,,3.0,,Study has been suspended due to clinical hold.,False,,,,,,,,,,,,,,,,,2020-02-01 13:27:15.097847,2020-02-01 13:27:15.097847,FORUM Pharmaceuticals Inc,Industry,Drug: EVP-6124,Drug
NCT01928420,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-17,,2016-10-07,2016-10-14,2013-08-20,2013-08-26,Estimate,,,,2016-10-14,2016-10-17,Estimate,2016-10-14,2016-10-17,Estimate,April 2007,,2007-04-30,October 2016,2016-10-31,June 2014,Actual,2014-06-30,June 2014,Actual,2014-06-30,,Interventional,,,"A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease","A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease",Completed,,Phase 2,30.0,Actual,Humanetics Corporation,,2.0,,,False,,,,True,,,,,,,,,,,Undecided,,2020-02-01 13:38:52.901927,2020-02-01 13:38:52.901927,Humanetics Corporation,Industry,Drug: NIC5-15,Drug
NCT01276353,"ClinicalTrials.gov processed this data on January 31, 2020",2011-01-12,2014-02-24,,2014-08-05,2011-01-12,2011-01-13,Estimate,2014-07-07,2014-08-01,Estimate,,,,2014-08-05,2014-08-08,Estimate,January 2011,,2011-01-31,August 2014,2014-08-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,,,A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia,"A Randomized, Double Blind, Parallel-Group Comparison Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia",Completed,,Phase 2,45.0,Actual,Eisai Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 16:29:41.006388,2020-02-01 16:29:41.006388,Eisai Inc.,Industry,E2020,Drug
NCT01404169,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-26,,,2017-03-07,2011-07-26,2011-07-27,Estimate,,,,,,,2017-03-07,2017-03-08,Actual,September 2011,Actual,2011-09-30,March 2017,2017-03-31,September 2014,Actual,2014-09-30,July 2014,Actual,2014-07-31,,Interventional,,,"A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease","A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease",Completed,,Phase 3,260.0,Actual,Eisai Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:54:49.274654,2020-02-01 15:54:49.274654,Eisai Limited,Industry,E2020,Drug
NCT01539031,"ClinicalTrials.gov processed this data on January 31, 2020",2012-02-21,,,2015-09-16,2012-02-24,2012-02-27,Estimate,,,,,,,2015-09-16,2015-09-17,Estimate,March 2012,,2012-03-31,September 2015,2015-09-30,March 2015,Actual,2015-03-31,January 2015,Actual,2015-01-31,,Interventional,,,Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease,"Randomized, Multicenter, Double-blind, Double-dummy, Parallel-Group Study With an Open-label Extension Phase to Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease",Completed,,Phase 3,351.0,Actual,Eisai Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:19:37.202868,2020-02-01 15:19:37.202868,"Eisai Co., Ltd.",Industry,E2020,Drug
NCT01221259,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-13,,,2013-05-20,2010-10-13,2010-10-14,Estimate,,,,,,,2013-05-20,2013-05-22,Estimate,January 2010,,2010-01-31,February 2013,2013-02-28,November 2012,Actual,2012-11-30,October 2011,Actual,2011-10-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects","A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects",Completed,,Phase 1,60.0,Actual,Eisai Inc.,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:46:00.362394,2020-02-01 16:46:00.362394,Eisai Inc.,Industry,E2212,Drug
NCT01600859,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-15,,,2016-12-29,2012-05-15,2012-05-17,Estimate,,,,,,,2016-12-29,2016-12-30,Estimate,July 2012,,2012-07-31,December 2016,2016-12-31,October 2013,Actual,2013-10-31,September 2013,Actual,2013-09-30,,Interventional,,,Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02),"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease",Completed,,Phase 1,65.0,Actual,Eisai Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:04:28.156755,2020-02-01 15:04:28.156755,Eisai Inc.,Industry,E2609,Drug
NCT01716897,"ClinicalTrials.gov processed this data on January 31, 2020",2012-10-23,,,2013-05-20,2012-10-29,2012-10-30,Estimate,,,,,,,2013-05-20,2013-05-22,Estimate,October 2012,,2012-10-31,February 2013,2013-02-28,February 2013,Actual,2013-02-28,December 2012,Actual,2012-12-31,,Interventional,,,An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption,"A Randomized, Open-label, 3-treatment Crossover Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption in Healthy Caucasian Male Adults",Completed,,Phase 1,18.0,Actual,Eisai Inc.,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:33:53.663559,2020-02-01 14:33:53.663559,Eisai Inc.,Industry,E2609,Drug
NCT02859207,"ClinicalTrials.gov processed this data on January 31, 2020",2016-08-04,,,2017-06-07,2016-08-04,2016-08-08,Estimate,,,,,,,2017-06-07,2017-06-08,Actual,August 2016,Actual,2016-08-31,May 2017,2017-05-31,"January 25, 2017",Actual,2017-01-25,"December 6, 2016",Actual,2016-12-06,,Interventional,,,A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects,An Open-Label Parallel-Group Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects,Completed,,Phase 1,32.0,Actual,Eisai Inc.,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 10:06:47.542642,2020-02-01 10:06:47.542642,Eisai Inc.,Industry,E2609,Drug
NCT01849042,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-06,,,2014-08-12,2013-05-07,2013-05-08,Estimate,,,,,,,2014-08-12,2014-08-13,Estimate,January 2013,,2013-01-31,August 2014,2014-08-31,August 2015,Anticipated,2015-08-31,August 2014,Anticipated,2014-08-31,,Interventional,ROMEO-AD,,Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease,"A Multicenter, Randomized, Open-label, Prospective Study to Estimate the add-on Effects of Memantine as Ebixa Oral Pump on Language in Moderate to Severe Alzheimer's Disease Patients Already Receiving Donepezil.",Unknown status,Recruiting,Phase 4,188.0,Anticipated,Konkuk University Medical Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:00:52.134192,2020-02-01 14:00:52.134192,Konkuk University Medical Center,Other,Ebixa,Drug
NCT00814346,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-23,2015-09-11,,2019-01-24,2008-12-23,2008-12-24,Estimate,2016-02-26,2016-03-28,Estimate,,,,2019-01-24,2019-02-08,Actual,October 2008,,2008-10-31,January 2019,2019-01-31,July 2012,Actual,2012-07-31,July 2012,Actual,2012-07-31,,Interventional,,,Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions,"Effect of Oral EGb761® on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-blind, Parallel Groups, Placebo-controlled Study",Completed,,Phase 2,49.0,Actual,Ipsen,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:49:41.213666,2020-02-01 18:49:41.213666,Ipsen,Industry,EGb761®,Drug
NCT00276510,"ClinicalTrials.gov processed this data on January 31, 2020",2006-01-12,,,2019-01-11,2006-01-12,2006-01-13,Estimate,,,,,,,2019-01-11,2019-01-15,Actual,February 2002,,2002-02-28,January 2019,2019-01-31,November 2009,Actual,2009-11-30,November 2009,Actual,2009-11-30,,Interventional,,,A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints,"Efficacy and Tolerance of EGb 761® 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70",Completed,,Phase 4,2878.0,Actual,Ipsen,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:31:39.900717,2020-02-01 21:31:39.900717,Ipsen,Industry,EGb 761® (Tanakan®),Drug
NCT00500500,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-11,,,2013-10-10,2007-07-11,2007-07-12,Estimate,,,,,,,2013-10-10,2013-10-11,Estimate,July 2005,,2005-07-31,October 2013,2013-10-31,April 2008,Actual,2008-04-30,April 2008,Actual,2008-04-30,,Interventional,,,Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease,"Effect of EGb 761® on the Ratio of the Isoforms of the Protein Precursor of Beta Amyloid Platelets on Patients With Mild to Moderate Alzheimer's Disease. A Phase II, Randomised, Double-blind Trial, on Parallel Groups Versus Placebo.",Terminated,,Phase 2,40.0,Actual,Ipsen,,2.0,,Inability to recruit sufficient number of patients,False,,,,,,,,,,,,,,,,,2020-02-01 20:24:29.403973,2020-02-01 20:24:29.403973,Ipsen,Industry,EGb 761® (Tanakan®),Drug
NCT00880412,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-10,,,2009-09-18,2009-04-10,2009-04-13,Estimate,,,,,,,2009-09-18,2009-09-21,Estimate,April 2008,,2008-04-30,September 2009,2009-09-30,August 2009,Actual,2009-08-31,June 2009,Actual,2009-06-30,,Interventional,EHT0202/002,,A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease,"A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase IIA Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 (40 and 80 mg Bid) as Adjunctive Therapy to Acetylcholinesterase Inhibitor Over a 3-month Period in Ambulatory Patients Suffering From Mild to Moderate Alzheimer's Disease (EHT 0202/002 Protocol)",Completed,,Phase 2,197.0,Actual,Exonhit,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:30:27.434852,2020-02-01 18:30:27.434852,Exonhit,Industry,EHT 0202 etazolate,Drug
NCT02322021,"ClinicalTrials.gov processed this data on January 31, 2020",2014-12-17,,2019-06-07,2019-06-07,2014-12-19,2014-12-22,Estimate,,,,2019-06-07,2019-06-10,Actual,2019-06-07,2019-06-10,Actual,"November 26, 2014",Actual,2014-11-26,June 2018,2018-06-30,"July 31, 2022",Anticipated,2022-07-31,"March 27, 2018",Actual,2018-03-27,,Interventional,,,Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease,"A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease","Active, not recruiting",,Phase 2,71.0,Actual,Eisai Inc.,,8.0,,,False,,,,True,True,,,,,,,,,,Undecided,,2020-02-01 12:01:27.666580,2020-02-01 12:01:27.666580,Eisai Inc.,Industry,Elenbecestat (E2609),Drug
NCT02956486,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-03,,,2019-09-18,2016-11-03,2016-11-06,Estimate,,,,,,,2019-09-18,2019-09-19,Actual,"October 20, 2016",Actual,2016-10-20,September 2018,2018-09-30,"November 21, 2023",Anticipated,2023-11-21,"November 21, 2023",Anticipated,2023-11-21,,Interventional,MissionAD1,,A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease,"A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 3,950.0,Anticipated,Eisai Inc.,,3.0,,,False,,,,True,True,,,,,,,,,,Undecided,,2020-02-01 09:45:53.235437,2020-02-01 09:45:53.235437,"Eisai Co., Ltd.",Industry,Elenbecestat (E2609),Drug
NCT03036280,"ClinicalTrials.gov processed this data on January 31, 2020",2017-01-26,,,2019-09-18,2017-01-26,2017-01-30,Estimate,,,,,,,2019-09-18,2019-09-19,Actual,"December 29, 2016",Actual,2016-12-29,September 2019,2019-09-30,"November 21, 2023",Anticipated,2023-11-21,"November 21, 2023",Anticipated,2023-11-21,,Interventional,MissionAD2,,A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease_,"A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 3,950.0,Anticipated,Eisai Inc.,,3.0,,,False,,,,True,True,,,,,,,,,,Undecided,,2020-02-01 09:30:30.434411,2020-02-01 09:30:30.434411,"Eisai Co., Ltd.",Industry,Elenbecestat (E2609),Drug
NCT00568776,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-04,2011-09-27,,2019-10-17,2007-12-04,2007-12-06,Estimate,2012-03-01,2012-03-29,Estimate,,,,2019-10-17,2019-11-01,Actual,December 2007,,2007-12-31,October 2019,2019-10-31,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,,ELND005 in Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease",Completed,,Phase 2,353.0,Actual,"OPKO Health, Inc.","The two high dose groups of ELND005 were discontinued before study end, so the efficacy analysis was based only on placebo and ELND005 250 mg bid groups.",4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:01:52.395629,2020-02-01 20:01:52.395629,"OPKO Health, Inc.",Industry,ELND005,Drug
NCT01735630,"ClinicalTrials.gov processed this data on January 31, 2020",2012-11-25,2016-04-07,,2019-10-17,2012-11-27,2012-11-28,Estimate,2016-07-06,2016-08-15,Estimate,,,,2019-10-17,2019-10-21,Actual,November 2012,,2012-11-30,October 2019,2019-10-31,May 2015,Actual,2015-05-31,May 2015,Actual,2015-05-31,,Interventional,,,Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease",Completed,,Phase 2,350.0,Actual,"OPKO Health, Inc.",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:29:01.435468,2020-02-01 14:29:01.435468,"OPKO Health, Inc.",Industry,ELND005,Drug
NCT00934050,"ClinicalTrials.gov processed this data on January 31, 2020",2009-06-29,2015-04-22,,2019-10-17,2009-07-06,2009-07-08,Estimate,2015-05-12,2015-05-13,Estimate,,,,2019-10-17,2019-10-21,Actual,June 2009,,2009-06-30,October 2019,2019-10-31,June 2011,Actual,2011-06-30,June 2011,Actual,2011-06-30,,Interventional,,,ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease,A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease,Completed,,Phase 2,103.0,Actual,"OPKO Health, Inc.",,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:14:56.331849,2020-02-01 18:14:56.331849,"OPKO Health, Inc.",Industry,ELND005 (scyllo-inositol),Drug
NCT01047254,"ClinicalTrials.gov processed this data on January 31, 2020",2010-01-11,,,2017-05-08,2010-01-11,2010-01-12,Estimate,,,,,,,2017-05-08,2017-05-09,Actual,January 2010,,2010-01-31,May 2017,2017-05-31,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,APA-AD,,Bupropion for the Treatment of Apathy in Alzheimer's Dementia,"A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Bupropion for the Treatment of Apathy in Alzheimer's Dementia(Apa-AD)",Completed,,Phase 3,110.0,Actual,"University Hospital, Bonn",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:37:20.131108,2020-02-01 17:37:20.131108,"University Hospital, Bonn",Other,Elontril,Drug
NCT01585272,"ClinicalTrials.gov processed this data on January 31, 2020",2012-04-23,2016-06-24,,2018-04-16,2012-04-24,2012-04-25,Estimate,2016-09-22,2016-11-10,Estimate,,,,2018-04-16,2018-04-18,Actual,August 2012,,2012-08-31,April 2018,2018-04-30,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,,,Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia,"A 52-week, Prospective, Multi-center, Open-label Study to Assess the Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Patients With Alzheimer's Dementia in a Controlled Titration Schedule",Completed,,Phase 4,121.0,Actual,Novartis,,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:08:31.931167,2020-02-01 15:08:31.931167,Novartis Pharmaceuticals,Industry,ENA713,Drug
NCT01614886,"ClinicalTrials.gov processed this data on January 31, 2020",2012-06-06,2015-04-16,,2016-06-30,2012-06-07,2012-06-08,Estimate,2015-04-16,2015-05-12,Estimate,,,,2016-06-30,2016-08-01,Estimate,July 2012,,2012-07-31,June 2015,2015-06-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,"Randomized set (RAN) The RAN consisted of all randomized patients. Patients were analyzed according to the treatment group they were assigned to at randomization. A patient was diagnosed of dementia with Lewy Bodies, different from AD, after randomization and was excluded from all analysis (SAF and FAS).","Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)","A 24-week, Multicenter, Parallel-group, Randomized,Double-blind Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Methods of Rivastigmine Patch (ENA713D/ONO-2540) in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-20)",Completed,,Phase 3,216.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:00:51.368993,2020-02-01 15:00:51.368993,Novartis Pharmaceuticals,Industry,ENA713,Drug
NCT01948791,"ClinicalTrials.gov processed this data on January 31, 2020",2013-09-19,2016-09-27,,2016-12-20,2013-09-19,2013-09-24,Estimate,2016-12-20,2017-02-13,Actual,,,,2016-12-20,2017-02-13,Actual,August 2014,,2014-08-31,December 2016,2016-12-31,September 2015,Actual,2015-09-30,September 2015,Actual,2015-09-30,,Interventional,INSTINCT,"Subjects who received at least one treatment, and had at least one post-baseline assessment on primary efficacy variables.",16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients,16 Weeks Interventional Study on Titration and Dose/Efficacy Assessment of Exelon (Rivastigmine) in Chinese Alzheimer's Disease Patients (INSTINCT),Completed,,Phase 4,222.0,Actual,Novartis,"Of the total recruited subjects, 181 subjects received at least one drug treatment and there were post-baseline safety assessment. They were incorporated into the safety population.",1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:33:03.414376,2020-02-01 13:33:03.414376,Novartis Pharmaceuticals,Industry,ENA713,Drug
NCT00580931,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-24,,,2017-01-23,2007-12-26,2007-12-27,Estimate,,,,,,,2017-01-23,2017-01-25,Estimate,January 2008,Actual,2008-01-31,January 2017,2017-01-31,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,,,Safety Study of Nicotinamide to Treat Alzheimer's Disease,Efficacy of Nicotinamide for the Treatment of Alzheimer's Disease,Completed,,Phase 1/Phase 2,50.0,Actual,"University of California, Irvine",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:58:33.890191,2020-02-01 19:58:33.890191,"University of California, Irvine",Other,Enduramide placebo,Drug
NCT00211159,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-13,,,2017-07-27,2005-09-13,2005-09-21,Estimate,,,,,,,2017-07-27,2017-07-31,Actual,December 2000,,2000-12-31,April 2005,2005-04-30,,,,,,,,Interventional,,,OmegAD (Omega-3 and Alzheimer's Disease),Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimer's Disease (OmegAD): a Randomized Double-blind Trial,Completed,,N/A,204.0,,Karolinska University Hospital,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:47:17.648169,2020-02-01 21:47:17.648169,Karolinska University Hospital,Other,EPAX 1050TG,Drug
NCT00951834,"ClinicalTrials.gov processed this data on January 31, 2020",2009-08-03,,,2018-11-28,2009-08-03,2009-08-04,Estimate,,,,,,,2018-11-28,2018-11-29,Actual,October 2009,,2009-10-31,November 2018,2018-11-30,February 2015,Actual,2015-02-28,February 2015,Actual,2015-02-28,,Interventional,SUN-AK,,Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease,Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease,Completed,,Phase 2/Phase 3,21.0,Actual,"Charite University, Berlin, Germany",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:09:10.750449,2020-02-01 18:09:10.750449,"Charite University, Berlin, Germany",Other,Epigallocatechin-Gallate,Drug
NCT00702780,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-15,2014-04-10,,2014-05-13,2008-06-18,2008-06-20,Estimate,2014-05-13,2014-06-13,Estimate,,,,2014-05-13,2014-06-13,Estimate,November 2008,,2008-11-30,May 2014,2014-05-31,September 2011,Actual,2011-09-30,September 2011,Actual,2011-09-30,,Interventional,ESAD,,Progression Delaying Effect of Escitalopram in Alzheimer's Disease,"Multi-center, Randomized, Placebo-controlled, Double-blind Clinical Trial of Escitalopram on the Progression Delaying Effect in Alzheimer's Disease",Completed,,N/A,74.0,Actual,Seoul National University Hospital,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:23:05.471913,2020-02-01 19:23:05.471913,Seoul National University Hospital,Other,escitalopram,Drug
NCT01841125,"ClinicalTrials.gov processed this data on January 31, 2020",2013-04-18,,,2014-08-12,2013-04-25,2013-04-26,Estimate,,,,,,,2014-08-12,2014-08-13,Estimate,November 2011,,2011-11-30,August 2014,2014-08-31,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,Escitalopram,,Escitalopram for the Treatment of Depression in Alzheimer's Disease,"A 12-Week Randomized, Double-blind, Parallel-group, Placebo-controlled Trial With and Open-label, 12-week Extension, Multicenter to Evaluation of the Efficacy of Escitalopram for the Treatment of Depression in Alzheimer's Disease",Completed,,Phase 4,84.0,Actual,Konkuk University Medical Center,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:02:56.756489,2020-02-01 14:02:56.756489,Konkuk University Medical Center,Other,escitalopram,Drug
NCT01876823,"ClinicalTrials.gov processed this data on January 31, 2020",2013-06-05,2013-09-23,,2014-10-23,2013-06-10,2013-06-13,Estimate,2014-10-23,2014-10-24,Estimate,,,,2014-10-23,2014-10-24,Estimate,April 2006,,2006-04-30,September 2013,2013-09-30,March 2010,Actual,2010-03-31,March 2010,Actual,2010-03-31,,Interventional,,,Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment,Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment,Completed,,Phase 2/Phase 3,60.0,Actual,New York State Psychiatric Institute,"The inclusion criteria required all patients to have an MMSE of 24 or higher, which may have lowered the conversion rate to dementia
small sample size
cognitive improvement may have been due in part to combined es-citalopram and memantine",1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:51:09.358646,2020-02-01 13:51:09.358646,New York State Psychiatric Institute,Other,es-citalopram,Drug
NCT00229333,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-27,,,2006-08-28,2005-09-27,2005-09-29,Estimate,,,,,,,2006-08-28,2006-08-29,Estimate,December 2004,,2004-12-31,August 2006,2006-08-31,,,,,,,,Interventional,,,"Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia","Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia",Unknown status,Recruiting,Phase 4,40.0,,Sheba Medical Center,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:43:59.649458,2020-02-01 21:43:59.649458,Sheba Medical Center,Other,Escitalopram,Drug
NCT01119638,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-06,,,2015-06-23,2010-05-06,2010-05-07,Estimate,,,,,,,2015-06-23,2015-06-24,Estimate,April 2008,,2008-04-30,June 2015,2015-06-30,May 2010,Actual,2010-05-31,April 2010,Actual,2010-04-30,,Interventional,EscBPSD,,Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone,Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients,Completed,,Phase 4,40.0,Actual,Abarbanel Mental Health Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:16:52.586627,2020-02-01 17:16:52.586627,Abarbanel Mental Health Center,Other,Escitalopram,Drug
NCT03108846,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-06,,,2019-01-16,2017-04-06,2017-04-11,Actual,,,,,,,2019-01-16,2019-01-17,Actual,"January 3, 2018",Actual,2018-01-03,January 2019,2019-01-31,August 2022,Anticipated,2022-08-31,December 2021,Anticipated,2021-12-31,,Interventional,S-CitAD,,Escitalopram for Agitation in Alzheimer's Disease,Escitalopram for Agitation in Alzheimer's Disease,Recruiting,,Phase 3,392.0,Anticipated,JHSPH Center for Clinical Trials,,2.0,,,False,,,,True,True,False,,,True,,,,,,No,,2020-02-01 09:17:38.732615,2020-02-01 09:17:38.732615,JHSPH Center for Clinical Trials,Other,Escitalopram,Drug
NCT00260624,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-29,,,2012-02-23,2005-11-29,2005-12-01,Estimate,,,,,,,2012-02-23,2012-02-24,Estimate,February 2003,,2003-02-28,February 2012,2012-02-29,December 2006,Actual,2006-12-31,December 2006,Actual,2006-12-31,,Interventional,,,Escitalopram Treatment of Patients With Agitated Dementia,Escitalopram in the Treatment of Patients With Agitated Dementia,Completed,,Phase 4,20.0,Anticipated,University of Rochester,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:36:14.885353,2020-02-01 21:36:14.885353,University of Rochester,Other,Escitalopram (Lexapro),Drug
NCT00018343,"ClinicalTrials.gov processed this data on January 31, 2020",2001-07-03,,,2009-01-20,2001-07-04,2001-07-05,Estimate,,,,,,,2009-01-20,2009-01-21,Estimate,April 1998,,1998-04-30,December 2004,2004-12-31,March 2001,,2001-03-31,,,,,Interventional,,,Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen,Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen,Completed,,Phase 2,,,VA Office of Research and Development,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:17.324874,2020-02-01 22:48:17.324874,US Department of Veterans Affairs,U.S. Fed,estrogen,Drug
NCT00000177,"ClinicalTrials.gov processed this data on January 31, 2020",1999-10-29,,,2009-12-10,1999-10-29,1999-11-01,Estimate,,,,,,,2009-12-10,2009-12-11,Estimate,October 1995,,1995-10-31,September 2009,2009-09-30,January 1999,Actual,1999-01-31,January 1999,Actual,1999-01-31,,Interventional,,,Estrogen Hormone Protocol,,Completed,,Phase 3,120.0,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:51:08.138531,2020-02-01 22:51:08.138531,National Institute on Aging (NIA),NIH,Estrogen,Drug
NCT00006399,"ClinicalTrials.gov processed this data on January 31, 2020",2000-08-18,,,2009-01-13,2000-08-18,2000-08-21,Estimate,,,,,,,2009-01-13,2009-01-15,Estimate,September 1999,,1999-09-30,January 2009,2009-01-31,March 2004,Actual,2004-03-31,March 2004,Actual,2004-03-31,,Interventional,,,Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease,Estrogen Modulation Effects on Cholinergic Function in Normal Post-Menopausal Women and Patients With Alzheimer's Disease,Completed,,Phase 2,45.0,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:49:05.038881,2020-02-01 22:49:05.038881,National Center for Research Resources (NCRR),NIH,Estrogen,Drug
NCT00203320,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-12,,,2006-04-20,2005-09-12,2005-09-20,Estimate,,,,,,,2006-04-20,2006-04-24,Estimate,April 2005,,2005-04-30,April 2006,2006-04-30,January 2006,,2006-01-31,,,,,Interventional,,,TNF-Alpha Inhibition for Treatment of Alzheimer's Disease,Etanercept for Alzheimer's-Type Memory Loss Pilot Study II,Completed,,Phase 1,30.0,,"Tobinick, Edward Lewis, M.D.",,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:48:48.665223,2020-02-01 21:48:48.665223,"Tobinick, Edward Lewis, M.D.",Other,etanercept given by perispinal administration,Drug
NCT00203359,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-12,,,2006-04-20,2005-09-12,2005-09-20,Estimate,,,,,,,2006-04-20,2006-04-24,Estimate,September 2004,,2004-09-30,April 2006,2006-04-30,April 2006,,2006-04-30,,,,,Interventional,,,TNF-Alpha Inhibition for Treatment of Alzheimer's Disease,Etanercept for Alzheimer's-Type Memory Loss Pilot Study,Completed,,Phase 1,15.0,,"Tobinick, Edward Lewis, M.D.",,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:48:48.383552,2020-02-01 21:48:48.383552,"Tobinick, Edward Lewis, M.D.",Other,etanercept given by perispinal administration,Drug
NCT01661673,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-03,,,2014-01-10,2012-08-06,2012-08-09,Estimate,,,,,,,2014-01-10,2014-01-13,Estimate,November 2012,,2012-11-30,January 2014,2014-01-31,,,,October 2013,Actual,2013-10-31,,Interventional,,,"Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease","Safety, Tolerability, Pharmacokinetics, and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease",Completed,,Phase 2,52.0,Actual,FORUM Pharmaceuticals Inc,,5.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:49:17.382489,2020-02-01 14:49:17.382489,FORUM Pharmaceuticals Inc,Industry,EVP-0962,Drug
NCT01073228,"ClinicalTrials.gov processed this data on January 31, 2020",2010-02-19,,2013-02-19,2014-03-28,2010-02-22,2010-02-23,Estimate,,,,2013-02-19,2013-02-22,Estimate,2014-03-28,2014-04-25,Estimate,April 2010,,2010-04-30,February 2013,2013-02-28,February 2012,Actual,2012-02-29,November 2011,Actual,2011-11-30,,Interventional,,,Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 2,409.0,Actual,FORUM Pharmaceuticals Inc,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:30:03.549834,2020-02-01 17:30:03.549834,FORUM Pharmaceuticals Inc,Industry,EVP-6124,Drug
NCT02004392,"ClinicalTrials.gov processed this data on January 31, 2020",2013-11-27,,,2016-05-02,2013-12-03,2013-12-09,Estimate,,,,,,,2016-05-02,2016-05-03,Estimate,June 2014,,2014-06-30,September 2015,2015-09-30,August 2017,Anticipated,2017-08-31,August 2017,Anticipated,2017-08-31,,Interventional,,,Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025,A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects With Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication,Terminated,,Phase 3,348.0,Actual,FORUM Pharmaceuticals Inc,,2.0,,Study has been suspended due to clinical hold.,False,,,,True,,,,,,,,,,,,,2020-02-01 13:17:38.089038,2020-02-01 13:17:38.089038,FORUM Pharmaceuticals Inc,Industry,EVP-6124,Drug
NCT02246075,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-17,,,2015-10-13,2014-09-19,2014-09-22,Estimate,,,,,,,2015-10-13,2015-10-15,Estimate,July 2015,,2015-07-31,October 2015,2015-10-31,,,,October 2016,Anticipated,2016-10-31,,Interventional,,,Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 24-Week, Phase 2 Study of Two Doses of EVP-6124 Hydrochloride or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently Receiving Memantine Medication With or Without Additional Acetylcholinesterase Inhibitor Co-Medication",Withdrawn,,Phase 2,0.0,Actual,FORUM Pharmaceuticals Inc,,3.0,,Forum has decided not to proceed with this study at this time.,False,,,,True,,,,,,,,,,,,,2020-02-01 12:18:59.203192,2020-02-01 12:18:59.203192,FORUM Pharmaceuticals Inc,Industry,EVP-6124,Drug
NCT00766363,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-01,2011-06-16,,2012-04-18,2008-10-02,2008-10-03,Estimate,2011-06-16,2011-07-14,Estimate,,,,2012-04-18,2012-04-20,Estimate,October 2008,,2008-10-31,April 2012,2012-04-30,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 1,49.0,Actual,FORUM Pharmaceuticals Inc,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:04:53.564244,2020-02-01 19:04:53.564244,FORUM Pharmaceuticals Inc,Industry,EVP-6124 (0.1 mg/day),Drug
NCT00766363,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-01,2011-06-16,,2012-04-18,2008-10-02,2008-10-03,Estimate,2011-06-16,2011-07-14,Estimate,,,,2012-04-18,2012-04-20,Estimate,October 2008,,2008-10-31,April 2012,2012-04-30,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 1,49.0,Actual,FORUM Pharmaceuticals Inc,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:04:53.564244,2020-02-01 19:04:53.564244,FORUM Pharmaceuticals Inc,Industry,EVP-6124 (0.3 mg/day),Drug
NCT00766363,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-01,2011-06-16,,2012-04-18,2008-10-02,2008-10-03,Estimate,2011-06-16,2011-07-14,Estimate,,,,2012-04-18,2012-04-20,Estimate,October 2008,,2008-10-31,April 2012,2012-04-30,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 1,49.0,Actual,FORUM Pharmaceuticals Inc,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:04:53.564244,2020-02-01 19:04:53.564244,FORUM Pharmaceuticals Inc,Industry,EVP-6124 (1.0 mg/day),Drug
NCT00018278,"ClinicalTrials.gov processed this data on January 31, 2020",2001-07-03,,,2009-01-20,2001-07-04,2001-07-05,Estimate,,,,,,,2009-01-20,2009-01-21,Estimate,October 1998,,1998-10-31,December 2004,2004-12-31,September 2001,,2001-09-30,,,,,Interventional,,,Electrophysiologic Measures of Treatment Response in Alzheimer Disease,Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease,Completed,,Phase 4,,,VA Office of Research and Development,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:17.695761,2020-02-01 22:48:17.695761,US Department of Veterans Affairs,U.S. Fed,Exelon,Drug
NCT01255163,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-04,2017-11-08,,2018-01-23,2010-12-04,2010-12-07,Estimate,2018-01-23,2018-02-22,Actual,,,,2018-01-23,2018-02-22,Actual,"November 21, 2010",,2010-11-21,January 2018,2018-01-31,"November 18, 2016",Actual,2016-11-18,"November 18, 2016",Actual,2016-11-18,,Interventional,,"The baseline analysis population includes 27 participants who underwent randomization and received at least one dose of experimental medication. Of those 27, we have at least one outcome measure (i.e. at least the 6 months follow-up data point) for 21 participants. Of those 21, 18 completed the study (i.e. reached 18 months).",A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease,A Pilot Study of Exendin-4 in Alzheimer s Disease,Terminated,,Phase 2,57.0,Actual,National Institutes of Health Clinical Center (CC),The study was terminated after AstraZeneca withdrew support. Early termination lead to small number of subjects analyzed.,2.0,,AstraZeneca withdrew support for the study.,False,,,,True,True,False,,,False,,,,,,,,2020-02-01 16:35:47.564810,2020-02-01 16:35:47.564810,National Institute on Aging (NIA),NIH,Exendin-4 SC,Drug
NCT00403520,"ClinicalTrials.gov processed this data on January 31, 2020",2006-11-21,,,2014-07-11,2006-11-21,2006-11-23,Estimate,,,,,,,2014-07-11,2014-07-14,Estimate,November 2006,,2006-11-30,July 2014,2014-07-31,August 2010,Actual,2010-08-31,March 2008,Actual,2008-03-31,,Interventional,,,Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers,Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders,Completed,,Phase 4,240.0,Actual,Eisai Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:55:26.861622,2020-02-01 20:55:26.861622,Eisai Inc.,Industry,Experimental 1,Drug
NCT01254773,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-03,,2014-02-26,2014-04-21,2010-12-03,2010-12-07,Estimate,,,,2014-02-26,2014-03-26,Estimate,2014-04-21,2014-05-09,Estimate,December 2010,,2010-12-31,April 2014,2014-04-30,March 2013,Actual,2013-03-31,January 2013,Actual,2013-01-31,,Interventional,SUMMIT AD,,Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,146.0,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:35:52.472913,2020-02-01 16:35:52.472913,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Experimental Bapineuzumab,Drug
NCT04098666,"ClinicalTrials.gov processed this data on January 31, 2020",2019-09-19,,,2019-11-07,2019-09-19,2019-09-23,Actual,,,,,,,2019-11-07,2019-11-12,Actual,"August 1, 2020",Anticipated,2020-08-01,November 2019,2019-11-30,"April 30, 2024",Anticipated,2024-04-30,"March 30, 2024",Anticipated,2024-03-30,,Interventional,MAP,,Metformin in Alzheimer's Dementia Prevention,Metformin in Alzheimer's Dementia Prevention,Not yet recruiting,,Phase 2/Phase 3,370.0,Anticipated,Columbia University,,2.0,,,False,,,,True,True,False,,,,,,After reporting of main results,,,Yes,"All datasets used/generated on the project will be made accessible and reusable by qualified individuals other than the original data generators via web-based resources with the capacity to store large and diverse datasets (such as data about clinical phenotypes, genetics, epigenetics, proteomics, and metabolomics) to enable multiple parallel approaches to data analysis and interpretation. All analytical methodologies will be made fully reproducible and transparent so that results can be vetted and existing analysis techniques quickly applied to new application areas. We will comply with the data sharing arrangement decided by NIA.",2020-02-01 06:40:23.267307,2020-02-01 06:40:23.267307,Columbia University,Other,extended release metformin,Drug
NCT02380573,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-24,,,2019-05-06,2015-02-27,2015-03-05,Estimate,,,,,,,2019-05-06,2019-05-08,Actual,July 2015,,2015-07-31,April 2019,2019-04-30,July 2023,Anticipated,2023-07-31,July 2022,Anticipated,2022-07-31,,Interventional,MB2,,"Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease","Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease",Suspended,,Phase 2,117.0,Actual,The University of Texas Health Science Center at San Antonio,,8.0,,Pending enrollment of new subjects if new funding obtained,False,,,,True,,,,,,,,,,,,,2020-02-01 11:48:30.714225,2020-02-01 11:48:30.714225,The University of Texas Health Science Center at San Antonio,Other,FD&C Blue # 2,Drug
NCT03656042,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-23,,,2018-08-30,2018-08-30,2018-09-04,Actual,,,,,,,2018-08-30,2018-09-04,Actual,March 2009,Actual,2009-03-31,February 2017,2017-02-28,August 2014,Actual,2014-08-31,July 2014,Actual,2014-07-31,,Interventional,,,To Evaluate the Efficacy and Safety/Tolerability Profiles of G-CSF in Subjects With Mild to Moderate Alzheimer's Disease,"A Open-label, No-treatment-controlled, Parallel, Pilot Phase Ⅱ Study to Evaluate the Efficacy and Safety/Tolerability Profiles of G-CSF in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,21.0,Actual,Chang Gung Memorial Hospital,,2.0,,,False,,,,True,False,False,,,False,,,,,,Undecided,Individual participant data sets including IPD that underlie results in a publication have not yet decided to be shared under the consideration of patient privacy.,2020-02-01 07:45:30.262847,2020-02-01 07:45:30.262847,Chang Gung Memorial Hospital,Other,Filgrastim (75mcg/0.3ml),Drug
NCT00087724,"ClinicalTrials.gov processed this data on January 31, 2020",2004-07-12,,,2012-06-06,2004-07-13,2004-07-14,Estimate,,,,,,,2012-06-06,2012-06-07,Estimate,July 2004,,2004-07-31,June 2012,2012-06-30,September 2006,Actual,2006-09-30,,,,,Interventional,,,A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects With Mild to Moderate Alzheimer's Disease",Terminated,,Phase 2,510.0,,Astellas Pharma Inc,,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:23:41.086728,2020-02-01 22:23:41.086728,Astellas Pharma Inc,Industry,FK962,Drug
NCT02667496,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-26,,,2017-04-05,2016-01-28,2016-01-29,Estimate,,,,,,,2017-04-05,2017-04-07,Actual,November 2016,,2016-11-30,April 2017,2017-04-30,"March 31, 2017",Actual,2017-03-31,"March 31, 2017",Actual,2017-03-31,,Interventional,,,Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine® (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,Withdrawn,,Phase 2,0.0,Actual,Sanofi,,2.0,,Slow recruitment,False,,,,True,,,,,,,,,,,,,2020-02-01 10:44:33.482652,2020-02-01 10:44:33.482652,Sanofi,Industry,Florbetapir F18,Drug
NCT00056225,"ClinicalTrials.gov processed this data on January 31, 2020",2003-03-07,,,2009-06-10,2003-03-08,2003-03-10,Estimate,,,,,,,2009-06-10,2009-06-12,Estimate,January 2003,,2003-01-31,June 2009,2009-06-30,June 2007,Actual,2007-06-30,June 2007,Actual,2007-06-30,,Interventional,,,VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study),High Dose Supplements to Reduce Homocysteine and Slow the Rate of Cognitive Decline in Alzheimer's Disease (Vitamins to Slow Alzheimer's - VITAL),Completed,,Phase 3,340.0,Actual,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:35:04.175801,2020-02-01 22:35:04.175801,National Institute on Aging (NIA),NIH,Folate,Drug
NCT02500784,"ClinicalTrials.gov processed this data on January 31, 2020",2015-05-19,,,2019-04-01,2015-07-15,2015-07-17,Estimate,,,,,,,2019-04-01,2019-04-03,Actual,January 2023,Anticipated,2023-01-31,April 2019,2019-04-30,July 2025,Anticipated,2025-07-31,April 2025,Anticipated,2025-04-30,,Interventional,,,Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease,Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease,Suspended,,Phase 2,60.0,Anticipated,Palo Alto Veterans Institute for Research,,2.0,,"Funding ran out before study started, prior PI left institution.",False,,,,False,True,False,,,,,,,,,,,2020-02-01 11:21:41.477120,2020-02-01 11:21:41.477120,Palo Alto Veterans Institute for Research,Other,Formoterol A,Drug
NCT00018291,"ClinicalTrials.gov processed this data on January 31, 2020",2001-07-03,,,2009-01-20,2001-07-04,2001-07-05,Estimate,,,,,,,2009-01-20,2009-01-21,Estimate,January 2001,,2001-01-31,December 2004,2004-12-31,January 2005,,2005-01-31,,,,,Interventional,,,Specific Interventions for Agitation in Alzheimer's Disease,Specific Interventions for Agitation in Alzheimer's Disease,Completed,,N/A,,,VA Office of Research and Development,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:17.637032,2020-02-01 22:48:17.637032,US Department of Veterans Affairs,U.S. Fed,Gabapentin,Drug
NCT03082755,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-06,,,2019-10-23,2017-03-10,2017-03-17,Actual,,,,,,,2019-10-23,2019-10-25,Actual,"July 1, 2017",Actual,2017-07-01,October 2019,2019-10-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,,Interventional,,,Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease,Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease,Recruiting,,Phase 4,136.0,Anticipated,University of Texas at Austin,,2.0,,,False,,,,True,True,False,,,False,,,Data will be made available 6 months after publication of the main study findings and will be available in perpetuity.,IPD will be publicly available via the following url,https://dataverse.tdl.org/dataset.xhtml?persistentId=doi:10.18738/T8/GDSFSQ,Yes,Data have been prepared for sharing with other investigators. All collected individual participant data (IPD) can be accessed at https://dataverse.tdl.org/dataset.xhtml?persistentId=doi:10.18738/T8/GDSFSQ after publication of the main study findings,2020-02-01 09:22:16.586579,2020-02-01 09:22:16.586579,University of Texas at Austin,Other,Gabapentin Enacarbil,Drug
NCT00035204,"ClinicalTrials.gov processed this data on January 31, 2020",2002-05-02,,,2011-06-06,2002-05-02,2002-05-03,Estimate,,,,,,,2011-06-06,2011-06-08,Estimate,,,,April 2010,2010-04-30,May 2003,Actual,2003-05-31,,,,,Interventional,,,"A Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer's Disease","A Double-blind, Randomized Pilot Study to Evaluate the Effects of Galantamine and Donepezil on Sleep and Attention and Gastrointestinal (GI) Tolerance in Patients With Mild to Moderate Alzheimer's Disease (AD)",Completed,,Phase 4,63.0,Actual,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:44:37.779398,2020-02-01 22:44:37.779398,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Industry,galantamine,Drug
NCT00301574,"ClinicalTrials.gov processed this data on January 31, 2020",2006-03-10,,,2011-05-16,2006-03-10,2006-03-13,Estimate,,,,,,,2011-05-16,2011-05-17,Estimate,April 2001,,2001-04-30,January 2011,2011-01-31,February 2004,Actual,2004-02-29,,,,,Interventional,,,An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease.,"Placebo-Controlled, Double-Blind Study of Galantamine (R113675) in the Treatment of Alzheimer's Disease.",Completed,,Phase 3,398.0,Actual,Janssen Pharmaceutical K.K.,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:25:06.063117,2020-02-01 21:25:06.063117,Janssen Pharmaceutical K.K.,Industry,galantamine,Drug
NCT00304629,"ClinicalTrials.gov processed this data on January 31, 2020",2006-03-17,,,2011-01-31,2006-03-17,2006-03-20,Estimate,,,,,,,2011-01-31,2011-02-01,Estimate,March 2000,,2000-03-31,January 2011,2011-01-31,March 2002,Actual,2002-03-31,,,,,Interventional,,,Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease,Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8),Completed,,Phase 3,241.0,Actual,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:24:13.464563,2020-02-01 21:24:13.464563,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Industry,galantamine,Drug
NCT00309725,"ClinicalTrials.gov processed this data on January 31, 2020",2006-03-31,,,2011-05-17,2006-03-31,2006-04-03,Estimate,,,,,,,2011-05-17,2011-05-18,Estimate,,,,January 2011,2011-01-31,October 1999,Actual,1999-10-31,,,,,Interventional,,,A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease.,Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: A Cardiac Safety Study.,Completed,,Phase 3,139.0,Actual,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:22:48.818418,2020-02-01 21:22:48.818418,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Industry,galantamine,Drug
NCT00000172,"ClinicalTrials.gov processed this data on January 31, 2020",1999-10-29,,,2005-06-23,1999-10-29,1999-11-01,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,November 2002,2002-11-30,,,,,,,,Interventional,,,Evaluation of Galantamine in the Treatment of Alzheimer's Disease,Placebo Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy Under a Slow-Titration Regimen,Completed,,Phase 3,,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:51:08.607936,2020-02-01 22:51:08.607936,"Janssen, LP",Industry,Galantamine,Drug
NCT00679627,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-15,2013-04-23,,2013-09-10,2008-05-15,2008-05-19,Estimate,2013-07-30,2013-09-02,Estimate,,,,2013-09-10,2013-09-19,Estimate,June 2008,,2008-06-30,September 2013,2013-09-30,May 2012,Actual,2012-05-31,April 2012,Actual,2012-04-30,,Interventional,,,A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease",Terminated,,Phase 3,2051.0,Actual,"Janssen Research & Development, LLC",,2.0,,"Due to a pre-specified imbalance of deaths between treatment groups, the DSMB recommended early
    termination of the trial",False,,,,,,,,,,,,,,,,,2020-02-01 19:29:53.904574,2020-02-01 19:29:53.904574,"Janssen Research & Development, LLC",Industry,Galantamine,Drug
NCT01054976,"ClinicalTrials.gov processed this data on January 31, 2020",2010-01-21,2012-05-04,,2012-11-23,2010-01-21,2010-01-22,Estimate,2012-11-23,2012-12-24,Estimate,,,,2012-11-23,2012-12-24,Estimate,October 2006,,2006-10-31,November 2012,2012-11-30,February 2009,Actual,2009-02-28,February 2009,Actual,2009-02-28,,Interventional,,,The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease,The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease,Completed,,Phase 4,99.0,Actual,"Janssen Korea, Ltd., Korea","A relatively low number of patients finished the study, which may have had an impact on the statistical power of data analysis. Difficulties in performing computer-based tests for elderly patients may have hampered detection of changes in attention.",1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 17:35:21.384527,2020-02-01 17:35:21.384527,"Janssen Korea, Ltd., Korea",Industry,Galantamine,Drug
NCT01362686,"ClinicalTrials.gov processed this data on January 31, 2020",2011-05-26,2016-07-22,,2017-01-08,2011-05-27,2011-05-30,Estimate,2017-01-08,2017-02-27,Actual,,,,2017-01-08,2017-02-27,Actual,April 2011,,2011-04-30,January 2017,2017-01-31,October 2015,Actual,2015-10-31,October 2015,Actual,2015-10-31,,Interventional,COMET-AD,,Comparative Research of Alzheimer's Disease Drugs,Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs,Terminated,,N/A,200.0,Actual,Indiana University,Small sample size limits generalizability and may introduce type II error. The study took place at a time when most third-party payers declared donepezil the preferred AChEI due to cost that may have influenced study’s results.,3.0,,Low study accrual caused the study to be ended early.,False,,,,True,,,,,,,,,,,,,2020-02-01 16:05:14.947359,2020-02-01 16:05:14.947359,Indiana University,Other,Galantamine,Drug
NCT01478633,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-03,,,2014-03-24,2011-11-21,2011-11-23,Estimate,,,,,,,2014-03-24,2014-03-26,Estimate,September 2011,,2011-09-30,March 2014,2014-03-31,June 2013,Actual,2013-06-30,June 2013,Actual,2013-06-30,,Interventional,,,Evaluation of Efficacy and Safety of Galantamine in Patients With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil,Evaluation of Efficacy and Safety of Galantamine in Subjects With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil,Completed,,Phase 4,102.0,Actual,Janssen Pharmaceutical K.K.,,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:34:27.951407,2020-02-01 15:34:27.951407,Janssen Pharmaceutical K.K.,Industry,Galantamine,Drug
NCT01677754,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-30,,2016-07-20,2017-05-25,2012-08-30,2012-09-03,Estimate,,,,2016-07-20,2016-07-22,Estimate,2017-05-25,2017-05-30,Actual,"October 24, 2012",Actual,2012-10-24,May 2017,2017-05-31,"June 12, 2015",Actual,2015-06-12,"June 12, 2015",Actual,2015-06-12,,Interventional,MAyflOwer RoAD,,A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy,"A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease",Completed,,Phase 2,542.0,Actual,Hoffmann-La Roche,,3.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 14:44:43.645589,2020-02-01 14:44:43.645589,Hoffmann-La Roche,Industry,Galantamine,Drug
NCT00814801,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-24,2012-03-13,,2014-03-31,2008-12-24,2008-12-25,Estimate,2012-06-01,2012-07-04,Estimate,,,,2014-03-31,2014-04-17,Estimate,February 2007,,2007-02-28,March 2014,2014-03-31,September 2008,Actual,2008-09-30,September 2008,Actual,2008-09-30,,Interventional,,,An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease,Placebo-controlled Confirmatory Study of Galantamine (R113675) for Alzheimer's Type Dementia,Completed,,Phase 3,580.0,Actual,Janssen Pharmaceutical K.K.,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:49:31.270103,2020-02-01 18:49:31.270103,Janssen Pharmaceutical K.K.,Industry,Galantamine 16 mg/day,Drug
NCT00814801,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-24,2012-03-13,,2014-03-31,2008-12-24,2008-12-25,Estimate,2012-06-01,2012-07-04,Estimate,,,,2014-03-31,2014-04-17,Estimate,February 2007,,2007-02-28,March 2014,2014-03-31,September 2008,Actual,2008-09-30,September 2008,Actual,2008-09-30,,Interventional,,,An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease,Placebo-controlled Confirmatory Study of Galantamine (R113675) for Alzheimer's Type Dementia,Completed,,Phase 3,580.0,Actual,Janssen Pharmaceutical K.K.,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:49:31.270103,2020-02-01 18:49:31.270103,Janssen Pharmaceutical K.K.,Industry,Galantamine 24 mg/day,Drug
NCT00750529,"ClinicalTrials.gov processed this data on January 31, 2020",2008-09-09,,,2014-07-04,2008-09-09,2008-09-10,Estimate,,,,,,,2014-07-04,2014-07-08,Estimate,November 2008,,2008-11-30,July 2014,2014-07-31,September 2013,Actual,2013-09-30,September 2013,Actual,2013-09-30,,Interventional,,,Alzheimer and Sleep,Effects of Galantamine and Donépézil on the Amount and the Quality oh the Sleep in Patients Suffering From Alzheimer Disease.,Completed,,Phase 1,15.0,Actual,"University Hospital, Clermont-Ferrand",,1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:09:16.943500,2020-02-01 19:09:16.943500,"University Hospital, Clermont-Ferrand",Other,Galantamine and Donepezil,Drug
NCT01921972,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-07,,,2013-08-12,2013-08-12,2013-08-14,Estimate,,,,,,,2013-08-12,2013-08-14,Estimate,November 2004,,2004-11-30,August 2013,2013-08-31,May 2009,Actual,2009-05-31,November 2008,Actual,2008-11-30,,Interventional,AD-Combi,,The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease,"Competence Network - Dementia (BMBF) ""Pharmacological and Psychosocial Treatment"" (Modul E.2) Part II: The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 4,232.0,Actual,"Charite University, Berlin, Germany",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:40:38.562936,2020-02-01 13:40:38.562936,"Charite University, Berlin, Germany",Other,Galantamine CR,Drug
NCT00082602,"ClinicalTrials.gov processed this data on January 31, 2020",2004-05-12,,,2011-05-19,2004-05-14,2004-05-17,Estimate,,,,,,,2011-05-19,2011-05-20,Estimate,May 2004,,2004-05-31,April 2009,2009-04-30,April 2005,Actual,2005-04-30,,,,,Interventional,,,Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease,Galantamine ER Open Label Rapid Dose Escalation Trial in Alzheimer's Disease,Completed,,Phase 3,83.0,Actual,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:25:51.337958,2020-02-01 22:25:51.337958,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Industry,galantamine ER,Drug
NCT00645190,"ClinicalTrials.gov processed this data on January 31, 2020",2008-03-24,,,2011-05-18,2008-03-24,2008-03-27,Estimate,,,,,,,2011-05-18,2011-05-19,Estimate,March 2004,,2004-03-31,March 2010,2010-03-31,February 2005,Actual,2005-02-28,,,,,Interventional,,,"A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease","A Randomized, Double Blind, Active Control, Flexible Dose, Multicenter Study to Evaluate Galantamine HBr in the Treatment of Alzheimer's Disease:Safety and Effectiveness of an Immediate-release Table Formulation.",Completed,,Phase 3,215.0,Actual,Xian-Janssen Pharmaceutical Ltd.,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:39:50.011480,2020-02-01 19:39:50.011480,Xian-Janssen Pharmaceutical Ltd.,Industry,Galantamine HBr,Drug
NCT00216502,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-13,,,2011-01-20,2005-09-13,2005-09-22,Estimate,,,,,,,2011-01-20,2011-01-24,Estimate,August 2001,,2001-08-31,January 2011,2011-01-31,November 2005,Actual,2005-11-30,,,,,Interventional,,,A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease,Long Term Treatment With Galantamine In Dementia,Completed,,Phase 3,254.0,Actual,Janssen-Cilag S.p.A.,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:46:15.990279,2020-02-01 21:46:15.990279,Janssen-Cilag S.p.A.,Industry,galantamine hydrobromide,Drug
NCT00216515,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-13,,,2011-01-20,2005-09-13,2005-09-22,Estimate,,,,,,,2011-01-20,2011-01-24,Estimate,March 2004,,2004-03-31,January 2011,2011-01-31,November 2005,Actual,2005-11-30,,,,,Interventional,,,The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type,"A Prospective, Open-labeled, Multicenter Study of Galantamine on the Attention and Frontal Function of the Patients With Dementia of Alzheimer Type",Completed,,Phase 4,102.0,Actual,"Janssen Korea, Ltd., Korea",,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:46:15.892781,2020-02-01 21:46:15.892781,"Janssen Korea, Ltd., Korea",Industry,galantamine hydrobromide,Drug
NCT00216593,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-13,,2011-06-07,2011-06-07,2005-09-13,2005-09-22,Estimate,,,,2011-06-07,2011-06-21,Estimate,2011-06-07,2011-06-21,Estimate,December 2003,,2003-12-31,April 2010,2010-04-30,March 2008,Actual,2008-03-31,September 2007,Actual,2007-09-30,,Interventional,,,Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study,"Treatment of Severe Alzheimer's Disease in a Residential Home, Nursing Home, or Geriatric Residential Setting: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Randomised, Doubleblind, Placebo-Controlled Study.",Completed,,Phase 3,415.0,Actual,"Janssen Pharmaceutica N.V., Belgium",,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:46:15.326680,2020-02-01 21:46:15.326680,"Janssen Pharmaceutica N.V., Belgium",Industry,galantamine hydrobromide,Drug
NCT00253188,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-10,,,2011-05-17,2005-11-10,2005-11-15,Estimate,,,,,,,2011-05-17,2011-05-18,Estimate,February 1997,,1997-02-28,November 2010,2010-11-30,December 1998,Actual,1998-12-31,,,,,Interventional,,,A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease,"Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease",Completed,,Phase 3,653.0,Actual,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:38:00.274307,2020-02-01 21:38:00.274307,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Industry,galantamine hydrobromide,Drug
NCT00253201,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-10,,,2011-05-17,2005-11-10,2005-11-15,Estimate,,,,,,,2011-05-17,2011-05-18,Estimate,,,,November 2010,2010-11-30,October 1997,Actual,1997-10-31,,,,,Interventional,,,A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease,"Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease",Completed,,Phase 3,636.0,Actual,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:38:00.219740,2020-02-01 21:38:00.219740,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Industry,galantamine hydrobromide,Drug
NCT00253214,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-10,,,2011-05-19,2005-11-10,2005-11-15,Estimate,,,,,,,2011-05-19,2011-05-23,Estimate,March 2001,,2001-03-31,November 2010,2010-11-30,July 2002,Actual,2002-07-31,,,,,Interventional,,,Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation,Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation,Completed,,Phase 3,973.0,Actual,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:38:00.159075,2020-02-01 21:38:00.159075,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Industry,galantamine hydrobromide,Drug
NCT00253227,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-10,,,2011-05-17,2005-11-10,2005-11-15,Estimate,,,,,,,2011-05-17,2011-05-18,Estimate,July 1997,,1997-07-31,November 2010,2010-11-30,December 1998,Actual,1998-12-31,,,,,Interventional,,,A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease,Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial,Completed,,Phase 3,387.0,Actual,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:38:00.099051,2020-02-01 21:38:00.099051,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Industry,galantamine hydrobromide,Drug
NCT00261573,"ClinicalTrials.gov processed this data on January 31, 2020",2005-12-02,,,2011-05-17,2005-12-02,2005-12-05,Estimate,,,,,,,2011-05-17,2011-05-18,Estimate,December 1998,,1998-12-31,November 2010,2010-11-30,December 2000,Actual,2000-12-31,,,,,Interventional,,,A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia,The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia,Completed,,Phase 3,593.0,Actual,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:35:58.861491,2020-02-01 21:35:58.861491,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Industry,galantamine hydrobromide,Drug
NCT00236431,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-07,,,2011-06-06,2005-10-07,2005-10-12,Estimate,,,,,,,2011-06-06,2011-06-08,Estimate,May 2001,,2001-05-31,November 2010,2010-11-30,December 2003,Actual,2003-12-31,,,,,Interventional,,,A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment,A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease,Completed,,Phase 3,1063.0,Actual,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:42:07.012348,2020-02-01 21:42:07.012348,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Industry,Galantamine hydrobromide,Drug
NCT00236574,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-07,,,2011-06-06,2005-10-07,2005-10-12,Estimate,,,,,,,2011-06-06,2011-06-08,Estimate,May 2001,,2001-05-31,November 2010,2010-11-30,November 2003,Actual,2003-11-30,,,,,Interventional,,,A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment,A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease.,Completed,,Phase 3,974.0,Actual,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:42:06.385972,2020-02-01 21:42:06.385972,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Industry,Galantamine hydrobromide,Drug
NCT00338117,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-16,,,2010-04-26,2006-06-16,2006-06-20,Estimate,,,,,,,2010-04-26,2010-04-28,Estimate,August 1995,,1995-08-31,April 2010,2010-04-30,May 1997,Actual,1997-05-31,,,,,Interventional,,,"Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease","A European Multi-Center Study to Determine the Safety and Efficacy of Galanthamine Hydrobromide 40mg/Day (32 mg /Day GAL Base, Tid Dose Regimen) in Patients Diagnosed With Alzheimer-Type Dementia",Completed,,Phase 3,554.0,Actual,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:14:17.932582,2020-02-01 21:14:17.932582,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Industry,Galantamine hydrobromide,Drug
NCT00523666,"ClinicalTrials.gov processed this data on January 31, 2020",2007-08-29,,,2007-08-29,2007-08-29,2007-08-31,Estimate,,,,,,,2007-08-29,2007-08-31,Estimate,September 2006,,2006-09-30,August 2007,2007-08-31,September 2008,Anticipated,2008-09-30,,,,,Interventional,,,Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®),Diffusion Tensor Weighted MRI in Alzheimer's Disease: Prediction and Mapping of Symptomatic and Disease Modifying Treatment Effects of Galantamine (Reminyl®),Unknown status,Recruiting,Phase 4,20.0,Anticipated,Ludwig-Maximilians - University of Munich,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:17:42.425707,2020-02-01 20:17:42.425707,Ludwig-Maximilians - University of Munich,Other,Galantamine (Reminyl®),Drug
NCT00531804,"ClinicalTrials.gov processed this data on January 31, 2020",2007-09-18,,,2016-11-01,2007-09-18,2007-09-19,Estimate,,,,,,,2016-11-01,2016-11-02,Estimate,December 2006,,2006-12-31,November 2016,2016-11-30,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.,"A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO4909832 Following Intravenous Infusion in AD Patients",Completed,,Phase 1,60.0,Actual,Hoffmann-La Roche,,1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:14:39.861669,2020-02-01 20:14:39.861669,Hoffmann-La Roche,Industry,gantenerumab,Drug
NCT01224106,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-14,,,2019-11-05,2010-10-18,2010-10-19,Estimate,,,,,,,2019-11-05,2019-11-06,Actual,"November 30, 2010",Actual,2010-11-30,November 2019,2019-11-30,"August 28, 2020",Anticipated,2020-08-28,"August 28, 2020",Anticipated,2020-08-28,,Interventional,,,A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease,"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment","Active, not recruiting",,Phase 3,799.0,Actual,Hoffmann-La Roche,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 16:45:18.177127,2020-02-01 16:45:18.177127,Hoffmann-La Roche,Industry,Gantenerumab,Drug
NCT01656525,"ClinicalTrials.gov processed this data on January 31, 2020",2012-06-05,,,2014-09-17,2012-08-01,2012-08-03,Estimate,,,,,,,2014-09-17,2014-09-19,Estimate,June 2012,,2012-06-30,September 2014,2014-09-30,June 2014,Actual,2014-06-30,March 2014,Actual,2014-03-31,,Interventional,,,A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients,"A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients",Completed,,Phase 1,28.0,Actual,Chugai Pharmaceutical,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:50:26.009270,2020-02-01 14:50:26.009270,Chugai Pharmaceutical,Industry,Gantenerumab,Drug
NCT01760005,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-26,,,2019-10-01,2012-12-31,2013-01-03,Estimate,,,,,,,2019-10-01,2019-10-03,Actual,December 2012,,2012-12-31,October 2019,2019-10-31,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,,Interventional,DIAN-TU,,Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.,"A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease",Recruiting,,Phase 2/Phase 3,490.0,Anticipated,Washington University School of Medicine,,5.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:23:00.489600,2020-02-01 14:23:00.489600,Washington University School of Medicine,Other,Gantenerumab,Drug
NCT02051608,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-30,,,2020-01-21,2014-01-30,2014-01-31,Estimate,,,,,,,2020-01-21,2020-01-22,Actual,"March 27, 2014",Actual,2014-03-27,January 2020,2020-01-31,"April 22, 2021",Anticipated,2021-04-22,"April 22, 2021",Anticipated,2021-04-22,,Interventional,,,A Study of Gantenerumab in Participants With Mild Alzheimer Disease,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Gantenerumab in Patients With Mild Alzheimer's Disease; Part II: Open-Label Extension For Participating Patients","Active, not recruiting",,Phase 3,389.0,Actual,Hoffmann-La Roche,,2.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 13:05:33.470350,2020-02-01 13:05:33.470350,Hoffmann-La Roche,Industry,Gantenerumab,Drug
NCT03443973,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-19,,,2020-01-09,2018-02-19,2018-02-23,Actual,,,,,,,2020-01-09,2020-01-13,Actual,"August 22, 2018",Actual,2018-08-22,January 2020,2020-01-31,"March 2, 2023",Anticipated,2023-03-02,"May 31, 2022",Anticipated,2022-05-31,,Interventional,,,Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease",Recruiting,,Phase 3,760.0,Anticipated,Hoffmann-La Roche,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:19:15.567106,2020-02-01 08:19:15.567106,Hoffmann-La Roche,Industry,Gantenerumab,Drug
NCT03444870,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-19,,,2020-01-09,2018-02-19,2018-02-23,Actual,,,,,,,2020-01-09,2020-01-13,Actual,"June 6, 2018",Actual,2018-06-06,January 2020,2020-01-31,"March 2, 2023",Anticipated,2023-03-02,"May 31, 2022",Anticipated,2022-05-31,,Interventional,,,Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease",Recruiting,,Phase 3,814.0,Anticipated,Hoffmann-La Roche,,2.0,,,,,,,True,True,False,,,,,,,,,,,2020-02-01 08:19:06.396961,2020-02-01 08:19:06.396961,Hoffmann-La Roche,Industry,Gantenerumab,Drug
NCT02386306,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-16,,,2016-02-01,2015-03-10,2015-03-11,Estimate,,,,,,,2016-02-01,2016-02-03,Estimate,February 2015,,2015-02-28,July 2015,2015-07-31,October 2015,Actual,2015-10-31,October 2015,Actual,2015-10-31,,Interventional,,,"Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled; Phase 1b, Safety, Tolerability, and Pharmacokinetic Study of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,39.0,Actual,"GliaCure, Inc.",,6.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 11:47:27.909553,2020-02-01 11:47:27.909553,"GliaCure, Inc.",Industry,GC021109,Drug
NCT01617577,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-08,2012-06-29,,2012-11-26,2012-06-11,2012-06-12,Estimate,2012-11-26,2012-12-27,Estimate,,,,2012-11-26,2012-12-27,Estimate,June 2009,,2009-06-30,June 2012,2012-06-30,February 2012,Actual,2012-02-29,February 2012,Actual,2012-02-29,,Interventional,FFAD,,Efficacy and Safety of Filgrastim in Alzheimer's Disease,Efficacy and Safety of Filgrastim as a Pro‐Cognitive Agent in Alzheimer's Disease,Completed,,Phase 1/Phase 2,8.0,Actual,University of South Florida,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:00:17.017452,2020-02-01 15:00:17.017452,University of South Florida,Other,G-CSF; filgrastim,Drug
NCT03090516,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-04,,,2019-08-05,2017-03-23,2017-03-24,Actual,,,,,,,2019-08-05,2019-08-07,Actual,"August 10, 2016",Actual,2016-08-10,August 2019,2019-08-31,"March 10, 2020",Anticipated,2020-03-10,"March 10, 2020",Anticipated,2020-03-10,,Interventional,,,Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease,Clinical Study on Improving the Cognitive Function of Patients With Mild to Moderate Alzheimer's Disease by Using Ginkgo Biloba Dispersible Tablets,Recruiting,,Phase 2/Phase 3,240.0,Anticipated,The First Affiliated Hospital with Nanjing Medical University,,3.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 09:20:54.354890,2020-02-01 09:20:54.354890,The First Affiliated Hospital with Nanjing Medical University,Other,Ginkgo biloba dispersible tablets,Drug
NCT03090516,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-04,,,2019-08-05,2017-03-23,2017-03-24,Actual,,,,,,,2019-08-05,2019-08-07,Actual,"August 10, 2016",Actual,2016-08-10,August 2019,2019-08-31,"March 10, 2020",Anticipated,2020-03-10,"March 10, 2020",Anticipated,2020-03-10,,Interventional,,,Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Alzheimer's Disease,Clinical Study on Improving the Cognitive Function of Patients With Mild to Moderate Alzheimer's Disease by Using Ginkgo Biloba Dispersible Tablets,Recruiting,,Phase 2/Phase 3,240.0,Anticipated,The First Affiliated Hospital with Nanjing Medical University,,3.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 09:20:54.354890,2020-02-01 09:20:54.354890,The First Affiliated Hospital with Nanjing Medical University,Other,Ginkgo biloba dispersible tablets and Donepezil,Drug
NCT00042172,"ClinicalTrials.gov processed this data on January 31, 2020",2002-07-24,,,2014-02-27,2002-07-25,2002-07-26,Estimate,,,,,,,2014-02-27,2014-03-03,Estimate,June 2002,,2002-06-30,February 2014,2014-02-28,September 2004,Actual,2004-09-30,September 2004,Actual,2004-09-30,,Interventional,,,Treatment for Early Memory Loss,Cognitive Enhancers Explored With PET Imaging,Completed,,Phase 4,40.0,,University of Iowa,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:43:17.651846,2020-02-01 22:43:17.651846,University of Iowa,Other,Ginkgo Biloba Extract,Drug
NCT03520998,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-25,,,2019-07-15,2018-05-08,2018-05-11,Actual,,,,,,,2019-07-15,2019-07-16,Actual,"April 16, 2018",Actual,2018-04-16,August 2018,2018-08-31,"May 24, 2019",Actual,2019-05-24,"May 24, 2019",Actual,2019-05-24,,Interventional,,,A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease,"A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,40.0,Actual,"Alkahest, Inc.",,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 08:06:55.302057,2020-02-01 08:06:55.302057,"Alkahest, Inc.",Industry,GRF6019,Drug
NCT03765762,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-29,,,2020-01-29,2018-12-04,2018-12-05,Actual,,,,,,,2020-01-29,2020-01-31,Estimate,"January 15, 2019",Actual,2019-01-15,May 2019,2019-05-31,March 2020,Anticipated,2020-03-31,March 2020,Anticipated,2020-03-31,,Interventional,,,A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of Pulsed GRF6019 Infusions in Subjects With Severe Alzheimer's Disease","Active, not recruiting",,Phase 2,20.0,Anticipated,"Alkahest, Inc.",,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-04 05:13:33.658930,2020-02-04 05:13:33.658930,"Alkahest, Inc.",Industry,GRF6019,Drug
NCT01766336,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-08,2016-04-07,,2019-10-17,2013-01-10,2013-01-11,Estimate,2016-04-07,2016-05-13,Estimate,,,,2019-10-17,2019-10-21,Actual,January 2013,,2013-01-31,October 2019,2019-10-31,August 2015,Actual,2015-08-31,August 2015,Actual,2015-08-31,,Interventional,,,A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease,Terminated,,Phase 2,296.0,Actual,"OPKO Health, Inc.",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:21:02.495392,2020-02-01 14:21:02.495392,"OPKO Health, Inc.",Industry,Group 1 ELND005,Drug
NCT01766336,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-08,2016-04-07,,2019-10-17,2013-01-10,2013-01-11,Estimate,2016-04-07,2016-05-13,Estimate,,,,2019-10-17,2019-10-21,Actual,January 2013,,2013-01-31,October 2019,2019-10-31,August 2015,Actual,2015-08-31,August 2015,Actual,2015-08-31,,Interventional,,,A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease,Terminated,,Phase 2,296.0,Actual,"OPKO Health, Inc.",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:21:02.495392,2020-02-01 14:21:02.495392,"OPKO Health, Inc.",Industry,Group 2 ELND005,Drug
NCT00719394,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-17,,,2009-07-08,2008-07-18,2008-07-21,Estimate,,,,,,,2009-07-08,2009-07-10,Estimate,March 2008,,2008-03-31,July 2009,2009-07-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males,"Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-136 Administered Orally to Healthy Japanese Male Subjects and Healthy Japanese Elderly Male Subjects",Completed,,Phase 1,72.0,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:17:48.931302,2020-02-01 19:17:48.931302,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,GSI 136,Drug
NCT00718731,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-17,,,2010-04-01,2008-07-18,2008-07-21,Estimate,,,,,,,2010-04-01,2010-04-02,Estimate,March 2008,,2008-03-31,April 2010,2010-04-30,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,Study GSI-136 in Healthy Young and Healthy Elderly Subjects,"Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI 136 Administered Orally to Healthy Young and Healthy Elderly Subjects",Completed,,Phase 1,80.0,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:18:04.008559,2020-02-01 19:18:04.008559,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,GSI-136,Drug
NCT00441987,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-28,,,2010-06-17,2007-02-28,2007-03-01,Estimate,,,,,,,2010-06-17,2010-06-22,Estimate,February 2007,,2007-02-28,June 2010,2010-06-30,July 2009,Actual,2009-07-31,July 2009,Actual,2009-07-31,,Interventional,,,Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953,"A Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 Administered Orally to Healthy Japanese Male Subjects and Healthy Elderly Male Japanese Subjects.",Completed,,Phase 1,96.0,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:42:06.218004,2020-02-01 20:42:06.218004,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,GSI-953,Drug
NCT00479219,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-25,,,2008-07-09,2007-05-25,2007-05-28,Estimate,,,,,,,2008-07-09,2008-07-10,Estimate,May 2007,,2007-05-31,July 2008,2008-07-31,October 2007,Actual,2007-10-31,October 2007,Actual,2007-10-31,,Interventional,,,Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients,"A Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 in Blood and Cerebrospinal Fluid, When Administered Orally to Healthy Young Subjects and Patients With Alzheimer Disease",Completed,,Phase 1,17.0,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:30:46.442536,2020-02-01 20:30:46.442536,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,GSI-953,Drug
NCT00675090,"ClinicalTrials.gov processed this data on January 31, 2020",2008-04-24,,,2017-07-05,2008-05-07,2008-05-08,Estimate,,,,,,,2017-07-05,2017-07-07,Actual,"February 21, 2008",Actual,2008-02-21,July 2017,2017-07-31,"June 16, 2009",Actual,2009-06-16,"June 16, 2009",Actual,2009-06-16,,Interventional,,,Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease,"A Single Blind, Placebo-controlled, Randomised Study in Mild to Moderate Alzheimer's Disease Patients to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK239512, a Selective Histamine H3 Receptor Antagonist",Completed,,Phase 1,28.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 19:31:21.789058,2020-02-01 19:31:21.789058,GlaxoSmithKline,Industry,GSK239512,Drug
NCT01009255,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-05,,,2017-04-11,2009-11-05,2009-11-06,Estimate,,,,,,,2017-04-11,2017-04-13,Actual,"November 2, 2009",Actual,2009-11-02,April 2017,2017-04-30,"November 10, 2010",Actual,2010-11-10,"November 10, 2010",Actual,2010-11-10,,Interventional,,,Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease,"A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the H3 Receptor Antagonist, GSK239512 in Subjects With Mild to Moderate Alzheimer's Disease.",Completed,,Phase 2,196.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,False,False,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 17:48:00.502559,2020-02-01 17:48:00.502559,GlaxoSmithKline,Industry,GSK239512,Drug
NCT01702467,"ClinicalTrials.gov processed this data on January 31, 2020",2012-10-04,,,2017-10-16,2012-10-04,2012-10-08,Estimate,,,,,,,2017-10-16,2017-10-18,Actual,"October 19, 2012",Actual,2012-10-19,October 2017,2017-10-31,"May 15, 2013",Actual,2013-05-15,"May 15, 2013",Actual,2013-05-15,,Interventional,,,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers","A Single-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers",Completed,,Phase 1,27.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 14:38:19.515848,2020-02-01 14:38:19.515848,GlaxoSmithKline,Industry,GSK2647544,Drug
NCT01978327,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-31,,,2017-06-07,2013-10-31,2013-11-07,Estimate,,,,,,,2017-06-07,2017-06-08,Actual,"November 22, 2013",Actual,2013-11-22,June 2017,2017-06-30,"March 3, 2014",Actual,2014-03-03,"March 3, 2014",Actual,2014-03-03,,Interventional,,,"GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers","Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of GSK2647544 and Its Potential Pharmacokinetic Interaction With Simvastatin in Healthy Volunteers",Terminated,,Phase 1,12.0,Actual,GlaxoSmithKline,,4.0,,"Given the strength of CYP3A4 inhibition observed in Cohort 1, there is no rationale to
    investigate higher doses of GSK2647544 in the following two cohorts",False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 13:24:18.754282,2020-02-01 13:24:18.754282,GlaxoSmithKline,Industry,GSK2647544,Drug
NCT01924858,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-15,,,2017-10-17,2013-08-15,2013-08-19,Estimate,,,,,,,2017-10-17,2017-10-19,Actual,"August 19, 2013",Actual,2013-08-19,October 2017,2017-10-31,"March 3, 2014",Actual,2014-03-03,"March 3, 2014",Actual,2014-03-03,,Interventional,,,A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.,An Open Label Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F-GSK2647544 in Healthy Subjects,Terminated,,Phase 1,4.0,Actual,GlaxoSmithKline,,1.0,,Study objectives met so study concluded earlier than planned hence we terminated the study.,False,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 13:39:49.836625,2020-02-01 13:39:49.836625,GlaxoSmithKline,Industry,GSK2647544 oral,Drug
NCT01702480,"ClinicalTrials.gov processed this data on January 31, 2020",2012-10-04,,,2017-05-05,2012-10-04,2012-10-08,Estimate,,,,,,,2017-05-05,2017-05-09,Actual,"November 5, 2012",Actual,2012-11-05,May 2017,2017-05-31,"July 3, 2015",Actual,2015-07-03,"July 3, 2015",Actual,2015-07-03,,Interventional,,,Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects,Effects of Medium-Chain Triglycerides on Cognitive Function in Older Subjects With Age-Related Cognitive Decline,Completed,,Phase 1,116.0,Actual,GlaxoSmithKline,,7.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:38:19.414695,2020-02-01 14:38:19.414695,GlaxoSmithKline,Industry,GSK2981710,Drug
NCT00459550,"ClinicalTrials.gov processed this data on January 31, 2020",2007-04-11,,,2017-07-18,2007-04-11,2007-04-12,Estimate,,,,,,,2017-07-18,2017-07-21,Actual,"March 12, 2007",Actual,2007-03-12,July 2017,2017-07-31,"May 30, 2011",Actual,2011-05-30,"May 30, 2011",Actual,2011-05-30,,Interventional,,,A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease,"A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776 in Patients With Alzheimer's Disease.",Completed,,Phase 1,50.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,True,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 20:36:43.972662,2020-02-01 20:36:43.972662,GlaxoSmithKline,Industry,GSK933776,Drug
NCT03116126,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-04,,,2019-06-10,2017-04-11,2017-04-14,Actual,,,,,,,2019-06-10,2019-06-12,Actual,"January 4, 2019",Actual,2019-01-04,June 2019,2019-06-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,,Interventional,NorAD,,Noradrenergic Add-on Therapy With Guanfacine,Randomised Clinical Trial of Noradrenergic Add-on Therapy With Extended-Release Guanfacine in Alzheimer's Disease,Recruiting,,Phase 3,160.0,Anticipated,Imperial College London,,2.0,,,False,,,,True,False,False,,,False,,,,,,,,2020-02-01 09:16:26.690225,2020-02-01 09:16:26.690225,Imperial College London,Other,Guanfacine,Drug
NCT03959553,"ClinicalTrials.gov processed this data on January 31, 2020",2019-05-08,,,2019-05-23,2019-05-21,2019-05-22,Actual,,,,,,,2019-05-23,2019-05-28,Actual,"September 1, 2019",Anticipated,2019-09-01,May 2019,2019-05-31,"February 28, 2022",Anticipated,2022-02-28,"August 31, 2021",Anticipated,2021-08-31,,Interventional,,,GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Moderate Alzheimer's Disease",Not yet recruiting,,Phase 2,90.0,Anticipated,GemVax & Kael,,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 07:00:23.340260,2020-02-01 07:00:23.340260,GemVax & Kael,Industry,GV1001,Drug
NCT03184467,"ClinicalTrials.gov processed this data on January 31, 2020",2017-06-09,,,2017-06-09,2017-06-09,2017-06-12,Actual,,,,,,,2017-06-09,2017-06-12,Actual,June 2017,Anticipated,2017-06-30,June 2017,2017-06-30,June 2019,Anticipated,2019-06-30,June 2019,Anticipated,2019-06-30,,Interventional,,,Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients",Unknown status,Recruiting,Phase 2,90.0,Anticipated,GemVax & Kael,,3.0,,,False,,,,False,False,False,,,,,,,,,Undecided,,2020-02-01 09:04:28.719332,2020-02-01 09:04:28.719332,GemVax & Kael,Industry,GV1001 0.56 mg,Drug
NCT03184467,"ClinicalTrials.gov processed this data on January 31, 2020",2017-06-09,,,2017-06-09,2017-06-09,2017-06-12,Actual,,,,,,,2017-06-09,2017-06-12,Actual,June 2017,Anticipated,2017-06-30,June 2017,2017-06-30,June 2019,Anticipated,2019-06-30,June 2019,Anticipated,2019-06-30,,Interventional,,,Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients",Unknown status,Recruiting,Phase 2,90.0,Anticipated,GemVax & Kael,,3.0,,,False,,,,False,False,False,,,,,,,,,Undecided,,2020-02-01 09:04:28.719332,2020-02-01 09:04:28.719332,GemVax & Kael,Industry,GV1001 1.12 mg,Drug
NCT00000179,"ClinicalTrials.gov processed this data on January 31, 2020",1999-10-29,,,2005-06-23,1999-10-29,1999-11-01,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,March 2005,2005-03-31,,,,,,,,Interventional,,,Agitation in Alzheimer's Disease,,Completed,,Phase 3,,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:51:07.954349,2020-02-01 22:51:07.954349,National Institute on Aging (NIA),NIH,Haloperidol,Drug
NCT00009217,"ClinicalTrials.gov processed this data on January 31, 2020",2001-01-23,,,2016-05-23,2001-01-23,2001-01-24,Estimate,,,,,,,2016-05-23,2016-05-24,Estimate,January 1999,,1999-01-31,February 2012,2012-02-29,December 2004,Actual,2004-12-31,December 2004,Actual,2004-12-31,,Interventional,,,Treatment of Behavioral Symptoms in Alzheimer's Disease,Treatment of Behavioral Symptoms in Alzheimer's Disease,Completed,,Phase 4,44.0,Actual,New York State Psychiatric Institute,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 22:48:44.873571,2020-02-01 22:48:44.873571,New York State Psychiatric Institute,Other,Haloperidol-Haloperidol,Drug
NCT00009217,"ClinicalTrials.gov processed this data on January 31, 2020",2001-01-23,,,2016-05-23,2001-01-23,2001-01-24,Estimate,,,,,,,2016-05-23,2016-05-24,Estimate,January 1999,,1999-01-31,February 2012,2012-02-29,December 2004,Actual,2004-12-31,December 2004,Actual,2004-12-31,,Interventional,,,Treatment of Behavioral Symptoms in Alzheimer's Disease,Treatment of Behavioral Symptoms in Alzheimer's Disease,Completed,,Phase 4,44.0,Actual,New York State Psychiatric Institute,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 22:48:44.873571,2020-02-01 22:48:44.873571,New York State Psychiatric Institute,Other,Haloperidol-Placebo,Drug
NCT04228666,"ClinicalTrials.gov processed this data on January 31, 2020",2020-01-03,,,2020-01-23,2020-01-10,2020-01-14,Actual,,,,,,,2020-01-23,2020-01-27,Actual,"December 27, 2019",Actual,2019-12-27,January 2020,2020-01-31,"February 1, 2021",Anticipated,2021-02-01,"February 1, 2021",Anticipated,2021-02-01,,Interventional,,,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease,"Active, not recruiting",,Phase 1/Phase 2,24.0,Anticipated,Hope Biosciences,,1.0,,,,,,,True,True,False,,,,,,,,,No,,2020-02-01 06:23:00.399535,2020-02-01 06:23:00.399535,Hope Biosciences,Industry,HB-adMSCs,Drug
NCT03838952,"ClinicalTrials.gov processed this data on January 31, 2020",2019-02-01,,,2019-02-11,2019-02-11,2019-02-12,Actual,,,,,,,2019-02-11,2019-02-12,Actual,"February 11, 2019",Anticipated,2019-02-11,February 2019,2019-02-28,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2019",Anticipated,2019-12-31,,Interventional,,,The Efficacy of Traditional Chinese Herbal Medicine for Dementia,The Efficacy of Traditional Chinese Herbal Medicine for Dementia: a Pilot Study,Not yet recruiting,,N/A,20.0,Anticipated,"Taipei Veterans General Hospital, Taiwan",,1.0,,,False,,,,True,False,False,,,,,,,,,,,2020-02-01 07:18:31.379975,2020-02-01 07:18:31.379975,"Taipei Veterans General Hospital, Taiwan",Other,Herbal medicine,Drug
NCT00357357,"ClinicalTrials.gov processed this data on January 31, 2020",2006-07-26,,,2008-08-20,2006-07-26,2006-07-27,Estimate,,,,,,,2008-08-20,2008-08-21,Estimate,July 2006,,2006-07-31,August 2008,2008-08-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients,Clinical Safety/Tolerability of HF0220 and Its Effect on Biochemical Markers Relevant to Patients With a Diagnosis of Mild to Moderate Alzheimer' Disease,Completed,,Phase 2,40.0,Anticipated,Hunter-Fleming Ltd,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:09:43.209165,2020-02-01 21:09:43.209165,Hunter-Fleming Ltd,Industry,HF0220,Drug
NCT04075435,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-29,,,2019-09-25,2019-08-29,2019-08-30,Actual,,,,,,,2019-09-25,2019-09-27,Actual,"November 1, 2019",Anticipated,2019-11-01,September 2019,2019-09-30,"November 1, 2021",Anticipated,2021-11-01,"November 1, 2021",Anticipated,2021-11-01,,Interventional,CBD,,Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Alzheimer's Dementia,Open-Label Trial of a Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Alzheimer's Dementia,Not yet recruiting,,Early Phase 1,12.0,Anticipated,Mclean Hospital,,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 06:43:37.219138,2020-02-01 06:43:37.219138,Mclean Hospital,Other,high CBD/low THC sublingual solution,Drug
NCT03790709,"ClinicalTrials.gov processed this data on January 31, 2020",2018-12-24,,,2019-11-17,2018-12-31,2019-01-02,Actual,,,,,,,2019-11-17,2019-11-19,Actual,"July 3, 2018",Actual,2018-07-03,August 2019,2019-08-31,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,,Interventional,,,ANAVEX2-73 for Treatment of Early Alzheimer's Disease,"A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)",Recruiting,,Phase 2/Phase 3,450.0,Anticipated,Anavex Life Sciences Corp.,,3.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:25:39.943948,2020-02-01 07:25:39.943948,Anavex Life Sciences Corp.,Industry,High dose ANAVEX2-73,Drug
NCT01482013,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-10,,,2012-08-29,2011-11-28,2011-11-30,Estimate,,,,,,,2012-08-29,2012-08-30,Estimate,October 2011,,2011-10-31,August 2012,2012-08-31,March 2012,Actual,2012-03-31,March 2012,Actual,2012-03-31,,Interventional,,,Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease,"A Double-blind, Randomized, Placebo-controlled, Phase I , Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease",Terminated,,Phase 1,7.0,Actual,"High Point Pharmaceuticals, LLC.",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:33:39.759571,2020-02-01 15:33:39.759571,"High Point Pharmaceuticals, LLC.",Industry,HPP854,Drug
NCT02291783,"ClinicalTrials.gov processed this data on January 31, 2020",2014-10-07,,,2017-06-19,2014-11-11,2014-11-14,Estimate,,,,,,,2017-06-19,2017-06-20,Actual,November 2013,,2013-11-30,June 2017,2017-06-30,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,,,"Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment","A Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of HTL0009936 in Healthy Subjects",Completed,,Phase 1,108.0,Actual,Heptares Therapeutics Limited,,2.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 12:08:34.341587,2020-02-01 12:08:34.341587,Heptares Therapeutics Limited,Industry,HTL0009936,Drug
NCT02710188,"ClinicalTrials.gov processed this data on January 31, 2020",2016-03-02,,,2016-10-17,2016-03-15,2016-03-16,Estimate,,,,,,,2016-10-17,2016-10-18,Estimate,February 2016,,2016-02-29,October 2016,2016-10-31,August 2016,Actual,2016-08-31,July 2016,Actual,2016-07-31,,Interventional,,,Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation,"A Phase 1 Relative Bioavailability Study in Healthy CYP2D6 Intermediate (IM) and Extensive Metaboliser (EM) Subjects, Designed to Evaluate the Pharmacokinetic (PK) Profile of HTL0009936 Following Single Dose Administration of Modified Release (MR) Prototype Formulations",Completed,,Phase 1,14.0,Actual,Heptares Therapeutics Limited,,2.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 10:35:27.459784,2020-02-01 10:35:27.459784,Heptares Therapeutics Limited,Industry,HTL0009936 immediate release,Drug
NCT02710188,"ClinicalTrials.gov processed this data on January 31, 2020",2016-03-02,,,2016-10-17,2016-03-15,2016-03-16,Estimate,,,,,,,2016-10-17,2016-10-18,Estimate,February 2016,,2016-02-29,October 2016,2016-10-31,August 2016,Actual,2016-08-31,July 2016,Actual,2016-07-31,,Interventional,,,Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation,"A Phase 1 Relative Bioavailability Study in Healthy CYP2D6 Intermediate (IM) and Extensive Metaboliser (EM) Subjects, Designed to Evaluate the Pharmacokinetic (PK) Profile of HTL0009936 Following Single Dose Administration of Modified Release (MR) Prototype Formulations",Completed,,Phase 1,14.0,Actual,Heptares Therapeutics Limited,,2.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 10:35:27.459784,2020-02-01 10:35:27.459784,Heptares Therapeutics Limited,Industry,HTL0009936 modified release,Drug
NCT02291783,"ClinicalTrials.gov processed this data on January 31, 2020",2014-10-07,,,2017-06-19,2014-11-11,2014-11-14,Estimate,,,,,,,2017-06-19,2017-06-20,Actual,November 2013,,2013-11-30,June 2017,2017-06-30,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,,,"Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment","A Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of HTL0009936 in Healthy Subjects",Completed,,Phase 1,108.0,Actual,Heptares Therapeutics Limited,,2.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 12:08:34.341587,2020-02-01 12:08:34.341587,Heptares Therapeutics Limited,Industry,HTL0009936 placebo,Drug
NCT03456349,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-22,,,2018-07-19,2018-03-05,2018-03-07,Actual,,,,,,,2018-07-19,2018-07-20,Actual,"November 10, 2017",Actual,2017-11-10,July 2018,2018-07-31,"July 16, 2018",Actual,2018-07-16,"July 16, 2018",Actual,2018-07-16,,Interventional,,,Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care,"A Phase 1b Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With Alzheimer's Disease Receiving Standard-of-care",Completed,,Phase 1,60.0,Actual,Heptares Therapeutics Limited,,4.0,,,False,,,,True,False,False,,,,,,,,,,,2020-02-01 08:17:20.213225,2020-02-01 08:17:20.213225,Heptares Therapeutics Limited,Industry,HTL0018318,Drug
NCT02833792,"ClinicalTrials.gov processed this data on January 31, 2020",2016-06-20,,,2019-04-04,2016-07-13,2016-07-14,Estimate,,,,,,,2019-04-04,2019-04-09,Actual,June 2016,,2016-06-30,April 2019,2019-04-30,June 2020,Anticipated,2020-06-30,December 2019,Anticipated,2019-12-31,,Interventional,,,Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease,A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease,Recruiting,,Phase 2,40.0,Anticipated,"Stemedica Cell Technologies, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 10:11:12.537881,2020-02-01 10:11:12.537881,"Stemedica Cell Technologies, Inc.",Industry,Human Mesenchymal Stem Cells and Lactated Riunger's Solution,Drug
NCT00083590,"ClinicalTrials.gov processed this data on January 31, 2020",2004-05-26,,,2008-02-19,2004-05-26,2004-05-27,Estimate,,,,,,,2008-02-19,2008-02-21,Estimate,April 2004,,2004-04-30,February 2008,2008-02-29,November 2007,Actual,2007-11-30,November 2007,Actual,2007-11-30,,Interventional,,,Huperzine A in Alzheimer's Disease,"A Multi-Center, Double-Blind, Placebo-Controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function",Completed,,Phase 2,150.0,Anticipated,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:25:21.830228,2020-02-01 22:25:21.830228,National Institute on Aging (NIA),NIH,Huperzine A,Drug
NCT00385684,"ClinicalTrials.gov processed this data on January 31, 2020",2006-10-06,2014-06-02,,2015-11-18,2006-10-06,2006-10-11,Estimate,2015-11-18,2015-11-20,Estimate,,,,2015-11-18,2015-11-20,Estimate,October 2007,,2007-10-31,November 2015,2015-11-30,June 2014,Actual,2014-06-30,December 2011,Actual,2011-12-31,,Interventional,LDOT,Veterans with severe dementia residing in VA nursing home.,Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),Completed,,Phase 4,11.0,Actual,VA Office of Research and Development,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:00:50.049144,2020-02-01 21:00:50.049144,VA Office of Research and Development,U.S. Fed,hydrocodone/APAP,Drug
NCT00385684,"ClinicalTrials.gov processed this data on January 31, 2020",2006-10-06,2014-06-02,,2015-11-18,2006-10-06,2006-10-11,Estimate,2015-11-18,2015-11-20,Estimate,,,,2015-11-18,2015-11-20,Estimate,October 2007,,2007-10-31,November 2015,2015-11-30,June 2014,Actual,2014-06-30,December 2011,Actual,2011-12-31,,Interventional,LDOT,Veterans with severe dementia residing in VA nursing home.,Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),Completed,,Phase 4,11.0,Actual,VA Office of Research and Development,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:00:50.049144,2020-02-01 21:00:50.049144,VA Office of Research and Development,U.S. Fed,hydrocodone/APAP w placebo PRN,Drug
NCT00046358,"ClinicalTrials.gov processed this data on January 31, 2020",2002-09-26,,,2008-03-03,2002-09-26,2002-09-27,Estimate,,,,,,,2008-03-03,2008-03-04,Estimate,September 2002,,2002-09-30,August 2005,2005-08-31,August 2005,,2005-08-31,,,,,Interventional,,,"The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease",The Effect of Short-Term Statin and NSAID Treatment on CSF Beta-Amyloid,Completed,,Phase 4,50.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:42:35.955048,2020-02-01 22:42:35.955048,National Institute of Mental Health (NIMH),NIH,Ibuprofen,Drug
NCT00239746,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-13,,,2009-04-28,2005-10-13,2005-10-17,Estimate,,,,,,,2009-04-28,2009-04-29,Estimate,October 2005,,2005-10-31,April 2009,2009-04-30,August 2009,Anticipated,2009-08-31,August 2009,Anticipated,2009-08-31,,Interventional,,,BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories,Biomarkers of Nonsteroidal Anti-Inflammatories,Unknown status,"Active, not recruiting",Phase 1,40.0,Anticipated,National Institute on Aging (NIA),,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:41:15.228944,2020-02-01 21:41:15.228944,National Institute on Aging (NIA),NIH,Ibuprofen,Drug
NCT03363269,"ClinicalTrials.gov processed this data on January 31, 2020",2017-11-30,,,2019-06-03,2017-11-30,2017-12-06,Actual,,,,,,,2019-06-03,2019-06-04,Actual,"April 12, 2016",Actual,2016-04-12,June 2019,2019-06-30,"April 17, 2019",Actual,2019-04-17,"December 31, 2018",Actual,2018-12-31,,Interventional,,,Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease,"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease",Completed,,Phase 2,116.0,Actual,IlDong Pharmaceutical Co Ltd,,4.0,,,False,,,,,False,False,,,,,,,,,No,,2020-02-01 08:33:03.068167,2020-02-01 08:33:03.068167,IlDong Pharmaceutical Co Ltd,Industry,ID1201,Drug
NCT01955161,"ClinicalTrials.gov processed this data on January 31, 2020",2013-09-27,2017-07-11,,2017-08-22,2013-09-27,2013-10-07,Estimate,2017-08-22,2017-09-19,Actual,,,,2017-08-22,2017-09-19,Actual,October 2013,,2013-10-31,August 2017,2017-08-31,July 2016,Actual,2016-07-31,July 2016,Actual,2016-07-31,,Interventional,STARSHINE,A total of 933 patients were randomized into the study but 3 patients were not treated (did not receive IMP). The baseline analysis population only consist of patients who have been treated.,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil",Completed,,Phase 3,933.0,Actual,H. Lundbeck A/S,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:31:12.067407,2020-02-01 13:31:12.067407,H. Lundbeck A/S,Industry,Idalopirdine,Drug
NCT02006641,"ClinicalTrials.gov processed this data on January 31, 2020",2013-12-05,2017-12-19,,2018-01-23,2013-12-05,2013-12-10,Estimate,2018-01-23,2018-02-20,Actual,,,,2018-01-23,2018-02-20,Actual,February 2014,,2014-02-28,January 2018,2018-01-31,December 2016,Actual,2016-12-31,December 2016,Actual,2016-12-31,,Interventional,STARBEAM,A total of 858 patients were randomized into the study but 10 patients were not treated (did not receive IMP). The baseline analysis population only consist of patients who have been treated.,Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil",Completed,,Phase 3,858.0,Actual,H. Lundbeck A/S,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:17:05.953656,2020-02-01 13:17:05.953656,H. Lundbeck A/S,Industry,Idalopirdine,Drug
NCT02006654,"ClinicalTrials.gov processed this data on January 31, 2020",2013-12-05,2018-01-12,,2018-01-12,2013-12-09,2013-12-10,Estimate,2018-01-12,2018-02-07,Actual,,,,2018-01-12,2018-02-07,Actual,March 2014,,2014-03-31,January 2018,2018-01-31,January 2017,Actual,2017-01-31,January 2017,Actual,2017-01-31,,Interventional,STARBRIGHT,A total of 734 patients were randomized into the study but 6 patients were not treated (did not receive IMP). The baseline analysis population only consist of patients who have been treated.,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor,"Randomised, Double-blind, Parallel-group, Placebo-controlled Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor",Completed,,Phase 3,734.0,Actual,H. Lundbeck A/S,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:17:04.911285,2020-02-01 13:17:04.911285,H. Lundbeck A/S,Industry,Idalopirdine,Drug
NCT03307993,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-26,,,2018-04-03,2017-10-11,2017-10-12,Actual,,,,,,,2018-04-03,2018-04-04,Actual,"September 22, 2017",Actual,2017-09-22,April 2018,2018-04-30,"February 19, 2018",Actual,2018-02-19,"February 19, 2018",Actual,2018-02-19,,Interventional,,,Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease,"Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating the Brain Receptor Occupancy of Idalopirdine in Patients With Alzheimer's Disease",Terminated,,Phase 1,3.0,Actual,H. Lundbeck A/S,,1.0,,The study was terminated for strategic reasons.,False,,,,False,True,False,,,,,,,,,,,2020-02-01 08:42:22.774244,2020-02-01 08:42:22.774244,H. Lundbeck A/S,Industry,Idalopirdine,Drug
NCT02079246,"ClinicalTrials.gov processed this data on January 31, 2020",2014-02-28,2018-07-06,,2018-08-09,2014-03-04,2014-03-05,Estimate,2018-08-09,2018-08-10,Actual,,,,2018-08-09,2018-08-10,Actual,"April 7, 2014",Actual,2014-04-07,August 2018,2018-08-31,"July 6, 2017",Actual,2017-07-06,"July 6, 2017",Actual,2017-07-06,,Interventional,STAR Extension,A total of 1463 patients were enrolled into the study but 1 patient was not treated (did not receive IMP). The baseline analysis population only consist of patients who have been treated. The baseline measures are those collected at entry into the lead-in studies (Baseline I).,Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease,An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease,Completed,,Phase 3,1463.0,Actual,H. Lundbeck A/S,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:58:42.524277,2020-02-01 12:58:42.524277,H. Lundbeck A/S,Industry,Idalopirdine 60 mg,Drug
NCT02340195,"ClinicalTrials.gov processed this data on January 31, 2020",2015-01-13,,,2015-11-06,2015-01-13,2015-01-16,Estimate,,,,,,,2015-11-06,2015-11-09,Estimate,January 2015,,2015-01-31,November 2015,2015-11-30,,,,September 2015,Actual,2015-09-30,,Interventional,,,Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function,"Interventional, Single-site, Open-label, Reduced/Staged, Multiple-dose Study Investigating the Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Patients With Renal Impairment and in Healthy Subjects",Completed,,Phase 1,16.0,Actual,H. Lundbeck A/S,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 11:57:37.867093,2020-02-01 11:57:37.867093,H. Lundbeck A/S,Industry,Idalopirdine (Lu AE58054) 60 mg,Drug
NCT00031018,"ClinicalTrials.gov processed this data on January 31, 2020",2002-02-20,,,2008-02-04,2002-02-21,2002-02-22,Estimate,,,,,,,2008-02-04,2008-02-05,Estimate,,,,February 2008,2008-02-29,,,,,,,,Interventional,,,Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha,Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha,Unknown status,"Active, not recruiting",Phase 2,,,National Center for Research Resources (NCRR),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:45:20.829825,2020-02-01 22:45:20.829825,National Center for Research Resources (NCRR),NIH,IFN-alpha2A,Drug
NCT01736579,"ClinicalTrials.gov processed this data on January 31, 2020",2012-11-27,2016-07-13,,2017-10-19,2012-11-27,2012-11-29,Estimate,2016-07-13,2016-08-23,Estimate,,,,2017-10-19,2017-10-23,Actual,November 2012,,2012-11-30,October 2016,2016-10-31,June 2013,Actual,2013-06-30,June 2013,Actual,2013-06-30,,Interventional,,,"Long-Term Study of IGIV, 10% in Alzheimer´s Disease","A Study of the Long-Term Safety and Efficacy of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) in Mild to Moderate Alzheimer´s Disease",Terminated,,Phase 3,6.0,Actual,Shire,This study was an extension of study 160701 and was stopped early due to lack of evidence of clinical benefit of IGIV treatment in Alzheimer's Disease patients in Baxalta study 160701. Summary tables available for safety data only.,2.0,,"The study was terminated because the first Phase 3 did not demonstrate efficacy on the
    co-primary endpoints. The known safety profile remained unchanged.",False,,,,True,,,,,,,,,,,,,2020-02-01 14:28:45.422522,2020-02-01 14:28:45.422522,Baxalta now part of Shire,Industry,"Immune Globulin Intravenous (Human), 10% (IGIV, 10%)",Drug
NCT00432081,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-05,,,2007-02-05,2007-02-05,2007-02-06,Estimate,,,,,,,2007-02-05,2007-02-06,Estimate,May 2000,,2000-05-31,February 2007,2007-02-28,August 2005,,2005-08-31,,,,,Interventional,,,Effect of Indomethacin on the Progression of Alzheimer's Disease,Effect of Indomethacin on the Progression of Alzheimer's Disease,Completed,,Phase 3,160.0,,Radboud University,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:45:30.594643,2020-02-01 20:45:30.594643,Radboud University,Other,indomethacin,Drug
NCT01245530,"ClinicalTrials.gov processed this data on January 31, 2020",2010-11-01,,,2011-06-09,2010-11-18,2010-11-22,Estimate,,,,,,,2011-06-09,2011-06-13,Estimate,June 2008,,2008-06-30,June 2011,2011-06-30,March 2011,Actual,2011-03-31,February 2011,Actual,2011-02-28,,Interventional,,,An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia,"Probable Alzheimer Type Dementia Compare INM-176 1200~1600mg/Day With Donepezil 5~10mg/Day of Safety and Efficacy to Randomization, Multicenter, Double-blind, Double-dummy, Parallel Phase III Clinical Study",Completed,,Phase 3,280.0,Actual,Whanin Pharmaceutical Company,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:38:35.536182,2020-02-01 16:38:35.536182,Whanin Pharmaceutical Company,Industry,INM-176,Drug
NCT01595646,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-08,2017-04-17,,2018-04-23,2012-05-09,2012-05-10,Estimate,2018-01-05,2018-02-01,Actual,,,,2018-04-23,2018-05-22,Actual,November 2011,Actual,2011-11-30,April 2018,2018-04-30,"March 12, 2015",Actual,2015-03-12,"March 12, 2015",Actual,2015-03-12,,Interventional,SL120,,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Completed,,Phase 2,37.0,Actual,Wake Forest University Health Sciences,,3.0,,,False,,,,True,True,False,,,,,,,,,No,There is no plan to share individual participant data with other researchers.,2020-02-01 15:05:56.020319,2020-02-01 15:05:56.020319,Wake Forest University Health Sciences,Other,Insulin,Drug
NCT02462161,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-01,,,2019-08-29,2015-06-02,2015-06-03,Estimate,,,,,,,2019-08-29,2019-09-03,Actual,"March 20, 2015",Actual,2015-03-20,August 2019,2019-08-31,"April 16, 2019",Actual,2019-04-16,"April 16, 2019",Actual,2019-04-16,,Interventional,SNIFF-Quick,,Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart,Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart,Completed,,Phase 1,24.0,Actual,Wake Forest University Health Sciences,,2.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 11:30:11.664980,2020-02-01 11:30:11.664980,Wake Forest University Health Sciences,Other,Insulin aspart,Drug
NCT01547169,"ClinicalTrials.gov processed this data on January 31, 2020",2012-02-07,,,2012-12-17,2012-03-06,2012-03-07,Estimate,,,,,,,2012-12-17,2012-12-18,Estimate,March 2011,,2011-03-31,December 2012,2012-12-31,December 2012,Actual,2012-12-31,December 2012,Actual,2012-12-31,,Interventional,SNIFF-LONG 21,,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days,Completed,,Phase 2,60.0,Actual,University of Washington,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:17:31.332607,2020-02-01 15:17:31.332607,University of Washington,Other,insulin detemir,Drug
NCT01595646,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-08,2017-04-17,,2018-04-23,2012-05-09,2012-05-10,Estimate,2018-01-05,2018-02-01,Actual,,,,2018-04-23,2018-05-22,Actual,November 2011,Actual,2011-11-30,April 2018,2018-04-30,"March 12, 2015",Actual,2015-03-12,"March 12, 2015",Actual,2015-03-12,,Interventional,SL120,,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Completed,,Phase 2,37.0,Actual,Wake Forest University Health Sciences,,3.0,,,False,,,,True,True,False,,,,,,,,,No,There is no plan to share individual participant data with other researchers.,2020-02-01 15:05:56.020319,2020-02-01 15:05:56.020319,Wake Forest University Health Sciences,Other,Insulin detemir,Drug
NCT01436045,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-16,2015-04-09,,2015-09-25,2011-09-16,2011-09-19,Estimate,2015-09-25,2015-10-19,Estimate,,,,2015-09-25,2015-10-19,Estimate,September 2011,,2011-09-30,September 2015,2015-09-30,June 2013,Actual,2013-06-30,June 2013,Actual,2013-06-30,,Interventional,,,Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.,"A Double-Blind, Placebo-Controlled Single Dose Study of the Safety and Efficacy of Glulisine on Cognitive Function and Memory in Individuals Diagnosed With Probable Mild to Moderate Alzheimer's Disease/Intranasal Insulin Study.",Completed,,Phase 2,12.0,Actual,HealthPartners Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:46:57.736752,2020-02-01 15:46:57.736752,HealthPartners Institute,Other,Insulin glulisine,Drug
NCT02503501,"ClinicalTrials.gov processed this data on January 31, 2020",2015-07-14,,,2020-01-29,2015-07-17,2015-07-21,Estimate,,,,,,,2020-01-29,2020-01-31,Estimate,August 2015,,2015-08-31,January 2020,2020-01-31,February 2020,Anticipated,2020-02-29,February 2020,Anticipated,2020-02-29,,Interventional,,,Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease,"A Phase II, Single Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and the Therapeutic Effectiveness of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,49.0,Actual,HealthPartners Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-04 05:17:00.541400,2020-02-04 05:17:00.541400,HealthPartners Institute,Other,Insulin glulisine,Drug
NCT01767909,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-10,,,2019-01-16,2013-01-11,2013-01-15,Estimate,,,,,,,2019-01-16,2019-01-18,Actual,"January 8, 2014",Actual,2014-01-08,January 2019,2019-01-31,"December 11, 2018",Actual,2018-12-11,"December 11, 2018",Actual,2018-12-11,,Interventional,,,The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF),Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD),Completed,,Phase 2/Phase 3,239.0,Actual,University of Southern California,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:20:36.780945,2020-02-01 14:20:36.780945,University of Southern California,Other,Insulin (Humulin® R U-100),Drug
NCT01636596,"ClinicalTrials.gov processed this data on January 31, 2020",2012-07-06,,,2014-03-12,2012-07-09,2012-07-10,Estimate,,,,,,,2014-03-12,2014-03-13,Estimate,September 2013,,2013-09-30,March 2014,2014-03-31,January 2015,Anticipated,2015-01-31,January 2015,Anticipated,2015-01-31,,Interventional,,,Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease,Evaluating the Efficacy of Controlled Pulsatile Intravenous Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease- A Pilot Study,Withdrawn,,N/A,0.0,Actual,Louisiana State University Health Sciences Center Shreveport,,,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:55:56.081980,2020-02-01 14:55:56.081980,Louisiana State University Health Sciences Center Shreveport,Other,Insulin LISPRO,Drug
NCT00726726,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-30,,,2008-11-04,2008-07-30,2008-08-01,Estimate,,,,,,,2008-11-04,2008-11-05,Estimate,August 2008,,2008-08-31,November 2008,2008-11-30,October 2008,Actual,2008-10-31,October 2008,Actual,2008-10-31,,Interventional,,,Drug Interaction Study With a Potential Alzheimer's Disease Compound,"Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Midazolam, Warfarin, Caffeine, Omeprazole and Dextromethorphan in Healthy Male Subjects by Administration of a Modified Cooperstown Cocktail",Completed,,Phase 1,22.0,Actual,Bristol-Myers Squibb,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:15:36.229229,2020-02-01 19:15:36.229229,Bristol-Myers Squibb,Industry,"Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)",Drug
NCT01075763,"ClinicalTrials.gov processed this data on January 31, 2020",2010-02-24,2012-03-07,,2014-01-20,2010-02-24,2010-02-25,Estimate,2012-03-07,2012-04-04,Estimate,,,,2014-01-20,2014-02-13,Estimate,November 2004,,2004-11-30,January 2014,2014-01-31,May 2008,Actual,2008-05-31,May 2008,Actual,2008-05-31,,Interventional,REAL,,A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease,Pilot Trial of Interferon Beta-1a in Alzheimer's Disease,Completed,,Phase 2,42.0,Actual,"Merck KGaA, Darmstadt, Germany",,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 17:29:21.471563,2020-02-01 17:29:21.471563,"Merck KGaA, Darmstadt, Germany",Industry,Interferon beta-1a,Drug
NCT00006187,"ClinicalTrials.gov processed this data on January 31, 2020",2000-08-25,,,2009-12-10,2000-08-25,2000-08-28,Estimate,,,,,,,2009-12-10,2009-12-11,Estimate,,,,October 2003,2003-10-31,June 2005,Anticipated,2005-06-30,June 2005,Anticipated,2005-06-30,,Interventional,,,The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease,,Terminated,,Phase 3,,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:49:04.068007,2020-02-01 22:49:04.068007,Merck Sharp & Dohme Corp.,Industry,Investigational drug,Drug
NCT01560585,"ClinicalTrials.gov processed this data on January 31, 2020",2012-03-15,,,2014-08-27,2012-03-21,2012-03-22,Estimate,,,,,,,2014-08-27,2014-08-28,Estimate,April 2012,,2012-04-30,August 2014,2014-08-31,August 2014,Actual,2014-08-31,August 2014,Actual,2014-08-31,,Interventional,,,Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease,Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease,Terminated,,Phase 1/Phase 2,10.0,Anticipated,University Hospitals Cleveland Medical Center,,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:14:31.128171,2020-02-01 15:14:31.128171,University Hospitals Cleveland Medical Center,Other,Isotretinoin,Drug
NCT02817906,"ClinicalTrials.gov processed this data on January 31, 2020",2016-06-27,,,2018-12-18,2016-06-27,2016-06-29,Estimate,,,,,,,2018-12-18,2018-12-20,Actual,June 2016,Actual,2016-06-30,December 2018,2018-12-31,December 2018,Actual,2018-12-31,December 2018,Actual,2018-12-31,,Interventional,,,"ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease",Terminated,,Phase 3,177.0,Actual,"Intra-Cellular Therapies, Inc.",,2.0,,Pre-specified Interim Analysis Indicated Futility,False,,,,,True,False,,,,,,,,,,,2020-02-01 10:14:10.009879,2020-02-01 10:14:10.009879,"Intra-Cellular Therapies, Inc.",Industry,ITI-007,Drug
NCT02130661,"ClinicalTrials.gov processed this data on January 31, 2020",2014-05-01,,,2016-12-12,2014-05-01,2014-05-05,Estimate,,,,,,,2016-12-12,2016-12-13,Estimate,October 2017,,2017-10-31,December 2016,2016-12-31,January 2018,Anticipated,2018-01-31,January 2018,Anticipated,2018-01-31,,Interventional,,,Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers,"A Phase I, Two-part, Open-label Study to Evaluate the Pharmacokinetics of Rilapladib (SB-659032) and Its Metabolites, and to Determine the Effect of Repeat Dose Itraconazole on the Pharmacokinetics of Rilapladib in Healthy Volunteers",Withdrawn,,Phase 1,0.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 12:46:22.393870,2020-02-01 12:46:22.393870,GlaxoSmithKline,Industry,Itraconazole,Drug
NCT03838185,"ClinicalTrials.gov processed this data on January 31, 2020",2019-02-07,,,2019-02-09,2019-02-09,2019-02-12,Actual,,,,,,,2019-02-09,2019-02-12,Actual,"January 22, 2019",Actual,2019-01-22,February 2019,2019-02-28,January 2020,Anticipated,2020-01-31,October 2019,Anticipated,2019-10-31,,Interventional,,,"Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147","A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147 in Healthy Young Volunteers and Healthy Elderly Volunteers",Recruiting,,Phase 1,64.0,Anticipated,"Abrexa Pharmaceuticals, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 07:18:39.582788,2020-02-01 07:18:39.582788,"Abrexa Pharmaceuticals, Inc.",Industry,J147,Drug
NCT01137799,"ClinicalTrials.gov processed this data on January 31, 2020",2010-06-03,,,2012-11-07,2010-06-03,2010-06-04,Estimate,,,,,,,2012-11-07,2012-11-08,Estimate,August 2009,,2009-08-31,November 2012,2012-11-30,March 2011,Actual,2011-03-31,,,,,Interventional,,,The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients,"A Double-Blind, Placebo-Controlled, Randomized, Four-Way Cross-Over Study To Investigate Effect Of Single Oral Doses Of JNJ-39393406 On Event-Related Potentials In Subjects With Stable Schizophrenia",Terminated,,Phase 1,47.0,Actual,"Janssen Pharmaceutica N.V., Belgium",,6.0,,Efficacy signals were insufficiently strong to justify recruitment of additional patients.,False,,,,False,,,,,,,,,,,,,2020-02-01 17:11:10.402638,2020-02-01 17:11:10.402638,"Janssen Pharmaceutica N.V., Belgium",Industry,JNJ-39393406,Drug
NCT01978548,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-31,,,2015-06-24,2013-10-31,2013-11-07,Estimate,,,,,,,2015-06-24,2015-06-25,Estimate,December 2013,,2013-12-31,June 2015,2015-06-30,April 2015,Actual,2015-04-30,April 2015,Actual,2015-04-30,,Interventional,,,A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease,"A Double-blind, Placebo-Controlled, Randomized, 4-Week, Multiple-Dose, Proof-of-Mechanism Study in Subjects With Prodromal Alzheimer's Disease Investigating the Effects of JNJ-54861911 on Aβ Processing in CSF and Plasma",Completed,,Phase 1,45.0,Actual,"Janssen Research & Development, LLC",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:24:17.334831,2020-02-01 13:24:17.334831,"Janssen Research & Development, LLC",Industry,JNJ-54861911 10 mg,Drug
NCT02360657,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-05,,,2019-01-31,2015-02-05,2015-02-10,Estimate,,,,,,,2019-01-31,2019-02-04,Actual,"February 16, 2015",Actual,2015-02-16,January 2019,2019-01-31,"September 8, 2015",Actual,2015-09-08,"September 8, 2015",Actual,2015-09-08,,Interventional,,,Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia,"A Double-blind, Placebo-controlled, Randomized, 4-Week, Multiple-dose, Proof of Mechanism (POM) Study in Japanese Subjects Asymptomatic at Risk for Alzheimer Dementia (ARAD) Investigating the Effects of JNJ-54861911 on A-beta Processing in Cerebrospinal Fluid (CSF) and Plasma",Completed,,Phase 1,18.0,Actual,Janssen Pharmaceutical K.K.,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 11:52:56.242572,2020-02-01 11:52:56.242572,Janssen Pharmaceutical K.K.,Industry,"JNJ-54861911, 10 mg",Drug
NCT02406027,"ClinicalTrials.gov processed this data on January 31, 2020",2015-03-27,2019-06-25,,2019-09-05,2015-03-27,2015-04-01,Estimate,2019-09-05,2019-09-09,Actual,,,,2019-09-05,2019-09-09,Actual,"July 2, 2015",Actual,2015-07-02,September 2019,2019-09-30,"June 28, 2018",Actual,2018-06-28,"June 28, 2018",Actual,2018-06-28,,Interventional,,Double-blind safety analysis set included all participants who received study treatment during period 1.,An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum,"A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzheimer's Disease Spectrum",Terminated,,Phase 2,90.0,Actual,"Janssen Research & Development, LLC","The major limitation of this study was early termination of the study/program by the sponsor, which resulted in small numbers of participants in groups, precluding meaningful interpretation of some of the analyses.",5.0,,,False,,,,True,,False,,,,,,,,,,,2020-02-01 11:43:20.601413,2020-02-01 11:43:20.601413,"Janssen Research & Development, LLC",Industry,"JNJ-54861911, 10 mg",Drug
NCT02260674,"ClinicalTrials.gov processed this data on January 31, 2020",2014-10-06,,2017-03-01,2017-03-01,2014-10-06,2014-10-09,Estimate,,,,2017-03-01,2017-03-03,Actual,2017-03-01,2017-03-03,Actual,November 2014,,2014-11-30,March 2017,2017-03-31,June 2016,Actual,2016-06-30,June 2016,Actual,2016-06-30,,Interventional,,,A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease,"A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects With Early Alzheimer's Disease",Completed,,Phase 2,114.0,Actual,"Janssen Research & Development, LLC",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:15:34.625870,2020-02-01 12:15:34.625870,"Janssen Research & Development, LLC",Industry,"JNJ-54861911, 10 milligram (mg)",Drug
NCT02406027,"ClinicalTrials.gov processed this data on January 31, 2020",2015-03-27,2019-06-25,,2019-09-05,2015-03-27,2015-04-01,Estimate,2019-09-05,2019-09-09,Actual,,,,2019-09-05,2019-09-09,Actual,"July 2, 2015",Actual,2015-07-02,September 2019,2019-09-30,"June 28, 2018",Actual,2018-06-28,"June 28, 2018",Actual,2018-06-28,,Interventional,,Double-blind safety analysis set included all participants who received study treatment during period 1.,An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum,"A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzheimer's Disease Spectrum",Terminated,,Phase 2,90.0,Actual,"Janssen Research & Development, LLC","The major limitation of this study was early termination of the study/program by the sponsor, which resulted in small numbers of participants in groups, precluding meaningful interpretation of some of the analyses.",5.0,,,False,,,,True,,False,,,,,,,,,,,2020-02-01 11:43:20.601413,2020-02-01 11:43:20.601413,"Janssen Research & Development, LLC",Industry,"JNJ-54861911, 25 mg",Drug
NCT01978548,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-31,,,2015-06-24,2013-10-31,2013-11-07,Estimate,,,,,,,2015-06-24,2015-06-25,Estimate,December 2013,,2013-12-31,June 2015,2015-06-30,April 2015,Actual,2015-04-30,April 2015,Actual,2015-04-30,,Interventional,,,A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease,"A Double-blind, Placebo-Controlled, Randomized, 4-Week, Multiple-Dose, Proof-of-Mechanism Study in Subjects With Prodromal Alzheimer's Disease Investigating the Effects of JNJ-54861911 on Aβ Processing in CSF and Plasma",Completed,,Phase 1,45.0,Actual,"Janssen Research & Development, LLC",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:24:17.334831,2020-02-01 13:24:17.334831,"Janssen Research & Development, LLC",Industry,JNJ-54861911 50 mg,Drug
NCT02260674,"ClinicalTrials.gov processed this data on January 31, 2020",2014-10-06,,2017-03-01,2017-03-01,2014-10-06,2014-10-09,Estimate,,,,2017-03-01,2017-03-03,Actual,2017-03-01,2017-03-03,Actual,November 2014,,2014-11-30,March 2017,2017-03-31,June 2016,Actual,2016-06-30,June 2016,Actual,2016-06-30,,Interventional,,,A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease,"A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects With Early Alzheimer's Disease",Completed,,Phase 2,114.0,Actual,"Janssen Research & Development, LLC",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:15:34.625870,2020-02-01 12:15:34.625870,"Janssen Research & Development, LLC",Industry,"JNJ-54861911, 50 mg",Drug
NCT02360657,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-05,,,2019-01-31,2015-02-05,2015-02-10,Estimate,,,,,,,2019-01-31,2019-02-04,Actual,"February 16, 2015",Actual,2015-02-16,January 2019,2019-01-31,"September 8, 2015",Actual,2015-09-08,"September 8, 2015",Actual,2015-09-08,,Interventional,,,Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia,"A Double-blind, Placebo-controlled, Randomized, 4-Week, Multiple-dose, Proof of Mechanism (POM) Study in Japanese Subjects Asymptomatic at Risk for Alzheimer Dementia (ARAD) Investigating the Effects of JNJ-54861911 on A-beta Processing in Cerebrospinal Fluid (CSF) and Plasma",Completed,,Phase 1,18.0,Actual,Janssen Pharmaceutical K.K.,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 11:52:56.242572,2020-02-01 11:52:56.242572,Janssen Pharmaceutical K.K.,Industry,"JNJ-54861911, 50 mg",Drug
NCT02406027,"ClinicalTrials.gov processed this data on January 31, 2020",2015-03-27,2019-06-25,,2019-09-05,2015-03-27,2015-04-01,Estimate,2019-09-05,2019-09-09,Actual,,,,2019-09-05,2019-09-09,Actual,"July 2, 2015",Actual,2015-07-02,September 2019,2019-09-30,"June 28, 2018",Actual,2018-06-28,"June 28, 2018",Actual,2018-06-28,,Interventional,,Double-blind safety analysis set included all participants who received study treatment during period 1.,An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum,"A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzheimer's Disease Spectrum",Terminated,,Phase 2,90.0,Actual,"Janssen Research & Development, LLC","The major limitation of this study was early termination of the study/program by the sponsor, which resulted in small numbers of participants in groups, precluding meaningful interpretation of some of the analyses.",5.0,,,False,,,,True,,False,,,,,,,,,,,2020-02-01 11:43:20.601413,2020-02-01 11:43:20.601413,"Janssen Research & Development, LLC",Industry,"JNJ-54861911, 5 mg",Drug
NCT03375697,"ClinicalTrials.gov processed this data on January 31, 2020",2017-12-13,,,2020-01-10,2017-12-13,2017-12-18,Actual,,,,,,,2020-01-10,2020-01-13,Actual,"December 22, 2017",Actual,2017-12-22,January 2020,2020-01-31,"December 16, 2019",Actual,2019-12-16,"December 16, 2019",Actual,2019-12-16,,Interventional,,,"A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease","A 2-Part Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease",Completed,,Phase 1,72.0,Actual,"Janssen Research & Development, LLC",,2.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 08:30:47.390139,2020-02-01 08:30:47.390139,"Janssen Research & Development, LLC",Industry,JNJ-63733657,Drug
NCT00142805,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-01,,,2008-12-30,2005-09-01,2005-09-02,Estimate,,,,,,,2008-12-30,2008-12-31,Estimate,October 2004,,2004-10-31,September 2006,2006-09-30,March 2006,,2006-03-31,,,,,Interventional,,,Ketasyn in Mild to Moderate Alzheimer's Disease,"Safety, Tolerability and Efficacy Study of Ketasyn™ (AC-1202) Administered for Ninety Days in Subjects With Probable Alzheimer's Disease of Mild to Moderate Severity",Completed,,Phase 2,100.0,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:04:41.693699,2020-02-01 22:04:41.693699,Cerecin,Industry,Ketasyn™ (AC-1202),Drug
NCT02127476,"ClinicalTrials.gov processed this data on January 31, 2020",2014-04-24,,,2017-05-31,2014-04-28,2014-04-30,Estimate,,,,,,,2017-05-31,2017-06-01,Actual,July 2014,,2014-07-31,May 2017,2017-05-31,May 2017,Actual,2017-05-31,May 2017,Actual,2017-05-31,,Interventional,,,A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease,"A Phase 1 Double-blind, Placebo-controlled, Single- and Multiple-ascending-dose Study of KHK6640 in Alzheimer's Disease",Completed,,Phase 1,57.0,Actual,"Kyowa Kirin Pharmaceutical Development, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:47:13.721981,2020-02-01 12:47:13.721981,"Kyowa Hakko Kirin Pharma, Inc.",Industry,KHK6640,Drug
NCT02377713,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-25,,,2016-12-06,2015-03-02,2015-03-04,Estimate,,,,,,,2016-12-06,2016-12-07,Estimate,March 2015,,2015-03-31,December 2016,2016-12-31,September 2016,Actual,2016-09-30,September 2016,Actual,2016-09-30,,Interventional,,,A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.,"A Phase 1 Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.",Completed,,Phase 1,20.0,Actual,"Kyowa Kirin Co., Ltd.",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 11:49:05.330787,2020-02-01 11:49:05.330787,"Kyowa Kirin Co., Ltd.",Industry,KHK6640,Drug
NCT03093519,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-22,,,2018-03-18,2017-03-22,2017-03-28,Actual,,,,,,,2018-03-18,2018-03-20,Actual,"March 3, 2017",Actual,2017-03-03,March 2018,2018-03-31,"December 6, 2017",Actual,2017-12-06,"December 6, 2017",Actual,2017-12-06,,Interventional,,,A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease,"A Phase 1 Randomized, Double-blind, Placebo-controlled, Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease",Completed,,Phase 1,21.0,Actual,"Kyowa Kirin Co., Ltd.",,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2020-02-01 09:20:20.897418,2020-02-01 09:20:20.897418,"Kyowa Kirin Co., Ltd.",Industry,KHK6640,Drug
NCT01354691,"ClinicalTrials.gov processed this data on January 31, 2020",2011-05-01,,,2013-07-22,2011-05-14,2011-05-17,Estimate,,,,,,,2013-07-22,2013-07-23,Estimate,February 2011,,2011-02-28,July 2013,2013-07-31,March 2013,Actual,2013-03-31,September 2012,Actual,2012-09-30,,Interventional,,,Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease,"A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease With a 6-Month Open Label Follow-Up Period",Completed,,Phase 2,201.0,Actual,Avraham Pharmaceuticals Ltd,,1.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:07:25.394126,2020-02-01 16:07:25.394126,Avraham Pharmaceuticals Ltd,Industry,ladostigil hemitartrate,Drug
NCT02245737,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-18,2019-06-11,,2019-11-19,2014-09-18,2014-09-22,Estimate,2019-07-15,2019-08-06,Actual,,,,2019-11-19,2019-12-03,Actual,"September 30, 2014",Actual,2014-09-30,October 2019,2019-10-31,"October 4, 2018",Actual,2018-10-04,"October 4, 2018",Actual,2018-10-04,,Interventional,AMARANTH,All randomized participants,An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease,"A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)",Terminated,,Phase 2/Phase 3,2218.0,Actual,AstraZeneca,"An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility.",3.0,,"An independent assessment concluded the trial was not likely to meet the primary endpoint upon
    completion and therefore, trial stopped for futility",False,,,,True,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://www.clinicalstudydatarequest.com/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 12:19:02.029274,2020-02-01 12:19:02.029274,AstraZeneca,Industry,Lanabecestat,Drug
NCT02783573,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-24,2019-06-11,,2019-11-19,2016-05-24,2016-05-26,Estimate,2019-07-15,2019-08-06,Actual,,,,2019-11-19,2019-12-03,Actual,"July 1, 2016",Actual,2016-07-01,October 2019,2019-10-31,"September 28, 2018",Actual,2018-09-28,"September 28, 2018",Actual,2018-09-28,,Interventional,DAYBREAK-ALZ,All randomized participants who received at least one dose of study drug.,A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia,"A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia",Terminated,,Phase 3,1722.0,Actual,AstraZeneca,"An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility.",4.0,,"An independent assessment concluded the trial was not likely to meet the primary endpoint upon
    completion and therefore, trial stopped for futility.",False,,,,True,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://www.clinicalstudydatarequest.com/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 10:20:35.671465,2020-02-01 10:20:35.671465,AstraZeneca,Industry,Lanabecestat,Drug
NCT02972658,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-21,2019-06-11,,2019-11-19,2016-11-21,2016-11-23,Estimate,2019-06-11,2019-07-05,Actual,,,,2019-11-19,2019-12-03,Actual,"March 15, 2017",Actual,2017-03-15,November 2019,2019-11-30,"October 2, 2018",Actual,2018-10-02,"October 2, 2018",Actual,2018-10-02,,Interventional,,All randomized participants who received study drug.,A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia,"A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)",Terminated,,Phase 3,421.0,Actual,AstraZeneca,"This study was stopped after an independent assessment concluded that the feeder study AZES was futile. Because of this, the originally planned delayed-start analysis for this study was not performed.",4.0,,"As the feeder study (AZES) was stopped for futility after an independent assessment, this trial
    was also stopped.",False,,,,True,True,False,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://www.clinicalstudydatarequest.com/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 09:42:22.888512,2020-02-01 09:42:22.888512,AstraZeneca,Industry,Lanabecestat,Drug
NCT01439555,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-16,2019-05-23,,2019-07-11,2011-09-21,2011-09-23,Estimate,2019-07-11,2019-07-30,Actual,,,,2019-07-11,2019-07-30,Actual,November 2011,,2011-11-30,July 2019,2019-07-31,November 2017,Actual,2017-11-30,November 2017,Actual,2017-11-30,,Interventional,,"Prospective, open-label, single group assignment, single center study conducted by UMass Medical School at the UMass Memorial Medical Center in Worcester, MA. 11 subjects total were screened and enrolled in this study, 10 subjects completed the study as 1 subject was initially enrolled but was excluded due to not meeting inclusion criteria.",Endothelial Facilitation in Alzheimer's Disease,"Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease.",Completed,,Phase 2,11.0,Actual,"University of Massachusetts, Worcester","The data for the MRI measurements (cerebral blood flow) experienced file corruption, rendering segments of data irretrievable and the whole set non-analyzable.",1.0,,,False,,,,False,True,False,,,True,,,,,,,,2020-02-01 15:45:59.915593,2020-02-01 15:45:59.915593,"University of Massachusetts, Worcester",Other,L-Arginine,Drug
NCT00563732,"ClinicalTrials.gov processed this data on January 31, 2020",2007-11-21,,,2008-09-08,2007-11-23,2007-11-26,Estimate,,,,,,,2008-09-08,2008-09-09,Estimate,December 2007,,2007-12-31,September 2008,2008-09-30,September 2008,Actual,2008-09-30,September 2008,Actual,2008-09-30,,Interventional,,,Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin,"An Open-Label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Lecozotan SR and a Single Oral Dose of Digoxin When Administered Orally to Healthy Adult Subjects",Completed,,Phase 1,,,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,,,,,,,,,,,,,,,,2020-02-01 20:03:22.544505,2020-02-01 20:03:22.544505,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,Lecozotan,Drug
NCT00151398,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-06,,2013-02-07,2013-02-07,2005-09-07,2005-09-08,Estimate,,,,2013-02-07,2013-02-11,Estimate,2013-02-07,2013-02-11,Estimate,September 2005,,2005-09-30,July 2008,2008-07-31,March 2008,Actual,2008-03-31,March 2008,Actual,2008-03-31,,Interventional,,,Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD),"A 3-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study Of 3 Doses Of Lecozotan (SRA-333) SR In Outpatients With Mild To Moderate Alzheimer's Disease With Donepezil As Active Control.",Completed,,Phase 2,229.0,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:02:22.166435,2020-02-01 22:02:22.166435,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,lecozotan SR,Drug
NCT00366483,"ClinicalTrials.gov processed this data on January 31, 2020",2006-08-17,,,2007-03-15,2006-08-18,2006-08-21,Estimate,,,,,,,2007-03-15,2007-03-16,Estimate,May 2006,,2006-05-31,March 2007,2007-03-31,,,,,,,,Interventional,,,Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects,"A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of Lecozotan SR Administered Orally to Healthy Young and Elderly Subjects",Completed,,Phase 1,40.0,,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:06:50.665014,2020-02-01 21:06:50.665014,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,Lecozotan SR,Drug
NCT00499642,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-10,,,2007-12-19,2007-07-10,2007-07-11,Estimate,,,,,,,2007-12-19,2007-12-28,Estimate,June 2007,,2007-06-30,December 2007,2007-12-31,August 2007,Actual,2007-08-31,,,,,Interventional,,,Study Evaluating the Effect of Lecozotan SR on the QTc Interval,"A Single-Dose, Double-Blind, Crossover, Placebo- and Moxifloxacin (Open-Label)-Controlled Study of the Effects of Lecozotan SR on Cardiac Repolarization in Healthy Adult Subjects",Completed,,Phase 1,,,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:24:43.811268,2020-02-01 20:24:43.811268,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,Lecozotan SR,Drug
NCT00277810,"ClinicalTrials.gov processed this data on January 31, 2020",2006-01-12,,2013-02-14,2013-02-14,2006-01-12,2006-01-16,Estimate,,,,2013-02-14,2013-02-21,Estimate,2013-02-14,2013-02-21,Estimate,March 2006,,2006-03-31,July 2008,2008-07-31,June 2008,Actual,2008-06-30,June 2008,Actual,2008-06-30,,Interventional,,,"Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease","A 6-Month, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Safety, Tolerability, and Efficacy Study of 3 Doses of Lecozotan (SRA-333) SR in Outpatients With Mild to Moderate Alzheimer's Disease Treated With a Cholinesterase Inhibitor",Completed,,Phase 2/Phase 3,250.0,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:31:26.378509,2020-02-01 21:31:26.378509,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,lecozotan SR (SRA-333),Drug
NCT03001557,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-16,2020-01-03,2019-07-22,2020-01-03,2016-12-20,2016-12-23,Estimate,2020-01-03,2020-01-14,Actual,2019-07-22,2019-07-29,Actual,2020-01-03,2020-01-14,Actual,"December 20, 2016",Actual,2016-12-20,July 2019,2019-07-31,"April 9, 2020",Anticipated,2020-04-09,"July 26, 2018",Actual,2018-07-26,,Interventional,,The safety analysis set included the group of randomized participants who received at least 1 dose of randomized study drug and had at least 1 postdose safety assessment.,Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia","Active, not recruiting",,Phase 2,63.0,Actual,Eisai Inc.,,5.0,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:37:08.757519,2020-02-01 09:37:08.757519,Eisai Inc.,Industry,Lemborexant 10 mg,Drug
NCT03001557,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-16,2020-01-03,2019-07-22,2020-01-03,2016-12-20,2016-12-23,Estimate,2020-01-03,2020-01-14,Actual,2019-07-22,2019-07-29,Actual,2020-01-03,2020-01-14,Actual,"December 20, 2016",Actual,2016-12-20,July 2019,2019-07-31,"April 9, 2020",Anticipated,2020-04-09,"July 26, 2018",Actual,2018-07-26,,Interventional,,The safety analysis set included the group of randomized participants who received at least 1 dose of randomized study drug and had at least 1 postdose safety assessment.,Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia","Active, not recruiting",,Phase 2,63.0,Actual,Eisai Inc.,,5.0,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:37:08.757519,2020-02-01 09:37:08.757519,Eisai Inc.,Industry,Lemborexant 15 mg,Drug
NCT03001557,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-16,2020-01-03,2019-07-22,2020-01-03,2016-12-20,2016-12-23,Estimate,2020-01-03,2020-01-14,Actual,2019-07-22,2019-07-29,Actual,2020-01-03,2020-01-14,Actual,"December 20, 2016",Actual,2016-12-20,July 2019,2019-07-31,"April 9, 2020",Anticipated,2020-04-09,"July 26, 2018",Actual,2018-07-26,,Interventional,,The safety analysis set included the group of randomized participants who received at least 1 dose of randomized study drug and had at least 1 postdose safety assessment.,Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia","Active, not recruiting",,Phase 2,63.0,Actual,Eisai Inc.,,5.0,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:37:08.757519,2020-02-01 09:37:08.757519,Eisai Inc.,Industry,Lemborexant 2.5 mg,Drug
NCT03001557,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-16,2020-01-03,2019-07-22,2020-01-03,2016-12-20,2016-12-23,Estimate,2020-01-03,2020-01-14,Actual,2019-07-22,2019-07-29,Actual,2020-01-03,2020-01-14,Actual,"December 20, 2016",Actual,2016-12-20,July 2019,2019-07-31,"April 9, 2020",Anticipated,2020-04-09,"July 26, 2018",Actual,2018-07-26,,Interventional,,The safety analysis set included the group of randomized participants who received at least 1 dose of randomized study drug and had at least 1 postdose safety assessment.,Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia","Active, not recruiting",,Phase 2,63.0,Actual,Eisai Inc.,,5.0,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:37:08.757519,2020-02-01 09:37:08.757519,Eisai Inc.,Industry,Lemborexant 5 mg,Drug
NCT03001557,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-16,2020-01-03,2019-07-22,2020-01-03,2016-12-20,2016-12-23,Estimate,2020-01-03,2020-01-14,Actual,2019-07-22,2019-07-29,Actual,2020-01-03,2020-01-14,Actual,"December 20, 2016",Actual,2016-12-20,July 2019,2019-07-31,"April 9, 2020",Anticipated,2020-04-09,"July 26, 2018",Actual,2018-07-26,,Interventional,,The safety analysis set included the group of randomized participants who received at least 1 dose of randomized study drug and had at least 1 postdose safety assessment.,Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia","Active, not recruiting",,Phase 2,63.0,Actual,Eisai Inc.,,5.0,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:37:08.757519,2020-02-01 09:37:08.757519,Eisai Inc.,Industry,Lemborexant-matched placebo,Drug
NCT00063310,"ClinicalTrials.gov processed this data on January 31, 2020",2003-06-25,,,2009-12-10,2003-06-25,2003-06-26,Estimate,,,,,,,2009-12-10,2009-12-11,Estimate,March 2003,,2003-03-31,February 2006,2006-02-28,February 2006,Actual,2006-02-28,February 2006,Actual,2006-02-28,,Interventional,,,ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation,Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN),Completed,,Phase 2,90.0,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:33:20.450308,2020-02-01 22:33:20.450308,Voyager Pharmaceutical Corporation,Industry,Leuprolide acetate,Drug
NCT00076440,"ClinicalTrials.gov processed this data on January 31, 2020",2004-01-22,,,2009-12-10,2004-01-23,2004-01-26,Estimate,,,,,,,2009-12-10,2009-12-11,Estimate,December 2003,,2003-12-31,March 2007,2007-03-31,March 2007,Actual,2007-03-31,March 2007,Actual,2007-03-31,,Interventional,,,Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study,Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study,Completed,,Phase 2,90.0,,National Institute on Aging (NIA),,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:28:48.366250,2020-02-01 22:28:48.366250,Voyager Pharmaceutical Corporation,Industry,Leuprolide acetate,Drug
NCT02002819,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-25,,,2019-11-20,2013-12-02,2013-12-06,Estimate,,,,,,,2019-11-20,2019-11-22,Actual,June 2014,,2014-06-30,November 2019,2019-11-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,,Interventional,LEV-AD,,Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability,Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability,Recruiting,,Phase 2,36.0,Anticipated,University of Minnesota,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:18:12.700821,2020-02-01 13:18:12.700821,University of Minnesota,Other,levetiracetam,Drug
NCT03489044,"ClinicalTrials.gov processed this data on January 31, 2020",2018-03-09,,,2018-10-15,2018-03-28,2018-04-05,Actual,,,,,,,2018-10-15,2018-10-16,Actual,November 2018,Anticipated,2018-11-30,March 2018,2018-03-31,January 2020,Anticipated,2020-01-31,"November 1, 2019",Anticipated,2019-11-01,,Interventional,ILiAD,,An Investigation of Levetiracetam in Alzheimer's Disease,An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a Proof of Concept Study,Enrolling by invitation,,Phase 2,30.0,Anticipated,University of Oxford,,2.0,,,False,,,,False,False,False,,,,,,,,,Undecided,It is possible that irretrievably anonymised data will be shared with other researchers dependent on securing relevant ethical approval,2020-02-01 08:12:09.213728,2020-02-01 08:12:09.213728,University of Oxford,Other,Levetiracetam,Drug
NCT03875638,"ClinicalTrials.gov processed this data on January 31, 2020",2019-03-13,,,2019-09-09,2019-03-13,2019-03-15,Actual,,,,,,,2019-09-09,2019-09-10,Actual,"August 22, 2019",Actual,2019-08-22,September 2019,2019-09-30,November 2023,Anticipated,2023-11-30,August 2023,Anticipated,2023-08-31,,Interventional,,,Treating Hyperexcitability in AD With Levetiracetam,Treating Hyperexcitability in Alzheimer's Disease With Levetiracetam to Improve Brain Function and Cognition,Recruiting,,Phase 2,85.0,Anticipated,Beth Israel Deaconess Medical Center,,4.0,,,False,,,,True,True,False,,,False,,,,,,Undecided,,2020-02-01 07:13:04.175822,2020-02-01 07:13:04.175822,Beth Israel Deaconess Medical Center,Other,Levetiracetam,Drug
NCT04004702,"ClinicalTrials.gov processed this data on January 31, 2020",2019-06-27,,,2019-06-27,2019-06-27,2019-07-02,Actual,,,,,,,2019-06-27,2019-07-02,Actual,January 2020,Anticipated,2020-01-31,June 2019,2019-06-30,June 2025,Anticipated,2025-06-30,December 2024,Anticipated,2024-12-31,,Interventional,LAPSE,,Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE),Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) - A Phase II Exploratory Study,Not yet recruiting,,Phase 2,65.0,Anticipated,Walter Reed National Military Medical Center,,1.0,,,False,,,,True,True,False,,,True,,,,,,No,,2020-02-01 06:53:29.669469,2020-02-01 06:53:29.669469,Walter Reed National Military Medical Center,U.S. Fed,Levetiracetam,Drug
NCT00306124,"ClinicalTrials.gov processed this data on January 31, 2020",2006-03-21,,,2007-10-24,2006-03-21,2006-03-22,Estimate,,,,,,,2007-10-24,2007-10-25,Estimate,January 2006,,2006-01-31,October 2007,2007-10-31,March 2008,Anticipated,2008-03-31,,,,,Interventional,,,Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment,"Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dementia/MCI)",Unknown status,Recruiting,Phase 4,120.0,Anticipated,University Hospital Muenster,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:23:52.322723,2020-02-01 21:23:52.322723,University Hospital Muenster,Other,Levodopa,Drug
NCT01058941,"ClinicalTrials.gov processed this data on January 31, 2020",2010-01-27,2017-03-01,,2017-03-01,2010-01-28,2010-01-29,Estimate,2017-03-01,2017-04-13,Actual,,,,2017-03-01,2017-04-13,Actual,September 2010,,2010-09-30,March 2017,2017-03-31,December 2014,Actual,2014-12-31,December 2014,Actual,2014-12-31,,Interventional,,,Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease,Lipoic Acid and Omega-3 Fatty Acids in Alzheimer's Disease,Completed,,Phase 1/Phase 2,67.0,Actual,Oregon Health and Science University,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:34:22.620784,2020-02-01 17:34:22.620784,Oregon Health and Science University,Other,Lipoic acid and fish oil concentrate,Drug
NCT01469351,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-01,,,2013-04-18,2011-11-07,2011-11-10,Estimate,,,,,,,2013-04-18,2013-04-19,Estimate,January 2012,,2012-01-31,April 2013,2013-04-30,April 2013,Actual,2013-04-30,April 2013,Actual,2013-04-30,,Interventional,,,Identifying Potential Effects of Liraglutide on Degenerative Changes,Neurodegenerative Changes in Alzheimer's Disease: Identifying Potential Effects of Liraglutide on Degenerative Changes,Completed,,N/A,34.0,Actual,University of Aarhus,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:37:03.985693,2020-02-01 15:37:03.985693,University of Aarhus,Other,Liraglutide,Drug
NCT01843075,"ClinicalTrials.gov processed this data on January 31, 2020",2013-04-24,,,2019-06-06,2013-04-26,2013-04-30,Estimate,,,,,,,2019-06-06,2019-06-10,Actual,January 2014,Actual,2014-01-31,June 2019,2019-06-30,December 2019,Anticipated,2019-12-31,December 2019,Anticipated,2019-12-31,,Interventional,ELAD,,Evaluating Liraglutide in Alzheimer's Disease,"Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)","Active, not recruiting",,Phase 2,204.0,Actual,Imperial College London,,2.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 14:02:32.425844,2020-02-01 14:02:32.425844,Imperial College London,Other,Liraglutide,Drug
NCT00088387,"ClinicalTrials.gov processed this data on January 31, 2020",2004-07-23,,,2008-03-03,2004-07-23,2004-07-26,Estimate,,,,,,,2008-03-03,2008-03-04,Estimate,July 2004,,2004-07-31,March 2005,2005-03-31,March 2005,,2005-03-31,,,,,Interventional,,,Effect of Lithium and Divalproex in Alzheimer's Disease,Glycogen Synthetase Kinase 3 (GSK-3) Inhibition in Alzheimer's Disease,Completed,,Phase 2,35.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:23:17.991451,2020-02-01 22:23:17.991451,National Institute of Neurological Disorders and Stroke (NINDS),NIH,Lithium,Drug
NCT02129348,"ClinicalTrials.gov processed this data on January 31, 2020",2014-04-29,,,2019-08-19,2014-05-01,2014-05-02,Estimate,,,,,,,2019-08-19,2019-08-20,Actual,June 2014,,2014-06-30,August 2019,2019-08-31,January 2020,Anticipated,2020-01-31,January 2020,Anticipated,2020-01-31,,Interventional,,,Treatment of Psychosis and Agitation in Alzheimer's Disease,Treatment of Psychosis and Agitation in Alzheimer's Disease,Recruiting,,Phase 2,80.0,Anticipated,New York State Psychiatric Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:46:46.841558,2020-02-01 12:46:46.841558,New York State Psychiatric Institute,Other,Lithium,Drug
NCT01211782,"ClinicalTrials.gov processed this data on January 31, 2020",2010-09-24,,,2012-12-03,2010-09-28,2010-09-30,Estimate,,,,,,,2012-12-03,2012-12-04,Estimate,,,,December 2012,2012-12-31,,,,,,,,Interventional,ALERT,,AC-1204 Long-term Efficacy Response Trial (ALERT Protocol),"A Phase 2-3, 6-12 Month, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Subjects With Mild to Moderate Alzheimer's Disease Who Are APOE4(-)",Withdrawn,,Phase 2/Phase 3,0.0,Actual,Cerecin,,2.0,,Study never started. Study was redesgined.,False,,,,False,,,,,,,,,,,,,2020-02-01 16:49:09.095841,2020-02-01 16:49:09.095841,Cerecin,Industry,long-chain triglyceride,Drug
NCT01117948,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-04,2012-05-21,,2013-02-01,2010-05-04,2010-05-06,Estimate,2012-10-30,2012-11-29,Estimate,,,,2013-02-01,2013-02-06,Estimate,September 2009,,2009-09-30,February 2013,2013-02-28,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,,,Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.,"A Multicentre Double-blind, Placebo-controlled, Randomised, Parallel-group Study to Evaluate the Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.",Terminated,,Phase 2,219.0,Actual,JSW Lifesciences,,2.0,,Lack of Efficacy,False,,,,True,,,,,,,,,,,,,2020-02-01 17:17:20.477475,2020-02-01 17:17:20.477475,JSW Lifesciences,Other,Lornoxicam,Drug
NCT00046358,"ClinicalTrials.gov processed this data on January 31, 2020",2002-09-26,,,2008-03-03,2002-09-26,2002-09-27,Estimate,,,,,,,2008-03-03,2008-03-04,Estimate,September 2002,,2002-09-30,August 2005,2005-08-31,August 2005,,2005-08-31,,,,,Interventional,,,"The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease",The Effect of Short-Term Statin and NSAID Treatment on CSF Beta-Amyloid,Completed,,Phase 4,50.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:42:35.955048,2020-02-01 22:42:35.955048,National Institute of Mental Health (NIMH),NIH,Lovostatin,Drug
NCT03062449,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-20,,,2019-09-06,2017-02-20,2017-02-23,Actual,,,,,,,2019-09-06,2019-09-09,Actual,"March 1, 2017",Actual,2017-03-01,September 2019,2019-09-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,,Interventional,LSPI-2,,Phase IIa L-serine Trial for eAD,"A Phase IIa Proof of Concept, Randomized, Double-blind, Placebo-controlled Study of the Effects of L-serine on Early Stage Alzheimer's Disease Patients",Recruiting,,Phase 2,40.0,Anticipated,Dartmouth-Hitchcock Medical Center,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 09:25:52.371375,2020-02-01 09:25:52.371375,Aleksandra Stark,Other,L-Serine,Drug
NCT01019421,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-24,,,2012-01-05,2009-11-24,2009-11-25,Estimate,,,,,,,2012-01-05,2012-01-06,Estimate,December 2009,,2009-12-31,January 2012,2012-01-31,,,,December 2011,Actual,2011-12-31,,Interventional,,,Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease,"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Moderate Alzheimer's Disease Treated With Donepezil",Completed,,Phase 2,278.0,Actual,H. Lundbeck A/S,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:44:47.118417,2020-02-01 17:44:47.118417,H. Lundbeck A/S,Industry,Lu AE58054,Drug
NCT03668405,"ClinicalTrials.gov processed this data on January 31, 2020",2018-09-11,,,2019-11-20,2018-09-11,2018-09-12,Actual,,,,,,,2019-11-20,2019-11-21,Actual,"June 26, 2018",Actual,2018-06-26,November 2019,2019-11-30,"May 27, 2019",Actual,2019-05-27,"May 27, 2019",Actual,2019-05-27,,Interventional,,,A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD),"Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease",Terminated,,Phase 1,18.0,Actual,H. Lundbeck A/S,,1.0,,New data: The study was terminated based on new efficacy data from another study,False,,,,True,False,False,,,,,,,,,,,2020-02-01 07:43:46.433835,2020-02-01 07:43:46.433835,H. Lundbeck A/S,Industry,Lu AF20513,Drug
NCT03819699,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-25,,,2019-07-15,2019-01-25,2019-01-28,Actual,,,,,,,2019-07-15,2019-07-17,Actual,"December 12, 2018",Actual,2018-12-12,July 2019,2019-07-31,"June 27, 2019",Actual,2019-06-27,"March 11, 2019",Actual,2019-03-11,,Interventional,,,Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD,"Interventional, Open-label, Multiple-immunisation Study of the Immunogenicity, Pharmacodynamics and Safety of Lu AF20513 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment Due to Alzheimer's Disease",Terminated,,Phase 1,3.0,Actual,H. Lundbeck A/S,,3.0,,New data: The study was terminated based on new efficacy data from another study,False,,,,False,False,False,,,False,,,,,,,,2020-02-01 07:21:19.402761,2020-02-01 07:21:19.402761,H. Lundbeck A/S,Industry,Lu AF20513,Drug
NCT02388152,"ClinicalTrials.gov processed this data on January 31, 2020",2015-03-03,,,2019-11-27,2015-03-12,2015-03-13,Estimate,,,,,,,2019-11-27,2019-11-29,Actual,March 2015,,2015-03-31,November 2019,2019-11-30,"July 4, 2019",Actual,2019-07-04,"July 4, 2019",Actual,2019-07-04,,Interventional,,,Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease,"Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease",Terminated,,Phase 1,50.0,Actual,H. Lundbeck A/S,,4.0,,New data: The study was terminated based on new efficacy data from another study,False,,,,True,,,,,,,,,,,,,2020-02-01 11:47:06.621861,2020-02-01 11:47:06.621861,H. Lundbeck A/S,Industry,"Lu AF20513, double high dose",Drug
NCT02388152,"ClinicalTrials.gov processed this data on January 31, 2020",2015-03-03,,,2019-11-27,2015-03-12,2015-03-13,Estimate,,,,,,,2019-11-27,2019-11-29,Actual,March 2015,,2015-03-31,November 2019,2019-11-30,"July 4, 2019",Actual,2019-07-04,"July 4, 2019",Actual,2019-07-04,,Interventional,,,Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease,"Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease",Terminated,,Phase 1,50.0,Actual,H. Lundbeck A/S,,4.0,,New data: The study was terminated based on new efficacy data from another study,False,,,,True,,,,,,,,,,,,,2020-02-01 11:47:06.621861,2020-02-01 11:47:06.621861,H. Lundbeck A/S,Industry,"Lu AF20513, high dose",Drug
NCT02388152,"ClinicalTrials.gov processed this data on January 31, 2020",2015-03-03,,,2019-11-27,2015-03-12,2015-03-13,Estimate,,,,,,,2019-11-27,2019-11-29,Actual,March 2015,,2015-03-31,November 2019,2019-11-30,"July 4, 2019",Actual,2019-07-04,"July 4, 2019",Actual,2019-07-04,,Interventional,,,Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease,"Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease",Terminated,,Phase 1,50.0,Actual,H. Lundbeck A/S,,4.0,,New data: The study was terminated based on new efficacy data from another study,False,,,,True,,,,,,,,,,,,,2020-02-01 11:47:06.621861,2020-02-01 11:47:06.621861,H. Lundbeck A/S,Industry,"Lu AF20513, low dose",Drug
NCT02388152,"ClinicalTrials.gov processed this data on January 31, 2020",2015-03-03,,,2019-11-27,2015-03-12,2015-03-13,Estimate,,,,,,,2019-11-27,2019-11-29,Actual,March 2015,,2015-03-31,November 2019,2019-11-30,"July 4, 2019",Actual,2019-07-04,"July 4, 2019",Actual,2019-07-04,,Interventional,,,Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease,"Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease",Terminated,,Phase 1,50.0,Actual,H. Lundbeck A/S,,4.0,,New data: The study was terminated based on new efficacy data from another study,False,,,,True,,,,,,,,,,,,,2020-02-01 11:47:06.621861,2020-02-01 11:47:06.621861,H. Lundbeck A/S,Industry,"Lu AF20513, medium dose",Drug
NCT04149860,"ClinicalTrials.gov processed this data on January 31, 2020",2019-10-31,,,2019-11-01,2019-11-01,2019-11-04,Actual,,,,,,,2019-11-01,2019-11-04,Actual,"September 27, 2019",Actual,2019-09-27,August 2019,2019-08-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,,Interventional,,,Study With Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease,"Interventional, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease",Recruiting,,Phase 1,96.0,Anticipated,H. Lundbeck A/S,,3.0,,,False,,,,False,True,False,,,,,,,,,Undecided,,2020-02-01 06:33:22.390960,2020-02-01 06:33:22.390960,H. Lundbeck A/S,Industry,Lu AF87908,Drug
NCT03649724,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-22,,,2019-09-25,2018-08-22,2018-08-28,Actual,,,,,,,2019-09-25,2019-09-30,Actual,February 2020,Anticipated,2020-02-29,September 2019,2019-09-30,February 2026,Anticipated,2026-02-28,February 2025,Anticipated,2025-02-28,,Interventional,LUCINDA,,The LUCINDA Trial: LUpron Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's,The LUCINDA Trial: LUpron Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's,Not yet recruiting,,Phase 2,50.0,Anticipated,Weill Medical College of Cornell University,,2.0,,,False,,,,True,True,False,,,False,,,"Baseline, 48 Weeks",Approval from PI,,Yes,"The data and resources sharing plan for this project is in accordance with both Weill Cornell and NIH Data Sharing Policies. All raw clinical, genetic, and imaging data from this project will be available upon written request. Deidentified neuroimaging data may be uploaded to one or more of several available data sharing sites designed for this purpose. The final data will be available in acceptable formats such as presentations and publications.
Research data and results that document and support the study aims will be available after the final results are accepted for publication. The data to be shared will be anonymized and there will be no fees or other restrictions.",2020-02-01 07:46:25.751941,2020-02-01 07:46:25.751941,Weill Medical College of Cornell University,Other,LUPRON DEPOT 22.5 mg,Drug
NCT00329082,"ClinicalTrials.gov processed this data on January 31, 2020",2006-05-19,,2009-06-10,2009-10-05,2006-05-19,2006-05-24,Estimate,,,,2009-10-05,2009-10-07,Estimate,2009-10-05,2009-10-07,Estimate,May 2006,,2006-05-31,October 2009,2009-10-31,May 2008,Actual,2008-05-31,May 2008,Actual,2008-05-31,,Interventional,,,Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers,LY2062430: Multiple-Dose Safety in Subjects With Mild-to-Moderate Alzheimer's Disease and Single-Dose Safety in Healthy Volunteers,Completed,,Phase 2,25.0,Actual,Eli Lilly and Company,,5.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:16:51.782807,2020-02-01 21:16:51.782807,Eli Lilly and Company,Industry,LY2062430,Drug
NCT00904683,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-18,,2012-09-18,2012-12-11,2009-05-18,2009-05-20,Estimate,,,,2012-09-18,2012-09-25,Estimate,2012-12-11,2012-12-13,Estimate,May 2009,,2009-05-31,December 2012,2012-12-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,EXPEDITION2,,Effect of LY2062430 on the Progression of Alzheimer's Disease,Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo,Completed,,Phase 3,1040.0,Actual,Eli Lilly and Company,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:23:37.732667,2020-02-01 18:23:37.732667,Eli Lilly and Company,Industry,LY2062430,Drug
NCT00905372,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-18,,2012-09-18,2012-09-18,2009-05-18,2009-05-20,Estimate,,,,2012-09-18,2012-09-25,Estimate,2012-09-18,2012-09-25,Estimate,May 2009,,2009-05-31,May 2012,2012-05-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,EXPEDITION,,Effect of LY2062430 on the Progression of Alzheimer's Disease,"Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo",Completed,,Phase 3,1000.0,Anticipated,Eli Lilly and Company,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:23:26.031400,2020-02-01 18:23:26.031400,Eli Lilly and Company,Industry,LY2062430,Drug
NCT02614131,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-23,2019-06-28,,2019-08-21,2015-11-23,2015-11-25,Estimate,2019-08-21,2019-09-23,Actual,,,,2019-08-21,2019-09-23,Actual,December 2015,,2015-12-31,August 2019,2019-08-31,December 2016,Actual,2016-12-31,December 2016,Actual,2016-12-31,,Interventional,,All randomized participants.,A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD),"Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease",Terminated,,Phase 1,50.0,Actual,Eli Lilly and Company,"Development of LY2599666 was stopped based on lack of efficacy of another compound directed against the same target. Following the enrollment of seven participants into Part B Cohort 5, enrollment was stopped.",6.0,,New data suggests that insufficient target engagement would be achieved for efficacy.,False,,,,False,,,,,,,,,,,,,2020-02-01 10:55:28.881506,2020-02-01 10:55:28.881506,Eli Lilly and Company,Industry,LY2599666,Drug
NCT03367403,"ClinicalTrials.gov processed this data on January 31, 2020",2017-12-05,,,2019-08-02,2017-12-05,2017-12-08,Actual,,,,,,,2019-08-02,2019-08-05,Actual,"December 18, 2017",Actual,2017-12-18,"August 1, 2019",2019-08-01,"November 12, 2021",Anticipated,2021-11-12,"December 11, 2020",Anticipated,2020-12-11,,Interventional,,,A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ),"Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease","Active, not recruiting",,Phase 2,266.0,Anticipated,Eli Lilly and Company,,2.0,,,False,,,,True,True,False,,,,,,,,,Yes,"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.",2020-02-01 08:32:22.240538,2020-02-01 08:32:22.240538,Eli Lilly and Company,Industry,LY3002813,Drug
NCT03305809,"ClinicalTrials.gov processed this data on January 31, 2020",2017-10-04,,,2020-01-16,2017-10-05,2017-10-10,Actual,,,,,,,2020-01-16,2020-01-18,Actual,"November 9, 2017",Actual,2017-11-09,"January 1, 2020",2020-01-01,"June 22, 2020",Anticipated,2020-06-22,"June 22, 2020",Anticipated,2020-06-22,,Interventional,PRESENCE,,A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB),Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB),Recruiting,,Phase 2,340.0,Anticipated,Eli Lilly and Company,,4.0,,,False,,,,False,True,False,,,,,,,,,Yes,"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.",2020-02-01 08:42:45.155349,2020-02-01 08:42:45.155349,Eli Lilly and Company,Industry,LY3154207,Drug
NCT02791191,"ClinicalTrials.gov processed this data on January 31, 2020",2016-06-01,,2019-06-28,2019-09-25,2016-06-01,2016-06-06,Estimate,,,,2019-06-28,2019-07-05,Actual,2019-09-25,2019-10-08,Actual,"June 16, 2016",Actual,2016-06-16,September 2019,2019-09-30,"July 2, 2018",Actual,2018-07-02,"July 2, 2018",Actual,2018-07-02,,Interventional,NAVIGATE-AD,,A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia,Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia,Terminated,,Phase 2,316.0,Actual,Eli Lilly and Company,,3.0,,Low likelihood of identifying a statistically significant treatment effect.,False,,,,False,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 10:19:04.421085,2020-02-01 10:19:04.421085,Eli Lilly and Company,Industry,LY3202626,Drug
NCT03518073,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-26,,,2020-01-16,2018-05-01,2018-05-08,Actual,,,,,,,2020-01-16,2020-01-18,Actual,"April 30, 2018",Actual,2018-04-30,January 2020,2020-01-31,"October 22, 2021",Anticipated,2021-10-22,"August 23, 2021",Anticipated,2021-08-23,,Interventional,,,A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease,"Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease","Active, not recruiting",,Phase 2,285.0,Anticipated,Eli Lilly and Company,,3.0,,,False,,,,True,True,False,,,,,,,,,Yes,"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.",2020-02-01 08:07:30.073091,2020-02-01 08:07:30.073091,Eli Lilly and Company,Industry,LY3303560,Drug
NCT00594568,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-11,2013-11-06,2011-08-09,2015-03-13,2008-01-11,2008-01-15,Estimate,2014-09-22,2014-09-25,Estimate,2011-08-09,2011-08-15,Estimate,2015-03-13,2015-03-17,Estimate,March 2008,,2008-03-31,March 2015,2015-03-31,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Effect of LY450139 on the Long Term Progression of Alzheimer's Disease,Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo,Completed,,Phase 3,1537.0,Actual,Eli Lilly and Company,Outcomes with 4-week after study drug cessation timeframe=All dosing stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants; followed for 32 weeks; not all assessments were made.,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:55:02.296322,2020-02-01 19:55:02.296322,Eli Lilly and Company,Industry,LY450139,Drug
NCT00762411,"ClinicalTrials.gov processed this data on January 31, 2020",2008-09-26,2013-11-06,2011-08-22,2015-01-28,2008-09-26,2008-09-30,Estimate,2014-09-22,2014-09-25,Estimate,2011-08-22,2011-08-23,Estimate,2015-01-28,2015-02-16,Estimate,September 2008,,2008-09-30,January 2015,2015-01-31,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,IDENTITY-2,,"Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo","Effect of LY450139 a y-Secretase Inhibitor, on the Progression of Alzheimer's Disease as Compared With Placebo",Completed,,Phase 3,1111.0,Actual,Eli Lilly and Company,All dosing for 4-week post-study drug cessation timeframe outcome measures stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants. No assessments made during 32-week follow up.,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:05:56.411245,2020-02-01 19:05:56.411245,Eli Lilly and Company,Industry,LY450139,Drug
NCT00051909,"ClinicalTrials.gov processed this data on January 31, 2020",2003-01-17,,,2006-07-18,2003-01-17,2003-01-20,Estimate,,,,,,,2006-07-18,2006-07-19,Estimate,November 2002,,2002-11-30,July 2006,2006-07-31,June 2003,,2003-06-30,,,,,Interventional,,,Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease,Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease,Completed,,Phase 2,200.0,,Eli Lilly and Company,,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:41:03.885539,2020-02-01 22:41:03.885539,Eli Lilly and Company,Industry,LY451395,Drug
NCT00843518,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-12,2016-07-07,2011-09-20,2017-10-23,2009-02-12,2009-02-13,Estimate,2017-10-23,2017-11-29,Actual,2011-09-20,2011-09-26,Estimate,2017-10-23,2017-11-29,Actual,February 2009,,2009-02-28,October 2017,2017-10-31,June 2011,Actual,2011-06-30,June 2011,Actual,2011-06-30,,Interventional,,,Treatment for Aggression and Agitation in Patients With Alzheimer's Disease,Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease,Completed,,Phase 2,132.0,Actual,Eli Lilly and Company,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:41:24.194777,2020-02-01 18:41:24.194777,Eli Lilly and Company,Industry,LY451395,Drug
NCT03711825,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-14,,,2019-02-25,2018-10-16,2018-10-19,Actual,,,,,,,2019-02-25,2019-02-26,Actual,"September 10, 2018",Actual,2018-09-10,February 2019,2019-02-28,"November 13, 2018",Actual,2018-11-13,"October 1, 2018",Actual,2018-10-01,,Interventional,,,Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults,An Open Label Study to Evaluate the Safety and Gastric-Retentive Properties of Modified Release Capsules Containing Memantine Hydrochloride in Healthy Adults,Completed,,Early Phase 1,8.0,Actual,Lyndra Inc.,,1.0,,,False,,,,,False,False,,,,,,,,,No,,2020-02-01 07:37:14.282058,2020-02-01 07:37:14.282058,Lyndra Inc.,Industry,LYN-057,Drug
NCT01343966,"ClinicalTrials.gov processed this data on January 31, 2020",2011-04-27,,2016-08-10,2017-07-10,2011-04-27,2011-04-28,Estimate,,,,2016-08-10,2016-08-12,Estimate,2017-07-10,2017-07-12,Actual,"April 30, 2011",Actual,2011-04-30,July 2017,2017-07-31,"February 28, 2014",Actual,2014-02-28,"February 28, 2014",Actual,2014-02-28,,Interventional,,,A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY),"A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)",Completed,,Phase 2,448.0,Actual,"Genentech, Inc.",,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 16:10:32.090096,2020-02-01 16:10:32.090096,"Genentech, Inc.",Industry,MABT5102A,Drug
NCT01397578,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-18,,2016-08-10,2017-07-10,2011-07-18,2011-07-19,Estimate,,,,2016-08-10,2016-08-12,Estimate,2017-07-10,2017-07-12,Actual,"August 31, 2011",Actual,2011-08-31,July 2017,2017-07-31,"April 30, 2014",Actual,2014-04-30,"April 30, 2014",Actual,2014-04-30,,Interventional,,,A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,91.0,Actual,"Genentech, Inc.",,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:56:14.154499,2020-02-01 15:56:14.154499,"Genentech, Inc.",Industry,MABT5102A,Drug
NCT01872598,"ClinicalTrials.gov processed this data on January 31, 2020",2013-06-05,,,2019-06-13,2013-06-06,2013-06-07,Estimate,,,,,,,2019-06-13,2019-06-17,Actual,January 2012,,2012-01-31,June 2019,2019-06-30,December 2019,Anticipated,2019-12-31,December 2019,Anticipated,2019-12-31,,Interventional,,,Masitinib in Patients With Mild to Moderate Alzheimer's Disease,"A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease","Active, not recruiting",,Phase 3,721.0,Actual,AB Science,,5.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:52:27.547176,2020-02-01 13:52:27.547176,AB Science,Industry,Masitinib,Drug
NCT00976118,"ClinicalTrials.gov processed this data on January 31, 2020",2009-09-11,,,2018-12-12,2009-09-11,2009-09-14,Estimate,,,,,,,2018-12-12,2018-12-13,Actual,February 2006,,2006-02-28,December 2018,2018-12-31,February 2009,Actual,2009-02-28,July 2008,Actual,2008-07-31,,Interventional,,,Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease,"A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adults Patients With Mild to Moderate Alzheimer-type Disease.",Completed,,Phase 2,34.0,Actual,AB Science,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 18:02:06.818140,2020-02-01 18:02:06.818140,AB Science,Industry,masitinib (AB1010),Drug
NCT02886494,"ClinicalTrials.gov processed this data on January 31, 2020",2016-08-29,,,2019-07-29,2016-08-31,2016-09-01,Estimate,,,,,,,2019-07-29,2019-07-30,Actual,December 2016,Actual,2016-12-31,July 2019,2019-07-31,"November 1, 2018",Actual,2018-11-01,"November 1, 2018",Actual,2018-11-01,,Interventional,,,A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia,"A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia",Completed,,Phase 2,80.0,Actual,Charsire Biotechnology Corp.,,2.0,,,False,,,,False,,False,,,,,,,,,Undecided,,2020-02-01 10:02:06.140425,2020-02-01 10:02:06.140425,Charsire Biotechnology Corp.,Industry,Matched placebo,Drug
NCT02127476,"ClinicalTrials.gov processed this data on January 31, 2020",2014-04-24,,,2017-05-31,2014-04-28,2014-04-30,Estimate,,,,,,,2017-05-31,2017-06-01,Actual,July 2014,,2014-07-31,May 2017,2017-05-31,May 2017,Actual,2017-05-31,May 2017,Actual,2017-05-31,,Interventional,,,A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease,"A Phase 1 Double-blind, Placebo-controlled, Single- and Multiple-ascending-dose Study of KHK6640 in Alzheimer's Disease",Completed,,Phase 1,57.0,Actual,"Kyowa Kirin Pharmaceutical Development, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:47:13.721981,2020-02-01 12:47:13.721981,"Kyowa Hakko Kirin Pharma, Inc.",Industry,Matching Placebo,Drug
NCT01760005,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-26,,,2019-10-01,2012-12-31,2013-01-03,Estimate,,,,,,,2019-10-01,2019-10-03,Actual,December 2012,,2012-12-31,October 2019,2019-10-31,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,,Interventional,DIAN-TU,,Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.,"A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease",Recruiting,,Phase 2/Phase 3,490.0,Anticipated,Washington University School of Medicine,,5.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:23:00.489600,2020-02-01 14:23:00.489600,Washington University School of Medicine,Other,Matching Placebo (Gantenerumab),Drug
NCT01760005,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-26,,,2019-10-01,2012-12-31,2013-01-03,Estimate,,,,,,,2019-10-01,2019-10-03,Actual,December 2012,,2012-12-31,October 2019,2019-10-31,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,,Interventional,DIAN-TU,,Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.,"A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease",Recruiting,,Phase 2/Phase 3,490.0,Anticipated,Washington University School of Medicine,,5.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:23:00.489600,2020-02-01 14:23:00.489600,Washington University School of Medicine,Other,Matching Placebo (Solanezumab),Drug
NCT00066157,"ClinicalTrials.gov processed this data on January 31, 2020",2003-08-04,,,2018-08-22,2003-08-04,2003-08-05,Estimate,,,,,,,2018-08-22,2018-08-23,Actual,September 2001,,2001-09-30,August 2018,2018-08-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,Alzheimer's Disease: Therapeutic Potential of Estrogen,Alzheimer's Disease: Therapeutic Potential of Estrogen,Completed,,Phase 2/Phase 3,42.0,Actual,"University of Wisconsin, Madison",,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:32:28.672051,2020-02-01 22:32:28.672051,"University of Wisconsin, Madison",Other,Medroxyprogesterone,Drug
NCT02033941,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-09,,,2019-03-12,2014-01-09,2014-01-13,Estimate,,,,,,,2019-03-12,2019-03-13,Actual,November 2014,,2014-11-30,March 2019,2019-03-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,,,Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD),Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease,Recruiting,,Phase 2,20.0,Anticipated,Icahn School of Medicine at Mount Sinai,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 13:10:17.207831,2020-02-01 13:10:17.207831,Hillel Grossman,Other,Meganatural-Az Grapeseed Extract,Drug
NCT00000171,"ClinicalTrials.gov processed this data on January 31, 2020",1999-10-29,,,2005-06-23,1999-10-29,1999-11-01,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,March 2005,2005-03-31,,,,,,,,Interventional,,,Study of Melatonin: Sleep Problems in Alzheimer's Disease,,Completed,,Phase 3,,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:51:08.729281,2020-02-01 22:51:08.729281,National Institute on Aging (NIA),NIH,Melatonin,Drug
NCT00257673,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-22,,,2008-05-05,2005-11-22,2005-11-23,Estimate,,,,,,,2008-05-05,2008-05-06,Estimate,November 2005,,2005-11-30,May 2008,2008-05-31,October 2007,Actual,2007-10-31,October 2007,Actual,2007-10-31,,Interventional,,,Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,183.0,Actual,Memory Pharmaceuticals,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:36:50.716852,2020-02-01 21:36:50.716852,Memory Pharmaceuticals,Industry,MEM 1003,Drug
NCT00454870,"ClinicalTrials.gov processed this data on January 31, 2020",2007-03-30,,,2008-05-05,2007-03-30,2007-04-02,Estimate,,,,,,,2008-05-05,2008-05-06,Estimate,February 2007,,2007-02-28,May 2008,2008-05-31,October 2007,Actual,2007-10-31,October 2007,Actual,2007-10-31,,Interventional,,,Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of the Pharmacodynamics/Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Fixed Dosages of MEM 3454 (5 mg, 15 mg, and 50 mg) in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,80.0,Anticipated,Memory Pharmaceuticals,,,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:37:57.946570,2020-02-01 20:37:57.946570,Memory Pharmaceuticals,Industry,MEM 3454,Drug
NCT00401167,"ClinicalTrials.gov processed this data on January 31, 2020",2006-11-16,,,2012-05-24,2006-11-16,2006-11-17,Estimate,,,,,,,2012-05-24,2012-05-25,Estimate,November 2006,,2006-11-30,January 2010,2010-01-31,January 2010,Actual,2010-01-31,January 2010,Actual,2010-01-31,,Interventional,,,Memantine for Agitation and Aggression in Severe Alzheimer's Disease,Phase IV-An Open-Label Prospective Study of Memantine in Institutionalized Patients With Severe Alzheimer's Disease and Significant Behavioural and Psychological Symptoms of Dementia,Completed,,Phase 4,32.0,Anticipated,Sunnybrook Health Sciences Centre,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:56:18.722166,2020-02-01 20:56:18.722166,Sunnybrook Health Sciences Centre,Other,memantine,Drug
NCT00545974,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-16,2013-04-22,,2019-10-08,2007-10-17,2007-10-18,Estimate,2013-12-13,2014-02-05,Estimate,,,,2019-10-08,2019-10-17,Actual,October 2007,,2007-10-31,October 2019,2019-10-31,December 2012,Actual,2012-12-31,December 2012,Actual,2012-12-31,,Interventional,,,Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia,"A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia",Completed,,Phase 4,81.0,Actual,"University of California, San Francisco",Lower enrollment than planned may have limited ability detect a treatment effect; Small size of semantic dementia group limits generalizability of results to FTD syndrome;Newer tools have been developed to better capture FTD-specific behaviors.,2.0,,,,,,,True,,,,,,,,,,,,,2020-02-01 20:10:00.659080,2020-02-01 20:10:00.659080,"University of California, San Francisco",Other,memantine,Drug
NCT00551161,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-29,2013-04-30,,2013-12-20,2007-10-29,2007-10-30,Estimate,2013-10-28,2013-12-18,Estimate,,,,2013-12-20,2014-01-28,Estimate,August 2007,,2007-08-31,December 2013,2013-12-31,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,,,Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease,"An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 4,12.0,Actual,Northwell Health,,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:07:38.599191,2020-02-01 20:07:38.599191,Northwell Health,Other,memantine,Drug
NCT00235716,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-06,2013-12-06,,2014-07-14,2005-10-06,2005-10-10,Estimate,2014-01-23,2014-01-29,Estimate,,,,2014-07-14,2014-07-23,Estimate,August 2007,,2007-08-31,July 2014,2014-07-31,October 2012,Actual,2012-10-31,September 2012,Actual,2012-09-30,,Interventional,TEAM-AD,,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease","CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)",Completed,,Phase 3,613.0,Actual,VA Office of Research and Development,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:42:18.318346,2020-02-01 21:42:18.318346,US Department of Veterans Affairs,U.S. Fed,Memantine,Drug
NCT00255086,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-15,2016-08-23,,2017-02-23,2005-11-15,2005-11-17,Estimate,2017-02-23,2017-04-07,Actual,,,,2017-02-23,2017-04-07,Actual,May 2005,,2005-05-31,February 2017,2017-02-28,February 2010,Actual,2010-02-28,June 2009,Actual,2009-06-30,,Interventional,,"Per protocol, only participants who completed the study were evaluable for baseline characteristics.",The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,"The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients: A Randomized, Placebo-Controlled, 52-Week Clinical Trial",Completed,,Phase 3,17.0,Actual,Stanford University,,2.0,,,False,,,,False,,,,,,,,,,,Undecided,,2020-02-01 21:37:34.734231,2020-02-01 21:37:34.734231,Stanford University,Other,Memantine,Drug
NCT00469456,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-02,2009-11-03,,2009-12-21,2007-05-03,2007-05-04,Estimate,2009-11-03,2009-12-07,Estimate,,,,2009-12-21,2009-12-24,Estimate,April 2007,,2007-04-30,December 2009,2009-12-31,November 2008,Actual,2008-11-30,November 2008,Actual,2008-11-30,,Interventional,,,Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy of Memantine on Functional Communication in Patients With Alzheimer's Disease (AD)",Completed,,Phase 4,265.0,Actual,Forest Laboratories,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:33:36.860090,2020-02-01 20:33:36.860090,Forest Laboratories,Industry,Memantine,Drug
NCT00476008,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-17,2013-09-20,,2014-08-07,2007-05-17,2007-05-21,Estimate,2014-05-05,2014-06-03,Estimate,,,,2014-08-07,2014-08-11,Estimate,July 2007,,2007-07-31,August 2014,2014-08-31,October 2012,Actual,2012-10-31,October 2012,Actual,2012-10-31,,Interventional,,,Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease,Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease,Completed,,Phase 4,60.0,Actual,Florida Atlantic University,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:31:32.398133,2020-02-01 20:31:32.398133,Florida Atlantic University,Other,Memantine,Drug
NCT00505167,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-20,,,2008-12-26,2007-07-20,2007-07-23,Estimate,,,,,,,2008-12-26,2008-12-29,Estimate,July 2007,,2007-07-31,December 2008,2008-12-31,December 2008,Actual,2008-12-31,July 2008,Actual,2008-07-31,,Interventional,,,Memantine Versus Donepezil in Early Stages of Alzheimer's Disease,Memantine Versus Donepezil in Mild to Moderate Alzheimer's Disease. A Randomized Trial With Magnetic Resonance Spectroscopy.,Completed,,Phase 4,64.0,Actual,Hospital Miguel Servet,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:23:03.403094,2020-02-01 20:23:03.403094,Hospital Miguel Servet,Other,Memantine,Drug
NCT00630500,"ClinicalTrials.gov processed this data on January 31, 2020",2008-02-27,,,2015-07-27,2008-03-06,2008-03-07,Estimate,,,,,,,2015-07-27,2015-07-28,Estimate,February 2006,,2006-02-28,February 2009,2009-02-28,March 2009,Actual,2009-03-31,February 2009,Actual,2009-02-28,,Interventional,MEMPDD,,Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB),"A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies",Completed,,Phase 2,75.0,Actual,Helse Stavanger HF,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:44:12.140389,2020-02-01 19:44:12.140389,Helse Stavanger HF,Other,Memantine,Drug
NCT00649220,"ClinicalTrials.gov processed this data on January 31, 2020",2008-03-27,2011-08-09,,2011-09-22,2008-03-27,2008-04-01,Estimate,2011-08-09,2011-09-13,Estimate,,,,2011-09-22,2011-09-26,Estimate,July 2008,,2008-07-31,September 2011,2011-09-30,June 2009,Actual,2009-06-30,May 2009,Actual,2009-05-31,,Interventional,MemAP,,Memantine and Antipsychotics Use,"Prospective, Single-arm, Multi-centre, Open-label Study to Investigate the Potential to Reduce Concomitant Antipsychotics Use in Patients With Moderate to Severe Dementia of Alzheimer's Type (DAT) Treated With Memantine",Terminated,,Phase 4,19.0,Actual,Merz Pharmaceuticals GmbH,"Early termination due to too slow enrollment lead to a small sample size, limiting the ability for confirmatory analysis. All analysis of the primary efficacy endpoint were treated as exploratory.",1.0,,Study terminated due to too slow enrollment,False,,,,False,,,,,,,,,,,,,2020-02-01 19:38:52.523914,2020-02-01 19:38:52.523914,Merz Pharmaceuticals GmbH,Industry,Memantine,Drug
NCT00703430,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-20,,,2013-01-24,2008-06-20,2008-06-23,Estimate,,,,,,,2013-01-24,2013-01-25,Estimate,March 2008,,2008-03-31,January 2013,2013-01-31,June 2014,Anticipated,2014-06-30,December 2013,Anticipated,2013-12-31,,Interventional,,,Memantine on Aggression and Agitation of Alzheimer's Disease (AD),The Effect of Memantine on Aggression and Agitation and Its Impact on Caregiver Burden of Patients With Alzheimer's Disease: A 12-week Open-label Study,Unknown status,Recruiting,N/A,50.0,Anticipated,Peking University,,1.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:22:50.758975,2020-02-01 19:22:50.758975,Peking University,Other,Memantine,Drug
NCT00800709,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-23,,,2010-12-02,2008-12-01,2008-12-02,Estimate,,,,,,,2010-12-02,2010-12-03,Estimate,July 2008,,2008-07-31,December 2010,2010-12-31,October 2010,Actual,2010-10-31,October 2010,Actual,2010-10-31,,Interventional,,,Memantine and Changes of Biological Markers and Brain PET Imaging in Alzheimer's Disease,"Changes of Biological Markers and Brain PET Imaging and Clinical Effects of Memantine for Patients With Moderate to Severe Alzheimer's Disease: a 24 Week Double-blind, Randomized, Placebo-Controlled Study",Completed,,Phase 4,26.0,Anticipated,Shanghai Mental Health Center,,1.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:54:16.957917,2020-02-01 18:54:16.957917,Shanghai Mental Health Center,Other,Memantine,Drug
NCT00855686,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-03,,,2013-09-19,2009-03-03,2009-03-04,Estimate,,,,,,,2013-09-19,2013-09-20,Estimate,January 2007,,2007-01-31,September 2013,2013-09-30,January 2009,Actual,2009-01-31,December 2008,Actual,2008-12-31,,Interventional,,,Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies,"A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies",Completed,,Phase 4,199.0,Actual,H. Lundbeck A/S,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:37:39.865139,2020-02-01 18:37:39.865139,H. Lundbeck A/S,Industry,Memantine,Drug
NCT00857233,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-05,2012-07-26,,2012-07-26,2009-03-05,2009-03-06,Estimate,2012-07-26,2012-08-29,Estimate,,,,2012-07-26,2012-08-29,Estimate,June 2004,,2004-06-30,July 2012,2012-07-31,October 2010,Actual,2010-10-31,July 2010,Actual,2010-07-31,,Interventional,,,Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease,An Open-label Extension Study Examining the Safety and Tolerability of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type Having Completed Study 10158,Terminated,,Phase 3,297.0,Actual,H. Lundbeck A/S,"Long recruitment, premature termination.",1.0,,Please see explanation in the Detailed Description field.,False,,,,False,,,,,,,,,,,,,2020-02-01 18:37:00.855904,2020-02-01 18:37:00.855904,H. Lundbeck A/S,Industry,Memantine,Drug
NCT00857649,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-05,2011-10-26,,2013-11-12,2009-03-05,2009-03-06,Estimate,2011-12-05,2012-01-09,Estimate,,,,2013-11-12,2013-12-05,Estimate,December 2003,,2003-12-31,November 2013,2013-11-30,September 2010,Actual,2010-09-30,April 2010,Actual,2010-04-30,,Interventional,,,Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease,"A Randomised, Double-Blind, Parallel-Group Study Examining the Efficacy and Safety of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type",Terminated,,Phase 3,369.0,Actual,H. Lundbeck A/S,"Long recruitment, premature termination, substantial protocol changes; baseline imbalances (concomitant medication and severity of agitation). Variability across sites in reported events frequency (50% of agitation reports from a single site)",2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:36:53.724936,2020-02-01 18:36:53.724936,H. Lundbeck A/S,Industry,Memantine,Drug
NCT00862940,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-16,2010-11-23,,2012-08-29,2009-03-16,2009-03-17,Estimate,2011-05-05,2011-06-03,Estimate,,,,2012-08-29,2012-09-03,Estimate,September 2005,,2005-09-30,August 2012,2012-08-31,April 2009,Actual,2009-04-30,February 2009,Actual,2009-02-28,,Interventional,,,A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease,"A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease",Completed,,Phase 4,277.0,Actual,H. Lundbeck A/S,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:35:23.094115,2020-02-01 18:35:23.094115,H. Lundbeck A/S,Industry,Memantine,Drug
NCT00866060,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-19,,,2009-03-19,2009-03-19,2009-03-20,Estimate,,,,,,,2009-03-19,2009-03-20,Estimate,February 2008,,2008-02-29,March 2009,2009-03-31,June 2013,Anticipated,2013-06-30,February 2012,Anticipated,2012-02-29,,Interventional,DOMINO-AD,,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Unknown status,Recruiting,Phase 4,800.0,Anticipated,King's College London,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:34:35.920768,2020-02-01 18:34:35.920768,King's College London,Other,Memantine,Drug
NCT01409694,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-02,,,2016-09-21,2011-08-03,2011-08-04,Estimate,,,,,,,2016-09-21,2016-09-22,Estimate,September 2011,,2011-09-30,March 2011,2011-03-31,January 2016,Actual,2016-01-31,January 2016,Actual,2016-01-31,,Interventional,AD-IDEA,,Alzheimer's Disease - Input of Vitamin D With mEmantine Assay,Evaluation d'Une stratégie thérapeutique d'Association médicamenteuse Pour la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées au Stade modéré,Completed,,Phase 3,90.0,Actual,"University Hospital, Angers",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:53:36.184745,2020-02-01 15:53:36.184745,"University Hospital, Angers",Other,Memantine,Drug
NCT01677754,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-30,,2016-07-20,2017-05-25,2012-08-30,2012-09-03,Estimate,,,,2016-07-20,2016-07-22,Estimate,2017-05-25,2017-05-30,Actual,"October 24, 2012",Actual,2012-10-24,May 2017,2017-05-31,"June 12, 2015",Actual,2015-06-12,"June 12, 2015",Actual,2015-06-12,,Interventional,MAyflOwer RoAD,,A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy,"A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease",Completed,,Phase 2,542.0,Actual,Hoffmann-La Roche,,3.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 14:44:43.645589,2020-02-01 14:44:43.645589,Hoffmann-La Roche,Industry,Memantine,Drug
NCT01876823,"ClinicalTrials.gov processed this data on January 31, 2020",2013-06-05,2013-09-23,,2014-10-23,2013-06-10,2013-06-13,Estimate,2014-10-23,2014-10-24,Estimate,,,,2014-10-23,2014-10-24,Estimate,April 2006,,2006-04-30,September 2013,2013-09-30,March 2010,Actual,2010-03-31,March 2010,Actual,2010-03-31,,Interventional,,,Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment,Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment,Completed,,Phase 2/Phase 3,60.0,Actual,New York State Psychiatric Institute,"The inclusion criteria required all patients to have an MMSE of 24 or higher, which may have lowered the conversion rate to dementia
small sample size
cognitive improvement may have been due in part to combined es-citalopram and memantine",1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:51:09.358646,2020-02-01 13:51:09.358646,New York State Psychiatric Institute,Other,Memantine,Drug
NCT01921972,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-07,,,2013-08-12,2013-08-12,2013-08-14,Estimate,,,,,,,2013-08-12,2013-08-14,Estimate,November 2004,,2004-11-30,August 2013,2013-08-31,May 2009,Actual,2009-05-31,November 2008,Actual,2008-11-30,,Interventional,AD-Combi,,The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease,"Competence Network - Dementia (BMBF) ""Pharmacological and Psychosocial Treatment"" (Modul E.2) Part II: The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 4,232.0,Actual,"Charite University, Berlin, Germany",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:40:38.562936,2020-02-01 13:40:38.562936,"Charite University, Berlin, Germany",Other,Memantine,Drug
NCT02288000,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-06,,,2019-06-25,2014-11-06,2014-11-11,Estimate,,,,,,,2019-06-25,2019-06-27,Actual,"September 14, 2016",Actual,2016-09-14,June 2019,2019-06-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,WP3_P002,,Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases,Effect of a 15-day Memantine Treatment on Biomarkers of AD in Healthy Volunteers,Recruiting,,Phase 1,30.0,Anticipated,"University Hospital, Lille",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:09:22.892287,2020-02-01 12:09:22.892287,"University Hospital, Lille",Other,Memantine,Drug
NCT03316898,"ClinicalTrials.gov processed this data on January 31, 2020",2017-10-18,,,2018-10-31,2017-10-18,2017-10-20,Actual,,,,,,,2018-10-31,2018-11-02,Actual,"September 30, 2018",Anticipated,2018-09-30,October 2018,2018-10-31,"November 4, 2018",Anticipated,2018-11-04,"November 4, 2018",Anticipated,2018-11-04,,Interventional,,,A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease",Withdrawn,,Phase 1,0.0,Actual,Allergan,,4.0,,Business decision to stop the study.,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:40:51.152227,2020-02-01 08:40:51.152227,Allergan,Industry,Memantine,Drug
NCT03703856,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-09,,,2020-01-21,2018-10-10,2018-10-12,Actual,,,,,,,2020-01-21,2020-01-23,Actual,"January 31, 2019",Actual,2019-01-31,January 2020,2020-01-31,August 2023,Anticipated,2023-08-31,August 2023,Anticipated,2023-08-31,,Interventional,,,Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease,Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease,Recruiting,,Phase 4,88.0,Anticipated,"University of California, San Diego",,2.0,,,False,,,,,True,False,,,True,,,,,,,,2020-02-01 07:38:26.839208,2020-02-01 07:38:26.839208,"University of California, San Diego",Other,Memantine,Drug
NCT04117178,"ClinicalTrials.gov processed this data on January 31, 2020",2019-09-30,,,2019-10-02,2019-10-02,2019-10-07,Actual,,,,,,,2019-10-02,2019-10-07,Actual,November 2019,Anticipated,2019-11-30,October 2019,2019-10-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,,Interventional,MONANTI,,Monitoring Anti-Dementia Drugs by Serum Levels,"Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title)",Not yet recruiting,,Phase 4,110.0,Anticipated,Zealand University Hospital,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2020-02-01 06:37:51.700954,2020-02-01 06:37:51.700954,Zealand University Hospital,Other,Memantine,Drug
NCT00322153,"ClinicalTrials.gov processed this data on January 31, 2020",2006-05-03,2010-07-20,,2010-08-25,2006-05-04,2006-05-05,Estimate,2010-08-25,2010-09-16,Estimate,,,,2010-08-25,2010-09-16,Estimate,June 2005,,2005-06-30,August 2010,2010-08-31,January 2008,Actual,2008-01-31,October 2007,Actual,2007-10-31,,Interventional,,,A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type",Completed,,Phase 3,677.0,Actual,Forest Laboratories,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:18:57.061793,2020-02-01 21:18:57.061793,Forest Laboratories,Industry,memantine ER,Drug
NCT00097916,"ClinicalTrials.gov processed this data on January 31, 2020",2004-12-01,,,2012-03-01,2004-12-01,2004-12-02,Estimate,,,,,,,2012-03-01,2012-03-05,Estimate,September 2004,,2004-09-30,March 2012,2012-03-31,April 2006,Actual,2006-04-30,April 2006,Actual,2006-04-30,,Interventional,,,An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Non-Institutionalized Agitated Patients With Moderate to Severe Alzheimer's Disease",Completed,,Phase 3,34.0,Actual,Forest Laboratories,,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:18:40.664308,2020-02-01 22:18:40.664308,Forest Laboratories,Industry,memantine HCl,Drug
NCT00334906,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-06,,,2008-01-03,2006-06-06,2006-06-08,Estimate,,,,,,,2008-01-03,2008-01-07,Estimate,July 2005,,2005-07-31,January 2008,2008-01-31,,,,November 2007,Actual,2007-11-30,,Interventional,,,Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease),An Open-Label Exploratory Study With Memantine: Assessment of Selected Measures of Volumetric MRI and Cognition in Patients With Moderate Dementia of the Alzheimer's Type,Completed,,Phase 4,75.0,,Forest Laboratories,,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:15:12.883962,2020-02-01 21:15:12.883962,Forest Laboratories,Industry,memantine HCl,Drug
NCT00624026,"ClinicalTrials.gov processed this data on January 31, 2020",2008-02-14,,,2011-10-31,2008-02-14,2008-02-26,Estimate,,,,,,,2011-10-31,2011-11-01,Estimate,November 2007,,2007-11-30,October 2011,2011-10-31,December 2008,Actual,2008-12-31,December 2008,Actual,2008-12-31,,Interventional,,,Memantine - Communication Study,"Prospective, Single-arm, Multicenter, Open-label Study to Investigate the Efficacy and Tolerability of the Once Daily (OD) Memantine Treatment",Completed,,Phase 3,107.0,Actual,Merz Pharmaceuticals GmbH,,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:45:45.859174,2020-02-01 19:45:45.859174,Merz Pharmaceuticals GmbH,Industry,Memantine-HCl,Drug
NCT03168997,"ClinicalTrials.gov processed this data on January 31, 2020",2017-05-16,,,2017-05-25,2017-05-25,2017-05-30,Actual,,,,,,,2017-05-25,2017-05-30,Actual,"July 15, 2017",Anticipated,2017-07-15,May 2017,2017-05-31,"December 31, 2018",Anticipated,2018-12-31,"September 30, 2018",Anticipated,2018-09-30,,Interventional,,,Memantine Treatment in Alzheimer's Disease Patients,"Memantine Treatment in Alzheimer's Disease Patients Stratified With Behavioral and Psychological Symptoms of Dementia (BPSD) Symptoms and Cognitive Severity: A Multi-center, Open-label, Parallel-group and Prospective Clinical Study",Unknown status,Not yet recruiting,Phase 4,222.0,Anticipated,"Xuanwu Hospital, Beijing",,3.0,,,False,,,,,False,False,,,False,,,,,,Undecided,,2020-02-01 09:07:13.556546,2020-02-01 09:07:13.556546,Wei Cuibai,Other,Memantine Hydrochloride,Drug
NCT02553928,"ClinicalTrials.gov processed this data on January 31, 2020",2015-09-16,2017-07-10,,2018-11-28,2015-09-17,2015-09-18,Estimate,2018-11-28,2019-03-14,Actual,,,,2018-11-28,2019-03-14,Actual,October 2015,,2015-10-31,November 2018,2018-11-30,July 2016,Actual,2016-07-31,July 2016,Actual,2016-07-31,,Interventional,,,Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer,"Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and MMSE Range 5 - 18",Completed,,Phase 4,62.0,Actual,H. Lundbeck A/S,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:09:19.446762,2020-02-01 11:09:19.446762,H. Lundbeck A/S,Industry,Memantine (once daily),Drug
NCT02553928,"ClinicalTrials.gov processed this data on January 31, 2020",2015-09-16,2017-07-10,,2018-11-28,2015-09-17,2015-09-18,Estimate,2018-11-28,2019-03-14,Actual,,,,2018-11-28,2019-03-14,Actual,October 2015,,2015-10-31,November 2018,2018-11-30,July 2016,Actual,2016-07-31,July 2016,Actual,2016-07-31,,Interventional,,,Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer,"Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and MMSE Range 5 - 18",Completed,,Phase 4,62.0,Actual,H. Lundbeck A/S,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:09:19.446762,2020-02-01 11:09:19.446762,H. Lundbeck A/S,Industry,Memantine (twice daily),Drug
NCT04044131,"ClinicalTrials.gov processed this data on January 31, 2020",2019-07-17,,,2019-07-31,2019-07-31,2019-08-05,Actual,,,,,,,2019-07-31,2019-08-05,Actual,"September 1, 2019",Anticipated,2019-09-01,July 2019,2019-07-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,,,Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients,"A Phase 2, Randomized, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) And Parkinson's Disease (PD) Patients",Not yet recruiting,,Phase 2,120.0,Anticipated,Istanbul Medipol University Hospital,,2.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 06:48:09.330007,2020-02-01 06:48:09.330007,Istanbul Medipol University Hospital,Other,Metabolic Cofactor Supplementation,Drug
NCT01965756,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-16,2017-06-06,,2017-08-21,2013-10-16,2013-10-18,Estimate,2017-08-21,2017-09-21,Actual,,,,2017-08-21,2017-09-21,Actual,January 2013,,2013-01-31,August 2017,2017-08-31,April 2017,Actual,2017-04-30,"December 22, 2015",Actual,2015-12-22,,Interventional,,,Effect of Insulin Sensitizer Metformin on AD Biomarkers,"A Phase II Trial to Study the Effect of Metformin on AD Biomarkers: A Randomized Placebo Controlled Crossover Pilot Study of Metformin Effects on Cognitive, Physiological and Biochemical Biomarkers of MCI and Dementia Due to AD",Completed,,Phase 2,20.0,Actual,University of Pennsylvania,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:28:20.189926,2020-02-01 13:28:20.189926,University of Pennsylvania,Other,Metformin,Drug
NCT02380573,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-24,,,2019-05-06,2015-02-27,2015-03-05,Estimate,,,,,,,2019-05-06,2019-05-08,Actual,July 2015,,2015-07-31,April 2019,2019-04-30,July 2023,Anticipated,2023-07-31,July 2022,Anticipated,2022-07-31,,Interventional,MB2,,"Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease","Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease",Suspended,,Phase 2,117.0,Actual,The University of Texas Health Science Center at San Antonio,,8.0,,Pending enrollment of new subjects if new funding obtained,False,,,,True,,,,,,,,,,,,,2020-02-01 11:48:30.714225,2020-02-01 11:48:30.714225,The University of Texas Health Science Center at San Antonio,Other,Methylene Blue,Drug
NCT00254033,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-10,,,2017-04-26,2005-11-10,2005-11-15,Estimate,,,,,,,2017-04-26,2017-04-28,Actual,October 2003,,2003-10-31,April 2017,2017-04-30,October 2006,Actual,2006-10-31,,,,,Interventional,,,Apathy Associated With Alzheimer's Disease,The Role of the Dopaminergic Brain Reward System in Apathy Associated With Alzheimer's Disease,Completed,,Phase 4,40.0,,Sunnybrook Health Sciences Centre,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:37:52.210440,2020-02-01 21:37:52.210440,Sunnybrook Health Sciences Centre,Other,Methylphenidate,Drug
NCT00495820,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-02,2014-01-21,,2015-10-19,2007-07-02,2007-07-03,Estimate,2015-10-19,2015-11-20,Estimate,,,,2015-10-19,2015-11-20,Estimate,August 2007,,2007-08-31,October 2015,2015-10-31,June 2010,Actual,2010-06-30,March 2010,Actual,2010-03-31,,Interventional,,,Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study,Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study,Completed,,Phase 4,60.0,Actual,VA Office of Research and Development,Small sample size and short duration of the study are two important limitations of the study. All male subjects in the study also make it difficult to generalize the results.,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:25:52.440835,2020-02-01 20:25:52.440835,VA Office of Research and Development,U.S. Fed,Methylphenidate,Drug
NCT00792662,"ClinicalTrials.gov processed this data on January 31, 2020",2008-11-17,,,2018-03-27,2008-11-17,2008-11-18,Estimate,,,,,,,2018-03-27,2018-03-29,Actual,November 2008,Actual,2008-11-30,March 2018,2018-03-31,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,,,"Improving Function, Quality of Life, Glycemia in Diabetics With Dementia","Improving Function, Quality of Life, Glycemia in Diabetics With Dementia",Withdrawn,,Phase 4,0.0,Actual,University of Nebraska,,2.0,,No Subjects enrolled,False,,,,True,,,,,,,,,,,,,2020-02-01 18:56:39.297993,2020-02-01 18:56:39.297993,University of Nebraska,Other,Methylphenidate,Drug
NCT01117181,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-04,2013-02-11,,2018-06-07,2010-05-04,2010-05-05,Estimate,2013-04-01,2013-05-10,Estimate,,,,2018-06-07,2018-06-12,Actual,June 2010,,2010-06-30,June 2018,2018-06-30,August 2012,Actual,2012-08-31,August 2012,Actual,2012-08-31,,Interventional,ADMET,,Apathy in Dementia Methylphenidate Trial (ADMET),Apathy in Dementia Methylphenidate Trial (ADMET),Completed,,Phase 2,60.0,Actual,Johns Hopkins Bloomberg School of Public Health,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:17:32.212260,2020-02-01 17:17:32.212260,Johns Hopkins Bloomberg School of Public Health,Other,Methylphenidate,Drug
NCT02346201,"ClinicalTrials.gov processed this data on January 31, 2020",2015-01-20,,,2020-01-16,2015-01-20,2015-01-26,Estimate,,,,,,,2020-01-16,2020-01-21,Actual,January 2016,,2016-01-31,January 2020,2020-01-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,,Interventional,ADMET2,,Apathy in Dementia Methylphenidate Trial 2,Apathy in Dementia Methylphenidate Trial 2,"Active, not recruiting",,Phase 3,200.0,Actual,Johns Hopkins Bloomberg School of Public Health,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:56:10.970719,2020-02-01 11:56:10.970719,Johns Hopkins Bloomberg School of Public Health,Other,Methylphenidate,Drug
NCT03790709,"ClinicalTrials.gov processed this data on January 31, 2020",2018-12-24,,,2019-11-17,2018-12-31,2019-01-02,Actual,,,,,,,2019-11-17,2019-11-19,Actual,"July 3, 2018",Actual,2018-07-03,August 2019,2019-08-31,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,,Interventional,,,ANAVEX2-73 for Treatment of Early Alzheimer's Disease,"A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)",Recruiting,,Phase 2/Phase 3,450.0,Anticipated,Anavex Life Sciences Corp.,,3.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:25:39.943948,2020-02-01 07:25:39.943948,Anavex Life Sciences Corp.,Industry,Mid dose ANAVEX2-73,Drug
NCT00105105,"ClinicalTrials.gov processed this data on January 31, 2020",2005-03-04,,,2009-12-10,2005-03-04,2005-03-07,Estimate,,,,,,,2009-12-10,2009-12-11,Estimate,April 2003,,2003-04-30,September 2005,2005-09-30,November 2005,Actual,2005-11-30,November 2005,Actual,2005-11-30,,Interventional,,,Mifepristone as Adjunctive Therapy in Alzheimer's Disease,"A Double-blind, Placebo-controlled Trial of the Safety and Efficacy of C-1073 (Mifepristone) as Adjunctive Therapy in Alzheimer's Disease",Terminated,,Phase 2,160.0,,National Institute on Aging (NIA),,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:16:26.869476,2020-02-01 22:16:26.869476,Corcept Therapeutics,Industry,Mifepristone,Drug
NCT01463384,"ClinicalTrials.gov processed this data on January 31, 2020",2011-10-25,2012-10-25,,2014-09-23,2011-10-28,2011-11-01,Estimate,2014-09-23,2014-09-25,Estimate,,,,2014-09-23,2014-09-25,Estimate,September 2011,,2011-09-30,September 2014,2014-09-30,October 2012,Actual,2012-10-31,October 2012,Actual,2012-10-31,,Interventional,,,Minocycline in Patients With Alzheimer's Disease,MRI and MRS Diagnosis and Treatment Monitoring of Alzheimer's Disease With Novel Therapy,Completed,,Phase 2,13.0,Actual,Huntington Medical Research Institutes,,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:38:55.864537,2020-02-01 15:38:55.864537,Huntington Medical Research Institutes,Other,Minocycline,Drug
NCT01867775,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-30,,,2013-06-03,2013-06-03,2013-06-04,Estimate,,,,,,,2013-06-03,2013-06-04,Estimate,May 2012,,2012-05-31,May 2013,2013-05-31,May 2014,Anticipated,2014-05-31,December 2013,Anticipated,2013-12-31,,Interventional,,,Mirtazapine for Sleep Disorders in Alzheimer's Disease,"Mirtazapine for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Double-blind, Placebo-controlled Study",Unknown status,Recruiting,Phase 3,30.0,Anticipated,Brasilia University Hospital,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:53:58.997628,2020-02-01 13:53:58.997628,Brasilia University Hospital,Other,Mirtazapine,Drug
NCT00420420,"ClinicalTrials.gov processed this data on January 31, 2020",2007-01-09,2010-10-25,,2015-01-28,2007-01-10,2007-01-11,Estimate,2010-10-25,2010-11-18,Estimate,,,,2015-01-28,2015-02-12,Estimate,November 2006,,2006-11-30,January 2015,2015-01-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011),"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of MK0249 for the Symptomatic Treatment of Alzheimer's Disease",Completed,,Phase 2,144.0,Actual,Merck Sharp & Dohme Corp.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:49:44.724037,2020-02-01 20:49:44.724037,Merck Sharp & Dohme Corp.,Industry,MK0249,Drug
NCT00874939,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-02,2015-05-26,,2018-09-18,2009-04-02,2009-04-03,Estimate,2015-05-26,2015-06-08,Estimate,,,,2018-09-18,2018-10-17,Actual,"April 6, 2009",Actual,2009-04-06,September 2018,2018-09-30,"April 20, 2009",Actual,2009-04-20,"April 20, 2009",Actual,2009-04-20,,Interventional,,,A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023),A Randomized Clinical Trial To Evaluate the Single Dose Acute Effects of MK-0249 and Donepezil On Cognitive Function In Adult Patients With Alzheimer's Disease,Terminated,,Phase 1,4.0,Actual,Merck Sharp & Dohme Corp.,,12.0,,,False,,,,False,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2020-02-01 18:32:14.819408,2020-02-01 18:32:14.819408,Merck Sharp & Dohme Corp.,Industry,MK-0249 25 mg,Drug
NCT00874939,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-02,2015-05-26,,2018-09-18,2009-04-02,2009-04-03,Estimate,2015-05-26,2015-06-08,Estimate,,,,2018-09-18,2018-10-17,Actual,"April 6, 2009",Actual,2009-04-06,September 2018,2018-09-30,"April 20, 2009",Actual,2009-04-20,"April 20, 2009",Actual,2009-04-20,,Interventional,,,A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023),A Randomized Clinical Trial To Evaluate the Single Dose Acute Effects of MK-0249 and Donepezil On Cognitive Function In Adult Patients With Alzheimer's Disease,Terminated,,Phase 1,4.0,Actual,Merck Sharp & Dohme Corp.,,12.0,,,False,,,,False,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2020-02-01 18:32:14.819408,2020-02-01 18:32:14.819408,Merck Sharp & Dohme Corp.,Industry,MK-0249 7.5 mg,Drug
NCT00074529,"ClinicalTrials.gov processed this data on January 31, 2020",2003-12-15,,,2015-07-23,2003-12-15,2003-12-16,Estimate,,,,,,,2015-07-23,2015-07-24,Estimate,October 2003,,2003-10-31,July 2015,2015-07-31,January 2006,Actual,2006-01-31,January 2006,Actual,2006-01-31,,Interventional,,,Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED),"A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease",Completed,,Phase 2,512.0,Actual,Merck Sharp & Dohme Corp.,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:29:43.867688,2020-02-01 22:29:43.867688,Merck Sharp & Dohme Corp.,Industry,MK0677,Drug
NCT00362024,"ClinicalTrials.gov processed this data on January 31, 2020",2006-08-08,,,2016-05-13,2006-08-08,2006-08-09,Estimate,,,,,,,2016-05-13,2016-05-16,Estimate,November 2006,,2006-11-30,May 2016,2016-05-31,November 2007,Actual,2007-11-30,November 2007,Actual,2007-11-30,,Interventional,,,MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED),MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease,Terminated,,Phase 2,24.0,Actual,Merck Sharp & Dohme Corp.,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:08:11.924466,2020-02-01 21:08:11.924466,Merck Sharp & Dohme Corp.,Industry,MK0952,Drug
NCT03740178,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-12,,,2019-05-02,2018-11-12,2018-11-14,Actual,,,,,,,2019-05-02,2019-05-03,Actual,"September 27, 2019",Anticipated,2019-09-27,April 2019,2019-04-30,"February 28, 2020",Anticipated,2020-02-28,"February 28, 2020",Anticipated,2020-02-28,,Interventional,,,Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005),"A Randomized, Double-Blinded Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MK-4334 in Participants With Alzheimer's Clinical Syndrome on a Stable Dose of Donepezil",Not yet recruiting,,Phase 1,12.0,Anticipated,Merck Sharp & Dohme Corp.,,2.0,,,False,,,,False,True,False,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2020-02-01 07:32:49.642464,2020-02-01 07:32:49.642464,Merck Sharp & Dohme Corp.,Industry,MK-4334,Drug
NCT01852110,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-08,2018-01-08,,2018-08-20,2013-05-08,2013-05-13,Estimate,2018-01-08,2018-02-07,Actual,,,,2018-08-20,2018-09-18,Actual,"October 22, 2013",Actual,2013-10-22,August 2018,2018-08-31,"April 11, 2016",Actual,2016-04-11,"April 11, 2016",Actual,2016-04-11,,Interventional,,"Includes only participants in Stage 1 who were both randomized (i.e. started) and treated.
In stage 1:
MK-7622 High Dose - 45 mg: of the randomized participants (n=120), all but 1 randomized participant received study treatment (n=119).
Placebo: Of the randomized participants (n=120), all received study treatment (n=120).",Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012),"A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy for Symptomatic Treatment in Subjects With Alzheimer's Disease",Terminated,,Phase 2,240.0,Actual,Merck Sharp & Dohme Corp.,"Stage 1 Interim analysis of efficacy met the clinical criteria for early trial termination (futility). As a result, the trial was terminated at Stage 1 and did not proceed to Stage 2.",6.0,,"Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility).
    The trial was terminated at Stage 1; did not proceed to Stage 2.",False,,,,False,True,False,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2020-02-01 14:00:05.175571,2020-02-01 14:00:05.175571,Merck Sharp & Dohme Corp.,Industry,MK-7622,Drug
NCT01496170,"ClinicalTrials.gov processed this data on January 31, 2020",2011-12-06,,,2015-10-22,2011-12-16,2011-12-21,Estimate,,,,,,,2015-10-22,2015-10-23,Estimate,December 2011,,2011-12-31,October 2015,2015-10-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,,,"A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])","A Study to Assess the Safety, Tolerability, and Pharmacodynamics of MK-8931/SCH 900931 in Patients With Alzheimer's Disease [Phase 1b; Protocol No. 010-00 (Also Known as P07820)]",Completed,,Phase 1,32.0,Actual,Merck Sharp & Dohme Corp.,,5.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:30:09.701105,2020-02-01 15:30:09.701105,Merck Sharp & Dohme Corp.,Industry,MK-8931,Drug
NCT01537757,"ClinicalTrials.gov processed this data on January 31, 2020",2012-02-17,,,2015-01-23,2012-02-17,2012-02-23,Estimate,,,,,,,2015-01-23,2015-01-26,Estimate,March 2012,,2012-03-31,January 2015,2015-01-31,May 2012,Actual,2012-05-31,May 2012,Actual,2012-05-31,,Interventional,,,"A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])","An Open-Label, Two-Part, Single-Dose Study to Investigate the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (Protocol No. MK-8931-009 [P08535])",Completed,,Phase 1,12.0,Actual,Merck Sharp & Dohme Corp.,,6.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:19:48.924157,2020-02-01 15:19:48.924157,Merck Sharp & Dohme Corp.,Industry,MK-8931,Drug
NCT02910739,"ClinicalTrials.gov processed this data on January 31, 2020",2016-09-20,2018-01-11,,2018-02-07,2016-09-20,2016-09-22,Estimate,2018-02-07,2018-10-01,Actual,,,,2018-02-07,2018-10-01,Actual,"October 11, 2016",Actual,2016-10-11,February 2018,2018-02-28,"April 12, 2017",Actual,2017-04-12,"April 3, 2017",Actual,2017-04-03,,Interventional,,,An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016),"A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-8931 When Administered to Subjects With Mild and Moderate Hepatic Insufficiency",Completed,,Phase 1,16.0,Actual,Merck Sharp & Dohme Corp.,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 09:56:54.987079,2020-02-01 09:56:54.987079,Merck Sharp & Dohme Corp.,Industry,MK-8931,Drug
NCT01696123,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-21,,,2012-09-27,2012-09-27,2012-09-28,Estimate,,,,,,,2012-09-27,2012-09-28,Estimate,January 2011,,2011-01-31,September 2012,2012-09-30,August 2012,Actual,2012-08-31,January 2012,Actual,2012-01-31,,Interventional,,,Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine,,Completed,,Phase 2,125.0,Actual,Shahid Beheshti University of Medical Sciences,,1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 14:39:49.444520,2020-02-01 14:39:49.444520,Shahid Beheshti University of Medical Sciences,Other,MLC601,Drug
NCT03038035,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-01,,,2017-01-26,2017-01-26,2017-01-31,Estimate,,,,,,,2017-01-26,2017-01-31,Estimate,December 2016,,2016-12-31,January 2017,2017-01-31,June 2019,Anticipated,2019-06-30,June 2018,Anticipated,2018-06-30,,Interventional,ATHENE,,The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study,"The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study : Assessing the Safety and Efficacy of Neuroaid II (MLC901) in Patients With Mild to Moderate Alzheimer's Disease Stable on Cholinesterase Inhibitors or Memantine: A Randomized, Double Blind, Placebo Controlled Trial",Unknown status,Recruiting,Phase 2,150.0,Anticipated,"National University Hospital, Singapore",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 09:30:10.628210,2020-02-01 09:30:10.628210,"National University Hospital, Singapore",Other,MLC901,Drug
NCT00626210,"ClinicalTrials.gov processed this data on January 31, 2020",2008-02-20,2014-06-12,,2019-10-24,2008-02-20,2008-02-29,Estimate,2014-10-28,2014-10-30,Estimate,,,,2019-10-24,2019-10-28,Actual,February 2008,,2008-02-29,October 2019,2019-10-31,October 2012,Actual,2012-10-31,April 2011,Actual,2011-04-30,,Interventional,,,Modafinil Treatment for Sleep/Wake Disturbances in Older Adults,Modafinil Treatment for Sleep/Wake Disturbances in Older Adults,Terminated,,Phase 4,2.0,Actual,VA Palo Alto Health Care System,Early termination leading to small numbers of subjects analyzed,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:45:13.460062,2020-02-01 19:45:13.460062,VA Palo Alto Health Care System,U.S. Fed,modafinil,Drug
NCT01172145,"ClinicalTrials.gov processed this data on January 31, 2020",2010-07-28,2010-08-04,,2011-02-09,2010-07-28,2010-07-29,Estimate,2011-02-09,2011-03-04,Estimate,,,,2011-02-09,2011-03-04,Estimate,July 2005,,2005-07-31,September 2010,2010-09-30,September 2007,Actual,2007-09-30,,,,,Interventional,,,Treatment of Apathy in Alzheimer's Disease With Modafinil,Treatment of Apathy in Alzheimer's Disease With Modafinil,Completed,,Phase 3,22.0,Actual,Brown University,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:01:29.146927,2020-02-01 17:01:29.146927,Brown University,Other,Modafinil,Drug
NCT03991988,"ClinicalTrials.gov processed this data on January 31, 2020",2019-06-18,,,2019-09-27,2019-06-18,2019-06-19,Actual,,,,,,,2019-09-27,2019-09-30,Actual,"September 25, 2019",Actual,2019-09-25,September 2019,2019-09-30,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,,Interventional,,,Montelukast Therapy on Alzheimer's Disease,Effects of Montelukast Therapy on Alzheimer's Disease (EMERALD),Recruiting,,Phase 2,150.0,Anticipated,Emory University,,2.0,,,False,,,,False,True,False,,,False,,,,,,No,,2020-02-01 06:55:32.004687,2020-02-01 06:55:32.004687,Emory University,Other,Montelukast,Drug
NCT03402503,"ClinicalTrials.gov processed this data on January 31, 2020",2018-01-10,,,2020-01-13,2018-01-10,2018-01-18,Actual,,,,,,,2020-01-13,2020-01-18,Actual,"November 26, 2018",Actual,2018-11-26,October 2019,2019-10-31,"July 19, 2021",Anticipated,2021-07-19,"November 19, 2020",Anticipated,2020-11-19,,Interventional,BUENA,,"Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease","A Randomized Phase IIa, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 2,70.0,Anticipated,IntelGenx Corp.,,2.0,,,False,,,,True,False,False,,,False,,,,,,Undecided,,2020-02-01 08:26:26.385363,2020-02-01 08:26:26.385363,IntelGenx Corp.,Industry,Montelukast buccal film,Drug
NCT00499642,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-10,,,2007-12-19,2007-07-10,2007-07-11,Estimate,,,,,,,2007-12-19,2007-12-28,Estimate,June 2007,,2007-06-30,December 2007,2007-12-31,August 2007,Actual,2007-08-31,,,,,Interventional,,,Study Evaluating the Effect of Lecozotan SR on the QTc Interval,"A Single-Dose, Double-Blind, Crossover, Placebo- and Moxifloxacin (Open-Label)-Controlled Study of the Effects of Lecozotan SR on Cardiac Repolarization in Healthy Adult Subjects",Completed,,Phase 1,,,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:24:43.811268,2020-02-01 20:24:43.811268,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,Moxifloxacin,Drug
NCT00884533,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-16,,,2015-04-15,2009-04-16,2009-04-20,Estimate,,,,,,,2015-04-15,2015-04-17,Estimate,June 2009,,2009-06-30,April 2015,2015-04-30,August 2009,Anticipated,2009-08-31,August 2009,Anticipated,2009-08-31,,Interventional,Rosi XR,,QTc Study of Rosi XR in Healthy Volunteers,A Study to Evaluate the Effect of Extended Release Rosiglitazone (RSG XR) on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin,Withdrawn,,Phase 1,0.0,Actual,GlaxoSmithKline,,3.0,,The whole project was terminated,False,,,,,,,,,,,,,,,,,2020-02-01 18:29:05.782285,2020-02-01 18:29:05.782285,GlaxoSmithKline,Industry,Moxifloxacin,Drug
NCT03044249,"ClinicalTrials.gov processed this data on January 31, 2020",2017-01-31,,,2019-09-03,2017-02-02,2017-02-06,Estimate,,,,,,,2019-09-03,2019-09-06,Actual,"May 4, 2017",Actual,2017-05-04,September 2019,2019-09-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,,Interventional,,,A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression,"Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression",Recruiting,,Phase 2,100.0,Anticipated,Mediti Pharma Inc.,,2.0,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:29:03.053284,2020-02-01 09:29:03.053284,Mediti Pharma Inc.,Other,MP-101,Drug
NCT00105547,"ClinicalTrials.gov processed this data on January 31, 2020",2005-03-15,,,2009-05-03,2005-03-15,2005-03-16,Estimate,,,,,,,2009-05-03,2009-05-05,Estimate,February 2005,,2005-02-28,May 2009,2009-05-31,May 2008,Actual,2008-05-31,,,,,Interventional,,,Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's,"Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type",Completed,,Phase 3,1600.0,Actual,Myrexis Inc.,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:16:14.796657,2020-02-01 22:16:14.796657,Myrexis Inc.,Industry,MPC-7869,Drug
NCT00322036,"ClinicalTrials.gov processed this data on January 31, 2020",2006-05-02,,,2008-08-01,2006-05-02,2006-05-04,Estimate,,,,,,,2008-08-01,2008-08-05,Estimate,May 2006,,2006-05-31,August 2008,2008-08-31,December 2008,Anticipated,2008-12-31,,,,,Interventional,,,Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's,"Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type",Terminated,,Phase 3,800.0,Actual,Myrexis Inc.,,2.0,,Myriad has discontinued the development of Flurizan.,False,,,,True,,,,,,,,,,,,,2020-02-01 21:18:58.948666,2020-02-01 21:18:58.948666,Myrexis Inc.,Industry,MPC-7869,Drug
NCT00380276,"ClinicalTrials.gov processed this data on January 31, 2020",2006-09-21,,,2008-08-01,2006-09-22,2006-09-25,Estimate,,,,,,,2008-08-01,2008-08-05,Estimate,September 2006,,2006-09-30,August 2008,2008-08-31,December 2008,Anticipated,2008-12-31,,,,,Interventional,,,Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol,Open Label Study of the Effect of Daily Treatment With MPC-7869 in Subjects With Dementia of the Alzheimer's Type,Terminated,,Phase 3,1000.0,Anticipated,Myrexis Inc.,,1.0,,Myriad has discontinued the development of Flurizan.,False,,,,,,,,,,,,,,,,,2020-02-01 21:02:36.014010,2020-02-01 21:02:36.014010,Myrexis Inc.,Industry,MPC-7869,Drug
NCT01374438,"ClinicalTrials.gov processed this data on January 31, 2020",2011-06-14,2014-09-25,,2014-11-05,2011-06-15,2011-06-16,Estimate,2014-11-03,2014-11-05,Estimate,,,,2014-11-05,2014-11-18,Estimate,July 2011,,2011-07-31,November 2014,2014-11-30,May 2013,Actual,2013-05-31,March 2013,Actual,2013-03-31,,Interventional,,All randomized subjects completed the full study and are included in the analysis.,"3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease","A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease",Completed,,Phase 2,29.0,Actual,Metabolic Solutions Development Company,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:02:10.248730,2020-02-01 16:02:10.248730,Metabolic Solutions Development Company,Industry,MSDC-0160,Drug
NCT01764243,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-26,,,2015-09-24,2013-01-07,2013-01-09,Estimate,,,,,,,2015-09-24,2015-09-28,Estimate,November 2012,,2012-11-30,September 2015,2015-09-30,July 2015,Actual,2015-07-31,June 2015,Actual,2015-06-30,,Interventional,,,Safety and Efficacy of MT-4666,"A Double-Blind, Placebo-Controlled Phase2 Study of MT-4666 in Patients With Mild to Moderate Probable Alzheimer's Disease.",Completed,,Phase 2,450.0,Actual,Mitsubishi Tanabe Pharma Corporation,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:21:47.790249,2020-02-01 14:21:47.790249,Mitsubishi Tanabe Pharma Corporation,Industry,MT-4666,Drug
NCT02327182,"ClinicalTrials.gov processed this data on January 31, 2020",2014-12-23,,,2015-11-12,2014-12-29,2014-12-30,Estimate,,,,,,,2015-11-12,2015-11-13,Estimate,December 2014,,2014-12-31,November 2015,2015-11-30,October 2015,Actual,2015-10-31,September 2015,Actual,2015-09-30,,Interventional,,,Safety Study of MT-4666 in Subjects With Alzheimer's Disease,A Long-Term Safety Study of MT-4666 in Patients With Mild to Moderate Alzheimer's Disease (AD),Terminated,,Phase 3,117.0,Actual,Mitsubishi Tanabe Pharma Corporation,,2.0,,This study was terminated due to the benefit-risk balance of MT-4666.,False,,,,False,,,,,,,,,,,,,2020-02-01 12:00:19.911512,2020-02-01 12:00:19.911512,Mitsubishi Tanabe Pharma Corporation,Industry,MT-4666,Drug
NCT00056329,"ClinicalTrials.gov processed this data on January 31, 2020",2003-03-10,,,2012-05-02,2003-03-11,2003-03-12,Estimate,,,,,,,2012-05-02,2012-05-04,Estimate,April 2002,,2002-04-30,May 2012,2012-05-31,May 2012,Anticipated,2012-05-31,May 2012,Anticipated,2012-05-31,,Interventional,,,Vitamin E in Aging Persons With Down Syndrome,Multicenter Vitamin E Trial in Aging Persons With Down Syndrome,Unknown status,"Active, not recruiting",Phase 3,350.0,Actual,New York State Institute for Basic Research,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:35:03.109992,2020-02-01 22:35:03.109992,New York State Institute for Basic Research,Other,multivitamin,Drug
NCT02351882,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-17,,,2019-04-08,2015-01-27,2015-01-30,Estimate,,,,,,,2019-04-08,2019-04-10,Actual,January 2015,,2015-01-31,April 2019,2019-04-30,March 2019,Actual,2019-03-31,January 2018,Actual,2018-01-31,,Interventional,,,Safety and Efficacy of Nabilone in Alzheimer's Disease,Safety and Efficacy of Nabilone in Alzheimer's Disease: a Pilot Study,Completed,,Phase 2/Phase 3,38.0,Actual,Sunnybrook Health Sciences Centre,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:54:58.307512,2020-02-01 11:54:58.307512,Sunnybrook Health Sciences Centre,Other,Nabilone,Drug
NCT00004845,"ClinicalTrials.gov processed this data on January 31, 2020",2000-02-28,,,2009-12-10,2000-02-28,2000-02-29,Estimate,,,,,,,2009-12-10,2009-12-11,Estimate,,,,June 2009,2009-06-30,December 2001,Actual,2001-12-31,December 2001,Actual,2001-12-31,,Interventional,,,A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study),A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease,Completed,,Phase 2/Phase 3,,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:49:58.953737,2020-02-01 22:49:58.953737,National Institute on Aging (NIA),NIH,Naproxen,Drug
NCT03298672,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-21,,,2019-09-06,2017-09-26,2017-10-02,Actual,,,,,,,2019-09-06,2019-09-10,Actual,"October 9, 2017",Actual,2017-10-09,September 2019,2019-09-30,"September 5, 2019",Actual,2019-09-05,"September 5, 2019",Actual,2019-09-05,,Interventional,,,"Safety, Tolerability, and Pharmacokinetics Study of NDX-1017","A Randomized, Placebo-Controlled, Double-Blinded, First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part A) and Multiple Ascending Doses (Part B) of NDX-1017 in Healthy Young and Elderly Subjects",Completed,,Phase 1,88.0,Actual,Athira Pharma,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 08:43:58.167473,2020-02-01 08:43:58.167473,Athira Pharma,Industry,NDX-1017,Drug
NCT00001933,"ClinicalTrials.gov processed this data on January 31, 2020",1999-11-03,,,2008-03-03,1999-11-03,1999-11-04,Estimate,,,,,,,2008-03-03,2008-03-04,Estimate,July 1999,,1999-07-31,January 2002,2002-01-31,January 2002,,2002-01-31,,,,,Interventional,,,Nefiracetam in the Treatment of Alzheimer's Disease,Nefiracetam Therapy of Alzheimer's Type Dementia,Completed,,Phase 2,50.0,,National Institutes of Health Clinical Center (CC),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:50:18.761367,2020-02-01 22:50:18.761367,National Institute of Neurological Disorders and Stroke (NINDS),NIH,Nefiracetam,Drug
NCT03402659,"ClinicalTrials.gov processed this data on January 31, 2020",2018-01-11,,,2019-10-01,2018-01-11,2018-01-18,Actual,,,,,,,2019-10-01,2019-10-03,Actual,"December 29, 2017",Actual,2017-12-29,August 2018,2018-08-31,"July 31, 2019",Actual,2019-07-31,"June 30, 2019",Actual,2019-06-30,,Interventional,REVERSE-SD,,"Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease","A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease",Completed,,Phase 2,161.0,Actual,EIP Pharma Inc,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 08:26:25.557931,2020-02-01 08:26:25.557931,EIP Pharma Inc,Industry,neflamapimod,Drug
NCT02708186,"ClinicalTrials.gov processed this data on January 31, 2020",2016-03-10,,,2018-10-22,2016-03-14,2016-03-15,Estimate,,,,,,,2018-10-22,2018-10-23,Actual,March 2016,Actual,2016-03-31,April 2018,2018-04-30,May 2018,Actual,2018-05-31,May 2018,Actual,2018-05-31,,Interventional,,,Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD),"A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)",Completed,,Phase 2,29.0,Actual,Axovant Sciences Ltd.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 10:35:55.243047,2020-02-01 10:35:55.243047,Axovant Sciences Ltd.,Industry,Nelotanserin,Drug
NCT02871427,"ClinicalTrials.gov processed this data on January 31, 2020",2016-08-15,,,2019-03-26,2016-08-15,2016-08-18,Estimate,,,,,,,2019-03-26,2019-03-27,Actual,"October 20, 2016",Actual,2016-10-20,March 2019,2019-03-31,"January 17, 2019",Actual,2019-01-17,"January 17, 2019",Actual,2019-01-17,,Interventional,,,Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder,An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder,Terminated,,Phase 2,80.0,Anticipated,Axovant Sciences Ltd.,,1.0,,Changes to the overall development program for the study medication,False,,,,,,,,,,,,,,,,,2020-02-01 10:04:41.446379,2020-02-01 10:04:41.446379,Axovant Sciences Ltd.,Industry,Nelotanserin,Drug
NCT00090116,"ClinicalTrials.gov processed this data on January 31, 2020",2004-08-24,,,2012-03-01,2004-08-25,2004-08-26,Estimate,,,,,,,2012-03-01,2012-03-05,Estimate,March 2003,,2003-03-31,March 2012,2012-03-31,March 2005,Actual,2005-03-31,March 2005,Actual,2005-03-31,,Interventional,,,The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease,"A Randomized, Double-Blind,Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane Monotherapy in Patients With Moderate to Severe Dementia of the Alzheimer's Type",Completed,,Phase 3,400.0,,Forest Laboratories,,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:22:10.110151,2020-02-01 22:22:10.110151,Forest Laboratories,Industry,Neramexane,Drug
NCT01163825,"ClinicalTrials.gov processed this data on January 31, 2020",2010-07-14,,,2010-07-15,2010-07-15,2010-07-16,Estimate,,,,,,,2010-07-15,2010-07-16,Estimate,January 2008,,2008-01-31,July 2010,2010-07-31,,,,December 2011,Anticipated,2011-12-31,,Interventional,NsG0202,,Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer´s Disease Patients,"An Open Label, Dose-Escalation Study of Encapsulated Cell Biodelivery of Nerve Growth Factor to the Cholinergic Basal Forebrain of Alzheimer´s Disease Patients",Unknown status,"Active, not recruiting",Phase 1,6.0,Actual,NsGene A/S,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:03:51.789536,2020-02-01 17:03:51.789536,NsGene A/S,Industry,Nerve Growth Factor,Drug
NCT00470418,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-04,2014-01-16,,2017-01-05,2007-05-04,2007-05-07,Estimate,2017-01-05,2017-01-09,Estimate,,,,2017-01-05,2017-01-09,Estimate,January 2007,,2007-01-31,January 2017,2017-01-31,March 2010,Actual,2010-03-31,August 2008,Actual,2008-08-31,,Interventional,,,Development of NIC5-15 in the Treatment of Alzheimer's Disease,Development of NIC5-15 in the Treatment of Alzheimer's Disease,Completed,,Phase 2,15.0,Actual,VA Office of Research and Development,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:33:24.684642,2020-02-01 20:33:24.684642,VA Office of Research and Development,U.S. Fed,NIC5-15,Drug
NCT00018278,"ClinicalTrials.gov processed this data on January 31, 2020",2001-07-03,,,2009-01-20,2001-07-04,2001-07-05,Estimate,,,,,,,2009-01-20,2009-01-21,Estimate,October 1998,,1998-10-31,December 2004,2004-12-31,September 2001,,2001-09-30,,,,,Interventional,,,Electrophysiologic Measures of Treatment Response in Alzheimer Disease,Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease,Completed,,Phase 4,,,VA Office of Research and Development,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:17.695761,2020-02-01 22:48:17.695761,US Department of Veterans Affairs,U.S. Fed,Nicoderm Patch,Drug
NCT00580931,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-24,,,2017-01-23,2007-12-26,2007-12-27,Estimate,,,,,,,2017-01-23,2017-01-25,Estimate,January 2008,Actual,2008-01-31,January 2017,2017-01-31,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,,,Safety Study of Nicotinamide to Treat Alzheimer's Disease,Efficacy of Nicotinamide for the Treatment of Alzheimer's Disease,Completed,,Phase 1/Phase 2,50.0,Actual,"University of California, Irvine",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:58:33.890191,2020-02-01 19:58:33.890191,"University of California, Irvine",Other,Nicotinamide,Drug
NCT03061474,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-13,,,2019-09-24,2017-02-17,2017-02-23,Actual,,,,,,,2019-09-24,2019-09-26,Actual,"July 12, 2017",Actual,2017-07-12,September 2019,2019-09-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,,Interventional,NEAT,,Nicotinamide as an Early Alzheimer's Disease Treatment,"A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Dementia",Recruiting,,Phase 2,48.0,Anticipated,"University of California, Irvine",,2.0,,,,,,,True,True,False,,,,,,,,,Yes,,2020-02-01 09:26:00.923165,2020-02-01 09:26:00.923165,"University of California, Irvine",Other,Nicotinamide,Drug
NCT02947893,"ClinicalTrials.gov processed this data on January 31, 2020",2016-10-21,,,2019-03-12,2016-10-27,2016-10-28,Estimate,,,,,,,2019-03-12,2019-03-13,Actual,January 2017,Actual,2017-01-31,March 2019,2019-03-31,February 2020,Anticipated,2020-02-29,December 2019,Anticipated,2019-12-31,,Interventional,AD,,"Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease","A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease","Active, not recruiting",,Phase 2,42.0,Anticipated,Georgetown University,,2.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:47:48.303388,2020-02-01 09:47:48.303388,Georgetown University,Other,Nilotinib Capsule(s) Once a Day by Mouth,Drug
NCT02017340,"ClinicalTrials.gov processed this data on January 31, 2020",2013-12-16,,,2017-03-03,2013-12-16,2013-12-20,Estimate,,,,,,,2017-03-03,2017-03-06,Actual,"April 24, 2013",Actual,2013-04-24,March 2017,2017-03-31,"December 16, 2016",Actual,2016-12-16,"December 16, 2016",Actual,2016-12-16,,Interventional,NILVAD,,A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease,A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease,Completed,,Phase 3,511.0,Actual,"St. James's Hospital, Ireland",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:14:04.638889,2020-02-01 13:14:04.638889,Prof Brian Lawlor,Other,Nilvadipine,Drug
NCT04074837,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-27,,,2019-08-28,2019-08-28,2019-08-30,Actual,,,,,,,2019-08-28,2019-08-30,Actual,"August 1, 2019",Actual,2019-08-01,August 2019,2019-08-31,"April 1, 2020",Anticipated,2020-04-01,"March 1, 2020",Anticipated,2020-03-01,,Interventional,,,"Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers","Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age",Recruiting,,Phase 1,56.0,Anticipated,"Neuronascent, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,No,This clinical trial will be available for peer-reviewed publication.,2020-02-01 06:43:42.295547,2020-02-01 06:43:42.295547,"Neuronascent, Inc.",Industry,NNI-362,Drug
NCT01469351,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-01,,,2013-04-18,2011-11-07,2011-11-10,Estimate,,,,,,,2013-04-18,2013-04-19,Estimate,January 2012,,2012-01-31,April 2013,2013-04-30,April 2013,Actual,2013-04-30,April 2013,Actual,2013-04-30,,Interventional,,,Identifying Potential Effects of Liraglutide on Degenerative Changes,Neurodegenerative Changes in Alzheimer's Disease: Identifying Potential Effects of Liraglutide on Degenerative Changes,Completed,,N/A,34.0,Actual,University of Aarhus,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:37:03.985693,2020-02-01 15:37:03.985693,University of Aarhus,Other,non-active study drug,Drug
NCT03959553,"ClinicalTrials.gov processed this data on January 31, 2020",2019-05-08,,,2019-05-23,2019-05-21,2019-05-22,Actual,,,,,,,2019-05-23,2019-05-28,Actual,"September 1, 2019",Anticipated,2019-09-01,May 2019,2019-05-31,"February 28, 2022",Anticipated,2022-02-28,"August 31, 2021",Anticipated,2021-08-31,,Interventional,,,GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Moderate Alzheimer's Disease",Not yet recruiting,,Phase 2,90.0,Anticipated,GemVax & Kael,,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 07:00:23.340260,2020-02-01 07:00:23.340260,GemVax & Kael,Industry,Normal saline,Drug
NCT03184467,"ClinicalTrials.gov processed this data on January 31, 2020",2017-06-09,,,2017-06-09,2017-06-09,2017-06-12,Actual,,,,,,,2017-06-09,2017-06-12,Actual,June 2017,Anticipated,2017-06-30,June 2017,2017-06-30,June 2019,Anticipated,2019-06-30,June 2019,Anticipated,2019-06-30,,Interventional,,,Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients",Unknown status,Recruiting,Phase 2,90.0,Anticipated,GemVax & Kael,,3.0,,,False,,,,False,False,False,,,,,,,,,Undecided,,2020-02-01 09:04:28.719332,2020-02-01 09:04:28.719332,GemVax & Kael,Industry,Normal Saline 0.9%,Drug
NCT04052737,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-08,,,2019-08-11,2019-08-09,2019-08-12,Actual,,,,,,,2019-08-11,2019-08-13,Actual,"March 23, 2018",Actual,2018-03-23,August 2019,2019-08-31,July 2020,Anticipated,2020-07-31,December 2019,Anticipated,2019-12-31,,Interventional,,,PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease,"A Prospective, Multicentric, Randomized, Double Blind, Placebo Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy Along With Standard Supportive Care in Subjects of Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 2,80.0,Anticipated,"Pharmazz, Inc.",,2.0,,,False,,,,True,False,False,,,,,,,,,No,Results will be communicated and published as manuscript,2020-02-01 06:46:51.040091,2020-02-01 06:46:51.040091,"Pharmazz, Inc.",Industry,Normal Saline along with standard treatment,Drug
NCT00205179,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-13,2016-01-26,,2020-01-13,2005-09-13,2005-09-20,Estimate,2020-01-13,2020-01-22,Actual,,,,2020-01-13,2020-01-22,Actual,January 2005,,2005-01-31,January 2020,2020-01-31,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,Older adults with Alzheimer's disease,Alzheimer's Disease: Potential Benefit of Isoflavones,Alzheimer's Disease: Potential Benefit of Isoflavones,Completed,,Phase 2,72.0,Actual,"University of Wisconsin, Madison",,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 21:48:33.787059,2020-02-01 21:48:33.787059,"University of Wisconsin, Madison",Other,Novasoy,Drug
NCT00948259,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-27,,,2009-11-10,2009-07-28,2009-07-29,Estimate,,,,,,,2009-11-10,2009-11-11,Estimate,December 2008,,2008-12-31,November 2009,2009-11-30,November 2009,Actual,2009-11-30,November 2009,Actual,2009-11-30,,Interventional,,,Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease,"Phase IIa 20 Week Double-blind, Placebo-controlled, Randomized, Escalating Dose Study to Evaluate the Safety and Tolerability of Four Oral Doses of NP031112, a Novel GSK3 Inhibitor, in Mild to Moderate Alzheimer's Disease Patients With Stable Anticholinesterasic Treatment.",Completed,,Phase 1/Phase 2,30.0,Actual,Noscira SA,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:10:37.833566,2020-02-01 18:10:37.833566,Noscira SA,Industry,NP031112,Drug
NCT03008161,"ClinicalTrials.gov processed this data on January 31, 2020",2016-12-23,,,2019-08-14,2016-12-29,2017-01-02,Estimate,,,,,,,2019-08-14,2019-08-15,Actual,December 2016,Actual,2016-12-31,August 2019,2019-08-31,"February 6, 2019",Actual,2019-02-06,"February 6, 2019",Actual,2019-02-06,,Interventional,,,Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease,"A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease",Completed,,Phase 1,83.0,Actual,"Proclara Biosciences, Inc.",,4.0,,,False,,,,True,,,,,,,,,,,Undecided,,2020-02-01 09:35:53.375769,2020-02-01 09:35:53.375769,"Proclara Biosciences, Inc.",Industry,NPT088,Drug
NCT00153010,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-09,,,2013-10-28,2005-09-09,2005-09-12,Estimate,,,,,,,2013-10-28,2013-10-29,Estimate,February 2003,,2003-02-28,October 2013,2013-10-31,,,,March 2005,Actual,2005-03-31,,Interventional,,,An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type,"A Phase II Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Multicenter, Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type",Completed,,Phase 2,430.0,Actual,Boehringer Ingelheim,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:02:00.014299,2020-02-01 22:02:00.014299,Boehringer Ingelheim,Industry,NS 2330 (Tesofensine),Drug
NCT00795730,"ClinicalTrials.gov processed this data on January 31, 2020",2008-11-20,,,2009-07-20,2008-11-20,2008-11-21,Estimate,,,,,,,2009-07-20,2009-07-21,Estimate,January 2009,,2009-01-31,July 2009,2009-07-31,June 2009,Anticipated,2009-06-30,June 2009,Anticipated,2009-06-30,,Interventional,,,Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789,"An Ascending Multiple Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Healthy Subjects and Subjects With Alzheimer's Disease",Terminated,,Phase 1,56.0,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:55:51.138560,2020-02-01 18:55:51.138560,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,NSA-789,Drug
NCT00013923,"ClinicalTrials.gov processed this data on January 31, 2020",2001-04-02,,,2009-12-10,2001-04-02,2001-04-03,Estimate,,,,,,,2009-12-10,2009-12-11,Estimate,,,,August 2003,2003-08-31,June 2005,Actual,2005-06-30,June 2005,Actual,2005-06-30,,Interventional,,,Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease,A Nutritional Brain Metabolic Enhancer for Alzheimer Disease,Completed,,Phase 2,40.0,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:27.235018,2020-02-01 22:48:27.235018,National Institute on Aging (NIA),NIH,Nutritional Supplement,Drug
NCT03283059,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-12,,,2019-10-20,2017-09-12,2017-09-14,Actual,,,,,,,2019-10-20,2019-10-22,Actual,"August 16, 2017",Actual,2017-08-16,October 2019,2019-10-31,"February 16, 2021",Anticipated,2021-02-16,"September 16, 2020",Anticipated,2020-09-16,,Interventional,,,Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease,"Phase III Trial of Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease: a 26 Weeks, Randomized, Double-blind, Double-dummy, Placebo- and Positive- Parallel Controlled and Extended Single Arm to 54 Weeks Multicentre Study",Recruiting,,Phase 3,600.0,Anticipated,Shanghai Mental Health Center,,3.0,,,False,,,,,False,False,,,,,,,,,No,Other researchers should apply to the sponsor.,2020-02-01 08:46:31.811934,2020-02-01 08:46:31.811934,Shanghai Mental Health Center,Other,Octohydroaminoacridine Succinate,Drug
NCT01569516,"ClinicalTrials.gov processed this data on January 31, 2020",2012-03-30,,,2012-04-06,2012-03-30,2012-04-03,Estimate,,,,,,,2012-04-06,2012-04-09,Estimate,June 2011,,2011-06-30,May 2011,2011-05-31,October 2012,Anticipated,2012-10-31,July 2012,Anticipated,2012-07-31,,Interventional,,,Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease,"A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease",Unknown status,Recruiting,Phase 2,288.0,Anticipated,"Changchun Huayang High-tech Co., Ltd",,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:12:18.612653,2020-02-01 15:12:18.612653,"Changchun Huayang High-tech Co., Ltd",Industry,Octohydroaminoacridine succinate Tablets,Drug
NCT01569516,"ClinicalTrials.gov processed this data on January 31, 2020",2012-03-30,,,2012-04-06,2012-03-30,2012-04-03,Estimate,,,,,,,2012-04-06,2012-04-09,Estimate,June 2011,,2011-06-30,May 2011,2011-05-31,October 2012,Anticipated,2012-10-31,July 2012,Anticipated,2012-07-31,,Interventional,,,Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease,"A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease",Unknown status,Recruiting,Phase 2,288.0,Anticipated,"Changchun Huayang High-tech Co., Ltd",,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:12:18.612653,2020-02-01 15:12:18.612653,"Changchun Huayang High-tech Co., Ltd",Industry,Octohydroaminoacridine Succinate Tablets,Drug
NCT00208819,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-13,,,2013-11-12,2005-09-13,2005-09-21,Estimate,,,,,,,2013-11-12,2013-11-13,Estimate,September 2003,,2003-09-30,November 2013,2013-11-30,July 2007,Actual,2007-07-31,,,,,Interventional,,,A Comparison of Two Standard Therapies in the Management of Dementia With Agitation,"Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies",Completed,,Phase 4,50.0,Anticipated,Emory University,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:47:41.232383,2020-02-01 21:47:41.232383,Emory University,Other,olanzapine,Drug
NCT00015548,"ClinicalTrials.gov processed this data on January 31, 2020",2001-04-20,,,2015-06-16,2001-04-21,2001-04-23,Estimate,,,,,,,2015-06-16,2015-06-17,Estimate,March 2001,,2001-03-31,February 2009,2009-02-28,October 2004,,2004-10-31,,,,,Interventional,,,CATIE-Alzheimer's Disease Trial,Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial),Completed,,N/A,450.0,,National Institute of Mental Health (NIMH),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:23.664098,2020-02-01 22:48:23.664098,National Institute of Mental Health (NIMH),NIH,Olanzapine,Drug
NCT00245206,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-25,,,2018-12-13,2005-10-25,2005-10-27,Estimate,,,,,,,2018-12-13,2018-12-17,Actual,August 2005,,2005-08-31,December 2018,2018-12-31,October 2010,Actual,2010-10-31,October 2010,Actual,2010-10-31,,Interventional,,,Side Effects of Newer Antipsychotics in Older Adults,Metabolic Effects of Newer Antipsychotics in Older Patients,Completed,,Phase 4,406.0,Actual,Veterans Medical Research Foundation,,3.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 21:39:57.227437,2020-02-01 21:39:57.227437,Veterans Medical Research Foundation,Other,Olanzapine,Drug
NCT00083421,"ClinicalTrials.gov processed this data on January 31, 2020",2004-05-24,,,2012-06-12,2004-06-17,2004-06-18,Estimate,,,,,,,2012-06-12,2012-06-13,Estimate,June 2004,,2004-06-30,June 2012,2012-06-30,July 2007,Actual,2007-07-31,,,,,Interventional,,,Effects of ONO-2506PO in Patients With Alzheimer's Disease,Effects of ONO-2506PO in Patients With Alzheimer's Disease,Completed,,Phase 2,647.0,Actual,Ono Pharmaceutical Co. Ltd,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:24:27.296809,2020-02-01 22:24:27.296809,Ono Pharma USA Inc,Industry,ONO-2506PO,Drug
NCT01324518,"ClinicalTrials.gov processed this data on January 31, 2020",2011-03-24,,,2014-10-20,2011-03-25,2011-03-29,Estimate,,,,,,,2014-10-20,2014-10-21,Estimate,April 2011,,2011-04-30,October 2014,2014-10-31,October 2012,Actual,2012-10-31,September 2012,Actual,2012-09-30,,Interventional,ALPO,,Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease,Safety and Efficacy of ORM-12741 on Cognitive and Behavioral Symptoms in Patients With Alzheimer's Disease,Completed,,Phase 2,100.0,Actual,"Orion Corporation, Orion Pharma",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:16:14.110927,2020-02-01 16:16:14.110927,"Orion Corporation, Orion Pharma",Industry,ORM-12741,Drug
NCT02471196,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-08,,,2018-02-14,2015-06-12,2015-06-15,Estimate,,,,,,,2018-02-14,2018-02-15,Actual,"August 14, 2015",Actual,2015-08-14,February 2018,2018-02-28,"December 4, 2017",Actual,2017-12-04,"October 9, 2017",Actual,2017-10-09,,Interventional,Nebula,,Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease,"Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Patients With Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study of 12 Weeks",Completed,,Phase 2,308.0,Actual,"Orion Corporation, Orion Pharma",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:28:13.264712,2020-02-01 11:28:13.264712,"Orion Corporation, Orion Pharma",Industry,ORM-12741,Drug
NCT03867253,"ClinicalTrials.gov processed this data on January 31, 2020",2019-02-20,,,2019-12-02,2019-03-06,2019-03-07,Actual,,,,,,,2019-12-02,2019-12-03,Actual,"May 16, 2019",Actual,2019-05-16,November 2019,2019-11-30,"November 15, 2020",Anticipated,2020-11-15,"November 15, 2020",Anticipated,2020-11-15,,Interventional,ETHERAL-US,,Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease,"A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease",Recruiting,,Phase 2,33.0,Anticipated,Oryzon Genomics S.A.,,3.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 07:14:13.743720,2020-02-01 07:14:13.743720,Oryzon Genomics S.A.,Industry,ORY-2001 High dose,Drug
NCT03867253,"ClinicalTrials.gov processed this data on January 31, 2020",2019-02-20,,,2019-12-02,2019-03-06,2019-03-07,Actual,,,,,,,2019-12-02,2019-12-03,Actual,"May 16, 2019",Actual,2019-05-16,November 2019,2019-11-30,"November 15, 2020",Anticipated,2020-11-15,"November 15, 2020",Anticipated,2020-11-15,,Interventional,ETHERAL-US,,Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease,"A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease",Recruiting,,Phase 2,33.0,Anticipated,Oryzon Genomics S.A.,,3.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 07:14:13.743720,2020-02-01 07:14:13.743720,Oryzon Genomics S.A.,Industry,ORY-2001 Low dose,Drug
NCT02593318,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-08,,,2018-10-09,2015-10-30,2015-11-01,Estimate,,,,,,,2018-10-09,2018-10-12,Actual,October 2015,,2015-10-31,October 2018,2018-10-31,September 2018,Actual,2018-09-30,September 2018,Actual,2018-09-30,,Interventional,TOAD,,Trial of Oxaloacetate in Alzheimer's Disease (TOAD),Trial of Oxaloacetate in Alzheimer's Disease (TOAD),Completed,,Phase 1,30.0,Actual,University of Kansas Medical Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 10:59:57.546308,2020-02-01 10:59:57.546308,"Russell Swerdlow, MD",Other,Oxaloacetate (OAA),Drug
NCT00391833,"ClinicalTrials.gov processed this data on January 31, 2020",2006-10-22,,,2006-10-22,2006-10-22,2006-10-24,Estimate,,,,,,,2006-10-22,2006-10-24,Estimate,April 2004,,2004-04-30,October 2006,2006-10-31,October 2005,,2005-10-31,,,,,Interventional,,,Effect of Panax Ginseng on the Cognitive Performance in Alzheimer’s Disease,,Completed,,Phase 1/Phase 2,,,Seoul National University Hospital,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:58:57.936337,2020-02-01 20:58:57.936337,Seoul National University Hospital,Other,Panax Ginseng,Drug
NCT01454453,"ClinicalTrials.gov processed this data on January 31, 2020",2011-10-12,,,2017-04-18,2011-10-17,2011-10-19,Estimate,,,,,,,2017-04-18,2017-04-19,Actual,May 2012,,2012-05-31,April 2017,2017-04-30,July 2015,Actual,2015-07-31,July 2015,Actual,2015-07-31,,Interventional,,,Optimisation of Antipsychotic Drug Use in Older People,"Rationalisation of Antipsychotic Drug Use in Older People, Using [18F]-Fallypride PET",Terminated,,Phase 4,64.0,Actual,"Institute of Psychiatry, London",,1.0,,Failure to recruit people with very late onset schizophrenia like psychosis,False,,,,False,,,,,,,,,,,No,,2020-02-01 15:41:32.198305,2020-02-01 15:41:32.198305,"Institute of Psychiatry, London",Other,Patients- dose titration,Drug
NCT00684710,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-23,,,2009-01-28,2008-05-27,2008-05-28,Estimate,,,,,,,2009-01-28,2009-01-30,Estimate,April 2008,,2008-04-30,January 2009,2009-01-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,"Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects","Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of PAZ 417 Administered Orally to Healthy Young Japanese Male and Healthy Elderly Japanese Male Subjects",Completed,,Phase 1,56.0,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:28:29.702780,2020-02-01 19:28:29.702780,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,PAZ-417,Drug
NCT00471211,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-08,,,2008-01-13,2007-05-08,2007-05-09,Estimate,,,,,,,2008-01-13,2008-01-16,Estimate,December 2006,,2006-12-31,January 2008,2008-01-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,"Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease","A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Three-Group Study to Assess the Safety, Tolerability and Efficacy of Two Dose Levels of PBT2 to Slow Progression of Disease in Patients With Early Alzheimer's Disease",Completed,,Phase 2,80.0,Anticipated,Prana Biotechnology Limited,,,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:33:12.418997,2020-02-01 20:33:12.418997,Prana Biotechnology Limited,Industry,PBT2,Drug
NCT02085265,"ClinicalTrials.gov processed this data on January 31, 2020",2013-11-29,,,2017-11-23,2014-03-10,2014-03-12,Estimate,,,,,,,2017-11-23,2017-11-27,Actual,March 2014,,2014-03-31,November 2017,2017-11-30,March 2021,Anticipated,2021-03-31,March 2020,Anticipated,2020-03-31,,Interventional,SARTAN-AD,,Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients,"The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients",Recruiting,,Phase 2,240.0,Anticipated,Sunnybrook Health Sciences Centre,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 12:57:20.821541,2020-02-01 12:57:20.821541,Sunnybrook Health Sciences Centre,Other,Perindopril,Drug
NCT00009204,"ClinicalTrials.gov processed this data on January 31, 2020",2001-01-23,,,2017-06-14,2001-01-23,2001-01-24,Estimate,,,,,,,2017-06-14,2017-06-16,Actual,September 1995,,1995-09-30,June 2017,2017-06-30,April 2002,Actual,2002-04-30,April 2000,Actual,2000-04-30,,Interventional,SPAD,,Serotonergic Pharmacotherapy for Agitation of Dementia,Serotonergic Pharmacotherapy for Agitation of Dementia,Completed,,Phase 3,,,University of Pittsburgh,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:44.953490,2020-02-01 22:48:44.953490,Bruce Pollock,Other,Perphenazine [Trilafon],Drug
NCT01066481,"ClinicalTrials.gov processed this data on January 31, 2020",2010-02-09,,,2010-06-28,2010-02-09,2010-02-10,Estimate,,,,,,,2010-06-28,2010-06-29,Estimate,April 2010,,2010-04-30,June 2010,2010-06-30,April 2012,Anticipated,2012-04-30,March 2012,Anticipated,2012-03-31,,Interventional,,,A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease,"A Phase 2, Multi-Center, Double-Blinded, Placebo-Controlled Safety And Efficacy Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease",Withdrawn,,Phase 2,0.0,Actual,Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:31:59.842008,2020-02-01 17:31:59.842008,Pfizer,Industry,PF-01913539 5 mg,Drug
NCT01028911,"ClinicalTrials.gov processed this data on January 31, 2020",2009-12-07,2014-04-09,,2014-05-16,2009-12-08,2009-12-09,Estimate,2014-05-16,2014-06-04,Estimate,,,,2014-05-16,2014-06-04,Estimate,December 2009,,2009-12-31,May 2014,2014-05-31,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,Safety population included all participants who took at least 1 dose of study drug.,"A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease","A Phase 1, Double-Blind, Placebo-Controlled, Sponsor-Open, Randomized, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-03654746 in Mild to Moderate Alzheimer's Disease Patients on Stable Donepezil Therapy",Terminated,,Phase 1,9.0,Actual,Pfizer,The study was terminated early due to slow recruitment and the need to use the existing information to determine dosing for another study.,2.0,,"This study terminated 27Apr2010 due to slow recruitment and the need to use the existing
    information to determine dosing for another study.",False,,,,False,,,,,,,,,,,,,2020-02-01 17:42:14.368255,2020-02-01 17:42:14.368255,Pfizer,Industry,PF-03654746,Drug
NCT00930059,"ClinicalTrials.gov processed this data on January 31, 2020",2009-06-29,,2013-04-09,2013-04-09,2009-06-29,2009-06-30,Estimate,,,,2013-04-09,2013-04-16,Estimate,2013-04-09,2013-04-16,Estimate,September 2009,,2009-09-30,April 2013,2013-04-30,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease,"A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study Of PF-04447943 In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,198.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:16:09.262269,2020-02-01 18:16:09.262269,Pfizer,Industry,PF-04447943,Drug
NCT00988598,"ClinicalTrials.gov processed this data on January 31, 2020",2009-10-01,,,2010-08-05,2009-10-01,2009-10-02,Estimate,,,,,,,2010-08-05,2010-08-09,Estimate,October 2009,,2009-10-31,August 2010,2010-08-31,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,"A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease","A Phase 1, Double-Blind, Placebo-Controlled, Sponsor Open, Randomized, Multiple Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04447943 In Mild To Moderate Alzheimer's Disease Subjects On Stable Donepezil Therapy",Completed,,Phase 1,15.0,Actual,Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:55:55.298687,2020-02-01 17:55:55.298687,Pfizer,Industry,PF-04447943,Drug
NCT00566397,"ClinicalTrials.gov processed this data on January 31, 2020",2007-11-29,,2013-03-19,2018-11-28,2007-11-29,2007-12-03,Estimate,,,,2013-03-19,2013-03-25,Estimate,2018-11-28,2018-11-30,Actual,December 2007,,2007-12-31,November 2018,2018-11-30,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,,,A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease,"A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,402.0,Actual,Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:02:38.629333,2020-02-01 20:02:38.629333,Pfizer,Industry,PF-04494700,Drug
NCT00141661,"ClinicalTrials.gov processed this data on January 31, 2020",2005-08-30,,,2009-08-19,2005-08-30,2005-09-01,Estimate,,,,,,,2009-08-19,2009-08-20,Estimate,October 2005,,2005-10-31,August 2009,2009-08-31,June 2006,Actual,2006-06-30,June 2006,Actual,2006-06-30,,Interventional,,,A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients,"A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700",Completed,,Phase 2,67.0,Actual,Pfizer,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 22:05:05.719845,2020-02-01 22:05:05.719845,Pfizer,Industry,PF-04494700 - High Dose Arm,Drug
NCT00141661,"ClinicalTrials.gov processed this data on January 31, 2020",2005-08-30,,,2009-08-19,2005-08-30,2005-09-01,Estimate,,,,,,,2009-08-19,2009-08-20,Estimate,October 2005,,2005-10-31,August 2009,2009-08-31,June 2006,Actual,2006-06-30,June 2006,Actual,2006-06-30,,Interventional,,,A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients,"A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700",Completed,,Phase 2,67.0,Actual,Pfizer,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 22:05:05.719845,2020-02-01 22:05:05.719845,Pfizer,Industry,PF-04494700 - Low Dose Arm,Drug
NCT01712074,"ClinicalTrials.gov processed this data on January 31, 2020",2012-10-19,2016-08-26,,2017-01-30,2012-10-19,2012-10-23,Estimate,2017-01-30,2017-03-20,Actual,,,,2017-01-30,2017-03-20,Actual,November 2012,,2012-11-30,January 2017,2017-01-31,September 2015,Actual,2015-09-30,September 2015,Actual,2015-09-30,,Interventional,,One (1) of participant randomized but not treated appeared under placebo run-in including his/her discontinued and safety information,Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil,"A Randomized, 18-week, Placebo-controlled, Double-blind, Parallel Group Study Of The Safety And Efficacy Of Pf-05212377 (Sam-760) In Subjects With Mild-to-moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donepezil",Terminated,,Phase 2,186.0,Actual,Pfizer,,2.0,,"The study was terminated October 23, 2015 as pre-specified, interim analysis futility criteria
    were met. The termination was not due to safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 14:35:19.013899,2020-02-01 14:35:19.013899,Pfizer,Industry,PF-05212377 (SAM-760),Drug
NCT02380573,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-24,,,2019-05-06,2015-02-27,2015-03-05,Estimate,,,,,,,2019-05-06,2019-05-08,Actual,July 2015,,2015-07-31,April 2019,2019-04-30,July 2023,Anticipated,2023-07-31,July 2022,Anticipated,2022-07-31,,Interventional,MB2,,"Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease","Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease",Suspended,,Phase 2,117.0,Actual,The University of Texas Health Science Center at San Antonio,,8.0,,Pending enrollment of new subjects if new funding obtained,False,,,,True,,,,,,,,,,,,,2020-02-01 11:48:30.714225,2020-02-01 11:48:30.714225,The University of Texas Health Science Center at San Antonio,Other,Phenazopyridine hydrochloride,Drug
NCT03118947,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-12,,,2019-05-30,2017-04-17,2017-04-18,Actual,,,,,,,2019-05-30,2019-05-31,Actual,"February 23, 2017",Actual,2017-02-23,May 2019,2019-05-31,"February 25, 2019",Actual,2019-02-25,"February 25, 2019",Actual,2019-02-25,,Interventional,,,A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease,A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease,Completed,,Phase 2,79.0,Actual,ACADIA Pharmaceuticals Inc.,,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 09:15:55.025965,2020-02-01 09:15:55.025965,ACADIA Pharmaceuticals Inc.,Industry,Pimavanserin,Drug
NCT02992132,"ClinicalTrials.gov processed this data on January 31, 2020",2016-12-12,2019-01-25,,2019-03-07,2016-12-13,2016-12-14,Estimate,2019-03-07,2019-03-28,Actual,,,,2019-03-07,2019-03-28,Actual,November 2016,,2016-11-30,March 2019,2019-03-31,"February 16, 2018",Actual,2018-02-16,"January 25, 2018",Actual,2018-01-25,,Interventional,,All patients randomized,Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE),"A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease",Terminated,,Phase 2,111.0,Actual,ACADIA Pharmaceuticals Inc.,"The original study (n=432) was powered to detect a treatment effect on CMAI, however recruitment was discontinued early for business reasons and amended accordingly The final study (n=111) was no longer adequately powered to detect a treatment effect",3.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:38:59.986951,2020-02-01 09:38:59.986951,ACADIA Pharmaceuticals Inc.,Industry,Pimavanserin 20 mg,Drug
NCT02992132,"ClinicalTrials.gov processed this data on January 31, 2020",2016-12-12,2019-01-25,,2019-03-07,2016-12-13,2016-12-14,Estimate,2019-03-07,2019-03-28,Actual,,,,2019-03-07,2019-03-28,Actual,November 2016,,2016-11-30,March 2019,2019-03-31,"February 16, 2018",Actual,2018-02-16,"January 25, 2018",Actual,2018-01-25,,Interventional,,All patients randomized,Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE),"A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease",Terminated,,Phase 2,111.0,Actual,ACADIA Pharmaceuticals Inc.,"The original study (n=432) was powered to detect a treatment effect on CMAI, however recruitment was discontinued early for business reasons and amended accordingly The final study (n=111) was no longer adequately powered to detect a treatment effect",3.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:38:59.986951,2020-02-01 09:38:59.986951,ACADIA Pharmaceuticals Inc.,Industry,Pimavanserin 34 mg,Drug
NCT02035553,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-13,2017-09-28,,2017-09-28,2014-01-13,2014-01-14,Estimate,2017-09-28,2017-10-25,Actual,,,,2017-09-28,2017-10-25,Actual,November 2013,,2013-11-30,September 2017,2017-09-30,"October 27, 2016",Actual,2016-10-27,"September 28, 2016",Actual,2016-09-28,,Interventional,,,A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis,"A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease",Completed,,Phase 2,181.0,Actual,ACADIA Pharmaceuticals Inc.,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:09:51.019135,2020-02-01 13:09:51.019135,ACADIA Pharmaceuticals Inc.,Industry,Pimavanserin tartrate,Drug
NCT00982202,"ClinicalTrials.gov processed this data on January 31, 2020",2009-09-22,,,2009-09-22,2009-09-22,2009-09-23,Estimate,,,,,,,2009-09-22,2009-09-23,Estimate,January 2002,,2002-01-31,September 2009,2009-09-30,January 2005,Actual,2005-01-31,January 2005,Actual,2005-01-31,,Interventional,,,Pioglitazone in Alzheimer Disease,Pioglitazone in Alzheimer Disease Progression,Completed,,Phase 2,25.0,Actual,National Institute on Aging (NIA),,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:59:55.966871,2020-02-01 17:59:55.966871,National Institute on Aging (NIA),NIH,pioglitazone,Drug
NCT01931566,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-26,2019-07-22,,2019-08-29,2013-08-26,2013-08-29,Estimate,2019-07-22,2019-08-14,Actual,,,,2019-08-29,2019-09-16,Actual,"August 1, 2013",Actual,2013-08-01,August 2019,2019-08-31,"September 6, 2018",Actual,2018-09-06,"July 24, 2018",Actual,2018-07-24,,Interventional,TOMMORROW,Randomized Set included all participants who were randomized in the study.,Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset,"A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects",Terminated,,Phase 3,3494.0,Actual,Takeda,,3.0,,Lack of efficacy of the drug; no safety concern,False,,,,True,,,,,,,,,,,Yes,"Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.",2020-02-01 13:37:58.521166,2020-02-01 13:37:58.521166,Takeda,Industry,Pioglitazone,Drug
NCT02284906,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-04,2019-05-07,,2019-06-11,2014-11-04,2014-11-06,Estimate,2019-06-11,2019-07-02,Actual,,,,2019-06-11,2019-07-02,Actual,"February 12, 2015",Actual,2015-02-12,June 2019,2019-06-30,"May 8, 2018",Actual,2018-05-08,"January 31, 2018",Actual,2018-01-31,,Interventional,,Safety analysis set included all participants who received at least 1 dose of blinded study medication.,AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease,A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease,Terminated,,Phase 3,40.0,Actual,Takeda,,2.0,,Lack of efficacy of the drug; no safety concern,False,,,,True,True,,,,,,,,,,Yes,"Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.",2020-02-01 12:10:02.597766,2020-02-01 12:10:02.597766,Takeda,Industry,Pioglitazone,Drug
NCT01931566,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-26,2019-07-22,,2019-08-29,2013-08-26,2013-08-29,Estimate,2019-07-22,2019-08-14,Actual,,,,2019-08-29,2019-09-16,Actual,"August 1, 2013",Actual,2013-08-01,August 2019,2019-08-31,"September 6, 2018",Actual,2018-09-06,"July 24, 2018",Actual,2018-07-24,,Interventional,TOMMORROW,Randomized Set included all participants who were randomized in the study.,Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset,"A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects",Terminated,,Phase 3,3494.0,Actual,Takeda,,3.0,,Lack of efficacy of the drug; no safety concern,False,,,,True,,,,,,,,,,,Yes,"Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.",2020-02-01 13:37:58.521166,2020-02-01 13:37:58.521166,Takeda,Industry,Pioglitazone placebo,Drug
NCT02615002,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-18,,,2019-08-20,2015-11-22,2015-11-25,Estimate,,,,,,,2019-08-20,2019-08-21,Actual,November 2015,,2015-11-30,August 2019,2019-08-31,"November 30, 2019",Anticipated,2019-11-30,November 2019,Anticipated,2019-11-30,,Interventional,,,Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION),"Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease","Active, not recruiting",,Phase 2,500.0,Anticipated,Neurim Pharmaceuticals Ltd.,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 10:55:14.266636,2020-02-01 10:55:14.266636,Neurim Pharmaceuticals Ltd.,Industry,Piromelatine,Drug
NCT00548145,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-22,2011-12-28,,2012-05-14,2007-10-22,2007-10-23,Estimate,2012-05-14,2012-06-14,Estimate,,,,2012-05-14,2012-06-14,Estimate,November 2007,,2007-11-30,May 2012,2012-05-31,March 2012,Actual,2012-03-31,October 2011,Actual,2011-10-31,,Interventional,PIT-ROAD,,The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease,,Terminated,,N/A,38.0,Actual,Osaka University,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:09:00.633969,2020-02-01 20:09:00.633969,Osaka University,Other,Pitavastatin,Drug
NCT00191009,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-12,,,2007-11-05,2005-09-12,2005-09-19,Estimate,,,,,,,2007-11-05,2007-11-06,Estimate,October 2003,,2003-10-31,November 2007,2007-11-30,January 2006,Actual,2006-01-31,,,,,Interventional,,,Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease,Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer's Disease,Completed,,Phase 2/Phase 3,124.0,,Eli Lilly and Company,,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:51:38.399108,2020-02-01 21:51:38.399108,Eli Lilly and Company,Industry,placebo,Drug
NCT00469456,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-02,2009-11-03,,2009-12-21,2007-05-03,2007-05-04,Estimate,2009-11-03,2009-12-07,Estimate,,,,2009-12-21,2009-12-24,Estimate,April 2007,,2007-04-30,December 2009,2009-12-31,November 2008,Actual,2008-11-30,November 2008,Actual,2008-11-30,,Interventional,,,Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy of Memantine on Functional Communication in Patients With Alzheimer's Disease (AD)",Completed,,Phase 4,265.0,Actual,Forest Laboratories,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:33:36.860090,2020-02-01 20:33:36.860090,Forest Laboratories,Industry,placebo,Drug
NCT00555204,"ClinicalTrials.gov processed this data on January 31, 2020",2007-11-07,,2011-08-19,2011-08-19,2007-11-07,2007-11-08,Estimate,,,,2011-08-19,2011-08-23,Estimate,2011-08-19,2011-08-23,Estimate,November 2007,,2007-11-30,August 2011,2011-08-31,,,,June 2009,Actual,2009-06-30,,Interventional,,,Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of ABT-089 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",Terminated,,Phase 2,337.0,Actual,Abbott,,7.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:06:30.241600,2020-02-01 20:06:30.241600,Abbott,Industry,placebo,Drug
NCT00602680,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-16,,,2009-07-17,2008-01-16,2008-01-28,Estimate,,,,,,,2009-07-17,2009-07-20,Estimate,January 2008,,2008-01-31,July 2009,2009-07-31,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,,,Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease,"A Multicenter, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance and Safety/Tolerability of SSR180711C for 4 Weeks, Using Donepezil as Calibrator, in Patients With Mild Alzheimer's Disease",Terminated,,Phase 2,1.0,Actual,Sanofi,,5.0,,Insufficient expected benefit risk,False,,,,True,,,,,,,,,,,,,2020-02-01 19:52:44.951641,2020-02-01 19:52:44.951641,Sanofi,Industry,placebo,Drug
NCT00663026,"ClinicalTrials.gov processed this data on January 31, 2020",2008-04-17,2013-09-11,2012-03-27,2013-09-11,2008-04-19,2008-04-21,Estimate,2013-09-11,2013-11-15,Estimate,2012-03-27,2012-03-30,Estimate,2013-09-11,2013-11-15,Estimate,November 2008,,2008-11-30,September 2013,2013-09-30,October 2010,Actual,2010-10-31,October 2010,Actual,2010-10-31,,Interventional,,,Study Evaluating Bapineuzumab In Alzheimer Disease Subjects,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Safety, Tolerability, Reactogenicity, And Pharmacokinetic Study Of Bapineuzumab (AAB 001) Administered Subcutaneously In Subjects With Mild To Moderate AD",Completed,,Phase 2,79.0,Actual,Pfizer,"Designation of outcomes as primary, secondary was based on study team’s input as study did not specify them as primary or secondary.",3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:34:44.032122,2020-02-01 19:34:44.032122,Pfizer,Industry,placebo,Drug
NCT00667810,"ClinicalTrials.gov processed this data on January 31, 2020",2008-04-24,2013-10-22,,2015-12-04,2008-04-25,2008-04-28,Estimate,2015-12-04,2016-01-08,Estimate,,,,2015-12-04,2016-01-08,Estimate,June 2008,,2008-06-30,December 2015,2015-12-31,August 2013,Actual,2013-08-31,October 2012,Actual,2012-10-31,,Interventional,,Safety population included all randomized participants who received at least one infusion or portion of an infusion of study drug.,Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients,"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers",Terminated,,Phase 3,901.0,Actual,Pfizer,"The impact of study termination, the shorter observational periods and the resulting small sample size coupled with not having enough participants with post baseline assessments for various reasons were limiting factors for data interpretation.",3.0,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 19:33:15.927565,2020-02-01 19:33:15.927565,Pfizer,Industry,placebo,Drug
NCT00676143,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-02,2013-10-14,,2016-05-03,2008-05-09,2008-05-12,Estimate,2016-05-03,2016-06-10,Estimate,,,,2016-05-03,2016-06-10,Estimate,January 2008,,2008-01-31,May 2016,2016-05-31,November 2012,Actual,2012-11-30,October 2012,Actual,2012-10-31,,Interventional,,Safety population included all randomized participants who received at least one infusion or portion of an infusion of study drug.,Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients,"A Phase Iii, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy And Safety Trial Of Bapineuzumab (Aab 001, Eln115727) In Subjects With Mild To Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Carriers",Terminated,,Phase 3,1100.0,Actual,Pfizer,,2.0,,"The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical
    benefit. This decision was not based on any new safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 19:31:07.517307,2020-02-01 19:31:07.517307,Pfizer,Industry,placebo,Drug
NCT00702780,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-15,2014-04-10,,2014-05-13,2008-06-18,2008-06-20,Estimate,2014-05-13,2014-06-13,Estimate,,,,2014-05-13,2014-06-13,Estimate,November 2008,,2008-11-30,May 2014,2014-05-31,September 2011,Actual,2011-09-30,September 2011,Actual,2011-09-30,,Interventional,ESAD,,Progression Delaying Effect of Escitalopram in Alzheimer's Disease,"Multi-center, Randomized, Placebo-controlled, Double-blind Clinical Trial of Escitalopram on the Progression Delaying Effect in Alzheimer's Disease",Completed,,N/A,74.0,Actual,Seoul National University Hospital,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:23:05.471913,2020-02-01 19:23:05.471913,Seoul National University Hospital,Other,placebo,Drug
NCT00715858,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-11,,,2009-02-03,2008-07-11,2008-07-15,Estimate,,,,,,,2009-02-03,2009-02-04,Estimate,May 2008,,2008-05-31,February 2009,2009-02-28,October 2009,Anticipated,2009-10-31,August 2009,Anticipated,2009-08-31,,Interventional,,,A Pilot Study of Inflammatory Markers in Alzheimer's Disease,A Pilot Study Comparing Inflammatory Biomarkers in Blood and CSF in Patients With Alzheimer's Disease and Age-Matched Controls,Unknown status,Recruiting,Phase 3,21.0,Anticipated,McMaster University,,5.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:19:02.908370,2020-02-01 19:19:02.908370,McMaster University,Other,placebo,Drug
NCT00719394,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-17,,,2009-07-08,2008-07-18,2008-07-21,Estimate,,,,,,,2009-07-08,2009-07-10,Estimate,March 2008,,2008-03-31,July 2009,2009-07-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males,"Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-136 Administered Orally to Healthy Japanese Male Subjects and Healthy Japanese Elderly Male Subjects",Completed,,Phase 1,72.0,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:17:48.931302,2020-02-01 19:17:48.931302,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,placebo,Drug
NCT00726115,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-28,,,2009-07-29,2008-07-30,2008-07-31,Estimate,,,,,,,2009-07-29,2009-07-30,Estimate,August 2008,,2008-08-31,July 2009,2009-07-31,February 2009,Actual,2009-02-28,February 2009,Actual,2009-02-28,,Interventional,,,"Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531","Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Dose of SAM-531 Administered Orally To Healthy Young and Elderly Subjects",Completed,,Phase 1,56.0,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:15:48.399246,2020-02-01 19:15:48.399246,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,placebo,Drug
NCT00736775,"ClinicalTrials.gov processed this data on January 31, 2020",2008-08-15,,,2010-10-26,2008-08-15,2008-08-18,Estimate,,,,,,,2010-10-26,2010-10-27,Estimate,August 2008,,2008-08-31,October 2010,2010-10-31,,,,May 2010,Actual,2010-05-31,,Interventional,,,"A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease","A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MABT5102A Administered in a Single-Dose, Dose-Escalation Stage Followed by a Multidose, Parallel-Treatment Stage in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,56.0,Actual,"Genentech, Inc.",,,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:12:36.840794,2020-02-01 19:12:36.840794,"Genentech, Inc.",Industry,placebo,Drug
NCT00898807,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-11,2014-03-19,,2014-06-26,2009-05-11,2009-05-12,Estimate,2014-06-26,2014-06-27,Estimate,,,,2014-06-26,2014-06-27,Estimate,July 2009,,2009-07-31,June 2014,2014-06-30,September 2013,Actual,2013-09-30,September 2013,Actual,2013-09-30,,Interventional,CitAD,,Citalopram for Agitation in Alzheimer's Disease,A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease,Completed,,Phase 3,186.0,Actual,JHSPH Center for Clinical Trials,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:25:13.871439,2020-02-01 18:25:13.871439,JHSPH Center for Clinical Trials,Other,placebo,Drug
NCT00945672,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-22,,2016-04-08,2016-04-08,2009-07-23,2009-07-24,Estimate,,,,2016-04-08,2016-05-05,Estimate,2016-04-08,2016-05-05,Estimate,August 2009,,2009-08-31,June 2011,2011-06-30,June 2011,Actual,2011-06-30,June 2011,Actual,2011-06-30,,Interventional,,,A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease,"A Phase 2 Double-Blinded, Randomized, Placebo-Controlled, Multicenter Study Evaluating The Safety, Tolerability And Pharmacokinetics/ Pharmacodynamics Of PF-04360365 In Mild To Moderate Alzheimer's Disease Patients",Completed,,Phase 2,36.0,Actual,Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:11:25.195262,2020-02-01 18:11:25.195262,Pfizer,Industry,placebo,Drug
NCT00976118,"ClinicalTrials.gov processed this data on January 31, 2020",2009-09-11,,,2018-12-12,2009-09-11,2009-09-14,Estimate,,,,,,,2018-12-12,2018-12-13,Actual,February 2006,,2006-02-28,December 2018,2018-12-31,February 2009,Actual,2009-02-28,July 2008,Actual,2008-07-31,,Interventional,,,Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease,"A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adults Patients With Mild to Moderate Alzheimer-type Disease.",Completed,,Phase 2,34.0,Actual,AB Science,,2.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 18:02:06.818140,2020-02-01 18:02:06.818140,AB Science,Industry,placebo,Drug
NCT01018875,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-20,,2012-02-01,2018-06-01,2009-11-23,2009-11-24,Estimate,,,,2012-02-01,2012-02-03,Estimate,2018-06-01,2018-06-06,Actual,December 2009,,2009-12-31,January 2013,2013-01-31,February 2011,Actual,2011-02-28,February 2011,Actual,2011-02-28,,Interventional,,,Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Active- and Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 2,242.0,Actual,AbbVie,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:45:00.201179,2020-02-01 17:45:00.201179,"AbbVie (prior sponsor, Abbott)",Industry,placebo,Drug
NCT01047254,"ClinicalTrials.gov processed this data on January 31, 2020",2010-01-11,,,2017-05-08,2010-01-11,2010-01-12,Estimate,,,,,,,2017-05-08,2017-05-09,Actual,January 2010,,2010-01-31,May 2017,2017-05-31,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,APA-AD,,Bupropion for the Treatment of Apathy in Alzheimer's Dementia,"A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Bupropion for the Treatment of Apathy in Alzheimer's Dementia(Apa-AD)",Completed,,Phase 3,110.0,Actual,"University Hospital, Bonn",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:37:20.131108,2020-02-01 17:37:20.131108,"University Hospital, Bonn",Other,placebo,Drug
NCT01117181,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-04,2013-02-11,,2018-06-07,2010-05-04,2010-05-05,Estimate,2013-04-01,2013-05-10,Estimate,,,,2018-06-07,2018-06-12,Actual,June 2010,,2010-06-30,June 2018,2018-06-30,August 2012,Actual,2012-08-31,August 2012,Actual,2012-08-31,,Interventional,ADMET,,Apathy in Dementia Methylphenidate Trial (ADMET),Apathy in Dementia Methylphenidate Trial (ADMET),Completed,,Phase 2,60.0,Actual,Johns Hopkins Bloomberg School of Public Health,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:17:32.212260,2020-02-01 17:17:32.212260,Johns Hopkins Bloomberg School of Public Health,Other,placebo,Drug
NCT01137526,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-07,,2012-07-20,2013-01-24,2010-06-03,2010-06-04,Estimate,,,,2012-07-20,2012-07-27,Estimate,2013-01-24,2013-01-29,Estimate,May 2010,,2010-05-31,January 2013,2013-01-31,July 2011,Actual,2011-07-31,July 2011,Actual,2011-07-31,,Interventional,,,Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 2,267.0,Actual,AbbVie,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:11:16.177593,2020-02-01 17:11:16.177593,"AbbVie (prior sponsor, Abbott)",Industry,placebo,Drug
NCT01137799,"ClinicalTrials.gov processed this data on January 31, 2020",2010-06-03,,,2012-11-07,2010-06-03,2010-06-04,Estimate,,,,,,,2012-11-07,2012-11-08,Estimate,August 2009,,2009-08-31,November 2012,2012-11-30,March 2011,Actual,2011-03-31,,,,,Interventional,,,The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients,"A Double-Blind, Placebo-Controlled, Randomized, Four-Way Cross-Over Study To Investigate Effect Of Single Oral Doses Of JNJ-39393406 On Event-Related Potentials In Subjects With Stable Schizophrenia",Terminated,,Phase 1,47.0,Actual,"Janssen Pharmaceutica N.V., Belgium",,6.0,,Efficacy signals were insufficiently strong to justify recruitment of additional patients.,False,,,,False,,,,,,,,,,,,,2020-02-01 17:11:10.402638,2020-02-01 17:11:10.402638,"Janssen Pharmaceutica N.V., Belgium",Industry,placebo,Drug
NCT01221259,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-13,,,2013-05-20,2010-10-13,2010-10-14,Estimate,,,,,,,2013-05-20,2013-05-22,Estimate,January 2010,,2010-01-31,February 2013,2013-02-28,November 2012,Actual,2012-11-30,October 2011,Actual,2011-10-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects","A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects",Completed,,Phase 1,60.0,Actual,Eisai Inc.,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:46:00.362394,2020-02-01 16:46:00.362394,Eisai Inc.,Industry,placebo,Drug
NCT01255046,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-03,,,2014-08-19,2010-12-05,2010-12-07,Estimate,,,,,,,2014-08-19,2014-08-20,Estimate,December 2015,,2015-12-31,August 2014,2014-08-31,,,,December 2018,Anticipated,2018-12-31,,Interventional,,,Study of STA-1 as an Add-on Treatment to Donepezil,"A Phase II Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of STA-1 as an Add-on Treatment to Donepezil in Patients With Mild to Moderate Alzheimer's Disease",Unknown status,Not yet recruiting,Phase 2,136.0,Anticipated,"Sinphar Pharmaceutical Co., Ltd",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:35:48.924341,2020-02-01 16:35:48.924341,"Sinphar Pharmaceutical Co., Ltd",Other,placebo,Drug
NCT01343966,"ClinicalTrials.gov processed this data on January 31, 2020",2011-04-27,,2016-08-10,2017-07-10,2011-04-27,2011-04-28,Estimate,,,,2016-08-10,2016-08-12,Estimate,2017-07-10,2017-07-12,Actual,"April 30, 2011",Actual,2011-04-30,July 2017,2017-07-31,"February 28, 2014",Actual,2014-02-28,"February 28, 2014",Actual,2014-02-28,,Interventional,,,A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY),"A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)",Completed,,Phase 2,448.0,Actual,"Genentech, Inc.",,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 16:10:32.090096,2020-02-01 16:10:32.090096,"Genentech, Inc.",Industry,placebo,Drug
NCT01397578,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-18,,2016-08-10,2017-07-10,2011-07-18,2011-07-19,Estimate,,,,2016-08-10,2016-08-12,Estimate,2017-07-10,2017-07-12,Actual,"August 31, 2011",Actual,2011-08-31,July 2017,2017-07-31,"April 30, 2014",Actual,2014-04-30,"April 30, 2014",Actual,2014-04-30,,Interventional,,,A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,91.0,Actual,"Genentech, Inc.",,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:56:14.154499,2020-02-01 15:56:14.154499,"Genentech, Inc.",Industry,placebo,Drug
NCT01428453,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-01,2017-03-07,2015-04-27,2018-08-07,2011-09-01,2011-09-05,Estimate,2018-08-07,2018-09-24,Actual,2015-04-27,2015-05-13,Estimate,2018-08-07,2018-09-24,Actual,"October 1, 2011",,2011-10-01,July 2017,2017-07-31,"February 18, 2013",Actual,2013-02-18,"February 4, 2013",Actual,2013-02-04,,Interventional,,"The data for ITT population is presented and defined as participants who were randomized, received at least one dose of study medication and had at least one non-missing post Baseline efficacy assessment. One participant from each group was excluded from ITT population as no post-baseline efficacy data available and total ITT population was 121.",A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease,A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) on Biomarkers Related to the Pathogenesis and Progression of Alzheimer's Disease,Completed,,Phase 2,124.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 15:48:59.078910,2020-02-01 15:48:59.078910,GlaxoSmithKline,Industry,placebo,Drug
NCT01527916,"ClinicalTrials.gov processed this data on January 31, 2020",2012-02-03,,2014-11-06,2014-11-06,2012-02-03,2012-02-07,Estimate,,,,2014-11-06,2014-11-19,Estimate,2014-11-06,2014-11-19,Estimate,February 2012,,2012-02-29,November 2014,2014-11-30,November 2013,Actual,2013-11-30,November 2013,Actual,2013-11-30,,Interventional,,,Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,438.0,Actual,AbbVie,,5.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:22:19.770584,2020-02-01 15:22:19.770584,"AbbVie (prior sponsor, Abbott)",Industry,placebo,Drug
NCT01549834,"ClinicalTrials.gov processed this data on January 31, 2020",2012-03-07,,2014-10-24,2014-10-24,2012-03-07,2012-03-09,Estimate,,,,2014-10-24,2014-10-31,Estimate,2014-10-24,2014-10-31,Estimate,March 2012,,2012-03-31,October 2014,2014-10-31,October 2013,Actual,2013-10-31,October 2013,Actual,2013-10-31,,Interventional,,,Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",Completed,,Phase 2,434.0,Actual,AbbVie,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:17:02.274308,2020-02-01 15:17:02.274308,"AbbVie (prior sponsor, Abbott)",Industry,placebo,Drug
NCT01860625,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-15,,,2014-06-27,2013-05-22,2013-05-23,Estimate,,,,,,,2014-06-27,2014-06-30,Estimate,April 2013,,2013-04-30,June 2014,2014-06-30,February 2014,Actual,2014-02-28,December 2013,Actual,2013-12-31,,Interventional,,,"A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects",,Completed,,Phase 1,36.0,Actual,Icure Pharmaceutical Inc.,,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 13:56:59.008525,2020-02-01 13:56:59.008525,Icure Pharmaceutical Inc.,Industry,placebo,Drug
NCT02178124,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-27,,,2015-03-23,2014-06-27,2014-06-30,Estimate,,,,,,,2015-03-23,2015-03-25,Estimate,July 2014,,2014-07-31,March 2015,2015-03-31,December 2014,Actual,2014-12-31,December 2014,Actual,2014-12-31,,Interventional,,,"A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.",,Completed,,Phase 1,24.0,Actual,Icure Pharmaceutical Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:35:08.640851,2020-02-01 12:35:08.640851,Icure Pharmaceutical Inc.,Industry,placebo,Drug
NCT02361424,"ClinicalTrials.gov processed this data on January 31, 2020",2014-12-19,,,2016-02-12,2015-02-06,2015-02-11,Estimate,,,,,,,2016-02-12,2016-02-15,Estimate,February 2013,,2013-02-28,October 2015,2015-10-31,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,PLEODIAL-I,,Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD),First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients,Completed,,Phase 2,47.0,Actual,Pharnext SA,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:52:50.624085,2020-02-01 11:52:50.624085,Pharnext SA,Other,placebo,Drug
NCT03435861,"ClinicalTrials.gov processed this data on January 31, 2020",2017-12-22,,,2018-11-19,2018-02-09,2018-02-19,Actual,,,,,,,2018-11-19,2018-11-21,Actual,"October 8, 2018",Actual,2018-10-08,November 2018,2018-11-30,"January 30, 2021",Anticipated,2021-01-30,"January 30, 2020",Anticipated,2020-01-30,,Interventional,VIP,,Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients,Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients,Recruiting,,Phase 2,40.0,Anticipated,"University Hospital, Toulouse",,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2020-02-01 08:20:44.789272,2020-02-01 08:20:44.789272,"University Hospital, Toulouse",Other,placebo,Drug
NCT00056329,"ClinicalTrials.gov processed this data on January 31, 2020",2003-03-10,,,2012-05-02,2003-03-11,2003-03-12,Estimate,,,,,,,2012-05-02,2012-05-04,Estimate,April 2002,,2002-04-30,May 2012,2012-05-31,May 2012,Anticipated,2012-05-31,May 2012,Anticipated,2012-05-31,,Interventional,,,Vitamin E in Aging Persons With Down Syndrome,Multicenter Vitamin E Trial in Aging Persons With Down Syndrome,Unknown status,"Active, not recruiting",Phase 3,350.0,Actual,New York State Institute for Basic Research,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:35:03.109992,2020-02-01 22:35:03.109992,New York State Institute for Basic Research,Other,Placebo,Drug
NCT00066157,"ClinicalTrials.gov processed this data on January 31, 2020",2003-08-04,,,2018-08-22,2003-08-04,2003-08-05,Estimate,,,,,,,2018-08-22,2018-08-23,Actual,September 2001,,2001-09-30,August 2018,2018-08-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,Alzheimer's Disease: Therapeutic Potential of Estrogen,Alzheimer's Disease: Therapeutic Potential of Estrogen,Completed,,Phase 2/Phase 3,42.0,Actual,"University of Wisconsin, Madison",,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:32:28.672051,2020-02-01 22:32:28.672051,"University of Wisconsin, Madison",Other,Placebo,Drug
NCT00071721,"ClinicalTrials.gov processed this data on January 31, 2020",2003-10-29,2010-07-06,,2014-09-15,2003-10-30,2003-10-31,Estimate,2010-09-24,2010-10-20,Estimate,,,,2014-09-15,2014-09-25,Estimate,October 2003,,2003-10-31,September 2014,2014-09-30,December 2009,Actual,2009-12-31,February 2009,Actual,2009-02-28,,Interventional,,,Valproate in Dementia (VALID),"A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)",Completed,,Phase 3,313.0,Actual,Alzheimer's Disease Cooperative Study (ADCS),,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:30:40.191422,2020-02-01 22:30:40.191422,Alzheimer's Disease Cooperative Study (ADCS),Other,Placebo,Drug
NCT00086138,"ClinicalTrials.gov processed this data on January 31, 2020",2004-06-25,2016-03-08,,2017-02-28,2004-06-25,2004-06-28,Estimate,2017-02-28,2017-04-11,Actual,,,,2017-02-28,2017-04-11,Actual,July 2004,,2004-07-31,February 2017,2017-02-28,July 2009,Actual,2009-07-31,July 2008,Actual,2008-07-31,,Interventional,DIADS-2,,Depression in Alzheimer's Disease-2,Depression in Alzheimer's Disease (DIADS-2),Completed,,Phase 2/Phase 3,131.0,Actual,Johns Hopkins University,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:24:18.842269,2020-02-01 22:24:18.842269,Johns Hopkins University,Other,Placebo,Drug
NCT00095719,"ClinicalTrials.gov processed this data on January 31, 2020",2004-11-09,,,2013-11-07,2004-11-08,2004-11-09,Estimate,,,,,,,2013-11-07,2013-11-11,Estimate,December 2003,,2003-12-31,August 2008,2008-08-31,March 2005,Actual,2005-03-31,March 2005,Actual,2005-03-31,,Interventional,,,Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia,A Safety & Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia,Completed,,Phase 3,125.0,,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:19:47.546763,2020-02-01 22:19:47.546763,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,Placebo,Drug
NCT00160147,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-08,,2015-01-29,2015-01-29,2005-09-08,2005-09-12,Estimate,,,,2015-01-29,2015-02-09,Estimate,2015-01-29,2015-02-09,Estimate,December 2005,,2005-12-31,June 2009,2009-06-30,January 2008,Actual,2008-01-31,January 2008,Actual,2008-01-31,,Interventional,,,Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type,"A Randomized, Double-Blind, Placebo-controlled, Efficacy, Safety, and Tolerability Study of Bifeprunox in the Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type",Terminated,,Phase 3,60.0,Actual,Solvay Pharmaceuticals,,2.0,,The study was discontinued prematurely on 25 February 2008 due to slow enrollment,False,,,,,,,,,,,,,,,,,2020-02-01 21:59:51.819507,2020-02-01 21:59:51.819507,Solvay Pharmaceuticals,Industry,Placebo,Drug
NCT00205179,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-13,2016-01-26,,2020-01-13,2005-09-13,2005-09-20,Estimate,2020-01-13,2020-01-22,Actual,,,,2020-01-13,2020-01-22,Actual,January 2005,,2005-01-31,January 2020,2020-01-31,December 2009,Actual,2009-12-31,December 2009,Actual,2009-12-31,,Interventional,,Older adults with Alzheimer's disease,Alzheimer's Disease: Potential Benefit of Isoflavones,Alzheimer's Disease: Potential Benefit of Isoflavones,Completed,,Phase 2,72.0,Actual,"University of Wisconsin, Madison",,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 21:48:33.787059,2020-02-01 21:48:33.787059,"University of Wisconsin, Madison",Other,Placebo,Drug
NCT00235716,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-06,2013-12-06,,2014-07-14,2005-10-06,2005-10-10,Estimate,2014-01-23,2014-01-29,Estimate,,,,2014-07-14,2014-07-23,Estimate,August 2007,,2007-08-31,July 2014,2014-07-31,October 2012,Actual,2012-10-31,September 2012,Actual,2012-09-30,,Interventional,TEAM-AD,,"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease","CSP #546 - A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)",Completed,,Phase 3,613.0,Actual,VA Office of Research and Development,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:42:18.318346,2020-02-01 21:42:18.318346,US Department of Veterans Affairs,U.S. Fed,Placebo,Drug
NCT00239746,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-13,,,2009-04-28,2005-10-13,2005-10-17,Estimate,,,,,,,2009-04-28,2009-04-29,Estimate,October 2005,,2005-10-31,April 2009,2009-04-30,August 2009,Anticipated,2009-08-31,August 2009,Anticipated,2009-08-31,,Interventional,,,BONSAI: Biomarkers of Nonsteroidal Anti-Inflammatories,Biomarkers of Nonsteroidal Anti-Inflammatories,Unknown status,"Active, not recruiting",Phase 1,40.0,Anticipated,National Institute on Aging (NIA),,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:41:15.228944,2020-02-01 21:41:15.228944,National Institute on Aging (NIA),NIH,Placebo,Drug
NCT00322153,"ClinicalTrials.gov processed this data on January 31, 2020",2006-05-03,2010-07-20,,2010-08-25,2006-05-04,2006-05-05,Estimate,2010-08-25,2010-09-16,Estimate,,,,2010-08-25,2010-09-16,Estimate,June 2005,,2005-06-30,August 2010,2010-08-31,January 2008,Actual,2008-01-31,October 2007,Actual,2007-10-31,,Interventional,,,A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients With Moderate-to-Severe Dementia of the Alzheimer's Type",Completed,,Phase 3,677.0,Actual,Forest Laboratories,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:18:57.061793,2020-02-01 21:18:57.061793,Forest Laboratories,Industry,Placebo,Drug
NCT00325728,"ClinicalTrials.gov processed this data on January 31, 2020",2006-05-11,,,2017-08-10,2006-05-11,2006-05-15,Estimate,,,,,,,2017-08-10,2017-08-14,Actual,"March 21, 2006",Actual,2006-03-21,August 2017,2017-08-31,"August 20, 2007",Actual,2007-08-20,"August 1, 2007",Actual,2007-08-01,,Interventional,,,Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease,"A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects",Completed,,Phase 2,74.0,Actual,Takeda,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:17:49.788554,2020-02-01 21:17:49.788554,Takeda,Industry,Placebo,Drug
NCT00329082,"ClinicalTrials.gov processed this data on January 31, 2020",2006-05-19,,2009-06-10,2009-10-05,2006-05-19,2006-05-24,Estimate,,,,2009-10-05,2009-10-07,Estimate,2009-10-05,2009-10-07,Estimate,May 2006,,2006-05-31,October 2009,2009-10-31,May 2008,Actual,2008-05-31,May 2008,Actual,2008-05-31,,Interventional,,,Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers,LY2062430: Multiple-Dose Safety in Subjects With Mild-to-Moderate Alzheimer's Disease and Single-Dose Safety in Healthy Volunteers,Completed,,Phase 2,25.0,Actual,Eli Lilly and Company,,5.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:16:51.782807,2020-02-01 21:16:51.782807,Eli Lilly and Company,Industry,Placebo,Drug
NCT00334568,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-06,,,2013-01-10,2006-06-06,2006-06-08,Estimate,,,,,,,2013-01-10,2013-01-14,Estimate,December 2004,,2004-12-31,January 2013,2013-01-31,July 2007,Actual,2007-07-31,July 2007,Actual,2007-07-31,,Interventional,,,Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease,"A Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilisation and Cognition in Subjects With Mild to Moderate Alzheimers Disease (AD)",Terminated,,Phase 2,12.0,Actual,GlaxoSmithKline,,2.0,,Slow recruitment,False,,,,,,,,,,,,,,,,,2020-02-01 21:15:19.556863,2020-02-01 21:15:19.556863,GlaxoSmithKline,Industry,Placebo,Drug
NCT00368459,"ClinicalTrials.gov processed this data on January 31, 2020",2006-08-22,2015-03-01,,2015-03-20,2006-08-22,2006-08-24,Estimate,2015-03-20,2015-04-02,Estimate,,,,2015-03-20,2015-04-02,Estimate,August 2006,,2006-08-31,March 2015,2015-03-31,January 2012,Actual,2012-01-31,March 2011,Actual,2011-03-31,,Interventional,,Postmenopausal women with Alzheimer's disease of mild to moderate severity,Raloxifene for Women With Alzheimer's Disease,Raloxifene in Women With AD: Randomized Controlled Trial,Completed,,Phase 2,42.0,Actual,Stanford University,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:06:20.426774,2020-02-01 21:06:20.426774,Stanford University,Other,Placebo,Drug
NCT00377715,"ClinicalTrials.gov processed this data on January 31, 2020",2006-09-15,,,2015-11-09,2006-09-15,2006-09-18,Estimate,,,,,,,2015-11-09,2015-11-11,Estimate,September 2005,,2005-09-30,November 2015,2015-11-30,,,,August 2006,Actual,2006-08-31,,Interventional,,,"Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease","Phase 2, Double-Blind, Placebo-Controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,183.0,Actual,"Medivation, Inc.",,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:03:34.573776,2020-02-01 21:03:34.573776,"Medivation, Inc.",Industry,Placebo,Drug
NCT00411580,"ClinicalTrials.gov processed this data on January 31, 2020",2006-12-13,,,2013-03-27,2006-12-13,2006-12-14,Estimate,,,,,,,2013-03-27,2013-03-29,Estimate,June 2005,,2005-06-30,March 2013,2013-03-31,December 2008,Actual,2008-12-31,December 2008,Actual,2008-12-31,,Interventional,,,Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD),"A 52-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Time-lagged, Parallel Group Study in Patients With Mild to Moderate Alzheimer's Disease (AD) to Investigate the Safety, Tolerability and Aß-specific Antibody Response Following Three Subcutaneous Injections of CAD106",Completed,,Phase 1,58.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:52:37.297594,2020-02-01 20:52:37.297594,Novartis Pharmaceuticals,Industry,Placebo,Drug
NCT00423085,"ClinicalTrials.gov processed this data on January 31, 2020",2007-01-11,2011-04-27,,2014-01-14,2007-01-12,2007-01-17,Estimate,2011-04-27,2011-05-25,Estimate,,,,2014-01-14,2014-02-10,Estimate,January 2007,,2007-01-31,January 2014,2014-01-31,April 2010,Actual,2010-04-30,March 2009,Actual,2009-03-31,,Interventional,,,Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease,"A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)",Completed,,Phase 3,859.0,Actual,Novartis,,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:48:41.903816,2020-02-01 20:48:41.903816,Novartis Pharmaceuticals,Industry,Placebo,Drug
NCT00438568,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-21,,,2012-09-12,2007-02-21,2007-02-22,Estimate,,,,,,,2012-09-12,2012-09-14,Estimate,June 2006,,2006-06-30,September 2012,2012-09-30,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,SNIFF 120,,SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days),Therapeutic Effects of Intranasal Insulin Administration in AD,Completed,,Phase 2,173.0,Actual,University of Washington,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:43:16.502687,2020-02-01 20:43:16.502687,University of Washington,Other,Placebo,Drug
NCT00440050,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-22,2010-05-28,,2014-09-15,2007-02-22,2007-02-26,Estimate,2010-07-28,2010-08-30,Estimate,,,,2014-09-15,2014-09-25,Estimate,February 2007,,2007-02-28,September 2014,2014-09-30,May 2009,Actual,2009-05-31,May 2009,Actual,2009-05-31,,Interventional,DHA,,"DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease",A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease,Completed,,Phase 3,402.0,Actual,Alzheimer's Disease Cooperative Study (ADCS),,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:42:48.181086,2020-02-01 20:42:48.181086,Alzheimer's Disease Cooperative Study (ADCS),Other,Placebo,Drug
NCT00455000,"ClinicalTrials.gov processed this data on January 31, 2020",2007-03-29,,,2009-10-12,2007-03-30,2007-04-02,Estimate,,,,,,,2009-10-12,2009-10-14,Estimate,March 2007,,2007-03-31,October 2009,2009-10-31,September 2009,Actual,2009-09-30,September 2009,Actual,2009-09-30,,Interventional,,,"A Phase I, Single IV Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease","A Phase I, Randomized, Placebo Controlled, Double Blind Dose Escalation Study Of The Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, And Immunogenicity Of A Single Intravenous Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease",Completed,,Phase 1,37.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:37:55.242333,2020-02-01 20:37:55.242333,Pfizer,Industry,Placebo,Drug
NCT00470418,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-04,2014-01-16,,2017-01-05,2007-05-04,2007-05-07,Estimate,2017-01-05,2017-01-09,Estimate,,,,2017-01-05,2017-01-09,Estimate,January 2007,,2007-01-31,January 2017,2017-01-31,March 2010,Actual,2010-03-31,August 2008,Actual,2008-08-31,,Interventional,,,Development of NIC5-15 in the Treatment of Alzheimer's Disease,Development of NIC5-15 in the Treatment of Alzheimer's Disease,Completed,,Phase 2,15.0,Actual,VA Office of Research and Development,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:33:24.684642,2020-02-01 20:33:24.684642,VA Office of Research and Development,U.S. Fed,Placebo,Drug
NCT00476008,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-17,2013-09-20,,2014-08-07,2007-05-17,2007-05-21,Estimate,2014-05-05,2014-06-03,Estimate,,,,2014-08-07,2014-08-11,Estimate,July 2007,,2007-07-31,August 2014,2014-08-31,October 2012,Actual,2012-10-31,October 2012,Actual,2012-10-31,,Interventional,,,Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease,Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease,Completed,,Phase 4,60.0,Actual,Florida Atlantic University,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:31:32.398133,2020-02-01 20:31:32.398133,Florida Atlantic University,Other,Placebo,Drug
NCT00480870,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-30,,,2007-12-03,2007-05-30,2007-05-31,Estimate,,,,,,,2007-12-03,2007-12-04,Estimate,April 1999,,1999-04-30,December 2007,2007-12-31,January 2005,Actual,2005-01-31,,,,,Interventional,ACHALZSLEEP,,The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients,The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients,Completed,,Phase 4,65.0,Actual,Associacao Fundo de Incentivo a Psicofarmcologia,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:30:18.858543,2020-02-01 20:30:18.858543,Associacao Fundo de Incentivo a Psicofarmcologia,Other,Placebo,Drug
NCT00515333,"ClinicalTrials.gov processed this data on January 31, 2020",2007-08-10,,,2008-02-19,2007-08-10,2007-08-13,Estimate,,,,,,,2008-02-19,2008-02-20,Estimate,August 2004,,2004-08-31,February 2008,2008-02-29,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,TRx0014 in Patients With Mild or Moderate Alzheimer's Disease,"An Exploratory Placebo-Controlled, Dose-Ranging Study of the Effects of TRx0014 30 MG TID, 60 MG TID AND 100 MG TID in Patients With Mild or Moderate Dementia of the Alzheimer Type",Completed,,Phase 2,323.0,Actual,TauRx Therapeutics Ltd,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:19:58.910572,2020-02-01 20:19:58.910572,TauRx Therapeutics Ltd,Industry,Placebo,Drug
NCT00566397,"ClinicalTrials.gov processed this data on January 31, 2020",2007-11-29,,2013-03-19,2018-11-28,2007-11-29,2007-12-03,Estimate,,,,2013-03-19,2013-03-25,Estimate,2018-11-28,2018-11-30,Actual,December 2007,,2007-12-31,November 2018,2018-11-30,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,,,A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease,"A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,402.0,Actual,Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:02:38.629333,2020-02-01 20:02:38.629333,Pfizer,Industry,Placebo,Drug
NCT00582855,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-21,,,2016-04-15,2007-12-21,2007-12-28,Estimate,,,,,,,2016-04-15,2016-04-19,Estimate,December 2007,,2007-12-31,April 2016,2016-04-30,,,,February 2009,Actual,2009-02-28,,Interventional,,,Effect of AQW051 in Patients With Memory Impairment,"A 4-week, Parallel-group, Randomized, Double-blind, Placebo-controlled, Adaptive Proof of Concept Study of AQW051 at up to Three Dose Levels for the Treatment of Patients With Findings Consistent With Mild Alzheimer's Disease (AD) or Amnestic Mild Cognitive Impairment (Amnestic MCI)",Terminated,,Phase 2,54.0,Actual,Novartis,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:58:11.171904,2020-02-01 19:58:11.171904,Novartis Pharmaceuticals,Industry,Placebo,Drug
NCT00594568,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-11,2013-11-06,2011-08-09,2015-03-13,2008-01-11,2008-01-15,Estimate,2014-09-22,2014-09-25,Estimate,2011-08-09,2011-08-15,Estimate,2015-03-13,2015-03-17,Estimate,March 2008,,2008-03-31,March 2015,2015-03-31,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Effect of LY450139 on the Long Term Progression of Alzheimer's Disease,Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo,Completed,,Phase 3,1537.0,Actual,Eli Lilly and Company,Outcomes with 4-week after study drug cessation timeframe=All dosing stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants; followed for 32 weeks; not all assessments were made.,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:55:02.296322,2020-02-01 19:55:02.296322,Eli Lilly and Company,Industry,Placebo,Drug
NCT00606164,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-21,,,2008-01-21,2008-01-21,2008-02-01,Estimate,,,,,,,2008-01-21,2008-02-01,Estimate,April 2008,,2008-04-30,January 2008,2008-01-31,December 2008,Anticipated,2008-12-31,December 2008,Anticipated,2008-12-31,,Interventional,,,"Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Mild to Moderate Alzheimer's Disease",Unknown status,Not yet recruiting,Phase 2,9.0,Anticipated,Blanchette Rockefeller Neurosciences Insitute,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:51:23.445840,2020-02-01 19:51:23.445840,Blanchette Rockefeller Neurosciences Insitute,Other,Placebo,Drug
NCT00607308,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-22,,,2010-12-06,2008-01-22,2008-02-05,Estimate,,,,,,,2010-12-06,2010-12-07,Estimate,February 2008,,2008-02-29,December 2010,2010-12-31,October 2010,Actual,2010-10-31,October 2010,Actual,2010-10-31,,Interventional,,,"A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease","A Phase 1, Randomized, Placebo-Controlled, Double Blind, Dose-Escalation, Multicenter Study Of The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Immunogenicity Of A Single Intravenous Dose Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease",Completed,,Phase 1,20.0,Actual,Pfizer,,6.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:51:05.641137,2020-02-01 19:51:05.641137,Pfizer,Industry,Placebo,Drug
NCT00621647,"ClinicalTrials.gov processed this data on January 31, 2020",2008-02-06,,,2009-03-24,2008-02-11,2008-02-22,Estimate,,,,,,,2009-03-24,2009-03-25,Estimate,September 2002,,2002-09-30,March 2009,2009-03-31,November 2003,Actual,2003-11-30,November 2003,Actual,2003-11-30,,Interventional,,,Seroquel- Agitation Associated With Dementia,"A Multicenter, Double-Blind, Randomized, Comparison of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Agitation Associated With Dementia.",Completed,,Phase 3,333.0,Actual,AstraZeneca,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:46:29.171385,2020-02-01 19:46:29.171385,AstraZeneca,Industry,Placebo,Drug
NCT00630500,"ClinicalTrials.gov processed this data on January 31, 2020",2008-02-27,,,2015-07-27,2008-03-06,2008-03-07,Estimate,,,,,,,2015-07-27,2015-07-28,Estimate,February 2006,,2006-02-28,February 2009,2009-02-28,March 2009,Actual,2009-03-31,February 2009,Actual,2009-02-28,,Interventional,MEMPDD,,Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB),"A Double-blind, Placebo-controlled Multicentre Trial of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies",Completed,,Phase 2,75.0,Actual,Helse Stavanger HF,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:44:12.140389,2020-02-01 19:44:12.140389,Helse Stavanger HF,Other,Placebo,Drug
NCT00630851,"ClinicalTrials.gov processed this data on January 31, 2020",2008-02-27,,,2015-03-04,2008-02-27,2008-03-07,Estimate,,,,,,,2015-03-04,2015-03-05,Estimate,October 2002,,2002-10-31,March 2015,2015-03-31,October 2004,Actual,2004-10-31,,,,,Interventional,,,A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes,"A Six-month, Multicenter, Double-blind, Parallel, Placebo-controlled Study of the Effect on Global/Behavioural/ADL Functions and Tolerability of Aricept in Patients Wtih Severe Alzheimer's Disease Living in an Assisted Care Facility",Completed,,Phase 3,249.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:44:05.194318,2020-02-01 19:44:05.194318,Pfizer,Industry,Placebo,Drug
NCT00663936,"ClinicalTrials.gov processed this data on January 31, 2020",2008-04-18,,2012-12-09,2013-10-09,2008-04-21,2008-04-22,Estimate,,,,2012-12-10,2012-12-12,Estimate,2013-10-09,2013-11-05,Estimate,April 2008,,2008-04-30,December 2012,2012-12-31,June 2011,Actual,2011-06-30,May 2011,Actual,2011-05-31,,Interventional,,,Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease,"A Phase 2a Multi-center, Randomized, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of T-817MAa in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,373.0,Actual,"FUJIFILM Toyama Chemical Co., Ltd.",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:34:29.421057,2020-02-01 19:34:29.421057,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,Placebo,Drug
NCT00672945,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-02,,,2009-07-28,2008-05-05,2008-05-06,Estimate,,,,,,,2009-07-28,2009-07-30,Estimate,April 2008,,2008-04-30,July 2009,2009-07-31,,,,January 2010,Anticipated,2010-01-31,,Interventional,,,A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil,Phase 2 Double-Blind Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil,Terminated,,Phase 2,420.0,Anticipated,"Epix Pharmaceuticals, Inc.",,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:32:01.805046,2020-02-01 19:32:01.805046,"Epix Pharmaceuticals, Inc.",Industry,Placebo,Drug
NCT00675090,"ClinicalTrials.gov processed this data on January 31, 2020",2008-04-24,,,2017-07-05,2008-05-07,2008-05-08,Estimate,,,,,,,2017-07-05,2017-07-07,Actual,"February 21, 2008",Actual,2008-02-21,July 2017,2017-07-31,"June 16, 2009",Actual,2009-06-16,"June 16, 2009",Actual,2009-06-16,,Interventional,,,Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease,"A Single Blind, Placebo-controlled, Randomised Study in Mild to Moderate Alzheimer's Disease Patients to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK239512, a Selective Histamine H3 Receptor Antagonist",Completed,,Phase 1,28.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 19:31:21.789058,2020-02-01 19:31:21.789058,GlaxoSmithKline,Industry,Placebo,Drug
NCT00675623,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-07,,2016-09-24,2016-09-24,2008-05-08,2008-05-09,Estimate,,,,2016-09-24,2016-09-27,Estimate,2016-09-24,2016-09-27,Estimate,May 2008,,2008-05-31,September 2016,2016-09-30,,,,December 2009,Actual,2009-12-31,,Interventional,CONNECTION,,A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease,"A Global Phase 3, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease (CONNECTION)",Completed,,Phase 3,598.0,Actual,"Medivation, Inc.",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:31:17.244228,2020-02-01 19:31:17.244228,"Medivation, Inc.",Industry,Placebo,Drug
NCT00679627,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-15,2013-04-23,,2013-09-10,2008-05-15,2008-05-19,Estimate,2013-07-30,2013-09-02,Estimate,,,,2013-09-10,2013-09-19,Estimate,June 2008,,2008-06-30,September 2013,2013-09-30,May 2012,Actual,2012-05-31,April 2012,Actual,2012-04-30,,Interventional,,,A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease",Terminated,,Phase 3,2051.0,Actual,"Janssen Research & Development, LLC",,2.0,,"Due to a pre-specified imbalance of deaths between treatment groups, the DSMB recommended early
    termination of the trial",False,,,,,,,,,,,,,,,,,2020-02-01 19:29:53.904574,2020-02-01 19:29:53.904574,"Janssen Research & Development, LLC",Industry,Placebo,Drug
NCT00684710,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-23,,,2009-01-28,2008-05-27,2008-05-28,Estimate,,,,,,,2009-01-28,2009-01-30,Estimate,April 2008,,2008-04-30,January 2009,2009-01-31,August 2008,Actual,2008-08-31,August 2008,Actual,2008-08-31,,Interventional,,,"Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects","Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of PAZ 417 Administered Orally to Healthy Young Japanese Male and Healthy Elderly Japanese Male Subjects",Completed,,Phase 1,56.0,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:28:29.702780,2020-02-01 19:28:29.702780,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,Placebo,Drug
NCT00693004,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-30,,,2009-07-28,2008-06-05,2008-06-06,Estimate,,,,,,,2009-07-28,2009-07-30,Estimate,May 2008,,2008-05-31,July 2009,2009-07-31,,,,January 2010,Anticipated,2010-01-31,,Interventional,,,Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of PRX-03140 as Monotherapy in Subjects With Alzheimer's Disease",Terminated,,Phase 2,236.0,Anticipated,"Epix Pharmaceuticals, Inc.",,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:26:04.087803,2020-02-01 19:26:04.087803,"Epix Pharmaceuticals, Inc.",Industry,Placebo,Drug
NCT00708552,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-30,2017-07-24,2012-02-23,2018-05-31,2008-06-30,2008-07-02,Estimate,2017-07-24,2018-02-12,Actual,2012-02-23,2012-02-28,Estimate,2018-05-31,2018-07-27,Actual,"July 4, 2008",,2008-07-04,May 2018,2018-05-31,"March 9, 2010",Actual,2010-03-09,"March 1, 2010",Actual,2010-03-01,,Interventional,,"The population used to define the Baseline Characteristics was the Intent-to-Treat (ITT Population) which comprised of all participants randomized to treatment, and who received at least one dose of study medication and who had at least one post baseline assessment.",Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease,"Study AZ3110865, a Study Comparing SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease",Completed,,Phase 2,576.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:21:02.377486,2020-02-01 19:21:02.377486,GlaxoSmithKline,Industry,Placebo,Drug
NCT00710684,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-30,2017-08-18,2011-03-17,2017-11-03,2008-07-03,2008-07-04,Estimate,2017-11-03,2017-12-07,Actual,2011-04-21,2011-04-28,Estimate,2017-11-03,2017-12-07,Actual,"July 1, 2008",Actual,2008-07-01,November 2017,2017-11-30,"November 16, 2010",Actual,2010-11-16,"May 21, 2010",Actual,2010-05-21,,Interventional,,"Out of 682 participants, 5 participants did not have at least one post-Baseline or health outcomes assessment. Hence a total of 677 participants were included in intent-to-treat (ITT) population and they were used to assess Baseline characteristics.","A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease","Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease",Completed,,Phase 2,682.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:20:26.859390,2020-02-01 19:20:26.859390,GlaxoSmithKline,Industry,Placebo,Drug
NCT00722046,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-23,,2012-10-08,2016-04-08,2008-07-24,2008-07-25,Estimate,,,,2012-10-08,2012-10-11,Estimate,2016-04-08,2016-05-05,Estimate,December 2008,,2008-12-31,October 2012,2012-10-31,August 2011,Actual,2011-08-31,August 2011,Actual,2011-08-31,,Interventional,,,Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease,"A Phase 2 Multicenter, Randomized, Double Blind, Placebo-Controlled Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,198.0,Actual,Pfizer,,6.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:16:57.975986,2020-02-01 19:16:57.975986,Pfizer,Industry,Placebo,Drug
NCT00744978,"ClinicalTrials.gov processed this data on January 31, 2020",2008-08-29,2011-10-12,,2011-10-12,2008-08-29,2008-09-01,Estimate,2011-10-12,2011-11-22,Estimate,,,,2011-10-12,2011-11-22,Estimate,July 2009,,2009-07-31,October 2011,2011-10-31,November 2010,Actual,2010-11-30,November 2010,Actual,2010-11-30,,Interventional,,,"Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease","A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Crossover Trial of Varenicline Tartrate (CP-526,555) in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,66.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:10:28.516695,2020-02-01 19:10:28.516695,Pfizer,Industry,Placebo,Drug
NCT00762411,"ClinicalTrials.gov processed this data on January 31, 2020",2008-09-26,2013-11-06,2011-08-22,2015-01-28,2008-09-26,2008-09-30,Estimate,2014-09-22,2014-09-25,Estimate,2011-08-22,2011-08-23,Estimate,2015-01-28,2015-02-16,Estimate,September 2008,,2008-09-30,January 2015,2015-01-31,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,IDENTITY-2,,"Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo","Effect of LY450139 a y-Secretase Inhibitor, on the Progression of Alzheimer's Disease as Compared With Placebo",Completed,,Phase 3,1111.0,Actual,Eli Lilly and Company,All dosing for 4-week post-study drug cessation timeframe outcome measures stopped after protocol-specified interim review showed dose-dependent cognitive/functional worsening for LY450139 participants. No assessments made during 32-week follow up.,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:05:56.411245,2020-02-01 19:05:56.411245,Eli Lilly and Company,Industry,Placebo,Drug
NCT00792662,"ClinicalTrials.gov processed this data on January 31, 2020",2008-11-17,,,2018-03-27,2008-11-17,2008-11-18,Estimate,,,,,,,2018-03-27,2018-03-29,Actual,November 2008,Actual,2008-11-30,March 2018,2018-03-31,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,,,"Improving Function, Quality of Life, Glycemia in Diabetics With Dementia","Improving Function, Quality of Life, Glycemia in Diabetics With Dementia",Withdrawn,,Phase 4,0.0,Actual,University of Nebraska,,2.0,,No Subjects enrolled,False,,,,True,,,,,,,,,,,,,2020-02-01 18:56:39.297993,2020-02-01 18:56:39.297993,University of Nebraska,Other,Placebo,Drug
NCT00810147,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-16,,2012-03-24,2015-09-23,2008-12-16,2008-12-17,Estimate,,,,2015-09-23,2015-10-12,Estimate,2015-09-23,2015-10-12,Estimate,February 2009,,2009-02-28,September 2015,2015-09-30,June 2010,Actual,2010-06-30,June 2010,Actual,2010-06-30,,Interventional,,,"A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease","Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,209.0,Actual,Bristol-Myers Squibb,,5.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:51:11.554481,2020-02-01 18:51:11.554481,Bristol-Myers Squibb,Industry,Placebo,Drug
NCT00812565,"ClinicalTrials.gov processed this data on January 31, 2020",2008-11-10,2013-12-02,,2014-04-02,2008-12-19,2008-12-22,Estimate,2014-04-02,2014-05-05,Estimate,,,,2014-04-02,2014-05-05,Estimate,February 2009,,2009-02-28,April 2014,2014-04-30,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,Full analysis set: All randomized patients who received at least 1 infusion of the study medication and had at least 1 post-baseline efficacy assessment.,Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease,"Prospective 24-week, Double-blind, Randomised, Placebo-controlled, Multicenter Study Evaluating Safety and Change in Efficacy-related Surrogate Parameters in Patients With Dementia of the Alzheimer's Type Under Treatment With Increasing Dosages of Intravenous Immunoglobulin (Octagam 10%)",Completed,,Phase 2,58.0,Actual,Octapharma,Small numbers of patients per treatment group (between 5 and 8) and variable total Aβ levels over time.,8.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:50:23.862407,2020-02-01 18:50:23.862407,Octapharma,Industry,Placebo,Drug
NCT00814346,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-23,2015-09-11,,2019-01-24,2008-12-23,2008-12-24,Estimate,2016-02-26,2016-03-28,Estimate,,,,2019-01-24,2019-02-08,Actual,October 2008,,2008-10-31,January 2019,2019-01-31,July 2012,Actual,2012-07-31,July 2012,Actual,2012-07-31,,Interventional,,,Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions,"Effect of Oral EGb761® on Brain Glucose Metabolism in Three Groups of Elderly With Memory Complaint, Mild Alzheimer's Disease, and Cognitively Normal Elderly. Phase II, Randomised, Double-blind, Parallel Groups, Placebo-controlled Study",Completed,,Phase 2,49.0,Actual,Ipsen,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:49:41.213666,2020-02-01 18:49:41.213666,Ipsen,Industry,Placebo,Drug
NCT00814502,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-18,2017-02-02,,2017-04-12,2008-12-24,2008-12-25,Estimate,2017-04-12,2017-05-22,Actual,,,,2017-04-12,2017-05-22,Actual,December 2008,,2008-12-31,April 2017,2017-04-30,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,,Interventional,,,Zolpidem CR and Hospitalized Patients With Dementia,Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study,Completed,,N/A,20.0,Actual,Massachusetts General Hospital,Small sample size. We were unable to control for different treatments that our subjects received as inpatients.,2.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 18:49:38.034289,2020-02-01 18:49:38.034289,Massachusetts General Hospital,Other,Placebo,Drug
NCT00814801,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-24,2012-03-13,,2014-03-31,2008-12-24,2008-12-25,Estimate,2012-06-01,2012-07-04,Estimate,,,,2014-03-31,2014-04-17,Estimate,February 2007,,2007-02-28,March 2014,2014-03-31,September 2008,Actual,2008-09-30,September 2008,Actual,2008-09-30,,Interventional,,,An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease,Placebo-controlled Confirmatory Study of Galantamine (R113675) for Alzheimer's Type Dementia,Completed,,Phase 3,580.0,Actual,Janssen Pharmaceutical K.K.,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:49:31.270103,2020-02-01 18:49:31.270103,Janssen Pharmaceutical K.K.,Industry,Placebo,Drug
NCT00829816,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-12,,,2015-11-06,2009-01-23,2009-01-27,Estimate,,,,,,,2015-11-06,2015-11-10,Estimate,December 2008,,2008-12-31,November 2015,2015-11-30,August 2010,Actual,2010-08-31,April 2009,Actual,2009-04-30,,Interventional,,,"Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil",A Multi-Center Phase 1 Study of the Safety and Tolerability of Dimebon in Alzheimer's Disease Patients on Memantine (Cohort 1) and Memantine Plus Donepezil (Cohort 2),Completed,,Phase 1,46.0,Actual,"Medivation, Inc.",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:45:21.480398,2020-02-01 18:45:21.480398,"Medivation, Inc.",Industry,Placebo,Drug
NCT00838110,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-05,2012-10-11,2011-03-14,2018-11-06,2009-02-05,2009-02-06,Estimate,2013-01-07,2013-02-08,Estimate,2011-03-14,2011-03-25,Estimate,2018-11-06,2018-12-06,Actual,February 2009,,2009-02-28,November 2018,2018-11-30,January 2010,Actual,2010-01-31,January 2010,Actual,2010-01-31,,Interventional,,,A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease,"A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease",Completed,,Phase 3,742.0,Actual,Pfizer,This safety study did not specify primary or secondary outcome measures. Relevant summaries of all safety assessments are thus provided. Urine blood abnormalities seen are deemed due to interference with dipstick test by a metabolite of dimebon.,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:42:54.285215,2020-02-01 18:42:54.285215,Pfizer,Industry,Placebo,Drug
NCT00842673,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-10,,,2012-06-05,2009-02-10,2009-02-12,Estimate,,,,,,,2012-06-05,2012-06-07,Estimate,February 2009,,2009-02-28,June 2012,2012-06-30,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease,"A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease",Completed,,Phase 2,168.0,Actual,"Sonexa Therapeutics, Inc.",,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:41:39.618333,2020-02-01 18:41:39.618333,"Sonexa Therapeutics, Inc.",Industry,Placebo,Drug
NCT00842816,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-10,,,2012-06-05,2009-02-11,2009-02-12,Estimate,,,,,,,2012-06-05,2012-06-07,Estimate,February 2009,,2009-02-28,June 2012,2012-06-30,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease,"A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease in Subjects Concurrently Receiving Donepezil (Aricept®)",Completed,,Phase 2,210.0,Actual,"Sonexa Therapeutics, Inc.",,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:41:36.501371,2020-02-01 18:41:36.501371,"Sonexa Therapeutics, Inc.",Industry,Placebo,Drug
NCT00843518,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-12,2016-07-07,2011-09-20,2017-10-23,2009-02-12,2009-02-13,Estimate,2017-10-23,2017-11-29,Actual,2011-09-20,2011-09-26,Estimate,2017-10-23,2017-11-29,Actual,February 2009,,2009-02-28,October 2017,2017-10-31,June 2011,Actual,2011-06-30,June 2011,Actual,2011-06-30,,Interventional,,,Treatment for Aggression and Agitation in Patients With Alzheimer's Disease,Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease,Completed,,Phase 2,132.0,Actual,Eli Lilly and Company,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:41:24.194777,2020-02-01 18:41:24.194777,Eli Lilly and Company,Industry,Placebo,Drug
NCT00855686,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-03,,,2013-09-19,2009-03-03,2009-03-04,Estimate,,,,,,,2013-09-19,2013-09-20,Estimate,January 2007,,2007-01-31,September 2013,2013-09-30,January 2009,Actual,2009-01-31,December 2008,Actual,2008-12-31,,Interventional,,,Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies,"A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies",Completed,,Phase 4,199.0,Actual,H. Lundbeck A/S,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:37:39.865139,2020-02-01 18:37:39.865139,H. Lundbeck A/S,Industry,Placebo,Drug
NCT00857649,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-05,2011-10-26,,2013-11-12,2009-03-05,2009-03-06,Estimate,2011-12-05,2012-01-09,Estimate,,,,2013-11-12,2013-12-05,Estimate,December 2003,,2003-12-31,November 2013,2013-11-30,September 2010,Actual,2010-09-30,April 2010,Actual,2010-04-30,,Interventional,,,Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease,"A Randomised, Double-Blind, Parallel-Group Study Examining the Efficacy and Safety of Memantine in Patients With Moderate to Severe Dementia of the Alzheimer's Type",Terminated,,Phase 3,369.0,Actual,H. Lundbeck A/S,"Long recruitment, premature termination, substantial protocol changes; baseline imbalances (concomitant medication and severity of agitation). Variability across sites in reported events frequency (50% of agitation reports from a single site)",2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:36:53.724936,2020-02-01 18:36:53.724936,H. Lundbeck A/S,Industry,Placebo,Drug
NCT00862940,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-16,2010-11-23,,2012-08-29,2009-03-16,2009-03-17,Estimate,2011-05-05,2011-06-03,Estimate,,,,2012-08-29,2012-09-03,Estimate,September 2005,,2005-09-30,August 2012,2012-08-31,April 2009,Actual,2009-04-30,February 2009,Actual,2009-02-28,,Interventional,,,A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease,"A 1-year Randomised, Double-blind Placebo-controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients With Alzheimer's Disease",Completed,,Phase 4,277.0,Actual,H. Lundbeck A/S,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:35:23.094115,2020-02-01 18:35:23.094115,H. Lundbeck A/S,Industry,Placebo,Drug
NCT00880412,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-10,,,2009-09-18,2009-04-10,2009-04-13,Estimate,,,,,,,2009-09-18,2009-09-21,Estimate,April 2008,,2008-04-30,September 2009,2009-09-30,August 2009,Actual,2009-08-31,June 2009,Actual,2009-06-30,,Interventional,EHT0202/002,,A Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 as Adjunctive Therapy to Acetylcholinesterase Inhibitor in Mild to Moderate Alzheimer's Disease,"A Pilot, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase IIA Study to Determine the Clinical Safety/Tolerability and Exploratory Efficacy of EHT 0202 (40 and 80 mg Bid) as Adjunctive Therapy to Acetylcholinesterase Inhibitor Over a 3-month Period in Ambulatory Patients Suffering From Mild to Moderate Alzheimer's Disease (EHT 0202/002 Protocol)",Completed,,Phase 2,197.0,Actual,Exonhit,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:30:27.434852,2020-02-01 18:30:27.434852,Exonhit,Industry,Placebo,Drug
NCT00884507,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-17,,2016-07-08,2016-11-01,2009-04-17,2009-04-20,Estimate,,,,2016-07-08,2016-07-12,Estimate,2016-11-01,2016-11-02,Estimate,May 2009,,2009-05-31,November 2016,2016-11-30,November 2010,Actual,2010-11-30,November 2010,Actual,2010-11-30,,Interventional,,,A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease,"A Dose-ranging, Randomized, Double-blind , Placebo-controlled Study of the Effect of RO5313534, Used as add-on Therapy to Donepezil, on Cognitive Function in Patients With Mild to Moderate Symptoms of Alzheimer's Disease",Completed,,Phase 2,389.0,Actual,Hoffmann-La Roche,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:29:05.945872,2020-02-01 18:29:05.945872,Hoffmann-La Roche,Industry,Placebo,Drug
NCT00890890,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-29,,2015-09-23,2015-09-23,2009-04-29,2009-04-30,Estimate,,,,2015-09-23,2015-10-12,Estimate,2015-09-23,2015-10-12,Estimate,May 2009,,2009-05-31,September 2015,2015-09-30,July 2013,Actual,2013-07-31,July 2013,Actual,2013-07-31,,Interventional,,,"A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease","Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients With Prodromal Alzheimer's Disease",Terminated,,Phase 2,263.0,Actual,Bristol-Myers Squibb,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:27:25.082950,2020-02-01 18:27:25.082950,Bristol-Myers Squibb,Industry,Placebo,Drug
NCT00895895,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-07,2012-12-21,,2012-12-21,2009-05-07,2009-05-08,Estimate,2012-12-21,2013-01-31,Estimate,,,,2012-12-21,2013-01-31,Estimate,May 2009,,2009-05-31,December 2012,2012-12-31,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease,"A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease",Terminated,,Phase 2,526.0,Actual,Pfizer,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,5.0,,See termination reason in detailed description.,False,,,,True,,,,,,,,,,,,,2020-02-01 18:26:03.286124,2020-02-01 18:26:03.286124,Pfizer,Industry,Placebo,Drug
NCT00904683,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-18,,2012-09-18,2012-12-11,2009-05-18,2009-05-20,Estimate,,,,2012-09-18,2012-09-25,Estimate,2012-12-11,2012-12-13,Estimate,May 2009,,2009-05-31,December 2012,2012-12-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,EXPEDITION2,,Effect of LY2062430 on the Progression of Alzheimer's Disease,Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo,Completed,,Phase 3,1040.0,Actual,Eli Lilly and Company,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:23:37.732667,2020-02-01 18:23:37.732667,Eli Lilly and Company,Industry,Placebo,Drug
NCT00905372,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-18,,2012-09-18,2012-09-18,2009-05-18,2009-05-20,Estimate,,,,2012-09-18,2012-09-25,Estimate,2012-09-18,2012-09-25,Estimate,May 2009,,2009-05-31,May 2012,2012-05-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,EXPEDITION,,Effect of LY2062430 on the Progression of Alzheimer's Disease,"Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo",Completed,,Phase 3,1000.0,Anticipated,Eli Lilly and Company,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:23:26.031400,2020-02-01 18:23:26.031400,Eli Lilly and Company,Industry,Placebo,Drug
NCT00930059,"ClinicalTrials.gov processed this data on January 31, 2020",2009-06-29,,2013-04-09,2013-04-09,2009-06-29,2009-06-30,Estimate,,,,2013-04-09,2013-04-16,Estimate,2013-04-09,2013-04-16,Estimate,September 2009,,2009-09-30,April 2013,2013-04-30,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease,"A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study Of PF-04447943 In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,198.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:16:09.262269,2020-02-01 18:16:09.262269,Pfizer,Industry,Placebo,Drug
NCT00940589,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-15,2018-03-28,,2018-05-29,2009-07-15,2009-07-16,Estimate,2018-05-29,2018-06-01,Actual,,,,2018-05-29,2018-06-01,Actual,September 2009,,2009-09-30,May 2018,2018-05-31,May 2013,Actual,2013-05-31,February 2013,Actual,2013-02-28,,Interventional,,,Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor,"A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor",Completed,,Phase 2,73.0,Actual,Neurim Pharmaceuticals Ltd.,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:12:57.684048,2020-02-01 18:12:57.684048,Neurim Pharmaceuticals Ltd.,Industry,Placebo,Drug
NCT00948259,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-27,,,2009-11-10,2009-07-28,2009-07-29,Estimate,,,,,,,2009-11-10,2009-11-11,Estimate,December 2008,,2008-12-31,November 2009,2009-11-30,November 2009,Actual,2009-11-30,November 2009,Actual,2009-11-30,,Interventional,,,Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease,"Phase IIa 20 Week Double-blind, Placebo-controlled, Randomized, Escalating Dose Study to Evaluate the Safety and Tolerability of Four Oral Doses of NP031112, a Novel GSK3 Inhibitor, in Mild to Moderate Alzheimer's Disease Patients With Stable Anticholinesterasic Treatment.",Completed,,Phase 1/Phase 2,30.0,Actual,Noscira SA,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:10:37.833566,2020-02-01 18:10:37.833566,Noscira SA,Industry,Placebo,Drug
NCT00948766,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-28,2013-01-08,,2013-08-19,2009-07-28,2009-07-29,Estimate,2013-01-08,2013-02-11,Estimate,,,,2013-08-19,2013-08-28,Estimate,July 2009,,2009-07-31,August 2013,2013-08-31,June 2012,Actual,2012-06-30,January 2012,Actual,2012-01-31,,Interventional,ACTION,,"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44",Completed,,Phase 4,716.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:10:30.542059,2020-02-01 18:10:30.542059,Novartis,Industry,Placebo,Drug
NCT00948909,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-24,,2011-11-22,2013-01-29,2009-07-28,2009-07-29,Estimate,,,,2011-11-22,2011-11-24,Estimate,2013-01-29,2013-01-31,Estimate,October 2009,,2009-10-31,January 2013,2013-01-31,November 2010,Actual,2010-11-30,November 2010,Actual,2010-11-30,,Interventional,,,Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 2,274.0,Actual,AbbVie,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:10:27.171592,2020-02-01 18:10:27.171592,"AbbVie (prior sponsor, Abbott)",Industry,Placebo,Drug
NCT00951834,"ClinicalTrials.gov processed this data on January 31, 2020",2009-08-03,,,2018-11-28,2009-08-03,2009-08-04,Estimate,,,,,,,2018-11-28,2018-11-29,Actual,October 2009,,2009-10-31,November 2018,2018-11-30,February 2015,Actual,2015-02-28,February 2015,Actual,2015-02-28,,Interventional,SUN-AK,,Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease,Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease,Completed,,Phase 2/Phase 3,21.0,Actual,"Charite University, Berlin, Germany",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:09:10.750449,2020-02-01 18:09:10.750449,"Charite University, Berlin, Germany",Other,Placebo,Drug
NCT00954590,"ClinicalTrials.gov processed this data on January 31, 2020",2009-08-06,,2016-09-24,2016-09-24,2009-08-06,2009-08-07,Estimate,,,,2016-09-24,2016-09-27,Estimate,2016-09-24,2016-09-27,Estimate,October 2009,,2009-10-31,September 2016,2016-09-30,,,,August 2010,Actual,2010-08-31,,Interventional,CONTACT,,A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease,"CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease",Terminated,,Phase 3,89.0,Actual,"Medivation, Inc.",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:08:26.614707,2020-02-01 18:08:26.614707,"Medivation, Inc.",Industry,Placebo,Drug
NCT00982202,"ClinicalTrials.gov processed this data on January 31, 2020",2009-09-22,,,2009-09-22,2009-09-22,2009-09-23,Estimate,,,,,,,2009-09-22,2009-09-23,Estimate,January 2002,,2002-01-31,September 2009,2009-09-30,January 2005,Actual,2005-01-31,January 2005,Actual,2005-01-31,,Interventional,,,Pioglitazone in Alzheimer Disease,Pioglitazone in Alzheimer Disease Progression,Completed,,Phase 2,25.0,Actual,National Institute on Aging (NIA),,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:59:55.966871,2020-02-01 17:59:55.966871,National Institute on Aging (NIA),NIH,Placebo,Drug
NCT00988598,"ClinicalTrials.gov processed this data on January 31, 2020",2009-10-01,,,2010-08-05,2009-10-01,2009-10-02,Estimate,,,,,,,2010-08-05,2010-08-09,Estimate,October 2009,,2009-10-31,August 2010,2010-08-31,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,"A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease","A Phase 1, Double-Blind, Placebo-Controlled, Sponsor Open, Randomized, Multiple Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04447943 In Mild To Moderate Alzheimer's Disease Subjects On Stable Donepezil Therapy",Completed,,Phase 1,15.0,Actual,Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:55:55.298687,2020-02-01 17:55:55.298687,Pfizer,Industry,Placebo,Drug
NCT01005862,"ClinicalTrials.gov processed this data on January 31, 2020",2009-10-30,,,2012-09-25,2009-10-30,2009-11-01,Estimate,,,,,,,2012-09-25,2012-09-26,Estimate,March 2010,,2010-03-31,September 2012,2012-09-30,September 2012,Actual,2012-09-30,September 2012,Actual,2012-09-30,,Interventional,,,Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers,"A Randomized, Investigator And Subject-Blind, Sponsor-Open, Placebo-Controlled Study To Examine The Effects Of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers",Completed,,Phase 1,17.0,Actual,Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:49:05.613368,2020-02-01 17:49:05.613368,Pfizer,Industry,Placebo,Drug
NCT01009255,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-05,,,2017-04-11,2009-11-05,2009-11-06,Estimate,,,,,,,2017-04-11,2017-04-13,Actual,"November 2, 2009",Actual,2009-11-02,April 2017,2017-04-30,"November 10, 2010",Actual,2010-11-10,"November 10, 2010",Actual,2010-11-10,,Interventional,,,Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease,"A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the H3 Receptor Antagonist, GSK239512 in Subjects With Mild to Moderate Alzheimer's Disease.",Completed,,Phase 2,196.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,False,False,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 17:48:00.502559,2020-02-01 17:48:00.502559,GlaxoSmithKline,Industry,Placebo,Drug
NCT01019421,"ClinicalTrials.gov processed this data on January 31, 2020",2009-11-24,,,2012-01-05,2009-11-24,2009-11-25,Estimate,,,,,,,2012-01-05,2012-01-06,Estimate,December 2009,,2009-12-31,January 2012,2012-01-31,,,,December 2011,Actual,2011-12-31,,Interventional,,,Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease,"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Moderate Alzheimer's Disease Treated With Donepezil",Completed,,Phase 2,278.0,Actual,H. Lundbeck A/S,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:44:47.118417,2020-02-01 17:44:47.118417,H. Lundbeck A/S,Industry,Placebo,Drug
NCT01028911,"ClinicalTrials.gov processed this data on January 31, 2020",2009-12-07,2014-04-09,,2014-05-16,2009-12-08,2009-12-09,Estimate,2014-05-16,2014-06-04,Estimate,,,,2014-05-16,2014-06-04,Estimate,December 2009,,2009-12-31,May 2014,2014-05-31,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,Safety population included all participants who took at least 1 dose of study drug.,"A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease","A Phase 1, Double-Blind, Placebo-Controlled, Sponsor-Open, Randomized, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-03654746 in Mild to Moderate Alzheimer's Disease Patients on Stable Donepezil Therapy",Terminated,,Phase 1,9.0,Actual,Pfizer,The study was terminated early due to slow recruitment and the need to use the existing information to determine dosing for another study.,2.0,,"This study terminated 27Apr2010 due to slow recruitment and the need to use the existing
    information to determine dosing for another study.",False,,,,False,,,,,,,,,,,,,2020-02-01 17:42:14.368255,2020-02-01 17:42:14.368255,Pfizer,Industry,Placebo,Drug
NCT01039701,"ClinicalTrials.gov processed this data on January 31, 2020",2009-12-20,,,2010-08-10,2009-12-24,2009-12-25,Estimate,,,,,,,2010-08-10,2010-08-11,Estimate,December 2009,,2009-12-31,August 2010,2010-08-31,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,ROBIN,,"4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease","Safety, Tolerability and Pharmacokinetics of 3 Dose Regimens of AZD1446 vs. Placebo as an Add-on Treatment to Donepezil: A Multi-centre, Double-blind, Randomised, Placebo Controlled, Parallel Group Phase IIa Study in Patients With Mild to Moderate Alzheimer's Disease During 4 Weeks of Treatment",Completed,,Phase 2,99.0,Actual,AstraZeneca,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:39:10.889364,2020-02-01 17:39:10.889364,AstraZeneca,Industry,Placebo,Drug
NCT01058941,"ClinicalTrials.gov processed this data on January 31, 2020",2010-01-27,2017-03-01,,2017-03-01,2010-01-28,2010-01-29,Estimate,2017-03-01,2017-04-13,Actual,,,,2017-03-01,2017-04-13,Actual,September 2010,,2010-09-30,March 2017,2017-03-31,December 2014,Actual,2014-12-31,December 2014,Actual,2014-12-31,,Interventional,,,Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease,Lipoic Acid and Omega-3 Fatty Acids in Alzheimer's Disease,Completed,,Phase 1/Phase 2,67.0,Actual,Oregon Health and Science University,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:34:22.620784,2020-02-01 17:34:22.620784,Oregon Health and Science University,Other,Placebo,Drug
NCT01066481,"ClinicalTrials.gov processed this data on January 31, 2020",2010-02-09,,,2010-06-28,2010-02-09,2010-02-10,Estimate,,,,,,,2010-06-28,2010-06-29,Estimate,April 2010,,2010-04-30,June 2010,2010-06-30,April 2012,Anticipated,2012-04-30,March 2012,Anticipated,2012-03-31,,Interventional,,,A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease,"A Phase 2, Multi-Center, Double-Blinded, Placebo-Controlled Safety And Efficacy Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease",Withdrawn,,Phase 2,0.0,Actual,Pfizer,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:31:59.842008,2020-02-01 17:31:59.842008,Pfizer,Industry,Placebo,Drug
NCT01073228,"ClinicalTrials.gov processed this data on January 31, 2020",2010-02-19,,2013-02-19,2014-03-28,2010-02-22,2010-02-23,Estimate,,,,2013-02-19,2013-02-22,Estimate,2014-03-28,2014-04-25,Estimate,April 2010,,2010-04-30,February 2013,2013-02-28,February 2012,Actual,2012-02-29,November 2011,Actual,2011-11-30,,Interventional,,,Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-blind, Placebo-Controlled, Parallel, 24-Week, Phase 2 Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Subjects With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 2,409.0,Actual,FORUM Pharmaceuticals Inc,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:30:03.549834,2020-02-01 17:30:03.549834,FORUM Pharmaceuticals Inc,Industry,Placebo,Drug
NCT01075763,"ClinicalTrials.gov processed this data on January 31, 2020",2010-02-24,2012-03-07,,2014-01-20,2010-02-24,2010-02-25,Estimate,2012-03-07,2012-04-04,Estimate,,,,2014-01-20,2014-02-13,Estimate,November 2004,,2004-11-30,January 2014,2014-01-31,May 2008,Actual,2008-05-31,May 2008,Actual,2008-05-31,,Interventional,REAL,,A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease,Pilot Trial of Interferon Beta-1a in Alzheimer's Disease,Completed,,Phase 2,42.0,Actual,"Merck KGaA, Darmstadt, Germany",,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 17:29:21.471563,2020-02-01 17:29:21.471563,"Merck KGaA, Darmstadt, Germany",Industry,Placebo,Drug
NCT01078168,"ClinicalTrials.gov processed this data on January 31, 2020",2010-03-01,2016-03-14,,2017-07-18,2010-03-01,2010-03-02,Estimate,2017-07-18,2018-02-05,Actual,,,,2017-07-18,2018-02-05,Actual,March 2010,,2010-03-31,July 2017,2017-07-31,May 2013,Actual,2013-05-31,January 2013,Actual,2013-01-31,,Interventional,ADAM,,Alzheimer`s Disease Acitretin Medication,Changes of Cerebral Spinal Fluid APPSα Levels Under Oral Therapy With Acitretin 30 mg Daily in Patients With Mild to Moderate Alzheimer's Disease: a Multicenter Prospective Randomised Placebo-controlled Parallel-group Study,Completed,,Phase 2,22.0,Actual,Johannes Gutenberg University Mainz,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:28:20.384900,2020-02-01 17:28:20.384900,K. Lieb,Other,Placebo,Drug
NCT01117948,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-04,2012-05-21,,2013-02-01,2010-05-04,2010-05-06,Estimate,2012-10-30,2012-11-29,Estimate,,,,2013-02-01,2013-02-06,Estimate,September 2009,,2009-09-30,February 2013,2013-02-28,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,,,Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.,"A Multicentre Double-blind, Placebo-controlled, Randomised, Parallel-group Study to Evaluate the Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.",Terminated,,Phase 2,219.0,Actual,JSW Lifesciences,,2.0,,Lack of Efficacy,False,,,,True,,,,,,,,,,,,,2020-02-01 17:17:20.477475,2020-02-01 17:17:20.477475,JSW Lifesciences,Other,Placebo,Drug
NCT01120002,"ClinicalTrials.gov processed this data on January 31, 2020",2010-04-30,,,2011-07-21,2010-05-07,2010-05-10,Estimate,,,,,,,2011-07-21,2011-07-22,Estimate,May 2010,,2010-05-31,July 2011,2011-07-31,December 2012,Anticipated,2012-12-31,December 2012,Anticipated,2012-12-31,,Interventional,,,Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease,,Unknown status,Recruiting,Phase 2,50.0,Anticipated,Osaka City University,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 17:16:39.773727,2020-02-01 17:16:39.773727,Osaka City University,Other,Placebo,Drug
NCT01125631,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-17,,,2011-08-11,2010-05-17,2010-05-18,Estimate,,,,,,,2011-08-11,2011-08-12,Estimate,May 2010,,2010-05-31,August 2011,2011-08-31,August 2011,Actual,2011-08-31,August 2011,Actual,2011-08-31,,Interventional,,,Multiple Intravenous Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease,"A Phase 1, Randomized, Placebo-Controlled, Double Blind, Multicenter Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenous Doses Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease",Completed,,Phase 1,8.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:14:51.996100,2020-02-01 17:14:51.996100,Pfizer,Industry,Placebo,Drug
NCT01126099,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-17,2014-07-15,,2015-05-19,2010-05-18,2010-05-19,Estimate,2015-05-19,2015-05-21,Estimate,,,,2015-05-19,2015-05-21,Estimate,March 2010,,2010-03-31,May 2015,2015-05-31,March 2014,Actual,2014-03-31,March 2014,Actual,2014-03-31,,Interventional,,,Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease,Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease,Completed,,N/A,20.0,Actual,Seattle Institute for Biomedical and Clinical Research,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:14:44.218519,2020-02-01 17:14:44.218519,Seattle Institute for Biomedical and Clinical Research,Other,Placebo,Drug
NCT01127633,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-19,2018-02-12,2014-09-29,2019-09-25,2010-05-19,2010-05-21,Estimate,2018-04-02,2018-05-03,Actual,2014-09-29,2014-10-08,Estimate,2019-09-25,2019-10-08,Actual,December 2010,,2010-12-31,September 2019,2019-09-30,February 2017,Actual,2017-02-28,July 2014,Actual,2014-07-31,,Interventional,EXPEDITION EXT,All randomized participants who received at least 1 dose of study drug.,Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease,"Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease",Terminated,,Phase 3,1457.0,Actual,Eli Lilly and Company,,2.0,,Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.,False,,,,True,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 17:14:11.538960,2020-02-01 17:14:11.538960,Eli Lilly and Company,Industry,Placebo,Drug
NCT01142258,"ClinicalTrials.gov processed this data on January 31, 2020",2010-06-09,,,2012-10-12,2010-06-10,2010-06-11,Estimate,,,,,,,2012-10-12,2012-10-15,Estimate,March 2010,,2010-03-31,October 2012,2012-10-31,August 2012,Actual,2012-08-31,April 2012,Actual,2012-04-30,,Interventional,,,Trazodone for Sleep Disorders in Alzheimer's Disease,"Trazodone for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study",Completed,,Phase 3,40.0,Actual,Brasilia University Hospital,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:10:10.737717,2020-02-01 17:10:10.737717,Brasilia University Hospital,Other,Placebo,Drug
NCT01172145,"ClinicalTrials.gov processed this data on January 31, 2020",2010-07-28,2010-08-04,,2011-02-09,2010-07-28,2010-07-29,Estimate,2011-02-09,2011-03-04,Estimate,,,,2011-02-09,2011-03-04,Estimate,July 2005,,2005-07-31,September 2010,2010-09-30,September 2007,Actual,2007-09-30,,,,,Interventional,,,Treatment of Apathy in Alzheimer's Disease With Modafinil,Treatment of Apathy in Alzheimer's Disease With Modafinil,Completed,,Phase 3,22.0,Actual,Brown University,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:01:29.146927,2020-02-01 17:01:29.146927,Brown University,Other,Placebo,Drug
NCT01203384,"ClinicalTrials.gov processed this data on January 31, 2020",2010-09-15,,,2015-02-09,2010-09-15,2010-09-16,Estimate,,,,,,,2015-02-09,2015-02-10,Estimate,September 2010,,2010-09-30,February 2015,2015-02-28,December 2010,Actual,2010-12-31,December 2010,Actual,2010-12-31,,Interventional,CT02,,"Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects","Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects",Completed,,Phase 1,48.0,Actual,CERESPIR,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:51:33.506485,2020-02-01 16:51:33.506485,CERESPIR,Industry,Placebo,Drug
NCT01224106,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-14,,,2019-11-05,2010-10-18,2010-10-19,Estimate,,,,,,,2019-11-05,2019-11-06,Actual,"November 30, 2010",Actual,2010-11-30,November 2019,2019-11-30,"August 28, 2020",Anticipated,2020-08-28,"August 28, 2020",Anticipated,2020-08-28,,Interventional,,,A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease,"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment","Active, not recruiting",,Phase 3,799.0,Actual,Hoffmann-La Roche,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 16:45:18.177127,2020-02-01 16:45:18.177127,Hoffmann-La Roche,Industry,Placebo,Drug
NCT01294540,"ClinicalTrials.gov processed this data on January 31, 2020",2011-02-10,,,2013-08-28,2011-02-10,2011-02-11,Estimate,,,,,,,2013-08-28,2013-08-29,Estimate,December 2010,,2010-12-31,August 2013,2013-08-31,December 2011,Actual,2011-12-31,October 2011,Actual,2011-10-31,,Interventional,,,"Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Subjects and an Elderly Cohort","A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Doses of E2609 in Healthy Subjects and an Elderly Cohort",Completed,,Phase 1,73.0,Actual,Eisai Inc.,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:24:31.268851,2020-02-01 16:24:31.268851,Eisai Inc.,Industry,Placebo,Drug
NCT01303744,"ClinicalTrials.gov processed this data on January 31, 2020",2011-02-23,2015-10-16,2012-05-18,2015-12-02,2011-02-23,2011-02-25,Estimate,2015-12-02,2016-01-11,Estimate,2012-05-18,2012-05-30,Estimate,2015-12-02,2016-01-11,Estimate,March 2011,,2011-03-31,December 2015,2015-12-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,CT04,,Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074,"A Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Tolerability of Multiple Dose Regimens of CHF 5074 and to Explore the Effects in Patients With Mild Cognitive Impairment",Completed,,Phase 2,96.0,Actual,CERESPIR,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:21:56.018097,2020-02-01 16:21:56.018097,CERESPIR,Industry,Placebo,Drug
NCT01350362,"ClinicalTrials.gov processed this data on January 31, 2020",2011-05-06,,,2012-10-01,2011-05-06,2011-05-09,Estimate,,,,,,,2012-10-01,2012-10-02,Estimate,April 2011,,2011-04-30,October 2012,2012-10-31,October 2012,Actual,2012-10-31,July 2012,Actual,2012-07-31,,Interventional,ARGO,,"Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients","A Multicenter, Randomized, Double-blind, Placebo-controlled, 4-arm, 26 Week Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of 2 Oral Doses and 2 Regimes of Tideglusib vs Placebo in Mild-to-Moderate AD Patients",Completed,,Phase 2,306.0,Actual,Noscira SA,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:08:35.589262,2020-02-01 16:08:35.589262,Noscira SA,Industry,Placebo,Drug
NCT01354444,"ClinicalTrials.gov processed this data on January 31, 2020",2011-05-09,2017-10-26,,2018-01-08,2011-05-13,2011-05-16,Estimate,2018-01-08,2018-02-06,Actual,,,,2018-01-08,2018-02-06,Actual,June 2011,Actual,2011-06-30,January 2018,2018-01-31,January 2017,Actual,2017-01-31,December 2016,Actual,2016-12-31,,Interventional,,,Trial of Carvedilol in Alzheimer's Disease,Pilot Trial of Carvedilol in Alzheimer's Disease,Completed,,Phase 4,29.0,Actual,Johns Hopkins University,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:07:28.450704,2020-02-01 16:07:28.450704,Johns Hopkins University,Other,Placebo,Drug
NCT01374438,"ClinicalTrials.gov processed this data on January 31, 2020",2011-06-14,2014-09-25,,2014-11-05,2011-06-15,2011-06-16,Estimate,2014-11-03,2014-11-05,Estimate,,,,2014-11-05,2014-11-18,Estimate,July 2011,,2011-07-31,November 2014,2014-11-30,May 2013,Actual,2013-05-31,March 2013,Actual,2013-03-31,,Interventional,,All randomized subjects completed the full study and are included in the analysis.,"3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease","A 3-month Randomized, Double-Blind, Placebo-Controlled, Feasibility Study to Evaluate the Effects of MSDC-0160 on Brain Glucose Utilization, Cognition, Safety and Tolerability in Older Persons With Mild Alzheimer's Disease",Completed,,Phase 2,29.0,Actual,Metabolic Solutions Development Company,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:02:10.248730,2020-02-01 16:02:10.248730,Metabolic Solutions Development Company,Industry,Placebo,Drug
NCT01404169,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-26,,,2017-03-07,2011-07-26,2011-07-27,Estimate,,,,,,,2017-03-07,2017-03-08,Actual,September 2011,Actual,2011-09-30,March 2017,2017-03-31,September 2014,Actual,2014-09-30,July 2014,Actual,2014-07-31,,Interventional,,,"A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease","A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease",Completed,,Phase 3,260.0,Actual,Eisai Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:54:49.274654,2020-02-01 15:54:49.274654,Eisai Limited,Industry,Placebo,Drug
NCT01406145,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-06,,,2019-01-28,2011-07-28,2011-08-01,Estimate,,,,,,,2019-01-28,2019-01-30,Actual,"June 16, 2011",Actual,2011-06-16,January 2019,2019-01-31,"November 4, 2011",Actual,2011-11-04,"November 4, 2011",Actual,2011-11-04,,Interventional,,,A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil,"A Phase 1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Sequential Dose Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease on Donepezil",Completed,,Phase 1,60.0,Actual,Astellas Pharma Inc,,4.0,,,False,,,,False,,,,,,,,Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.,"Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.",https://www.clinicalstudydatarequest.com/,Yes,"Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.",2020-02-01 15:54:20.292494,2020-02-01 15:54:20.292494,Astellas Pharma Inc,Industry,Placebo,Drug
NCT01409564,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-03,2013-08-19,,2014-04-14,2011-08-03,2011-08-04,Estimate,2014-04-14,2014-05-13,Estimate,,,,2014-04-14,2014-05-13,Estimate,May 2010,,2010-05-31,April 2014,2014-04-30,July 2013,Actual,2013-07-31,June 2012,Actual,2012-06-30,,Interventional,,18 subjects for each group were enrolled in the final list.,Cilostazol Augmentation Study in Dementia,"Cilostazol Augmentation Study In Dementia (CASID): A Randomized, Placebo-controlled Pilot Study to Compare the Efficacy Between Donepezil Monotherapy and Cilostazol Augmentation Therapy in Alzheimer's Disease Patients With Subcortical White Matter Hyperintensities",Completed,,Phase 4,46.0,Actual,Seoul National University Hospital,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:53:37.059474,2020-02-01 15:53:37.059474,Seoul National University Hospital,Other,Placebo,Drug
NCT01428362,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-31,,2013-10-23,2013-11-15,2011-08-31,2011-09-05,Estimate,,,,2013-10-23,2013-11-15,Estimate,2013-11-15,2013-12-11,Estimate,August 2011,,2011-08-31,November 2013,2013-11-30,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,AD-201,,VI-1121 for the Treatment Alzheimer's Disease,"A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease",Completed,,Phase 2,61.0,Actual,"VIVUS, Inc.",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:49:01.052351,2020-02-01 15:49:01.052351,"VIVUS, Inc.",Industry,Placebo,Drug
NCT01438060,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-02,2012-02-01,,2013-11-07,2011-09-20,2011-09-21,Estimate,2012-02-01,2012-03-05,Estimate,,,,2013-11-07,2013-12-02,Estimate,August 2000,,2000-08-31,November 2013,2013-11-30,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type,"A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type",Completed,,Phase 3,232.0,Actual,"Otsuka Pharmaceutical Development & Commercialization, Inc.","Limitations of the study, such as early termination leading to small numbers of subjects analyzed and technical problems with measurement leading to unreliable or uninterpretable data",2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:46:23.659143,2020-02-01 15:46:23.659143,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,Placebo,Drug
NCT01453569,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-30,2014-11-13,,2015-01-25,2011-10-13,2011-10-18,Estimate,2015-01-25,2015-01-27,Estimate,,,,2015-01-25,2015-01-27,Estimate,October 2011,,2011-10-31,January 2015,2015-01-31,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,,"All the treated subjects were evaluated for safety. 2, 8 and 3 subjects were excluded from FAS in placebo, 600 mg and 900 mg group respectively. So the case No. were 83, 76, 83 for placebo, 600 mg and 900 mg group respectively.","Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease",Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease,Completed,,Phase 2,255.0,Actual,"Shanghai Greenvalley Pharmaceutical Co., Ltd.",,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:41:57.383248,2020-02-01 15:41:57.383248,"Shanghai Greenvalley Pharmaceutical Co., Ltd.",Industry,Placebo,Drug
NCT01467726,"ClinicalTrials.gov processed this data on January 31, 2020",2011-10-28,,,2014-12-01,2011-11-04,2011-11-09,Estimate,,,,,,,2014-12-01,2014-12-03,Estimate,November 2011,,2011-11-30,December 2014,2014-12-31,January 2012,Actual,2012-01-31,January 2012,Actual,2012-01-31,,Interventional,,,"Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects","A Phase 1, Randomized, Placebo−Controlled, Double−Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects",Completed,,Phase 1,40.0,Actual,Theravance Biopharma,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:37:39.137884,2020-02-01 15:37:39.137884,Theravance Biopharma,Industry,Placebo,Drug
NCT01482013,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-10,,,2012-08-29,2011-11-28,2011-11-30,Estimate,,,,,,,2012-08-29,2012-08-30,Estimate,October 2011,,2011-10-31,August 2012,2012-08-31,March 2012,Actual,2012-03-31,March 2012,Actual,2012-03-31,,Interventional,,,Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease,"A Double-blind, Randomized, Placebo-controlled, Phase I , Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease",Terminated,,Phase 1,7.0,Actual,"High Point Pharmaceuticals, LLC.",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:33:39.759571,2020-02-01 15:33:39.759571,"High Point Pharmaceuticals, LLC.",Industry,Placebo,Drug
NCT01487395,"ClinicalTrials.gov processed this data on January 31, 2020",2011-12-05,,,2015-04-08,2011-12-06,2011-12-07,Estimate,,,,,,,2015-04-08,2015-04-09,Estimate,December 2011,,2011-12-31,April 2015,2015-04-30,December 2013,Actual,2013-12-31,December 2012,Actual,2012-12-31,,Interventional,PharmacogWP3,,Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development,Effect of a 15-day Donepezil Treatment on Biomarkers of AD in Healthy Volunteers,Completed,,Phase 1,30.0,Actual,"University Hospital, Lille",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:32:28.068353,2020-02-01 15:32:28.068353,"University Hospital, Lille",Other,Placebo,Drug
NCT01496170,"ClinicalTrials.gov processed this data on January 31, 2020",2011-12-06,,,2015-10-22,2011-12-16,2011-12-21,Estimate,,,,,,,2015-10-22,2015-10-23,Estimate,December 2011,,2011-12-31,October 2015,2015-10-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,,,"A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])","A Study to Assess the Safety, Tolerability, and Pharmacodynamics of MK-8931/SCH 900931 in Patients With Alzheimer's Disease [Phase 1b; Protocol No. 010-00 (Also Known as P07820)]",Completed,,Phase 1,32.0,Actual,Merck Sharp & Dohme Corp.,,5.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:30:09.701105,2020-02-01 15:30:09.701105,Merck Sharp & Dohme Corp.,Industry,Placebo,Drug
NCT01504854,"ClinicalTrials.gov processed this data on January 31, 2020",2011-12-23,2016-01-28,,2016-05-06,2012-01-03,2012-01-06,Estimate,2016-05-06,2016-06-14,Estimate,,,,2016-05-06,2016-06-14,Estimate,May 2012,,2012-05-31,April 2016,2016-04-30,March 2014,Actual,2014-03-31,March 2014,Actual,2014-03-31,,Interventional,,,Resveratrol for Alzheimer's Disease,Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease,Completed,,Phase 2,119.0,Actual,Alzheimer's Disease Cooperative Study (ADCS),This phase 2 study has limitations. A larger study is required to determine whether resveratrol may be beneficial. More potent and bioavailable SIRT1 activators are also in development.,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:28:15.052585,2020-02-01 15:28:15.052585,Alzheimer's Disease Cooperative Study (ADCS),Other,Placebo,Drug
NCT01513967,"ClinicalTrials.gov processed this data on January 31, 2020",2012-01-17,,,2016-12-05,2012-01-17,2012-01-20,Estimate,,,,,,,2016-12-05,2016-12-06,Estimate,January 2012,,2012-01-31,June 2015,2015-06-30,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,,,A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease,A Randomized Single and Multiple Dose Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease,Completed,,Phase 1/Phase 2,36.0,Actual,Regenera Pharma Ltd,,14.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:26:07.384967,2020-02-01 15:26:07.384967,Regenera Pharma Ltd,Industry,Placebo,Drug
NCT01569516,"ClinicalTrials.gov processed this data on January 31, 2020",2012-03-30,,,2012-04-06,2012-03-30,2012-04-03,Estimate,,,,,,,2012-04-06,2012-04-09,Estimate,June 2011,,2011-06-30,May 2011,2011-05-31,October 2012,Anticipated,2012-10-31,July 2012,Anticipated,2012-07-31,,Interventional,,,Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease,"A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease",Unknown status,Recruiting,Phase 2,288.0,Anticipated,"Changchun Huayang High-tech Co., Ltd",,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:12:18.612653,2020-02-01 15:12:18.612653,"Changchun Huayang High-tech Co., Ltd",Industry,Placebo,Drug
NCT01584440,"ClinicalTrials.gov processed this data on January 31, 2020",2012-04-23,,2018-01-08,2018-01-08,2012-04-24,2012-04-25,Estimate,,,,2018-01-08,2018-01-11,Actual,2018-01-08,2018-01-11,Actual,June 2012,,2012-06-30,January 2018,2018-01-31,September 2014,Actual,2014-09-30,July 2014,Actual,2014-07-31,,Interventional,,,"Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients","A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.",Completed,,Phase 2,220.0,Actual,Avanir Pharmaceuticals,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:08:45.066700,2020-02-01 15:08:45.066700,Avanir Pharmaceuticals,Industry,Placebo,Drug
NCT01608217,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-25,,,2014-06-26,2012-05-25,2012-05-31,Estimate,,,,,,,2014-06-26,2014-06-30,Estimate,June 2012,,2012-06-30,June 2014,2014-06-30,June 2014,Actual,2014-06-30,June 2014,Actual,2014-06-30,,Interventional,,,Delta-THC in Dementia,Efficacy and Safety of Delta-9-tetrahydrocannabinol (∆9-THC) in Behavioural Disturbances and Pain in Dementia,Completed,,Phase 2,50.0,Actual,Radboud University,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:02:26.242272,2020-02-01 15:02:26.242272,Radboud University,Other,Placebo,Drug
NCT01609348,"ClinicalTrials.gov processed this data on January 31, 2020",2012-04-27,2017-10-16,,2018-01-04,2012-05-29,2012-06-01,Estimate,2018-01-04,2018-01-31,Actual,,,,2018-01-04,2018-01-31,Actual,April 2012,,2012-04-30,January 2018,2018-01-31,January 2017,Actual,2017-01-31,December 2016,Actual,2016-12-31,,Interventional,DIADs-3,,Venlafaxine for Depression in Alzheimer's Disease (DIADs-3),Venlafaxine for Depression in Alzheimer's Disease,Completed,,N/A,5.0,Actual,Johns Hopkins University,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:02:11.829599,2020-02-01 15:02:11.829599,Johns Hopkins University,Other,Placebo,Drug
NCT01617577,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-08,2012-06-29,,2012-11-26,2012-06-11,2012-06-12,Estimate,2012-11-26,2012-12-27,Estimate,,,,2012-11-26,2012-12-27,Estimate,June 2009,,2009-06-30,June 2012,2012-06-30,February 2012,Actual,2012-02-29,February 2012,Actual,2012-02-29,,Interventional,FFAD,,Efficacy and Safety of Filgrastim in Alzheimer's Disease,Efficacy and Safety of Filgrastim as a Pro‐Cognitive Agent in Alzheimer's Disease,Completed,,Phase 1/Phase 2,8.0,Actual,University of South Florida,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:00:17.017452,2020-02-01 15:00:17.017452,University of South Florida,Other,Placebo,Drug
NCT01626391,"ClinicalTrials.gov processed this data on January 31, 2020",2012-06-20,2014-04-28,,2014-06-10,2012-06-20,2012-06-22,Estimate,2014-06-10,2014-07-11,Estimate,,,,2014-06-10,2014-07-11,Estimate,September 2012,,2012-09-30,June 2014,2014-06-30,March 2013,Actual,2013-03-31,March 2013,Actual,2013-03-31,,Interventional,,Safety Population,Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease,"A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease on Pre-Existing Stable Acetylcholinesterase Inhibitor and/or Memantine Therapy",Terminated,,Phase 2,9.0,Actual,TauRx Therapeutics Ltd,Early termination leading to small numbers of subjects analyzed,2.0,,This study has been terminated for administrative reasons only.,False,,,,True,,,,,,,,,,,,,2020-02-01 14:58:05.465796,2020-02-01 14:58:05.465796,TauRx Therapeutics Ltd,Industry,Placebo,Drug
NCT01656525,"ClinicalTrials.gov processed this data on January 31, 2020",2012-06-05,,,2014-09-17,2012-08-01,2012-08-03,Estimate,,,,,,,2014-09-17,2014-09-19,Estimate,June 2012,,2012-06-30,September 2014,2014-09-30,June 2014,Actual,2014-06-30,March 2014,Actual,2014-03-31,,Interventional,,,A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients,"A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients",Completed,,Phase 1,28.0,Actual,Chugai Pharmaceutical,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:50:26.009270,2020-02-01 14:50:26.009270,Chugai Pharmaceutical,Industry,Placebo,Drug
NCT01661673,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-03,,,2014-01-10,2012-08-06,2012-08-09,Estimate,,,,,,,2014-01-10,2014-01-13,Estimate,November 2012,,2012-11-30,January 2014,2014-01-31,,,,October 2013,Actual,2013-10-31,,Interventional,,,"Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease","Safety, Tolerability, Pharmacokinetics, and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease",Completed,,Phase 2,52.0,Actual,FORUM Pharmaceuticals Inc,,5.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:49:17.382489,2020-02-01 14:49:17.382489,FORUM Pharmaceuticals Inc,Industry,Placebo,Drug
NCT01677572,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-30,,,2019-11-07,2012-08-31,2012-09-03,Estimate,,,,,,,2019-11-07,2019-11-12,Actual,"October 5, 2012",Actual,2012-10-05,November 2019,2019-11-30,"July 31, 2019",Actual,2019-07-31,"March 21, 2019",Actual,2019-03-21,,Interventional,PRIME,,"Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease","A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease",Terminated,,Phase 1,197.0,Actual,Biogen,,9.0,,"Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and
    NCT02484547) and not based on safety concerns.",False,,,,True,,,,,,,,,,,,,2020-02-01 14:44:45.388276,2020-02-01 14:44:45.388276,Biogen,Industry,Placebo,Drug
NCT01677754,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-30,,2016-07-20,2017-05-25,2012-08-30,2012-09-03,Estimate,,,,2016-07-20,2016-07-22,Estimate,2017-05-25,2017-05-30,Actual,"October 24, 2012",Actual,2012-10-24,May 2017,2017-05-31,"June 12, 2015",Actual,2015-06-12,"June 12, 2015",Actual,2015-06-12,,Interventional,MAyflOwer RoAD,,A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy,"A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease",Completed,,Phase 2,542.0,Actual,Hoffmann-La Roche,,3.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 14:44:43.645589,2020-02-01 14:44:43.645589,Hoffmann-La Roche,Industry,Placebo,Drug
NCT01689233,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-14,,2018-03-12,2018-03-12,2012-09-20,2012-09-21,Estimate,,,,2018-03-12,2018-03-14,Actual,2018-03-12,2018-03-14,Actual,October 2012,,2012-10-31,March 2018,2018-03-31,May 2016,Actual,2016-05-31,May 2016,Actual,2016-05-31,,Interventional,,,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of TRx0237 in Subjects With Mild Alzheimer's Disease",Completed,,Phase 3,800.0,Actual,TauRx Therapeutics Ltd,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:41:34.512210,2020-02-01 14:41:34.512210,TauRx Therapeutics Ltd,Industry,Placebo,Drug
NCT01689246,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-14,,2018-03-12,2018-03-12,2012-09-20,2012-09-21,Estimate,,,,2018-03-12,2018-03-14,Actual,2018-03-12,2018-03-14,Actual,January 2013,,2013-01-31,March 2018,2018-03-31,November 2015,Actual,2015-11-30,November 2015,Actual,2015-11-30,,Interventional,,,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,891.0,Actual,TauRx Therapeutics Ltd,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:41:34.220277,2020-02-01 14:41:34.220277,TauRx Therapeutics Ltd,Industry,Placebo,Drug
NCT01702467,"ClinicalTrials.gov processed this data on January 31, 2020",2012-10-04,,,2017-10-16,2012-10-04,2012-10-08,Estimate,,,,,,,2017-10-16,2017-10-18,Actual,"October 19, 2012",Actual,2012-10-19,October 2017,2017-10-31,"May 15, 2013",Actual,2013-05-15,"May 15, 2013",Actual,2013-05-15,,Interventional,,,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers","A Single-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers",Completed,,Phase 1,27.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 14:38:19.515848,2020-02-01 14:38:19.515848,GlaxoSmithKline,Industry,Placebo,Drug
NCT01702480,"ClinicalTrials.gov processed this data on January 31, 2020",2012-10-04,,,2017-05-05,2012-10-04,2012-10-08,Estimate,,,,,,,2017-05-05,2017-05-09,Actual,"November 5, 2012",Actual,2012-11-05,May 2017,2017-05-31,"July 3, 2015",Actual,2015-07-03,"July 3, 2015",Actual,2015-07-03,,Interventional,,,Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects,Effects of Medium-Chain Triglycerides on Cognitive Function in Older Subjects With Age-Related Cognitive Decline,Completed,,Phase 1,116.0,Actual,GlaxoSmithKline,,7.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:38:19.414695,2020-02-01 14:38:19.414695,GlaxoSmithKline,Industry,Placebo,Drug
NCT01703117,"ClinicalTrials.gov processed this data on January 31, 2020",2012-10-04,,,2020-01-28,2012-10-05,2012-10-10,Estimate,,,,,,,2020-01-28,2020-01-30,Actual,November 2013,Actual,2013-11-30,January 2020,2020-01-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,,,Riluzole in Mild Alzheimer's Disease,Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Alzheimer's Disease,"Active, not recruiting",,Phase 2,42.0,Anticipated,Icahn School of Medicine at Mount Sinai,,2.0,,,False,,,,True,True,,,,,,,,,,,,2020-02-03 05:32:16.066889,2020-02-03 05:32:16.066889,Icahn School of Medicine at Mount Sinai,Other,Placebo,Drug
NCT01715350,"ClinicalTrials.gov processed this data on January 31, 2020",2012-10-24,,,2016-04-15,2012-10-25,2012-10-26,Estimate,,,,,,,2016-04-15,2016-04-18,Estimate,May 2012,,2012-05-31,April 2016,2016-04-30,June 2015,Actual,2015-06-30,September 2014,Actual,2014-09-30,,Interventional,ADD,,Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease,"A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease: Double-Blind, Randomized Between Placebo Control Group and Dose Groups, Parallel-Design, Multicenter Study",Completed,,Phase 2,151.0,Actual,"GMP BIO Co., LTD.",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:34:17.112760,2020-02-01 14:34:17.112760,"GMP BIO Co., LTD.",Industry,Placebo,Drug
NCT01735630,"ClinicalTrials.gov processed this data on January 31, 2020",2012-11-25,2016-04-07,,2019-10-17,2012-11-27,2012-11-28,Estimate,2016-07-06,2016-08-15,Estimate,,,,2019-10-17,2019-10-21,Actual,November 2012,,2012-11-30,October 2019,2019-10-31,May 2015,Actual,2015-05-31,May 2015,Actual,2015-05-31,,Interventional,,,Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease,"A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease",Completed,,Phase 2,350.0,Actual,"OPKO Health, Inc.",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:29:01.435468,2020-02-01 14:29:01.435468,"OPKO Health, Inc.",Industry,Placebo,Drug
NCT01764243,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-26,,,2015-09-24,2013-01-07,2013-01-09,Estimate,,,,,,,2015-09-24,2015-09-28,Estimate,November 2012,,2012-11-30,September 2015,2015-09-30,July 2015,Actual,2015-07-31,June 2015,Actual,2015-06-30,,Interventional,,,Safety and Efficacy of MT-4666,"A Double-Blind, Placebo-Controlled Phase2 Study of MT-4666 in Patients With Mild to Moderate Probable Alzheimer's Disease.",Completed,,Phase 2,450.0,Actual,Mitsubishi Tanabe Pharma Corporation,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:21:47.790249,2020-02-01 14:21:47.790249,Mitsubishi Tanabe Pharma Corporation,Industry,Placebo,Drug
NCT01767311,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-08,,,2019-12-02,2013-01-10,2013-01-14,Estimate,,,,,,,2019-12-02,2019-12-03,Actual,"December 20, 2012",Actual,2012-12-20,July 2018,2018-07-31,"January 27, 2022",Anticipated,2022-01-27,"January 27, 2022",Anticipated,2022-01-27,,Interventional,,,"A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease","A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 2,800.0,Actual,Eisai Inc.,,7.0,,,False,,,,True,True,,,,,,,,,,,,2020-02-01 14:20:49.513489,2020-02-01 14:20:49.513489,Eisai Inc.,Industry,Placebo,Drug
NCT01767909,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-10,,,2019-01-16,2013-01-11,2013-01-15,Estimate,,,,,,,2019-01-16,2019-01-18,Actual,"January 8, 2014",Actual,2014-01-08,January 2019,2019-01-31,"December 11, 2018",Actual,2018-12-11,"December 11, 2018",Actual,2018-12-11,,Interventional,,,The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF),Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD),Completed,,Phase 2/Phase 3,239.0,Actual,University of Southern California,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:20:36.780945,2020-02-01 14:20:36.780945,University of Southern California,Other,Placebo,Drug
NCT01782742,"ClinicalTrials.gov processed this data on January 31, 2020",2013-01-29,2016-02-10,,2016-02-10,2013-02-01,2013-02-04,Estimate,2016-02-10,2016-02-12,Estimate,,,,2016-02-10,2016-02-12,Estimate,February 2013,,2013-02-28,February 2016,2016-02-29,December 2014,Actual,2014-12-31,August 2014,Actual,2014-08-31,,Interventional,BEAT-AD,,Bexarotene Amyloid Treatment for Alzheimer's Disease,A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and Safety of Bexarotene in Patients With Mild to Moderate Alzheimer's Disease,Completed,,Phase 2,20.0,Actual,The Cleveland Clinic,Sample size of this trial is small. There was 1 participant withdrawal due to adverse event. Primary outcome measures were completed by all 20 participants as anticipated.,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:16:32.938142,2020-02-01 14:16:32.938142,The Cleveland Clinic,Other,Placebo,Drug
NCT01841125,"ClinicalTrials.gov processed this data on January 31, 2020",2013-04-18,,,2014-08-12,2013-04-25,2013-04-26,Estimate,,,,,,,2014-08-12,2014-08-13,Estimate,November 2011,,2011-11-30,August 2014,2014-08-31,July 2014,Actual,2014-07-31,July 2014,Actual,2014-07-31,,Interventional,Escitalopram,,Escitalopram for the Treatment of Depression in Alzheimer's Disease,"A 12-Week Randomized, Double-blind, Parallel-group, Placebo-controlled Trial With and Open-label, 12-week Extension, Multicenter to Evaluation of the Efficacy of Escitalopram for the Treatment of Depression in Alzheimer's Disease",Completed,,Phase 4,84.0,Actual,Konkuk University Medical Center,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 14:02:56.756489,2020-02-01 14:02:56.756489,Konkuk University Medical Center,Other,Placebo,Drug
NCT01843075,"ClinicalTrials.gov processed this data on January 31, 2020",2013-04-24,,,2019-06-06,2013-04-26,2013-04-30,Estimate,,,,,,,2019-06-06,2019-06-10,Actual,January 2014,Actual,2014-01-31,June 2019,2019-06-30,December 2019,Anticipated,2019-12-31,December 2019,Anticipated,2019-12-31,,Interventional,ELAD,,Evaluating Liraglutide in Alzheimer's Disease,"Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)","Active, not recruiting",,Phase 2,204.0,Actual,Imperial College London,,2.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 14:02:32.425844,2020-02-01 14:02:32.425844,Imperial College London,Other,Placebo,Drug
NCT01852110,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-08,2018-01-08,,2018-08-20,2013-05-08,2013-05-13,Estimate,2018-01-08,2018-02-07,Actual,,,,2018-08-20,2018-09-18,Actual,"October 22, 2013",Actual,2013-10-22,August 2018,2018-08-31,"April 11, 2016",Actual,2016-04-11,"April 11, 2016",Actual,2016-04-11,,Interventional,,"Includes only participants in Stage 1 who were both randomized (i.e. started) and treated.
In stage 1:
MK-7622 High Dose - 45 mg: of the randomized participants (n=120), all but 1 randomized participant received study treatment (n=119).
Placebo: Of the randomized participants (n=120), all received study treatment (n=120).",Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012),"A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy for Symptomatic Treatment in Subjects With Alzheimer's Disease",Terminated,,Phase 2,240.0,Actual,Merck Sharp & Dohme Corp.,"Stage 1 Interim analysis of efficacy met the clinical criteria for early trial termination (futility). As a result, the trial was terminated at Stage 1 and did not proceed to Stage 2.",6.0,,"Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility).
    The trial was terminated at Stage 1; did not proceed to Stage 2.",False,,,,False,True,False,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2020-02-01 14:00:05.175571,2020-02-01 14:00:05.175571,Merck Sharp & Dohme Corp.,Industry,Placebo,Drug
NCT01864655,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-08,,,2014-06-12,2013-05-28,2013-05-29,Estimate,,,,,,,2014-06-12,2014-06-13,Estimate,July 2013,,2013-07-31,June 2014,2014-06-30,,,,March 2014,Actual,2014-03-31,,Interventional,,,Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease,"A Phase Ib Multiple Ascending Dose Study of the Safety, Tolerability, and CNS Availability of AZD0530 in Alzheimer's Disease",Completed,,Phase 1,24.0,Actual,Yale University,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:55:28.062074,2020-02-01 13:55:28.062074,Stephen M. Strittmatter,Other,Placebo,Drug
NCT01872598,"ClinicalTrials.gov processed this data on January 31, 2020",2013-06-05,,,2019-06-13,2013-06-06,2013-06-07,Estimate,,,,,,,2019-06-13,2019-06-17,Actual,January 2012,,2012-01-31,June 2019,2019-06-30,December 2019,Anticipated,2019-12-31,December 2019,Anticipated,2019-12-31,,Interventional,,,Masitinib in Patients With Mild to Moderate Alzheimer's Disease,"A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease","Active, not recruiting",,Phase 3,721.0,Actual,AB Science,,5.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:52:27.547176,2020-02-01 13:52:27.547176,AB Science,Industry,Placebo,Drug
NCT01900665,"ClinicalTrials.gov processed this data on January 31, 2020",2013-07-12,2018-02-16,2016-12-21,2019-09-25,2013-07-12,2013-07-16,Estimate,2018-02-16,2018-03-14,Actual,2016-12-21,2016-12-23,Estimate,2019-09-25,2019-10-09,Actual,July 2013,,2013-07-31,September 2019,2019-09-30,February 2017,Actual,2017-02-28,October 2016,Actual,2016-10-31,,Interventional,EXPEDITION 3,All randomized participants.,Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo,Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo,Terminated,,Phase 3,2129.0,Actual,Eli Lilly and Company,,2.0,,Solanezumab did not meet the study's primary endpoint.,False,,,,True,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 13:45:21.891307,2020-02-01 13:45:21.891307,Eli Lilly and Company,Industry,Placebo,Drug
NCT01908010,"ClinicalTrials.gov processed this data on January 31, 2020",2013-07-23,,,2013-12-09,2013-07-23,2013-07-25,Estimate,,,,,,,2013-12-09,2013-12-11,Estimate,July 2013,,2013-07-31,December 2013,2013-12-31,November 2013,Actual,2013-11-30,November 2013,Actual,2013-11-30,,Interventional,,,"Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors","A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",Completed,,Phase 1,20.0,Actual,AbbVie,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:43:36.072132,2020-02-01 13:43:36.072132,AbbVie,Industry,Placebo,Drug
NCT01921972,"ClinicalTrials.gov processed this data on January 31, 2020",2013-08-07,,,2013-08-12,2013-08-12,2013-08-14,Estimate,,,,,,,2013-08-12,2013-08-14,Estimate,November 2004,,2004-11-30,August 2013,2013-08-31,May 2009,Actual,2009-05-31,November 2008,Actual,2008-11-30,,Interventional,AD-Combi,,The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease,"Competence Network - Dementia (BMBF) ""Pharmacological and Psychosocial Treatment"" (Modul E.2) Part II: The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 4,232.0,Actual,"Charite University, Berlin, Germany",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:40:38.562936,2020-02-01 13:40:38.562936,"Charite University, Berlin, Germany",Other,Placebo,Drug
NCT01928420,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-17,,2016-10-07,2016-10-14,2013-08-20,2013-08-26,Estimate,,,,2016-10-14,2016-10-17,Estimate,2016-10-14,2016-10-17,Estimate,April 2007,,2007-04-30,October 2016,2016-10-31,June 2014,Actual,2014-06-30,June 2014,Actual,2014-06-30,,Interventional,,,"A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease","A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease",Completed,,Phase 2,30.0,Actual,Humanetics Corporation,,2.0,,,False,,,,True,,,,,,,,,,,Undecided,,2020-02-01 13:38:52.901927,2020-02-01 13:38:52.901927,Humanetics Corporation,Industry,Placebo,Drug
NCT01955161,"ClinicalTrials.gov processed this data on January 31, 2020",2013-09-27,2017-07-11,,2017-08-22,2013-09-27,2013-10-07,Estimate,2017-08-22,2017-09-19,Actual,,,,2017-08-22,2017-09-19,Actual,October 2013,,2013-10-31,August 2017,2017-08-31,July 2016,Actual,2016-07-31,July 2016,Actual,2016-07-31,,Interventional,STARSHINE,A total of 933 patients were randomized into the study but 3 patients were not treated (did not receive IMP). The baseline analysis population only consist of patients who have been treated.,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil,"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil",Completed,,Phase 3,933.0,Actual,H. Lundbeck A/S,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:31:12.067407,2020-02-01 13:31:12.067407,H. Lundbeck A/S,Industry,Placebo,Drug
NCT01969123,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-21,,,2016-05-02,2013-10-24,2013-10-25,Estimate,,,,,,,2016-05-02,2016-05-03,Estimate,October 2013,,2013-10-31,September 2015,2015-09-30,January 2017,Anticipated,2017-01-31,January 2017,Anticipated,2017-01-31,,Interventional,,,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication",Terminated,,Phase 3,474.0,Actual,FORUM Pharmaceuticals Inc,,3.0,,Study has been suspended due to clinical hold.,False,,,,,,,,,,,,,,,,,2020-02-01 13:27:15.310397,2020-02-01 13:27:15.310397,FORUM Pharmaceuticals Inc,Industry,Placebo,Drug
NCT01969136,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-21,,,2016-05-02,2013-10-24,2013-10-25,Estimate,,,,,,,2016-05-02,2016-05-03,Estimate,October 2013,,2013-10-31,September 2015,2015-09-30,January 2017,Anticipated,2017-01-31,January 2017,Anticipated,2017-01-31,,Interventional,,,Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease,"A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication",Terminated,,Phase 3,403.0,Actual,FORUM Pharmaceuticals Inc,,3.0,,Study has been suspended due to clinical hold.,False,,,,,,,,,,,,,,,,,2020-02-01 13:27:15.097847,2020-02-01 13:27:15.097847,FORUM Pharmaceuticals Inc,Industry,Placebo,Drug
NCT01978548,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-31,,,2015-06-24,2013-10-31,2013-11-07,Estimate,,,,,,,2015-06-24,2015-06-25,Estimate,December 2013,,2013-12-31,June 2015,2015-06-30,April 2015,Actual,2015-04-30,April 2015,Actual,2015-04-30,,Interventional,,,A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease,"A Double-blind, Placebo-Controlled, Randomized, 4-Week, Multiple-Dose, Proof-of-Mechanism Study in Subjects With Prodromal Alzheimer's Disease Investigating the Effects of JNJ-54861911 on Aβ Processing in CSF and Plasma",Completed,,Phase 1,45.0,Actual,"Janssen Research & Development, LLC",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:24:17.334831,2020-02-01 13:24:17.334831,"Janssen Research & Development, LLC",Industry,Placebo,Drug
NCT01998841,"ClinicalTrials.gov processed this data on January 31, 2020",2013-11-22,,,2019-11-05,2013-11-25,2013-12-02,Estimate,,,,,,,2019-11-05,2019-11-06,Actual,"December 20, 2013",Actual,2013-12-20,November 2019,2019-11-30,"February 25, 2022",Anticipated,2022-02-25,"February 25, 2022",Anticipated,2022-02-25,,Interventional,,,"A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort","A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease","Active, not recruiting",,Phase 2,252.0,Actual,"Genentech, Inc.",,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 13:19:17.748616,2020-02-01 13:19:17.748616,"Genentech, Inc.",Industry,Placebo,Drug
NCT02006641,"ClinicalTrials.gov processed this data on January 31, 2020",2013-12-05,2017-12-19,,2018-01-23,2013-12-05,2013-12-10,Estimate,2018-01-23,2018-02-20,Actual,,,,2018-01-23,2018-02-20,Actual,February 2014,,2014-02-28,January 2018,2018-01-31,December 2016,Actual,2016-12-31,December 2016,Actual,2016-12-31,,Interventional,STARBEAM,A total of 858 patients were randomized into the study but 10 patients were not treated (did not receive IMP). The baseline analysis population only consist of patients who have been treated.,Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil,"Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil",Completed,,Phase 3,858.0,Actual,H. Lundbeck A/S,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:17:05.953656,2020-02-01 13:17:05.953656,H. Lundbeck A/S,Industry,Placebo,Drug
NCT02006654,"ClinicalTrials.gov processed this data on January 31, 2020",2013-12-05,2018-01-12,,2018-01-12,2013-12-09,2013-12-10,Estimate,2018-01-12,2018-02-07,Actual,,,,2018-01-12,2018-02-07,Actual,March 2014,,2014-03-31,January 2018,2018-01-31,January 2017,Actual,2017-01-31,January 2017,Actual,2017-01-31,,Interventional,STARBRIGHT,A total of 734 patients were randomized into the study but 6 patients were not treated (did not receive IMP). The baseline analysis population only consist of patients who have been treated.,Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor,"Randomised, Double-blind, Parallel-group, Placebo-controlled Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor",Completed,,Phase 3,734.0,Actual,H. Lundbeck A/S,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:17:04.911285,2020-02-01 13:17:04.911285,H. Lundbeck A/S,Industry,Placebo,Drug
NCT02017340,"ClinicalTrials.gov processed this data on January 31, 2020",2013-12-16,,,2017-03-03,2013-12-16,2013-12-20,Estimate,,,,,,,2017-03-03,2017-03-06,Actual,"April 24, 2013",Actual,2013-04-24,March 2017,2017-03-31,"December 16, 2016",Actual,2016-12-16,"December 16, 2016",Actual,2016-12-16,,Interventional,NILVAD,,A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease,A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease,Completed,,Phase 3,511.0,Actual,"St. James's Hospital, Ireland",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:14:04.638889,2020-02-01 13:14:04.638889,Prof Brian Lawlor,Other,Placebo,Drug
NCT02033941,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-09,,,2019-03-12,2014-01-09,2014-01-13,Estimate,,,,,,,2019-03-12,2019-03-13,Actual,November 2014,,2014-11-30,March 2019,2019-03-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,,,Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD),Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease,Recruiting,,Phase 2,20.0,Anticipated,Icahn School of Medicine at Mount Sinai,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 13:10:17.207831,2020-02-01 13:10:17.207831,Hillel Grossman,Other,Placebo,Drug
NCT02035553,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-13,2017-09-28,,2017-09-28,2014-01-13,2014-01-14,Estimate,2017-09-28,2017-10-25,Actual,,,,2017-09-28,2017-10-25,Actual,November 2013,,2013-11-30,September 2017,2017-09-30,"October 27, 2016",Actual,2016-10-27,"September 28, 2016",Actual,2016-09-28,,Interventional,,,A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis,"A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease",Completed,,Phase 2,181.0,Actual,ACADIA Pharmaceuticals Inc.,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:09:51.019135,2020-02-01 13:09:51.019135,ACADIA Pharmaceuticals Inc.,Industry,Placebo,Drug
NCT02035982,"ClinicalTrials.gov processed this data on January 31, 2020",2013-11-25,,,2017-04-26,2014-01-13,2014-01-14,Estimate,,,,,,,2017-04-26,2017-04-28,Actual,July 2010,,2010-07-31,April 2017,2017-04-30,September 2015,Actual,2015-09-30,May 2014,Actual,2014-05-31,,Interventional,,,Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease,A Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease in Long Term Care Setting,Completed,,Phase 3,40.0,Actual,Sunnybrook Health Sciences Centre,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:09:43.530864,2020-02-01 13:09:43.530864,Sunnybrook Health Sciences Centre,Other,Placebo,Drug
NCT02051608,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-30,,,2020-01-21,2014-01-30,2014-01-31,Estimate,,,,,,,2020-01-21,2020-01-22,Actual,"March 27, 2014",Actual,2014-03-27,January 2020,2020-01-31,"April 22, 2021",Anticipated,2021-04-22,"April 22, 2021",Anticipated,2021-04-22,,Interventional,,,A Study of Gantenerumab in Participants With Mild Alzheimer Disease,"A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Gantenerumab in Patients With Mild Alzheimer's Disease; Part II: Open-Label Extension For Participating Patients","Active, not recruiting",,Phase 3,389.0,Actual,Hoffmann-La Roche,,2.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 13:05:33.470350,2020-02-01 13:05:33.470350,Hoffmann-La Roche,Industry,Placebo,Drug
NCT02079909,"ClinicalTrials.gov processed this data on January 31, 2020",2014-03-04,2018-05-07,2016-02-23,2019-02-12,2014-03-04,2014-03-06,Estimate,2018-07-12,2018-08-09,Actual,2016-06-22,2016-06-27,Estimate,2019-02-12,2019-02-26,Actual,March 2014,,2014-03-31,February 2019,2019-02-28,"May 5, 2017",Actual,2017-05-05,"May 5, 2017",Actual,2017-05-05,,Interventional,,"The overall numbers of baseline participants display patient numbers in the mITT population, the primary analysis population. The mITT population excludes patients who did not take any study drug or did not perform any efficacy evaluation post-baseline. Thus, the numbers are slightly difference from the ones in the participant flow.",Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202),"A Phase 2 Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,482.0,Actual,"FUJIFILM Toyama Chemical Co., Ltd.",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:58:33.435431,2020-02-01 12:58:33.435431,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,Placebo,Drug
NCT02080364,"ClinicalTrials.gov processed this data on January 31, 2020",2014-02-25,,2019-05-08,2019-05-13,2014-03-04,2014-03-06,Estimate,,,,2019-05-13,2019-05-17,Actual,2019-05-13,2019-05-17,Actual,April 2015,Actual,2015-04-30,May 2019,2019-05-31,"June 1, 2018",Actual,2018-06-01,"June 1, 2018",Actual,2018-06-01,,Interventional,STEADFAST,,Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease,"Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine",Terminated,,Phase 3,880.0,Actual,vTv Therapeutics,,2.0,,Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.,False,,,,True,True,False,,,,,,,,,,,2020-02-01 12:58:28.399182,2020-02-01 12:58:28.399182,vTv Therapeutics,Industry,Placebo,Drug
NCT02094729,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-09,,,2015-06-04,2014-03-19,2014-03-24,Estimate,,,,,,,2015-06-04,2015-06-08,Estimate,September 2013,,2013-09-30,June 2015,2015-06-30,May 2015,Actual,2015-05-31,March 2015,Actual,2015-03-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease","A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease",Completed,,Phase 1,26.0,Actual,Eisai Inc.,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 12:55:16.323716,2020-02-01 12:55:16.323716,"Eisai Co., Ltd.",Industry,Placebo,Drug
NCT02103673,"ClinicalTrials.gov processed this data on January 31, 2020",2014-04-01,,,2018-01-23,2014-04-03,2014-04-04,Estimate,,,,,,,2018-01-23,2018-01-24,Actual,February 2014,,2014-02-28,January 2018,2018-01-31,November 2017,Actual,2017-11-30,November 2017,Actual,2017-11-30,,Interventional,,,DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia,,Completed,,Phase 2,90.0,Actual,Chang Gung Memorial Hospital,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:53:13.868291,2020-02-01 12:53:13.868291,Chang Gung Memorial Hospital,Other,Placebo,Drug
NCT02129348,"ClinicalTrials.gov processed this data on January 31, 2020",2014-04-29,,,2019-08-19,2014-05-01,2014-05-02,Estimate,,,,,,,2019-08-19,2019-08-20,Actual,June 2014,,2014-06-30,August 2019,2019-08-31,January 2020,Anticipated,2020-01-31,January 2020,Anticipated,2020-01-31,,Interventional,,,Treatment of Psychosis and Agitation in Alzheimer's Disease,Treatment of Psychosis and Agitation in Alzheimer's Disease,Recruiting,,Phase 2,80.0,Anticipated,New York State Psychiatric Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:46:46.841558,2020-02-01 12:46:46.841558,New York State Psychiatric Institute,Other,Placebo,Drug
NCT02142777,"ClinicalTrials.gov processed this data on January 31, 2020",2014-05-08,,,2016-08-12,2014-05-19,2014-05-20,Estimate,,,,,,,2016-08-12,2016-08-16,Estimate,July 2014,,2014-07-31,August 2016,2016-08-31,April 2016,Actual,2016-04-30,April 2016,Actual,2016-04-30,,Interventional,SEAD,,S-Equol in Alzheimer's Disease (SEAD) Trial,S-Equol in Alzheimer's Disease (SEAD) Trial,Completed,,Phase 1,15.0,Actual,University of Kansas Medical Center,,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 12:43:36.267085,2020-02-01 12:43:36.267085,"Russell Swerdlow, MD",Other,Placebo,Drug
NCT02167256,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-12,2019-06-19,,2019-07-25,2014-06-16,2014-06-19,Estimate,2019-07-25,2019-08-14,Actual,,,,2019-07-25,2019-08-14,Actual,December 2014,Actual,2014-12-31,July 2019,2019-07-31,"February 27, 2018",Actual,2018-02-27,"February 27, 2018",Actual,2018-02-27,,Interventional,,,"A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease","A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease",Completed,,Phase 2,159.0,Actual,Yale University,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:40.784913,2020-02-01 12:37:40.784913,Yale University,Other,Placebo,Drug
NCT02221947,"ClinicalTrials.gov processed this data on January 31, 2020",2014-07-02,2016-03-21,,2017-10-03,2014-08-20,2014-08-21,Estimate,2016-03-21,2016-04-21,Estimate,,,,2017-10-03,2017-11-06,Actual,June 2014,,2014-06-30,October 2017,2017-10-31,December 2014,Actual,2014-12-31,December 2014,Actual,2014-12-31,,Interventional,,,"Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Preliminary Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Alzheimer's Disease",Terminated,,Phase 1/Phase 2,9.0,Actual,"Neurotrope Bioscience, Inc.",,2.0,,"Part 2 of study replaced by NTRP-101-202, assessing 3 doses of bryostatin.",False,,,,False,,,,,,,,,,,No,,2020-02-01 12:24:20.790879,2020-02-01 12:24:20.790879,"Neurotrope Bioscience, Inc.",Industry,Placebo,Drug
NCT02240693,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-15,2018-09-11,,2018-10-31,2014-09-15,2014-09-16,Estimate,2018-10-31,2018-11-28,Actual,,,,2018-10-31,2018-11-28,Actual,"January 15, 2015",Actual,2015-01-15,October 2018,2018-10-31,"October 9, 2017",Actual,2017-10-09,"September 18, 2017",Actual,2017-09-18,,Interventional,,"Treated set:
The treated set (TS) included all patients who were randomised and treated with at least one dose of trial medication.",Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo,"A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease",Completed,,Phase 2,128.0,Actual,Boehringer Ingelheim,,5.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:20:03.237659,2020-02-01 12:20:03.237659,Boehringer Ingelheim,Industry,Placebo,Drug
NCT02245737,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-18,2019-06-11,,2019-11-19,2014-09-18,2014-09-22,Estimate,2019-07-15,2019-08-06,Actual,,,,2019-11-19,2019-12-03,Actual,"September 30, 2014",Actual,2014-09-30,October 2019,2019-10-31,"October 4, 2018",Actual,2018-10-04,"October 4, 2018",Actual,2018-10-04,,Interventional,AMARANTH,All randomized participants,An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease,"A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)",Terminated,,Phase 2/Phase 3,2218.0,Actual,AstraZeneca,"An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility.",3.0,,"An independent assessment concluded the trial was not likely to meet the primary endpoint upon
    completion and therefore, trial stopped for futility",False,,,,True,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://www.clinicalstudydatarequest.com/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 12:19:02.029274,2020-02-01 12:19:02.029274,AstraZeneca,Industry,Placebo,Drug
NCT02249351,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-23,,,2014-09-25,2014-09-23,2014-09-25,Estimate,,,,,,,2014-09-25,2014-09-26,Estimate,December 1999,,1999-12-31,September 2014,2014-09-30,,,,May 2000,Actual,2000-05-31,,Interventional,,,Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type,"Efficacy and Safety of 48 mg Talsaclidine (Free Base) Tid po (Panel 1) and 60 mg Talsaclidine (Free Base) Tid po (Panel 2) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Within Escalating Dose Panels in 150 Patients With Mild to Moderate Dementia of Alzheimer Type",Terminated,,Phase 2,54.0,Actual,Boehringer Ingelheim,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:18:03.473505,2020-02-01 12:18:03.473505,Boehringer Ingelheim,Industry,Placebo,Drug
NCT02249403,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-23,,,2014-09-25,2014-09-23,2014-09-25,Estimate,,,,,,,2014-09-25,2014-09-26,Estimate,January 1999,,1999-01-31,September 2014,2014-09-30,,,,January 2000,Actual,2000-01-31,,Interventional,,,Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type,"Efficacy and Safety of 6, 12, 24, and 36 mg Tid po and 36 mg Bid po Talsaclidine (Free Base) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Parallel Group Comparison in Patients With Mild to Moderate Dementia of Alzheimer Type",Completed,,Phase 2,362.0,Actual,Boehringer Ingelheim,,6.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:18:03.208888,2020-02-01 12:18:03.208888,Boehringer Ingelheim,Industry,Placebo,Drug
NCT02260674,"ClinicalTrials.gov processed this data on January 31, 2020",2014-10-06,,2017-03-01,2017-03-01,2014-10-06,2014-10-09,Estimate,,,,2017-03-01,2017-03-03,Actual,2017-03-01,2017-03-03,Actual,November 2014,,2014-11-30,March 2017,2017-03-31,June 2016,Actual,2016-06-30,June 2016,Actual,2016-06-30,,Interventional,,,A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease,"A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects With Early Alzheimer's Disease",Completed,,Phase 2,114.0,Actual,"Janssen Research & Development, LLC",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:15:34.625870,2020-02-01 12:15:34.625870,"Janssen Research & Development, LLC",Industry,Placebo,Drug
NCT02284906,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-04,2019-05-07,,2019-06-11,2014-11-04,2014-11-06,Estimate,2019-06-11,2019-07-02,Actual,,,,2019-06-11,2019-07-02,Actual,"February 12, 2015",Actual,2015-02-12,June 2019,2019-06-30,"May 8, 2018",Actual,2018-05-08,"January 31, 2018",Actual,2018-01-31,,Interventional,,Safety analysis set included all participants who received at least 1 dose of blinded study medication.,AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease,A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease,Terminated,,Phase 3,40.0,Actual,Takeda,,2.0,,Lack of efficacy of the drug; no safety concern,False,,,,True,True,,,,,,,,,,Yes,"Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.",2020-02-01 12:10:02.597766,2020-02-01 12:10:02.597766,Takeda,Industry,Placebo,Drug
NCT02288000,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-06,,,2019-06-25,2014-11-06,2014-11-11,Estimate,,,,,,,2019-06-25,2019-06-27,Actual,"September 14, 2016",Actual,2016-09-14,June 2019,2019-06-30,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,WP3_P002,,Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases,Effect of a 15-day Memantine Treatment on Biomarkers of AD in Healthy Volunteers,Recruiting,,Phase 1,30.0,Anticipated,"University Hospital, Lille",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:09:22.892287,2020-02-01 12:09:22.892287,"University Hospital, Lille",Other,Placebo,Drug
NCT02293915,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-13,,,2018-10-09,2014-11-13,2014-11-19,Estimate,,,,,,,2018-10-09,2018-10-10,Actual,"April 1, 2014",Actual,2014-04-01,October 2018,2018-10-31,"September 28, 2018",Actual,2018-09-28,"June 29, 2018",Actual,2018-06-29,,Interventional,,,An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease,Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer Disease,Completed,,Phase 3,818.0,Actual,"Shanghai Greenvalley Pharmaceutical Co., Ltd.",,2.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 12:08:03.265956,2020-02-01 12:08:03.265956,"Shanghai Greenvalley Pharmaceutical Co., Ltd.",Industry,Placebo,Drug
NCT02322021,"ClinicalTrials.gov processed this data on January 31, 2020",2014-12-17,,2019-06-07,2019-06-07,2014-12-19,2014-12-22,Estimate,,,,2019-06-07,2019-06-10,Actual,2019-06-07,2019-06-10,Actual,"November 26, 2014",Actual,2014-11-26,June 2018,2018-06-30,"July 31, 2022",Anticipated,2022-07-31,"March 27, 2018",Actual,2018-03-27,,Interventional,,,Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease,"A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease","Active, not recruiting",,Phase 2,71.0,Actual,Eisai Inc.,,8.0,,,False,,,,True,True,,,,,,,,,,Undecided,,2020-02-01 12:01:27.666580,2020-02-01 12:01:27.666580,Eisai Inc.,Industry,Placebo,Drug
NCT02337907,"ClinicalTrials.gov processed this data on January 31, 2020",2014-12-23,2018-08-29,,2018-10-18,2015-01-09,2015-01-14,Estimate,2018-10-18,2018-11-14,Actual,,,,2018-10-18,2018-11-14,Actual,"January 21, 2015",Actual,2015-01-21,October 2018,2018-10-31,"October 10, 2017",Actual,2017-10-10,"September 15, 2017",Actual,2017-09-15,,Interventional,,Treated Set (TS) included all patients who were randomised and treated with at least one dose of trial medication.,BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,"A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease",Completed,,Phase 2,329.0,Actual,Boehringer Ingelheim,"There were 5 patients who were randomised to donepezil arm which was dropped from the trial with protocol amendment. No further patients were randomised to this arm, but patients already randomised continued in the trial as originally planned.",6.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 11:58:09.189083,2020-02-01 11:58:09.189083,Boehringer Ingelheim,Industry,Placebo,Drug
NCT02346201,"ClinicalTrials.gov processed this data on January 31, 2020",2015-01-20,,,2020-01-16,2015-01-20,2015-01-26,Estimate,,,,,,,2020-01-16,2020-01-21,Actual,January 2016,,2016-01-31,January 2020,2020-01-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,,Interventional,ADMET2,,Apathy in Dementia Methylphenidate Trial 2,Apathy in Dementia Methylphenidate Trial 2,"Active, not recruiting",,Phase 3,200.0,Actual,Johns Hopkins Bloomberg School of Public Health,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:56:10.970719,2020-02-01 11:56:10.970719,Johns Hopkins Bloomberg School of Public Health,Other,Placebo,Drug
NCT02351882,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-17,,,2019-04-08,2015-01-27,2015-01-30,Estimate,,,,,,,2019-04-08,2019-04-10,Actual,January 2015,,2015-01-31,April 2019,2019-04-30,March 2019,Actual,2019-03-31,January 2018,Actual,2018-01-31,,Interventional,,,Safety and Efficacy of Nabilone in Alzheimer's Disease,Safety and Efficacy of Nabilone in Alzheimer's Disease: a Pilot Study,Completed,,Phase 2/Phase 3,38.0,Actual,Sunnybrook Health Sciences Centre,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:54:58.307512,2020-02-01 11:54:58.307512,Sunnybrook Health Sciences Centre,Other,Placebo,Drug
NCT02353598,"ClinicalTrials.gov processed this data on January 31, 2020",2015-01-23,,,2019-07-23,2015-01-30,2015-02-03,Estimate,,,,,,,2019-07-23,2019-07-24,Actual,"February 26, 2015",Actual,2015-02-26,July 2019,2019-07-31,"March 26, 2019",Actual,2019-03-26,"November 30, 2016",Actual,2016-11-30,,Interventional,,,A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease,"A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,77.0,Actual,"Genentech, Inc.",,5.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 11:54:27.261965,2020-02-01 11:54:27.261965,"Genentech, Inc.",Industry,Placebo,Drug
NCT02359552,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-05,,,2019-05-06,2015-02-05,2015-02-10,Estimate,,,,,,,2019-05-06,2019-05-08,Actual,May 2015,Actual,2015-05-31,May 2019,2019-05-31,"January 4, 2019",Actual,2019-01-04,"August 29, 2018",Actual,2018-08-29,,Interventional,R2,,Rasagiline Rescue in Alzheimer's Disease Clinical Trial,"A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,27.0,Actual,The Cleveland Clinic,,2.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 11:53:08.896672,2020-02-01 11:53:08.896672,The Cleveland Clinic,Other,Placebo,Drug
NCT02360657,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-05,,,2019-01-31,2015-02-05,2015-02-10,Estimate,,,,,,,2019-01-31,2019-02-04,Actual,"February 16, 2015",Actual,2015-02-16,January 2019,2019-01-31,"September 8, 2015",Actual,2015-09-08,"September 8, 2015",Actual,2015-09-08,,Interventional,,,Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia,"A Double-blind, Placebo-controlled, Randomized, 4-Week, Multiple-dose, Proof of Mechanism (POM) Study in Japanese Subjects Asymptomatic at Risk for Alzheimer Dementia (ARAD) Investigating the Effects of JNJ-54861911 on A-beta Processing in Cerebrospinal Fluid (CSF) and Plasma",Completed,,Phase 1,18.0,Actual,Janssen Pharmaceutical K.K.,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 11:52:56.242572,2020-02-01 11:52:56.242572,Janssen Pharmaceutical K.K.,Industry,Placebo,Drug
NCT02377713,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-25,,,2016-12-06,2015-03-02,2015-03-04,Estimate,,,,,,,2016-12-06,2016-12-07,Estimate,March 2015,,2015-03-31,December 2016,2016-12-31,September 2016,Actual,2016-09-30,September 2016,Actual,2016-09-30,,Interventional,,,A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.,"A Phase 1 Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.",Completed,,Phase 1,20.0,Actual,"Kyowa Kirin Co., Ltd.",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 11:49:05.330787,2020-02-01 11:49:05.330787,"Kyowa Kirin Co., Ltd.",Industry,Placebo,Drug
NCT02406027,"ClinicalTrials.gov processed this data on January 31, 2020",2015-03-27,2019-06-25,,2019-09-05,2015-03-27,2015-04-01,Estimate,2019-09-05,2019-09-09,Actual,,,,2019-09-05,2019-09-09,Actual,"July 2, 2015",Actual,2015-07-02,September 2019,2019-09-30,"June 28, 2018",Actual,2018-06-28,"June 28, 2018",Actual,2018-06-28,,Interventional,,Double-blind safety analysis set included all participants who received study treatment during period 1.,An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum,"A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzheimer's Disease Spectrum",Terminated,,Phase 2,90.0,Actual,"Janssen Research & Development, LLC","The major limitation of this study was early termination of the study/program by the sponsor, which resulted in small numbers of participants in groups, precluding meaningful interpretation of some of the analyses.",5.0,,,False,,,,True,,False,,,,,,,,,,,2020-02-01 11:43:20.601413,2020-02-01 11:43:20.601413,"Janssen Research & Development, LLC",Industry,Placebo,Drug
NCT02434718,"ClinicalTrials.gov processed this data on January 31, 2020",2015-04-30,,,2017-04-07,2015-04-30,2015-05-05,Estimate,,,,,,,2017-04-07,2017-04-10,Actual,"June 30, 2015",Actual,2015-06-30,April 2017,2017-04-30,"December 9, 2016",Actual,2016-12-09,"December 9, 2016",Actual,2016-12-09,,Interventional,PROPEL,,Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Aducanumab (BIIB037) in Japanese Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,21.0,Actual,Biogen,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:36:45.852771,2020-02-01 11:36:45.852771,Biogen,Industry,Placebo,Drug
NCT02442765,"ClinicalTrials.gov processed this data on January 31, 2020",2015-05-11,,,2019-03-04,2015-05-11,2015-05-13,Estimate,,,,,,,2019-03-04,2019-03-06,Actual,September 2015,,2015-09-30,March 2019,2019-03-31,"February 27, 2019",Actual,2019-02-27,"January 30, 2019",Actual,2019-01-30,,Interventional,,,"Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Completed,,Phase 3,410.0,Actual,Avanir Pharmaceuticals,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:35:00.526050,2020-02-01 11:35:00.526050,Avanir Pharmaceuticals,Industry,Placebo,Drug
NCT02442778,"ClinicalTrials.gov processed this data on January 31, 2020",2015-05-11,,,2019-10-13,2015-05-11,2015-05-13,Estimate,,,,,,,2019-10-13,2019-10-15,Actual,September 2015,,2015-09-30,October 2019,2019-10-31,"September 9, 2019",Actual,2019-09-09,"August 14, 2019",Actual,2019-08-14,,Interventional,,,"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.",Completed,,Phase 3,522.0,Actual,Avanir Pharmaceuticals,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:34:59.205605,2020-02-01 11:34:59.205605,Avanir Pharmaceuticals,Industry,Placebo,Drug
NCT02462161,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-01,,,2019-08-29,2015-06-02,2015-06-03,Estimate,,,,,,,2019-08-29,2019-09-03,Actual,"March 20, 2015",Actual,2015-03-20,August 2019,2019-08-31,"April 16, 2019",Actual,2019-04-16,"April 16, 2019",Actual,2019-04-16,,Interventional,SNIFF-Quick,,Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart,Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart,Completed,,Phase 1,24.0,Actual,Wake Forest University Health Sciences,,2.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 11:30:11.664980,2020-02-01 11:30:11.664980,Wake Forest University Health Sciences,Other,Placebo,Drug
NCT02471196,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-08,,,2018-02-14,2015-06-12,2015-06-15,Estimate,,,,,,,2018-02-14,2018-02-15,Actual,"August 14, 2015",Actual,2015-08-14,February 2018,2018-02-28,"December 4, 2017",Actual,2017-12-04,"October 9, 2017",Actual,2017-10-09,,Interventional,Nebula,,Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease,"Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Patients With Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study of 12 Weeks",Completed,,Phase 2,308.0,Actual,"Orion Corporation, Orion Pharma",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:28:13.264712,2020-02-01 11:28:13.264712,"Orion Corporation, Orion Pharma",Industry,Placebo,Drug
NCT02477800,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-18,,,2019-11-07,2015-06-18,2015-06-23,Estimate,,,,,,,2019-11-07,2019-11-12,Actual,"August 31, 2015",Actual,2015-08-31,November 2019,2019-11-30,"August 8, 2019",Actual,2019-08-08,"August 8, 2019",Actual,2019-08-08,,Interventional,ENGAGE,,221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease",Terminated,,Phase 3,1647.0,Actual,Biogen,,2.0,,"Study was discontinued based on futility analysis done and not based on safety concerns.
    Follow-up visits and closing out study activities are completed",False,,,,True,,,,,,,,,,,,,2020-02-01 11:26:54.149156,2020-02-01 11:26:54.149156,Biogen,Industry,Placebo,Drug
NCT02484547,"ClinicalTrials.gov processed this data on January 31, 2020",2015-06-18,,,2019-11-07,2015-06-26,2015-06-29,Estimate,,,,,,,2019-11-07,2019-11-12,Actual,"September 30, 2015",Actual,2015-09-30,November 2019,2019-11-30,"August 5, 2019",Actual,2019-08-05,"August 5, 2019",Actual,2019-08-05,,Interventional,EMERGE,,221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease",Terminated,,Phase 3,1638.0,Actual,Biogen,,2.0,,"Study was discontinued based on futility analysis done and not based on safety concerns.
    Follow-up visits and closing out study activities are completed",False,,,,True,,,,,,,,,,,,,2020-02-01 11:25:35.474212,2020-02-01 11:25:35.474212,Biogen,Industry,Placebo,Drug
NCT02503501,"ClinicalTrials.gov processed this data on January 31, 2020",2015-07-14,,,2020-01-29,2015-07-17,2015-07-21,Estimate,,,,,,,2020-01-29,2020-01-31,Estimate,August 2015,,2015-08-31,January 2020,2020-01-31,February 2020,Anticipated,2020-02-29,February 2020,Anticipated,2020-02-29,,Interventional,,,Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease,"A Phase II, Single Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and the Therapeutic Effectiveness of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,49.0,Actual,HealthPartners Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-04 05:17:00.541400,2020-02-04 05:17:00.541400,HealthPartners Institute,Other,Placebo,Drug
NCT02551809,"ClinicalTrials.gov processed this data on January 31, 2020",2015-09-10,2019-12-24,,2020-01-13,2015-09-14,2015-09-16,Estimate,2019-12-24,2020-01-13,Actual,,,,2020-01-13,2020-01-27,Actual,October 2015,Actual,2015-10-31,January 2020,2020-01-31,August 2018,Actual,2018-08-31,August 2018,Actual,2018-08-31,,Interventional,,,"Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients","A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311) in Patients With Mild Alzheimer's Disease",Completed,,Phase 2,43.0,Actual,United Neuroscience Ltd.,,3.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 11:09:50.743500,2020-02-01 11:09:50.743500,United Neuroscience Ltd.,Industry,Placebo,Drug
NCT02569398,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-05,,,2019-01-18,2015-10-05,2015-10-06,Estimate,,,,,,,2019-01-18,2019-01-22,Actual,"October 29, 2015",Actual,2015-10-29,January 2019,2019-01-31,"December 20, 2018",Actual,2018-12-20,"December 20, 2018",Actual,2018-12-20,,Interventional,EARLY,,An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia,"A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic At Risk for Developing Alzheimer's Dementia",Completed,,Phase 2/Phase 3,596.0,Actual,"Janssen Research & Development, LLC",,3.0,,,False,,,,True,,False,,,,,,,,,,,2020-02-01 11:05:32.593875,2020-02-01 11:05:32.593875,"Janssen Research & Development, LLC",Industry,Placebo,Drug
NCT02579252,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-09,,,2019-11-13,2015-10-15,2015-10-19,Estimate,,,,,,,2019-11-13,2019-11-14,Actual,March 2016,,2016-03-31,November 2019,2019-11-30,June 2019,Actual,2019-06-30,June 2019,Actual,2019-06-30,,Interventional,ADAMANT,,24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease,"A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease",Completed,,Phase 2,208.0,Actual,Axon Neuroscience SE,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:03:14.453391,2020-02-01 11:03:14.453391,Axon Neuroscience SE,Industry,Placebo,Drug
NCT02580305,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-17,,,2019-11-15,2015-10-17,2015-10-20,Estimate,,,,,,,2019-11-15,2019-11-18,Actual,September 2015,,2015-09-30,November 2019,2019-11-30,"November 7, 2019",Actual,2019-11-07,"November 5, 2019",Actual,2019-11-05,,Interventional,,,SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study,"A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride",Completed,,Phase 2,563.0,Actual,Suven Life Sciences Limited,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:02:59.952283,2020-02-01 11:02:59.952283,Suven Life Sciences Limited,Industry,Placebo,Drug
NCT02585934,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-22,2018-09-30,,2018-11-08,2015-10-22,2015-10-26,Estimate,2018-11-08,2018-12-05,Actual,,,,2018-11-08,2018-12-05,Actual,October 2015,Actual,2015-10-31,November 2018,2018-11-30,September 2017,Actual,2017-09-30,September 2017,Actual,2017-09-30,,Interventional,,ITT population,Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study,"A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,1315.0,Actual,Axovant Sciences Ltd.,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:01:27.758831,2020-02-01 11:01:27.758831,Axovant Sciences Ltd.,Industry,Placebo,Drug
NCT02615002,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-18,,,2019-08-20,2015-11-22,2015-11-25,Estimate,,,,,,,2019-08-20,2019-08-21,Actual,November 2015,,2015-11-30,August 2019,2019-08-31,"November 30, 2019",Anticipated,2019-11-30,November 2019,Anticipated,2019-11-30,,Interventional,,,Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION),"Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease","Active, not recruiting",,Phase 2,500.0,Anticipated,Neurim Pharmaceuticals Ltd.,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 10:55:14.266636,2020-02-01 10:55:14.266636,Neurim Pharmaceuticals Ltd.,Industry,Placebo,Drug
NCT02626572,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-04,,,2018-08-13,2015-12-07,2015-12-10,Estimate,,,,,,,2018-08-13,2018-08-15,Actual,February 2015,,2015-02-28,August 2018,2018-08-31,September 2017,Actual,2017-09-30,September 2017,Actual,2017-09-30,,Interventional,,,Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms,"Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.",Completed,,Phase 2,500.0,Anticipated,Servier,,4.0,,,False,,,,True,,,,,,,,After Marketing Authorisation in EEA or US if the study is used for the approval.,Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.,http://clinicaltrials.servier.com,Yes,"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.",2020-02-01 10:52:59.050457,2020-02-01 10:52:59.050457,Institut de Recherches Internationales Servier,Other,Placebo,Drug
NCT02646982,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-04,,,2019-02-15,2016-01-04,2016-01-06,Estimate,,,,,,,2019-02-15,2019-02-18,Actual,June 2016,,2016-06-30,February 2019,2019-02-28,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,,Interventional,CEDAR,,Candesartan's Effects on Alzheimer's Disease And Related Biomarkers,Candesartan's Effects on Alzheimer's Disease And Related Biomarkers,Recruiting,,Phase 2,72.0,Anticipated,Emory University,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 10:48:22.473223,2020-02-01 10:48:22.473223,Emory University,Other,Placebo,Drug
NCT02648672,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-04,,,2017-01-17,2016-01-05,2016-01-07,Estimate,,,,,,,2017-01-17,2017-01-18,Estimate,December 2015,,2015-12-31,January 2017,2017-01-31,July 2016,Actual,2016-07-31,February 2016,Actual,2016-02-29,,Interventional,,,BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects,"A Single Ascending Dose Study to Examine the Safety, Tolerability, and Pharmacokinetic Profile of BPN14770 in Healthy Male and Female Subjects",Completed,,Phase 1,32.0,Actual,Tetra Discovery Partners,,2.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 10:47:58.768447,2020-02-01 10:47:58.768447,Tetra Discovery Partners,Industry,Placebo,Drug
NCT02648906,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-05,,,2016-11-01,2016-01-05,2016-01-07,Estimate,,,,,,,2016-11-01,2016-11-02,Estimate,July 2015,,2015-07-31,November 2016,2016-11-30,,,,November 2018,Anticipated,2018-11-30,,Interventional,,,A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients,,Unknown status,Recruiting,Phase 4,128.0,Anticipated,Daewoong Pharmaceutical Co. LTD.,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 10:47:56.128964,2020-02-01 10:47:56.128964,Daewoong Pharmaceutical Co. LTD.,Industry,Placebo,Drug
NCT02667496,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-26,,,2017-04-05,2016-01-28,2016-01-29,Estimate,,,,,,,2017-04-05,2017-04-07,Actual,November 2016,,2016-11-30,April 2017,2017-04-30,"March 31, 2017",Actual,2017-03-31,"March 31, 2017",Actual,2017-03-31,,Interventional,,,Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine® (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,Withdrawn,,Phase 2,0.0,Actual,Sanofi,,2.0,,Slow recruitment,False,,,,True,,,,,,,,,,,,,2020-02-01 10:44:33.482652,2020-02-01 10:44:33.482652,Sanofi,Industry,Placebo,Drug
NCT02670083,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-28,,,2019-09-23,2016-01-28,2016-02-01,Estimate,,,,,,,2019-09-23,2019-09-24,Actual,"March 22, 2016",Actual,2016-03-22,September 2019,2019-09-30,"May 31, 2019",Actual,2019-05-31,"May 31, 2019",Actual,2019-05-31,,Interventional,,,CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease",Completed,,Phase 3,813.0,Actual,Hoffmann-La Roche,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 10:44:00.131105,2020-02-01 10:44:00.131105,Hoffmann-La Roche,Industry,Placebo,Drug
NCT02708186,"ClinicalTrials.gov processed this data on January 31, 2020",2016-03-10,,,2018-10-22,2016-03-14,2016-03-15,Estimate,,,,,,,2018-10-22,2018-10-23,Actual,March 2016,Actual,2016-03-31,April 2018,2018-04-30,May 2018,Actual,2018-05-31,May 2018,Actual,2018-05-31,,Interventional,,,Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD),"A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)",Completed,,Phase 2,29.0,Actual,Axovant Sciences Ltd.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 10:35:55.243047,2020-02-01 10:35:55.243047,Axovant Sciences Ltd.,Industry,Placebo,Drug
NCT02750306,"ClinicalTrials.gov processed this data on January 31, 2020",2016-04-21,2019-09-25,,2019-09-25,2016-04-21,2016-04-25,Estimate,2019-09-25,2019-10-16,Actual,,,,2019-09-25,2019-10-16,Actual,"May 23, 2016",Actual,2016-05-23,September 2019,2019-09-30,"September 30, 2018",Actual,2018-09-30,"September 30, 2018",Actual,2018-09-30,,Interventional,,,Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061),"A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease",Completed,,Phase 3,285.0,Actual,Merck Sharp & Dohme Corp.,,2.0,,,False,,,,False,True,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2020-02-01 10:27:18.152403,2020-02-01 10:27:18.152403,Merck Sharp & Dohme Corp.,Industry,Placebo,Drug
NCT02760602,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-02,2018-05-08,,2019-09-25,2016-05-02,2016-05-03,Estimate,2018-06-25,2018-07-24,Actual,,,,2019-09-25,2019-10-10,Actual,June 2016,,2016-06-30,September 2019,2019-09-30,May 2017,Actual,2017-05-31,May 2017,Actual,2017-05-31,,Interventional,ExpeditionPRO,All enrolled participants who received at least one dose of study drug.,A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease,"A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease",Terminated,,Phase 3,26.0,Actual,Eli Lilly and Company,The study was terminated due to insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit to pts with prodromal AD as defined by the study protocol. Zero pts were analyzed as no data collected for outcomes.,2.0,,"Insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit
    to participants with prodromal AD as defined by study protocol.",False,,,,True,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 10:25:04.531045,2020-02-01 10:25:04.531045,Eli Lilly and Company,Industry,Placebo,Drug
NCT02783573,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-24,2019-06-11,,2019-11-19,2016-05-24,2016-05-26,Estimate,2019-07-15,2019-08-06,Actual,,,,2019-11-19,2019-12-03,Actual,"July 1, 2016",Actual,2016-07-01,October 2019,2019-10-31,"September 28, 2018",Actual,2018-09-28,"September 28, 2018",Actual,2018-09-28,,Interventional,DAYBREAK-ALZ,All randomized participants who received at least one dose of study drug.,A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia,"A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia",Terminated,,Phase 3,1722.0,Actual,AstraZeneca,"An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility.",4.0,,"An independent assessment concluded the trial was not likely to meet the primary endpoint upon
    completion and therefore, trial stopped for futility.",False,,,,True,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://www.clinicalstudydatarequest.com/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 10:20:35.671465,2020-02-01 10:20:35.671465,AstraZeneca,Industry,Placebo,Drug
NCT02788513,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-27,,,2019-10-24,2016-05-27,2016-06-02,Estimate,,,,,,,2019-10-24,2019-10-25,Actual,"August 11, 2016",Actual,2016-08-11,October 2019,2019-10-31,"October 11, 2019",Actual,2019-10-11,"September 12, 2019",Actual,2019-09-12,,Interventional,,,BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.,"A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy and Safety of Orally Administered BI 425809 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease.",Completed,,Phase 2,611.0,Actual,Boehringer Ingelheim,,5.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 10:19:26.691184,2020-02-01 10:19:26.691184,Boehringer Ingelheim,Industry,Placebo,Drug
NCT02791191,"ClinicalTrials.gov processed this data on January 31, 2020",2016-06-01,,2019-06-28,2019-09-25,2016-06-01,2016-06-06,Estimate,,,,2019-06-28,2019-07-05,Actual,2019-09-25,2019-10-08,Actual,"June 16, 2016",Actual,2016-06-16,September 2019,2019-09-30,"July 2, 2018",Actual,2018-07-02,"July 2, 2018",Actual,2018-07-02,,Interventional,NAVIGATE-AD,,A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia,Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia,Terminated,,Phase 2,316.0,Actual,Eli Lilly and Company,,3.0,,Low likelihood of identifying a statistically significant treatment effect.,False,,,,False,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 10:19:04.421085,2020-02-01 10:19:04.421085,Eli Lilly and Company,Industry,Placebo,Drug
NCT02792257,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-26,,,2019-06-25,2016-06-01,2016-06-07,Estimate,,,,,,,2019-06-25,2019-06-27,Actual,"March 1, 2017",Actual,2017-03-01,June 2019,2019-06-30,December 2020,Anticipated,2020-12-31,August 2020,Anticipated,2020-08-31,,Interventional,THC-AD,,Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD),Pilot Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD),Recruiting,,Phase 2,160.0,Anticipated,Johns Hopkins University,,2.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 10:18:48.371685,2020-02-01 10:18:48.371685,Johns Hopkins University,Other,Placebo,Drug
NCT02817906,"ClinicalTrials.gov processed this data on January 31, 2020",2016-06-27,,,2018-12-18,2016-06-27,2016-06-29,Estimate,,,,,,,2018-12-18,2018-12-20,Actual,June 2016,Actual,2016-06-30,December 2018,2018-12-31,December 2018,Actual,2018-12-31,December 2018,Actual,2018-12-31,,Interventional,,,"ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease",Terminated,,Phase 3,177.0,Actual,"Intra-Cellular Therapies, Inc.",,2.0,,Pre-specified Interim Analysis Indicated Futility,False,,,,,True,False,,,,,,,,,,,2020-02-01 10:14:10.009879,2020-02-01 10:14:10.009879,"Intra-Cellular Therapies, Inc.",Industry,Placebo,Drug
NCT02820896,"ClinicalTrials.gov processed this data on January 31, 2020",2016-06-29,,,2017-07-19,2016-06-29,2016-07-01,Estimate,,,,,,,2017-07-19,2017-07-21,Actual,"June 29, 2016",Actual,2016-06-29,July 2017,2017-07-31,"June 26, 2017",Actual,2017-06-26,"June 26, 2017",Actual,2017-06-26,,Interventional,,,A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease,"A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous and Subcutaneous RO7105705 Administered in Healthy Volunteers and Patients With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 1,74.0,Actual,"Genentech, Inc.",,5.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 10:13:34.158224,2020-02-01 10:13:34.158224,"Genentech, Inc.",Industry,Placebo,Drug
NCT02840279,"ClinicalTrials.gov processed this data on January 31, 2020",2016-07-19,,,2017-01-17,2016-07-19,2016-07-21,Estimate,,,,,,,2017-01-17,2017-01-18,Estimate,June 2016,,2016-06-30,December 2016,2016-12-31,December 2016,Actual,2016-12-31,November 2016,Actual,2016-11-30,,Interventional,,,A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects,"A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Examine the Safety, Tolerability, Pharmacokinetic, and Preliminary Cognitive Profile of BPN14770 in Healthy Young and Elderly Male and Female Subjects",Completed,,Phase 1,77.0,Actual,Tetra Discovery Partners,,2.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 10:09:58.152357,2020-02-01 10:09:58.152357,Tetra Discovery Partners,Industry,Placebo,Drug
NCT02907567,"ClinicalTrials.gov processed this data on January 31, 2020",2016-09-05,,,2018-07-24,2016-09-15,2016-09-20,Estimate,,,,,,,2018-07-24,2018-07-26,Actual,September 2016,Actual,2016-09-30,July 2018,2018-07-31,September 2017,Actual,2017-09-30,"August 24, 2017",Actual,2017-08-24,,Interventional,,,Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 1/Phase 2,19.0,Actual,Cognition Therapeutics,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 09:57:57.979312,2020-02-01 09:57:57.979312,Cognition Therapeutics,Industry,Placebo,Drug
NCT02910102,"ClinicalTrials.gov processed this data on January 31, 2020",2016-09-16,,,2017-12-22,2016-09-19,2016-09-21,Estimate,,,,,,,2017-12-22,2017-12-27,Actual,October 2016,Actual,2016-10-31,December 2017,2017-12-31,November 2017,Actual,2017-11-30,November 2017,Actual,2017-11-30,,Interventional,,,Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia,"A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia",Completed,,Phase 2,38.0,Actual,Axovant Sciences Ltd.,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 09:57:01.127041,2020-02-01 09:57:01.127041,Axovant Sciences Ltd.,Industry,Placebo,Drug
NCT02925650,"ClinicalTrials.gov processed this data on January 31, 2020",2016-09-29,,,2020-01-18,2016-10-04,2016-10-06,Estimate,,,,,,,2020-01-18,2020-01-22,Actual,"March 2, 2017",Actual,2017-03-02,January 2020,2020-01-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,,Interventional,DISCOVER,,"Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD)",Recruiting,,Phase 1/Phase 2,24.0,Anticipated,QR Pharma Inc.,,4.0,,,False,,,,True,True,False,,,,,,,,,Yes,"Data from this research will be shared with other researchers pursuant to the 02/26/2003 ""NIH Final Statement on Sharing Research Data"".",2020-02-01 09:52:28.469882,2020-02-01 09:52:28.469882,QR Pharma Inc.,Industry,Placebo,Drug
NCT02956486,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-03,,,2019-09-18,2016-11-03,2016-11-06,Estimate,,,,,,,2019-09-18,2019-09-19,Actual,"October 20, 2016",Actual,2016-10-20,September 2018,2018-09-30,"November 21, 2023",Anticipated,2023-11-21,"November 21, 2023",Anticipated,2023-11-21,,Interventional,MissionAD1,,A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease,"A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 3,950.0,Anticipated,Eisai Inc.,,3.0,,,False,,,,True,True,,,,,,,,,,Undecided,,2020-02-01 09:45:53.235437,2020-02-01 09:45:53.235437,"Eisai Co., Ltd.",Industry,Placebo,Drug
NCT03008161,"ClinicalTrials.gov processed this data on January 31, 2020",2016-12-23,,,2019-08-14,2016-12-29,2017-01-02,Estimate,,,,,,,2019-08-14,2019-08-15,Actual,December 2016,Actual,2016-12-31,August 2019,2019-08-31,"February 6, 2019",Actual,2019-02-06,"February 6, 2019",Actual,2019-02-06,,Interventional,,,Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease,"A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease",Completed,,Phase 1,83.0,Actual,"Proclara Biosciences, Inc.",,4.0,,,False,,,,True,,,,,,,,,,,Undecided,,2020-02-01 09:35:53.375769,2020-02-01 09:35:53.375769,"Proclara Biosciences, Inc.",Industry,Placebo,Drug
NCT03036280,"ClinicalTrials.gov processed this data on January 31, 2020",2017-01-26,,,2019-09-18,2017-01-26,2017-01-30,Estimate,,,,,,,2019-09-18,2019-09-19,Actual,"December 29, 2016",Actual,2016-12-29,September 2019,2019-09-30,"November 21, 2023",Anticipated,2023-11-21,"November 21, 2023",Anticipated,2023-11-21,,Interventional,MissionAD2,,A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease_,"A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 3,950.0,Anticipated,Eisai Inc.,,3.0,,,False,,,,True,True,,,,,,,,,,Undecided,,2020-02-01 09:30:30.434411,2020-02-01 09:30:30.434411,"Eisai Co., Ltd.",Industry,Placebo,Drug
NCT03038035,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-01,,,2017-01-26,2017-01-26,2017-01-31,Estimate,,,,,,,2017-01-26,2017-01-31,Estimate,December 2016,,2016-12-31,January 2017,2017-01-31,June 2019,Anticipated,2019-06-30,June 2018,Anticipated,2018-06-30,,Interventional,ATHENE,,The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study,"The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study : Assessing the Safety and Efficacy of Neuroaid II (MLC901) in Patients With Mild to Moderate Alzheimer's Disease Stable on Cholinesterase Inhibitors or Memantine: A Randomized, Double Blind, Placebo Controlled Trial",Unknown status,Recruiting,Phase 2,150.0,Anticipated,"National University Hospital, Singapore",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 09:30:10.628210,2020-02-01 09:30:10.628210,"National University Hospital, Singapore",Other,Placebo,Drug
NCT03044249,"ClinicalTrials.gov processed this data on January 31, 2020",2017-01-31,,,2019-09-03,2017-02-02,2017-02-06,Estimate,,,,,,,2019-09-03,2019-09-06,Actual,"May 4, 2017",Actual,2017-05-04,September 2019,2019-09-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,,Interventional,,,A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression,"Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression",Recruiting,,Phase 2,100.0,Anticipated,Mediti Pharma Inc.,,2.0,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:29:03.053284,2020-02-01 09:29:03.053284,Mediti Pharma Inc.,Other,Placebo,Drug
NCT03055741,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-14,,,2019-08-19,2017-02-15,2017-02-16,Actual,,,,,,,2019-08-19,2019-08-20,Actual,"December 28, 2016",Actual,2016-12-28,August 2019,2019-08-31,August 2019,Actual,2019-08-31,February 2019,Actual,2019-02-28,,Interventional,,,Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA),"A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIb, Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)",Completed,,Phase 2,180.0,Actual,"Daehwa Pharmaceutical Co., Ltd.",,3.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:26:53.735013,2020-02-01 09:26:53.735013,"Daehwa Pharmaceutical Co., Ltd.",Industry,Placebo,Drug
NCT03056729,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-15,,,2019-11-08,2017-02-15,2017-02-17,Actual,,,,,,,2019-11-08,2019-11-12,Actual,"February 17, 2017",Actual,2017-02-17,November 2019,2019-11-30,"March 3, 2020",Anticipated,2020-03-03,"March 3, 2020",Anticipated,2020-03-03,,Interventional,,,Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease,"A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB076 in Healthy Volunteers and Subjects With Alzheimer's Disease","Active, not recruiting",,Phase 1,46.0,Actual,Biogen,,6.0,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 09:26:43.137705,2020-02-01 09:26:43.137705,Biogen,Industry,Placebo,Drug
NCT03075241,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-05,,,2019-07-07,2017-03-05,2017-03-09,Actual,,,,,,,2019-07-07,2019-07-09,Actual,October 2016,Actual,2016-10-31,July 2019,2019-07-31,December 2020,Anticipated,2020-12-31,January 2020,Anticipated,2020-01-31,,Interventional,,,Z-Drugs for Sleep Disorders in Alzheimer's Disease,"Z-Drugs for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study",Recruiting,,Phase 3,60.0,Anticipated,Brasilia University Hospital,,3.0,,,False,,,,False,False,False,,,False,,,,,,No,,2020-02-01 09:23:32.069605,2020-02-01 09:23:32.069605,Brasilia University Hospital,Other,Placebo,Drug
NCT03093519,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-22,,,2018-03-18,2017-03-22,2017-03-28,Actual,,,,,,,2018-03-18,2018-03-20,Actual,"March 3, 2017",Actual,2017-03-03,March 2018,2018-03-31,"December 6, 2017",Actual,2017-12-06,"December 6, 2017",Actual,2017-12-06,,Interventional,,,A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease,"A Phase 1 Randomized, Double-blind, Placebo-controlled, Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease",Completed,,Phase 1,21.0,Actual,"Kyowa Kirin Co., Ltd.",,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2020-02-01 09:20:20.897418,2020-02-01 09:20:20.897418,"Kyowa Kirin Co., Ltd.",Industry,Placebo,Drug
NCT03108846,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-06,,,2019-01-16,2017-04-06,2017-04-11,Actual,,,,,,,2019-01-16,2019-01-17,Actual,"January 3, 2018",Actual,2018-01-03,January 2019,2019-01-31,August 2022,Anticipated,2022-08-31,December 2021,Anticipated,2021-12-31,,Interventional,S-CitAD,,Escitalopram for Agitation in Alzheimer's Disease,Escitalopram for Agitation in Alzheimer's Disease,Recruiting,,Phase 3,392.0,Anticipated,JHSPH Center for Clinical Trials,,2.0,,,False,,,,True,True,False,,,True,,,,,,No,,2020-02-01 09:17:38.732615,2020-02-01 09:17:38.732615,JHSPH Center for Clinical Trials,Other,Placebo,Drug
NCT03113812,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-04,,,2017-04-10,2017-04-10,2017-04-14,Actual,,,,,,,2017-04-10,2017-04-14,Actual,"January 1, 2014",Actual,2014-01-01,April 2017,2017-04-30,"July 30, 2015",Actual,2015-07-30,"July 30, 2015",Actual,2015-07-30,,Interventional,,,Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients,"A Randomized, Placebo-controlled, Parallel Group, Double-blinded, Single-center Phase-I, Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of ABvac40 in Patients With Mild to Moderate Alzheimer's Disease.",Completed,,Phase 1,24.0,Actual,Araclon Biotech S.L.,,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2020-02-01 09:16:52.146443,2020-02-01 09:16:52.146443,Araclon Biotech S.L.,Industry,Placebo,Drug
NCT03114657,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-28,,,2019-10-03,2017-04-10,2017-04-14,Actual,,,,,,,2019-10-03,2019-10-04,Actual,"March 29, 2017",Actual,2017-03-29,October 2019,2019-10-31,"June 11, 2019",Actual,2019-06-11,"June 11, 2019",Actual,2019-06-11,,Interventional,CREAD 2,,A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease",Completed,,Phase 3,806.0,Actual,Hoffmann-La Roche,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 09:16:44.983523,2020-02-01 09:16:44.983523,Hoffmann-La Roche,Industry,Placebo,Drug
NCT03116126,"ClinicalTrials.gov processed this data on January 31, 2020",2017-04-04,,,2019-06-10,2017-04-11,2017-04-14,Actual,,,,,,,2019-06-10,2019-06-12,Actual,"January 4, 2019",Actual,2019-01-04,June 2019,2019-06-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,,Interventional,NorAD,,Noradrenergic Add-on Therapy With Guanfacine,Randomised Clinical Trial of Noradrenergic Add-on Therapy With Extended-Release Guanfacine in Alzheimer's Disease,Recruiting,,Phase 3,160.0,Anticipated,Imperial College London,,2.0,,,False,,,,True,False,False,,,False,,,,,,,,2020-02-01 09:16:26.690225,2020-02-01 09:16:26.690225,Imperial College London,Other,Placebo,Drug
NCT03226522,"ClinicalTrials.gov processed this data on January 31, 2020",2017-07-20,,,2020-01-11,2017-07-20,2017-07-21,Actual,,,,,,,2020-01-11,2020-01-14,Actual,"July 13, 2017",Actual,2017-07-13,January 2020,2020-01-31,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,,Interventional,ADVANCE,,Addressing Dementia Via Agitation-Centered Evaluation,"A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type",Recruiting,,Phase 2/Phase 3,435.0,Anticipated,"Axsome Therapeutics, Inc.",,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 08:57:30.107770,2020-02-01 08:57:30.107770,"Axsome Therapeutics, Inc.",Industry,Placebo,Drug
NCT03277573,"ClinicalTrials.gov processed this data on January 31, 2020",2017-07-27,,,2018-05-01,2017-09-07,2017-09-11,Actual,,,,,,,2018-05-01,2018-05-03,Actual,"July 21, 2017",Actual,2017-07-21,May 2018,2018-05-31,"October 21, 2019",Anticipated,2019-10-21,"July 21, 2019",Anticipated,2019-07-21,,Interventional,SAL-AD,,Salsalate in Patients Mild to Moderate Alzheimer's Disease,"A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 1,40.0,Anticipated,"University of California, San Francisco",,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:48:11.130970,2020-02-01 08:48:11.130970,Adam Boxer,Other,Placebo,Drug
NCT03282916,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-12,,,2020-01-05,2017-09-12,2017-09-14,Actual,,,,,,,2020-01-05,2020-01-07,Actual,"February 12, 2018",Actual,2018-02-12,January 2020,2020-01-31,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,,Interventional,,,Anti-viral Therapy in Alzheimer's Disease,Anti-viral Therapy in Alzheimer's Disease,Recruiting,,Phase 2,130.0,Anticipated,New York State Psychiatric Institute,,2.0,,,,,,,True,True,False,,,,,,,,,No,,2020-02-01 08:46:33.166581,2020-02-01 08:46:33.166581,New York State Psychiatric Institute,Other,Placebo,Drug
NCT03289143,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-18,,,2020-01-06,2017-09-18,2017-09-20,Actual,,,,,,,2020-01-06,2020-01-09,Actual,"October 4, 2017",Actual,2017-10-04,January 2020,2020-01-31,"September 20, 2022",Anticipated,2022-09-20,"June 24, 2020",Anticipated,2020-06-24,,Interventional,,,A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,457.0,Actual,"Genentech, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:45:33.720811,2020-02-01 08:45:33.720811,"Genentech, Inc.",Industry,Placebo,Drug
NCT03298672,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-21,,,2019-09-06,2017-09-26,2017-10-02,Actual,,,,,,,2019-09-06,2019-09-10,Actual,"October 9, 2017",Actual,2017-10-09,September 2019,2019-09-30,"September 5, 2019",Actual,2019-09-05,"September 5, 2019",Actual,2019-09-05,,Interventional,,,"Safety, Tolerability, and Pharmacokinetics Study of NDX-1017","A Randomized, Placebo-Controlled, Double-Blinded, First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part A) and Multiple Ascending Doses (Part B) of NDX-1017 in Healthy Young and Elderly Subjects",Completed,,Phase 1,88.0,Actual,Athira Pharma,,2.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 08:43:58.167473,2020-02-01 08:43:58.167473,Athira Pharma,Industry,Placebo,Drug
NCT03305809,"ClinicalTrials.gov processed this data on January 31, 2020",2017-10-04,,,2020-01-16,2017-10-05,2017-10-10,Actual,,,,,,,2020-01-16,2020-01-18,Actual,"November 9, 2017",Actual,2017-11-09,"January 1, 2020",2020-01-01,"June 22, 2020",Anticipated,2020-06-22,"June 22, 2020",Anticipated,2020-06-22,,Interventional,PRESENCE,,A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB),Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB),Recruiting,,Phase 2,340.0,Anticipated,Eli Lilly and Company,,4.0,,,False,,,,False,True,False,,,,,,,,,Yes,"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.",2020-02-01 08:42:45.155349,2020-02-01 08:42:45.155349,Eli Lilly and Company,Industry,Placebo,Drug
NCT03316898,"ClinicalTrials.gov processed this data on January 31, 2020",2017-10-18,,,2018-10-31,2017-10-18,2017-10-20,Actual,,,,,,,2018-10-31,2018-11-02,Actual,"September 30, 2018",Anticipated,2018-09-30,October 2018,2018-10-31,"November 4, 2018",Anticipated,2018-11-04,"November 4, 2018",Anticipated,2018-11-04,,Interventional,,,A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease",Withdrawn,,Phase 1,0.0,Actual,Allergan,,4.0,,Business decision to stop the study.,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:40:51.152227,2020-02-01 08:40:51.152227,Allergan,Industry,Placebo,Drug
NCT03352557,"ClinicalTrials.gov processed this data on January 31, 2020",2017-11-21,,,2020-01-20,2017-11-21,2017-11-24,Actual,,,,,,,2020-01-20,2020-01-22,Actual,"May 3, 2018",Actual,2018-05-03,January 2020,2020-01-31,"March 26, 2024",Anticipated,2024-03-26,"March 26, 2024",Anticipated,2024-03-26,,Interventional,TANGO,,Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,654.0,Actual,Biogen,,4.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:34:31.539157,2020-02-01 08:34:31.539157,Biogen,Industry,Placebo,Drug
NCT03367403,"ClinicalTrials.gov processed this data on January 31, 2020",2017-12-05,,,2019-08-02,2017-12-05,2017-12-08,Actual,,,,,,,2019-08-02,2019-08-05,Actual,"December 18, 2017",Actual,2017-12-18,"August 1, 2019",2019-08-01,"November 12, 2021",Anticipated,2021-11-12,"December 11, 2020",Anticipated,2020-12-11,,Interventional,,,A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ),"Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease","Active, not recruiting",,Phase 2,266.0,Anticipated,Eli Lilly and Company,,2.0,,,False,,,,True,True,False,,,,,,,,,Yes,"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.",2020-02-01 08:32:22.240538,2020-02-01 08:32:22.240538,Eli Lilly and Company,Industry,Placebo,Drug
NCT03375697,"ClinicalTrials.gov processed this data on January 31, 2020",2017-12-13,,,2020-01-10,2017-12-13,2017-12-18,Actual,,,,,,,2020-01-10,2020-01-13,Actual,"December 22, 2017",Actual,2017-12-22,January 2020,2020-01-31,"December 16, 2019",Actual,2019-12-16,"December 16, 2019",Actual,2019-12-16,,Interventional,,,"A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease","A 2-Part Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease",Completed,,Phase 1,72.0,Actual,"Janssen Research & Development, LLC",,2.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 08:30:47.390139,2020-02-01 08:30:47.390139,"Janssen Research & Development, LLC",Industry,Placebo,Drug
NCT03393520,"ClinicalTrials.gov processed this data on January 31, 2020",2018-01-03,,,2020-01-24,2018-01-03,2018-01-08,Actual,,,,,,,2020-01-24,2020-01-27,Actual,"October 13, 2017",Actual,2017-10-13,January 2020,2020-01-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,,Interventional,,,"Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",Recruiting,,Phase 3,412.0,Anticipated,Avanir Pharmaceuticals,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:27:50.083519,2020-02-01 08:27:50.083519,Avanir Pharmaceuticals,Industry,Placebo,Drug
NCT03418688,"ClinicalTrials.gov processed this data on January 31, 2020",2018-01-26,,,2018-11-05,2018-01-26,2018-02-01,Actual,,,,,,,2018-11-05,2018-11-07,Actual,"March 6, 2018",Actual,2018-03-06,November 2018,2018-11-30,"October 15, 2018",Actual,2018-10-15,"October 15, 2018",Actual,2018-10-15,,Interventional,,,A Multiple Ascending Dose Study of COR388,"A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of COR388 in Older Healthy Volunteers and Patients With Alzheimer's Disease",Completed,,Phase 1,33.0,Actual,Cortexyme Inc.,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 08:23:47.480357,2020-02-01 08:23:47.480357,Cortexyme Inc.,Industry,Placebo,Drug
NCT03443973,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-19,,,2020-01-09,2018-02-19,2018-02-23,Actual,,,,,,,2020-01-09,2020-01-13,Actual,"August 22, 2018",Actual,2018-08-22,January 2020,2020-01-31,"March 2, 2023",Anticipated,2023-03-02,"May 31, 2022",Anticipated,2022-05-31,,Interventional,,,Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease",Recruiting,,Phase 3,760.0,Anticipated,Hoffmann-La Roche,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:19:15.567106,2020-02-01 08:19:15.567106,Hoffmann-La Roche,Industry,Placebo,Drug
NCT03444870,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-19,,,2020-01-09,2018-02-19,2018-02-23,Actual,,,,,,,2020-01-09,2020-01-13,Actual,"June 6, 2018",Actual,2018-06-06,January 2020,2020-01-31,"March 2, 2023",Anticipated,2023-03-02,"May 31, 2022",Anticipated,2022-05-31,,Interventional,,,Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD),"A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease",Recruiting,,Phase 3,814.0,Anticipated,Hoffmann-La Roche,,2.0,,,,,,,True,True,False,,,,,,,,,,,2020-02-01 08:19:06.396961,2020-02-01 08:19:06.396961,Hoffmann-La Roche,Industry,Placebo,Drug
NCT03446001,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-08,,,2020-01-22,2018-02-20,2018-02-26,Actual,,,,,,,2020-01-22,2020-01-23,Actual,"January 10, 2018",Actual,2018-01-10,January 2020,2020-01-31,December 2022,Anticipated,2022-12-31,December 2021,Anticipated,2021-12-31,,Interventional,,,Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment,"Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment",Recruiting,,Phase 3,450.0,Anticipated,TauRx Therapeutics Ltd,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:18:55.846673,2020-02-01 08:18:55.846673,TauRx Therapeutics Ltd,Industry,Placebo,Drug
NCT03456349,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-22,,,2018-07-19,2018-03-05,2018-03-07,Actual,,,,,,,2018-07-19,2018-07-20,Actual,"November 10, 2017",Actual,2017-11-10,July 2018,2018-07-31,"July 16, 2018",Actual,2018-07-16,"July 16, 2018",Actual,2018-07-16,,Interventional,,,Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care,"A Phase 1b Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With Alzheimer's Disease Receiving Standard-of-care",Completed,,Phase 1,60.0,Actual,Heptares Therapeutics Limited,,4.0,,,False,,,,True,False,False,,,,,,,,,,,2020-02-01 08:17:20.213225,2020-02-01 08:17:20.213225,Heptares Therapeutics Limited,Industry,Placebo,Drug
NCT03493282,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-14,,,2019-03-29,2018-04-03,2018-04-10,Actual,,,,,,,2019-03-29,2019-04-02,Actual,"April 20, 2018",Actual,2018-04-20,March 2019,2019-03-31,"July 30, 2020",Anticipated,2020-07-30,"January 31, 2020",Anticipated,2020-01-31,,Interventional,,,Effect of CT1812 Treatment on Brain Synaptic Density,A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease,Recruiting,,Phase 1/Phase 2,21.0,Anticipated,Cognition Therapeutics,,3.0,,,,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 08:11:27.828530,2020-02-01 08:11:27.828530,Cognition Therapeutics,Industry,Placebo,Drug
NCT03507790,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-10,,,2020-01-20,2018-04-16,2018-04-25,Actual,,,,,,,2020-01-20,2020-01-22,Actual,"October 2, 2018",Actual,2018-10-02,January 2020,2020-01-31,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,,Interventional,,,A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.",Recruiting,,Phase 2,120.0,Anticipated,Cognition Therapeutics,,3.0,,,,,,,True,True,False,,,,,,,,,No,,2020-02-01 08:09:06.429952,2020-02-01 08:09:06.429952,Cognition Therapeutics,Industry,Placebo,Drug
NCT03518073,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-26,,,2020-01-16,2018-05-01,2018-05-08,Actual,,,,,,,2020-01-16,2020-01-18,Actual,"April 30, 2018",Actual,2018-04-30,January 2020,2020-01-31,"October 22, 2021",Anticipated,2021-10-22,"August 23, 2021",Anticipated,2021-08-23,,Interventional,,,A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease,"Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease","Active, not recruiting",,Phase 2,285.0,Anticipated,Eli Lilly and Company,,3.0,,,False,,,,True,True,False,,,,,,,,,Yes,"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.",2020-02-01 08:07:30.073091,2020-02-01 08:07:30.073091,Eli Lilly and Company,Industry,Placebo,Drug
NCT03522129,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-30,,,2019-02-25,2018-04-30,2018-05-11,Actual,,,,,,,2019-02-25,2019-02-26,Actual,"May 16, 2018",Actual,2018-05-16,February 2019,2019-02-28,"December 31, 2019",Anticipated,2019-12-31,"September 30, 2019",Anticipated,2019-09-30,,Interventional,,,Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease,A Pilot Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease,Recruiting,,Phase 1,18.0,Anticipated,Cognition Therapeutics,,4.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:06:42.545213,2020-02-01 08:06:42.545213,Cognition Therapeutics,Industry,Placebo,Drug
NCT03531710,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-06,,,2019-12-06,2018-05-08,2018-05-22,Actual,,,,,,,2019-12-06,2019-12-10,Actual,"August 10, 2018",Actual,2018-08-10,December 2019,2019-12-31,"October 31, 2019",Actual,2019-10-31,"October 31, 2019",Actual,2019-10-31,,Interventional,,,"An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311","An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311)",Terminated,,Phase 2,34.0,Actual,United Neuroscience Ltd.,,2.0,,"United Neuroscience has decided to terminate V203-AD-EXT study based on review of baseline
    data, and the treatment assignment error issue.",False,,,,,True,False,,,,,,,,,,,2020-02-01 08:05:08.060905,2020-02-01 08:05:08.060905,United Neuroscience Ltd.,Industry,Placebo,Drug
NCT03533257,"ClinicalTrials.gov processed this data on January 31, 2020",2018-04-30,,,2020-01-15,2018-05-10,2018-05-23,Actual,,,,,,,2020-01-15,2020-01-18,Actual,"August 27, 2018",Actual,2018-08-27,January 2020,2020-01-31,"September 1, 2020",Anticipated,2020-09-01,"July 1, 2020",Anticipated,2020-07-01,,Interventional,PEGASUS,,Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease,"Phase II Study to Assess the Safety, Tolerability, and Target Engagement of AMX0035, a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimer's Disease",Recruiting,,Phase 2,100.0,Anticipated,Amylyx Pharmaceuticals Inc.,,2.0,,,,,,,False,True,False,,,,,,,,,Undecided,,2020-02-01 08:04:53.807069,2020-02-01 08:04:53.807069,Amylyx Pharmaceuticals Inc.,Industry,Placebo,Drug
NCT03620981,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-05,,,2019-07-09,2018-08-05,2018-08-08,Actual,,,,,,,2019-07-09,2019-07-11,Actual,"August 20, 2018",Actual,2018-08-20,July 2019,2019-07-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,,Interventional,,,Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,"A Phase 2/3 Multicenter, Placebo-controlled, Randomized, Double-blind, Parallel-group Comparison Trial to Evaluate the Efficacy and Safety of Brexpiprazole (OPC-34712) in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",Recruiting,,Phase 2/Phase 3,407.0,Anticipated,"Otsuka Pharmaceutical Co., Ltd.",,3.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2020-02-01 07:51:00.823260,2020-02-01 07:51:00.823260,"Otsuka Pharmaceutical Co., Ltd.",Industry,Placebo,Drug
NCT03625622,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-08,,,2019-03-28,2018-08-08,2018-08-10,Actual,,,,,,,2019-03-28,2019-04-01,Actual,"January 15, 2019",Actual,2019-01-15,March 2019,2019-03-31,"August 1, 2020",Anticipated,2020-08-01,"June 1, 2020",Anticipated,2020-06-01,,Interventional,,,Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease,"A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 2,210.0,Anticipated,"AriBio Co., Ltd.",,3.0,,,,,,,False,True,False,,,,,,,,,,,2020-02-01 07:50:16.488873,2020-02-01 07:50:16.488873,"AriBio Co., Ltd.",Industry,Placebo,Drug
NCT03639987,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-17,,,2019-11-07,2018-08-17,2018-08-21,Actual,,,,,,,2019-11-07,2019-11-12,Actual,"December 20, 2018",Actual,2018-12-20,November 2019,2019-11-30,"July 30, 2019",Actual,2019-07-30,"July 30, 2019",Actual,2019-07-30,,Interventional,EVOLVE,,A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities,"A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Subjects With Asymptomatic Amyloid-Related Imaging Abnormalities",Terminated,,Phase 2,500.0,Actual,Biogen,,2.0,,"Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and
    NCT02484547) and not based on safety concerns.",False,,,,True,True,False,,,,,,,,,,,2020-02-01 07:47:53.971667,2020-02-01 07:47:53.971667,Biogen,Industry,Placebo,Drug
NCT03649724,"ClinicalTrials.gov processed this data on January 31, 2020",2018-08-22,,,2019-09-25,2018-08-22,2018-08-28,Actual,,,,,,,2019-09-25,2019-09-30,Actual,February 2020,Anticipated,2020-02-29,September 2019,2019-09-30,February 2026,Anticipated,2026-02-28,February 2025,Anticipated,2025-02-28,,Interventional,LUCINDA,,The LUCINDA Trial: LUpron Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's,The LUCINDA Trial: LUpron Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's,Not yet recruiting,,Phase 2,50.0,Anticipated,Weill Medical College of Cornell University,,2.0,,,False,,,,True,True,False,,,False,,,"Baseline, 48 Weeks",Approval from PI,,Yes,"The data and resources sharing plan for this project is in accordance with both Weill Cornell and NIH Data Sharing Policies. All raw clinical, genetic, and imaging data from this project will be available upon written request. Deidentified neuroimaging data may be uploaded to one or more of several available data sharing sites designed for this purpose. The final data will be available in acceptable formats such as presentations and publications.
Research data and results that document and support the study aims will be available after the final results are accepted for publication. The data to be shared will be anonymized and there will be no fees or other restrictions.",2020-02-01 07:46:25.751941,2020-02-01 07:46:25.751941,Weill Medical College of Cornell University,Other,Placebo,Drug
NCT03698695,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-02,,,2020-01-21,2018-10-03,2018-10-09,Actual,,,,,,,2020-01-21,2020-01-22,Actual,"September 27, 2018",Actual,2018-09-27,January 2020,2020-01-31,"December 20, 2019",Actual,2019-12-20,"October 20, 2019",Actual,2019-10-20,,Interventional,,,"A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers","A Double Blind, Placebo-controlled, Randomized, 15-day Treatment, Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil Administered Orally to Healthy Male Volunteers Including a Scopolamine Challenge",Completed,,Phase 1,152.0,Actual,Theranexus,,3.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:39:11.698156,2020-02-01 07:39:11.698156,Theranexus,Industry,Placebo,Drug
NCT03703856,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-09,,,2020-01-21,2018-10-10,2018-10-12,Actual,,,,,,,2020-01-21,2020-01-23,Actual,"January 31, 2019",Actual,2019-01-31,January 2020,2020-01-31,August 2023,Anticipated,2023-08-31,August 2023,Anticipated,2023-08-31,,Interventional,,,Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease,Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease,Recruiting,,Phase 4,88.0,Anticipated,"University of California, San Diego",,2.0,,,False,,,,,True,False,,,True,,,,,,,,2020-02-01 07:38:26.839208,2020-02-01 07:38:26.839208,"University of California, San Diego",Other,Placebo,Drug
NCT03757325,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-27,,,2020-01-08,2018-11-27,2018-11-28,Actual,,,,,,,2020-01-08,2020-01-13,Actual,"February 13, 2019",Actual,2019-02-13,January 2020,2020-01-31,"December 5, 2019",Actual,2019-12-05,"December 5, 2019",Actual,2019-12-05,,Interventional,,,Study to Evaluate DNL747 in Subjects With Alzheimer's Disease,"A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Alzheimer's Disease",Completed,,Phase 1,16.0,Actual,Denali Therapeutics Inc.,,2.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 07:30:24.698174,2020-02-01 07:30:24.698174,Denali Therapeutics Inc.,Industry,Placebo,Drug
NCT03817684,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-18,,,2019-10-30,2019-01-23,2019-01-25,Actual,,,,,,,2019-10-30,2019-10-31,Actual,"April 30, 2019",Actual,2019-04-30,October 2019,2019-10-31,February 2020,Anticipated,2020-02-29,February 2020,Anticipated,2020-02-29,,Interventional,,,Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects,"A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease","Active, not recruiting",,Phase 2,255.0,Actual,Tetra Discovery Partners,,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 07:21:36.297810,2020-02-01 07:21:36.297810,Tetra Discovery Partners,Industry,Placebo,Drug
NCT03828747,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-29,,,2020-01-06,2019-01-31,2019-02-04,Actual,,,,,,,2020-01-06,2020-01-09,Actual,"January 30, 2019",Actual,2019-01-30,January 2020,2020-01-31,"June 2, 2023",Anticipated,2023-06-02,"May 7, 2021",Anticipated,2021-05-07,,Interventional,,,A Study of Semorinemab in Patients With Moderate Alzheimer's Disease,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease",Recruiting,,Phase 2,260.0,Anticipated,"Genentech, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)",2020-02-01 07:20:05.785221,2020-02-01 07:20:05.785221,"Genentech, Inc.",Industry,Placebo,Drug
NCT03838185,"ClinicalTrials.gov processed this data on January 31, 2020",2019-02-07,,,2019-02-09,2019-02-09,2019-02-12,Actual,,,,,,,2019-02-09,2019-02-12,Actual,"January 22, 2019",Actual,2019-01-22,February 2019,2019-02-28,January 2020,Anticipated,2020-01-31,October 2019,Anticipated,2019-10-31,,Interventional,,,"Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147","A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147 in Healthy Young Volunteers and Healthy Elderly Volunteers",Recruiting,,Phase 1,64.0,Anticipated,"Abrexa Pharmaceuticals, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 07:18:39.582788,2020-02-01 07:18:39.582788,"Abrexa Pharmaceuticals, Inc.",Industry,Placebo,Drug
NCT03867253,"ClinicalTrials.gov processed this data on January 31, 2020",2019-02-20,,,2019-12-02,2019-03-06,2019-03-07,Actual,,,,,,,2019-12-02,2019-12-03,Actual,"May 16, 2019",Actual,2019-05-16,November 2019,2019-11-30,"November 15, 2020",Anticipated,2020-11-15,"November 15, 2020",Anticipated,2020-11-15,,Interventional,ETHERAL-US,,Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease,"A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease",Recruiting,,Phase 2,33.0,Anticipated,Oryzon Genomics S.A.,,3.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 07:14:13.743720,2020-02-01 07:14:13.743720,Oryzon Genomics S.A.,Industry,Placebo,Drug
NCT03887455,"ClinicalTrials.gov processed this data on January 31, 2020",2019-03-21,,,2019-07-10,2019-03-21,2019-03-25,Actual,,,,,,,2019-07-10,2019-07-12,Actual,"March 27, 2019",Actual,2019-03-27,March 2019,2019-03-31,"March 7, 2024",Anticipated,2024-03-07,"February 24, 2022",Anticipated,2022-02-24,,Interventional,Clarity AD,,A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease,"A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease",Recruiting,,Phase 3,1566.0,Anticipated,Eisai Inc.,,3.0,,,False,,,,True,True,False,,,False,,,,,,Yes,Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.,2020-02-01 07:11:13.548680,2020-02-01 07:11:13.548680,Eisai Inc.,Industry,Placebo,Drug
NCT03935568,"ClinicalTrials.gov processed this data on January 31, 2020",2019-04-24,,,2019-12-23,2019-04-30,2019-05-02,Actual,,,,,,,2019-12-23,2019-12-26,Actual,"June 24, 2019",Actual,2019-06-24,December 2019,2019-12-31,"December 23, 2019",Actual,2019-12-23,"December 23, 2019",Actual,2019-12-23,,Interventional,,,A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects,A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects,Completed,,Phase 1,40.0,Actual,"Samus Therapeutics, Inc.",,4.0,,,False,,,,False,True,False,,,False,,,,,,No,,2020-02-01 07:04:00.603763,2020-02-01 07:04:00.603763,"Samus Therapeutics, Inc.",Industry,Placebo,Drug
NCT03980730,"ClinicalTrials.gov processed this data on January 31, 2020",2019-05-31,,,2020-01-13,2019-06-06,2019-06-10,Actual,,,,,,,2020-01-13,2020-01-14,Actual,"June 27, 2019",Actual,2019-06-27,January 2020,2020-01-31,July 2023,Anticipated,2023-07-31,April 2023,Anticipated,2023-04-30,,Interventional,Elevage,,Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance,"Randomized, Double-blind, Placebo-controlled, Multicenter Studies to Evaluate the Safety and Efficacy of Azeliragon as a Treatment for Subjects With Mild Alzheimer's Disease and Impaired Glucose Tolerance",Recruiting,,Phase 2/Phase 3,300.0,Anticipated,vTv Therapeutics,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 06:57:16.531793,2020-02-01 06:57:16.531793,vTv Therapeutics,Industry,Placebo,Drug
NCT04023994,"ClinicalTrials.gov processed this data on January 31, 2020",2019-07-16,,,2020-01-03,2019-07-16,2019-07-18,Actual,,,,,,,2020-01-03,2020-01-06,Actual,"August 3, 2019",Actual,2019-08-03,January 2020,2020-01-31,"May 7, 2020",Anticipated,2020-05-07,"May 7, 2020",Anticipated,2020-05-07,,Interventional,,,"A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants","A Single-Center, Randomized, Adaptive, Investigator/Subject Blind, Single Ascending Dose, Placebo-Controlled Phase I Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants",Recruiting,,Phase 1,60.0,Anticipated,Hoffmann-La Roche,,5.0,,,False,,,,False,True,False,,,,,,,,,No,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2020-02-01 06:50:54.951052,2020-02-01 06:50:54.951052,Hoffmann-La Roche,Industry,Placebo,Drug
NCT04074837,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-27,,,2019-08-28,2019-08-28,2019-08-30,Actual,,,,,,,2019-08-28,2019-08-30,Actual,"August 1, 2019",Actual,2019-08-01,August 2019,2019-08-31,"April 1, 2020",Anticipated,2020-04-01,"March 1, 2020",Anticipated,2020-03-01,,Interventional,,,"Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers","Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age",Recruiting,,Phase 1,56.0,Anticipated,"Neuronascent, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,No,This clinical trial will be available for peer-reviewed publication.,2020-02-01 06:43:42.295547,2020-02-01 06:43:42.295547,"Neuronascent, Inc.",Industry,Placebo,Drug
NCT04149860,"ClinicalTrials.gov processed this data on January 31, 2020",2019-10-31,,,2019-11-01,2019-11-01,2019-11-04,Actual,,,,,,,2019-11-01,2019-11-04,Actual,"September 27, 2019",Actual,2019-09-27,August 2019,2019-08-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,,Interventional,,,Study With Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease,"Interventional, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease",Recruiting,,Phase 1,96.0,Anticipated,H. Lundbeck A/S,,3.0,,,False,,,,False,True,False,,,,,,,,,Undecided,,2020-02-01 06:33:22.390960,2020-02-01 06:33:22.390960,H. Lundbeck A/S,Industry,Placebo,Drug
NCT04187547,"ClinicalTrials.gov processed this data on January 31, 2020",2019-11-29,,,2019-12-05,2019-12-03,2019-12-05,Actual,,,,,,,2019-12-05,2019-12-06,Actual,"April 30, 2020",Anticipated,2020-04-30,December 2019,2019-12-31,"July 14, 2022",Anticipated,2022-07-14,"June 21, 2022",Anticipated,2022-06-21,,Interventional,,,A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease,"A 20-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Subjects With Mild to Moderately Severe Probable Alzheimer's Disease and Who Are Non-carriers of the APOE4 Allele",Not yet recruiting,,Phase 3,300.0,Anticipated,Cerecin,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 06:28:14.549852,2020-02-01 06:28:14.549852,Cerecin,Industry,Placebo,Drug
NCT04191486,"ClinicalTrials.gov processed this data on January 31, 2020",2019-11-26,,,2020-01-20,2019-12-05,2019-12-09,Actual,,,,,,,2020-01-20,2020-01-22,Actual,"December 24, 2019",Actual,2019-12-24,January 2020,2020-01-31,October 2022,Anticipated,2022-10-31,September 2022,Anticipated,2022-09-30,,Interventional,,,Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD,"A Phase 2 Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease",Recruiting,,Phase 2,200.0,Anticipated,"FUJIFILM Toyama Chemical Co., Ltd.",,2.0,,,False,,,,True,False,False,,,,,,,,,Undecided,Details for sharing data have not been decided yet.,2020-02-01 06:27:45.932872,2020-02-01 06:27:45.932872,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,Placebo,Drug
NCT02168920,"ClinicalTrials.gov processed this data on January 31, 2020",2014-06-18,,,2017-10-13,2014-06-18,2014-06-20,Estimate,,,,,,,2017-10-13,2017-10-16,Actual,"June 11, 2014",Actual,2014-06-11,October 2017,2017-10-31,"March 18, 2016",Actual,2016-03-18,"March 18, 2016",Actual,2016-03-18,,Interventional,,,Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type,"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type",Terminated,,Phase 3,150.0,Actual,"Otsuka Pharmaceutical Co., Ltd.",,4.0,,It was difficult to secure enrollment of the targeted number of subjects.,False,,,,True,,,,,,,,,,,,,2020-02-01 12:37:21.845361,2020-02-01 12:37:21.845361,"Otsuka Pharmaceutical Co., Ltd.",Industry,Placebo (0 mg/day),Drug
NCT00164749,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-09,,,2008-04-25,2005-09-09,2005-09-14,Estimate,,,,,,,2008-04-25,2008-04-30,Estimate,October 2004,,2004-10-31,April 2008,2008-04-30,July 2006,Actual,2006-07-31,July 2006,Actual,2006-07-31,,Interventional,,,A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease,A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease,Completed,,Phase 1/Phase 2,36.0,Actual,Chinese University of Hong Kong,,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:58:50.067117,2020-02-01 21:58:50.067117,Chinese University of Hong Kong,Other,Placebo and ginkgo extract,Drug
NCT03752294,"ClinicalTrials.gov processed this data on January 31, 2020",2018-05-15,,,2018-11-20,2018-11-20,2018-11-23,Actual,,,,,,,2018-11-20,2018-11-23,Actual,November 2018,Anticipated,2018-11-30,November 2018,2018-11-30,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,,Interventional,,,A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.,"A 24-month, Randomized-control, Double-blind, Multi-center, Delayed-start, Pilot Study Evaluating Thrombin Inhibitions Alzheimer's Disease Using 150mg Dabigatran Daily: A Novel Therapeutic Target for Alzheimer's Disease",Not yet recruiting,,Phase 1,40.0,Anticipated,University of Rhode Island,,3.0,,,False,,,,True,False,False,,,False,,,,,,Undecided,,2020-02-01 07:31:02.811291,2020-02-01 07:31:02.811291,University of Rhode Island,Other,Placebo - Cap,Drug
NCT03823404,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-24,,,2020-01-10,2019-01-29,2019-01-30,Actual,,,,,,,2020-01-10,2020-01-13,Actual,"March 28, 2019",Actual,2019-03-28,December 2019,2019-12-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,,Interventional,,,GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease,"GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease",Recruiting,,Phase 2/Phase 3,573.0,Anticipated,Cortexyme Inc.,,3.0,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 07:20:47.948947,2020-02-01 07:20:47.948947,Cortexyme Inc.,Industry,Placebo capsule,Drug
NCT00117403,"ClinicalTrials.gov processed this data on January 31, 2020",2005-06-30,,,2009-04-01,2005-06-30,2005-07-06,Estimate,,,,,,,2009-04-01,2009-04-03,Estimate,January 2006,,2006-01-31,April 2008,2008-04-30,September 2007,Actual,2007-09-30,September 2007,Actual,2007-09-30,,Interventional,,,Anti-Oxidant Treatment of Alzheimer's Disease,"Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,75.0,Anticipated,National Institute on Aging (NIA),,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:12:02.293739,2020-02-01 22:12:02.293739,National Institute on Aging (NIA),NIH,Placebo capsules,Drug
NCT02947893,"ClinicalTrials.gov processed this data on January 31, 2020",2016-10-21,,,2019-03-12,2016-10-27,2016-10-28,Estimate,,,,,,,2019-03-12,2019-03-13,Actual,January 2017,Actual,2017-01-31,March 2019,2019-03-31,February 2020,Anticipated,2020-02-29,December 2019,Anticipated,2019-12-31,,Interventional,AD,,"Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease","A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease","Active, not recruiting",,Phase 2,42.0,Anticipated,Georgetown University,,2.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:47:48.303388,2020-02-01 09:47:48.303388,Georgetown University,Other,Placebo Capsule(s) Once a Day by Mouth,Drug
NCT00829374,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-23,,2016-09-24,2016-09-24,2009-01-23,2009-01-27,Estimate,,,,2016-09-24,2016-09-27,Estimate,2016-09-24,2016-09-27,Estimate,March 2009,,2009-03-31,September 2016,2016-09-30,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,CONCERT,,Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil,"CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil",Completed,,Phase 3,1003.0,Actual,"Medivation, Inc.",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:45:29.101700,2020-02-01 18:45:29.101700,"Medivation, Inc.",Industry,Placebo comparator,Drug
NCT00141661,"ClinicalTrials.gov processed this data on January 31, 2020",2005-08-30,,,2009-08-19,2005-08-30,2005-09-01,Estimate,,,,,,,2009-08-19,2009-08-20,Estimate,October 2005,,2005-10-31,August 2009,2009-08-31,June 2006,Actual,2006-06-30,June 2006,Actual,2006-06-30,,Interventional,,,A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients,"A Double-Blind, Randomized, Placebo-Controlled, Phase IIa, Multiple Dose, Multicenter Study in Subjects With Mild to Moderate Dementia of the Alzheimer's Type to Evaluate the Safety and Tolerability of Two 10-Week Dose Regimens of Orally-Administered PF-04494700",Completed,,Phase 2,67.0,Actual,Pfizer,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 22:05:05.719845,2020-02-01 22:05:05.719845,Pfizer,Industry,Placebo Comparator,Drug
NCT00403520,"ClinicalTrials.gov processed this data on January 31, 2020",2006-11-21,,,2014-07-11,2006-11-21,2006-11-23,Estimate,,,,,,,2014-07-11,2014-07-14,Estimate,November 2006,,2006-11-30,July 2014,2014-07-31,August 2010,Actual,2010-08-31,March 2008,Actual,2008-03-31,,Interventional,,,Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers,Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders,Completed,,Phase 4,240.0,Actual,Eisai Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:55:26.861622,2020-02-01 20:55:26.861622,Eisai Inc.,Industry,Placebo Comparator,Drug
NCT01547169,"ClinicalTrials.gov processed this data on January 31, 2020",2012-02-07,,,2012-12-17,2012-03-06,2012-03-07,Estimate,,,,,,,2012-12-17,2012-12-18,Estimate,March 2011,,2011-03-31,December 2012,2012-12-31,December 2012,Actual,2012-12-31,December 2012,Actual,2012-12-31,,Interventional,SNIFF-LONG 21,,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days,Completed,,Phase 2,60.0,Actual,University of Washington,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:17:31.332607,2020-02-01 15:17:31.332607,University of Washington,Other,Placebo Comparator,Drug
NCT03061474,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-13,,,2019-09-24,2017-02-17,2017-02-23,Actual,,,,,,,2019-09-24,2019-09-26,Actual,"July 12, 2017",Actual,2017-07-12,September 2019,2019-09-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,,Interventional,NEAT,,Nicotinamide as an Early Alzheimer's Disease Treatment,"A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Dementia",Recruiting,,Phase 2,48.0,Anticipated,"University of California, Irvine",,2.0,,,,,,,True,True,False,,,,,,,,,Yes,,2020-02-01 09:26:00.923165,2020-02-01 09:26:00.923165,"University of California, Irvine",Other,Placebo Comparator,Drug
NCT01230853,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-27,,,2013-05-20,2010-10-28,2010-10-29,Estimate,,,,,,,2013-05-20,2013-05-22,Estimate,August 2010,,2010-08-31,February 2013,2013-02-28,February 2013,Actual,2013-02-28,October 2012,Actual,2012-10-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study","A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer?s Disease",Completed,,Phase 1,80.0,Actual,Eisai Inc.,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:43:04.642093,2020-02-01 16:43:04.642093,Eisai Inc.,Industry,Placebo Comparator A,Drug
NCT01230853,"ClinicalTrials.gov processed this data on January 31, 2020",2010-10-27,,,2013-05-20,2010-10-28,2010-10-29,Estimate,,,,,,,2013-05-20,2013-05-22,Estimate,August 2010,,2010-08-31,February 2013,2013-02-28,February 2013,Actual,2013-02-28,October 2012,Actual,2012-10-31,,Interventional,,,"A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study","A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer?s Disease",Completed,,Phase 1,80.0,Actual,Eisai Inc.,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:43:04.642093,2020-02-01 16:43:04.642093,Eisai Inc.,Industry,Placebo Comparator B,Drug
NCT00568776,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-04,2011-09-27,,2019-10-17,2007-12-04,2007-12-06,Estimate,2012-03-01,2012-03-29,Estimate,,,,2019-10-17,2019-11-01,Actual,December 2007,,2007-12-31,October 2019,2019-10-31,May 2010,Actual,2010-05-31,May 2010,Actual,2010-05-31,,Interventional,,,ELND005 in Patients With Mild to Moderate Alzheimer's Disease,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease",Completed,,Phase 2,353.0,Actual,"OPKO Health, Inc.","The two high dose groups of ELND005 were discontinued before study end, so the efficacy analysis was based only on placebo and ELND005 250 mg bid groups.",4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:01:52.395629,2020-02-01 20:01:52.395629,"OPKO Health, Inc.",Industry,Placebo Control,Drug
NCT00574132,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-10,,2013-09-27,2013-10-30,2007-12-13,2007-12-17,Estimate,,,,2013-09-27,2013-10-28,Estimate,2013-10-30,2013-11-25,Estimate,December 2007,,2007-12-31,October 2013,2013-10-31,June 2012,Actual,2012-06-30,June 2012,Actual,2012-06-30,,Interventional,,,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Non- Carriers.",Completed,,Phase 3,1331.0,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:00:25.535905,2020-02-01 20:00:25.535905,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Placebo Control,Drug
NCT00575055,"ClinicalTrials.gov processed this data on January 31, 2020",2007-12-10,,2013-09-27,2013-10-30,2007-12-13,2007-12-17,Estimate,,,,2013-09-27,2013-10-28,Estimate,2013-10-30,2013-11-25,Estimate,December 2007,,2007-12-31,October 2013,2013-10-31,April 2012,Actual,2012-04-30,April 2012,Actual,2012-04-30,,Interventional,,,Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier),"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients With Mild to Moderate Alzheimer's Disease Who Are Apolipoprotein E4 Carriers.",Completed,,Phase 3,1121.0,Actual,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:00:04.969013,2020-02-01 20:00:04.969013,"JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Industry,Placebo Control,Drug
NCT00866060,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-19,,,2009-03-19,2009-03-19,2009-03-20,Estimate,,,,,,,2009-03-19,2009-03-20,Estimate,February 2008,,2008-02-29,March 2009,2009-03-31,June 2013,Anticipated,2013-06-30,February 2012,Anticipated,2012-02-29,,Interventional,DOMINO-AD,,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Unknown status,Recruiting,Phase 4,800.0,Anticipated,King's College London,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:34:35.920768,2020-02-01 18:34:35.920768,King's College London,Other,Placebo donepezil,Drug
NCT01940952,"ClinicalTrials.gov processed this data on January 31, 2020",2013-09-09,,,2013-09-09,2013-09-09,2013-09-12,Estimate,,,,,,,2013-09-09,2013-09-12,Estimate,September 2013,,2013-09-30,September 2013,2013-09-30,,,,August 2015,Anticipated,2015-08-31,,Interventional,,,Zydena on Cognitive Function of Alzheimer's Disease Patients,"Efficacy of Zydena (Udenafil) on Cognitive Function of Alzheimer's Disease Patients: A Randomized, Double Blind, Placebo-controlled Multicenter Study",Unknown status,Not yet recruiting,Phase 3,210.0,Anticipated,Samsung Medical Center,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:35:04.954668,2020-02-01 13:35:04.954668,Samsung Medical Center,Other,Placebo + Donepezil 5mg or 10mg,Drug
NCT02880956,"ClinicalTrials.gov processed this data on January 31, 2020",2016-08-24,,,2020-01-14,2016-08-24,2016-08-26,Estimate,,,,,,,2020-01-14,2020-01-18,Actual,"October 17, 2016",Actual,2016-10-17,January 2020,2020-01-31,"July 28, 2021",Anticipated,2021-07-28,"April 30, 2021",Anticipated,2021-04-30,,Interventional,,,A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease,"A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease","Active, not recruiting",,Phase 2,453.0,Actual,AbbVie,,4.0,,,True,,,,True,True,False,,,False,,,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.","Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.",https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2020-02-01 10:02:59.856443,2020-02-01 10:02:59.856443,AbbVie,Industry,placebo for ABBV-8E12,Drug
NCT01600859,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-15,,,2016-12-29,2012-05-15,2012-05-17,Estimate,,,,,,,2016-12-29,2016-12-30,Estimate,July 2012,,2012-07-31,December 2016,2016-12-31,October 2013,Actual,2013-10-31,September 2013,Actual,2013-09-30,,Interventional,,,Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02),"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease",Completed,,Phase 1,65.0,Actual,Eisai Inc.,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:04:28.156755,2020-02-01 15:04:28.156755,Eisai Inc.,Industry,Placebo for E2609,Drug
NCT00257673,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-22,,,2008-05-05,2005-11-22,2005-11-23,Estimate,,,,,,,2008-05-05,2008-05-06,Estimate,November 2005,,2005-11-30,May 2008,2008-05-31,October 2007,Actual,2007-10-31,October 2007,Actual,2007-10-31,,Interventional,,,Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,183.0,Actual,Memory Pharmaceuticals,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:36:50.716852,2020-02-01 21:36:50.716852,Memory Pharmaceuticals,Industry,Placebo for MEM 1003,Drug
NCT01324518,"ClinicalTrials.gov processed this data on January 31, 2020",2011-03-24,,,2014-10-20,2011-03-25,2011-03-29,Estimate,,,,,,,2014-10-20,2014-10-21,Estimate,April 2011,,2011-04-30,October 2014,2014-10-31,October 2012,Actual,2012-10-31,September 2012,Actual,2012-09-30,,Interventional,ALPO,,Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease,Safety and Efficacy of ORM-12741 on Cognitive and Behavioral Symptoms in Patients With Alzheimer's Disease,Completed,,Phase 2,100.0,Actual,"Orion Corporation, Orion Pharma",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:16:14.110927,2020-02-01 16:16:14.110927,"Orion Corporation, Orion Pharma",Industry,Placebo for ORM-12741,Drug
NCT01266525,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-23,,2016-02-12,2016-02-12,2010-12-23,2010-12-24,Estimate,,,,2016-02-12,2016-03-14,Estimate,2016-02-12,2016-03-14,Estimate,February 2011,,2011-02-28,February 2016,2016-02-29,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,,Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil,"A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy",Completed,,Phase 2,291.0,Actual,Sanofi,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:32:09.069267,2020-02-01 16:32:09.069267,Sanofi,Industry,placebo (for SAR110894),Drug
NCT02727699,"ClinicalTrials.gov processed this data on January 31, 2020",2016-03-21,,,2019-09-09,2016-03-30,2016-04-05,Estimate,,,,,,,2019-09-09,2019-09-11,Actual,"March 23, 2017",Actual,2017-03-23,September 2019,2019-09-30,"March 15, 2019",Actual,2019-03-15,"March 15, 2019",Actual,2019-03-15,,Interventional,XanADu,,"A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)","XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)",Completed,,Phase 2,186.0,Actual,Actinogen Medical,,2.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 10:31:55.688352,2020-02-01 10:31:55.688352,Actinogen Medical,Industry,Placebo (for Xanamem™),Drug
NCT00523666,"ClinicalTrials.gov processed this data on January 31, 2020",2007-08-29,,,2007-08-29,2007-08-29,2007-08-31,Estimate,,,,,,,2007-08-29,2007-08-31,Estimate,September 2006,,2006-09-30,August 2007,2007-08-31,September 2008,Anticipated,2008-09-30,,,,,Interventional,,,Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®),Diffusion Tensor Weighted MRI in Alzheimer's Disease: Prediction and Mapping of Symptomatic and Disease Modifying Treatment Effects of Galantamine (Reminyl®),Unknown status,Recruiting,Phase 4,20.0,Anticipated,Ludwig-Maximilians - University of Munich,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:17:42.425707,2020-02-01 20:17:42.425707,Ludwig-Maximilians - University of Munich,Other,Placebo/Galantamine (Reminyl®),Drug
NCT00539305,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-03,2013-03-15,,2014-07-10,2007-10-03,2007-10-04,Estimate,2014-07-10,2014-07-14,Estimate,,,,2014-07-10,2014-07-14,Estimate,July 2009,,2009-07-31,July 2014,2014-07-31,May 2012,Actual,2012-05-31,July 2011,Actual,2011-07-31,,Interventional,HIP,,Hormone and Information Processing Study,Testosterone Supplementation in Men With MCI,Completed,,Phase 3,22.0,Actual,University of Washington,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:12:13.088046,2020-02-01 20:12:13.088046,University of Washington,Other,placebo gel,Drug
NCT03625401,"ClinicalTrials.gov processed this data on January 31, 2020",2018-07-24,,,2019-01-09,2018-08-07,2018-08-10,Actual,,,,,,,2019-01-09,2019-01-11,Actual,"October 4, 2018",Actual,2018-10-04,January 2019,2019-01-31,"July 31, 2020",Anticipated,2020-07-31,"July 31, 2019",Anticipated,2019-07-31,,Interventional,ROAD,,Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease,"A Pilot, Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety and Tolerability, Efficacy, and Pharmacokinetics of AD-35 in Subjects With Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 2,88.0,Anticipated,Zhejiang Hisun Pharmaceutical Co. Ltd.,,3.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 07:50:18.156416,2020-02-01 07:50:18.156416,Zhejiang Hisun Pharmaceutical Co. Ltd.,Industry,Placebo group,Drug
NCT00161473,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-08,2012-02-24,,2012-06-26,2005-09-08,2005-09-12,Estimate,2012-06-26,2012-08-02,Estimate,,,,2012-06-26,2012-08-02,Estimate,January 2001,,2001-01-31,June 2012,2012-06-30,September 2009,Actual,2009-09-30,September 2009,Actual,2009-09-30,,Interventional,,,Alzheimer's in Long-Term Care--Treatment for Agitation,Alzheimer's in Long-Term Care--Treatment for Agitation,Completed,,N/A,24.0,Actual,University of Washington,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:59:31.636454,2020-02-01 21:59:31.636454,University of Washington,Other,placebo (inert substance),Drug
NCT02221622,"ClinicalTrials.gov processed this data on January 31, 2020",2014-07-02,,,2019-07-02,2014-08-18,2014-08-20,Estimate,,,,,,,2019-07-02,2019-07-05,Actual,August 2014,,2014-08-31,May 2018,2018-05-31,February 2018,Actual,2018-02-28,February 2018,Actual,2018-02-28,,Interventional,Allo,,Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD,Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase 1,Completed,,Phase 1,24.0,Actual,University of Southern California,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:24:27.622064,2020-02-01 12:24:27.622064,University of Southern California,Other,Placebo injection (intravenous solution),Drug
NCT02614131,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-23,2019-06-28,,2019-08-21,2015-11-23,2015-11-25,Estimate,2019-08-21,2019-09-23,Actual,,,,2019-08-21,2019-09-23,Actual,December 2015,,2015-12-31,August 2019,2019-08-31,December 2016,Actual,2016-12-31,December 2016,Actual,2016-12-31,,Interventional,,All randomized participants.,A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD),"Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease",Terminated,,Phase 1,50.0,Actual,Eli Lilly and Company,"Development of LY2599666 was stopped based on lack of efficacy of another compound directed against the same target. Following the enrollment of seven participants into Part B Cohort 5, enrollment was stopped.",6.0,,New data suggests that insufficient target engagement would be achieved for efficacy.,False,,,,False,,,,,,,,,,,,,2020-02-01 10:55:28.881506,2020-02-01 10:55:28.881506,Eli Lilly and Company,Industry,Placebo IV,Drug
NCT00439166,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-20,,,2018-03-15,2007-02-21,2007-02-23,Estimate,,,,,,,2018-03-15,2018-03-19,Actual,February 2007,,2007-02-28,March 2017,2017-03-31,December 2010,Actual,2010-12-31,April 2010,Actual,2010-04-30,,Interventional,,,Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Completed,,Phase 3,100.0,Actual,McMaster University,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:43:09.592414,2020-02-01 20:43:09.592414,Hamilton Health Sciences Corporation,Other,Placebo matched to doxycycline,Drug
NCT00439166,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-20,,,2018-03-15,2007-02-21,2007-02-23,Estimate,,,,,,,2018-03-15,2018-03-19,Actual,February 2007,,2007-02-28,March 2017,2017-03-31,December 2010,Actual,2010-12-31,April 2010,Actual,2010-04-30,,Interventional,,,Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Completed,,Phase 3,100.0,Actual,McMaster University,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:43:09.592414,2020-02-01 20:43:09.592414,Hamilton Health Sciences Corporation,Other,Placebo matched to Rifampin,Drug
NCT01492374,"ClinicalTrials.gov processed this data on January 31, 2020",2011-12-13,,,2014-07-23,2011-12-13,2011-12-15,Estimate,,,,,,,2014-07-23,2014-07-24,Estimate,February 2012,,2012-02-29,October 2013,2013-10-31,October 2013,Actual,2013-10-31,October 2013,Actual,2013-10-31,,Interventional,,,"Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease",Completed,,Phase 1,40.0,Actual,Bristol-Myers Squibb,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:31:09.583952,2020-02-01 15:31:09.583952,Bristol-Myers Squibb,Industry,Placebo matching BMS-241027,Drug
NCT00866060,"ClinicalTrials.gov processed this data on January 31, 2020",2009-03-19,,,2009-03-19,2009-03-19,2009-03-20,Estimate,,,,,,,2009-03-19,2009-03-20,Estimate,February 2008,,2008-02-29,March 2009,2009-03-31,June 2013,Anticipated,2013-06-30,February 2012,Anticipated,2012-02-29,,Interventional,DOMINO-AD,,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Donepezil and Memantine in Moderate to Severe Alzheimer's Disease,Unknown status,Recruiting,Phase 4,800.0,Anticipated,King's College London,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 18:34:35.920768,2020-02-01 18:34:35.920768,King's College London,Other,Placebo memantine,Drug
NCT02955706,"ClinicalTrials.gov processed this data on January 31, 2020",2016-11-02,,,2016-11-06,2016-11-02,2016-11-04,Estimate,,,,,,,2016-11-06,2016-11-08,Estimate,April 2016,,2016-04-30,November 2016,2016-11-30,February 2019,Anticipated,2019-02-28,September 2018,Anticipated,2018-09-30,,Interventional,,,Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease,"A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease",Unknown status,Recruiting,Phase 4,328.0,Anticipated,"Dong-A ST Co., Ltd.",,2.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 09:45:59.593009,2020-02-01 09:45:59.593009,"Dong-A ST Co., Ltd.",Industry,Placebo of Acetyl-L-Carnitine,Drug
NCT03790982,"ClinicalTrials.gov processed this data on January 31, 2020",2018-12-18,,,2018-12-29,2018-12-29,2019-01-02,Actual,,,,,,,2018-12-29,2019-01-02,Actual,"December 1, 2018",Actual,2018-12-01,December 2018,2018-12-31,"July 30, 2021",Anticipated,2021-07-30,"December 30, 2020",Anticipated,2020-12-30,,Interventional,WAY,,Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease,"A Randomized, Double Blind, Placebo Controlled, Parallel-Group 52-week Multicenter Phase II Study to Investigate the Safety, Efficacy and Pharmacokinetics of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease","Active, not recruiting",,Phase 2,240.0,Anticipated,Zhejiang Hisun Pharmaceutical Co. Ltd.,,4.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:25:35.066475,2020-02-01 07:25:35.066475,Zhejiang Hisun Pharmaceutical Co. Ltd.,Industry,Placebo of AD-35 60mg /AD-35 30mg,Drug
NCT03790982,"ClinicalTrials.gov processed this data on January 31, 2020",2018-12-18,,,2018-12-29,2018-12-29,2019-01-02,Actual,,,,,,,2018-12-29,2019-01-02,Actual,"December 1, 2018",Actual,2018-12-01,December 2018,2018-12-31,"July 30, 2021",Anticipated,2021-07-30,"December 30, 2020",Anticipated,2020-12-30,,Interventional,WAY,,Evaluate the Safety and Efficacy of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease,"A Randomized, Double Blind, Placebo Controlled, Parallel-Group 52-week Multicenter Phase II Study to Investigate the Safety, Efficacy and Pharmacokinetics of AD-35 Tablet in Subjects With Mild to Moderate Alzheimer's Disease","Active, not recruiting",,Phase 2,240.0,Anticipated,Zhejiang Hisun Pharmaceutical Co. Ltd.,,4.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:25:35.066475,2020-02-01 07:25:35.066475,Zhejiang Hisun Pharmaceutical Co. Ltd.,Industry,Placebo of AD-35 60mg /AD-35 60mg,Drug
NCT03605667,"ClinicalTrials.gov processed this data on January 31, 2020",2018-07-23,,,2019-11-05,2018-07-27,2018-07-30,Actual,,,,,,,2019-11-05,2019-11-06,Actual,"July 31, 2018",Actual,2018-07-31,November 2019,2019-11-30,"December 20, 2020",Anticipated,2020-12-20,"December 5, 2020",Anticipated,2020-12-05,,Interventional,T2 Protect AD,,Study of BHV-4157 in Alzheimer's Disease,A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease,"Active, not recruiting",,Phase 2/Phase 3,336.0,Anticipated,"Biohaven Pharmaceuticals, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 07:53:25.938765,2020-02-01 07:53:25.938765,"Biohaven Pharmaceuticals, Inc.",Industry,Placebo oral capsule,Drug
NCT03710642,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-09,,,2019-06-24,2018-10-16,2018-10-18,Actual,,,,,,,2019-06-24,2019-06-26,Actual,"July 30, 2019",Anticipated,2019-07-30,February 2019,2019-02-28,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,,Interventional,,,Prazosin for Agitation in Alzheimer's Disease,Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD),Recruiting,,Phase 2,186.0,Anticipated,Alzheimer's Disease Cooperative Study (ADCS),,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 07:37:23.070907,2020-02-01 07:37:23.070907,Alzheimer's Disease Cooperative Study (ADCS),Other,Placebo oral capsule,Drug
NCT03752463,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-21,,,2018-11-21,2018-11-21,2018-11-26,Actual,,,,,,,2018-11-21,2018-11-26,Actual,"May 22, 2015",Actual,2015-05-22,April 2018,2018-04-30,"December 31, 2019",Anticipated,2019-12-31,"December 31, 2019",Anticipated,2019-12-31,,Interventional,,,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,NMDA Enhancer for the Treatment of Mild Alzheimer's Disease,Recruiting,,Phase 2,160.0,Anticipated,Chang Gung Memorial Hospital,,4.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 07:31:01.934898,2020-02-01 07:31:01.934898,Chang Gung Memorial Hospital,Other,Placebo oral capsule,Drug
NCT03790709,"ClinicalTrials.gov processed this data on January 31, 2020",2018-12-24,,,2019-11-17,2018-12-31,2019-01-02,Actual,,,,,,,2019-11-17,2019-11-19,Actual,"July 3, 2018",Actual,2018-07-03,August 2019,2019-08-31,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,,Interventional,,,ANAVEX2-73 for Treatment of Early Alzheimer's Disease,"A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy Trial of ANAVEX2-73 for the Treatment of Early Alzheimer's Disease (AD)",Recruiting,,Phase 2/Phase 3,450.0,Anticipated,Anavex Life Sciences Corp.,,3.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:25:39.943948,2020-02-01 07:25:39.943948,Anavex Life Sciences Corp.,Industry,Placebo oral capsule,Drug
NCT03875638,"ClinicalTrials.gov processed this data on January 31, 2020",2019-03-13,,,2019-09-09,2019-03-13,2019-03-15,Actual,,,,,,,2019-09-09,2019-09-10,Actual,"August 22, 2019",Actual,2019-08-22,September 2019,2019-09-30,November 2023,Anticipated,2023-11-30,August 2023,Anticipated,2023-08-31,,Interventional,,,Treating Hyperexcitability in AD With Levetiracetam,Treating Hyperexcitability in Alzheimer's Disease With Levetiracetam to Improve Brain Function and Cognition,Recruiting,,Phase 2,85.0,Anticipated,Beth Israel Deaconess Medical Center,,4.0,,,False,,,,True,True,False,,,False,,,,,,Undecided,,2020-02-01 07:13:04.175822,2020-02-01 07:13:04.175822,Beth Israel Deaconess Medical Center,Other,Placebo oral capsule,Drug
NCT03991988,"ClinicalTrials.gov processed this data on January 31, 2020",2019-06-18,,,2019-09-27,2019-06-18,2019-06-19,Actual,,,,,,,2019-09-27,2019-09-30,Actual,"September 25, 2019",Actual,2019-09-25,September 2019,2019-09-30,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,,Interventional,,,Montelukast Therapy on Alzheimer's Disease,Effects of Montelukast Therapy on Alzheimer's Disease (EMERALD),Recruiting,,Phase 2,150.0,Anticipated,Emory University,,2.0,,,False,,,,False,True,False,,,False,,,,,,No,,2020-02-01 06:55:32.004687,2020-02-01 06:55:32.004687,Emory University,Other,Placebo oral tablet,Drug
NCT04079803,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-26,,,2019-09-04,2019-09-04,2019-09-06,Actual,,,,,,,2019-09-04,2019-09-06,Actual,"August 15, 2019",Actual,2019-08-15,August 2019,2019-08-31,"April 15, 2020",Anticipated,2020-04-15,"January 15, 2020",Anticipated,2020-01-15,,Interventional,,,PTI-125 for Mild-to-moderate Alzheimer's Disease Patients,"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients",Recruiting,,Phase 2,60.0,Anticipated,"Cassava Sciences, Inc.",,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 06:43:02.419451,2020-02-01 06:43:02.419451,"Cassava Sciences, Inc.",Industry,Placebo oral tablet,Drug
NCT04098666,"ClinicalTrials.gov processed this data on January 31, 2020",2019-09-19,,,2019-11-07,2019-09-19,2019-09-23,Actual,,,,,,,2019-11-07,2019-11-12,Actual,"August 1, 2020",Anticipated,2020-08-01,November 2019,2019-11-30,"April 30, 2024",Anticipated,2024-04-30,"March 30, 2024",Anticipated,2024-03-30,,Interventional,MAP,,Metformin in Alzheimer's Dementia Prevention,Metformin in Alzheimer's Dementia Prevention,Not yet recruiting,,Phase 2/Phase 3,370.0,Anticipated,Columbia University,,2.0,,,False,,,,True,True,False,,,,,,After reporting of main results,,,Yes,"All datasets used/generated on the project will be made accessible and reusable by qualified individuals other than the original data generators via web-based resources with the capacity to store large and diverse datasets (such as data about clinical phenotypes, genetics, epigenetics, proteomics, and metabolomics) to enable multiple parallel approaches to data analysis and interpretation. All analytical methodologies will be made fully reproducible and transparent so that results can be vetted and existing analysis techniques quickly applied to new application areas. We will comply with the data sharing arrangement decided by NIA.",2020-02-01 06:40:23.267307,2020-02-01 06:40:23.267307,Columbia University,Other,Placebo oral tablet,Drug
NCT01862640,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-22,,2018-01-22,2019-03-11,2013-05-22,2013-05-24,Estimate,,,,2018-01-22,2018-01-26,Actual,2019-03-11,2019-03-14,Actual,July 2013,,2013-07-31,March 2019,2019-03-31,March 2017,Actual,2017-03-31,March 2017,Actual,2017-03-31,,Interventional,,,Safety and Tolerability Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type,"A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type",Completed,,Phase 3,433.0,Actual,"Otsuka Pharmaceutical Development & Commercialization, Inc.",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:56:29.292305,2020-02-01 13:56:29.292305,"Otsuka Pharmaceutical Development & Commercialization, Inc.",Industry,Placebo Oral Tablet,Drug
NCT03082755,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-06,,,2019-10-23,2017-03-10,2017-03-17,Actual,,,,,,,2019-10-23,2019-10-25,Actual,"July 1, 2017",Actual,2017-07-01,October 2019,2019-10-31,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,,Interventional,,,Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease,Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease,Recruiting,,Phase 4,136.0,Anticipated,University of Texas at Austin,,2.0,,,False,,,,True,True,False,,,False,,,Data will be made available 6 months after publication of the main study findings and will be available in perpetuity.,IPD will be publicly available via the following url,https://dataverse.tdl.org/dataset.xhtml?persistentId=doi:10.18738/T8/GDSFSQ,Yes,Data have been prepared for sharing with other investigators. All collected individual participant data (IPD) can be accessed at https://dataverse.tdl.org/dataset.xhtml?persistentId=doi:10.18738/T8/GDSFSQ after publication of the main study findings,2020-02-01 09:22:16.586579,2020-02-01 09:22:16.586579,University of Texas at Austin,Other,Placebo Oral Tablet,Drug
NCT03234686,"ClinicalTrials.gov processed this data on January 31, 2020",2017-07-23,,,2018-01-22,2017-07-26,2017-07-31,Actual,,,,,,,2018-01-22,2018-01-24,Actual,"January 19, 2018",Actual,2018-01-19,January 2018,2018-01-31,December 2021,Anticipated,2021-12-31,July 2021,Anticipated,2021-07-31,,Interventional,,,Deferiprone to Delay Dementia (The 3D Study),Deferiprone to Delay Dementia (The 3D Study): a Clinical Proof of Concept Study,Recruiting,,Phase 2,171.0,Anticipated,Neuroscience Trials Australia,,2.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 08:55:35.440556,2020-02-01 08:55:35.440556,Neuroscience Trials Australia,Other,Placebo Oral Tablet,Drug
NCT03486938,"ClinicalTrials.gov processed this data on January 31, 2020",2018-03-28,,,2020-01-02,2018-04-02,2018-04-03,Actual,,,,,,,2020-01-02,2020-01-03,Actual,"January 15, 2019",Actual,2019-01-15,November 2019,2019-11-30,November 2022,Anticipated,2022-11-30,November 2021,Anticipated,2021-11-30,,Interventional,HOPE4MCI,,Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease",Recruiting,,Phase 3,830.0,Anticipated,AgeneBio,,2.0,,,False,,,,True,True,False,,,,,,,,,No,,2020-02-01 08:12:28.060228,2020-02-01 08:12:28.060228,AgeneBio,Industry,Placebo Oral Tablet,Drug
NCT03489044,"ClinicalTrials.gov processed this data on January 31, 2020",2018-03-09,,,2018-10-15,2018-03-28,2018-04-05,Actual,,,,,,,2018-10-15,2018-10-16,Actual,November 2018,Anticipated,2018-11-30,March 2018,2018-03-31,January 2020,Anticipated,2020-01-31,"November 1, 2019",Anticipated,2019-11-01,,Interventional,ILiAD,,An Investigation of Levetiracetam in Alzheimer's Disease,An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a Proof of Concept Study,Enrolling by invitation,,Phase 2,30.0,Anticipated,University of Oxford,,2.0,,,False,,,,False,False,False,,,,,,,,,Undecided,It is possible that irretrievably anonymised data will be shared with other researchers dependent on securing relevant ethical approval,2020-02-01 08:12:09.213728,2020-02-01 08:12:09.213728,University of Oxford,Other,Placebo Oral Tablet,Drug
NCT01739348,"ClinicalTrials.gov processed this data on January 31, 2020",2012-11-29,2018-04-11,,2018-09-24,2012-11-29,2012-12-03,Estimate,2018-04-11,2018-05-16,Actual,,,,2018-09-24,2018-10-24,Actual,"November 30, 2012",Actual,2012-11-30,September 2018,2018-09-30,"April 14, 2017",Actual,2017-04-14,"April 14, 2017",Actual,2017-04-14,,Interventional,EPOCH,All randomized participants in Study Part I (Base Study),An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738),"A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)",Terminated,,Phase 2/Phase 3,2211.0,Actual,Merck Sharp & Dohme Corp.,,4.0,,,False,,,,True,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2020-02-01 14:27:54.749867,2020-02-01 14:27:54.749867,Merck Sharp & Dohme Corp.,Industry,Placebo (Part I),Drug
NCT00066157,"ClinicalTrials.gov processed this data on January 31, 2020",2003-08-04,,,2018-08-22,2003-08-04,2003-08-05,Estimate,,,,,,,2018-08-22,2018-08-23,Actual,September 2001,,2001-09-30,August 2018,2018-08-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,Alzheimer's Disease: Therapeutic Potential of Estrogen,Alzheimer's Disease: Therapeutic Potential of Estrogen,Completed,,Phase 2/Phase 3,42.0,Actual,"University of Wisconsin, Madison",,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:32:28.672051,2020-02-01 22:32:28.672051,"University of Wisconsin, Madison",Other,Placebo Patch,Drug
NCT00479557,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-24,2014-05-06,,2015-11-30,2007-05-24,2007-05-28,Estimate,2015-11-30,2016-01-01,Estimate,,,,2015-11-30,2016-01-01,Estimate,May 2007,,2007-05-31,November 2015,2015-11-30,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,245 participants were randomized in both studies (86 participants in 3134K1-200-EU [B2571004] and 159 participants in 3134K1-2201-US [B2571005]) and included in the analysis below. One participant of the randomized participants did not receive treatment.,"Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease","A Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease",Completed,,Phase 2,86.0,Actual,Pfizer,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:30:37.798575,2020-02-01 20:30:37.798575,Pfizer,Industry,Placebo: Phosphate buffered saline,Drug
NCT00255086,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-15,2016-08-23,,2017-02-23,2005-11-15,2005-11-17,Estimate,2017-02-23,2017-04-07,Actual,,,,2017-02-23,2017-04-07,Actual,May 2005,,2005-05-31,February 2017,2017-02-28,February 2010,Actual,2010-02-28,June 2009,Actual,2009-06-30,,Interventional,,"Per protocol, only participants who completed the study were evaluable for baseline characteristics.",The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients,"The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients: A Randomized, Placebo-Controlled, 52-Week Clinical Trial",Completed,,Phase 3,17.0,Actual,Stanford University,,2.0,,,False,,,,False,,,,,,,,,,,Undecided,,2020-02-01 21:37:34.734231,2020-02-01 21:37:34.734231,Stanford University,Other,Placebo pill,Drug
NCT00545974,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-16,2013-04-22,,2019-10-08,2007-10-17,2007-10-18,Estimate,2013-12-13,2014-02-05,Estimate,,,,2019-10-08,2019-10-17,Actual,October 2007,,2007-10-31,October 2019,2019-10-31,December 2012,Actual,2012-12-31,December 2012,Actual,2012-12-31,,Interventional,,,Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia,"A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia",Completed,,Phase 4,81.0,Actual,"University of California, San Francisco",Lower enrollment than planned may have limited ability detect a treatment effect; Small size of semantic dementia group limits generalizability of results to FTD syndrome;Newer tools have been developed to better capture FTD-specific behaviors.,2.0,,,,,,,True,,,,,,,,,,,,,2020-02-01 20:10:00.659080,2020-02-01 20:10:00.659080,"University of California, San Francisco",Other,Placebo pill,Drug
NCT00912288,"ClinicalTrials.gov processed this data on January 31, 2020",2009-06-01,2012-07-30,2011-09-08,2012-08-30,2009-06-01,2009-06-03,Estimate,2012-08-30,2012-10-02,Estimate,2011-09-08,2011-09-12,Estimate,2012-08-30,2012-10-02,Estimate,September 2009,,2009-09-30,August 2012,2012-08-31,August 2010,Actual,2010-08-31,August 2010,Actual,2010-08-31,,Interventional,,,A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease,"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease",Terminated,,Phase 3,86.0,Actual,Pfizer,Results are not summarized because of early termination of the study due to modification in the development plan of the study medication following lack of demonstration of efficacy in the completed DIM14 CONNECTION (B1451002/NCT00675623) study.,2.0,,See termination reason in detailed description.,False,,,,True,,,,,,,,,,,,,2020-02-01 18:21:11.647277,2020-02-01 18:21:11.647277,Pfizer,Industry,Placebo po TID,Drug
NCT01965756,"ClinicalTrials.gov processed this data on January 31, 2020",2013-10-16,2017-06-06,,2017-08-21,2013-10-16,2013-10-18,Estimate,2017-08-21,2017-09-21,Actual,,,,2017-08-21,2017-09-21,Actual,January 2013,,2013-01-31,August 2017,2017-08-31,April 2017,Actual,2017-04-30,"December 22, 2015",Actual,2015-12-22,,Interventional,,,Effect of Insulin Sensitizer Metformin on AD Biomarkers,"A Phase II Trial to Study the Effect of Metformin on AD Biomarkers: A Randomized Placebo Controlled Crossover Pilot Study of Metformin Effects on Cognitive, Physiological and Biochemical Biomarkers of MCI and Dementia Due to AD",Completed,,Phase 2,20.0,Actual,University of Pennsylvania,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:28:20.189926,2020-02-01 13:28:20.189926,University of Pennsylvania,Other,Placebos,Drug
NCT03069014,"ClinicalTrials.gov processed this data on January 31, 2020",2017-02-03,,,2019-04-16,2017-03-01,2017-03-03,Actual,,,,,,,2019-04-16,2019-04-17,Actual,"February 15, 2017",Actual,2017-02-15,April 2019,2019-04-30,"October 31, 2019",Anticipated,2019-10-31,"October 10, 2019",Anticipated,2019-10-10,,Interventional,,,Study of LM11A-31-BHS in Mild-moderate AD Patients,"A 6-months Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Adaptive-trial-design Study to Evaluate Safety, Tolerability and Exploratory Endpoints of Either Placebo or Two Different Oral Doses of LM11A-31-BHS in Patients With Mild to Moderate Probable Alzheimer's Disease",Recruiting,,Phase 1/Phase 2,190.0,Anticipated,PharmatrophiX Inc.,,3.0,,,False,,,,True,False,False,,,,,,,,,No,,2020-02-01 09:24:45.384915,2020-02-01 09:24:45.384915,PharmatrophiX Inc.,Industry,Placebos,Drug
NCT03283059,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-12,,,2019-10-20,2017-09-12,2017-09-14,Actual,,,,,,,2019-10-20,2019-10-22,Actual,"August 16, 2017",Actual,2017-08-16,October 2019,2019-10-31,"February 16, 2021",Anticipated,2021-02-16,"September 16, 2020",Anticipated,2020-09-16,,Interventional,,,Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease,"Phase III Trial of Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease: a 26 Weeks, Randomized, Double-blind, Double-dummy, Placebo- and Positive- Parallel Controlled and Extended Single Arm to 54 Weeks Multicentre Study",Recruiting,,Phase 3,600.0,Anticipated,Shanghai Mental Health Center,,3.0,,,False,,,,,False,False,,,,,,,,,No,Other researchers should apply to the sponsor.,2020-02-01 08:46:31.811934,2020-02-01 08:46:31.811934,Shanghai Mental Health Center,Other,Placebos,Drug
NCT04251182,"ClinicalTrials.gov processed this data on January 31, 2020",2020-01-24,,,2020-01-29,2020-01-29,2020-01-31,Estimate,,,,,,,2020-01-29,2020-01-31,Estimate,"February 5, 2020",Anticipated,2020-02-05,January 2020,2020-01-31,"August 13, 2021",Anticipated,2021-08-13,"August 13, 2021",Anticipated,2021-08-13,,Interventional,,,Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects,"A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease",Not yet recruiting,,Phase 2,256.0,Anticipated,"T3D Therapeutics, Inc.",,4.0,,,,,,,True,True,False,,,,,,,,,No,A Clinical Study Report (CSR) will be generated within 9 months after database lock. Aggregate study data will be made available in this report.,2020-02-04 05:09:35.057386,2020-02-04 05:09:35.057386,"T3D Therapeutics, Inc.",Industry,Placebos,Drug
NCT01255163,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-04,2017-11-08,,2018-01-23,2010-12-04,2010-12-07,Estimate,2018-01-23,2018-02-22,Actual,,,,2018-01-23,2018-02-22,Actual,"November 21, 2010",,2010-11-21,January 2018,2018-01-31,"November 18, 2016",Actual,2016-11-18,"November 18, 2016",Actual,2016-11-18,,Interventional,,"The baseline analysis population includes 27 participants who underwent randomization and received at least one dose of experimental medication. Of those 27, we have at least one outcome measure (i.e. at least the 6 months follow-up data point) for 21 participants. Of those 21, 18 completed the study (i.e. reached 18 months).",A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease,A Pilot Study of Exendin-4 in Alzheimer s Disease,Terminated,,Phase 2,57.0,Actual,National Institutes of Health Clinical Center (CC),The study was terminated after AstraZeneca withdrew support. Early termination lead to small number of subjects analyzed.,2.0,,AstraZeneca withdrew support for the study.,False,,,,True,True,False,,,False,,,,,,,,2020-02-01 16:35:47.564810,2020-02-01 16:35:47.564810,National Institute on Aging (NIA),NIH,Placebo SC,Drug
NCT02614131,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-23,2019-06-28,,2019-08-21,2015-11-23,2015-11-25,Estimate,2019-08-21,2019-09-23,Actual,,,,2019-08-21,2019-09-23,Actual,December 2015,,2015-12-31,August 2019,2019-08-31,December 2016,Actual,2016-12-31,December 2016,Actual,2016-12-31,,Interventional,,All randomized participants.,A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD),"Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease",Terminated,,Phase 1,50.0,Actual,Eli Lilly and Company,"Development of LY2599666 was stopped based on lack of efficacy of another compound directed against the same target. Following the enrollment of seven participants into Part B Cohort 5, enrollment was stopped.",6.0,,New data suggests that insufficient target engagement would be achieved for efficacy.,False,,,,False,,,,,,,,,,,,,2020-02-01 10:55:28.881506,2020-02-01 10:55:28.881506,Eli Lilly and Company,Industry,Placebo SC,Drug
NCT00506415,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-20,2012-05-01,,2012-09-17,2007-07-20,2007-07-25,Estimate,2012-09-17,2012-09-19,Estimate,,,,2012-09-17,2012-09-19,Estimate,June 2007,,2007-06-30,September 2012,2012-09-30,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline","A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline",Completed,,Phase 3,1584.0,Actual,Novartis,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:22:40.338815,2020-02-01 20:22:40.338815,Novartis Pharmaceuticals,Industry,Placebo to 10 cm^2 patch,Drug
NCT00506415,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-20,2012-05-01,,2012-09-17,2007-07-20,2007-07-25,Estimate,2012-09-17,2012-09-19,Estimate,,,,2012-09-17,2012-09-19,Estimate,June 2007,,2007-06-30,September 2012,2012-09-30,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline","A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline",Completed,,Phase 3,1584.0,Actual,Novartis,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:22:40.338815,2020-02-01 20:22:40.338815,Novartis Pharmaceuticals,Industry,Placebo to 15 cm^2 patch,Drug
NCT00874939,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-02,2015-05-26,,2018-09-18,2009-04-02,2009-04-03,Estimate,2015-05-26,2015-06-08,Estimate,,,,2018-09-18,2018-10-17,Actual,"April 6, 2009",Actual,2009-04-06,September 2018,2018-09-30,"April 20, 2009",Actual,2009-04-20,"April 20, 2009",Actual,2009-04-20,,Interventional,,,A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023),A Randomized Clinical Trial To Evaluate the Single Dose Acute Effects of MK-0249 and Donepezil On Cognitive Function In Adult Patients With Alzheimer's Disease,Terminated,,Phase 1,4.0,Actual,Merck Sharp & Dohme Corp.,,12.0,,,False,,,,False,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2020-02-01 18:32:14.819408,2020-02-01 18:32:14.819408,Merck Sharp & Dohme Corp.,Industry,Placebo to Donepezil,Drug
NCT00459550,"ClinicalTrials.gov processed this data on January 31, 2020",2007-04-11,,,2017-07-18,2007-04-11,2007-04-12,Estimate,,,,,,,2017-07-18,2017-07-21,Actual,"March 12, 2007",Actual,2007-03-12,July 2017,2017-07-31,"May 30, 2011",Actual,2011-05-30,"May 30, 2011",Actual,2011-05-30,,Interventional,,,A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease,"A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776 in Patients With Alzheimer's Disease.",Completed,,Phase 1,50.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,True,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 20:36:43.972662,2020-02-01 20:36:43.972662,GlaxoSmithKline,Industry,Placebo to match GSK933776,Drug
NCT00874939,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-02,2015-05-26,,2018-09-18,2009-04-02,2009-04-03,Estimate,2015-05-26,2015-06-08,Estimate,,,,2018-09-18,2018-10-17,Actual,"April 6, 2009",Actual,2009-04-06,September 2018,2018-09-30,"April 20, 2009",Actual,2009-04-20,"April 20, 2009",Actual,2009-04-20,,Interventional,,,A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023),A Randomized Clinical Trial To Evaluate the Single Dose Acute Effects of MK-0249 and Donepezil On Cognitive Function In Adult Patients With Alzheimer's Disease,Terminated,,Phase 1,4.0,Actual,Merck Sharp & Dohme Corp.,,12.0,,,False,,,,False,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2020-02-01 18:32:14.819408,2020-02-01 18:32:14.819408,Merck Sharp & Dohme Corp.,Industry,Placebo to MK-0249,Drug
NCT03740178,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-12,,,2019-05-02,2018-11-12,2018-11-14,Actual,,,,,,,2019-05-02,2019-05-03,Actual,"September 27, 2019",Anticipated,2019-09-27,April 2019,2019-04-30,"February 28, 2020",Anticipated,2020-02-28,"February 28, 2020",Anticipated,2020-02-28,,Interventional,,,Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005),"A Randomized, Double-Blinded Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MK-4334 in Participants With Alzheimer's Clinical Syndrome on a Stable Dose of Donepezil",Not yet recruiting,,Phase 1,12.0,Anticipated,Merck Sharp & Dohme Corp.,,2.0,,,False,,,,False,True,False,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2020-02-01 07:32:49.642464,2020-02-01 07:32:49.642464,Merck Sharp & Dohme Corp.,Industry,Placebo to MK-4334,Drug
NCT01399125,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-19,2014-05-05,,2014-07-10,2011-07-20,2011-07-21,Estimate,2014-07-10,2014-08-04,Estimate,,,,2014-07-10,2014-08-04,Estimate,July 2011,,2011-07-31,July 2014,2014-07-31,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease","A 24-Week, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled Study to Assess the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (Mini-Mental State Examination (MMSE) 10-20)",Completed,,Phase 3,501.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:55:55.772860,2020-02-01 15:55:55.772860,Novartis Pharmaceuticals,Industry,Placebo to Rivastigmine capsules,Drug
NCT01399125,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-19,2014-05-05,,2014-07-10,2011-07-20,2011-07-21,Estimate,2014-07-10,2014-08-04,Estimate,,,,2014-07-10,2014-08-04,Estimate,July 2011,,2011-07-31,July 2014,2014-07-31,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease","A 24-Week, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled Study to Assess the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (Mini-Mental State Examination (MMSE) 10-20)",Completed,,Phase 3,501.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:55:55.772860,2020-02-01 15:55:55.772860,Novartis Pharmaceuticals,Industry,Placebo to Rivastigmine patch,Drug
NCT00117403,"ClinicalTrials.gov processed this data on January 31, 2020",2005-06-30,,,2009-04-01,2005-06-30,2005-07-06,Estimate,,,,,,,2009-04-01,2009-04-03,Estimate,January 2006,,2006-01-31,April 2008,2008-04-30,September 2007,Actual,2007-09-30,September 2007,Actual,2007-09-30,,Interventional,,,Anti-Oxidant Treatment of Alzheimer's Disease,"Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,75.0,Anticipated,National Institute on Aging (NIA),,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:12:02.293739,2020-02-01 22:12:02.293739,National Institute on Aging (NIA),NIH,Placebo wafers,Drug
NCT00385684,"ClinicalTrials.gov processed this data on January 31, 2020",2006-10-06,2014-06-02,,2015-11-18,2006-10-06,2006-10-11,Estimate,2015-11-18,2015-11-20,Estimate,,,,2015-11-18,2015-11-20,Estimate,October 2007,,2007-10-31,November 2015,2015-11-30,June 2014,Actual,2014-06-30,December 2011,Actual,2011-12-31,,Interventional,LDOT,Veterans with severe dementia residing in VA nursing home.,Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT),Completed,,Phase 4,11.0,Actual,VA Office of Research and Development,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:00:50.049144,2020-02-01 21:00:50.049144,VA Office of Research and Development,U.S. Fed,placebo with hydrocodone/APAP PRN,Drug
NCT01715350,"ClinicalTrials.gov processed this data on January 31, 2020",2012-10-24,,,2016-04-15,2012-10-25,2012-10-26,Estimate,,,,,,,2016-04-15,2016-04-18,Estimate,May 2012,,2012-05-31,April 2016,2016-04-30,June 2015,Actual,2015-06-30,September 2014,Actual,2014-09-30,,Interventional,ADD,,Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease,"A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease: Double-Blind, Randomized Between Placebo Control Group and Dose Groups, Parallel-Design, Multicenter Study",Completed,,Phase 2,151.0,Actual,"GMP BIO Co., LTD.",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:34:17.112760,2020-02-01 14:34:17.112760,"GMP BIO Co., LTD.",Industry,PM012,Drug
NCT04052737,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-08,,,2019-08-11,2019-08-09,2019-08-12,Actual,,,,,,,2019-08-11,2019-08-13,Actual,"March 23, 2018",Actual,2018-03-23,August 2019,2019-08-31,July 2020,Anticipated,2020-07-31,December 2019,Anticipated,2019-12-31,,Interventional,,,PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease,"A Prospective, Multicentric, Randomized, Double Blind, Placebo Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy Along With Standard Supportive Care in Subjects of Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 2,80.0,Anticipated,"Pharmazz, Inc.",,2.0,,,False,,,,True,False,False,,,,,,,,,No,Results will be communicated and published as manuscript,2020-02-01 06:46:51.040091,2020-02-01 06:46:51.040091,"Pharmazz, Inc.",Industry,PMZ-1620 (sovateltide) along with standard treatment,Drug
NCT02925650,"ClinicalTrials.gov processed this data on January 31, 2020",2016-09-29,,,2020-01-18,2016-10-04,2016-10-06,Estimate,,,,,,,2020-01-18,2020-01-22,Actual,"March 2, 2017",Actual,2017-03-02,January 2020,2020-01-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,,Interventional,DISCOVER,,"Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD)",Recruiting,,Phase 1/Phase 2,24.0,Anticipated,QR Pharma Inc.,,4.0,,,False,,,,True,True,False,,,,,,,,,Yes,"Data from this research will be shared with other researchers pursuant to the 02/26/2003 ""NIH Final Statement on Sharing Research Data"".",2020-02-01 09:52:28.469882,2020-02-01 09:52:28.469882,QR Pharma Inc.,Industry,Posiphen,Drug
NCT01072812,"ClinicalTrials.gov processed this data on January 31, 2020",2010-02-19,,,2015-04-20,2010-02-19,2010-02-22,Estimate,,,,,,,2015-04-20,2015-04-22,Estimate,February 2010,,2010-02-28,April 2015,2015-04-30,July 2010,Actual,2010-07-31,July 2010,Actual,2010-07-31,,Interventional,,,Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment,"An Open-Label, Two-Stage Study to Evaluate the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Plasma and CSF After a 10-Day Treatment Period in Subjects With Amnestic Mild Cognitive Impairment",Terminated,,Phase 1,5.0,Actual,QR Pharma Inc.,,1.0,,Business decision based on funding,False,,,,False,,,,,,,,,,,,,2020-02-01 17:30:11.271107,2020-02-01 17:30:11.271107,QR Pharma Inc.,Industry,Posiphen® tartrate capsules,Drug
NCT00100282,"ClinicalTrials.gov processed this data on January 31, 2020",2004-12-27,,,2006-09-18,2004-12-27,2004-12-28,Estimate,,,,,,,2006-09-18,2006-09-19,Estimate,May 2003,,2003-05-31,September 2006,2006-09-30,June 2005,,2005-06-30,,,,,Interventional,,,Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer’s Disease,Single Dose Escalation Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer’s Disease,Completed,,Phase 1,125.0,,PRAECIS Pharmaceuticals Inc.,,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:17:56.343559,2020-02-01 22:17:56.343559,PRAECIS Pharmaceuticals Inc.,Industry,PPI-1019 (APAN),Drug
NCT00100334,"ClinicalTrials.gov processed this data on January 31, 2020",2004-12-29,,,2006-09-18,2004-12-29,2004-12-30,Estimate,,,,,,,2006-09-18,2006-09-19,Estimate,December 2004,,2004-12-31,September 2006,2006-09-30,August 2005,,2005-08-31,,,,,Interventional,,,Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease,Multiple Dose Safety and Preliminary Pharmacodynamic Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer’s Disease,Completed,,Phase 1/Phase 2,24.0,,PRAECIS Pharmaceuticals Inc.,,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:17:56.101297,2020-02-01 22:17:56.101297,PRAECIS Pharmaceuticals Inc.,Industry,PPI-1019 (APAN),Drug
NCT03919162,"ClinicalTrials.gov processed this data on January 31, 2020",2019-04-15,,,2019-04-17,2019-04-17,2019-04-18,Actual,,,,,,,2019-04-17,2019-04-19,Actual,January 2020,Anticipated,2020-01-31,April 2019,2019-04-30,April 2023,Anticipated,2023-04-30,December 2022,Anticipated,2022-12-31,,Interventional,,,A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD,A Seamless Phase 2A-B Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early Alzheimer's Disease,Not yet recruiting,,Phase 2,462.0,Anticipated,Vivoryon Therapeutics AG,,4.0,,,False,,,,True,True,False,,,,,,,,,Yes,,2020-02-01 07:06:31.634812,2020-02-01 07:06:31.634812,Vivoryon Therapeutics AG,Industry,PQ912,Drug
NCT02389413,"ClinicalTrials.gov processed this data on January 31, 2020",2015-03-05,,,2017-05-31,2015-03-16,2015-03-17,Estimate,,,,,,,2017-05-31,2017-06-01,Actual,March 2015,,2015-03-31,January 2017,2017-01-31,April 2017,Actual,2017-04-30,April 2017,Actual,2017-04-30,,Interventional,SAPHIR,,Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease,"A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease",Completed,,Phase 2,120.0,Actual,Vivoryon Therapeutics AG,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:46:50.270362,2020-02-01 11:46:50.270362,Vivoryon Therapeutics AG,Industry,PQ912 oral,Drug
NCT00161473,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-08,2012-02-24,,2012-06-26,2005-09-08,2005-09-12,Estimate,2012-06-26,2012-08-02,Estimate,,,,2012-06-26,2012-08-02,Estimate,January 2001,,2001-01-31,June 2012,2012-06-30,September 2009,Actual,2009-09-30,September 2009,Actual,2009-09-30,,Interventional,,,Alzheimer's in Long-Term Care--Treatment for Agitation,Alzheimer's in Long-Term Care--Treatment for Agitation,Completed,,N/A,24.0,Actual,University of Washington,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:59:31.636454,2020-02-01 21:59:31.636454,University of Washington,Other,prazosin,Drug
NCT01126099,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-17,2014-07-15,,2015-05-19,2010-05-18,2010-05-19,Estimate,2015-05-19,2015-05-21,Estimate,,,,2015-05-19,2015-05-21,Estimate,March 2010,,2010-03-31,May 2015,2015-05-31,March 2014,Actual,2014-03-31,March 2014,Actual,2014-03-31,,Interventional,,,Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease,Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease,Completed,,N/A,20.0,Actual,Seattle Institute for Biomedical and Clinical Research,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:14:44.218519,2020-02-01 17:14:44.218519,Seattle Institute for Biomedical and Clinical Research,Other,Prazosin,Drug
NCT03710642,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-09,,,2019-06-24,2018-10-16,2018-10-18,Actual,,,,,,,2019-06-24,2019-06-26,Actual,"July 30, 2019",Anticipated,2019-07-30,February 2019,2019-02-28,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,,Interventional,,,Prazosin for Agitation in Alzheimer's Disease,Prazosin for Disruptive Agitation in Alzheimer's Disease (AD) (PEACE-AD),Recruiting,,Phase 2,186.0,Anticipated,Alzheimer's Disease Cooperative Study (ADCS),,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 07:37:23.070907,2020-02-01 07:37:23.070907,Alzheimer's Disease Cooperative Study (ADCS),Other,Prazosin,Drug
NCT00000178,"ClinicalTrials.gov processed this data on January 31, 2020",1999-10-29,,,2005-06-23,1999-10-29,1999-11-01,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,February 2005,2005-02-28,,,,,,,,Interventional,,,Multicenter Trial of Prednisone in Alzheimer's Disease,Multicenter Trial of Prednisone in Alzheimer's Disease,Completed,,Phase 3,,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:51:08.040711,2020-02-01 22:51:08.040711,National Institute on Aging (NIA),NIH,Prednisone,Drug
NCT00006399,"ClinicalTrials.gov processed this data on January 31, 2020",2000-08-18,,,2009-01-13,2000-08-18,2000-08-21,Estimate,,,,,,,2009-01-13,2009-01-15,Estimate,September 1999,,1999-09-30,January 2009,2009-01-31,March 2004,Actual,2004-03-31,March 2004,Actual,2004-03-31,,Interventional,,,Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease,Estrogen Modulation Effects on Cholinergic Function in Normal Post-Menopausal Women and Patients With Alzheimer's Disease,Completed,,Phase 2,45.0,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:49:05.038881,2020-02-01 22:49:05.038881,National Center for Research Resources (NCRR),NIH,Progesterone,Drug
NCT00384423,"ClinicalTrials.gov processed this data on January 31, 2020",2006-10-04,,,2008-01-29,2006-10-04,2006-10-06,Estimate,,,,,,,2008-01-29,2008-01-30,Estimate,October 2006,,2006-10-31,January 2008,2008-01-31,,,,October 2007,Actual,2007-10-31,,Interventional,,,Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept,"A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination With Donepezil in Subjects With Mild Alzheimer's Disease.",Completed,,Phase 2,80.0,Anticipated,"Epix Pharmaceuticals, Inc.",,,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:01:14.715563,2020-02-01 21:01:14.715563,"Epix Pharmaceuticals, Inc.",Industry,PRX-03140,Drug
NCT00672945,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-02,,,2009-07-28,2008-05-05,2008-05-06,Estimate,,,,,,,2009-07-28,2009-07-30,Estimate,April 2008,,2008-04-30,July 2009,2009-07-31,,,,January 2010,Anticipated,2010-01-31,,Interventional,,,A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil,Phase 2 Double-Blind Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil,Terminated,,Phase 2,420.0,Anticipated,"Epix Pharmaceuticals, Inc.",,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:32:01.805046,2020-02-01 19:32:01.805046,"Epix Pharmaceuticals, Inc.",Industry,PRX-03140,Drug
NCT00693004,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-30,,,2009-07-28,2008-06-05,2008-06-06,Estimate,,,,,,,2009-07-28,2009-07-30,Estimate,May 2008,,2008-05-31,July 2009,2009-07-31,,,,January 2010,Anticipated,2010-01-31,,Interventional,,,Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of PRX-03140 as Monotherapy in Subjects With Alzheimer's Disease",Terminated,,Phase 2,236.0,Anticipated,"Epix Pharmaceuticals, Inc.",,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:26:04.087803,2020-02-01 19:26:04.087803,"Epix Pharmaceuticals, Inc.",Industry,PRX-03140,Drug
NCT04123314,"ClinicalTrials.gov processed this data on January 31, 2020",2019-10-09,,,2020-01-14,2019-10-09,2019-10-10,Actual,,,,,,,2020-01-14,2020-01-18,Actual,"January 31, 2020",Anticipated,2020-01-31,January 2020,2020-01-31,"March 8, 2022",Anticipated,2022-03-08,"March 1, 2022",Anticipated,2022-03-01,,Interventional,,,Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease,Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease,Recruiting,,Early Phase 1,20.0,Anticipated,Johns Hopkins University,,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 06:37:02.595708,2020-02-01 06:37:02.595708,Johns Hopkins University,Other,Psilocybin,Drug
NCT04079803,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-26,,,2019-09-04,2019-09-04,2019-09-06,Actual,,,,,,,2019-09-04,2019-09-06,Actual,"August 15, 2019",Actual,2019-08-15,August 2019,2019-08-31,"April 15, 2020",Anticipated,2020-04-15,"January 15, 2020",Anticipated,2020-01-15,,Interventional,,,PTI-125 for Mild-to-moderate Alzheimer's Disease Patients,"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients",Recruiting,,Phase 2,60.0,Anticipated,"Cassava Sciences, Inc.",,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 06:43:02.419451,2020-02-01 06:43:02.419451,"Cassava Sciences, Inc.",Industry,PTI-125 100 mg oral tablet,Drug
NCT03748706,"ClinicalTrials.gov processed this data on January 31, 2020",2018-11-13,,,2019-09-04,2018-11-18,2018-11-21,Actual,,,,,,,2019-09-04,2019-09-06,Actual,"March 7, 2019",Actual,2019-03-07,September 2019,2019-09-30,"May 8, 2019",Actual,2019-05-08,"May 8, 2019",Actual,2019-05-08,,Interventional,,,PTI-125 for Mild-to-moderate Alzheimer's Disease Patients,"A Phase 2a, Open-label, Multiple Dose, Safety, Pharmacokinetic and Biomarker Study of PTl-125 in Mild-to-moderate Alzheimer's Disease Patients",Completed,,Phase 2,12.0,Actual,"Cassava Sciences, Inc.",,1.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 07:31:30.656714,2020-02-01 07:31:30.656714,Pain Therapeutics,Industry,"PTI-125, 100 mg tablets",Drug
NCT04079803,"ClinicalTrials.gov processed this data on January 31, 2020",2019-08-26,,,2019-09-04,2019-09-04,2019-09-06,Actual,,,,,,,2019-09-04,2019-09-06,Actual,"August 15, 2019",Actual,2019-08-15,August 2019,2019-08-31,"April 15, 2020",Anticipated,2020-04-15,"January 15, 2020",Anticipated,2020-01-15,,Interventional,,,PTI-125 for Mild-to-moderate Alzheimer's Disease Patients,"A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients",Recruiting,,Phase 2,60.0,Anticipated,"Cassava Sciences, Inc.",,3.0,,,False,,,,False,True,False,,,,,,,,,No,,2020-02-01 06:43:02.419451,2020-02-01 06:43:02.419451,"Cassava Sciences, Inc.",Industry,PTI-125 50 mg tablet,Drug
NCT03935568,"ClinicalTrials.gov processed this data on January 31, 2020",2019-04-24,,,2019-12-23,2019-04-30,2019-05-02,Actual,,,,,,,2019-12-23,2019-12-26,Actual,"June 24, 2019",Actual,2019-06-24,December 2019,2019-12-31,"December 23, 2019",Actual,2019-12-23,"December 23, 2019",Actual,2019-12-23,,Interventional,,,A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects,A Single and Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of PU-AD in Healthy Subjects,Completed,,Phase 1,40.0,Actual,"Samus Therapeutics, Inc.",,4.0,,,False,,,,False,True,False,,,False,,,,,,No,,2020-02-01 07:04:00.603763,2020-02-01 07:04:00.603763,"Samus Therapeutics, Inc.",Industry,PU-AD,Drug
NCT02361242,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-06,,,2016-02-12,2015-02-06,2015-02-11,Estimate,,,,,,,2016-02-12,2016-02-15,Estimate,June 2013,,2013-06-30,December 2014,2014-12-31,December 2015,Actual,2015-12-31,December 2015,Actual,2015-12-31,,Interventional,PLEODIAL-II,,24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion,24-week Open-label Extension Study Evaluating the Effect of PXT00864 in Mild Alzheimer's Disease Patients Further to PLEODIAL-I Completion,Completed,,Phase 2,45.0,Actual,Pharnext SA,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:52:51.701385,2020-02-01 11:52:51.701385,Pharnext SA,Other,PXT00864,Drug
NCT02361424,"ClinicalTrials.gov processed this data on January 31, 2020",2014-12-19,,,2016-02-12,2015-02-06,2015-02-11,Estimate,,,,,,,2016-02-12,2016-02-15,Estimate,February 2013,,2013-02-28,October 2015,2015-10-31,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,PLEODIAL-I,,Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD),First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients,Completed,,Phase 2,47.0,Actual,Pharnext SA,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:52:50.624085,2020-02-01 11:52:50.624085,Pharnext SA,Other,PXT00864,Drug
NCT00130429,"ClinicalTrials.gov processed this data on January 31, 2020",2005-08-12,,,2009-08-20,2005-08-12,2005-08-15,Estimate,,,,,,,2009-08-20,2009-08-21,Estimate,January 2004,,2004-01-31,August 2009,2009-08-31,September 2005,Actual,2005-09-30,,,,,Interventional,,,Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease,"Phase II Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Effect on Cognition and Pharmacokinetic Profile of PYM50028 in Subjects With Mild Dementia of the Alzheimer's Type",Completed,,Phase 2,250.0,,Phytopharm,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:08:07.055265,2020-02-01 22:08:07.055265,Phytopharm,Industry,PYM50028,Drug
NCT00208819,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-13,,,2013-11-12,2005-09-13,2005-09-21,Estimate,,,,,,,2013-11-12,2013-11-13,Estimate,September 2003,,2003-09-30,November 2013,2013-11-30,July 2007,Actual,2007-07-31,,,,,Interventional,,,A Comparison of Two Standard Therapies in the Management of Dementia With Agitation,"Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies",Completed,,Phase 4,50.0,Anticipated,Emory University,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:47:41.232383,2020-02-01 21:47:41.232383,Emory University,Other,quetiapine,Drug
NCT00232570,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-30,,,2009-05-04,2005-09-30,2005-10-04,Estimate,,,,,,,2009-05-04,2009-05-05,Estimate,November 2005,,2005-11-30,May 2009,2009-05-31,January 2010,Anticipated,2010-01-31,December 2009,Anticipated,2009-12-31,,Interventional,,,Quetiapine for the Treatment of Insomnia in Alzheimer's Disease,Quetiapine for the Treatment of Insomnia Associated With Alzheimer's Disease,Unknown status,Recruiting,N/A,18.0,Anticipated,University of Vermont,,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:43:08.663511,2020-02-01 21:43:08.663511,University of Vermont,Other,quetiapine,Drug
NCT00015548,"ClinicalTrials.gov processed this data on January 31, 2020",2001-04-20,,,2015-06-16,2001-04-21,2001-04-23,Estimate,,,,,,,2015-06-16,2015-06-17,Estimate,March 2001,,2001-03-31,February 2009,2009-02-28,October 2004,,2004-10-31,,,,,Interventional,,,CATIE-Alzheimer's Disease Trial,Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial),Completed,,N/A,450.0,,National Institute of Mental Health (NIMH),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:23.664098,2020-02-01 22:48:23.664098,National Institute of Mental Health (NIMH),NIH,Quetiapine,Drug
NCT00375557,"ClinicalTrials.gov processed this data on January 31, 2020",2006-09-11,,,2015-05-26,2006-09-11,2006-09-13,Estimate,,,,,,,2015-05-26,2015-05-27,Estimate,October 2006,,2006-10-31,May 2015,2015-05-31,September 2007,Actual,2007-09-30,,,,,Interventional,,,Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients,"An Open Label, Randomized, Flexible Dose, 6-week Clinical Trial of the Safety and Efficacy of Divalproex ER vs Quetiapine in the Treatment of Behavioral Symptoms in the Elderly With Moderate to Severe Alzheimer's Dementia",Withdrawn,,Phase 4,0.0,Actual,University of Cincinnati,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:04:09.030665,2020-02-01 21:04:09.030665,University of Cincinnati,Other,Quetiapine,Drug
NCT00621647,"ClinicalTrials.gov processed this data on January 31, 2020",2008-02-06,,,2009-03-24,2008-02-11,2008-02-22,Estimate,,,,,,,2009-03-24,2009-03-25,Estimate,September 2002,,2002-09-30,March 2009,2009-03-31,November 2003,Actual,2003-11-30,November 2003,Actual,2003-11-30,,Interventional,,,Seroquel- Agitation Associated With Dementia,"A Multicenter, Double-Blind, Randomized, Comparison of the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Agitation Associated With Dementia.",Completed,,Phase 3,333.0,Actual,AstraZeneca,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:46:29.171385,2020-02-01 19:46:29.171385,AstraZeneca,Industry,Quetiapine Fumarate,Drug
NCT00368459,"ClinicalTrials.gov processed this data on January 31, 2020",2006-08-22,2015-03-01,,2015-03-20,2006-08-22,2006-08-24,Estimate,2015-03-20,2015-04-02,Estimate,,,,2015-03-20,2015-04-02,Estimate,August 2006,,2006-08-31,March 2015,2015-03-31,January 2012,Actual,2012-01-31,March 2011,Actual,2011-03-31,,Interventional,,Postmenopausal women with Alzheimer's disease of mild to moderate severity,Raloxifene for Women With Alzheimer's Disease,Raloxifene in Women With AD: Randomized Controlled Trial,Completed,,Phase 2,42.0,Actual,Stanford University,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 21:06:20.426774,2020-02-01 21:06:20.426774,Stanford University,Other,raloxifene,Drug
NCT00065767,"ClinicalTrials.gov processed this data on January 31, 2020",2003-07-31,,,2015-10-01,2003-08-01,2003-08-04,Estimate,,,,,,,2015-10-01,2015-10-05,Estimate,September 2001,,2001-09-30,September 2010,2010-09-30,March 2005,Actual,2005-03-31,March 2005,Actual,2005-03-31,,Interventional,,,Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease,Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease,Completed,,Phase 2/Phase 3,20.0,,"University of Wisconsin, Madison",,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:32:33.685829,2020-02-01 22:32:33.685829,"University of Wisconsin, Madison",Other,Raloxifene,Drug
NCT00325728,"ClinicalTrials.gov processed this data on January 31, 2020",2006-05-11,,,2017-08-10,2006-05-11,2006-05-15,Estimate,,,,,,,2017-08-10,2017-08-14,Actual,"March 21, 2006",Actual,2006-03-21,August 2017,2017-08-31,"August 20, 2007",Actual,2007-08-20,"August 1, 2007",Actual,2007-08-01,,Interventional,,,Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease,"A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects",Completed,,Phase 2,74.0,Actual,Takeda,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 21:17:49.788554,2020-02-01 21:17:49.788554,Takeda,Industry,Ramelteon,Drug
NCT04200911,"ClinicalTrials.gov processed this data on January 31, 2020",2019-12-06,,,2019-12-12,2019-12-12,2019-12-16,Actual,,,,,,,2019-12-12,2019-12-16,Actual,March 2020,Anticipated,2020-03-31,December 2019,2019-12-31,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,,Interventional,(CARPE DIEM),,"Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway","Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway (CARPE DIEM)",Not yet recruiting,,Early Phase 1,10.0,Anticipated,The University of Texas Health Science Center at San Antonio,,1.0,,,False,,,,True,True,False,,,True,,,,,,,,2020-02-01 06:26:28.222050,2020-02-01 06:26:28.222050,The University of Texas Health Science Center at San Antonio,Other,Rapamune,Drug
NCT00104273,"ClinicalTrials.gov processed this data on January 31, 2020",2005-02-24,,,2009-07-14,2005-02-24,2005-02-25,Estimate,,,,,,,2009-07-14,2009-07-15,Estimate,August 2004,,2004-08-31,April 2008,2008-04-30,,,,March 2007,Actual,2007-03-31,,Interventional,,,Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD),"A 1-Year, Double-Blind, Randomized, Placebo-Controlled, Study of Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Dementia of the Alzheimer's Type",Completed,,Phase 2,376.0,Actual,Teva Pharmaceutical Industries,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:16:43.526824,2020-02-01 22:16:43.526824,Teva Pharmaceutical Industries,Industry,Rasagiline,Drug
NCT02359552,"ClinicalTrials.gov processed this data on January 31, 2020",2015-02-05,,,2019-05-06,2015-02-05,2015-02-10,Estimate,,,,,,,2019-05-06,2019-05-08,Actual,May 2015,Actual,2015-05-31,May 2019,2019-05-31,"January 4, 2019",Actual,2019-01-04,"August 29, 2018",Actual,2018-08-29,,Interventional,R2,,Rasagiline Rescue in Alzheimer's Disease Clinical Trial,"A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,27.0,Actual,The Cleveland Clinic,,2.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 11:53:08.896672,2020-02-01 11:53:08.896672,The Cleveland Clinic,Other,Rasagiline,Drug
NCT00369603,"ClinicalTrials.gov processed this data on January 31, 2020",2006-08-28,,,2013-04-09,2006-08-28,2006-08-29,Estimate,,,,,,,2013-04-09,2013-04-11,Estimate,October 2006,,2006-10-31,June 2008,2008-06-30,November 2007,Actual,2007-11-30,October 2007,Actual,2007-10-31,,Interventional,,,Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients,Functional Neuroimaging (fMRI) Biomarker of Allosteric Nicotinic Receptor Modulation in Mild Alzheimer's Disease Patients: A Razadyne vs. Aricept Dose Escalation Trial,Terminated,,Phase 4,4.0,Actual,Duke University,,2.0,,Reduced access to AchEI medication-naive mild AD patients.,False,,,,True,,,,,,,,,,,,,2020-02-01 21:06:00.631738,2020-02-01 21:06:00.631738,Duke University,Other,Razadyne ER,Drug
NCT00438568,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-21,,,2012-09-12,2007-02-21,2007-02-22,Estimate,,,,,,,2012-09-12,2012-09-14,Estimate,June 2006,,2006-06-30,September 2012,2012-09-30,December 2011,Actual,2011-12-31,December 2011,Actual,2011-12-31,,Interventional,SNIFF 120,,SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days),Therapeutic Effects of Intranasal Insulin Administration in AD,Completed,,Phase 2,173.0,Actual,University of Washington,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:43:16.502687,2020-02-01 20:43:16.502687,University of Washington,Other,Regular Insulin,Drug
NCT01504854,"ClinicalTrials.gov processed this data on January 31, 2020",2011-12-23,2016-01-28,,2016-05-06,2012-01-03,2012-01-06,Estimate,2016-05-06,2016-06-14,Estimate,,,,2016-05-06,2016-06-14,Estimate,May 2012,,2012-05-31,April 2016,2016-04-30,March 2014,Actual,2014-03-31,March 2014,Actual,2014-03-31,,Interventional,,,Resveratrol for Alzheimer's Disease,Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients With Mild to Moderate Alzheimer's Disease,Completed,,Phase 2,119.0,Actual,Alzheimer's Disease Cooperative Study (ADCS),This phase 2 study has limitations. A larger study is required to determine whether resveratrol may be beneficial. More potent and bioavailable SIRT1 activators are also in development.,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:28:15.052585,2020-02-01 15:28:15.052585,Alzheimer's Disease Cooperative Study (ADCS),Other,Resveratrol,Drug
NCT00439166,"ClinicalTrials.gov processed this data on January 31, 2020",2007-02-20,,,2018-03-15,2007-02-21,2007-02-23,Estimate,,,,,,,2018-03-15,2018-03-19,Actual,February 2007,,2007-02-28,March 2017,2017-03-31,December 2010,Actual,2010-12-31,April 2010,Actual,2010-04-30,,Interventional,,,Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Effects of Treatment With Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid,Completed,,Phase 3,100.0,Actual,McMaster University,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:43:09.592414,2020-02-01 20:43:09.592414,Hamilton Health Sciences Corporation,Other,rifampicin,Drug
NCT00715858,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-11,,,2009-02-03,2008-07-11,2008-07-15,Estimate,,,,,,,2009-02-03,2009-02-04,Estimate,May 2008,,2008-05-31,February 2009,2009-02-28,October 2009,Anticipated,2009-10-31,August 2009,Anticipated,2009-08-31,,Interventional,,,A Pilot Study of Inflammatory Markers in Alzheimer's Disease,A Pilot Study Comparing Inflammatory Biomarkers in Blood and CSF in Patients With Alzheimer's Disease and Age-Matched Controls,Unknown status,Recruiting,Phase 3,21.0,Anticipated,McMaster University,,5.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:19:02.908370,2020-02-01 19:19:02.908370,McMaster University,Other,rifampin,Drug
NCT03856359,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-31,,,2019-04-10,2019-02-25,2019-02-27,Actual,,,,,,,2019-04-10,2019-04-11,Actual,"April 9, 2019",Actual,2019-04-09,April 2019,2019-04-30,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,,Interventional,,,Trial of Rifaximin in Probable Alzheimer's Disease,"Pilot, Single Center, Open, Trial of Rifaximin in Probable Alzheimer's Disease",Recruiting,,Phase 2,10.0,Anticipated,Duke University,,1.0,,,False,,,,,True,False,,,True,,,,,,No,,2020-02-01 07:15:50.322302,2020-02-01 07:15:50.322302,Duke University,Other,Rifaximin 550 milligrams (MG),Drug
NCT02130661,"ClinicalTrials.gov processed this data on January 31, 2020",2014-05-01,,,2016-12-12,2014-05-01,2014-05-05,Estimate,,,,,,,2016-12-12,2016-12-13,Estimate,October 2017,,2017-10-31,December 2016,2016-12-31,January 2018,Anticipated,2018-01-31,January 2018,Anticipated,2018-01-31,,Interventional,,,Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers,"A Phase I, Two-part, Open-label Study to Evaluate the Pharmacokinetics of Rilapladib (SB-659032) and Its Metabolites, and to Determine the Effect of Repeat Dose Itraconazole on the Pharmacokinetics of Rilapladib in Healthy Volunteers",Withdrawn,,Phase 1,0.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 12:46:22.393870,2020-02-01 12:46:22.393870,GlaxoSmithKline,Industry,Rilapladib 250 mg,Drug
NCT02130661,"ClinicalTrials.gov processed this data on January 31, 2020",2014-05-01,,,2016-12-12,2014-05-01,2014-05-05,Estimate,,,,,,,2016-12-12,2016-12-13,Estimate,October 2017,,2017-10-31,December 2016,2016-12-31,January 2018,Anticipated,2018-01-31,January 2018,Anticipated,2018-01-31,,Interventional,,,Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers,"A Phase I, Two-part, Open-label Study to Evaluate the Pharmacokinetics of Rilapladib (SB-659032) and Its Metabolites, and to Determine the Effect of Repeat Dose Itraconazole on the Pharmacokinetics of Rilapladib in Healthy Volunteers",Withdrawn,,Phase 1,0.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 12:46:22.393870,2020-02-01 12:46:22.393870,GlaxoSmithKline,Industry,Rilapladib 25 mg,Drug
NCT01703117,"ClinicalTrials.gov processed this data on January 31, 2020",2012-10-04,,,2020-01-28,2012-10-05,2012-10-10,Estimate,,,,,,,2020-01-28,2020-01-30,Actual,November 2013,Actual,2013-11-30,January 2020,2020-01-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,,,Riluzole in Mild Alzheimer's Disease,Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Alzheimer's Disease,"Active, not recruiting",,Phase 2,42.0,Anticipated,Icahn School of Medicine at Mount Sinai,,2.0,,,False,,,,True,True,,,,,,,,,,,,2020-02-03 05:32:16.066889,2020-02-03 05:32:16.066889,Icahn School of Medicine at Mount Sinai,Other,Riluzole,Drug
NCT00034762,"ClinicalTrials.gov processed this data on January 31, 2020",2002-05-02,,,2011-01-31,2002-05-02,2002-05-03,Estimate,,,,,,,2011-01-31,2011-02-01,Estimate,December 2000,,2000-12-31,January 2011,2011-01-31,January 2003,Actual,2003-01-31,,,,,Interventional,,,Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease,Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.,Completed,,Phase 3,473.0,Actual,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:44:46.596305,2020-02-01 22:44:46.596305,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Industry,risperidone,Drug
NCT00208819,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-13,,,2013-11-12,2005-09-13,2005-09-21,Estimate,,,,,,,2013-11-12,2013-11-13,Estimate,September 2003,,2003-09-30,November 2013,2013-11-30,July 2007,Actual,2007-07-31,,,,,Interventional,,,A Comparison of Two Standard Therapies in the Management of Dementia With Agitation,"Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies",Completed,,Phase 4,50.0,Anticipated,Emory University,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:47:41.232383,2020-02-01 21:47:41.232383,Emory University,Other,risperidone,Drug
NCT00249145,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-04,,,2011-01-13,2005-11-04,2005-11-07,Estimate,,,,,,,2011-01-13,2011-01-14,Estimate,April 1995,,1995-04-30,January 2011,2011-01-31,December 1996,Actual,1996-12-31,,,,,Interventional,,,A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia,"Risperidone in the Treatment of Behavioral Disturbances in Demented Patients: an International, Multicenter, Placebo-controlled, Double-blind, Parallel-group Trial Using Haloperidol as Internal Reference",Completed,,Phase 3,349.0,Actual,"Janssen Pharmaceutica N.V., Belgium",,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:39:03.607573,2020-02-01 21:39:03.607573,"Janssen Pharmaceutica N.V., Belgium",Industry,risperidone,Drug
NCT00253123,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-10,,,2010-12-02,2005-11-10,2005-11-15,Estimate,,,,,,,2010-12-02,2010-12-03,Estimate,,,,December 2010,2010-12-31,March 1997,Actual,1997-03-31,,,,,Interventional,,,A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia,"A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia",Completed,,Phase 3,626.0,Actual,"Janssen, LP",,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:38:00.542647,2020-02-01 21:38:00.542647,"Janssen, LP",Industry,risperidone,Drug
NCT00287742,"ClinicalTrials.gov processed this data on January 31, 2020",2006-02-03,,,2011-05-20,2006-02-03,2006-02-07,Estimate,,,,,,,2011-05-20,2011-05-24,Estimate,March 2002,,2002-03-31,November 2010,2010-11-30,March 2003,Actual,2003-03-31,,,,,Interventional,,,A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease,"Double-blind, Placebo-controlled Clinical Trial of JK6476 (Risperidone) in Patients With Hallucinations and Delusions Associated With Alzheimer's Disease",Terminated,,Phase 3,33.0,Actual,Janssen Pharmaceutical K.K.,,,,"A decision was made to discontinue the study due to a change in the strategic direction of the
    company.",False,,,,False,,,,,,,,,,,,,2020-02-01 21:28:54.965447,2020-02-01 21:28:54.965447,Janssen Pharmaceutical K.K.,Industry,risperidone,Drug
NCT00417482,"ClinicalTrials.gov processed this data on January 31, 2020",2006-12-28,2013-02-11,,2013-03-14,2006-12-28,2007-01-01,Estimate,2013-03-14,2013-04-24,Estimate,,,,2013-03-14,2013-04-24,Estimate,August 2004,,2004-08-31,March 2013,2013-03-31,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,ADAD,,Antipsychotic Discontinuation in Alzheimer's Disease,Antipsychotic Discontinuation in Alzheimer's Disease,Completed,,Phase 4,180.0,Actual,New York State Psychiatric Institute,Comparisons of adverse events in Phase B were limited by the small sample & the truncated observation period for relapsed subjects. Identification of predictors of relapse after discontinuation of treatment was limited by the small sample.,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:50:35.722713,2020-02-01 20:50:35.722713,New York State Psychiatric Institute,Other,risperidone,Drug
NCT00015548,"ClinicalTrials.gov processed this data on January 31, 2020",2001-04-20,,,2015-06-16,2001-04-21,2001-04-23,Estimate,,,,,,,2015-06-16,2015-06-17,Estimate,March 2001,,2001-03-31,February 2009,2009-02-28,October 2004,,2004-10-31,,,,,Interventional,,,CATIE-Alzheimer's Disease Trial,Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial),Completed,,N/A,450.0,,National Institute of Mental Health (NIMH),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:23.664098,2020-02-01 22:48:23.664098,National Institute of Mental Health (NIMH),NIH,Risperidone,Drug
NCT00018291,"ClinicalTrials.gov processed this data on January 31, 2020",2001-07-03,,,2009-01-20,2001-07-04,2001-07-05,Estimate,,,,,,,2009-01-20,2009-01-21,Estimate,January 2001,,2001-01-31,December 2004,2004-12-31,January 2005,,2005-01-31,,,,,Interventional,,,Specific Interventions for Agitation in Alzheimer's Disease,Specific Interventions for Agitation in Alzheimer's Disease,Completed,,N/A,,,VA Office of Research and Development,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:17.637032,2020-02-01 22:48:17.637032,US Department of Veterans Affairs,U.S. Fed,Risperidone,Drug
NCT00245206,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-25,,,2018-12-13,2005-10-25,2005-10-27,Estimate,,,,,,,2018-12-13,2018-12-17,Actual,August 2005,,2005-08-31,December 2018,2018-12-31,October 2010,Actual,2010-10-31,October 2010,Actual,2010-10-31,,Interventional,,,Side Effects of Newer Antipsychotics in Older Adults,Metabolic Effects of Newer Antipsychotics in Older Patients,Completed,,Phase 4,406.0,Actual,Veterans Medical Research Foundation,,3.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 21:39:57.227437,2020-02-01 21:39:57.227437,Veterans Medical Research Foundation,Other,Risperidone,Drug
NCT00249158,"ClinicalTrials.gov processed this data on January 31, 2020",2005-11-04,,,2010-11-18,2005-11-04,2005-11-07,Estimate,,,,,,,2010-11-18,2010-11-19,Estimate,March 1998,,1998-03-31,November 2010,2010-11-30,February 2001,Actual,2001-02-28,,,,,Interventional,,,A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia,"Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial",Completed,,Phase 3,344.0,Actual,Janssen-Cilag Pty Ltd,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:39:03.558169,2020-02-01 21:39:03.558169,Janssen-Cilag Pty Ltd,Industry,Risperidone,Drug
NCT01119638,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-06,,,2015-06-23,2010-05-06,2010-05-07,Estimate,,,,,,,2015-06-23,2015-06-24,Estimate,April 2008,,2008-04-30,June 2015,2015-06-30,May 2010,Actual,2010-05-31,April 2010,Actual,2010-04-30,,Interventional,EscBPSD,,Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone,Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients,Completed,,Phase 4,40.0,Actual,Abarbanel Mental Health Center,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:16:52.586627,2020-02-01 17:16:52.586627,Abarbanel Mental Health Center,Other,Risperidone,Drug
NCT00000174,"ClinicalTrials.gov processed this data on January 31, 2020",1999-10-29,,,2005-06-23,1999-10-29,1999-11-01,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,January 2000,2000-01-31,,,,,,,,Interventional,,,Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx),,Completed,,Phase 3,,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:51:08.377710,2020-02-01 22:51:08.377710,Novartis,Industry,Rivastigmine,Drug
NCT00104442,"ClinicalTrials.gov processed this data on January 31, 2020",2005-02-28,,,2007-12-17,2005-02-28,2005-03-01,Estimate,,,,,,,2007-12-17,2007-12-21,Estimate,October 2003,,2003-10-31,December 2007,2007-12-31,April 2006,Actual,2006-04-30,,,,,Interventional,,,Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease,Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease,Completed,,Phase 4,80.0,,Novartis,,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:16:39.147924,2020-02-01 22:16:39.147924,Novartis,Industry,Rivastigmine,Drug
NCT00766363,"ClinicalTrials.gov processed this data on January 31, 2020",2008-10-01,2011-06-16,,2012-04-18,2008-10-02,2008-10-03,Estimate,2011-06-16,2011-07-14,Estimate,,,,2012-04-18,2012-04-20,Estimate,October 2008,,2008-10-31,April 2012,2012-04-30,March 2009,Actual,2009-03-31,March 2009,Actual,2009-03-31,,Interventional,,,"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease",Completed,,Phase 1,49.0,Actual,FORUM Pharmaceuticals Inc,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:04:53.564244,2020-02-01 19:04:53.564244,FORUM Pharmaceuticals Inc,Industry,Rivastigmine,Drug
NCT01183806,"ClinicalTrials.gov processed this data on January 31, 2020",2010-08-16,,,2012-03-19,2010-08-17,2010-08-18,Estimate,,,,,,,2012-03-19,2012-03-20,Estimate,July 2010,,2010-07-31,March 2012,2012-03-31,March 2012,Actual,2012-03-31,January 2012,Actual,2012-01-31,,Interventional,,,Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients,Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients,Completed,,Phase 3,40.0,Actual,Federal University of Bahia,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 16:57:58.023663,2020-02-01 16:57:58.023663,Federal University of Bahia,Other,Rivastigmine,Drug
NCT01362686,"ClinicalTrials.gov processed this data on January 31, 2020",2011-05-26,2016-07-22,,2017-01-08,2011-05-27,2011-05-30,Estimate,2017-01-08,2017-02-27,Actual,,,,2017-01-08,2017-02-27,Actual,April 2011,,2011-04-30,January 2017,2017-01-31,October 2015,Actual,2015-10-31,October 2015,Actual,2015-10-31,,Interventional,COMET-AD,,Comparative Research of Alzheimer's Disease Drugs,Comparative Effectiveness Research Trial of Alzheimer's Disease Drugs,Terminated,,N/A,200.0,Actual,Indiana University,Small sample size limits generalizability and may introduce type II error. The study took place at a time when most third-party payers declared donepezil the preferred AChEI due to cost that may have influenced study’s results.,3.0,,Low study accrual caused the study to be ended early.,False,,,,True,,,,,,,,,,,,,2020-02-01 16:05:14.947359,2020-02-01 16:05:14.947359,Indiana University,Other,Rivastigmine,Drug
NCT01677754,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-30,,2016-07-20,2017-05-25,2012-08-30,2012-09-03,Estimate,,,,2016-07-20,2016-07-22,Estimate,2017-05-25,2017-05-30,Actual,"October 24, 2012",Actual,2012-10-24,May 2017,2017-05-31,"June 12, 2015",Actual,2015-06-12,"June 12, 2015",Actual,2015-06-12,,Interventional,MAyflOwer RoAD,,A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy,"A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease",Completed,,Phase 2,542.0,Actual,Hoffmann-La Roche,,3.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 14:44:43.645589,2020-02-01 14:44:43.645589,Hoffmann-La Roche,Industry,Rivastigmine,Drug
NCT02444637,"ClinicalTrials.gov processed this data on January 31, 2020",2015-04-28,,,2015-05-11,2015-05-11,2015-05-14,Estimate,,,,,,,2015-05-11,2015-05-14,Estimate,April 2015,,2015-04-30,May 2015,2015-05-31,,,,April 2017,Anticipated,2017-04-30,,Interventional,,,Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD,Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease,Unknown status,Recruiting,Phase 4,100.0,Anticipated,National Neuroscience Institute,,1.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:34:37.519671,2020-02-01 11:34:37.519671,National Neuroscience Institute,Other,Rivastigmine,Drug
NCT02989402,"ClinicalTrials.gov processed this data on January 31, 2020",2016-12-08,,,2020-01-09,2016-12-08,2016-12-12,Estimate,,,,,,,2020-01-09,2020-01-13,Actual,"December 31, 2018",Actual,2018-12-31,January 2020,2020-01-31,"May 5, 2021",Anticipated,2021-05-05,"February 3, 2020",Anticipated,2020-02-03,,Interventional,,,"A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.","A Prospective, 16 Week, Phase IV Study to Evaluate Safety, Tolerability and Effectiveness in Patients With Severe Dementia of the Alzheimer's Type Exposed to Rivastigmine (Exelon)15cm2 Transdermal Patch",Recruiting,,Phase 4,102.0,Anticipated,Novartis,,1.0,,,False,,,,False,False,False,,,,,,,,,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2020-02-01 09:39:24.547256,2020-02-01 09:39:24.547256,Novartis Pharmaceuticals,Industry,Rivastigmine,Drug
NCT00506415,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-20,2012-05-01,,2012-09-17,2007-07-20,2007-07-25,Estimate,2012-09-17,2012-09-19,Estimate,,,,2012-09-17,2012-09-19,Estimate,June 2007,,2007-06-30,September 2012,2012-09-30,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline","A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline",Completed,,Phase 3,1584.0,Actual,Novartis,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:22:40.338815,2020-02-01 20:22:40.338815,Novartis Pharmaceuticals,Industry,Rivastigmine 10 cm^2,Drug
NCT00428389,"ClinicalTrials.gov processed this data on January 31, 2020",2007-01-26,2010-12-22,,2014-06-05,2007-01-26,2007-01-30,Estimate,2011-05-27,2011-06-27,Estimate,,,,2014-06-05,2014-06-11,Estimate,January 2007,,2007-01-31,June 2014,2014-06-30,February 2008,Actual,2008-02-29,February 2008,Actual,2008-02-29,,Interventional,,,Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease,"A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study With a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching From Donepezil to an Initial Dose of 5 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease",Completed,,Phase 3,262.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:46:37.092606,2020-02-01 20:46:37.092606,Novartis,Industry,Rivastigmine 10 cm^2 transdermal patch,Drug
NCT00948766,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-28,2013-01-08,,2013-08-19,2009-07-28,2009-07-29,Estimate,2013-01-08,2013-02-11,Estimate,,,,2013-08-19,2013-08-28,Estimate,July 2009,,2009-07-31,August 2013,2013-08-31,June 2012,Actual,2012-06-30,January 2012,Actual,2012-01-31,,Interventional,ACTION,,"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44",Completed,,Phase 4,716.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:10:30.542059,2020-02-01 18:10:30.542059,Novartis,Industry,Rivastigmine 13.3 mg/24 h (15 cm^2),Drug
NCT00506415,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-20,2012-05-01,,2012-09-17,2007-07-20,2007-07-25,Estimate,2012-09-17,2012-09-19,Estimate,,,,2012-09-17,2012-09-19,Estimate,June 2007,,2007-06-30,September 2012,2012-09-30,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline","A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline",Completed,,Phase 3,1584.0,Actual,Novartis,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:22:40.338815,2020-02-01 20:22:40.338815,Novartis Pharmaceuticals,Industry,Rivastigmine 15 cm^2,Drug
NCT00948766,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-28,2013-01-08,,2013-08-19,2009-07-28,2009-07-29,Estimate,2013-01-08,2013-02-11,Estimate,,,,2013-08-19,2013-08-28,Estimate,July 2009,,2009-07-31,August 2013,2013-08-31,June 2012,Actual,2012-06-30,January 2012,Actual,2012-01-31,,Interventional,ACTION,,"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44",Completed,,Phase 4,716.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:10:30.542059,2020-02-01 18:10:30.542059,Novartis,Industry,Rivastigmine 4.6 mg/24 h (5 cm^2),Drug
NCT00561392,"ClinicalTrials.gov processed this data on January 31, 2020",2007-11-19,2010-12-15,,2012-04-10,2007-11-19,2007-11-21,Estimate,2011-02-15,2011-03-11,Estimate,,,,2012-04-10,2012-04-16,Estimate,November 2007,,2007-11-30,April 2012,2012-04-30,November 2008,Actual,2008-11-30,November 2008,Actual,2008-11-30,,Interventional,ADEPT,,Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease,"A 24-week, Multi-center, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE10-26)",Completed,,Phase 4,208.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:04:08.404893,2020-02-01 20:04:08.404893,Novartis,Industry,Rivastigmine 5 and 10 cm^2 patch,Drug
NCT00506415,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-20,2012-05-01,,2012-09-17,2007-07-20,2007-07-25,Estimate,2012-09-17,2012-09-19,Estimate,,,,2012-09-17,2012-09-19,Estimate,June 2007,,2007-06-30,September 2012,2012-09-30,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline","A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline",Completed,,Phase 3,1584.0,Actual,Novartis,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:22:40.338815,2020-02-01 20:22:40.338815,Novartis Pharmaceuticals,Industry,Rivastigmine 5 cm^2,Drug
NCT00428389,"ClinicalTrials.gov processed this data on January 31, 2020",2007-01-26,2010-12-22,,2014-06-05,2007-01-26,2007-01-30,Estimate,2011-05-27,2011-06-27,Estimate,,,,2014-06-05,2014-06-11,Estimate,January 2007,,2007-01-31,June 2014,2014-06-30,February 2008,Actual,2008-02-29,February 2008,Actual,2008-02-29,,Interventional,,,Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease,"A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study With a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching From Donepezil to an Initial Dose of 5 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease",Completed,,Phase 3,262.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:46:37.092606,2020-02-01 20:46:37.092606,Novartis,Industry,Rivastigmine 5 cm^2 transdermal patch,Drug
NCT00948766,"ClinicalTrials.gov processed this data on January 31, 2020",2009-07-28,2013-01-08,,2013-08-19,2009-07-28,2009-07-29,Estimate,2013-01-08,2013-02-11,Estimate,,,,2013-08-19,2013-08-28,Estimate,July 2009,,2009-07-31,August 2013,2013-08-31,June 2012,Actual,2012-06-30,January 2012,Actual,2012-01-31,,Interventional,ACTION,,"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44",Completed,,Phase 4,716.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:10:30.542059,2020-02-01 18:10:30.542059,Novartis,Industry,Rivastigmine 9.5 mg/24 h (10 cm^2),Drug
NCT01399125,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-19,2014-05-05,,2014-07-10,2011-07-20,2011-07-21,Estimate,2014-07-10,2014-08-04,Estimate,,,,2014-07-10,2014-08-04,Estimate,July 2011,,2011-07-31,July 2014,2014-07-31,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease","A 24-Week, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled Study to Assess the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (Mini-Mental State Examination (MMSE) 10-20)",Completed,,Phase 3,501.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:55:55.772860,2020-02-01 15:55:55.772860,Novartis Pharmaceuticals,Industry,Rivastigmine Capsules,Drug
NCT00549601,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-24,2011-01-05,,2011-02-24,2007-10-25,2007-10-26,Estimate,2011-02-24,2011-03-24,Estimate,,,,2011-02-24,2011-03-24,Estimate,September 2007,,2007-09-30,February 2011,2011-02-28,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,,Interventional,KAPA,,"Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","A Multi-center, Randomised, Open-label Study to Evaluate Convenience and Safety of Change in the Mode of Administration of Rivastigmine (From Capsules to a Transdermal Patch) in Patients With Alzheimer's Disease",Completed,,Phase 4,142.0,Actual,Novartis,,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:08:31.748764,2020-02-01 20:08:31.748764,Novartis,Industry,Rivastigmine capsules (6 mg to 12 mg/day),Drug
NCT00234637,"ClinicalTrials.gov processed this data on January 31, 2020",2005-10-05,,,2011-11-16,2005-10-05,2005-10-07,Estimate,,,,,,,2011-11-16,2011-11-17,Estimate,November 2003,,2003-11-30,November 2011,2011-11-30,June 2005,Actual,2005-06-30,June 2005,Actual,2005-06-30,,Interventional,,,Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment,An Open-label Study to Evaluate the Efficacy and Safety of add-on Memantine [5-10 mg b.i.d (10-20 mg/Day)] to Rivastigmine [1.5-6 mg b.i.d. (3-12 mg/Day)] Treatment in Patients With Alzheimer's Disease Who Continued With Rivastigmine Treatment After a Previous Decline While on Donepezil or Galantamine Treatment,Completed,,Phase 4,204.0,Actual,Novartis,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:42:42.414115,2020-02-01 21:42:42.414115,Novartis,Industry,"Rivastigmine, memantine",Drug
NCT00305903,"ClinicalTrials.gov processed this data on January 31, 2020",2006-03-20,,,2007-12-17,2006-03-20,2006-03-22,Estimate,,,,,,,2007-12-17,2007-12-21,Estimate,March 2006,,2006-03-31,December 2007,2007-12-31,August 2007,Actual,2007-08-31,,,,,Interventional,,,Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease,"A Prospective, 26-Week, Open-Label, Multi-Center, Single-Arm Pilot Study to Evaluate the Safety and Tolerability of Rivastigmine Capsule With Add on Memantine HCl in Patients With Probable Alzheimer's Disease (MMSE 10-20)",Completed,,Phase 4,150.0,Anticipated,Novartis,,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:23:53.947269,2020-02-01 21:23:53.947269,Novartis,Industry,"Rivastigmine, memantine",Drug
NCT01380288,"ClinicalTrials.gov processed this data on January 31, 2020",2011-06-21,,,2018-02-02,2011-06-23,2011-06-27,Estimate,,,,,,,2018-02-02,2018-02-05,Actual,June 2011,Actual,2011-06-30,February 2018,2018-02-28,"December 31, 2017",Actual,2017-12-31,December 2016,Actual,2016-12-31,,Interventional,CAREER,,Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine,"Changes of Cognitive Function in Patients With Mild to Moderate Alzheimer's Disease Associated With or Without White Matter Changes After Rivastigmine Patch Therapy - Multi-center, Prospective, Open-label Clinical Trial",Completed,,N/A,300.0,Actual,Dong-A University,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:00:42.985519,2020-02-01 16:00:42.985519,Dong-A University,Other,rivastigmine patch,Drug
NCT01399125,"ClinicalTrials.gov processed this data on January 31, 2020",2011-07-19,2014-05-05,,2014-07-10,2011-07-20,2011-07-21,Estimate,2014-07-10,2014-08-04,Estimate,,,,2014-07-10,2014-08-04,Estimate,July 2011,,2011-07-31,July 2014,2014-07-31,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease","A 24-Week, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled Study to Assess the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (Mini-Mental State Examination (MMSE) 10-20)",Completed,,Phase 3,501.0,Actual,Novartis,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:55:55.772860,2020-02-01 15:55:55.772860,Novartis Pharmaceuticals,Industry,Rivastigmine Patch,Drug
NCT02703636,"ClinicalTrials.gov processed this data on January 31, 2020",2016-02-26,2019-05-06,,2019-08-05,2016-03-08,2016-03-09,Estimate,2019-08-05,2019-09-12,Actual,,,,2019-08-05,2019-09-12,Actual,"May 9, 2016",Actual,2016-05-09,August 2019,2019-08-31,"May 7, 2018",Actual,2018-05-07,"May 7, 2018",Actual,2018-05-07,,Interventional,ENA1stepswitch,FAS,"NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.","A 24-week, Open-label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch With 1-step Titration in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10 - 23) Switched Directly From Holinesterase Inhibitors (Donepezil, Galantamine)",Completed,,Phase 4,118.0,Actual,Novartis,,1.0,,,False,,,,False,False,False,,,,,,,,,Undecided,"Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2020-02-01 10:36:54.253780,2020-02-01 10:36:54.253780,Novartis Pharmaceuticals,Industry,Rivastigmine Patch,Drug
NCT00549601,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-24,2011-01-05,,2011-02-24,2007-10-25,2007-10-26,Estimate,2011-02-24,2011-03-24,Estimate,,,,2011-02-24,2011-03-24,Estimate,September 2007,,2007-09-30,February 2011,2011-02-28,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,,Interventional,KAPA,,"Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","A Multi-center, Randomised, Open-label Study to Evaluate Convenience and Safety of Change in the Mode of Administration of Rivastigmine (From Capsules to a Transdermal Patch) in Patients With Alzheimer's Disease",Completed,,Phase 4,142.0,Actual,Novartis,,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:08:31.748764,2020-02-01 20:08:31.748764,Novartis,Industry,Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day),Drug
NCT00549601,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-24,2011-01-05,,2011-02-24,2007-10-25,2007-10-26,Estimate,2011-02-24,2011-03-24,Estimate,,,,2011-02-24,2011-03-24,Estimate,September 2007,,2007-09-30,February 2011,2011-02-28,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,,Interventional,KAPA,,"Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","A Multi-center, Randomised, Open-label Study to Evaluate Convenience and Safety of Change in the Mode of Administration of Rivastigmine (From Capsules to a Transdermal Patch) in Patients With Alzheimer's Disease",Completed,,Phase 4,142.0,Actual,Novartis,,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:08:31.748764,2020-02-01 20:08:31.748764,Novartis,Industry,Rivastigmine patch (9.5 mg/day),Drug
NCT00099242,"ClinicalTrials.gov processed this data on January 31, 2020",2004-12-10,,,2017-10-12,2004-12-09,2004-12-10,Estimate,,,,,,,2017-10-12,2017-10-13,Actual,November 2003,,2003-11-30,October 2017,2017-10-31,January 2006,Actual,2006-01-31,,,,,Interventional,,,Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease,Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease,Completed,,Phase 3,1040.0,,Novartis,,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:18:10.923720,2020-02-01 22:18:10.923720,Novartis Pharmaceuticals,Industry,rivastigmine transdermal patch,Drug
NCT00423085,"ClinicalTrials.gov processed this data on January 31, 2020",2007-01-11,2011-04-27,,2014-01-14,2007-01-12,2007-01-17,Estimate,2011-04-27,2011-05-25,Estimate,,,,2014-01-14,2014-02-10,Estimate,January 2007,,2007-01-31,January 2014,2014-01-31,April 2010,Actual,2010-04-30,March 2009,Actual,2009-03-31,,Interventional,,,Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease,"A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)",Completed,,Phase 3,859.0,Actual,Novartis,,3.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:48:41.903816,2020-02-01 20:48:41.903816,Novartis Pharmaceuticals,Industry,Rivastigmine transdermal patch,Drug
NCT00622713,"ClinicalTrials.gov processed this data on January 31, 2020",2008-02-14,2010-12-10,,2011-06-27,2008-02-22,2008-02-25,Estimate,2011-06-27,2011-07-26,Estimate,,,,2011-06-27,2011-07-26,Estimate,January 2008,,2008-01-31,June 2011,2011-06-30,January 2009,Actual,2009-01-31,January 2009,Actual,2009-01-31,,Interventional,EXTRA,,"A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)","A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (MMSE 10-26)",Completed,,Phase 4,228.0,Actual,Novartis,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:46:08.764586,2020-02-01 19:46:08.764586,Novartis,Industry,Rivastigmine transdermal patch,Drug
NCT00731224,"ClinicalTrials.gov processed this data on January 31, 2020",2008-08-05,,,2017-03-24,2008-08-05,2008-08-08,Estimate,,,,,,,2017-03-24,2017-03-28,Actual,July 2008,,2008-07-31,March 2017,2017-03-31,October 2011,Actual,2011-10-31,October 2011,Actual,2011-10-31,,Interventional,CARE,,Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.,"A 24-week, Multi-center, Open-label Evaluation of Compliance and Tolerability of the Once-daily 10 cm² Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease.",Completed,,Phase 4,380.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:14:18.730163,2020-02-01 19:14:18.730163,Novartis Pharmaceuticals,Industry,Rivastigmine transdermal patch,Drug
NCT01025466,"ClinicalTrials.gov processed this data on January 31, 2020",2009-12-02,,,2010-05-18,2009-12-02,2009-12-03,Estimate,,,,,,,2010-05-18,2010-05-19,Estimate,December 2008,,2008-12-31,May 2010,2010-05-31,April 2010,Actual,2010-04-30,November 2009,Actual,2009-11-30,,Interventional,EXPECT,,Exelon Patch and Combination With Memantine Comparative Trial,"A Multicenter, Randomized, Open-label Study to Compare the Tolerability Between Rivastigmine Patch Monotherapy and Combination Therapy With Memantine in Patients With Alzheimer's Disease",Completed,,Phase 4,206.0,Actual,Inha University Hospital,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:43:19.889179,2020-02-01 17:43:19.889179,Inha University Hospital,Other,Rivastigmine transdermal patch,Drug
NCT01529619,"ClinicalTrials.gov processed this data on January 31, 2020",2012-02-06,,,2016-11-16,2012-02-08,2012-02-09,Estimate,,,,,,,2016-11-16,2016-11-18,Estimate,March 2012,,2012-03-31,November 2016,2016-11-30,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,,Interventional,,,"Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors","A 24-week, Open-label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-23) Switched From Cholinesterase Inhibitors (Donepezil, Galantamine)",Completed,,Phase 4,52.0,Actual,Novartis,,1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 15:21:55.361868,2020-02-01 15:21:55.361868,Novartis Pharmaceuticals,Industry,Rivastigmine transdermal patch,Drug
NCT00219232,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-14,,,2017-02-21,2005-09-14,2005-09-22,Estimate,,,,,,,2017-02-21,2017-02-23,Actual,February 2003,,2003-02-28,February 2017,2017-02-28,July 2006,Actual,2006-07-31,July 2006,Actual,2006-07-31,,Interventional,,,An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease,An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease,Completed,,Phase 3,868.0,Actual,Novartis,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:45:44.993874,2020-02-01 21:45:44.993874,Novartis,Industry,Rivastigmine Transdermal Patch,Drug
NCT01025466,"ClinicalTrials.gov processed this data on January 31, 2020",2009-12-02,,,2010-05-18,2009-12-02,2009-12-03,Estimate,,,,,,,2010-05-18,2010-05-19,Estimate,December 2008,,2008-12-31,May 2010,2010-05-31,April 2010,Actual,2010-04-30,November 2009,Actual,2009-11-30,,Interventional,EXPECT,,Exelon Patch and Combination With Memantine Comparative Trial,"A Multicenter, Randomized, Open-label Study to Compare the Tolerability Between Rivastigmine Patch Monotherapy and Combination Therapy With Memantine in Patients With Alzheimer's Disease",Completed,,Phase 4,206.0,Actual,Inha University Hospital,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:43:19.889179,2020-02-01 17:43:19.889179,Inha University Hospital,Other,"Rivastigmine transdermal patch (Exelon patch), memantine",Drug
NCT01677754,"ClinicalTrials.gov processed this data on January 31, 2020",2012-08-30,,2016-07-20,2017-05-25,2012-08-30,2012-09-03,Estimate,,,,2016-07-20,2016-07-22,Estimate,2017-05-25,2017-05-30,Actual,"October 24, 2012",Actual,2012-10-24,May 2017,2017-05-31,"June 12, 2015",Actual,2015-06-12,"June 12, 2015",Actual,2015-06-12,,Interventional,MAyflOwer RoAD,,A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy,"A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease",Completed,,Phase 2,542.0,Actual,Hoffmann-La Roche,,3.0,,,False,,,,,True,False,,,,,,,,,,,2020-02-01 14:44:43.645589,2020-02-01 14:44:43.645589,Hoffmann-La Roche,Industry,RO4602522,Drug
NCT01701089,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-27,,,2016-11-01,2012-10-03,2012-10-04,Estimate,,,,,,,2016-11-01,2016-11-02,Estimate,September 2012,,2012-09-30,November 2016,2016-11-30,May 2013,Actual,2013-05-31,May 2013,Actual,2013-05-31,,Interventional,,,A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers,"An Open-Label, Parallel Group Study to Assess the Inhibition of Brain MAO-B by RO4602522 After Repeated Dosing in Patients With Alzheimer's Disease and in Healthy Control Subjects",Completed,,Phase 1,17.0,Actual,Hoffmann-La Roche,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 14:38:42.655878,2020-02-01 14:38:42.655878,Hoffmann-La Roche,Industry,RO4602522,Drug
NCT00884507,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-17,,2016-07-08,2016-11-01,2009-04-17,2009-04-20,Estimate,,,,2016-07-08,2016-07-12,Estimate,2016-11-01,2016-11-02,Estimate,May 2009,,2009-05-31,November 2016,2016-11-30,November 2010,Actual,2010-11-30,November 2010,Actual,2010-11-30,,Interventional,,,A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease,"A Dose-ranging, Randomized, Double-blind , Placebo-controlled Study of the Effect of RO5313534, Used as add-on Therapy to Donepezil, on Cognitive Function in Patients With Mild to Moderate Symptoms of Alzheimer's Disease",Completed,,Phase 2,389.0,Actual,Hoffmann-La Roche,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 18:29:05.945872,2020-02-01 18:29:05.945872,Hoffmann-La Roche,Industry,RO5313534,Drug
NCT02820896,"ClinicalTrials.gov processed this data on January 31, 2020",2016-06-29,,,2017-07-19,2016-06-29,2016-07-01,Estimate,,,,,,,2017-07-19,2017-07-21,Actual,"June 29, 2016",Actual,2016-06-29,July 2017,2017-07-31,"June 26, 2017",Actual,2017-06-26,"June 26, 2017",Actual,2017-06-26,,Interventional,,,A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease,"A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous and Subcutaneous RO7105705 Administered in Healthy Volunteers and Patients With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 1,74.0,Actual,"Genentech, Inc.",,5.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 10:13:34.158224,2020-02-01 10:13:34.158224,"Genentech, Inc.",Industry,RO7105705,Drug
NCT04023994,"ClinicalTrials.gov processed this data on January 31, 2020",2019-07-16,,,2020-01-03,2019-07-16,2019-07-18,Actual,,,,,,,2020-01-03,2020-01-06,Actual,"August 3, 2019",Actual,2019-08-03,January 2020,2020-01-31,"May 7, 2020",Anticipated,2020-05-07,"May 7, 2020",Anticipated,2020-05-07,,Interventional,,,"A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants","A Single-Center, Randomized, Adaptive, Investigator/Subject Blind, Single Ascending Dose, Placebo-Controlled Phase I Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants",Recruiting,,Phase 1,60.0,Anticipated,Hoffmann-La Roche,,5.0,,,False,,,,False,True,False,,,,,,,,,No,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2020-02-01 06:50:54.951052,2020-02-01 06:50:54.951052,Hoffmann-La Roche,Industry,RO7126209,Drug
NCT00004845,"ClinicalTrials.gov processed this data on January 31, 2020",2000-02-28,,,2009-12-10,2000-02-28,2000-02-29,Estimate,,,,,,,2009-12-10,2009-12-11,Estimate,,,,June 2009,2009-06-30,December 2001,Actual,2001-12-31,December 2001,Actual,2001-12-31,,Interventional,,,A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study),A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease,Completed,,Phase 2/Phase 3,,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:49:58.953737,2020-02-01 22:49:58.953737,National Institute on Aging (NIA),NIH,Rofecoxib,Drug
NCT02051335,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-29,2015-05-17,,2016-12-02,2014-01-29,2014-01-31,Estimate,2015-07-20,2015-08-17,Estimate,,,,2016-12-02,2017-02-01,Estimate,January 2014,,2014-01-31,September 2016,2016-09-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults,"A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (Hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults",Completed,,Phase 1,27.0,Actual,AstraZeneca,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:05:37.068408,2020-02-01 13:05:37.068408,AstraZeneca,Industry,Roflumilast,Drug
NCT02051335,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-29,2015-05-17,,2016-12-02,2014-01-29,2014-01-31,Estimate,2015-07-20,2015-08-17,Estimate,,,,2016-12-02,2017-02-01,Estimate,January 2014,,2014-01-31,September 2016,2016-09-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults,"A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (Hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults",Completed,,Phase 1,27.0,Actual,AstraZeneca,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:05:37.068408,2020-02-01 13:05:37.068408,AstraZeneca,Industry,Roflumilast placebo,Drug
NCT00018382,"ClinicalTrials.gov processed this data on January 31, 2020",2001-07-03,,,2009-01-20,2001-07-04,2001-07-05,Estimate,,,,,,,2009-01-20,2009-01-21,Estimate,October 1999,,1999-10-31,December 2004,2004-12-31,March 2003,,2003-03-31,,,,,Interventional,,,"Insulin, Neurogenetics and Memory in Alzheimer's Disease","Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach",Completed,,Phase 2,,,VA Office of Research and Development,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:17.168863,2020-02-01 22:48:17.168863,US Department of Veterans Affairs,U.S. Fed,rosiglitazone,Drug
NCT00381238,"ClinicalTrials.gov processed this data on January 31, 2020",2006-09-26,2017-02-22,2010-03-29,2017-04-18,2006-09-26,2006-09-27,Estimate,2017-04-18,2017-05-23,Actual,2010-03-29,2010-05-03,Estimate,2017-04-18,2017-05-23,Actual,"June 20, 2006",,2006-06-20,February 2017,2017-02-28,"February 3, 2009",Actual,2009-02-03,"February 1, 2009",Actual,2009-02-01,,Interventional,,,Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease,"An Open-label Extension to Study 49653/461, to Assess the Long-term Safety of Rosiglitazone (Extended Release Tablets) in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,33.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 21:02:21.880183,2020-02-01 21:02:21.880183,GlaxoSmithKline,Industry,rosiglitazone,Drug
NCT00265148,"ClinicalTrials.gov processed this data on January 31, 2020",2005-12-12,,2010-10-13,2016-11-15,2005-12-13,2005-12-14,Estimate,,,,2010-10-13,2010-11-18,Estimate,2016-11-15,2016-11-16,Estimate,May 2004,,2004-05-31,November 2016,2016-11-30,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,,,Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease,"A Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilization and Cognition in Subjects With Mild to Moderate Alzheimer's Disease (AD)",Completed,,Phase 2,80.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 21:34:31.049239,2020-02-01 21:34:31.049239,GlaxoSmithKline,Industry,Rosiglitazone,Drug
NCT00428090,"ClinicalTrials.gov processed this data on January 31, 2020",2007-01-25,2017-02-16,2010-10-13,2017-04-13,2007-01-25,2007-01-29,Estimate,2017-04-13,2017-05-19,Actual,2010-10-13,2010-11-18,Estimate,2017-04-13,2017-05-19,Actual,"February 27, 2007",,2007-02-27,April 2017,2017-04-30,"September 5, 2008",Actual,2008-09-05,"September 1, 2008",Actual,2008-09-01,,Interventional,,"The intent-to-treat (ITT) population was used and consist of all par. randomized to treatment, who have taken at least one dose of study medication and who have at least one post baseline efficacy assessment. The ITT population included 553 participants.",Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease,"A 24-week, Double-blind, Double-dummy, Randomized, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets), Donepezil, and Placebo as Monotherapy on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease. (REFLECT-1)",Completed,,Phase 3,862.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 20:46:40.615462,2020-02-01 20:46:40.615462,GlaxoSmithKline,Industry,Rosiglitazone,Drug
NCT00688207,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-28,,,2016-11-04,2008-05-30,2008-06-02,Estimate,,,,,,,2016-11-04,2016-11-07,Estimate,April 2008,,2008-04-30,November 2016,2016-11-30,September 2008,Actual,2008-09-30,September 2008,Actual,2008-09-30,,Interventional,,,Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR),An Open Label Single Oral Dose Study in Patients With Mild Alzheimer's Disease to Assess the Pharmacokinetics of Extended Release Formulation of Rosiglitazone (RSG XR) in This Population,Completed,,Phase 1,14.0,Actual,GlaxoSmithKline,,1.0,,,False,,,,False,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 19:27:30.939803,2020-02-01 19:27:30.939803,GlaxoSmithKline,Industry,Rosiglitazone (Extended Release),Drug
NCT00348140,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-30,2017-04-21,2010-03-29,2017-08-03,2006-06-30,2006-07-04,Estimate,2017-08-03,2017-09-05,Actual,2010-04-22,2010-05-03,Estimate,2017-08-03,2017-09-05,Actual,"July 12, 2006",Actual,2006-07-12,August 2017,2017-08-31,"March 20, 2009",Actual,2009-03-20,"March 20, 2009",Actual,2009-03-20,,Interventional,REFLECT-3,,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease,"A 54 Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE4-stratified Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,1468.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,True,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 21:12:00.421890,2020-02-01 21:12:00.421890,GlaxoSmithKline,Industry,Rosiglitazone Extended Release 2mg,Drug
NCT00348309,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-30,2017-04-21,2010-03-29,2017-10-23,2006-06-30,2006-07-04,Estimate,2017-10-23,2017-11-28,Actual,2010-04-22,2010-05-03,Estimate,2017-10-23,2017-11-28,Actual,"July 6, 2006",,2006-07-06,September 2017,2017-09-30,"January 28, 2009",Actual,2009-01-28,"January 1, 2009",Actual,2009-01-01,,Interventional,REFLECT-2,,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease,"A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.",Completed,,N/A,1496.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,True,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 21:11:56.425754,2020-02-01 21:11:56.425754,GlaxoSmithKline,Industry,Rosiglitazone Extended Release 2mg,Drug
NCT00348140,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-30,2017-04-21,2010-03-29,2017-08-03,2006-06-30,2006-07-04,Estimate,2017-08-03,2017-09-05,Actual,2010-04-22,2010-05-03,Estimate,2017-08-03,2017-09-05,Actual,"July 12, 2006",Actual,2006-07-12,August 2017,2017-08-31,"March 20, 2009",Actual,2009-03-20,"March 20, 2009",Actual,2009-03-20,,Interventional,REFLECT-3,,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease,"A 54 Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE4-stratified Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,1468.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,True,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 21:12:00.421890,2020-02-01 21:12:00.421890,GlaxoSmithKline,Industry,Rosiglitazone Extended Release 8mg,Drug
NCT00348309,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-30,2017-04-21,2010-03-29,2017-10-23,2006-06-30,2006-07-04,Estimate,2017-10-23,2017-11-28,Actual,2010-04-22,2010-05-03,Estimate,2017-10-23,2017-11-28,Actual,"July 6, 2006",,2006-07-06,September 2017,2017-09-30,"January 28, 2009",Actual,2009-01-28,"January 1, 2009",Actual,2009-01-01,,Interventional,REFLECT-2,,Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease,"A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.",Completed,,N/A,1496.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,True,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 21:11:56.425754,2020-02-01 21:11:56.425754,GlaxoSmithKline,Industry,Rosiglitazone Extended Release 8mg,Drug
NCT00490568,"ClinicalTrials.gov processed this data on January 31, 2020",2007-06-21,2017-09-05,2010-03-29,2017-10-11,2007-06-21,2007-06-22,Estimate,2017-10-11,2017-11-13,Actual,2010-03-29,2010-05-03,Estimate,2017-10-11,2017-11-13,Actual,"August 8, 2007",Actual,2007-08-08,September 2017,2017-09-30,"June 1, 2009",Actual,2009-06-01,"June 1, 2009",Actual,2009-06-01,,Interventional,,,Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers,"An Open-label Extension to Study AVA102670 and AVA102672, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.",Terminated,,Phase 3,1461.0,Actual,GlaxoSmithKline,,1.0,,Based on preliminary parent study results,False,,,,,,,,,,,,,,,,,2020-02-01 20:27:15.495525,2020-02-01 20:27:15.495525,GlaxoSmithKline,Industry,Rosiglitazone XR,Drug
NCT00550420,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-25,2017-08-31,2010-03-29,2017-10-09,2007-10-25,2007-10-29,Estimate,2017-10-09,2017-11-08,Actual,2010-03-29,2010-05-03,Estimate,2017-10-09,2017-11-08,Actual,"October 1, 2007",Actual,2007-10-01,August 2017,2017-08-31,"February 12, 2009",Actual,2009-02-12,"February 12, 2009",Actual,2009-02-12,,Interventional,,,Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers,"An Open-label Extension to Study AVA105640, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended Release Tablets) on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.",Terminated,,Phase 3,331.0,Actual,GlaxoSmithKline,The study was early terminated on 12 February 2009 because RSG XR as monotherapy in Alzheimer’s disease failed to demonstrate efficacy.,1.0,,Based on preliminary parent study results,False,,,,,,,,,,,,,,,Yes,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2020-02-01 20:08:05.723434,2020-02-01 20:08:05.723434,GlaxoSmithKline,Industry,Rosiglitazone XR,Drug
NCT00733785,"ClinicalTrials.gov processed this data on January 31, 2020",2008-08-12,,,2017-07-18,2008-08-12,2008-08-13,Estimate,,,,,,,2017-07-18,2017-07-21,Actual,"August 13, 2008",Actual,2008-08-13,July 2017,2017-07-31,"November 28, 2008",Actual,2008-11-28,"November 28, 2008",Actual,2008-11-28,,Interventional,Rosi XR,,"PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers","An Open-Label, Randomized, Crossover Study to the Dose Proportionality of RSG XR in Healthy Volunteers in Fasting Conditions",Completed,,Phase 1,60.0,Actual,GlaxoSmithKline,,7.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:13:39.265628,2020-02-01 19:13:39.265628,GlaxoSmithKline,Industry,Rosiglitazone XR,Drug
NCT00334568,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-06,,,2013-01-10,2006-06-06,2006-06-08,Estimate,,,,,,,2013-01-10,2013-01-14,Estimate,December 2004,,2004-12-31,January 2013,2013-01-31,July 2007,Actual,2007-07-31,July 2007,Actual,2007-07-31,,Interventional,,,Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease,"A Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) on Cerebral Glucose Utilisation and Cognition in Subjects With Mild to Moderate Alzheimers Disease (AD)",Terminated,,Phase 2,12.0,Actual,GlaxoSmithKline,,2.0,,Slow recruitment,False,,,,,,,,,,,,,,,,,2020-02-01 21:15:19.556863,2020-02-01 21:15:19.556863,GlaxoSmithKline,Industry,Rosiglitazone XR (extended release) oral tablets,Drug
NCT00884533,"ClinicalTrials.gov processed this data on January 31, 2020",2009-04-16,,,2015-04-15,2009-04-16,2009-04-20,Estimate,,,,,,,2015-04-15,2015-04-17,Estimate,June 2009,,2009-06-30,April 2015,2015-04-30,August 2009,Anticipated,2009-08-31,August 2009,Anticipated,2009-08-31,,Interventional,Rosi XR,,QTc Study of Rosi XR in Healthy Volunteers,A Study to Evaluate the Effect of Extended Release Rosiglitazone (RSG XR) on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin,Withdrawn,,Phase 1,0.0,Actual,GlaxoSmithKline,,3.0,,The whole project was terminated,False,,,,,,,,,,,,,,,,,2020-02-01 18:29:05.782285,2020-02-01 18:29:05.782285,GlaxoSmithKline,Industry,Rosi XR,Drug
NCT03250741,"ClinicalTrials.gov processed this data on January 31, 2020",2017-08-11,,,2018-12-14,2017-08-11,2017-08-16,Actual,,,,,,,2018-12-14,2018-12-17,Actual,June 2016,Actual,2016-06-30,December 2018,2018-12-31,November 2018,Actual,2018-11-30,November 2018,Actual,2018-11-30,,Interventional,DOPAD,,Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease,"Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease: a Phase II 24-week, Randomized, Double-blind Placebo Controlled Study.",Completed,,Phase 2,94.0,Actual,I.R.C.C.S. Fondazione Santa Lucia,,2.0,,,False,,,,False,False,,,,False,,,,,,Undecided,,2020-02-01 08:52:51.999359,2020-02-01 08:52:51.999359,I.R.C.C.S. Fondazione Santa Lucia,Other,Rotigotine transdermal patch,Drug
NCT03462121,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-16,,,2019-06-13,2018-03-08,2018-03-12,Actual,,,,,,,2019-06-13,2019-06-14,Actual,"March 1, 2018",Actual,2018-03-01,June 2019,2019-06-30,"July 30, 2020",Anticipated,2020-07-30,"December 28, 2019",Anticipated,2019-12-28,,Interventional,,,A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease,"A 6-Month, Double-Blind, Phase 2 Study and 6-Month Open- Label Extension Evaluating the Safety, Tolerability, and Clinical Benefit of RPh201 in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease",Recruiting,,Phase 2,81.0,Anticipated,Regenera Pharma Ltd,,2.0,,,False,,,,,False,False,,,,,,,,,Undecided,,2020-02-01 08:16:25.807860,2020-02-01 08:16:25.807860,Regenera Pharma Ltd,Industry,RPh201,Drug
NCT01513967,"ClinicalTrials.gov processed this data on January 31, 2020",2012-01-17,,,2016-12-05,2012-01-17,2012-01-20,Estimate,,,,,,,2016-12-05,2016-12-06,Estimate,January 2012,,2012-01-31,June 2015,2015-06-30,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,,,A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease,A Randomized Single and Multiple Dose Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease,Completed,,Phase 1/Phase 2,36.0,Actual,Regenera Pharma Ltd,,14.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:26:07.384967,2020-02-01 15:26:07.384967,Regenera Pharma Ltd,Industry,"RPh201, botanical drug product",Drug
NCT01513967,"ClinicalTrials.gov processed this data on January 31, 2020",2012-01-17,,,2016-12-05,2012-01-17,2012-01-20,Estimate,,,,,,,2016-12-05,2016-12-06,Estimate,January 2012,,2012-01-31,June 2015,2015-06-30,June 2015,Actual,2015-06-30,June 2015,Actual,2015-06-30,,Interventional,,,A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease,A Randomized Single and Multiple Dose Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease,Completed,,Phase 1/Phase 2,36.0,Actual,Regenera Pharma Ltd,,14.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:26:07.384967,2020-02-01 15:26:07.384967,Regenera Pharma Ltd,Industry,"RPh201, botanical extract product",Drug
NCT01388478,"ClinicalTrials.gov processed this data on January 31, 2020",2011-06-30,,2016-03-22,2016-03-22,2011-07-01,2011-07-06,Estimate,,,,2016-03-22,2016-04-25,Estimate,2016-03-22,2016-04-25,Estimate,July 2011,,2011-07-31,March 2016,2016-03-31,April 2014,Actual,2014-04-30,January 2014,Actual,2014-01-31,,Interventional,,,Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease,"Safety/Tolerability and Effects on Cognitive Impairment, Impaired Cerebral Cortical Metabolism and Oxidative Stress of R(+)Pramipexole Administered to Subjects With Early Alzheimer's Disease",Completed,,Phase 2,20.0,Actual,Virginia Commonwealth University,,1.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 15:58:46.100624,2020-02-01 15:58:46.100624,Virginia Commonwealth University,Other,R-pramipexole,Drug
NCT00468897,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-01,,,2017-08-03,2007-05-01,2007-05-03,Estimate,,,,,,,2017-08-03,2017-08-07,Actual,"March 21, 2007",Actual,2007-03-21,August 2017,2017-08-31,"May 2, 2007",Actual,2007-05-02,"May 2, 2007",Actual,2007-05-02,,Interventional,,,A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.,"An Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of a Tablet Formulation of Rosiglitazone XR (BRL-049653) 8mg Manufactured at Two Different Sites in Healthy Volunteers in Fasting Conditions",Completed,,Phase 1,50.0,Actual,GlaxoSmithKline,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:33:44.499893,2020-02-01 20:33:44.499893,GlaxoSmithKline,Industry,RSG XR,Drug
NCT02585934,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-22,2018-09-30,,2018-11-08,2015-10-22,2015-10-26,Estimate,2018-11-08,2018-12-05,Actual,,,,2018-11-08,2018-12-05,Actual,October 2015,Actual,2015-10-31,November 2018,2018-11-30,September 2017,Actual,2017-09-30,September 2017,Actual,2017-09-30,,Interventional,,ITT population,Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study,"A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,1315.0,Actual,Axovant Sciences Ltd.,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 11:01:27.758831,2020-02-01 11:01:27.758831,Axovant Sciences Ltd.,Industry,RVT-101,Drug
NCT02910102,"ClinicalTrials.gov processed this data on January 31, 2020",2016-09-16,,,2017-12-22,2016-09-19,2016-09-21,Estimate,,,,,,,2017-12-22,2017-12-27,Actual,October 2016,Actual,2016-10-31,December 2017,2017-12-31,November 2017,Actual,2017-11-30,November 2017,Actual,2017-11-30,,Interventional,,,Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia,"A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia",Completed,,Phase 2,38.0,Actual,Axovant Sciences Ltd.,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 09:57:01.127041,2020-02-01 09:57:01.127041,Axovant Sciences Ltd.,Industry,RVT-101 35 mg,Drug
NCT02586909,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-23,,,2018-03-16,2015-10-23,2015-10-27,Estimate,,,,,,,2018-03-16,2018-03-20,Actual,April 2016,Actual,2016-04-30,March 2018,2018-03-31,March 2018,Actual,2018-03-31,March 2018,Actual,2018-03-31,,Interventional,,,12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension,"A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease",Terminated,,Phase 3,1100.0,Actual,Axovant Sciences Ltd.,,1.0,,Intepirdine did not meet its primary efficacy endpoints in lead-in study RVT-101-3001.,False,,,,True,,,,,,,,,,,,,2020-02-01 11:01:15.237811,2020-02-01 11:01:15.237811,Axovant Sciences Ltd.,Industry,RVT-101 35 mg tablets,Drug
NCT02626572,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-04,,,2018-08-13,2015-12-07,2015-12-10,Estimate,,,,,,,2018-08-13,2018-08-15,Actual,February 2015,,2015-02-28,August 2018,2018-08-31,September 2017,Actual,2017-09-30,September 2017,Actual,2017-09-30,,Interventional,,,Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms,"Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.",Completed,,Phase 2,500.0,Anticipated,Servier,,4.0,,,False,,,,True,,,,,,,,After Marketing Authorisation in EEA or US if the study is used for the approval.,Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.,http://clinicaltrials.servier.com,Yes,"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.",2020-02-01 10:52:59.050457,2020-02-01 10:52:59.050457,Institut de Recherches Internationales Servier,Other,S47445 15mg,Drug
NCT02626572,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-04,,,2018-08-13,2015-12-07,2015-12-10,Estimate,,,,,,,2018-08-13,2018-08-15,Actual,February 2015,,2015-02-28,August 2018,2018-08-31,September 2017,Actual,2017-09-30,September 2017,Actual,2017-09-30,,Interventional,,,Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms,"Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.",Completed,,Phase 2,500.0,Anticipated,Servier,,4.0,,,False,,,,True,,,,,,,,After Marketing Authorisation in EEA or US if the study is used for the approval.,Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.,http://clinicaltrials.servier.com,Yes,"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.",2020-02-01 10:52:59.050457,2020-02-01 10:52:59.050457,Institut de Recherches Internationales Servier,Other,S47445 50mg,Drug
NCT02626572,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-04,,,2018-08-13,2015-12-07,2015-12-10,Estimate,,,,,,,2018-08-13,2018-08-15,Actual,February 2015,,2015-02-28,August 2018,2018-08-31,September 2017,Actual,2017-09-30,September 2017,Actual,2017-09-30,,Interventional,,,Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms,"Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.",Completed,,Phase 2,500.0,Anticipated,Servier,,4.0,,,False,,,,True,,,,,,,,After Marketing Authorisation in EEA or US if the study is used for the approval.,Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.,http://clinicaltrials.servier.com,Yes,"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).
They can ask all interventional clinical studies:
submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.",2020-02-01 10:52:59.050457,2020-02-01 10:52:59.050457,Institut de Recherches Internationales Servier,Other,S47445 5mg,Drug
NCT01409915,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-02,,,2019-04-15,2011-08-03,2011-08-04,Estimate,,,,,,,2019-04-15,2019-04-17,Actual,March 2011,,2011-03-31,April 2019,2019-04-30,"May 30, 2020",Anticipated,2020-05-30,"May 1, 2020",Anticipated,2020-05-01,,Interventional,,,Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease,Pilot Phase 2 Trial of the Safety & Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor (Leukine®) in the Treatment of Alzheimer's Disease,"Active, not recruiting",,Phase 2,40.0,Anticipated,"University of Colorado, Denver",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:53:34.168797,2020-02-01 15:53:34.168797,"University of Colorado, Denver",Other,Sagramostim,Drug
NCT01436045,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-16,2015-04-09,,2015-09-25,2011-09-16,2011-09-19,Estimate,2015-09-25,2015-10-19,Estimate,,,,2015-09-25,2015-10-19,Estimate,September 2011,,2011-09-30,September 2015,2015-09-30,June 2013,Actual,2013-06-30,June 2013,Actual,2013-06-30,,Interventional,,,Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.,"A Double-Blind, Placebo-Controlled Single Dose Study of the Safety and Efficacy of Glulisine on Cognitive Function and Memory in Individuals Diagnosed With Probable Mild to Moderate Alzheimer's Disease/Intranasal Insulin Study.",Completed,,Phase 2,12.0,Actual,HealthPartners Institute,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:46:57.736752,2020-02-01 15:46:57.736752,HealthPartners Institute,Other,Saline,Drug
NCT01595646,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-08,2017-04-17,,2018-04-23,2012-05-09,2012-05-10,Estimate,2018-01-05,2018-02-01,Actual,,,,2018-04-23,2018-05-22,Actual,November 2011,Actual,2011-11-30,April 2018,2018-04-30,"March 12, 2015",Actual,2015-03-12,"March 12, 2015",Actual,2015-03-12,,Interventional,SL120,,Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120),Completed,,Phase 2,37.0,Actual,Wake Forest University Health Sciences,,3.0,,,False,,,,True,True,False,,,,,,,,,No,There is no plan to share individual participant data with other researchers.,2020-02-01 15:05:56.020319,2020-02-01 15:05:56.020319,Wake Forest University Health Sciences,Other,Saline,Drug
NCT01409915,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-02,,,2019-04-15,2011-08-03,2011-08-04,Estimate,,,,,,,2019-04-15,2019-04-17,Actual,March 2011,,2011-03-31,April 2019,2019-04-30,"May 30, 2020",Anticipated,2020-05-30,"May 1, 2020",Anticipated,2020-05-01,,Interventional,,,Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease,Pilot Phase 2 Trial of the Safety & Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor (Leukine®) in the Treatment of Alzheimer's Disease,"Active, not recruiting",,Phase 2,40.0,Anticipated,"University of Colorado, Denver",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:53:34.168797,2020-02-01 15:53:34.168797,"University of Colorado, Denver",Other,Saline -- placebo comparator,Drug
NCT03277573,"ClinicalTrials.gov processed this data on January 31, 2020",2017-07-27,,,2018-05-01,2017-09-07,2017-09-11,Actual,,,,,,,2018-05-01,2018-05-03,Actual,"July 21, 2017",Actual,2017-07-21,May 2018,2018-05-31,"October 21, 2019",Anticipated,2019-10-21,"July 21, 2019",Anticipated,2019-07-21,,Interventional,SAL-AD,,Salsalate in Patients Mild to Moderate Alzheimer's Disease,"A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease",Recruiting,,Phase 1,40.0,Anticipated,"University of California, San Francisco",,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:48:11.130970,2020-02-01 08:48:11.130970,Adam Boxer,Other,Salsalate,Drug
NCT00110552,"ClinicalTrials.gov processed this data on January 31, 2020",2005-05-10,,,2014-10-27,2005-05-10,2005-05-11,Estimate,,,,,,,2014-10-27,2014-10-29,Estimate,July 2005,,2005-07-31,October 2014,2014-10-31,October 2014,Actual,2014-10-31,December 2012,Actual,2012-12-31,,Interventional,,,Effects of Sage on Memory and Mental Performance in Alzheimer's Disease Patients,Effects of a Cognitive Enhancer on Memory and Cognitive Performance,Completed,,Phase 1,111.0,Actual,Oregon Health and Science University,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:14:39.997030,2020-02-01 22:14:39.997030,Oregon Health and Science University,Other,Salvia officinalis (sage),Drug
NCT00474552,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-15,,,2008-02-13,2007-05-15,2007-05-17,Estimate,,,,,,,2008-02-13,2008-02-18,Estimate,June 2007,,2007-06-30,February 2008,2008-02-29,October 2007,Actual,2007-10-31,October 2007,Actual,2007-10-31,,Interventional,,,"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315","An Ascending Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 Administered Orally to Healthy Young Adult and Elderly Subjects",Terminated,,Phase 1,56.0,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:32:03.058855,2020-02-01 20:32:03.058855,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,SAM-315,Drug
NCT00479440,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-24,,,2007-12-03,2007-05-24,2007-05-28,Estimate,,,,,,,2007-12-03,2007-12-05,Estimate,August 2006,,2006-08-31,December 2007,2007-12-31,March 2007,Actual,2007-03-31,,,,,Interventional,,,"Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults","Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 Administered Orally to Healthy Adult Subjects",Completed,,Phase 1,56.0,,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,,,,,,,,,,,,,,,,2020-02-01 20:30:41.410395,2020-02-01 20:30:41.410395,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,SAM-315,Drug
NCT00480467,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-29,,,2007-12-03,2007-05-29,2007-05-31,Estimate,,,,,,,2007-12-03,2007-12-05,Estimate,September 2006,,2006-09-30,December 2007,2007-12-31,August 2007,Actual,2007-08-31,,,,,Interventional,,,"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-315 in Healthy Japanese Males","Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 Administered Orally to Healthy Japanese Male Subjects",Completed,,Phase 1,32.0,,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:30:22.421666,2020-02-01 20:30:22.421666,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,SAM-315,Drug
NCT00479297,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-24,,,2009-08-06,2007-05-24,2007-05-28,Estimate,,,,,,,2009-08-06,2009-08-07,Estimate,May 2006,,2006-05-31,August 2009,2009-08-31,February 2007,Actual,2007-02-28,February 2007,Actual,2007-02-28,,Interventional,,,"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males","Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Japanese Male Subjects",Completed,,Phase 1,72.0,,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:30:44.196920,2020-02-01 20:30:44.196920,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,SAM-531,Drug
NCT00479349,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-24,,,2009-07-06,2007-05-24,2007-05-28,Estimate,,,,,,,2009-07-06,2009-07-07,Estimate,May 2007,,2007-05-31,July 2009,2009-07-31,January 2008,Actual,2008-01-31,January 2008,Actual,2008-01-31,,Interventional,,,"Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531","An Ascending Multiple Dose Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Japanese Young Male and Elderly Subjects",Completed,,Phase 1,32.0,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:30:43.433741,2020-02-01 20:30:43.433741,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,SAM-531,Drug
NCT00479700,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-24,,,2007-12-07,2007-05-24,2007-05-28,Estimate,,,,,,,2007-12-07,2007-12-10,Estimate,May 2006,,2006-05-31,December 2007,2007-12-31,July 2006,Actual,2006-07-31,,,,,Interventional,,,"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects","Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Subjects",Completed,,Phase 1,80.0,,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,,,,,,,,,,,,,,,,2020-02-01 20:30:36.363953,2020-02-01 20:30:36.363953,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,SAM-531,Drug
NCT00480818,"ClinicalTrials.gov processed this data on January 31, 2020",2007-05-29,,,2007-12-09,2007-05-29,2007-05-31,Estimate,,,,,,,2007-12-09,2007-12-11,Estimate,September 2006,,2006-09-30,December 2007,2007-12-31,July 2007,Actual,2007-07-31,,,,,Interventional,,,"Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects","An Ascending Multiple Dose Study of the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-531 Administered Orally to Healthy Young and Elderly Subjects",Completed,,Phase 1,80.0,,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,,,,,,,,,,,,,,,,2020-02-01 20:30:19.308079,2020-02-01 20:30:19.308079,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,SAM-531,Drug
NCT00726115,"ClinicalTrials.gov processed this data on January 31, 2020",2008-07-28,,,2009-07-29,2008-07-30,2008-07-31,Estimate,,,,,,,2009-07-29,2009-07-30,Estimate,August 2008,,2008-08-31,July 2009,2009-07-31,February 2009,Actual,2009-02-28,February 2009,Actual,2009-02-28,,Interventional,,,"Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531","Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Dose of SAM-531 Administered Orally To Healthy Young and Elderly Subjects",Completed,,Phase 1,56.0,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:15:48.399246,2020-02-01 19:15:48.399246,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,SAM-531,Drug
NCT00745576,"ClinicalTrials.gov processed this data on January 31, 2020",2008-09-02,,,2010-02-05,2008-09-02,2008-09-03,Estimate,,,,,,,2010-02-05,2010-02-08,Estimate,October 2008,,2008-10-31,February 2010,2010-02-28,December 2008,Actual,2008-12-31,December 2008,Actual,2008-12-31,,Interventional,,,Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered,"An Open-label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Verapamil Immediate Release (IR) and a Single Dose of SAM-531 When Co-administered Orally to Healthy Young Adult Subjects",Completed,,Phase 1,14.0,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:10:21.751580,2020-02-01 19:10:21.751580,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,SAM-531,Drug
NCT00895895,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-07,2012-12-21,,2012-12-21,2009-05-07,2009-05-08,Estimate,2012-12-21,2013-01-31,Estimate,,,,2012-12-21,2013-01-31,Estimate,May 2009,,2009-05-31,December 2012,2012-12-31,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease,"A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease",Terminated,,Phase 2,526.0,Actual,Pfizer,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,5.0,,See termination reason in detailed description.,False,,,,True,,,,,,,,,,,,,2020-02-01 18:26:03.286124,2020-02-01 18:26:03.286124,Pfizer,Industry,SAM-531 1.5 mg,Drug
NCT00895895,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-07,2012-12-21,,2012-12-21,2009-05-07,2009-05-08,Estimate,2012-12-21,2013-01-31,Estimate,,,,2012-12-21,2013-01-31,Estimate,May 2009,,2009-05-31,December 2012,2012-12-31,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease,"A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease",Terminated,,Phase 2,526.0,Actual,Pfizer,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,5.0,,See termination reason in detailed description.,False,,,,True,,,,,,,,,,,,,2020-02-01 18:26:03.286124,2020-02-01 18:26:03.286124,Pfizer,Industry,SAM-531 3.0 mg,Drug
NCT00895895,"ClinicalTrials.gov processed this data on January 31, 2020",2009-05-07,2012-12-21,,2012-12-21,2009-05-07,2009-05-08,Estimate,2012-12-21,2013-01-31,Estimate,,,,2012-12-21,2013-01-31,Estimate,May 2009,,2009-05-31,December 2012,2012-12-31,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease,"A 52-Week, Two-Period, Multicenter, Randomized, Double-Blind, Donepezil-Referenced, Placebo-Controlled, Efficacy And Safety Study Of 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease",Terminated,,Phase 2,526.0,Actual,Pfizer,Study terminated early due to futility. Period 2 events include those that started in Period 2 or started in Period 1 and continued in to Period 2.,5.0,,See termination reason in detailed description.,False,,,,True,,,,,,,,,,,,,2020-02-01 18:26:03.286124,2020-02-01 18:26:03.286124,Pfizer,Industry,SAM-531 5.0 mg,Drug
NCT01266525,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-23,,2016-02-12,2016-02-12,2010-12-23,2010-12-24,Estimate,,,,2016-02-12,2016-03-14,Estimate,2016-02-12,2016-03-14,Estimate,February 2011,,2011-02-28,February 2016,2016-02-29,January 2013,Actual,2013-01-31,January 2013,Actual,2013-01-31,,Interventional,,,Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil,"A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance, Safety, and Tolerability of SAR110894D at the Doses of 0.5 mg, 2 mg, and 5 mg/Day for 24 Weeks in Patients With Mild to Moderate Alzheimer's Disease on Stable Donepezil Therapy",Completed,,Phase 2,291.0,Actual,Sanofi,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:32:09.069267,2020-02-01 16:32:09.069267,Sanofi,Industry,SAR110894,Drug
NCT01485302,"ClinicalTrials.gov processed this data on January 31, 2020",2011-11-16,,,2015-03-24,2011-12-01,2011-12-05,Estimate,,,,,,,2015-03-24,2015-03-25,Estimate,January 2012,,2012-01-31,March 2015,2015-03-31,February 2015,Actual,2015-02-28,February 2015,Actual,2015-02-28,,Interventional,,,Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients,"A Multi-center, Parallel-group, Double-blind, Placebo-controlled Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability and the Pharmacokinetic Properties of SAR228810 Given as IV Infusion or as SC Injection in Patients With Mild to Moderate Alzheimer's Disease.",Completed,,Phase 1,48.0,Actual,Sanofi,,6.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:32:51.185849,2020-02-01 15:32:51.185849,Sanofi,Industry,SAR228810,Drug
NCT01864655,"ClinicalTrials.gov processed this data on January 31, 2020",2013-05-08,,,2014-06-12,2013-05-28,2013-05-29,Estimate,,,,,,,2014-06-12,2014-06-13,Estimate,July 2013,,2013-07-31,June 2014,2014-06-30,,,,March 2014,Actual,2014-03-31,,Interventional,,,Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease,"A Phase Ib Multiple Ascending Dose Study of the Safety, Tolerability, and CNS Availability of AZD0530 in Alzheimer's Disease",Completed,,Phase 1,24.0,Actual,Yale University,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:55:28.062074,2020-02-01 13:55:28.062074,Stephen M. Strittmatter,Other,saracatinib,Drug
NCT02667496,"ClinicalTrials.gov processed this data on January 31, 2020",2016-01-26,,,2017-04-05,2016-01-28,2016-01-29,Estimate,,,,,,,2017-04-05,2017-04-07,Actual,November 2016,,2016-11-30,April 2017,2017-04-30,"March 31, 2017",Actual,2017-03-31,"March 31, 2017",Actual,2017-03-31,,Interventional,,,Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine® (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease,Withdrawn,,Phase 2,0.0,Actual,Sanofi,,2.0,,Slow recruitment,False,,,,True,,,,,,,,,,,,,2020-02-01 10:44:33.482652,2020-02-01 10:44:33.482652,Sanofi,Industry,Sargramostim GZ402664,Drug
NCT00224497,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-21,,,2009-12-23,2005-09-21,2005-09-23,Estimate,,,,,,,2009-12-23,2009-12-24,Estimate,September 2005,,2005-09-30,December 2009,2009-12-31,,,,,,,,Interventional,,,A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease,"A Phase IIa/b Double-blind, Randomised, Placebo-controlled, Linear Trend Design Dose-ranging Study to Investigate the Effects of 24 Weeks of Monotherapy With SB-742457 on Cognition in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,380.0,,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:44:48.847373,2020-02-01 21:44:48.847373,GlaxoSmithKline,Industry,SB-742457,Drug
NCT00348192,"ClinicalTrials.gov processed this data on January 31, 2020",2006-06-30,,,2009-05-28,2006-06-30,2006-07-04,Estimate,,,,,,,2009-05-28,2009-06-02,Estimate,May 2006,,2006-05-31,May 2009,2009-05-31,,,,,,,,Interventional,,,SB-742457 And Donepezil In Alzheimer's Disease,"A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Investigate the Effects of SB-742457, Donepezil and Placebo on Cognition in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,200.0,,GlaxoSmithKline,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:11:59.993954,2020-02-01 21:11:59.993954,GlaxoSmithKline,Industry,SB-742457,Drug
NCT00551772,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-29,,,2008-12-23,2007-10-29,2007-10-31,Estimate,,,,,,,2008-12-23,2008-12-25,Estimate,August 2007,,2007-08-31,December 2008,2008-12-31,,,,,,,,Interventional,,,A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.,"An Open-Label, Randomised, Two-Part Crossover Study to Assess the Pharmacokinetics of a Single Dose of SB-742457 Formulated as a Capsule and a Tablet in Healthy Elderly Volunteers.",Completed,,Phase 1,12.0,Anticipated,GlaxoSmithKline,,,,,,,,,,,,,,,,,,,,,,2020-02-01 20:07:28.769757,2020-02-01 20:07:28.769757,GlaxoSmithKline,Industry,SB-742457,Drug
NCT00708552,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-30,2017-07-24,2012-02-23,2018-05-31,2008-06-30,2008-07-02,Estimate,2017-07-24,2018-02-12,Actual,2012-02-23,2012-02-28,Estimate,2018-05-31,2018-07-27,Actual,"July 4, 2008",,2008-07-04,May 2018,2018-05-31,"March 9, 2010",Actual,2010-03-09,"March 1, 2010",Actual,2010-03-01,,Interventional,,"The population used to define the Baseline Characteristics was the Intent-to-Treat (ITT Population) which comprised of all participants randomized to treatment, and who received at least one dose of study medication and who had at least one post baseline assessment.",Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease,"Study AZ3110865, a Study Comparing SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease",Completed,,Phase 2,576.0,Actual,GlaxoSmithKline,,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 19:21:02.377486,2020-02-01 19:21:02.377486,GlaxoSmithKline,Industry,SB-742457,Drug
NCT00710684,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-30,2017-08-18,2011-03-17,2017-11-03,2008-07-03,2008-07-04,Estimate,2017-11-03,2017-12-07,Actual,2011-04-21,2011-04-28,Estimate,2017-11-03,2017-12-07,Actual,"July 1, 2008",Actual,2008-07-01,November 2017,2017-11-30,"November 16, 2010",Actual,2010-11-16,"May 21, 2010",Actual,2010-05-21,,Interventional,,"Out of 682 participants, 5 participants did not have at least one post-Baseline or health outcomes assessment. Hence a total of 677 participants were included in intent-to-treat (ITT) population and they were used to assess Baseline characteristics.","A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease","Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease",Completed,,Phase 2,682.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:20:26.859390,2020-02-01 19:20:26.859390,GlaxoSmithKline,Industry,SB-742457 15mg,Drug
NCT00710684,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-30,2017-08-18,2011-03-17,2017-11-03,2008-07-03,2008-07-04,Estimate,2017-11-03,2017-12-07,Actual,2011-04-21,2011-04-28,Estimate,2017-11-03,2017-12-07,Actual,"July 1, 2008",Actual,2008-07-01,November 2017,2017-11-30,"November 16, 2010",Actual,2010-11-16,"May 21, 2010",Actual,2010-05-21,,Interventional,,"Out of 682 participants, 5 participants did not have at least one post-Baseline or health outcomes assessment. Hence a total of 677 participants were included in intent-to-treat (ITT) population and they were used to assess Baseline characteristics.","A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease","Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease",Completed,,Phase 2,682.0,Actual,GlaxoSmithKline,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:20:26.859390,2020-02-01 19:20:26.859390,GlaxoSmithKline,Industry,SB-742457 35mg,Drug
NCT02051335,"ClinicalTrials.gov processed this data on January 31, 2020",2014-01-29,2015-05-17,,2016-12-02,2014-01-29,2014-01-31,Estimate,2015-07-20,2015-08-17,Estimate,,,,2016-12-02,2017-02-01,Estimate,January 2014,,2014-01-31,September 2016,2016-09-30,May 2014,Actual,2014-05-31,May 2014,Actual,2014-05-31,,Interventional,,,Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults,"A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (Hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults",Completed,,Phase 1,27.0,Actual,AstraZeneca,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:05:37.068408,2020-02-01 13:05:37.068408,AstraZeneca,Industry,Scopolamine,Drug
NCT03030105,"ClinicalTrials.gov processed this data on January 31, 2020",2017-01-17,,,2018-10-15,2017-01-20,2017-01-24,Estimate,,,,,,,2018-10-15,2018-10-16,Actual,January 2017,Actual,2017-01-31,October 2018,2018-10-31,June 2017,Actual,2017-06-30,May 2017,Actual,2017-05-31,,Interventional,,,Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers,"A Randomized, Double-blind, Placebo-controlled, Single-dose, 6-Period Crossover Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers",Completed,,Phase 1,38.0,Actual,Tetra Discovery Partners,,6.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 09:31:54.545833,2020-02-01 09:31:54.545833,Tetra Discovery Partners,Industry,Scopolamine 0.6 MG/ML,Drug
NCT03030105,"ClinicalTrials.gov processed this data on January 31, 2020",2017-01-17,,,2018-10-15,2017-01-20,2017-01-24,Estimate,,,,,,,2018-10-15,2018-10-16,Actual,January 2017,Actual,2017-01-31,October 2018,2018-10-31,June 2017,Actual,2017-06-30,May 2017,Actual,2017-05-31,,Interventional,,,Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers,"A Randomized, Double-blind, Placebo-controlled, Single-dose, 6-Period Crossover Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers",Completed,,Phase 1,38.0,Actual,Tetra Discovery Partners,,6.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 09:31:54.545833,2020-02-01 09:31:54.545833,Tetra Discovery Partners,Industry,Scopolamine placebo,Drug
NCT01035138,"ClinicalTrials.gov processed this data on January 31, 2020",2009-12-17,2013-11-06,2011-08-09,2014-09-22,2009-12-17,2009-12-18,Estimate,2014-09-22,2014-09-25,Estimate,2011-08-09,2011-08-15,Estimate,2014-09-22,2014-09-25,Estimate,December 2009,,2009-12-31,September 2014,2014-09-30,April 2011,Actual,2011-04-30,April 2011,Actual,2011-04-30,,Interventional,Identity XT,,A Study of Semagacestat for Alzheimer's Patients,Open-Label Extension for Alzheimer's Disease Patients Who Complete One of Two Semagacestat Phase 3 Double-Blind Studies (H6L-MC-LFAN or H6L-MC-LFBC),Completed,,Phase 3,180.0,Actual,Eli Lilly and Company,"Very few participants from LFBC rolled over into LFBF (N = 9). Due to insufficient sample size, the data for LFBC participants who rolled into LFBF were not analyzed.",1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:40:26.788427,2020-02-01 17:40:26.788427,Eli Lilly and Company,Industry,semagacestat,Drug
NCT03289143,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-18,,,2020-01-06,2017-09-18,2017-09-20,Actual,,,,,,,2020-01-06,2020-01-09,Actual,"October 4, 2017",Actual,2017-10-04,January 2020,2020-01-31,"September 20, 2022",Anticipated,2022-09-20,"June 24, 2020",Anticipated,2020-06-24,,Interventional,,,A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease","Active, not recruiting",,Phase 2,457.0,Actual,"Genentech, Inc.",,4.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:45:33.720811,2020-02-01 08:45:33.720811,"Genentech, Inc.",Industry,Semorinemab,Drug
NCT03828747,"ClinicalTrials.gov processed this data on January 31, 2020",2019-01-29,,,2020-01-06,2019-01-31,2019-02-04,Actual,,,,,,,2020-01-06,2020-01-09,Actual,"January 30, 2019",Actual,2019-01-30,January 2020,2020-01-31,"June 2, 2023",Anticipated,2023-06-02,"May 7, 2021",Anticipated,2021-05-07,,Interventional,,,A Study of Semorinemab in Patients With Moderate Alzheimer's Disease,"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease",Recruiting,,Phase 2,260.0,Anticipated,"Genentech, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)",2020-02-01 07:20:05.785221,2020-02-01 07:20:05.785221,"Genentech, Inc.",Industry,Semorinemab,Drug
NCT03101085,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-29,,,2019-09-30,2017-03-29,2017-04-04,Actual,,,,,,,2019-09-30,2019-10-01,Actual,"May 5, 2017",Actual,2017-05-05,September 2019,2019-09-30,"June 30, 2020",Anticipated,2020-06-30,"March 30, 2020",Anticipated,2020-03-30,,Interventional,SEAD2,,S-Equol in Alzheimer's Disease 2 Trial,S-Equol in Alzheimer's Disease 2 (SEAD2) Trial,Recruiting,,Phase 1/Phase 2,40.0,Anticipated,University of Kansas Medical Center,,2.0,,,False,,,,False,True,False,,,False,,,,,,No,,2020-02-01 09:18:57.573917,2020-02-01 09:18:57.573917,"Russell Swerdlow, MD",Other,S-equol,Drug
NCT02142777,"ClinicalTrials.gov processed this data on January 31, 2020",2014-05-08,,,2016-08-12,2014-05-19,2014-05-20,Estimate,,,,,,,2016-08-12,2016-08-16,Estimate,July 2014,,2014-07-31,August 2016,2016-08-31,April 2016,Actual,2016-04-30,April 2016,Actual,2016-04-30,,Interventional,SEAD,,S-Equol in Alzheimer's Disease (SEAD) Trial,S-Equol in Alzheimer's Disease (SEAD) Trial,Completed,,Phase 1,15.0,Actual,University of Kansas Medical Center,,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 12:43:36.267085,2020-02-01 12:43:36.267085,"Russell Swerdlow, MD",Other,S -Equol,Drug
NCT00086138,"ClinicalTrials.gov processed this data on January 31, 2020",2004-06-25,2016-03-08,,2017-02-28,2004-06-25,2004-06-28,Estimate,2017-02-28,2017-04-11,Actual,,,,2017-02-28,2017-04-11,Actual,July 2004,,2004-07-31,February 2017,2017-02-28,July 2009,Actual,2009-07-31,July 2008,Actual,2008-07-31,,Interventional,DIADS-2,,Depression in Alzheimer's Disease-2,Depression in Alzheimer's Disease (DIADS-2),Completed,,Phase 2/Phase 3,131.0,Actual,Johns Hopkins University,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:24:18.842269,2020-02-01 22:24:18.842269,Johns Hopkins University,Other,Sertraline (Zoloft),Drug
NCT00009191,"ClinicalTrials.gov processed this data on January 31, 2020",2001-01-23,,,2018-08-16,2001-01-23,2001-01-24,Estimate,,,,,,,2018-08-16,2018-08-20,Actual,November 2005,,2005-11-30,August 2018,2018-08-31,November 2007,Actual,2007-11-30,November 2006,Actual,2006-11-30,,Interventional,,,The Depression in Alzheimer's Disease Study (DIADS),,Completed,,Phase 4,,,Johns Hopkins University,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:48:45.048809,2020-02-01 22:48:45.048809,Johns Hopkins University,Other,Sertraline [Zoloft],Drug
NCT00093951,"ClinicalTrials.gov processed this data on January 31, 2020",2004-10-07,,,2009-12-10,2004-10-07,2004-10-08,Estimate,,,,,,,2009-12-10,2009-12-11,Estimate,April 2004,,2004-04-30,February 2009,2009-02-28,September 2007,Actual,2007-09-30,September 2007,Actual,2007-09-30,,Interventional,,,SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,280.0,,National Institute on Aging (NIA),,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:20:46.124356,2020-02-01 22:20:46.124356,Saegis Pharmaceuticals,Industry,SGS742,Drug
NCT00053599,"ClinicalTrials.gov processed this data on January 31, 2020",2003-02-03,,,2009-07-24,2003-02-03,2003-02-04,Estimate,,,,,,,2009-07-24,2009-07-28,Estimate,December 2002,,2002-12-31,June 2009,2009-06-30,October 2007,Actual,2007-10-31,October 2007,Actual,2007-10-31,,Interventional,,,Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin to Slow the Progression of Alzheimer's Disease",Completed,,Phase 3,400.0,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:35:42.585546,2020-02-01 22:35:42.585546,National Institute on Aging (NIA),NIH,Simvastatin,Drug
NCT01439555,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-16,2019-05-23,,2019-07-11,2011-09-21,2011-09-23,Estimate,2019-07-11,2019-07-30,Actual,,,,2019-07-11,2019-07-30,Actual,November 2011,,2011-11-30,July 2019,2019-07-31,November 2017,Actual,2017-11-30,November 2017,Actual,2017-11-30,,Interventional,,"Prospective, open-label, single group assignment, single center study conducted by UMass Medical School at the UMass Memorial Medical Center in Worcester, MA. 11 subjects total were screened and enrolled in this study, 10 subjects completed the study as 1 subject was initially enrolled but was excluded due to not meeting inclusion criteria.",Endothelial Facilitation in Alzheimer's Disease,"Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease.",Completed,,Phase 2,11.0,Actual,"University of Massachusetts, Worcester","The data for the MRI measurements (cerebral blood flow) experienced file corruption, rendering segments of data irretrievable and the whole set non-analyzable.",1.0,,,False,,,,False,True,False,,,True,,,,,,,,2020-02-01 15:45:59.915593,2020-02-01 15:45:59.915593,"University of Massachusetts, Worcester",Other,Simvastatin,Drug
NCT00443417,"ClinicalTrials.gov processed this data on January 31, 2020",2007-03-05,,,2009-12-08,2007-03-05,2007-03-06,Estimate,,,,,,,2009-12-08,2009-12-09,Estimate,April 2007,,2007-04-30,January 2008,2008-01-31,January 2009,Actual,2009-01-31,January 2009,Actual,2009-01-31,,Interventional,,,A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease,Dose Finding Study to Assess the Efficacy and Safety of SK-PC-B70M in Patients With Mild to Moderate Alzheimer's Disease,Completed,,Phase 2,188.0,Anticipated,"SK Chemicals Co., Ltd.",,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 20:41:35.760128,2020-02-01 20:41:35.760128,"SK Chemicals Co., Ltd.",Industry,SK-PC-B70M,Drug
NCT01249196,"ClinicalTrials.gov processed this data on January 31, 2020",2010-11-23,,,2013-11-25,2010-11-24,2010-11-29,Estimate,,,,,,,2013-11-25,2013-11-26,Estimate,May 2010,,2010-05-31,November 2010,2010-11-30,,,,August 2013,Actual,2013-08-31,,Interventional,,,A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease,,Completed,,Phase 3,256.0,Anticipated,"SK Chemicals Co., Ltd.",,4.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 16:37:39.761131,2020-02-01 16:37:39.761131,"SK Chemicals Co., Ltd.",Industry,SK-PC-B70M,Drug
NCT01453569,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-30,2014-11-13,,2015-01-25,2011-10-13,2011-10-18,Estimate,2015-01-25,2015-01-27,Estimate,,,,2015-01-25,2015-01-27,Estimate,October 2011,,2011-10-31,January 2015,2015-01-31,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,,"All the treated subjects were evaluated for safety. 2, 8 and 3 subjects were excluded from FAS in placebo, 600 mg and 900 mg group respectively. So the case No. were 83, 76, 83 for placebo, 600 mg and 900 mg group respectively.","Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease",Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease,Completed,,Phase 2,255.0,Actual,"Shanghai Greenvalley Pharmaceutical Co., Ltd.",,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:41:57.383248,2020-02-01 15:41:57.383248,"Shanghai Greenvalley Pharmaceutical Co., Ltd.",Industry,Sodium oligo-mannurarate 600mg,Drug
NCT01453569,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-30,2014-11-13,,2015-01-25,2011-10-13,2011-10-18,Estimate,2015-01-25,2015-01-27,Estimate,,,,2015-01-25,2015-01-27,Estimate,October 2011,,2011-10-31,January 2015,2015-01-31,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,,"All the treated subjects were evaluated for safety. 2, 8 and 3 subjects were excluded from FAS in placebo, 600 mg and 900 mg group respectively. So the case No. were 83, 76, 83 for placebo, 600 mg and 900 mg group respectively.","Safety, Efficacy and Dose Titration of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer's Disease",Phase II Study of Sodium Oligo-mannurarate Capsule on Mild to Moderate Alzheimer Disease,Completed,,Phase 2,255.0,Actual,"Shanghai Greenvalley Pharmaceutical Co., Ltd.",,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:41:57.383248,2020-02-01 15:41:57.383248,"Shanghai Greenvalley Pharmaceutical Co., Ltd.",Industry,Sodium oligo-mannurarate 900mg,Drug
NCT02293915,"ClinicalTrials.gov processed this data on January 31, 2020",2014-11-13,,,2018-10-09,2014-11-13,2014-11-19,Estimate,,,,,,,2018-10-09,2018-10-10,Actual,"April 1, 2014",Actual,2014-04-01,October 2018,2018-10-31,"September 28, 2018",Actual,2018-09-28,"June 29, 2018",Actual,2018-06-29,,Interventional,,,An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease,Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer Disease,Completed,,Phase 3,818.0,Actual,"Shanghai Greenvalley Pharmaceutical Co., Ltd.",,2.0,,,False,,,,False,,,,,,,,,,,No,,2020-02-01 12:08:03.265956,2020-02-01 12:08:03.265956,"Shanghai Greenvalley Pharmaceutical Co., Ltd.",Industry,Sodium oligo-mannurarate 900mg,Drug
NCT00706186,"ClinicalTrials.gov processed this data on January 31, 2020",2008-06-24,,,2010-07-06,2008-06-26,2008-06-27,Estimate,,,,,,,2010-07-06,2010-07-07,Estimate,,,,July 2010,2010-07-31,,,,,,,,Interventional,ALD,,Safety and Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients,Phase IV Study Safety & Feasibility of Sodium Oxybate in Mild Alzheimer's Disease Patients.,Terminated,,Phase 4,4.0,Actual,Clayton Sleep Insititute,,,,"Withdrawn by Investigator, protocol in revision",False,,,,True,,,,,,,,,,,,,2020-02-01 19:21:57.466268,2020-02-01 19:21:57.466268,Clayton Sleep Insititute,Industry,Sodium Oxybate,Drug
NCT00749216,"ClinicalTrials.gov processed this data on January 31, 2020",2008-09-05,,2010-05-27,2010-05-27,2008-09-05,2008-09-09,Estimate,,,,2010-05-27,2010-06-02,Estimate,2010-05-27,2010-06-02,Estimate,September 2008,,2008-09-30,May 2010,2010-05-31,July 2009,Actual,2009-07-31,July 2009,Actual,2009-07-31,,Interventional,,,Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease,Multiple-Dose Safety in Japanese Subjects With Mild-to-Moderate Alzheimer's Disease,Completed,,Phase 2,33.0,Actual,Eli Lilly and Company,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 19:09:35.901467,2020-02-01 19:09:35.901467,Eli Lilly and Company,Industry,Solanezumab,Drug
NCT01127633,"ClinicalTrials.gov processed this data on January 31, 2020",2010-05-19,2018-02-12,2014-09-29,2019-09-25,2010-05-19,2010-05-21,Estimate,2018-04-02,2018-05-03,Actual,2014-09-29,2014-10-08,Estimate,2019-09-25,2019-10-08,Actual,December 2010,,2010-12-31,September 2019,2019-09-30,February 2017,Actual,2017-02-28,July 2014,Actual,2014-07-31,,Interventional,EXPEDITION EXT,All randomized participants who received at least 1 dose of study drug.,Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease,"Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease",Terminated,,Phase 3,1457.0,Actual,Eli Lilly and Company,,2.0,,Solanezumab did not meet the primary endpoint in study H8A-MC-LZAX.,False,,,,True,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 17:14:11.538960,2020-02-01 17:14:11.538960,Eli Lilly and Company,Industry,Solanezumab,Drug
NCT01760005,"ClinicalTrials.gov processed this data on January 31, 2020",2012-12-26,,,2019-10-01,2012-12-31,2013-01-03,Estimate,,,,,,,2019-10-01,2019-10-03,Actual,December 2012,,2012-12-31,October 2019,2019-10-31,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,,Interventional,DIAN-TU,,Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.,"A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease",Recruiting,,Phase 2/Phase 3,490.0,Anticipated,Washington University School of Medicine,,5.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:23:00.489600,2020-02-01 14:23:00.489600,Washington University School of Medicine,Other,Solanezumab,Drug
NCT01900665,"ClinicalTrials.gov processed this data on January 31, 2020",2013-07-12,2018-02-16,2016-12-21,2019-09-25,2013-07-12,2013-07-16,Estimate,2018-02-16,2018-03-14,Actual,2016-12-21,2016-12-23,Estimate,2019-09-25,2019-10-09,Actual,July 2013,,2013-07-31,September 2019,2019-09-30,February 2017,Actual,2017-02-28,October 2016,Actual,2016-10-31,,Interventional,EXPEDITION 3,All randomized participants.,Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo,Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo,Terminated,,Phase 3,2129.0,Actual,Eli Lilly and Company,,2.0,,Solanezumab did not meet the study's primary endpoint.,False,,,,True,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 13:45:21.891307,2020-02-01 13:45:21.891307,Eli Lilly and Company,Industry,Solanezumab,Drug
NCT02614131,"ClinicalTrials.gov processed this data on January 31, 2020",2015-11-23,2019-06-28,,2019-08-21,2015-11-23,2015-11-25,Estimate,2019-08-21,2019-09-23,Actual,,,,2019-08-21,2019-09-23,Actual,December 2015,,2015-12-31,August 2019,2019-08-31,December 2016,Actual,2016-12-31,December 2016,Actual,2016-12-31,,Interventional,,All randomized participants.,A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD),"Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease",Terminated,,Phase 1,50.0,Actual,Eli Lilly and Company,"Development of LY2599666 was stopped based on lack of efficacy of another compound directed against the same target. Following the enrollment of seven participants into Part B Cohort 5, enrollment was stopped.",6.0,,New data suggests that insufficient target engagement would be achieved for efficacy.,False,,,,False,,,,,,,,,,,,,2020-02-01 10:55:28.881506,2020-02-01 10:55:28.881506,Eli Lilly and Company,Industry,Solanezumab,Drug
NCT02760602,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-02,2018-05-08,,2019-09-25,2016-05-02,2016-05-03,Estimate,2018-06-25,2018-07-24,Actual,,,,2019-09-25,2019-10-10,Actual,June 2016,,2016-06-30,September 2019,2019-09-30,May 2017,Actual,2017-05-31,May 2017,Actual,2017-05-31,,Interventional,ExpeditionPRO,All enrolled participants who received at least one dose of study drug.,A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease,"A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease",Terminated,,Phase 3,26.0,Actual,Eli Lilly and Company,The study was terminated due to insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit to pts with prodromal AD as defined by the study protocol. Zero pts were analyzed as no data collected for outcomes.,2.0,,"Insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit
    to participants with prodromal AD as defined by study protocol.",False,,,,True,,,,,,,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-02-01 10:25:04.531045,2020-02-01 10:25:04.531045,Eli Lilly and Company,Industry,Solanezumab,Drug
NCT02549196,"ClinicalTrials.gov processed this data on January 31, 2020",2015-08-27,2018-09-28,,2019-02-12,2015-09-11,2015-09-15,Estimate,2019-02-12,2019-03-05,Actual,,,,2019-02-12,2019-03-05,Actual,"October 7, 2015",Actual,2015-10-07,February 2019,2019-02-28,"September 28, 2017",Actual,2017-09-28,"September 28, 2017",Actual,2017-09-28,,Interventional,CPC-12,,A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type,"A Phase II, Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type",Completed,,Phase 2,28.0,Actual,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 11:10:22.839904,2020-02-01 11:10:22.839904,"Chase Pharmaceuticals Corporation, an affiliate of Allergan plc",Industry,Solifenacin,Drug
NCT04044131,"ClinicalTrials.gov processed this data on January 31, 2020",2019-07-17,,,2019-07-31,2019-07-31,2019-08-05,Actual,,,,,,,2019-07-31,2019-08-05,Actual,"September 1, 2019",Anticipated,2019-09-01,July 2019,2019-07-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,,Interventional,,,Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients,"A Phase 2, Randomized, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) And Parkinson's Disease (PD) Patients",Not yet recruiting,,Phase 2,120.0,Anticipated,Istanbul Medipol University Hospital,,2.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 06:48:09.330007,2020-02-01 06:48:09.330007,Istanbul Medipol University Hospital,Other,Sorbitol,Drug
NCT00285025,"ClinicalTrials.gov processed this data on January 31, 2020",2006-01-31,,,2006-01-31,2006-01-31,2006-02-01,Estimate,,,,,,,2006-01-31,2006-02-01,Estimate,March 2005,,2005-03-31,January 2006,2006-01-31,September 2005,,2005-09-30,,,,,Interventional,,,Study of the Effect of SR57667B in Patients With Alzheimer's Disease,"A Phase II, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Patients With Mild-to-Moderate Alzheimer's Disease",Completed,,Phase 2,500.0,,Sanofi,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:29:34.476404,2020-02-01 21:29:34.476404,Sanofi,Industry,SR57667B,Drug
NCT00285077,"ClinicalTrials.gov processed this data on January 31, 2020",2006-01-31,,,2008-12-22,2006-01-31,2006-02-01,Estimate,,,,,,,2008-12-22,2008-12-23,Estimate,March 2004,,2004-03-31,December 2008,2008-12-31,November 2006,Actual,2006-11-30,November 2006,Actual,2006-11-30,,Interventional,,,Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease,Long-Term Safety Extension of Phase II Study EFC5286 of SR57667B in Patients With Mild-to-Moderate Alzheimer's Disease,Completed,,Phase 2,390.0,Actual,Sanofi,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:29:34.154616,2020-02-01 21:29:34.154616,Sanofi,Industry,SR57667B,Drug
NCT00151333,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-06,,,2009-09-03,2005-09-06,2005-09-08,Estimate,,,,,,,2009-09-03,2009-09-04,Estimate,February 2005,,2005-02-28,September 2009,2009-09-30,April 2005,Actual,2005-04-30,April 2005,Actual,2005-04-30,,Interventional,,,Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD),"A Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics Trial of Multiple Ascending Fixed Doses of SRA-333 in Subjects With Mild to Moderate Alzheimer's Disease.",Completed,,Phase 2,16.0,,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,,,,,,,,,,,,,,,,2020-02-01 22:02:22.870666,2020-02-01 22:02:22.870666,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,SRA-333,Drug
NCT00452504,"ClinicalTrials.gov processed this data on January 31, 2020",2007-03-23,,,2007-12-03,2007-03-23,2007-03-27,Estimate,,,,,,,2007-12-03,2007-12-05,Estimate,February 2007,,2007-02-28,December 2007,2007-12-31,June 2007,Actual,2007-06-30,,,,,Interventional,,,Single Ascending Dose Study of SRA-444 in Healthy Subjects,"Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRA-444 Administered Orally to Healthy Adult Subjects",Completed,,Phase 1,64.0,Anticipated,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,,,,,,,,,,,,,,,,,,2020-02-01 20:38:47.286456,2020-02-01 20:38:47.286456,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,SRA-444,Drug
NCT00499200,"ClinicalTrials.gov processed this data on January 31, 2020",2007-07-09,,,2008-07-07,2007-07-10,2007-07-11,Estimate,,,,,,,2008-07-07,2008-07-09,Estimate,October 2007,,2007-10-31,July 2008,2008-07-31,June 2008,Actual,2008-06-30,June 2008,Actual,2008-06-30,,Interventional,,,"Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy",A Positron Emission Tomography Study to Assess the Level and Duration of Occupancy of Serotonin-1A Receptors Produced by Single Oral Doses of SRA-444 in Healthy Elderly Subjects and in Subjects With Alzheimer Disease,Completed,,Phase 1,42.0,Actual,Wyeth is now a wholly owned subsidiary of Pfizer,,1.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:24:56.430259,2020-02-01 20:24:56.430259,Wyeth is now a wholly owned subsidiary of Pfizer,Industry,SRA-444,Drug
NCT00602680,"ClinicalTrials.gov processed this data on January 31, 2020",2008-01-16,,,2009-07-17,2008-01-16,2008-01-28,Estimate,,,,,,,2009-07-17,2009-07-20,Estimate,January 2008,,2008-01-31,July 2009,2009-07-31,July 2008,Actual,2008-07-31,July 2008,Actual,2008-07-31,,Interventional,,,Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease,"A Multicenter, Double-blind, Parallel-group, Placebo-controlled Study of the Effect on Cognitive Performance and Safety/Tolerability of SSR180711C for 4 Weeks, Using Donepezil as Calibrator, in Patients With Mild Alzheimer's Disease",Terminated,,Phase 2,1.0,Actual,Sanofi,,5.0,,Insufficient expected benefit risk,False,,,,True,,,,,,,,,,,,,2020-02-01 19:52:44.951641,2020-02-01 19:52:44.951641,Sanofi,Industry,SSR180711C,Drug
NCT00842673,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-10,,,2012-06-05,2009-02-10,2009-02-12,Estimate,,,,,,,2012-06-05,2012-06-07,Estimate,February 2009,,2009-02-28,June 2012,2012-06-30,September 2010,Actual,2010-09-30,September 2010,Actual,2010-09-30,,Interventional,,,Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease,"A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease",Completed,,Phase 2,168.0,Actual,"Sonexa Therapeutics, Inc.",,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:41:39.618333,2020-02-01 18:41:39.618333,"Sonexa Therapeutics, Inc.",Industry,ST101,Drug
NCT00842816,"ClinicalTrials.gov processed this data on January 31, 2020",2009-02-10,,,2012-06-05,2009-02-11,2009-02-12,Estimate,,,,,,,2012-06-05,2012-06-07,Estimate,February 2009,,2009-02-28,June 2012,2012-06-30,May 2011,Actual,2011-05-31,May 2011,Actual,2011-05-31,,Interventional,,,Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease,"A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease in Subjects Concurrently Receiving Donepezil (Aricept®)",Completed,,Phase 2,210.0,Actual,"Sonexa Therapeutics, Inc.",,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:41:36.501371,2020-02-01 18:41:36.501371,"Sonexa Therapeutics, Inc.",Industry,ST101,Drug
NCT01255046,"ClinicalTrials.gov processed this data on January 31, 2020",2010-12-03,,,2014-08-19,2010-12-05,2010-12-07,Estimate,,,,,,,2014-08-19,2014-08-20,Estimate,December 2015,,2015-12-31,August 2014,2014-08-31,,,,December 2018,Anticipated,2018-12-31,,Interventional,,,Study of STA-1 as an Add-on Treatment to Donepezil,"A Phase II Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of STA-1 as an Add-on Treatment to Donepezil in Patients With Mild to Moderate Alzheimer's Disease",Unknown status,Not yet recruiting,Phase 2,136.0,Anticipated,"Sinphar Pharmaceutical Co., Ltd",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:35:48.924341,2020-02-01 16:35:48.924341,"Sinphar Pharmaceutical Co., Ltd",Other,STA-1,Drug
NCT01594346,"ClinicalTrials.gov processed this data on January 31, 2020",2012-05-02,,,2012-05-08,2012-05-08,2012-05-09,Estimate,,,,,,,2012-05-08,2012-05-09,Estimate,September 2000,,2000-09-30,May 2012,2012-05-31,April 2010,Actual,2010-04-30,April 2010,Actual,2010-04-30,,Interventional,,,Multicenter Vitamin E Trial in Aging Persons With Down Syndrome,,Completed,,Phase 3,349.0,Actual,New York State Institute for Basic Research,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:06:16.500865,2020-02-01 15:06:16.500865,New York State Institute for Basic Research,Other,Sugar Pill,Drug
NCT02580305,"ClinicalTrials.gov processed this data on January 31, 2020",2015-10-17,,,2019-11-15,2015-10-17,2015-10-20,Estimate,,,,,,,2019-11-15,2019-11-18,Actual,September 2015,,2015-09-30,November 2019,2019-11-30,"November 7, 2019",Actual,2019-11-07,"November 5, 2019",Actual,2019-11-05,,Interventional,,,SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study,"A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride",Completed,,Phase 2,563.0,Actual,Suven Life Sciences Limited,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 11:02:59.952283,2020-02-01 11:02:59.952283,Suven Life Sciences Limited,Industry,SUVN-502,Drug
NCT02750306,"ClinicalTrials.gov processed this data on January 31, 2020",2016-04-21,2019-09-25,,2019-09-25,2016-04-21,2016-04-25,Estimate,2019-09-25,2019-10-16,Actual,,,,2019-09-25,2019-10-16,Actual,"May 23, 2016",Actual,2016-05-23,September 2019,2019-09-30,"September 30, 2018",Actual,2018-09-30,"September 30, 2018",Actual,2018-09-30,,Interventional,,,Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061),"A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease",Completed,,Phase 3,285.0,Actual,Merck Sharp & Dohme Corp.,,2.0,,,False,,,,False,True,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2020-02-01 10:27:18.152403,2020-02-01 10:27:18.152403,Merck Sharp & Dohme Corp.,Industry,Suvorexant,Drug
NCT02560753,"ClinicalTrials.gov processed this data on January 31, 2020",2015-07-28,2018-03-06,,2018-07-26,2015-09-23,2015-09-25,Estimate,2018-07-26,2018-07-30,Actual,,,,2018-07-26,2018-07-30,Actual,July 2015,,2015-07-31,July 2018,2018-07-31,"June 30, 2016",Actual,2016-06-30,"May 30, 2016",Actual,2016-05-30,,Interventional,,,Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease,Phase 2a Feasibility Study of T3D-959 in Subjects With Mild to Moderate Alzheimer's Disease,Completed,,Phase 1/Phase 2,36.0,Actual,"T3D Therapeutics, Inc.",,4.0,,,False,,,,False,,,,,,,,,,,Undecided,,2020-02-01 11:07:48.435341,2020-02-01 11:07:48.435341,"T3D Therapeutics, Inc.",Industry,T3D-959,Drug
NCT00663936,"ClinicalTrials.gov processed this data on January 31, 2020",2008-04-18,,2012-12-09,2013-10-09,2008-04-21,2008-04-22,Estimate,,,,2012-12-10,2012-12-12,Estimate,2013-10-09,2013-11-05,Estimate,April 2008,,2008-04-30,December 2012,2012-12-31,June 2011,Actual,2011-06-30,May 2011,Actual,2011-05-31,,Interventional,,,Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease,"A Phase 2a Multi-center, Randomized, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of T-817MAa in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,373.0,Actual,"FUJIFILM Toyama Chemical Co., Ltd.",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:34:29.421057,2020-02-01 19:34:29.421057,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,T-817MA,Drug
NCT04191486,"ClinicalTrials.gov processed this data on January 31, 2020",2019-11-26,,,2020-01-20,2019-12-05,2019-12-09,Actual,,,,,,,2020-01-20,2020-01-22,Actual,"December 24, 2019",Actual,2019-12-24,January 2020,2020-01-31,October 2022,Anticipated,2022-10-31,September 2022,Anticipated,2022-09-30,,Interventional,,,Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD,"A Phase 2 Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease",Recruiting,,Phase 2,200.0,Anticipated,"FUJIFILM Toyama Chemical Co., Ltd.",,2.0,,,False,,,,True,False,False,,,,,,,,,Undecided,Details for sharing data have not been decided yet.,2020-02-01 06:27:45.932872,2020-02-01 06:27:45.932872,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,T-817MA,Drug
NCT02079909,"ClinicalTrials.gov processed this data on January 31, 2020",2014-03-04,2018-05-07,2016-02-23,2019-02-12,2014-03-04,2014-03-06,Estimate,2018-07-12,2018-08-09,Actual,2016-06-22,2016-06-27,Estimate,2019-02-12,2019-02-26,Actual,March 2014,,2014-03-31,February 2019,2019-02-28,"May 5, 2017",Actual,2017-05-05,"May 5, 2017",Actual,2017-05-05,,Interventional,,"The overall numbers of baseline participants display patient numbers in the mITT population, the primary analysis population. The mITT population excludes patients who did not take any study drug or did not perform any efficacy evaluation post-baseline. Thus, the numbers are slightly difference from the ones in the participant flow.",Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202),"A Phase 2 Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,482.0,Actual,"FUJIFILM Toyama Chemical Co., Ltd.",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:58:33.435431,2020-02-01 12:58:33.435431,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,T-817MA-H,Drug
NCT02079909,"ClinicalTrials.gov processed this data on January 31, 2020",2014-03-04,2018-05-07,2016-02-23,2019-02-12,2014-03-04,2014-03-06,Estimate,2018-07-12,2018-08-09,Actual,2016-06-22,2016-06-27,Estimate,2019-02-12,2019-02-26,Actual,March 2014,,2014-03-31,February 2019,2019-02-28,"May 5, 2017",Actual,2017-05-05,"May 5, 2017",Actual,2017-05-05,,Interventional,,"The overall numbers of baseline participants display patient numbers in the mITT population, the primary analysis population. The mITT population excludes patients who did not take any study drug or did not perform any efficacy evaluation post-baseline. Thus, the numbers are slightly difference from the ones in the participant flow.",Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202),"A Phase 2 Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,482.0,Actual,"FUJIFILM Toyama Chemical Co., Ltd.",,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:58:33.435431,2020-02-01 12:58:33.435431,"FUJIFILM Toyama Chemical Co., Ltd.",Industry,T-817MA-L,Drug
NCT02769065,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-10,2018-05-30,,2019-03-08,2016-05-10,2016-05-11,Estimate,2019-03-08,2019-06-10,Actual,,,,2019-03-08,2019-06-10,Actual,"May 5, 2016",Actual,2016-05-05,March 2019,2019-03-31,"June 8, 2017",Actual,2017-06-08,"June 8, 2017",Actual,2017-06-08,,Interventional,,Safety analysis set (SAS) included all participants who were enrolled and received at least 1 dose of the study drug.,Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants,"A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects",Terminated,,Phase 1,179.0,Actual,Takeda,,30.0,,Terminated prematurely as data from cohort no longer needed due to indication change.,False,,,,False,True,False,,,,,,,,,,,2020-02-01 10:23:19.348529,2020-02-01 10:23:19.348529,Takeda,Industry,TAK-071,Drug
NCT02769065,"ClinicalTrials.gov processed this data on January 31, 2020",2016-05-10,2018-05-30,,2019-03-08,2016-05-10,2016-05-11,Estimate,2019-03-08,2019-06-10,Actual,,,,2019-03-08,2019-06-10,Actual,"May 5, 2016",Actual,2016-05-05,March 2019,2019-03-31,"June 8, 2017",Actual,2017-06-08,"June 8, 2017",Actual,2017-06-08,,Interventional,,Safety analysis set (SAS) included all participants who were enrolled and received at least 1 dose of the study drug.,Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants,"A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects",Terminated,,Phase 1,179.0,Actual,Takeda,,30.0,,Terminated prematurely as data from cohort no longer needed due to indication change.,False,,,,False,True,False,,,,,,,,,,,2020-02-01 10:23:19.348529,2020-02-01 10:23:19.348529,Takeda,Industry,TAK-071 Placebo,Drug
NCT02248116,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-22,,,2014-09-22,2014-09-22,2014-09-25,Estimate,,,,,,,2014-09-22,2014-09-25,Estimate,May 1999,,1999-05-31,September 2014,2014-09-30,,,,September 2000,Actual,2000-09-30,,Interventional,,,Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type,"An Open-label Multicentre, Follow-up Trial to Assess the Long-term Safety and Tolerability of Oral Administration of Talsaclidine 24 mg Tid in Patients With Mild to Moderate Dementia of the Alzheimer Type",Terminated,,Phase 2/Phase 3,198.0,Actual,Boehringer Ingelheim,,1.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:18:22.606416,2020-02-01 12:18:22.606416,Boehringer Ingelheim,Industry,Talsaclidine,Drug
NCT02249351,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-23,,,2014-09-25,2014-09-23,2014-09-25,Estimate,,,,,,,2014-09-25,2014-09-26,Estimate,December 1999,,1999-12-31,September 2014,2014-09-30,,,,May 2000,Actual,2000-05-31,,Interventional,,,Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type,"Efficacy and Safety of 48 mg Talsaclidine (Free Base) Tid po (Panel 1) and 60 mg Talsaclidine (Free Base) Tid po (Panel 2) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Within Escalating Dose Panels in 150 Patients With Mild to Moderate Dementia of Alzheimer Type",Terminated,,Phase 2,54.0,Actual,Boehringer Ingelheim,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:18:03.473505,2020-02-01 12:18:03.473505,Boehringer Ingelheim,Industry,Talsaclidine,Drug
NCT02249403,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-23,,,2014-09-25,2014-09-23,2014-09-25,Estimate,,,,,,,2014-09-25,2014-09-26,Estimate,January 1999,,1999-01-31,September 2014,2014-09-30,,,,January 2000,Actual,2000-01-31,,Interventional,,,Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type,"Efficacy and Safety of 6, 12, 24, and 36 mg Tid po and 36 mg Bid po Talsaclidine (Free Base) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Parallel Group Comparison in Patients With Mild to Moderate Dementia of Alzheimer Type",Completed,,Phase 2,362.0,Actual,Boehringer Ingelheim,,6.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:18:03.208888,2020-02-01 12:18:03.208888,Boehringer Ingelheim,Industry,Talsaclidine 12 mg,Drug
NCT02249403,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-23,,,2014-09-25,2014-09-23,2014-09-25,Estimate,,,,,,,2014-09-25,2014-09-26,Estimate,January 1999,,1999-01-31,September 2014,2014-09-30,,,,January 2000,Actual,2000-01-31,,Interventional,,,Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type,"Efficacy and Safety of 6, 12, 24, and 36 mg Tid po and 36 mg Bid po Talsaclidine (Free Base) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Parallel Group Comparison in Patients With Mild to Moderate Dementia of Alzheimer Type",Completed,,Phase 2,362.0,Actual,Boehringer Ingelheim,,6.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:18:03.208888,2020-02-01 12:18:03.208888,Boehringer Ingelheim,Industry,Talsaclidine 24 mg,Drug
NCT02249403,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-23,,,2014-09-25,2014-09-23,2014-09-25,Estimate,,,,,,,2014-09-25,2014-09-26,Estimate,January 1999,,1999-01-31,September 2014,2014-09-30,,,,January 2000,Actual,2000-01-31,,Interventional,,,Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type,"Efficacy and Safety of 6, 12, 24, and 36 mg Tid po and 36 mg Bid po Talsaclidine (Free Base) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Parallel Group Comparison in Patients With Mild to Moderate Dementia of Alzheimer Type",Completed,,Phase 2,362.0,Actual,Boehringer Ingelheim,,6.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:18:03.208888,2020-02-01 12:18:03.208888,Boehringer Ingelheim,Industry,Talsaclidine 36 mg,Drug
NCT02249403,"ClinicalTrials.gov processed this data on January 31, 2020",2014-09-23,,,2014-09-25,2014-09-23,2014-09-25,Estimate,,,,,,,2014-09-25,2014-09-26,Estimate,January 1999,,1999-01-31,September 2014,2014-09-30,,,,January 2000,Actual,2000-01-31,,Interventional,,,Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type,"Efficacy and Safety of 6, 12, 24, and 36 mg Tid po and 36 mg Bid po Talsaclidine (Free Base) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Parallel Group Comparison in Patients With Mild to Moderate Dementia of Alzheimer Type",Completed,,Phase 2,362.0,Actual,Boehringer Ingelheim,,6.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 12:18:03.208888,2020-02-01 12:18:03.208888,Boehringer Ingelheim,Industry,Talsaclidine 6 mg,Drug
NCT01120002,"ClinicalTrials.gov processed this data on January 31, 2020",2010-04-30,,,2011-07-21,2010-05-07,2010-05-10,Estimate,,,,,,,2011-07-21,2011-07-22,Estimate,May 2010,,2010-05-31,July 2011,2011-07-31,December 2012,Anticipated,2012-12-31,December 2012,Anticipated,2012-12-31,,Interventional,,,Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease,,Unknown status,Recruiting,Phase 2,50.0,Anticipated,Osaka City University,,2.0,,,False,,,,,,,,,,,,,,,,,2020-02-01 17:16:39.773727,2020-02-01 17:16:39.773727,Osaka City University,Other,Tamibarotene,Drug
NCT03151382,"ClinicalTrials.gov processed this data on January 31, 2020",2017-05-08,,,2017-05-10,2017-05-10,2017-05-12,Actual,,,,,,,2017-05-10,2017-05-12,Actual,"May 20, 2017",Anticipated,2017-05-20,May 2017,2017-05-31,"June 30, 2018",Anticipated,2018-06-30,"December 31, 2017",Anticipated,2017-12-31,,Interventional,,,A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease,A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease,Unknown status,Not yet recruiting,Phase 4,30.0,Anticipated,Zhejiang Provincial People’s Hospital,,2.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 09:10:15.470273,2020-02-01 09:10:15.470273,Zhejiang Provincial People’s Hospital,Other,Tandospirone Citrate,Drug
NCT02085265,"ClinicalTrials.gov processed this data on January 31, 2020",2013-11-29,,,2017-11-23,2014-03-10,2014-03-12,Estimate,,,,,,,2017-11-23,2017-11-27,Actual,March 2014,,2014-03-31,November 2017,2017-11-30,March 2021,Anticipated,2021-03-31,March 2020,Anticipated,2020-03-31,,Interventional,SARTAN-AD,,Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients,"The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients",Recruiting,,Phase 2,240.0,Anticipated,Sunnybrook Health Sciences Centre,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 12:57:20.821541,2020-02-01 12:57:20.821541,Sunnybrook Health Sciences Centre,Other,Telmisartan,Drug
NCT03417986,"ClinicalTrials.gov processed this data on January 31, 2020",2017-11-29,,,2019-02-26,2018-01-30,2018-01-31,Actual,,,,,,,2019-02-26,2019-02-27,Actual,"November 24, 2017",Actual,2017-11-24,February 2019,2019-02-28,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,,Interventional,drainAD,,Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers,"An Open-label, Multicenter, Controlled Pharmaco-dynamic Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease in Comparison to Healthy Volunteers","Active, not recruiting",,Phase 2,100.0,Anticipated,Immungenetics AG,,3.0,,,False,,,,,False,False,,,,,,,,,,,2020-02-01 08:23:59.387747,2020-02-01 08:23:59.387747,Immungenetics AG,Industry,TEP,Drug
NCT00539305,"ClinicalTrials.gov processed this data on January 31, 2020",2007-10-03,2013-03-15,,2014-07-10,2007-10-03,2007-10-04,Estimate,2014-07-10,2014-07-14,Estimate,,,,2014-07-10,2014-07-14,Estimate,July 2009,,2009-07-31,July 2014,2014-07-31,May 2012,Actual,2012-05-31,July 2011,Actual,2011-07-31,,Interventional,HIP,,Hormone and Information Processing Study,Testosterone Supplementation in Men With MCI,Completed,,Phase 3,22.0,Actual,University of Washington,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:12:13.088046,2020-02-01 20:12:13.088046,University of Washington,Other,testosterone gel,Drug
NCT01439555,"ClinicalTrials.gov processed this data on January 31, 2020",2011-09-16,2019-05-23,,2019-07-11,2011-09-21,2011-09-23,Estimate,2019-07-11,2019-07-30,Actual,,,,2019-07-11,2019-07-30,Actual,November 2011,,2011-11-30,July 2019,2019-07-31,November 2017,Actual,2017-11-30,November 2017,Actual,2017-11-30,,Interventional,,"Prospective, open-label, single group assignment, single center study conducted by UMass Medical School at the UMass Memorial Medical Center in Worcester, MA. 11 subjects total were screened and enrolled in this study, 10 subjects completed the study as 1 subject was initially enrolled but was excluded due to not meeting inclusion criteria.",Endothelial Facilitation in Alzheimer's Disease,"Endothelial Facilitation in Alzheimer's Disease. An Open Label Pilot Study of the Sequential and Cumulative Effects of Simvastatin, L-Arginine, and Sapropterin (Kuvan) on Cerebral Blood Flow and Cognitive Function in Patients With Alzheimer's Disease.",Completed,,Phase 2,11.0,Actual,"University of Massachusetts, Worcester","The data for the MRI measurements (cerebral blood flow) experienced file corruption, rendering segments of data irretrievable and the whole set non-analyzable.",1.0,,,False,,,,False,True,False,,,True,,,,,,,,2020-02-01 15:45:59.915593,2020-02-01 15:45:59.915593,"University of Massachusetts, Worcester",Other,Tetrahydrobiopterin,Drug
NCT01094340,"ClinicalTrials.gov processed this data on January 31, 2020",2010-03-25,,,2012-08-06,2010-03-25,2010-03-26,Estimate,,,,,,,2012-08-06,2012-08-08,Estimate,March 2010,,2010-03-31,August 2012,2012-08-31,January 2013,Anticipated,2013-01-31,December 2012,Anticipated,2012-12-31,,Interventional,,,Thalidomide for Patients With Mild to Moderate Alzheimer's Disease,"""Twenty-Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Effect of Fixed Dose Regimens of Thalidomide and Placebo on CSF and Plasma Biomarkers in Patients With Mild to Moderate Alzheimer's Disease",Unknown status,Recruiting,Phase 2/Phase 3,20.0,Anticipated,Banner Health,,1.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 17:23:40.976717,2020-02-01 17:23:40.976717,Banner Health,Other,Thalidomide,Drug
NCT03698695,"ClinicalTrials.gov processed this data on January 31, 2020",2018-10-02,,,2020-01-21,2018-10-03,2018-10-09,Actual,,,,,,,2020-01-21,2020-01-22,Actual,"September 27, 2018",Actual,2018-09-27,January 2020,2020-01-31,"December 20, 2019",Actual,2019-12-20,"October 20, 2019",Actual,2019-10-20,,Interventional,,,"A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers","A Double Blind, Placebo-controlled, Randomized, 15-day Treatment, Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil Administered Orally to Healthy Male Volunteers Including a Scopolamine Challenge",Completed,,Phase 1,152.0,Actual,Theranexus,,3.0,,,False,,,,False,False,False,,,,,,,,,,,2020-02-01 07:39:11.698156,2020-02-01 07:39:11.698156,Theranexus,Industry,THN 201,Drug
NCT01350362,"ClinicalTrials.gov processed this data on January 31, 2020",2011-05-06,,,2012-10-01,2011-05-06,2011-05-09,Estimate,,,,,,,2012-10-01,2012-10-02,Estimate,April 2011,,2011-04-30,October 2012,2012-10-31,October 2012,Actual,2012-10-31,July 2012,Actual,2012-07-31,,Interventional,ARGO,,"Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients","A Multicenter, Randomized, Double-blind, Placebo-controlled, 4-arm, 26 Week Parallel-Group Study to Evaluate Efficacy, Safety and Tolerability of 2 Oral Doses and 2 Regimes of Tideglusib vs Placebo in Mild-to-Moderate AD Patients",Completed,,Phase 2,306.0,Actual,Noscira SA,,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 16:08:35.589262,2020-02-01 16:08:35.589262,Noscira SA,Industry,tideglusib,Drug
NCT00314912,"ClinicalTrials.gov processed this data on January 31, 2020",2006-04-13,,,2007-07-13,2006-04-13,2006-04-17,Estimate,,,,,,,2007-07-13,2007-07-16,Estimate,May 2006,,2006-05-31,July 2007,2007-07-31,,,,,,,,Interventional,,,Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease,An Open-Label Extension of the Phase III Study CL-758007 With Tramiprosate (3APS) in Patients With Alzheimer's Disease,Unknown status,"Active, not recruiting",Phase 3,650.0,,Bellus Health Inc,,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:21:14.663980,2020-02-01 21:21:14.663980,Bellus Health Inc,Industry,Tramiprosate (3APS),Drug
NCT00066157,"ClinicalTrials.gov processed this data on January 31, 2020",2003-08-04,,,2018-08-22,2003-08-04,2003-08-05,Estimate,,,,,,,2018-08-22,2018-08-23,Actual,September 2001,,2001-09-30,August 2018,2018-08-31,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,Alzheimer's Disease: Therapeutic Potential of Estrogen,Alzheimer's Disease: Therapeutic Potential of Estrogen,Completed,,Phase 2/Phase 3,42.0,Actual,"University of Wisconsin, Madison",,4.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:32:28.672051,2020-02-01 22:32:28.672051,"University of Wisconsin, Madison",Other,Transdermal estradiol,Drug
NCT00000179,"ClinicalTrials.gov processed this data on January 31, 2020",1999-10-29,,,2005-06-23,1999-10-29,1999-11-01,Estimate,,,,,,,2005-06-23,2005-06-24,Estimate,,,,March 2005,2005-03-31,,,,,,,,Interventional,,,Agitation in Alzheimer's Disease,,Completed,,Phase 3,,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:51:07.954349,2020-02-01 22:51:07.954349,National Institute on Aging (NIA),NIH,Trazodone,Drug
NCT01142258,"ClinicalTrials.gov processed this data on January 31, 2020",2010-06-09,,,2012-10-12,2010-06-10,2010-06-11,Estimate,,,,,,,2012-10-12,2012-10-15,Estimate,March 2010,,2010-03-31,October 2012,2012-10-31,August 2012,Actual,2012-08-31,April 2012,Actual,2012-04-30,,Interventional,,,Trazodone for Sleep Disorders in Alzheimer's Disease,"Trazodone for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study",Completed,,Phase 3,40.0,Actual,Brasilia University Hospital,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 17:10:10.737717,2020-02-01 17:10:10.737717,Brasilia University Hospital,Other,Trazodone,Drug
NCT04187547,"ClinicalTrials.gov processed this data on January 31, 2020",2019-11-29,,,2019-12-05,2019-12-03,2019-12-05,Actual,,,,,,,2019-12-05,2019-12-06,Actual,"April 30, 2020",Anticipated,2020-04-30,December 2019,2019-12-31,"July 14, 2022",Anticipated,2022-07-14,"June 21, 2022",Anticipated,2022-06-21,,Interventional,,,A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease,"A 20-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Trial to Investigate the Efficacy and Safety of Daily Administration of Tricaprilin as AC-SD-03 in Subjects With Mild to Moderately Severe Probable Alzheimer's Disease and Who Are Non-carriers of the APOE4 Allele",Not yet recruiting,,Phase 3,300.0,Anticipated,Cerecin,,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 06:28:14.549852,2020-02-01 06:28:14.549852,Cerecin,Industry,Tricaprilin,Drug
NCT03605667,"ClinicalTrials.gov processed this data on January 31, 2020",2018-07-23,,,2019-11-05,2018-07-27,2018-07-30,Actual,,,,,,,2019-11-05,2019-11-06,Actual,"July 31, 2018",Actual,2018-07-31,November 2019,2019-11-30,"December 20, 2020",Anticipated,2020-12-20,"December 5, 2020",Anticipated,2020-12-05,,Interventional,T2 Protect AD,,Study of BHV-4157 in Alzheimer's Disease,A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease,"Active, not recruiting",,Phase 2/Phase 3,336.0,Anticipated,"Biohaven Pharmaceuticals, Inc.",,2.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 07:53:25.938765,2020-02-01 07:53:25.938765,"Biohaven Pharmaceuticals, Inc.",Industry,troriluzole,Drug
NCT00515333,"ClinicalTrials.gov processed this data on January 31, 2020",2007-08-10,,,2008-02-19,2007-08-10,2007-08-13,Estimate,,,,,,,2008-02-19,2008-02-20,Estimate,August 2004,,2004-08-31,February 2008,2008-02-29,December 2007,Actual,2007-12-31,December 2007,Actual,2007-12-31,,Interventional,,,TRx0014 in Patients With Mild or Moderate Alzheimer's Disease,"An Exploratory Placebo-Controlled, Dose-Ranging Study of the Effects of TRx0014 30 MG TID, 60 MG TID AND 100 MG TID in Patients With Mild or Moderate Dementia of the Alzheimer Type",Completed,,Phase 2,323.0,Actual,TauRx Therapeutics Ltd,,4.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 20:19:58.910572,2020-02-01 20:19:58.910572,TauRx Therapeutics Ltd,Industry,TRx0014,Drug
NCT00684944,"ClinicalTrials.gov processed this data on January 31, 2020",2008-05-22,,2018-04-25,2018-04-25,2008-05-27,2008-05-28,Estimate,,,,2018-04-25,2018-04-27,Actual,2018-04-25,2018-04-27,Actual,"September 13, 2007",Actual,2007-09-13,April 2018,2018-04-30,"December 2, 2010",Actual,2010-12-02,"December 2, 2010",Actual,2010-12-02,,Interventional,,,Open Label Study of TRx0014 in Alzheimer's Disease,An Open Label Continuation Study of the Effects of TRx0014 30 mg TID and 60 mg TID in Patients With Alzheimer's Disease,Completed,,Phase 2,111.0,Actual,TauRx Therapeutics Ltd,,2.0,,,False,,,,False,True,False,,,,,,,,,,,2020-02-01 19:28:27.066170,2020-02-01 19:28:27.066170,TauRx Therapeutics Ltd,Industry,TRx0014,Drug
NCT01626391,"ClinicalTrials.gov processed this data on January 31, 2020",2012-06-20,2014-04-28,,2014-06-10,2012-06-20,2012-06-22,Estimate,2014-06-10,2014-07-11,Estimate,,,,2014-06-10,2014-07-11,Estimate,September 2012,,2012-09-30,June 2014,2014-06-30,March 2013,Actual,2013-03-31,March 2013,Actual,2013-03-31,,Interventional,,Safety Population,Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease,"A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease on Pre-Existing Stable Acetylcholinesterase Inhibitor and/or Memantine Therapy",Terminated,,Phase 2,9.0,Actual,TauRx Therapeutics Ltd,Early termination leading to small numbers of subjects analyzed,2.0,,This study has been terminated for administrative reasons only.,False,,,,True,,,,,,,,,,,,,2020-02-01 14:58:05.465796,2020-02-01 14:58:05.465796,TauRx Therapeutics Ltd,Industry,TRx0237,Drug
NCT02245568,"ClinicalTrials.gov processed this data on January 31, 2020",2014-08-27,,2018-05-15,2018-05-15,2014-09-17,2014-09-19,Estimate,,,,2018-05-15,2018-05-18,Actual,2018-05-15,2018-05-18,Actual,August 2014,,2014-08-31,May 2018,2018-05-31,May 2017,Actual,2017-05-31,May 2017,Actual,2017-05-31,,Interventional,,,Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD),"An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)",Terminated,,Phase 3,913.0,Actual,TauRx Therapeutics Ltd,,1.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 12:19:05.821794,2020-02-01 12:19:05.821794,TauRx Therapeutics Ltd,Industry,TRx0237,Drug
NCT01689246,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-14,,2018-03-12,2018-03-12,2012-09-20,2012-09-21,Estimate,,,,2018-03-12,2018-03-14,Actual,2018-03-12,2018-03-14,Actual,January 2013,,2013-01-31,March 2018,2018-03-31,November 2015,Actual,2015-11-30,November 2015,Actual,2015-11-30,,Interventional,,,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,891.0,Actual,TauRx Therapeutics Ltd,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:41:34.220277,2020-02-01 14:41:34.220277,TauRx Therapeutics Ltd,Industry,TRx0237 150 mg/day,Drug
NCT03446001,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-08,,,2020-01-22,2018-02-20,2018-02-26,Actual,,,,,,,2020-01-22,2020-01-23,Actual,"January 10, 2018",Actual,2018-01-10,January 2020,2020-01-31,December 2022,Anticipated,2022-12-31,December 2021,Anticipated,2021-12-31,,Interventional,,,Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment,"Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment",Recruiting,,Phase 3,450.0,Anticipated,TauRx Therapeutics Ltd,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:18:55.846673,2020-02-01 08:18:55.846673,TauRx Therapeutics Ltd,Industry,TRx0237 16 mg/day,Drug
NCT01689233,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-14,,2018-03-12,2018-03-12,2012-09-20,2012-09-21,Estimate,,,,2018-03-12,2018-03-14,Actual,2018-03-12,2018-03-14,Actual,October 2012,,2012-10-31,March 2018,2018-03-31,May 2016,Actual,2016-05-31,May 2016,Actual,2016-05-31,,Interventional,,,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of TRx0237 in Subjects With Mild Alzheimer's Disease",Completed,,Phase 3,800.0,Actual,TauRx Therapeutics Ltd,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:41:34.512210,2020-02-01 14:41:34.512210,TauRx Therapeutics Ltd,Industry,TRx0237 200 mg/day,Drug
NCT01689246,"ClinicalTrials.gov processed this data on January 31, 2020",2012-09-14,,2018-03-12,2018-03-12,2012-09-20,2012-09-21,Estimate,,,,2018-03-12,2018-03-14,Actual,2018-03-12,2018-03-14,Actual,January 2013,,2013-01-31,March 2018,2018-03-31,November 2015,Actual,2015-11-30,November 2015,Actual,2015-11-30,,Interventional,,,Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease,"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease",Completed,,Phase 3,891.0,Actual,TauRx Therapeutics Ltd,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 14:41:34.220277,2020-02-01 14:41:34.220277,TauRx Therapeutics Ltd,Industry,TRx0237 250 mg/day,Drug
NCT03446001,"ClinicalTrials.gov processed this data on January 31, 2020",2018-02-08,,,2020-01-22,2018-02-20,2018-02-26,Actual,,,,,,,2020-01-22,2020-01-23,Actual,"January 10, 2018",Actual,2018-01-10,January 2020,2020-01-31,December 2022,Anticipated,2022-12-31,December 2021,Anticipated,2021-12-31,,Interventional,,,Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment,"Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment",Recruiting,,Phase 3,450.0,Anticipated,TauRx Therapeutics Ltd,,3.0,,,False,,,,True,True,False,,,,,,,,,,,2020-02-01 08:18:55.846673,2020-02-01 08:18:55.846673,TauRx Therapeutics Ltd,Industry,TRx0237 8 mg/day,Drug
NCT00202124,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-13,,,2005-09-13,2005-09-13,2005-09-20,Estimate,,,,,,,2005-09-13,2005-09-20,Estimate,April 2001,,2001-04-30,November 2002,2002-11-30,March 2002,,2002-03-31,,,,,Interventional,,,Double Blind Study of Trp01 in Patients With Alzheimer's Disease,Double Blind Medium Term Efficacy Study of Trp01 in Patients With Mild to Moderate Alzheimer's Disease,Completed,,Phase 4,12.0,,Queen's University,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 21:49:07.265606,2020-02-01 21:49:07.265606,Queen's University,Other,Tryptophan,Drug
NCT02997982,"ClinicalTrials.gov processed this data on January 31, 2020",2016-12-06,,,2019-11-13,2016-12-15,2016-12-20,Estimate,,,,,,,2019-11-13,2019-11-15,Actual,December 2016,Actual,2016-12-31,November 2019,2019-11-30,April 2020,Anticipated,2020-04-30,April 2020,Anticipated,2020-04-30,,Interventional,VALZ-Pilot,,Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease,Feasibility and Effects on Markers in Spinal Fluid in Persons With Early Alzheimer's Disease When Treated With Valaciclovir - Open Fas II Pilot Study (VALZ-Pilot),Recruiting,,Phase 2,36.0,Anticipated,Umeå University,,1.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 09:37:57.969395,2020-02-01 09:37:57.969395,Hugo Lovheim,Other,Valaciclovir 500Mg Tablet,Drug
NCT03282916,"ClinicalTrials.gov processed this data on January 31, 2020",2017-09-12,,,2020-01-05,2017-09-12,2017-09-14,Actual,,,,,,,2020-01-05,2020-01-07,Actual,"February 12, 2018",Actual,2018-02-12,January 2020,2020-01-31,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,,Interventional,,,Anti-viral Therapy in Alzheimer's Disease,Anti-viral Therapy in Alzheimer's Disease,Recruiting,,Phase 2,130.0,Anticipated,New York State Psychiatric Institute,,2.0,,,,,,,True,True,False,,,,,,,,,No,,2020-02-01 08:46:33.166581,2020-02-01 08:46:33.166581,New York State Psychiatric Institute,Other,Valacyclovir,Drug
NCT00071721,"ClinicalTrials.gov processed this data on January 31, 2020",2003-10-29,2010-07-06,,2014-09-15,2003-10-30,2003-10-31,Estimate,2010-09-24,2010-10-20,Estimate,,,,2014-09-15,2014-09-25,Estimate,October 2003,,2003-10-31,September 2014,2014-09-30,December 2009,Actual,2009-12-31,February 2009,Actual,2009-02-28,,Interventional,,,Valproate in Dementia (VALID),"A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)",Completed,,Phase 3,313.0,Actual,Alzheimer's Disease Cooperative Study (ADCS),,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:30:40.191422,2020-02-01 22:30:40.191422,Alzheimer's Disease Cooperative Study (ADCS),Other,Valproate,Drug
NCT00744978,"ClinicalTrials.gov processed this data on January 31, 2020",2008-08-29,2011-10-12,,2011-10-12,2008-08-29,2008-09-01,Estimate,2011-10-12,2011-11-22,Estimate,,,,2011-10-12,2011-11-22,Estimate,July 2009,,2009-07-31,October 2011,2011-10-31,November 2010,Actual,2010-11-30,November 2010,Actual,2010-11-30,,Interventional,,,"Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to-Moderate Alzheimer's Disease","A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Crossover Trial of Varenicline Tartrate (CP-526,555) in Patients With Mild to Moderate Alzheimer's Disease",Completed,,Phase 2,66.0,Actual,Pfizer,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 19:10:28.516695,2020-02-01 19:10:28.516695,Pfizer,Industry,Varenicline,Drug
NCT01467726,"ClinicalTrials.gov processed this data on January 31, 2020",2011-10-28,,,2014-12-01,2011-11-04,2011-11-09,Estimate,,,,,,,2014-12-01,2014-12-03,Estimate,November 2011,,2011-11-30,December 2014,2014-12-31,January 2012,Actual,2012-01-31,January 2012,Actual,2012-01-31,,Interventional,,,"Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects","A Phase 1, Randomized, Placebo−Controlled, Double−Blind, Study of Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects",Completed,,Phase 1,40.0,Actual,Theravance Biopharma,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:37:39.137884,2020-02-01 15:37:39.137884,Theravance Biopharma,Industry,Velusetrag,Drug
NCT01609348,"ClinicalTrials.gov processed this data on January 31, 2020",2012-04-27,2017-10-16,,2018-01-04,2012-05-29,2012-06-01,Estimate,2018-01-04,2018-01-31,Actual,,,,2018-01-04,2018-01-31,Actual,April 2012,,2012-04-30,January 2018,2018-01-31,January 2017,Actual,2017-01-31,December 2016,Actual,2016-12-31,,Interventional,DIADs-3,,Venlafaxine for Depression in Alzheimer's Disease (DIADs-3),Venlafaxine for Depression in Alzheimer's Disease,Completed,,N/A,5.0,Actual,Johns Hopkins University,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:02:11.829599,2020-02-01 15:02:11.829599,Johns Hopkins University,Other,Venlafaxine,Drug
NCT01953601,"ClinicalTrials.gov processed this data on January 31, 2020",2013-09-25,2019-04-15,,2019-05-15,2013-09-25,2013-10-01,Estimate,2019-05-15,2019-05-17,Actual,,,,2019-05-15,2019-05-17,Actual,"November 5, 2013",Actual,2013-11-05,May 2019,2019-05-31,"April 17, 2018",Actual,2018-04-17,"April 17, 2018",Actual,2018-04-17,,Interventional,APECS,,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),"A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)",Terminated,,Phase 3,1454.0,Actual,Merck Sharp & Dohme Corp.,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:31:39.225008,2020-02-01 13:31:39.225008,Merck Sharp & Dohme Corp.,Industry,Verubecestat 12 mg (Parts 1 and 2),Drug
NCT01953601,"ClinicalTrials.gov processed this data on January 31, 2020",2013-09-25,2019-04-15,,2019-05-15,2013-09-25,2013-10-01,Estimate,2019-05-15,2019-05-17,Actual,,,,2019-05-15,2019-05-17,Actual,"November 5, 2013",Actual,2013-11-05,May 2019,2019-05-31,"April 17, 2018",Actual,2018-04-17,"April 17, 2018",Actual,2018-04-17,,Interventional,APECS,,Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019),"A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)",Terminated,,Phase 3,1454.0,Actual,Merck Sharp & Dohme Corp.,,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 13:31:39.225008,2020-02-01 13:31:39.225008,Merck Sharp & Dohme Corp.,Industry,Verubecestat 40 mg (Parts 1 and 2),Drug
NCT01739348,"ClinicalTrials.gov processed this data on January 31, 2020",2012-11-29,2018-04-11,,2018-09-24,2012-11-29,2012-12-03,Estimate,2018-04-11,2018-05-16,Actual,,,,2018-09-24,2018-10-24,Actual,"November 30, 2012",Actual,2012-11-30,September 2018,2018-09-30,"April 14, 2017",Actual,2017-04-14,"April 14, 2017",Actual,2017-04-14,,Interventional,EPOCH,All randomized participants in Study Part I (Base Study),An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738),"A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)",Terminated,,Phase 2/Phase 3,2211.0,Actual,Merck Sharp & Dohme Corp.,,4.0,,,False,,,,True,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2020-02-01 14:27:54.749867,2020-02-01 14:27:54.749867,Merck Sharp & Dohme Corp.,Industry,Verubecestat (Part I and Part II),Drug
NCT01739348,"ClinicalTrials.gov processed this data on January 31, 2020",2012-11-29,2018-04-11,,2018-09-24,2012-11-29,2012-12-03,Estimate,2018-04-11,2018-05-16,Actual,,,,2018-09-24,2018-10-24,Actual,"November 30, 2012",Actual,2012-11-30,September 2018,2018-09-30,"April 14, 2017",Actual,2017-04-14,"April 14, 2017",Actual,2017-04-14,,Interventional,EPOCH,All randomized participants in Study Part I (Base Study),An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738),"A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)",Terminated,,Phase 2/Phase 3,2211.0,Actual,Merck Sharp & Dohme Corp.,,4.0,,,False,,,,True,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,Yes,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2020-02-01 14:27:54.749867,2020-02-01 14:27:54.749867,Merck Sharp & Dohme Corp.,Industry,Verubecestat (Part II),Drug
NCT04249869,"ClinicalTrials.gov processed this data on January 31, 2020",2020-01-29,,,2020-01-29,2020-01-29,2020-01-31,Estimate,,,,,,,2020-01-29,2020-01-31,Estimate,"February 1, 2020",Anticipated,2020-02-01,January 2020,2020-01-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,,Interventional,,,The Efficacy of Traditional Chinese Herbal Medicine for Alzheimer's Disease,The Effect of Traditional Chinese Medicine (VGH-AD1) on Patients With Alzheimer's Disease: A Double-blinded Randomized Placebo-controlled Cross-over Study,Not yet recruiting,,Phase 1/Phase 2,28.0,Anticipated,"Taipei Veterans General Hospital, Taiwan",,2.0,,,False,,,,True,False,False,,,,,,,,,No,,2020-02-04 05:10:22.673280,2020-02-04 05:10:22.673280,"Taipei Veterans General Hospital, Taiwan",Other,VGH-AD1,Drug
NCT01428362,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-31,,2013-10-23,2013-11-15,2011-08-31,2011-09-05,Estimate,,,,2013-10-23,2013-11-15,Estimate,2013-11-15,2013-12-11,Estimate,August 2011,,2011-08-31,November 2013,2013-11-30,August 2013,Actual,2013-08-31,August 2013,Actual,2013-08-31,,Interventional,AD-201,,VI-1121 for the Treatment Alzheimer's Disease,"A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease",Completed,,Phase 2,61.0,Actual,"VIVUS, Inc.",,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 15:49:01.052351,2020-02-01 15:49:01.052351,"VIVUS, Inc.",Industry,VI-1121,Drug
NCT00056225,"ClinicalTrials.gov processed this data on January 31, 2020",2003-03-07,,,2009-06-10,2003-03-08,2003-03-10,Estimate,,,,,,,2009-06-10,2009-06-12,Estimate,January 2003,,2003-01-31,June 2009,2009-06-30,June 2007,Actual,2007-06-30,June 2007,Actual,2007-06-30,,Interventional,,,VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study),High Dose Supplements to Reduce Homocysteine and Slow the Rate of Cognitive Decline in Alzheimer's Disease (Vitamins to Slow Alzheimer's - VITAL),Completed,,Phase 3,340.0,Actual,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:35:04.175801,2020-02-01 22:35:04.175801,National Institute on Aging (NIA),NIH,Vitamin B12,Drug
NCT00056225,"ClinicalTrials.gov processed this data on January 31, 2020",2003-03-07,,,2009-06-10,2003-03-08,2003-03-10,Estimate,,,,,,,2009-06-10,2009-06-12,Estimate,January 2003,,2003-01-31,June 2009,2009-06-30,June 2007,Actual,2007-06-30,June 2007,Actual,2007-06-30,,Interventional,,,VITAL - VITamins to Slow ALzheimer's Disease (Homocysteine Study),High Dose Supplements to Reduce Homocysteine and Slow the Rate of Cognitive Decline in Alzheimer's Disease (Vitamins to Slow Alzheimer's - VITAL),Completed,,Phase 3,340.0,Actual,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:35:04.175801,2020-02-01 22:35:04.175801,National Institute on Aging (NIA),NIH,Vitamin B6,Drug
NCT01409694,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-02,,,2016-09-21,2011-08-03,2011-08-04,Estimate,,,,,,,2016-09-21,2016-09-22,Estimate,September 2011,,2011-09-30,March 2011,2011-03-31,January 2016,Actual,2016-01-31,January 2016,Actual,2016-01-31,,Interventional,AD-IDEA,,Alzheimer's Disease - Input of Vitamin D With mEmantine Assay,Evaluation d'Une stratégie thérapeutique d'Association médicamenteuse Pour la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées au Stade modéré,Completed,,Phase 3,90.0,Actual,"University Hospital, Angers",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:53:36.184745,2020-02-01 15:53:36.184745,"University Hospital, Angers",Other,Vitamin D,Drug
NCT01409694,"ClinicalTrials.gov processed this data on January 31, 2020",2011-08-02,,,2016-09-21,2011-08-03,2011-08-04,Estimate,,,,,,,2016-09-21,2016-09-22,Estimate,September 2011,,2011-09-30,March 2011,2011-03-31,January 2016,Actual,2016-01-31,January 2016,Actual,2016-01-31,,Interventional,AD-IDEA,,Alzheimer's Disease - Input of Vitamin D With mEmantine Assay,Evaluation d'Une stratégie thérapeutique d'Association médicamenteuse Pour la Prise en Charge de la Maladie d'Alzheimer et Des Maladies apparentées au Stade modéré,Completed,,Phase 3,90.0,Actual,"University Hospital, Angers",,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 15:53:36.184745,2020-02-01 15:53:36.184745,"University Hospital, Angers",Other,Vitamin D placebo,Drug
NCT00000173,"ClinicalTrials.gov processed this data on January 31, 2020",1999-10-29,,,2009-12-10,1999-10-29,1999-11-01,Estimate,,,,,,,2009-12-10,2009-12-11,Estimate,March 1999,,1999-03-31,June 2009,2009-06-30,January 2004,Actual,2004-01-31,January 2004,Actual,2004-01-31,,Interventional,,,Memory Impairment Study (Mild Cognitive Impairment Study),"A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)",Completed,,Phase 3,,,National Institute on Aging (NIA),,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:51:08.456650,2020-02-01 22:51:08.456650,National Institute on Aging (NIA),NIH,Vitamin E,Drug
NCT00056329,"ClinicalTrials.gov processed this data on January 31, 2020",2003-03-10,,,2012-05-02,2003-03-11,2003-03-12,Estimate,,,,,,,2012-05-02,2012-05-04,Estimate,April 2002,,2002-04-30,May 2012,2012-05-31,May 2012,Anticipated,2012-05-31,May 2012,Anticipated,2012-05-31,,Interventional,,,Vitamin E in Aging Persons With Down Syndrome,Multicenter Vitamin E Trial in Aging Persons With Down Syndrome,Unknown status,"Active, not recruiting",Phase 3,350.0,Actual,New York State Institute for Basic Research,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:35:03.109992,2020-02-01 22:35:03.109992,New York State Institute for Basic Research,Other,Vitamin E,Drug
NCT00117403,"ClinicalTrials.gov processed this data on January 31, 2020",2005-06-30,,,2009-04-01,2005-06-30,2005-07-06,Estimate,,,,,,,2009-04-01,2009-04-03,Estimate,January 2006,,2006-01-31,April 2008,2008-04-30,September 2007,Actual,2007-09-30,September 2007,Actual,2007-09-30,,Interventional,,,Anti-Oxidant Treatment of Alzheimer's Disease,"Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's Disease",Completed,,Phase 1,75.0,Anticipated,National Institute on Aging (NIA),,3.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 22:12:02.293739,2020-02-01 22:12:02.293739,National Institute on Aging (NIA),NIH,"Vitamin E, Vitamin C, and Alpha-lipoic Acid",Drug
NCT00231946,"ClinicalTrials.gov processed this data on January 31, 2020",2005-09-30,,,2007-09-18,2005-09-30,2005-10-04,Estimate,,,,,,,2007-09-18,2007-09-20,Estimate,September 2005,,2005-09-30,September 2007,2007-09-30,,,,,,,,Interventional,,,ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301),A Double-Blind Placebo-Controlled Study of VP4896 For the Treatment of Mild-to-Moderate Alzheimer's Disease,Completed,,Phase 3,555.0,,National Institute on Aging (NIA),,,,,,,,,,,,,,,,,,,,,,2020-02-01 21:43:23.039189,2020-02-01 21:43:23.039189,Voyager Pharmaceutical Corporation,Industry,VP4896,Drug
NCT02423122,"ClinicalTrials.gov processed this data on January 31, 2020",2015-04-14,2018-01-04,,2019-03-13,2015-04-17,2015-04-22,Estimate,2019-03-13,2019-06-14,Actual,,,,2019-03-13,2019-06-14,Actual,April 2015,,2015-04-30,January 2018,2018-01-31,September 2016,Actual,2016-09-30,July 2016,Actual,2016-07-31,,Interventional,,,"A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)","A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic 11C-PiB Positive Emission Tomography (PET) Amyloid Scanning",Completed,,Phase 2,16.0,Actual,EIP Pharma Inc,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 11:39:15.660589,2020-02-01 11:39:15.660589,EIP Pharma Inc,Industry,VX-745,Drug
NCT02423200,"ClinicalTrials.gov processed this data on January 31, 2020",2015-04-03,2018-01-02,,2018-04-02,2015-04-17,2015-04-22,Estimate,2018-04-02,2018-04-03,Actual,,,,2018-04-02,2018-04-03,Actual,April 2015,,2015-04-30,April 2018,2018-04-30,November 2016,Actual,2016-11-30,September 2016,Actual,2016-09-30,,Interventional,,,"Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD","A Randomized, Open-Label, Multiple Dose Clinical Pharmacology Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or With Mild AD",Completed,,Phase 2,16.0,Actual,EIP Pharma Inc,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 11:39:14.967409,2020-02-01 11:39:14.967409,EIP Pharma Inc,Industry,VX-745,Drug
NCT03435861,"ClinicalTrials.gov processed this data on January 31, 2020",2017-12-22,,,2018-11-19,2018-02-09,2018-02-19,Actual,,,,,,,2018-11-19,2018-11-21,Actual,"October 8, 2018",Actual,2018-10-08,November 2018,2018-11-30,"January 30, 2021",Anticipated,2021-01-30,"January 30, 2020",Anticipated,2020-01-30,,Interventional,VIP,,Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients,Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients,Recruiting,,Phase 2,40.0,Anticipated,"University Hospital, Toulouse",,2.0,,,False,,,,False,False,False,,,,,,,,,No,,2020-02-01 08:20:44.789272,2020-02-01 08:20:44.789272,"University Hospital, Toulouse",Other,VX-745,Drug
NCT00827034,"ClinicalTrials.gov processed this data on January 31, 2020",2009-01-20,,,2018-10-11,2009-01-21,2009-01-22,Estimate,,,,,,,2018-10-11,2018-10-16,Actual,February 2009,,2009-02-28,October 2018,2018-10-31,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,,Interventional,,,"A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects","A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects",Completed,,Phase 1,14.0,Actual,Pfizer,,2.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 18:46:11.984947,2020-02-01 18:46:11.984947,Pfizer,Industry,Warfarin,Drug
NCT00103649,"ClinicalTrials.gov processed this data on January 31, 2020",2005-02-11,,,2008-08-20,2005-02-11,2005-02-14,Estimate,,,,,,,2008-08-20,2008-08-21,Estimate,November 2003,,2003-11-30,August 2008,2008-08-31,October 2007,Actual,2007-10-31,October 2007,Actual,2007-10-31,,Interventional,,,18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type",Completed,,Phase 3,1306.0,Actual,Sanofi,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:16:53.818824,2020-02-01 22:16:53.818824,Sanofi,Industry,xaliproden (SR57746A),Drug
NCT00104013,"ClinicalTrials.gov processed this data on January 31, 2020",2005-02-18,,,2008-08-20,2005-02-18,2005-02-21,Estimate,,,,,,,2008-08-20,2008-08-21,Estimate,November 2003,,2003-11-30,August 2008,2008-08-31,November 2007,Actual,2007-11-30,November 2007,Actual,2007-11-30,,Interventional,,,Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type",Completed,,Phase 3,1455.0,Actual,Sanofi,,,,,False,,,,,,,,,,,,,,,,,2020-02-01 22:16:46.912809,2020-02-01 22:16:46.912809,Sanofi,Industry,xaliproden (SR57746A),Drug
NCT02727699,"ClinicalTrials.gov processed this data on January 31, 2020",2016-03-21,,,2019-09-09,2016-03-30,2016-04-05,Estimate,,,,,,,2019-09-09,2019-09-11,Actual,"March 23, 2017",Actual,2017-03-23,September 2019,2019-09-30,"March 15, 2019",Actual,2019-03-15,"March 15, 2019",Actual,2019-03-15,,Interventional,XanADu,,"A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)","XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)",Completed,,Phase 2,186.0,Actual,Actinogen Medical,,2.0,,,False,,,,True,True,False,,,,,,,,,Undecided,,2020-02-01 10:31:55.688352,2020-02-01 10:31:55.688352,Actinogen Medical,Industry,Xanamem™,Drug
NCT03943264,"ClinicalTrials.gov processed this data on January 31, 2020",2019-04-26,,,2020-01-17,2019-05-07,2019-05-09,Actual,,,,,,,2020-01-17,2020-01-22,Actual,"November 20, 2019",Actual,2019-11-20,January 2020,2020-01-31,December 2020,Anticipated,2020-12-31,August 2020,Anticipated,2020-08-31,,Interventional,,,A Biomarker-directed Study of XPro1595 in Patients With Mild to Moderate Alzheimer's,"Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients With Mild to Moderate Alzheimer's Disease With Elevated High Sensitivity C-reactive Protein in Blood",Recruiting,,Phase 1,18.0,Anticipated,"Inmune Bio, Inc.",,3.0,,,False,,,,True,False,False,,,,,,,,,Undecided,,2020-02-01 07:02:56.051565,2020-02-01 07:02:56.051565,"Inmune Bio, Inc.",Industry,XPro1595,Drug
NCT03075241,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-05,,,2019-07-07,2017-03-05,2017-03-09,Actual,,,,,,,2019-07-07,2019-07-09,Actual,October 2016,Actual,2016-10-31,July 2019,2019-07-31,December 2020,Anticipated,2020-12-31,January 2020,Anticipated,2020-01-31,,Interventional,,,Z-Drugs for Sleep Disorders in Alzheimer's Disease,"Z-Drugs for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study",Recruiting,,Phase 3,60.0,Anticipated,Brasilia University Hospital,,3.0,,,False,,,,False,False,False,,,False,,,,,,No,,2020-02-01 09:23:32.069605,2020-02-01 09:23:32.069605,Brasilia University Hospital,Other,Zolpidem,Drug
NCT00814502,"ClinicalTrials.gov processed this data on January 31, 2020",2008-12-18,2017-02-02,,2017-04-12,2008-12-24,2008-12-25,Estimate,2017-04-12,2017-05-22,Actual,,,,2017-04-12,2017-05-22,Actual,December 2008,,2008-12-31,April 2017,2017-04-30,December 2013,Actual,2013-12-31,December 2013,Actual,2013-12-31,,Interventional,,,Zolpidem CR and Hospitalized Patients With Dementia,Does Zolpidem CR Treatment Change Clinical Outcomes in Elderly Hospitalized Patients With Dementia- A Pilot Study,Completed,,N/A,20.0,Actual,Massachusetts General Hospital,Small sample size. We were unable to control for different treatments that our subjects received as inpatients.,2.0,,,False,,,,True,,,,,,,,,,,No,,2020-02-01 18:49:38.034289,2020-02-01 18:49:38.034289,Massachusetts General Hospital,Other,Zolpidem CR,Drug
NCT03075241,"ClinicalTrials.gov processed this data on January 31, 2020",2017-03-05,,,2019-07-07,2017-03-05,2017-03-09,Actual,,,,,,,2019-07-07,2019-07-09,Actual,October 2016,Actual,2016-10-31,July 2019,2019-07-31,December 2020,Anticipated,2020-12-31,January 2020,Anticipated,2020-01-31,,Interventional,,,Z-Drugs for Sleep Disorders in Alzheimer's Disease,"Z-Drugs for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study",Recruiting,,Phase 3,60.0,Anticipated,Brasilia University Hospital,,3.0,,,False,,,,False,False,False,,,False,,,,,,No,,2020-02-01 09:23:32.069605,2020-02-01 09:23:32.069605,Brasilia University Hospital,Other,Zoplicone,Drug
NCT00423228,"ClinicalTrials.gov processed this data on January 31, 2020",2007-01-17,,,2015-01-13,2007-01-17,2007-01-18,Estimate,,,,,,,2015-01-13,2015-01-14,Estimate,February 2007,,2007-02-28,January 2015,2015-01-31,April 2009,Actual,2009-04-30,April 2009,Actual,2009-04-30,,Interventional,BRAINz,,Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease,"A Randomised, Double-blind, Double-dummy, Oral Donepezil Controlled Study on the Safety and Efficacy of Repeated Monthly Subcutaneous Injections of a Sustained-release Implant of ZT 1 in Patients With Moderate Alzheimer's Disease",Completed,,N/A,228.0,Actual,Debiopharm International SA,,2.0,,,False,,,,True,,,,,,,,,,,,,2020-02-01 20:48:39.791345,2020-02-01 20:48:39.791345,Debiopharm International SA,Industry,ZT-1,Drug
NCT01940952,"ClinicalTrials.gov processed this data on January 31, 2020",2013-09-09,,,2013-09-09,2013-09-09,2013-09-12,Estimate,,,,,,,2013-09-09,2013-09-12,Estimate,September 2013,,2013-09-30,September 2013,2013-09-30,,,,August 2015,Anticipated,2015-08-31,,Interventional,,,Zydena on Cognitive Function of Alzheimer's Disease Patients,"Efficacy of Zydena (Udenafil) on Cognitive Function of Alzheimer's Disease Patients: A Randomized, Double Blind, Placebo-controlled Multicenter Study",Unknown status,Not yet recruiting,Phase 3,210.0,Anticipated,Samsung Medical Center,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:35:04.954668,2020-02-01 13:35:04.954668,Samsung Medical Center,Other,Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg,Drug
NCT01940952,"ClinicalTrials.gov processed this data on January 31, 2020",2013-09-09,,,2013-09-09,2013-09-09,2013-09-12,Estimate,,,,,,,2013-09-09,2013-09-12,Estimate,September 2013,,2013-09-30,September 2013,2013-09-30,,,,August 2015,Anticipated,2015-08-31,,Interventional,,,Zydena on Cognitive Function of Alzheimer's Disease Patients,"Efficacy of Zydena (Udenafil) on Cognitive Function of Alzheimer's Disease Patients: A Randomized, Double Blind, Placebo-controlled Multicenter Study",Unknown status,Not yet recruiting,Phase 3,210.0,Anticipated,Samsung Medical Center,,3.0,,,False,,,,False,,,,,,,,,,,,,2020-02-01 13:35:04.954668,2020-02-01 13:35:04.954668,Samsung Medical Center,Other,Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg,Drug
